<SEC-DOCUMENT>0001213900-17-005790.txt : 20170524
<SEC-HEADER>0001213900-17-005790.hdr.sgml : 20170524
<ACCEPTANCE-DATETIME>20170523204849
ACCESSION NUMBER:		0001213900-17-005790
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		61
CONFORMED PERIOD OF REPORT:	20161231
FILED AS OF DATE:		20170524
DATE AS OF CHANGE:		20170523

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Immudyne, Inc.
		CENTRAL INDEX KEY:			0000948320
		STANDARD INDUSTRIAL CLASSIFICATION:	MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
		IRS NUMBER:				760238453
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	333-184487
		FILM NUMBER:		17865351

	BUSINESS ADDRESS:	
		STREET 1:		50 SPRING MEADOW ROAD
		CITY:			MT. KISCO
		STATE:			NY
		ZIP:			10549
		BUSINESS PHONE:		(914) 244-1777

	MAIL ADDRESS:	
		STREET 1:		50 SPRING MEADOW ROAD
		CITY:			MT. KISCO
		STATE:			NY
		ZIP:			10549

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	IMMUDYNE INC
		DATE OF NAME CHANGE:	19950720
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>f10k2016_immudyneinc.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>

<BODY STYLE="font: 10pt Times New Roman, Times, Serif">
<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>FORM
10-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-size: 5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Mark
One)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt; text-align: center"><FONT STYLE="font-family: Wingdings"><B>&thorn;
</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ANNUAL REPORT PURSUANT TO SECTION 13 OR
15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For
the fiscal year ended December 31, 2016</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OR</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9744;&#9;TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For
the transition period from &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Commission
file number 333-184487</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B><U>IMMUDYNE,
INC.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Exact
name of registrant as specified in its charter)</I></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 49%; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 49%; font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>76-0238453</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(State
        or other jurisdiction of</I></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>incorporation
        or organization)</I></FONT></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(I.R.S.
        Employer</I></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Identification
        No.)</I></FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>50
Spring Meadow Rd.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Mount
Kisco, NY 10549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Address
of principal executive offices)</I>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registrant&rsquo;s
telephone number, including area code:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(914)
244-1777</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Securities
registered pursuant to Section 12(b) of the Act:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Securities
registered pursuant to Section 12(g) of the Act:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744; No <FONT STYLE="font-family: Wingdings">&thorn;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes &#9744;
No <FONT STYLE="font-family: Wingdings">&thorn;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities
Exchange Act of 1934, as amended (&ldquo;Exchange Act&rdquo;) during the preceding 12 months (or for such shorter period that
the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes <FONT STYLE="font-family: Wingdings">&thorn;</FONT> No &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically and posted on its corporate website, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such
shorter period that the registrant was required to submit and post such files). Yes <FONT STYLE="font-family: Wingdings">&thorn;</FONT>&nbsp;No &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not
be contained, to the best of registrant&rsquo;s knowledge, in definitive proxy or information statements incorporated by reference
in Part III of this Form 10-K or any amendment to this Form 10-K. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting
company, or an emerging growth company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo;
&ldquo;smaller reporting company,&rdquo; and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act.&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 20%; text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer &#9744;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 15%; text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer &#9744;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 38%; text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated
    filer &#9744;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24%; text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
reporting company</FONT><FONT STYLE="font-family: Wingdings; font-size: 10pt"> &thorn;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Do
    not check if a smaller reporting company)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company <FONT STYLE="font-family: Wingdings">&thorn;</FONT></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 6pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">If an
emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 8pt 0 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes &#9744; No <FONT STYLE="font-family: Wingdings">&thorn;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate market value of voting common stock held by non-affiliates computed by reference to the price at which the common stock
was last sold on June 30, 2016, was $5,290,842. All (i) executive officers and directors of the registrant and (ii) all persons
who hold 10% or more of the registrant&rsquo;s outstanding common stock, have been deemed, solely for the purpose of the foregoing
calculation, to be &ldquo;affiliates&rdquo; of the registrant. Accordingly, effective as of June 30, 2016, the registrant&rsquo;s
aggregate market value was less than $50 million and the registrant qualifies for &ldquo;smaller reporting company&rdquo; status
under Rule 12b-2 of the Exchange Act and is subject to the disclosure requirements and filing deadlines for smaller reporting
companies.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt">As of May 16, 2017 there were <FONT STYLE="background-color: white">38,406,601
sha</FONT>res of common stock outstanding.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DOCUMENTS
INCORPORATED BY REFERENCE:</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 5pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>IMMUDYNE, INC.</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Table
of Contents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; width: 0.6in; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 0.5in; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="3" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="3" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART I</FONT></A></TD></TR>
<TR STYLE="background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1.</FONT></A></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
<TR STYLE="background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1A.</FONT></A></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1B.</FONT></A></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unresolved Staff Comments</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</FONT></TD></TR>
<TR STYLE="background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2.</FONT></A></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Properties</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 3.</FONT></A></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Proceedings</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</FONT></TD></TR>
<TR STYLE="background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4.</FONT></A></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mine Safety Disclosures</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="3" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART II</FONT></A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 5.</FONT></A></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market for Registrant&rsquo;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center">20</TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 6.</FONT></A></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selected Financial Data</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD></TR>
<TR STYLE="background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 7.</FONT></A></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center">21</TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 7A.</FONT></A></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quantitative and Qualitative Disclosures about Market Risk</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</FONT></TD></TR>
<TR STYLE="background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 8.</FONT></A></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Statements and Supplementary Data</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9.</FONT></A></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</FONT></TD></TR>
<TR STYLE="background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_015"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9A.</FONT></A></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_015"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controls and Procedures</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_016"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9B.</FONT></A></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_016"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Information</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</FONT></TD></TR>
<TR STYLE="background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="3" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_017"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART III</FONT></A></TD></TR>
<TR STYLE="background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_018"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 10.</FONT></A></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_018"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors, Executive Officers and Corporate Governance</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif">29<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
<TR STYLE="background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_019"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 11.</FONT></A></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_019"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Compensation</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_020"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 12.</FONT></A></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_020"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</FONT></TD></TR>
<TR STYLE="background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_021"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 13.</FONT></A></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_021"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain Relationships and Related Transactions, and Director Independence</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_022"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 14.</FONT></A></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_022"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Accounting Fees and Services</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</FONT></TD></TR>
<TR STYLE="background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="3" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_023"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART IV</FONT></A></TD></TR>
<TR STYLE="background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"></TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_024"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 15.</FONT></A></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_024"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits, Financial Statement Schedules</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center">40</TD></TR>
<TR STYLE="background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_026"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Statements</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_027"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signatures</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTE
ABOUT FORWARD-LOOKING STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the &ldquo;Securities
Act&rdquo;), and Section 21E of the Securities Exchange Act of 1934, as amended, (the &ldquo;Exchange Act&rdquo;) regarding our
company that include, but are not limited to, projections of earnings, revenue or other financial items; statements of the plans,
strategies and objectives of management for future operations; statements concerning proposed new products, services or developments;
statements regarding future economic conditions or performance; statements of belief; and statements of assumptions underlying
any of the foregoing. These forward-looking statements are based on our current expectations, estimates and projections about
our industry, management&rsquo;s beliefs and certain assumptions made by us. Words such as &ldquo;anticipates,&rdquo; &ldquo;expects,&rdquo;
&ldquo;intends,&rdquo; &ldquo;plans,&rdquo; &ldquo;predicts,&rdquo; &ldquo;potential,&rdquo; &ldquo;believes,&rdquo; &ldquo;seeks,&rdquo;
&ldquo;hopes,&rdquo; &ldquo;estimates,&rdquo; &ldquo;should,&rdquo; &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;with a view
to&rdquo; and variations of these words or similar expressions are intended to identify forward-looking statements. These forward-looking
statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult
to predict. Although we believe that our expectations expressed in these forward-looking statements are reasonable, our expectations
may later be found to be incorrect. Our actual results could be materially different from our expectations. Important risks and
factors that could cause our actual results to be materially different from our expectations are set forth in &ldquo;Risk Factors,&rdquo;
&ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations,&rdquo; &ldquo;Our Business&rdquo;
and other sections in this report. Other sections of this report include additional factors that could adversely impact our business
and financial performance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise indicated, information in this report concerning economic conditions and our industry is based on information from independent
industry analysts and publications, as well as our estimates. Except where otherwise noted, our estimates are derived from publicly
available information released by third party sources, as well as data from our internal research, and are based on such data
and our knowledge of our industry, which we believe to be reasonable. Unless otherwise indicated, none of the independent industry
publication market data cited in this report was prepared on our or our affiliates&rsquo; behalf.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
forward-looking statements made in this report are based only on events or information as of the date on which the statements
are made in this report. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking
statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made
or to reflect the occurrence of unanticipated events. You should read this report and the documents we refer to in this report
and have filed as exhibits to this report completely and with the understanding that our actual future results may be materially
different from what we expect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
information on the various risks and uncertainties potentially affecting our operating results are discussed in this report and
other documents we file with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;). We undertake no obligation to revise
or update publicly any forward-looking statements for any reason, except as required by law. Given these risks and uncertainties,
readers are cautioned not to place undue reliance on these forward-looking statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
used in this report, &ldquo;Immudyne,&rdquo; &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;our&rdquo; and similar terms refer
to Immudyne, Inc., unless the context indicates otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_001"></A>PART
I</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><A NAME="a_002"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
1. Business</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Company</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We manufacture, distribute and sell natural immune support
products containing our proprietary yeast beta glucans, a group of beta glucans naturally occurring in the cell walls of yeast
that have been shown through testing and analysis to support the immune system. Our products include once a day oral intake tablets
and topical creams and gels for skin application. In addition, in the second quarter of 2017, we have launched an in-licensed patented
hair loss shampoo and conditioner. We believe, based on testing and analysis conducted by third parties on our behalf, that the
beta glucans derived from yeast we manufacture are superior to any other beta glucans available on the market.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Historically,
we have sold our proprietary additive, for both oral and topical use, primarily to large dietary supplement and cosmetic companies.
During fiscal year 2015, we saw increased interest in our SGM active agent delivery technology, which we believe may have additional
beneficial and marketable uses, and on which we are conducting further testing. In addition, during the fourth quarter of 2015,
we established a partnership with Inate Skincare, LLC (&ldquo;Inate&rdquo;) to launch a complete skin care regimen containing
our proprietary ingredients and to market such products directly to consumers. The Company entered into a limited liability company
operating agreement with its joint venture partners with respect to Inate under the legal name Immudyne PR LLC (&ldquo;Immudyne
PR&rdquo;). On April 1, 2016, the original operating agreement of Immudyne PR was amended and restated and we increased our ownership
and voting interest in Immudyne PR to 78.16667%. As a result of our ownership and control of Immudyne PR, we now operate in two
business segments, nutraceutical and cosmetic additives and finished cosmetic products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were originally incorporated under the laws of British Columbia, Canada, in 1987 under the name Anina Resources, Inc. and subsequently
changed our name to Immudyne, Inc. and our jurisdiction to the State of Wyoming by continuance in September 1987. On June 30,
1994, we changed our jurisdiction to Delaware by merger with and into Immudyne, Inc., a Delaware corporation formed on June 21,
1994.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None
of the testing and analysis or scientific research mentioned in this report has been subject to the oversight of the FDA or any
comparable regulatory body, and no regulatory body has attested to the efficacy of beta glucans in supporting the immune system
or otherwise treating disease. Further, the marketing of beta glucans is not subject to FDA approval, and we are prohibited by
Federal Trade Commission (&ldquo;FTC&rdquo;) and FDA regulations from suggesting in advertisements and product labels that our
products mitigate, treat, cure or prevent a specific disease or class of disease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Products</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have a developed proprietary approach to produce beta glucans derived from yeast which we believe are superior to any other beta
glucans on the market. Our yeast beta glucans are odorless and tasteless, making them suitable for use in a wide variety of oral
and topical applications, including in our nutraceutical and cosmetic product lines. As the U.S. and international markets become
more aware of the value of our proprietary products, we believe demand for our beta glucans will increase.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Beta
Glucans</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beta
glucans, or &beta;-Glucans, are a natural extract that are considered to be &ldquo;biological response modifiers&rdquo; that support
the immune system. The most common sources of beta glucans are from the cell walls of baker&rsquo;s yeast, the cellulose in plants,
the bran of cereal grains and certain fungi and bacteria. The differences between beta glucan chemical structures are significant
in regards to solubility and overall biological activity. In fact, beta glucans derived from mushrooms and cereals do not appear
to have the same effects on human health as beta glucans derived from yeast.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
derive our high-grade beta glucan from yeast cell walls using proprietary processes in our manufacturing facility. Our beta glucan
is generally free of yeast by-product and endotoxins, and has demonstrated reliability in terms of both stability and biological
response. In fact, we commissioned an analytical side-by-side comparison by a laboratory which conducts testing and analysis of
nutraceutical compounds, between our beta glucan and each of the beta glucans manufactured by our two main competitors. The results
of the analytical comparison demonstrated the superiority of our beta glucan which was far less impure and more uniform in composition
than those of our competitors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
health benefits of yeast beta glucans have been demonstrated through extensive testing and analysis and scientific research on
yeast beta glucans generally, and we are committed to supporting evidence-based studies that demonstrate the health benefits of
our products. General scientific research on beta glucan derived from yeast cell walls has been conducted in recent years by renowned
medical laboratories, including Baylor College of Medicine, U.S. Armed Forces Radiobiology Institute, Stanford University, Southwest
Research Institute, Case Western Reserve University, University of Arkansas, North Carolina State University, University of Bern,
Switzerland, and the China Agricultural University, China. As more studies are conducted on beta glucans, we believe the potential
benefits to human health will continue to emerge.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare
professionals, including licensed physicians, alternative medicine practitioners, scientists and researchers have taken an interest
in our immune-support products as a means of offering alternative or complementary approaches for maintaining a healthy and active
lifestyle. These expressions of interest have often resulted in proposals for research studies and recommendations of our products.
We plan to build upon this interest and hope to grow our contacts with licensed physicians who utilize our product in a clinical
setting and with researchers who have the resources to conduct testing and analysis on our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also have relationships with medical doctors who in the past have conducted self-funded studies in which we supplied our product
free of charge, though we do not have any formal clinical development or research agreements with these institutions and doctors.
In addition, Dr. Sven Rohmann, PhD is a director of the Company. Dr. Rohmann is a worldwide authority on innate immunity and has
an extensive medical and business background, including having spent 10 years with Merck Serono, where he served as the Global
Head, Strategic Marketing, Oncology. Dr. Joseph DiTrolio of the Roseland, New Jersey Surgery Center and St. George&rsquo;s University
School of Medicine is also a director of the Company. Dr. Allan Whitberg, previously of Roger Williams Medical Center in Providence,
Rhode Island and currently affiliated with Boston University School of Medicine, and Dr. Stephen Petteruti of The Petteruti Center
For Life Extension in Warwick, RI, are among the medical doctors with whom we have relationships and who have conducted self-funded
studies on our product. We also have established a relationship with National Jewish Health in Denver, Colorado and we are exploring
additional opportunities to have further studies conducted at leading institutions. We have also established a partnership with
the leading physicians of the Stone Center of New Jersey to educate patients about the benefits of supplementing their chemotherapy
and radiation treatments with our yeast-beta glucan products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
be sure, none of the testing and analysis or scientific research mentioned in this annual report has been subject to oversight
of the FDA or any comparable regulatory body, and no regulatory body has attested to the efficacy of beta glucans in supporting
the immune system or otherwise treating disease. Further, the marketing of beta glucans is not subject to FDA approval, and we
are prohibited by FTC and FDA regulations from suggesting in advertisements and product labels that our products mitigate, treat,
cure or prevent a specific disease or class of disease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Yeast
Beta Glucan Product Lines</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Our nutraceutical and cosmetic product lines consist of our
natural, premium yeast beta glucans in oral and topical applications. We offer our yeast beta glucans as natural raw material ingredients
in bulk quantities, our &ldquo;Nutraceutical and Cosmetic Additives&rdquo; segment, and finished, consumer products packaged under
our brands as well as private label brands, our &ldquo;Finished Cosmetic Products&rdquo; segment, which are marketed directly to
consumers. We have also launched an in-licensed patented hair loss shampoo and conditioner called ShapiroMD in the second quarter
of 2017.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
principal, branded nutraceutical and cosmetic products for our yeast beta glucans are oral daily supplements and topical lines
of rejuvenating serums and creams. Our oral supplements are dietary supplements containing proprietary combinations of our yeast
beta glucan to support immune system function. Our skin care serums and creams consist of our patented yeast-derived beta glucan
and other natural ingredients intended to support the skin&rsquo;s immune system response and defense, skin renewal and to repair
sun and environmental damage.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Sales
and Marketing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have performance based contracts with our sales and marketing executives, which allows us to continue to maintain a relatively
low overhead. Our priority is to actively pursue opportunities to market our products and increase sales. Our sales and marketing
strategy primarily consists of building the brand recognition of our product lines and our proprietary yeast beta glucans. We
plan to sell our products primarily on a word-of-mouth basis through distributors and our website as standalone product lines,
as well as business-to-business as a cosmetic enhancement or dietary supplement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
principal products are consumables with the goal of generating a stream of repeat sales with the same end customers over an extended
period of time. To reach these customers, our marketing strategy includes several online sales promotions. In addition, we are
building our brand recognition with healthcare professionals through further testing and analysis of our products and educating
practitioners and clinics on the benefits of our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also market out products direct to consumers through our joint venture with Inate established in October 2015 and through which
we intend to develop, launch and market additional SKU&rsquo;s based on our proprietary beta glucans. Inate benefits from a leadership
team that has deep experience in the direct marketing space and a proven track record in creating national brands.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Manufacturing
and Sourcing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have focused on the production of immune system support compounds including our beta glucans derived from yeast for over 20 years.
Our staff produces consistently high-grade, particulate and reliable beta glucans which are included in our nutraceutical and
cosmetic product lines. For certain of our packaged consumer goods, we use third party contractors for encapsulation, bottling
and labeling. These contractors are subject to regular government inspections, and to the best of our knowledge, comply with current
GMPs and hold the necessary drug manufacturing licenses and processed food registrations required by their respective state regulators.
Such packaging services are readily available from multiple sources.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
raw materials necessary to manufacture our beta glucans principally consist of baker&rsquo;s yeast and are common and readily
available. We hold our suppliers to strict quality and delivery specifications as part of our GMP compliance and quality control
procedures, including quality assurance of raw materials used in the production of our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
beta glucan products and manufacturing processes are protected by registered and pending patents and trade secrets. Our manufacturing
facilities and practices are compliant with published current GMPs established by the FDA for dietary supplements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Customers</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We sell our products direct to consumers and to pharmaceutical,
nutraceutical and consumer product companies principally in the U.S. market, but also have generated sales in Canada. We focus
on establishing and growing long-term relationships with our customers, and we believe that the majority of our customers and
partners view us as a strategic long-term supplier and value the quality of our beta glucan products. Our sales through distributors
typically are made pursuant to supplier agreements executed in the ordinary course of business with individual orders made on
purchase orders. As we have sought to expand our sales, we have marketed our nutraceutical and cosmetic product lines through
distributors, partnerships, and direct sales to consumers. We do not anticipate a seasonality of sales.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
largest customer, Michel Mercier Products, Inc. (d/b/a M.M.P, Inc.), accounted for 15% of our consolidated sales in 2016 and 73%
our consolidated sales in 2015. Our second largest customer accounted for 2% of our consolidated sales in 2016 and 12% our consolidated
sales in 2015. The remainder of our consolidated sales were attributable to our finished cosmetic products segment and which sales
were made through our joint venture with Inate, which sales are decreasing our reliance on MMP.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Competition</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
markets for nutritional supplements and skin care products are highly competitive, consisting of a large number of manufacturers,
distributors and retailers, none of which dominates the fragmented and diverse market. We compete for sales direct to consumers,
through distributors and business-to-business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we believe, based on testing and analysis by third parties on our behalf, that our yeast beta glucan is superior to others available
on the market, we compete with other companies manufacturing beta glucans from yeast and other sources as well as companies producing
other food ingredients and nutritional supplements for human use. Many end consumers may consider such products to be a replacement
for the products we manufacture and distribute. Many of our competitors have greater marketing, research and capital resources
than us, and may be able to offer their products at lower costs because of their greater purchasing power or lower cost of raw
materials and manufacturing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate continuing to expand our sales on a meaningful basis as part of our new marketing strategy focusing on our nutraceutical
and cosmetic product lines. We anticipate competing in these markets on the basis of quality, our proprietary manufacturing processes,
research data and effective marketing campaigns promoting the benefits of our natural immune support products. There are no assurances
that our products will be able to compete in these markets, however, or that our marketing strategy will be successful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Intellectual
Property </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely primarily on proprietary trade secret know how and protect our intellectual property and maintain our competitive position
in the marketplace. We maintain trademarks registered in the U.S. for our business name and related to our product brands. In
addition, we have registered and maintain internet domain names related to our businesses, including &ldquo;immudyne.com.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Governmental
and Environmental Regulation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business and the manufacturing, distribution and sale of our beta glucan products are regulated in the U.S. primarily by the FDA
and the FTC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA enforces the FDCA and Dietary Supplement Health and Education Act (&ldquo;DSHEA&rdquo;) as they pertain to foods, food ingredients,
cosmetics and dietary supplement production and marketing. Dietary supplements and nutraceuticals are regulated as a category
of food, not as drugs. The FDA classifies &ldquo;Yeast extract (Bakers)&rdquo; as generally recognized as safe (GRAS), which substances
by definition are not food additives. Most GRAS substances have no quantitative restrictions as to use, although their use must
conform to current GMPs. The FDA promulgates GMP guidelines to ensure that dietary supplements are produced in a quality manner,
do not contain contaminants or impurities and are accurately labeled. GMPs include requirements for establishing quality control
procedures, designing and constructing manufacturing plants, testing ingredients and finished products and record keeping and
handling of consumer product complaints. The FDA has broad authority to enforce the provisions of federal law applicable to dietary
supplements and cosmetics, including the power to monitor claims made in product labeling, to seize adulterated or misbranded
products or unapproved new drugs, to request product recall, to enjoin further manufacture or sale of a product, to issue warning
letters and to institute criminal proceedings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advertising
and product claims regarding the efficacy of products are also regulated by the FTC. The FTC regulates the advertising of dietary
supplements and other health-related products to ensure that any advertising is truthful and not misleading, and that an advertiser
maintains adequate substantiation for all product claims. FTC enforcement actions may result in consent decrees, cease and desist
orders, judicial injunctions and the payment of fines with respect to advertising claims that are found to be unsubstantiated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yeast
beta glucans are classified as GRAS by the FDA and our oral and topical-use product lines containing our yeast beta glucan are
marketed as dietary supplements and cosmetics, respectively. Under current U.S. regulations, our products must comply with certain
labeling requirements enforced by the FDA and FTC, but otherwise generally are not required to receive regulatory approval prior
to introduction into the U.S. market. We believe we are in compliance with all material government regulations applicable to our
products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the EU markets, the European Food Safety Authority (&ldquo;EFSA&rdquo;), an advisory panel to the European Commission, performs
all scientific assessments of health claims on food and supplement labels. The European Commission will consider the opinions
of EFSA in determining whether to include a health claim on a list of permissible claims. Once published, only health claims for
ingredients and products included on the list may be used in promotional materials for products marketed and sold in the European
Union. The marketability of our products may be limited as we look to expand our sales in the EU if the health claims of our products
are not included on the list.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the foregoing, our operations are subject to federal, foreign, state and local government laws and regulations, including
those relating to zoning, workplace safety and accommodations for the disabled, and our relationship with our employees is subject
to regulations, including minimum wage requirements, anti-discrimination laws, overtime, working conditions and citizenship requirements.
We currently do not incur any material costs in connection with our compliance with applicable environmental laws as our manufacturing
processes generate minimal discharge. Furthermore, the cost of maintaining compliance with applicable environmental laws has not,
and we believe, in the future, will not, have a material adverse effect on our business, results of operations and financial condition.
We believe we are in substantial compliance with all material governmental regulations applicable to our operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Employees</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2016, we had 11  employees, as well as numerous part-time employees and additional full-time consultants
worldwide. All employees and our officers and directors are eligible to participate in our group health and dental insurance
plans.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Website
Access Disclosure </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
internet website address is <I>http://www.immudyne.com</I>. We make available free of charge through our website our annual report
on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and all amendments to those, as soon as reasonably
practicable after such material is electronically filed with or furnished to the Securities and Exchange Commission (the &ldquo;SEC&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><A NAME="a_003"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
1A. Risk Factors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Our
business and an investment in our securities are subject to a variety of risks. The following risk factors describe the most significant
events, facts or circumstances that could have a material adverse effect upon our business, financial condition, results of operations,
ability to implement our business plan, and the market price for our securities. Many of these events are outside of our control.
If any of these risks actually occurs, our business, financial condition or results of operation may be materially adversely affected.
In such case, the trading price of our common stock could decline and investors in our common stock could lose all or part of
their investment.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Business</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
report of our independent registered public accounting firm contains explanatory language that substantial doubt exists about
our ability to continue as a going concern.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
independent auditor&rsquo;s report on our financial statements contains explanatory language that substantial doubt exists about
our ability to continue as a going concern as at December 31, 2016, we had a negative net working capital position. If we are
unable to fund operations through our operating business, and are unable to obtain sufficient financing in the near term as required
or achieve profitability, then we would, in all likelihood, experience severe liquidity problems and may have to curtail our operations.
If we curtail our operations, we may be placed into bankruptcy or undergo liquidation, the result of which will adversely affect
the value of our common shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have generated losses and not yet achieved positive cash flows, which may adversely affect our liquidity and ability to continue
as a going concern.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot assure you that we will be able to achieve revenue growth, profitability or positive cash flow, on either a quarterly or
annual basis, or that profitability, if achieved, will be sustained. Our ability to meet our long-term business objectives likely
will be dependent upon establishing increased cash flow from operations or securing other sources of financing. We have implemented
a new sales and marketing strategy to focus on higher-margin products that carry what we believe to be greater opportunities for
growth in the U.S. and international markets. In addition, management has instituted cost-cutting measures; including terminating
certain employees that were not contributing to the business and ceasing our operations in the low-margin feed additive product
line, which we believe should result in improved efficiencies of our operations going forward. If our losses continue, however,
our liquidity may be severely impaired, our stock price may fall and our shareholders may lose all or a significant portion of
their investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may not be able to implement our growth and marketing strategy successfully or on a timely basis or at all.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future success depends, in large part, on our ability to implement our growth strategy of expanding distribution and sales of
our beta glucan oral and topical application products, attracting new consumers to our brand and introducing new product lines
and product extensions. Our ability to implement this growth strategy depends, among other things, on our ability to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">enter
    into distribution and other strategic arrangements with other potential distributors of our all-natural raw material products;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">increase
    our brand recognition;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">expand
    and maintain brand loyalty; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">research
    new applications for existing products and develop new product lines and extensions.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
sales and operating results will be adversely affected if we fail to implement our growth strategy or if we invest resources in
a growth strategy that ultimately proves unsuccessful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we fail to develop and maintain our brand, our business could suffer.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that developing and maintaining our brand is critical to our success. The importance of our brand recognition may become
greater as competitors offer more products similar to ours. Our brand-building activities involve increasing awareness of our
brand, creating and maintaining brand loyalty and increasing the availability of our products. If our brand-building activities
are unsuccessful, we may never recover the expenses incurred in connection with these efforts, and we may be unable to implement
our business strategy and increase our future sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are subject to government regulation of the processing, formulation, packaging, labeling and advertising of our consumer products,
and any failure to comply with such regulations could require us to repackage, recall or undergo regulatory approval of our products,
which would have a material adverse effect on our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the FDCA and DSHEA companies that manufacture and distribute foods, food ingredients, cosmetics and dietary supplements in the
U.S., such as our yeast beta glucan products, are limited in the claims that they are permitted to make about nutritional support
on the product label without the approval of the FDA. Any failure by us to adhere to the labeling requirements could lead to the
FDA requiring that our products be repackaged and relabeled, which would have a material adverse effect on our business. In addition,
advertising and product claims regarding the efficacy of products are also regulated by the FTC. Companies are responsible for
the accuracy and truthfulness of, and must have substantiation for, any such statements. These claims must be truthful and not
misleading. Statements must not claim to diagnose, mitigate, treat, cure or prevent a specific disease or class of disease. We
are able to market our oral and topical application products in reliance on the GRAS status of our active ingredient, yeast beta
glucan. No governmental agency or other third party has made a determination as to whether or not our products have achieved GRAS
status. If the FDA, another regulatory authority or other third party denied our GRAS status for our yeast beta glucan products,
we could face significant penalties or be required to undergo the regulatory approval process in order to market our products.
In such event, our business, financial condition and results of operations would be adversely affected as we cannot assure you
that in such a situation our yeast beta glucan products would be approved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA&rsquo;s current GMPs describe policies and procedures designed to ensure that dietary supplements are produced in a quality
manner, do not contain contaminants or impurities, and are accurately labeled and cover the manufacturing, packaging, labeling
and storing of supplements, with requirements for quality control, design and construction of manufacturing plants, testing of
ingredients and final products, record keeping, and complaints processes. Those who manufacture, package or store dietary supplements
must comply with current GMPs. If we or our suppliers fail to comply with current GMP procedures, the FDA may take enforcement
action against us or our suppliers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
processing, formulation, packaging, labeling and advertising of our yeast beta glucan products in the U.S. are subject to regulation
by the FDA, FTC and other federal agencies, and our activities are also subject to regulation by various agencies of the states
and localities in which our yeast beta glucan products are sold. Any changes in the current regulatory environment could impose
requirements that would limit our ability to market our yeast beta glucan products and make bringing new products to market more
expensive. In addition, the adoption of new regulations or changes in the interpretation of existing regulations may result in
significant compliance costs or discontinuation of product sales and may adversely affect our business, financial condition and
results of operations. While our yeast beta glucan products currently are categorized as foods, it is possible that the FDA or
a state regulatory agency could classify these products as a cosmetic or a drug. If our products are classified as cosmetics rather
than a food, we would be limited to making claims that our products cleanse and beautify, rather than making structure or function
claims. If our yeast beta glucan products are classified as drugs, we would not be able to market our products without going through
the drug approval process. Either of these events would limit our ability to market our products effectively and cost-efficiently,
and would adversely affect our financial condition and results of operations. If the FDA or a state regulatory agency viewed our
products as cosmetics or drugs, they could claim that the products are misbranded and require that we repackage and relabel the
products and impose civil and criminal penalties on us. Either or both of these situations could adversely affect our business
and operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the European Union, or the EU, markets, the European Food Safety Authority, or EFSA, an advisory panel to the European Commission,
performs all scientific assessments of health claims on food and supplement labels. The European Commission will consider the
opinions of EFSA in determining whether to include a health claim on the list of permissible claims. Once published, only health
claims for ingredients and products included on the list may be used in promotional materials for products marketed and sold in
the European Union. The marketability of our products may be limited as we look to expand our sales in the EU if the health claims
of our products are not included on the list.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have subjected, and will continue to subject, our products to testing and analysis. If the findings of these studies are challenged
or found insufficient to support our health claims, we may need to perform additional testing and analysis before we are able
to successfully market such products.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
our yeast beta glucan products are supplements, as opposed to drugs, we have subjected, and will continue to subject, our products
to testing and analysis to ensure that we are able to continue to deliver a superior product so that we may successfully market
such products, though no such trials are currently required for marketing approval by the FDA or any comparable regulatory body.
Testing and analysis for new product uses can require a significant amount of resources and there is no assurance that the results
will be favorable to the claims we make for our products, or that they will be sufficient to support our claims. If the findings
of our testing and analysis are challenged or found to be insufficient to support our claims, additional testing and analysis
may be required before we are able to successfully market our products. No such testing and analysis has been, nor will it be
when conducted, subject to the approval by the FDA or any comparable regulatory body.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we undertake product recalls or incur liability claims with respect to our yeast beta glucan products, such recalls or claims
could increase our costs and adversely affect our reputation, business and results of operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
yeast beta glucan products are designed for human consumption and we face product recalls or liability claims if the use of our
products is alleged to have resulted in injury or death. To date, we have not (i) conducted any product recalls, (ii) received
any product liability claims from third parties, or (iii) received any reports from an end consumer of any adverse effect resulting
from our products. Yeast beta glucan is classified as a food ingredient and is not subject to pre-market regulatory approval in
the U.S. However, our yeast beta glucan products contain ingredients that do not have long histories of human consumption. Previously
unknown adverse reactions resulting from consumption of these ingredients could occur. We may have to undertake various product
recalls or be subject to liability claims, including, among others, that our yeast beta glucan products include inadequate instructions
for use or inadequate warnings concerning possible side effects and interactions with other substances. A product recall or liability
claim against us could result in increased costs and could adversely affect our reputation with our customers, which, in turn,
could have an adverse effect on our business, financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently do not maintain product liability insurance coverage. Product liability insurance is expensive, is subject to deductibles
and coverage limitations, and may not be available to us in the future. In addition, we cannot be sure that we will be able to
obtain or maintain insurance coverage at acceptable costs or in a sufficient amount, that our insurer will not disclaim coverage
as to a future claim or that a product liability claim would not otherwise adversely affect our business, financial condition
and results of operations. The cost of any product liability litigation or other proceeding, even if resolved in our favor, could
be substantial. Uncertainties resulting from the initiation and continuation of product liability litigation or other proceedings
could have an adverse effect on our ability to compete in the marketplace. Product liability litigation and other related proceedings
may also require significant management attention.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Our Nutraceutical and Cosmetic Additive segment derives a
substantial part of its sales from two major customers. If we lose either of these customers, or they reduce the amount of business
they do with us, or if they fail to meet their obligations to us, our sales, financial condition and results of operations would
be adversely affected.</I></B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
largest customer, Michel Mercier Products, Inc. (d/b/a M.M.P, Inc.) (&ldquo;MMP&rdquo;), accounted for 15% of our sales in 2016
and 73% of our sales in 2015. Our relationship with MMP is governed by a written contract, which is subject to a confidentiality
agreement. The initial term of our contract with MMP expired on December 19, 2016. Pursuant to its terms, the written contract
will be automatically renewed for continuous one-year periods unless either party gives notice of its intent to terminate at least
90 days prior to the expiration of any renewal term. Additionally, our second largest customer accounted for 2% of our sales in
2016 and 12% of our sales in 2015. If we lose either of these customers or they reduce the amount of business they do with us,
our sales and profitability would be adversely affected. In addition, we are subject to credit risk due to concentration of our
trade accounts receivables, and the inability of either of these customers to meet their obligations to us would adversely affect
our financial results. At December 31, 2016, accounts receivable from MMP amounted to 11% and at December 31, 2015 accounts receivable
from MMP amounted to 43% of total accounts receivable. We are making progress in decreasing our reliance on these two customers,
as evidenced by our increased sales in our finished cosmetic products business segment. However, if we lose either of these customers
or they reduces the amount of business they does with us, or if they fail to meet their obligations to us, our sales, financial
condition and results of operations would be adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
yeast beta glucan products face various forms of competition from other products in the marketplace, which could adversely affect
our market share and result in a decrease in our future sales and earnings.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
pharmaceutical and biotechnology industries are characterized by intense competition, rapid product development and technological
change. Most of the competition that our yeast beta glucan products face comes from companies that are larger and more well established,
with greater financial, marketing, sales and technological resources than we have. Our products compete with a range of consumer
and nutraceutical products. Our commercial success will depend on our ability to compete effectively in marketing and product
development areas including, but not limited to, sales and branding, product safety, efficacy, ease-of-use, customer compliance,
price, marketing and distribution. There can be no assurance that competitors will not succeed in developing and marketing products
that are more desirable or effective than our products or that would render our products obsolete and non-competitive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may, in the future, be subject to risks of doing business internationally as we attempt to expand our sales through international
consulting and distributor relationships.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate entering into international consulting and distributor agreements for our yeast beta glucan products. As a result,
we expect to increase our revenues from international sales. A number of factors can prevent international sales, or substantially
increase the cost of international sales, and we may encounter certain risks of doing business internationally including the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">increased
    government regulation of the processing, formulation, packaging, labeling and advertising of our consumer products for international
    markets;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced
    protection and enforcement for our intellectual property rights;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unexpected
    changes in, or impositions of, legislative or regulatory requirements that may limit our ability to sell our products and
    repatriate funds to the U.S.;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">political
    and economic instability;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">fluctuations
    in foreign currency exchange rates;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties
    in developing and maintaining distributor relationships in foreign countries;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties
    in negotiating acceptable contractual terms and enforcing contractual obligations;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">exposure
    to liabilities under the U.S. Foreign Corrupt Practices Act;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">potential
    trade restrictions and exchange controls;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">creditworthiness
    of foreign distributors, customer uncertainty and difficulty in foreign accounts receivable collection; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    burden of complying with foreign laws.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
we attempt to expand our sales internationally, our exposure to these risks could result in our inability to attain the anticipated
benefits of expanding internationally and our business could be adversely impacted. Our success will depend, in large part, on
our ability to anticipate and effectively manage these and other risks associated with our international operations. However,
any of these factors could adversely affect our international operations and, consequently, our operating results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>A
material disruption at our manufacturing facilities in Kentucky could result in material delays, quality control issues, increased
costs and loss of business opportunities, which may negatively impact our sales and financial results.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on our manufacturing facilities in Kentucky to operate our business and produce our yeast beta glucan products. Our manufacturing
facilities, or any of our machines within our otherwise operational facilities, could cease operations or no longer comply with
current GMP guidelines unexpectedly due to a number of events, including prolonged power or equipment failures, disruptions in
the transportation infrastructure, fires, floods or other catastrophes. If our manufacturing facilities no longer comply with
GMP, our products may be deemed adulterated under U.S. regulations and subject to recall. Furthermore, a significant majority
of our raw material product inventory is located in our Kentucky facility. If any material amount of our inventory were damaged
as a result of a material disruption, we would be unable to meet our contractual obligations. While we seek to operate our manufacturing
facilities in compliance with applicable rules and regulations and take measures to minimize the risks of disruption at our facilities,
any such material disruption at our facilities could prevent us from meeting customer demand, reduce our sales and negatively
impact our financial results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we lose our President, or are unable to attract and retain additional qualified personnel, the quality of our products may decline
and our business may be adversely affected.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely heavily on the expertise, experience and continued services of our President, Mark McLaughlin. Loss of his services could
adversely affect our ability to achieve our business objectives, if we are unable to find a suitable replacement. Mr. McLaughlin
is an integral factor in establishing relationships and the continued development of our business depends upon his continued employment.
If he were to resign or retire, we would have to find a suitable replacement who shared his expertise and relationships. Any delay
in finding a suitable replacement would adversely affect the pace at which we are able to successfully grow our business and could
harm our existing business, resulting in a decrease in sales and revenue. We have entered into an employment agreement with Mr.
McLaughlin that includes provisions for non-competition and confidentiality that expires in October 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe our future success will depend upon our ability to retain key employees and our ability to attract and retain other skilled
personnel and consultants. While we have been able to find a sufficient number of skilled personnel consistent with our growth
to date, we cannot guarantee that any employee will remain employed by us for any period of time or that we will be able to attract,
train or retain qualified personnel in the future consistent with our growth. Such loss of personnel could have a material adverse
effect on our business and company. Furthermore, we may need to employ additional personnel to expand our business. Qualified
employees and consultants in the dietary supplement industry are in great demand and may be unavailable in the time frame required
to satisfy our customers&rsquo; requirements. There is no assurance we will be able to attract and retain sufficient numbers of
highly skilled employees in the future. The loss of personnel or our inability to hire or retain sufficient personnel at competitive
rates could impair the growth of our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Current
and future economic and market conditions could adversely affect demand for our products.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Factors such as uncertainties in consumer spending, a sustained
regional and global economic downturn or slow recovery may reduce the demand for our yeast beta glucan products. Furthermore, challenging
economic conditions also may impair the ability of our customers to pay for our commercial, direct-to-consumer products. Consumer
spending for our yeast beta glucan products generally is considered a discretionary purchase because they are non-prescription
nutraceutical supplements and nutricosmetics, and we may experience a more negative impact on our business due to these conditions
than other companies that do not depend on discretionary spending. If demand for our products declines or our customers are otherwise
unable to pay for our products, we may be required to offer extensive discounts or spend more on marketing than budgeted and our
revenues, expense levels and profitability will be adversely affected.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
need additional capital to continue to conduct our business, execute our business plan and fund operations. We may not be able
to obtain such capital on acceptable terms or at all.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the development and expansion of our business, we incur significant capital and operational expenses. We believe
that we can increase our sales and net income by implementing a growth strategy that focuses on (i) diversifying revenues to include
greater direct-to-consumer and healthcare professional sales and (ii) expanding our distribution to Europe and Asia. To implement
our growth strategy, we anticipate (i) increasing our marketing to healthcare professionals and end consumers, (ii) entering into
distribution agreements with manufacturers and formulators in Europe and Asia and (iii) developing our branded product lines.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
existing capital resources and cash flows from operations are not adequate to satisfy the liquidity requirements of our business
for the next 12 months. We plan on our operating business in conjunction with proceeds from debt and equity financings completed
in 2016 and early 2017 to be able to fund operations through 2017. However, if available funds are not sufficient to meet our
current operating expenses or plans for expansion, we plan to pursue alternative financing arrangements, including bank loans,
advances from our directors and officers or funds raised through offerings of our equity or debt. Our ability to obtain additional
capital on acceptable terms or at all is subject to a variety of uncertainties, including: investors&rsquo; perceptions of, and
demand for, companies in our industry; conditions of the U.S. and other capital markets in which we may seek to raise funds; our
future results of operations, financial condition and cash flows; and economic, political and other conditions in the U.S.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no assurance we will be successful in locating a suitable financing transaction in a timely fashion or at all. In addition,
there is no assurance we will obtain the capital we require by any other means. Future financings through equity investments are
likely to be dilutive to our existing shareholders. Also, the rights and preferences of securities we may issue in future capital
transactions may be more favorable for our new investors. Newly-issued securities may include preferences or superior voting rights,
be combined with the issuance of warrants or other derivative securities, or be the issuances of incentive awards under equity
employee incentive plans, which may have additional dilutive effects. Furthermore, we may incur substantial costs in pursuing
future capital and financing, including investment banking fees, legal fees, accounting fees, printing and distribution expenses
and other costs. We may also be required to recognize non-cash expenses in connection with certain securities we may issue, such
as convertible notes and warrants, which will adversely impact our financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we cannot raise additional funds on favorable terms or at all, we may not be able to carry out all or parts of our strategy to
maintain our growth and competitiveness or to continue operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may not be able to protect our proprietary rights adequately, which could adversely affect our competitive position and reduce
the value of our products and brands, and litigation to protect our intellectual property rights may be costly.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
attempt to strengthen and differentiate our products by developing new and innovative yeast beta glucan products and manufacturing
processes. As a result, our patents, trademarks and other intellectual property rights are important assets to our business. Our
success will depend in part on our ability to obtain and protect our products, methods, processes and other technologies, to preserve
our trade secrets, and to operate without infringing on the proprietary rights of third parties in the U.S. and other international
markets. Despite our efforts, any of the following may reduce the value of our owned and used intellectual property:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">issued
    patents and trademarks that we own or have the right to use may not provide us with any competitive advantages;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
        efforts to protect our proprietary rights may not be effective in preventing misappropriation of our intellectual property;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    efforts may not prevent the development and design by others of products or technologies similar to or competitive with, or
    superior to those we use or develop;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">another
                                         party may obtain a blocking patent and we would need to either obtain a license or design
                                         around the patent in order to continue to offer the contested feature in our products
                                         or services; or</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may not have the financial resources to aggressively protect our intellectual property.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Policing
the unauthorized use of our proprietary technology can be difficult and expensive. Litigation might be necessary to protect our
intellectual property rights, which may be costly and may divert our management&rsquo;s attention away from our core business.
Furthermore, there is no guarantee that litigation would result in an outcome favorable to us. To date, we have no knowledge of
any infringement of our intellectual property by third parties. If we are unable to protect our proprietary rights adequately,
it would have a negative impact on our operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may be subject to claims that we have infringed the proprietary rights of others, which could require us to obtain a license or
otherwise change our manufacturing processes or product offerings.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we do not believe any of our products or manufacturing processes infringe upon the proprietary rights of others, there is no assurance
that infringement or invalidity claims, or claims for indemnification resulting from infringement claims, will not be asserted
or prosecuted against us or that any such assertions or prosecutions will not have a material adverse effect on our business.
To date, we are not aware of any material infringement nor have we been put on notice by third parties of any material infringement
of proprietary rights of others. Regardless of whether any such claims are valid or can be asserted successfully, defending against
such claims could cause us to incur significant costs and could divert resources away from our other activities. In addition,
assertion of infringement claims could result in injunctions that prevent us from distributing our products. If any claims or
actions are asserted against us, we may seek to obtain a license to the intellectual property rights that are in dispute. Such
a license may not be available on reasonable terms, or at all, which could force us to change our manufacturing processes or product
offerings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
incur significant costs as a result of our operating as a public reporting company and our management&rsquo;s requirement to devote
substantial time to new compliance initiatives, which may adversely affect our business and results of operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we are a public company quoted on the OTC Markets-OTCQB, our compliance costs prior to the effectiveness of our registration statement
were not substantial in light of our limited operations and limited public reporting obligations. As a company subject to public
reporting requirements under the Securities Exchange Act of 1934, as amended, or the Exchange Act, since May 2012 we have incurred
increased legal, accounting and other expenses. The costs of preparing and filing annual, quarterly and current reports and other
information with the SEC and furnishing audited reports to shareholders is time-consuming and costly, and may adversely affect
our business and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
will also be time-consuming, difficult and costly for us to develop and implement the internal controls and reporting procedures
required by the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act. Our management has limited or no experience operating a
company subject to the rules and reporting practices required by the federal securities laws and applicable to a publicly traded
company. Our management currently relies in many instances on the professional experience and advice of third parties including
our attorneys and accountants. Our current management and staff will need to be trained and we will need to retain additional
financial reporting, internal control and other personnel in order to develop and implement appropriate accounting, internal controls
and reporting procedures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Due
to our financial condition, we have not been able to implement and maintain an effective system of internal controls, and we may
not be able to report our financial results accurately. Any inability to report and file our financial results accurately and
timely could harm our business and adversely affect the trading price of our common stock.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are required to establish and maintain internal controls over financial reporting and disclosure controls and procedures and to
comply with other requirements of the Sarbanes-Oxley Act and the rules promulgated by the SEC. Our management will need to include
a report on our internal control over financial reporting and its assessment on whether such internal controls were effective
for the prior fiscal year with our annual reports that we file under the Exchange Act with the SEC. Under current federal securities
laws, our management has concluded that our internal control over financial reporting is not effective for the Company, our majority
owned subsidiaries and the VIEs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">However,
for as long as we remain an &ldquo;emerging growth company,&rdquo; or EGC, as defined in the Jumpstart our Business Startups Act
of 2012, or JOBS Act, we may, and we intend to, take advantage of certain exemptions from various reporting requirements that
are applicable to other public companies that are not EGCs, including not being required to comply with the auditor attestation
requirements concerning management&rsquo;s reports on effectiveness of internal controls over financial reporting otherwise required
under the Sarbanes-Oxley Act and the rules promulgated by the SEC. We may, and we intend to, take advantage of these reporting
exemptions until we are no longer an EGC. We will cease to be an EGC at the earliest of (A) the last day of the fiscal year in
which we have total annual gross revenues of $1,000,000,000 (as indexed for inflation in the manner set forth in the JOBS Act)
or more; (B) the last day of the fiscal year in which the fifth anniversary of the date of the first sale of our common stock
pursuant to an effective registration statement under the Securities Act occurs, which will be 2017; (C) the date on which we
have, during the previous 3-year period, issued more than $1,000,000,000 in non-convertible debt; or (D) the date on which we
are deemed to be a &ldquo;large accelerated filer,&rdquo; as defined in Rule 12b-2 under the Exchange Act or any successor thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we cease to be an EGC, as of each fiscal year end thereafter, our independent registered public accounting firm will be required
to evaluate and report on our internal controls over financial reporting in the event we become an accelerated filer or large
accelerated filer. To the extent we find material weaknesses or other deficiencies in our internal controls, we may determine
that we have ineffective internal controls over financial reporting as of any particular fiscal year end, and we may receive an
adverse assessment of our internal controls over financial reporting from our independent registered public accounting firm. Moreover,
any material weaknesses or other deficiencies in our internal controls may delay the conclusion of an annual audit or a review
of our quarterly financial results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management has limited or no experience operating as a public reporting company under the Exchange Act or establishing the level
of internal control over financial reporting required by the Sarbanes-Oxley Act. Our management currently relies in many instances
on the professional experience and advice of third parties including our attorneys and accountants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have material weaknesses in our internal control over financial reporting.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
identified material weaknesses in internal control over financial reporting for the years ended December 31, 2016 and 2015. Under
standards established by the Public Company Accounting Oversight Board, a deficiency in internal control over financial reporting
exists when the design or operation of a control does not allow management or personnel, in the normal course of performing their
assigned functions, to prevent or detect misstatements on a timely basis. A material weakness is a deficiency or combination of
deficiencies in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement
of our annual or interim financial statements will not be prevented or detected and corrected on a timely basis. We plan to remediate
the material weaknesses identified by us when we have sufficient funds to do so; however, we cannot assure you that there will
not be additional material weaknesses and significant deficiencies that we will identify. If we are unable to identify such issues
or if we are unable to produce accurate and timely financial statements, our stock price may be adversely affected and we may
be unable to maintain compliance with applicable securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that the material weaknesses did not have an effect on the reporting of the Company's financial results. However, we believe
that the lack of a functioning audit committee and lack of a majority of outside directors on the Company's board of directors,
results in ineffective oversight of the establishment and monitoring of required internal controls and procedures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
stock price may be volatile or may decline regardless of our operating performance, and you may lose part or all of your investment.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market price of our common stock may fluctuate widely in response to various factors, some of which are beyond our control, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">market
    conditions or trends in the dietary supplement industry or in the economy as a whole;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">actions
    by competitors;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
    or anticipated growth rates relative to our competitors;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    public&rsquo;s response to press releases or other public announcements by us or third parties, including our filings with
    the SEC;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">economic,
    legal and regulatory factors unrelated to our performance;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
        future guidance we may provide to the public, any changes in such guidance or any difference between our guidance and
        actual results;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in financial estimates or recommendations by any securities analysts who follow our common stock;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">speculation
    by the press or investment community regarding our business;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">litigation;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in key personnel; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">future
    sales of our common stock by our officers, directors and significant shareholders.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the stock markets, including the over-the-counter markets where we are quoted, have experienced extreme price and volume
fluctuations that have affected and continue to affect the market prices of equity securities of many companies. These broad market
fluctuations may materially affect our stock price, regardless of our operating results. Furthermore, the market for our common
stock historically has been limited and we cannot assure you that a larger market will ever be developed or maintained. The price
at which investors purchase shares of our common stock may not be indicative of the price that will prevail in the trading market.
Market fluctuations and volatility, as well as general economic, market and political conditions, could reduce our market price.
As a result, these factors may make it more difficult or impossible for you to sell our common stock for a positive return on
your investment. In the past, shareholders have instituted securities class action litigation following periods of market volatility.
If we were involved in securities litigation, we could incur substantial costs and our resources and the attention of management
could be diverted from our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Shares
of our common stock lack a significant trading market, which could make it more difficult for an investor to sell our common stock.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
of our common stock are not yet eligible for trading on any national securities exchange. Our common stock currently is quoted
in the over-the-counter market on the OTC Markets-OTCQB. This market tends to be highly illiquid. There is no assurance that an
active trading market in our common stock will develop, or if such a market develops, that it will be sustained. In addition,
there is a greater chance for market volatility for securities quoted in the over-the-counter markets as opposed to securities
traded on a national exchange. This volatility may be caused by a variety of factors, including the lack of readily available
quotations, the absence of consistent administrative supervision of &ldquo;bid&rdquo; and &ldquo;ask&rdquo; quotations and generally
lower trading volume. As a result, an investor may find it more difficult to dispose of, or to obtain accurate quotations as to
the market value of, our common stock, or to obtain coverage for significant news events concerning us, and our common stock could
become substantially less attractive for investment by financial institutions, as consideration in future capital raising transactions
or for other purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Future
sales of shares of our common stock, or the perception in the public markets that these sales may occur, may depress our stock
price.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market price of our common stock could decline significantly as a result of sales of a large number of shares of our common stock.
In addition, if our significant shareholders sell a large number of shares, or if we issue a large number of shares, the market
price of our stock could decline. Any issuance of additional common stock by us in the future, or warrants or options to purchase
our common stock, if exercised, would result in dilution to our existing shareholders. Such issuances could be made at a price
that reflects a discount or a premium to the then-current trading price of our common stock. Moreover, the perception in the public
market that shareholders might sell shares of our stock or that we could make a significant issuance of additional common stock
in the future could depress the market for our shares. These sales, or the perception that these sales might occur, could depress
the market price of our common stock or make it more difficult for us to sell equity securities in the future at a time and at
a price that we deem appropriate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have issued shares of common stock and warrants and options to purchase shares of our common stock in connection with our private
placement and certain employment, director and consultant agreements. In addition, we issued shares of our common stock, and options
and warrants to purchase shares of our common stock, in financing transactions and pursuant to employment agreements that are
deemed to be &ldquo;restricted securities,&rdquo; as that term is defined in Rule 144 promulgated under the Securities Act. From
time to time, certain of our shareholders may be eligible to sell all or some of their restricted shares of common stock by means
of ordinary brokerage transactions in the open market pursuant to Rule 144, subject to certain limitations. The resale pursuant
to Rule 144 of shares acquired from us in private transactions could cause our stock price to decline significantly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
could issue additional common stock, which might dilute the book value of our common stock.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors has authority, without action or vote of our shareholders, to issue all or a part of our authorized but unissued
shares. Our amended certificate of incorporation authorizes the issuance of up to 50,000,000 shares of common stock, par value
$0.01 per share. Although we have no commitments as of the date hereof to issue any securities, we may issue a substantial number
of additional shares of our common stock or debt securities to complete a business combination or to raise capital. Such stock
issuances could be made at a price that reflects a discount or a premium from the then-current trading price of our common stock.
In addition, in order to raise capital, we may need to issue securities that are convertible into or exchangeable for a significant
amount of our common stock. These issuances would dilute your percentage ownership interest, which would have the effect of reducing
your influence on matters on which our shareholders vote, and might dilute the book value of our common stock. You may incur additional
dilution if holders of stock options and warrants, whether currently outstanding or subsequently granted, exercise their options
or warrants to purchase shares of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are an EGC, and we cannot be certain if the reduced disclosure requirements applicable to EGCs will make our common stock less
attractive to investors.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an EGC, as defined in the JOBS Act, and we may take advantage of certain exemptions from various reporting requirements that
are applicable to other public companies that are not EGCs. The modified disclosure requirements available to EGCs include reduced
disclosure about our executive compensation and omission of a compensation discussion and analysis, which is also available to
us as a smaller reporting company, and an exemption from the requirement of holding a nonbinding advisory vote on executive compensation
and the requirement that shareholders approve any golden parachute payments not previously approved. In addition, we will not
be subject to certain requirements of Section 404 of the Sarbanes-Oxley Act, including the additional testing of our internal
control over financial reporting as may occur when outside auditors attest as to our internal controls over financial reporting,
which is also not required of smaller reporting companies. We could be an emerging growth company for up to five years, although
we could lose that status sooner if our revenues exceed $1 billion, if we issue more than $1 billion in non-convertible debt in
a three year period, or if the market value of our common stock exceeds $700 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors
find our common stock less attractive as a result, there may be a less active trading market for our common stock, and our stock
price may be more volatile.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
the JOBS Act permits an EGC such as us to take advantage of an extended transition period to comply with new or revised accounting
standards applicable to public companies, we are choosing to &ldquo;opt out&rdquo; of this provision, and, as a result, we will
comply with new or revised accounting standards as required when they are adopted, however do not currently believe that this
will have a material effect on the preparation of our financial statements. This decision to opt out of the extended transition
period under the JOBS Act is irrevocable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
application of the &ldquo;penny stock&rdquo; rules could adversely affect the market price of our common stock and increase your
transaction costs to sell those shares.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock may be subject to the &ldquo;penny stock&rdquo; rules adopted under Section 15(g) of the Exchange Act. The penny
stock rules apply to issuers whose common stock does not trade on a national securities exchange and trades at less than $5.00
per share, or that have a tangible net worth of less than $5,000,000 ($2,000,000 if the company has been operating for three or
more years). The penny stock rules require a broker-dealer, prior to a transaction in a penny stock not otherwise exempt from
those rules, to deliver a standardized risk disclosure document prepared by the SEC that contains the following information:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    description of the nature and level of risk in the market for penny stocks in both public offerings and secondary trading;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    description of the broker&rsquo;s or dealer&rsquo;s duties to the customer and of the rights and remedies available to the
    customer with respect to violation to such duties or other requirements of securities laws;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    brief, clear, narrative description of a dealer market, including &ldquo;bid&rdquo; and &ldquo;ask&rdquo; prices for penny
    stocks and the significance of the spread between the &ldquo;bid&rdquo; and &ldquo;ask&rdquo; prices;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    toll-free telephone number for inquiries on disciplinary actions;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">definitions
    of any significant terms in the disclosure document or in the conduct of trading in penny stocks; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">such
    other information and is in such form (including language, type, size and format), as the SEC shall require by rule or regulation.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to effecting any transaction in a penny stock, the broker-dealer also must provide the customer with the following information:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">bid
    and offer quotations for the penny stock;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">compensation
of the broker-dealer and our salesperson in the transaction;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">number
    of shares to which such bid and ask prices apply, or other comparable information relating to the depth and liquidity of the
    market for such stock; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">monthly
    account statements showing the market value of each penny stock held in the customer&rsquo;s account.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
penny stock rules further require that, prior to a transaction in a penny stock not otherwise exempt from those rules, the broker-dealer
must make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser&rsquo;s
written acknowledgment of the receipt of a risk disclosure statement, a written agreement to transactions involving penny stocks
and a signed and dated copy of a written suitability statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
to the requirements of the penny stock rules, many broker-dealers have decided not to trade penny stocks. As a result, the number
of broker-dealers willing to act as market makers in such securities is limited. If we remain subject to the penny stock rules
for any significant period, it could have an adverse effect on the market, if any, for our securities. Moreover, if our securities
are subject to the penny stock rules, investors will find it more difficult to dispose of our securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
principal shareholder has the ability to exert significant control in matters requiring a shareholder vote and could delay, deter
or prevent a change of control in our company.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of May 15, 2017, Mark McLaughlin, our President and largest shareholder, beneficially owns 24.5% of our outstanding shares of
common stock. In addition, Mr. McLaughlin has from time to time made advances us to support our ongoing capital needs. Mr. McLaughlin
exerts significant influence over us, giving him the ability, among other things, to exercise significant control over the election
of all or a majority of the Board of Directors and to approve significant corporate transactions. Such share ownership and control
may also have the effect of delaying or preventing a future change in control, impeding a merger, consolidation, takeover or other
business combination, or discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control
of our company. This, in turn, could have a negative effect on the market price of our common stock. It could also prevent our
shareholders from realizing a premium over the market price for their shares of common stock. Without the consent of Mr. McLaughlin,
we could be prevented from entering into potentially beneficial transactions if such transactions conflict with our principal
shareholder&rsquo;s interests.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
do not anticipate paying dividends in the foreseeable future, and, accordingly, any return on investment may be limited to the
value of our common stock.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not anticipate paying cash dividends on our common stock in the foreseeable future. The payment of dividends on our common
stock will depend on earnings, financial condition and other business and economic factors affecting it at such time as the Board
of Directors may consider relevant. We intend to follow a policy of retaining all of our earnings to finance the development and
execution of our strategy and the expansion of our business. If we do not pay dividends, our common stock may be less valuable
because a return on your investment will occur only if our stock price appreciates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
common stock is not registered under the Exchange Act and, as a result, we will not be subject to the federal proxy rules and
our directors, executive officers and 10% beneficial holders will not be subject to Section 16 of the Exchange Act. In addition,
our reporting obligations under Section 15(d) of the Exchange Act may be suspended automatically if we have fewer than 300 holders
of record on the first day of our fiscal year.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
of our common stock are not currently registered under the Exchange Act though we may register our common stock under the Exchange
Act in the foreseeable future. We will have to register our common stock under the Exchange Act if we have, after the last day
of our fiscal year, holders of record of more than either (1) 2,000 or more persons or (2) 500 or more persons who are not accredited
investors, in accordance with Section 12(g) of the Exchange Act, as amended by the JOBS Act. As a result, currently we are only
subject solely to the reporting obligations of Section 15(d) of the Exchange Act so long as we do not subsequently register under
Section 12(g) of the Exchange Act by filing a Form 8-A or another Exchange Act registration statement. As long as our common stock
is not registered under the Exchange Act, we will be required to file only annual, quarterly and current reports pursuant to Section
15(d) of the Exchange Act, and we will not be subject to Section 14 of the Exchange Act, which, among other things, prohibits
companies that have securities registered under the Exchange Act from soliciting proxies or consents from shareholders without
furnishing to shareholders and filing with the SEC a proxy statement and form of proxy complying with the proxy rules. In addition,
so long as our common shares are not registered under the Exchange Act, our directors, executive officers and beneficial holders
of 10% or more of our outstanding common stock will not be subject to Section 16 of the Exchange Act. Section 16(a) of the Exchange
Act requires directors, executive officers and persons who beneficially own more than 10% of a registered class of equity securities
to file with the SEC initial statements of beneficial ownership, reports of changes in ownership and annual reports concerning
their ownership of common stock and other equity securities on Forms 3, 4 and 5, respectively. Such information about our directors,
executive officers and 10% beneficial holders will only be available through this and any subsequent registration statement or
periodic reports we file pursuant to Section 15(d) of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
so long as our common stock is not registered under the Exchange Act, our obligation to file reports under Section 15(d) of the
Exchange Act will be automatically suspended if, on the first day of any fiscal year, other than a fiscal year in which a registration
statement under the Securities Act has gone effective, we have fewer than 300 holders of record. This suspension is automatic
and does not require any filing with the SEC. In such an event, we may cease providing periodic reports and current or periodic
information, including operational and financial information. As of May 12, 2017, we had approximately 324 holders of record.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Certain
provisions of our corporate governance documents and Delaware law could discourage, delay or prevent a merger or acquisition at
a premium price.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
amended certificate of incorporation and bylaws contain provisions that may make the acquisition of our company more difficult
without the approval of our Board of Directors. These include provisions that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide
    that our Board of Directors is expressly authorized to adopt, amend or repeal our bylaws;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide
    our Board of Directors with the sole power to set the size of our Board of Directors and fill vacancies; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide
    that special meetings of shareholders may be called only by our Board of Directors, Chairman of the Board of Directors, upon
    written notice of demand by our President or upon written notice of demand by the holders of at least 25% of the shares of
    our common stock outstanding and entitled to vote.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
and other provisions of our amended certificate of incorporation and bylaws could delay, defer or prevent us from experiencing
a change of control or changes in our Board of Directors and management and may adversely affect our shareholders&rsquo; voting
and other rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we are subject to Section 203 of the Delaware General Corporation Law, which generally prohibits a Delaware corporation
from engaging in any of a broad range of business combinations with a shareholder owning 15% or more of such corporation&rsquo;s
outstanding voting stock for a period of three years following the date on which such shareholder became an &ldquo;interested&rdquo;
shareholder. In order for us to consummate a business combination with an &ldquo;interested&rdquo; shareholder within three years
of the date on which the shareholder became &ldquo;interested,&rdquo; either (1) the business combination or the transaction that
resulted in the shareholder becoming &ldquo;interested&rdquo; must be approved by our board of directors prior to the date the
shareholder became &ldquo;interested,&rdquo; (2) the &ldquo;interested&rdquo; shareholder must own at least 85% of our outstanding
voting stock at the time the transaction commences (excluding voting stock owned by directors who are also officers and certain
employee stock plans) or (3) the business combination must be approved by our board of directors and authorized by at least two-thirds
of our shareholders (excluding the &ldquo;interested&rdquo; shareholder). This provision could have the effect of delaying or
preventing a change of control, whether or not it is desired by or beneficial to our shareholders. Any delay or prevention of
a change of control transaction or changes in our board of directors and management could deter potential acquirers or prevent
the completion of a transaction in which our shareholders could receive a substantial premium over the then-current market price
for their shares of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><A NAME="a_004"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
1B. Unresolved Staff Comments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><A NAME="a_005"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
2. Properties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
principal executive offices are in office spaces located in Mount Kisco, New York. We lease a manufacturing facility with warehouse
space consisting of approximately 15,000 square feet in Florence, Kentucky, in the vicinity of the Cincinnati, Ohio, airport on
a month-to-month basis. In addition, Immudyne PR operates in a subleased office space in Puerto Rico. We believe that our existing
office and manufacturing facilities are adequate for current and presently foreseeable operations. In general, our properties
are well maintained and are being utilized for their intended purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><A NAME="a_006"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
3. Legal Proceedings</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may become involved in various lawsuits and legal proceedings arising in the ordinary course of business. Litigation is subject
to inherent uncertainties and an adverse result in these or other matters may arise from time to time that may have an adverse
effect on our business, financial conditions or operating results. We are currently not aware of any such legal proceedings or
claims that will have, individually or in the aggregate, a material adverse effect on our business, financial condition or operating
results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><A NAME="a_007"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
4. Mine Safety Disclosures</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_008"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PART
II</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><A NAME="a_009"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
5. Market for Registrant&rsquo;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Market
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is qualified for quotation on the OTC Markets-OTCQB under the symbol &ldquo;IMMD&rdquo; and has been quoted on the
OTCQB since February 8, 2013. Previously, our common stock was quoted on the OTC Markets-OTC Pink Current, also under the symbol
&ldquo;IMMD.&rdquo; The following table sets forth the range of the high and low bid prices per share of our common stock for
each quarter as reported in the over-the-counter markets. These quotations represent interdealer prices, without retail markup,
markdown or commission, and may not represent actual transactions. There currently is no liquid trading market for our common
stock. There can be no assurance that a significant active trading market in our common stock will develop, or if such a market
develops, that it will be sustained.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2016</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2015</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">High</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Low</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">High</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Low</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left">First Quarter (through March 31)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">0.33</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">0.10</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">0.23</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">0.10</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Second Quarter (through June 30)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.40</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.17</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.16</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.03</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Third Quarter (through September 30)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.34</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.20</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.14</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.05</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Fourth Quarter (through December 31)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.30</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.21</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.17</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.06</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Holders
of Record</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 12, 2017, there were approximately 324 shareholders of record based on information provided by our transfer agent. Many of
our shares of common stock are held in street or nominee name by brokers and other institutions on behalf of shareholders and
we are unable to estimate the total number of shareholders represented by these record holders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dividend
Policy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not paid and do not expect to declare or pay any cash dividends on our common stock in the foreseeable future. We currently
expect to retain all future earnings for use in the operation and expansion of our business. The declaration and payment of any
cash dividends in the future will be determined by our Board of Directors, in its discretion, and will depend on a number of factors,
including our earnings, capital requirements, overall financial condition and contractual restrictions, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><A NAME="a_010"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
6. Selected Financial Data</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><A NAME="a_011"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
7. Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
manufacture, distribute and sell natural immune support products; namely proprietary yeast beta glucans which are natural extracts
that have been shown through testing and analysis and scientific research to support the immune system. Yeast beta glucans are
classified as generally recognized as safe (&ldquo;GRAS&rdquo;) by the Food and Drug Administration (&ldquo;FDA&rdquo;). We are
and have been a science driven company for more than 25 years. Our products are used in oral and topical applications. Historically,
we have sold our proprietary additives, for both oral and topical use, primarily via business-to-business to large dietary supplement
and cosmetic companies. During fiscal year 2015, we have seen increased interest in our proprietary GRAS topical delivery system,
which we believe may have additional beneficial and marketable uses (both topically and orally) and on which are conducting further
testing. In addition, during the fourth quarter of 2015, we established a joint venture, that does business under the name Inate
Scientific LLC (&ldquo;Inate&rdquo;), to launch a complete skin care regimen that contains our proprietary ingredients and which
contributed to our revenues in the year of 2016. We believe, based on testing and analysis conducted by third parties on our behalf,
that the beta glucans derived from yeast we manufacture are superior to any other beta glucans available on the market. The Company
entered into a limited liability company operating agreement with its joint venture partners with respect to Inate under the legal
name Immudyne PR LLC (&ldquo;Immudyne PR&rdquo;). On April 1, 2016, the original operating agreement was amended and restated
and we increased our ownership and voting interest in Immudyne PR to 78.16667%. As a result of our ownership and control of Immudyne
PR, we now operate in two business segments, nutraceutical and cosmetic additives and finished cosmetic products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have performance based contracts with our sales and marketing executives, which allows us to continue to maintain a relatively
low overhead. Our priority is to pursue opportunities to market our products and increase sales. We expect that a significant
component of our selling, general and administration expenses going forward will consist of equipment leasing costs relating to
improving our operating efficiencies, as well as conducting new studies which could open new markets. These aforementioned costs,
along with the additional costs resulting from our operations as a public reporting company, could adversely impact our future
results of operations. Additional significant factors that we believe will affect our operating results going forward are: (i)
protection of our intellectual property rights; (ii) imposition of more stringent government regulations of our products; and
(iii) marketing expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT>In the 2016 fiscal year, we utilized third party entities to provide and increase credit card
processing capacity and optimize corresponding rates and fees through one or more merchant bank accounts held by such entities.
A majority of these entities providing these services are consolidated as VIEs which received a one (1%) percent fee eliminated
in consolidation of the net revenues processed and collected by such contractors from sales initiated by the Company. The remaining
entities provided such services as independent contractors, the majority of which were considered related parties and no fee was
paid. Upon receipt of funds by such contractors from their respective merchant banks, the Company required the prompt transfer
of funds to Company controlled accounts. The Company reimbursed and/or advanced funds to such contractors for any deficit or charge
related to returns, chargeback and other fees charged by such merchant bank. Some of the entities contracted to provide these
services have been determined to be variable interest entities and consolidated in the Company&rsquo;s financial statements.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We historically
have expended a significant amount of our funds on obtaining and protecting our patents, trade secrets and proprietary products.
We rely on the patent and trademark protection laws in the U.S. to protect our intellectual property and maintain our competitive
position in the marketplace. For several years, we were involved in complex litigation regarding patents and licenses critical
to our products. In 2010, we prevailed on all major legal matters and reached favorable settlements. If additional litigation
becomes necessary to protect our intellectual property rights, such litigation may be costly, divert our management&rsquo;s attention
away from our core business and have a negative impact on our operations. Furthermore, there is no guarantee that litigation would
result in an outcome favorable to us. In addition, yeast beta glucans are designated as GRAS under current FDA regulations. Future
government regulations may prevent or delay the introduction or require the reformulation of our products. Some agencies, such
as the FDA, could require us to remove a particular product from the market, delay or prevent the import of raw materials for
the manufacture of our products or otherwise disrupt the marketing of our products. Any such government actions could result in
additional costs to us, reduced growth prospects, lost sales from products that we are required to remove from the market and
potential product liability litigation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have historically operated with limited
capital and have funded operations in the past through the sales of our products and loans and advances from Mark McLaughlin,
our President, and other directors. In 2015, we entered into a non-dilutive short term loan agreement with an investor for $100,000
and secured additional loans of $30,000 from our President and $75,000 from a greater than 5% shareholder of the Company. These
loans were satisfied in full as of December 31, 2015. Late in the 2016 fiscal year and early in 2017, the Company issued several
11% subordinated promissory notes to accredited investors for total borrowings of $200,000, which have been satisfied in 2016
and 2017. We plan on our operating business (in conjunction with proceeds from debt and equity financings completed in 2016 and
early 2017) to be able to fund operations through 2017. However, in the event we require additional operating capital we may have
to depend on sources other than operating revenues to meet our operating and capital needs. No assurance can be given that such
sources will be available and no assurance can be given that Mr. McLaughlin or other directors who have in the past willingly
funded operations will commit to do so in the future, or that we will be successful in our endeavors to raise additional capital.
For additional information regarding these and other risks please see &ldquo;Risk Factors&rdquo; contained in this annual report.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Results
of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Year
Ended December 31, 2016, Compared to the Year Ended December 31, 2015</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the results of our operations for the periods indicated as a percentage of net sales:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2016</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2015</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>$</I></B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>% of Sales</I></B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>$</I></B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>% of Sales</I></B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 52%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,238,604</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 9%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,218,862</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 9%; text-align: right">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost of sales</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,946,055</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">247,772</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross profit</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,292,549</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">971,090</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">80</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating expenses</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,467,231</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-85</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,233,307</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-101</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss from operations</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,174,682</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-22</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(262,217</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-22</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gain on sale of Adiuvo Investment S.A. stock</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">127,261</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other income (expenses), net</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(48,611</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(37,476</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-3</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income tax benefit</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,200</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net (loss)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,223,293</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-23</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(159,232</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-13</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net (loss) attributable to noncontrolling interests</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(115,749</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-2</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(97,240</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-8</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net (loss) attributable to Immudyne, Inc.</FONT></TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double">&nbsp;</TD>
    <TD STYLE="text-align: right; border-bottom: Black 4pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,107,544</FONT></TD>
    <TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double">&nbsp;</TD>
    <TD STYLE="text-align: right; border-bottom: Black 4pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-21</FONT></TD>
    <TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double">&nbsp;</TD>
    <TD STYLE="text-align: right; border-bottom: Black 4pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(61,992</FONT></TD>
    <TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-5</FONT></TD>
    <TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Overall
sales for the year ended December 31, 2016 were $5.24 million, an increase of 330% from $1.22 million in 2015. Our increase in
sales was primarily attributable to sales made by our finished cosmetic products segment of $4.24 million through our joint venture
with Inate. Net sales for our nutraceutical and cosmetic additives segment remained relatively consistent between periods at approximately
$1 million and were in line with our expectations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cost of sales consists primarily of material
costs, labor costs, marketing costs and related overhead directly attributable to the production of our products. Total cost of
sales increased 685% to $1.95 million in 2016 compared to $0.25 million in 2015, which costs in the 2015 period were primarily
attributable to our nutraceutical and cosmetic additives product segment. The increase in our cost of sales was due to our increased
advertising expenses incurred to generate our increase in sales from our finished cosmetic products segment, which costs were
not incurred in 2015.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Gross profit increased 239% to $3.29 million
in 2016 compared to $0.97 million in 2015 as a result of our increased sales offset by our advertising expenses for the year.
Gross profit as a percentage of sales decreased to 63% in 2016 from 80% in 2015 due to the shift in the composition of our sales
between periods from primarily topical and oral additives to primarily finished products sold through Inate, which products generally
have lower margins.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Operating expenses consisted of general and administrative expense, compensation and related expense, marketing,
research and development and professional fees. Overall operating expenses increased 262% to $4.47 million in 2016 from $1.23
million in 2015, primarily due to increased compensation related expenses with respect to shares issued to the Company&rsquo;s
joint venture partners pursuant to previously disclosed service agreements. The increase in our overall operating expenses was
also due to our increase in sales. General and administration expense increased 211% to $1.03 million in 2016 from $0.33 million
for in 2015. Compensation and related expense increased 134% to $1.25 million in 2016 from $0.53 million in 2015 due to the aforementioned
share issuance. Marketing expense increased 642% to $1.7 million in 2016 from $0.23 million for in 2015. Professional fees increased
316% to $.48 million in 2016 from approximately $0.11 million in 2015, due to increased legal and accounting fees incurred with
respect to Inate&rsquo;s operations.&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Net
loss attributable to Immudyne in 2016 was approximately $1.11 million compared to net loss of $0.06 million in 2015. We consolidated
the operations of our joint venture, Inate, and at December 31, 2016, reflected a non-controlling interest for 21.833% of these
operations. Net loss attributable to Immudyne, Inc. as a percentage of sales was 21% in 2016 compared to net loss as a percentage
of sales of 5% in 2015. Our net loss notwithstanding our substantial increase in sales was primarily due to the advertising expenses
we incurred in the year to help generate sales and our increased compensation expenses due to shares issued to the Company&rsquo;s
joint venture partners pursuant to previously disclosed service agreements. We believe these costs will decrease as a percentage
of sales over the course of the 2017 fiscal year as Inate continues to mature as a business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Liquidity and Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our principal demands for liquidity are
to increase sales, purchase inventory and for sales distribution and general corporate purposes. We incurred negative operating
cash flows in the 2016 and 2015 fiscal years. As a result, our auditors have raised substantial doubt about our ability to continue
as a going concern. In 2015, we entered into a non-dilutive short term loan agreement with an investor for $100,000 and secured
additional loans of $30,000 from our President and $75,000 from a greater than 5% shareholder of the Company. These loans were
satisfied in full as of December 31, 2015. Late in the 2016 fiscal year and early in 2017, the Company issued several 11% subordinated
promissory notes to accredited investors for total borrowings of $200,000 which have been satisfied in 2016 and 2017. We plan on
our operating business (in conjunction with proceeds from debt and equity financings completed in 2016 and early 2017) being able
to fund operations through 2017. However, if necessary, we may raise additional capital through a private placement of common stock,
obtaining debt financing or from advances from our President and/or directors; however, no assurances can be made that we will
be successful in our endeavors to raise additional capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There can be no assurance that required
future financing can be successfully completed on a timely basis, or on terms acceptable to us. Any future issuance of equity
securities could cause dilution to our shareholders. Any incurrence of indebtedness would increase our debt service obligations
and would cause us to be subject to restrictive operating and financial covenants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We had net working capital of approximately
$(361,725) at December 31, 2016, resulting in a decrease from net working capital of approximately $180,990 at December 31, 2015.
The ratio of current assets to current liabilities was 0. 69 to 1 at December 31, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of cash provided by or used in each of the indicated types of activities during the years ended December
31, 2016 and 2015:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>2016</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>2015</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>Cash provided by (used in):</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Operating activities</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(407,914</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(295,124</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">127,261</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Financing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">357,491</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">325,352</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash flow used by operating activities was $0.41 million for the year ended December 31, 2016, compared to net cash flow used
in operating activities of $0.30 million for the same period in 2015. The increase in the amount of cash used by our operating
activities was due to up-front advertising expenses incurred in the 2016 period. We expect that these expenses will decrease as
a percentage of sales as Inate continues to mature as a business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash flows provided by investing activities was $0 for the year ended December 31, 2016, compared to net cash flows provided by
financing activities of $0.127 million for the same period in 2015 due to gain on sale of Adiuvo Investment S.A. during the period
as further described below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash flows provided by financing activities was $0.36 million for the year ended December 31, 2016, compared to net cash flows
provided by financing activities of $0.33 million for the same period in 2015 due to additional indebtedness incurred during the
period as further described below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Indebtedness</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, our directors, officers and other related individuals have made short-term advances to us for our operating needs.
In 2015, we entered into a non-dilutive short term loan agreement with an investor for $100,000 and secured additional loans of
$30,000 from our President and $75,000 from a greater than 5% shareholder of the Company. These loans were satisfied in full as
of December 31, 2015. In addition, in November 2015, we secured a $100,000 line of credit with a commercial lender for our short-term
working capital needs, which has since been repaid in full. Late in the 2016 fiscal year and early in 2017, the Company issued
several 11% subordinated promissory notes to accredited investors for total borrowings of $200,000 which have been satisfied as
of the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to a royalty agreement pursuant to which we are required to pay a monthly royalty of 8% on all sales of certain skin
care products up to $227,175. During the year ended December 31, 2015 our sales reached the maximum amount under which we are
required to pay a royalty under this agreement. Royalty expense amounted to $0 and $20,157 for the years ended December 31, 2016
and 2015, respectively. During 2015, our President, who has a 60% interest in the royalties, converted all royalties payable (in
the amount of $84,868) to 499,225 shares of the company&rsquo;s stock valued at $0.17 cents a share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Off-Balance
Sheet Arrangements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no off-balance sheet arrangements between us and any other entity that have, or are reasonably likely to have, a current or
future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity,
capital expenditures or capital resources that is material to shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not entered into any financial guarantees or other commitments to guarantee the payment obligations of any third parties.
We have not entered into any derivative contracts that are indexed to our shares and classified as stockholders&rsquo; equity
or that are not reflected in our consolidated financial statements. Furthermore, we do not have any retained or contingent interest
in assets transferred to an unconsolidated entity that serves as credit, liquidity or market risk support to such entity. We do
not have any variable interest in any unconsolidated entity that provides financing, liquidity, market risk or credit support
to us or engages in leasing, hedging or research and development services with us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Critical
Accounting Policies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">While
our significant accounting policies are described more fully in Note 2 to our financial statements, we believe the following accounting
policies are the most critical to aid you in fully understanding and evaluating this management discussion and analysis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Basis
of Presentation and Use of Estimates</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying financial statements have
been prepared in conformity with accounting principles generally accepted in the U.S., or U.S. GAAP. The Consolidated Financial
Statements include the accounts of the Immudyne and its majority-owned subsidiaries and variable interest entities (&ldquo;VIE&rdquo;)
in which the Company has been determined to be the primary beneficiary. All significant inter-company transactions and balances
between the Company, its subsidiaries, and its VIEs have been eliminated in consolidation.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In preparing financial statements in conformity
with U.S. GAAP, management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures
of contingent assets and liabilities at the dates of the financial statements, as well as the reported amounts of revenues and
expenses during the reporting period. Significant estimates required by management include the valuation of inventory, stockholders&rsquo;
equity-based transactions, allowance for doubtful accounts, revenue recognition and sales returns and allowances. Actual results
could differ from those estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Inventory</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inventory is valued at the lower of cost
or market value with cost determined on a first-in, first-out basis. Management compares the cost of inventory with the net realizable
value and an allowance is made for writing down their inventories to market value, if lower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Revenue Recognition</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s policy is to record
revenue as earned when a firm commitment, indicating sales quantity and price exists, delivery has taken place and collectability
is reasonably assured. The Company generally records sales of nutraceutical and cosmetic additives once the product is shipped
to the customer, and for sales of finished cosmetic products once the customer places the order and the product is simultaneously
shipped, but in limited cases if title does not pass until the product reaches the customer&rsquo;s delivery site, then recognition
of revenue is deferred until that time. Delivery is considered to have occurred when title and risk of loss have transferred to
the customer. Provisions for discounts, returns, allowances, customer rebates and other adjustments are netted with gross sales.
The Company accounts for such provisions during the same period in which the related revenues are earned. Customer discounts, returns
and rebates approximated $1,926,000 for the year ended December 31, 2016. Customer discounts, returns and rebates were not significant
for the year ending December 31, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Delivery is considered to have occurred
when title and risk of loss have transferred to the customer. If title does not pass until the product reaches the customer&rsquo;s
delivery site, then recognition of revenue is deferred until that time. There are no formal sales incentives offered to any of
the Company&rsquo;s customers. Volume discounts may be offered from time to time to customers purchasing large quantities on a
per transaction basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Stock-based Compensation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company follows the provisions of ASC
718, &ldquo;Share-Based Payment&rdquo;. Under this guidance compensation cost generally is recognized at fair value on the date
of the grant and amortized over the respective vesting periods. The fair value of options at the date of grant is estimated using
the Black-Scholes option pricing model. The expected option life is derived from assumed exercise rates based upon historical exercise
patterns and represents the period of time that options granted are expected to be outstanding. The expected volatility is based
upon historical volatility of our shares using weekly price observations over an observation period that approximates the expected
life of the options. The risk-free rate approximates the U.S. Treasury yield curve rate in effect at the time of grant for periods
similar to the expected option life. Due to limited history of forfeitures, estimated forfeiture rate included in the option valuation
was zero. Many of the assumptions require significant judgment and any changes could have a material impact in the determination
of stock-based compensation expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Variable Interest Entities - Principles of Consolidation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Generally, the Company consolidates only
business enterprises that we control by ownership of a majority voting interest. However, there are situations in which consolidation
is required even though the usual condition of consolidation (ownership of a majority voting interest) does not apply. Generally,
this occurs when an entity holds an interest in another business enterprise that was achieved through arrangements that do not
involve voting interests, which results in a disproportionate relationship between such entity&rsquo;s voting interests in, and
its exposure to the economic risks and potential rewards of, the other business enterprise. This disproportionate relationship
results in what is known as a variable interest, and the entity in which we have the variable interest is referred to as a &ldquo;VIE.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company follows ASC 810-10-15 guidance
with respect to accounting for VIEs. A VIE is an entity that does not have sufficient equity at risk to finance its activities
without additional subordinated financial support from other parties, or whose equity investors lack any of the characteristics
of a controlling financial interest. A variable interest is an investment or other interest that will absorb portions of a VIE&rsquo;s
expected losses or receive portions of the entity&rsquo;s expected residual returns. Variable interests are contractual, ownership,
or other pecuniary interests that change with changes in the fair value of the entity&rsquo;s net assets. A party is the primary
beneficiary of a VIE and must consolidate it when that party has a variable interest, or combination of variable interests, that
provides the party with a controlling financial interest. A party is deemed to have a controlling financial interest if it meets
both of the power and losses/benefits criteria. The power criterion is the ability to direct the activities of the VIE that most
significantly impact its economic performance. The losses/benefits criterion is the obligation to absorb losses from, or right
to receive benefits from, the VIE that could potentially be significant to the VIE. The VIE model requires an ongoing reconsideration
of whether a reporting entity is the primary beneficiary of a VIE due to changes in facts and circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Noncontrolling Interests</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for its less than
100% interest in Inate and its VIEs in accordance with ASC Topic 810, Consolidation, and accordingly the Company presents noncontrolling
interests as a component of equity on its consolidated balance sheet and reports the noncontrolling interest&rsquo;s share of
Inate net loss attributable to noncontrolling interests in the consolidated statement of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>New
Accounting Pronouncements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and
Cash Payments (&ldquo;ASU 2016-15&rdquo;). ASU 2016-15 addresses eight specific cash flow issues with the objective of reducing
diversity in practice regarding how certain cash receipts and cash payments are presented in the statement of cash flows. The
standard provides guidance on the classification of the following items: (1) debt prepayment or debt extinguishment costs, (2)
settlement of zero-coupon debt instruments, (3) contingent consideration payments made after a business combination, (4) proceeds
from the settlement of insurance claims, (5) proceeds from the settlement of corporate-owned life insurance policies, (6) distributions
received from equity method investments, (7) beneficial interests in securitization transactions, and (8) separately identifiable
cash flows. The Company is required to adopt ASU 2016-15 for fiscal years, and for interim periods within those fiscal years,
beginning after December 15, 2017 on a retrospective basis. Early adoption is permitted, including adoption in an interim period.
The Company is currently evaluating the impact of adoption of ASU 2016-15.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2016, the Financial Accounting Standards Board (&ldquo;FASB&rdquo;) issued Accounting Standards Update (&ldquo;ASU&rdquo;)
2016-09, &ldquo;Compensation &ndash; Stock Compensation: Improvements to Employee Share-Based Payment Accounting,&rdquo; which
relates to the accounting for employee share-based payments. This standard addresses several aspects of the accounting for share-based
payment award transactions, including: (a) income tax consequences; (b) classification of awards as either equity or liabilities;
and (c) classification on the statement of cash flows. This standard will be effective for fiscal years beginning after December
15, 2016, including interim periods within those fiscal years. The adoption of ASU No. 2016-09 is not expected to have a material
impact on the Company's consolidated financial statements or related disclosures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2016, a pronouncement was issued that creates new accounting and reporting guidelines for leasing arrangements. The new
guidance requires organizations that lease assets to recognize assets and liabilities on the balance sheet related to the rights
and obligations created by those leases, regardless of whether they are classified as finance or operating leases. Consistent
with current guidance, the recognition, measurement, and presentation of expenses and cash flows arising from a lease primarily
will depend on its classification as a finance or operating lease. The guidance also requires new disclosures to help financial
statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. The new standard is effective
for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period, with early
application permitted. The new standard is to be applied using a modified retrospective approach. The Company is in the process
of evaluating the impact of the new pronouncement on its consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2014, the Financial Accounting Standards Board (&quot;FASB&quot;) issued accounting guidance, &quot;Revenue from Contracts
with Customers.&quot; The core principle of the new standard is for companies to recognize revenue to depict the transfer of goods
or services to customers in amounts that reflect the consideration (that is, payment) to which the company expects to be entitled
in exchange for those goods or services. The new standard also will result in enhanced disclosures about revenue, provide guidance
for transactions that were not previously addressed comprehensively (for example, service revenue and contract modifications)
and clarify guidance for multiple-element arrangements. The standard will be effective for fiscal years and interim periods within
those years beginning after December 15, 2017. Accordingly, the Company will adopt this standard in the first quarter of fiscal
year 2018. The Company is currently evaluating the impact this guidance will have on the consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
July 2015, the Financial Accounting Standards Board (&ldquo;FASB&rdquo;) issued Accounting Standards Update (&ldquo;ASU&rdquo;)
2015-11, &ldquo;Simplifying the Measurement of Inventory.&rdquo; ASU 2015-11 applies to inventory that is measured using first-in,
first-out (FIFO) or average cost. An entity should measure inventory within the scope of ASU 2015-11 at the lower of cost and
net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably
predictable costs of completion, disposal and transportation. ASU 2015-11 is effective for fiscal years beginning after December
15, 2016. The adoption of ASU No. 2015-11 is not expected to have a material impact on the Company's consolidated financial statements
or related disclosures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In August 2014, the FASB issued ASU 2014-15,
&quot;Presentation of Financial Statements-Going Concern&quot;. This ASU is intended to define management's responsibility to
evaluate whether there is substantial doubt about an organization's ability to continue as a going concern and to provide related
footnote disclosures. It is effective for annual periods ending after December 15, 2016, with early adoption permitted. The Company
does not expect it to have a material effect on the Company's consolidated financial condition, results of operations, and cash
flows.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2017, the FASB issued ASU 2017-09,
Compensation - Stock Compensation (Topic 718) : Scope of Modification Accounting. The new standard provides guidance about which
changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718.
This pronouncement is effective for annual reporting periods beginning after December 15, 2017 but early adoption is permitted.
The Company is currently evaluating the impact of adopting this guidance.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
other accounting standards that have been issued or proposed by the FASB that do not require adoption until a future date are
not expected to have a material impact on the consolidated financial statements upon adoption.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><A NAME="a_012"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
7A. Quantitative and Qualitative Disclosures about Market Risk</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><A NAME="a_013"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
8. Financial Statements and Supplementary Data</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
financial statements, together with the report thereon, appear in a separate section of this Annual Report beginning on page F-1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><A NAME="a_014"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><A NAME="a_015"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
9A. Controls and Procedures</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Evaluation
of Disclosure Controls and Procedures</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT>We carried out an evaluation, under the supervision and with the participation
of our Principal Executive Officer (&ldquo;PEO&rdquo;), who is also our Principal Financial Officer (&ldquo;PFO&rdquo;), of the
design and effectiveness of our &ldquo;disclosure controls and procedures&rdquo; (as defined under Rules 13a-15(e) and 15d-15(e)
of the Securities Exchange Act of 1934) as of the end of the period covered by this report. Based on this evaluation, our PEO/PFO
concluded that as of the end of the period covered by this report, these disclosure controls and procedures were not effective
for the Company, our majority owned subsidiaries and the VIEs and the increased concentration of operations of Immudyne PR. The
conclusion that our disclosure controls and procedures were not effective was due to the presence of the following material weaknesses
in disclosure controls and procedures which are indicative of many small companies with small staff: (i) inadequate segregation
of duties and effective risk assessment as the Company had only one officer; (ii) insufficient written policies and procedures
for accounting and financial reporting with respect to the requirements and application of both US GAAP and SEC Guidelines; and
(iii) inadequate security and restricted access to computer systems including insufficient disaster recovery plans; and (iv) no
written whistleblower policy.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Our PEO/PFO has started to implement appropriate disclosure
controls and procedures to remediate these material weaknesses, including the engagement of two accounting firms providing bookkeeping
and accounting services (i) to address inadequate segregation of duties and ineffective risk management and (ii) assist in preparing
sufficient written policies and procedures for accounting and financial reporting and a whistle blower policy; and with when sufficient
funds are available (iii) implement sufficient security and restricted access measures regarding our computer systems and implement
a disaster recovery plan.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Management&rsquo;s
Annual Report on Internal Control over Financial Reporting</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
PEO/PFO is responsible for establishing and maintaining adequate internal control over financial reporting as defined under Rule
13a-15(f) and Rule 15d-15(f) under the Securities Exchange Act of 1934. As of December 31, 2016 our PEO/PFO assessed the effectiveness
of the Company&rsquo;s internal control over financial reporting based on the internal control framework promulgated by the Committee
of Sponsoring Organizations of the Treadway Commission (&ldquo;COSO&rdquo;), &ldquo;Internal Control &mdash; Integrated Framework&rdquo;
(&ldquo;COSO 2013&rdquo;) provides guidance for designing, implementing and conducting internal control and assessing its effectiveness.
Our PEO/PFO used the COSO 2013 framework to assess the effectiveness of the Firm&rsquo;s internal control over financial reporting
as of December 31, 2016. Based on that evaluation, our PEO/PFO concluded that, during the period covered by this report, such
internal controls and procedures were not effective to detect the inappropriate application of US GAAP rules as more fully described
below. This was due to deficiencies that existed in the design or operation of our internal control over financial reporting that
adversely affected our internal controls.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
matters involving internal controls and procedures that the Company&rsquo;s PEO/PFO considered to be material weaknesses
under the standards of the Public Company Accounting Oversight Board were: (1) lack of a functioning audit committee and lack
of a majority of outside directors on the Company's board of directors, resulting in ineffective oversight in the
establishment and monitoring of required internal controls and procedures; and (2) inadequate segregation of duties
consistent with control objectives; (3) insufficient written policies and procedures for accounting and financial reporting
with respect to the requirements and application of US GAAP and SEC disclosure requirements; and (4) ineffective controls
over period end financial disclosure and reporting processes. The aforementioned material weaknesses were identified by the
Company's PEO/PFO in connection with his review of our financial statements as of December 31, 2016.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
PEO/PFO believes that the material weaknesses set forth above did not have an effect on the Company's financial results. However,
our PEO/PFO believes that the lack of a functioning audit committee and lack of a majority of outside directors on the Company's
board of directors, results in ineffective oversight of the establishment and monitoring of required internal controls and procedures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will continue to monitor and evaluate the effectiveness of our internal controls and procedures and our internal controls over
financial reporting on an ongoing basis and are committed to taking action and implementing additional enhancements or improvements
as funds allow.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been no significant changes in our internal controls over financial reporting that occurred during the year ended December
31, 2016 that have materially affected or are reasonably likely to materially affect, our internal controls over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
annual report does not include an attestation report of the Company&rsquo;s independent registered public accounting firm regarding
internal control over financial reporting. Management&rsquo;s report was not subject to attestation by the Company&rsquo;s independent
registered public accounting firm pursuant to rules of the Securities and Exchange Commission that permit the Company to provide
only its management report in the Annual Report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><A NAME="a_016"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
9B. Other Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 1, 2017, Ryan Aldridge was appointed to our Board of Directors. There is no arrangement or understanding between Mr.
Aldridge and any other person pursuant to which he was appointed as a director of the Company. There has been no transaction,
or proposed transaction, since January 1, 2015, to which Mr. Aldridge or any member of his respective immediate family had or
is to have a direct or indirect material interest or any other related transaction with the Company within the meaning of Item
404(a) of Regulation S-K. There are no family relationships between Mr. Aldridge and any of the Company&rsquo;s other directors,
executive officers or persons nominated or chosen by the Company to become directors or executive officers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the third quarter of 2016, the Company sold several 11% subordinated promissory notes along with shares of the
Company&rsquo;s common stock. A total of $200,000 of these notes, together with a total of 250,000 shares of Common Stock,
were issued and sold to five investors. The notes have varying maturity dates based on their date of issuance between
February and October 2017. All of the notes have been satisfied as of the date hereof. The Company issued the Notes to
accredited investors only pursuant to Rule 506 of Regulation D promulgated under the Securities Act of 1933, as
amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the fourth quarter of 2016, the Company issued 275,000 shares of common stock and 137,500 two-year warrants with an exercise price
of $0.50 per share for $63,250 to two accredited investors in reliance on Section 4(a)(2) of the Securities Act of 1933, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="a_017"></A><B>PART
III</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><A NAME="a_018"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
10. Directors, Executive Officers and Corporate Governance</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the names of our directors, executive officer and certain significant employees and their ages, positions
and biographical information as of the date of this annual report. Our executive officer is appointed by, and serves at the discretion
of, our Board of Directors. There are no other family relationships among our directors or executive officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 39%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 50%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Position</B></FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 9%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Age</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anthony
    G. Bruzzese, M.D.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark
    McLaughlin</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President,
Chief Executive Officer and Director</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
    R. Strawn, Jr.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Joseph DiTrolio, M.D.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    and Chief Medical Officer (North America)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Sven Rohmann M.D. </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    and Chief Medical Officer (Global)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ryan
    Aldridge </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Justin
    Schreiber </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President,
    Immudyne PR</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stefan
    Galluppi</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer, Immudyne PR</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Anthony
G. Bruzzese, M.D., Chairman</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Bruzzese has served as Chairman of our Board of Directors since April 2004. He is a practicing radiologist in Warwick, Rhode Island,
certified by both the American Board of Internal Medicine and the American Board of Radiology. Since 1997, Dr. Bruzzese has served
as a principal at Toll Gate Radiology, Inc., providing patients with comprehensive diagnostic imaging services. Dr. Bruzzese also
has served on the medical staffs at Roger Williams Medical Center since 2008 and Landmark Medical Center since 2011. He previously
served on the medical staff at Kent County Memorial Hospital in Rhode Island from 1997 to 2005. Dr. Bruzzese has served as a Fellow,
Councilor and Alternate Councilor to the American College of Radiology on behalf of the Rhode Island Radiology Society. Dr. Bruzzese
received his Bachelor of Science and Doctor of Medicine from Brown University. Dr. Bruzzese brings to the Board of Directors over
20 years of experience in medical practice. The Board of Directors believes that Dr. Bruzzese&rsquo;s knowledge of internal medicine
and life sciences will assist us in our future growth and expansion plans.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Mark
McLaughlin, President, Chief Executive Officer and Director</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
McLaughlin has served as our President and member of the Board of Directors since March 2004 and Chief Executive Officer since
April 2011. Mr. McLaughlin brings extensive knowledge about raising capital, marketing, business and corporate development, and
of our operations and long-term strategy to the Board of Directors. In addition, Mr. McLaughlin played an integral role in successfully
prosecuting several intellectual property violations in our favor. Since 1994, he has served as President of McLaughlin International,
Inc., or MII, a management consulting firm controlled by Mr. McLaughlin. Previously, Mr. McLaughlin served as Senior Vice President
at Oppenheimer &amp; Co. from 1990 to 1992 and Lehman Brothers from 1981 to 1990. Mr. McLaughlin graduated from the College of
the Holy Cross. The Board of Directors believes that Mr. McLaughlin&rsquo;s leadership and extensive knowledge about us is essential
to our future growth</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>John
R. Strawn, Jr., Director</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Strawn has served as a member of our Board of Directors since July 2011. Mr. Strawn brings to the Board of Directors over 25 years
of legal experience, including extensive knowledge of our intellectual property portfolio. His practice focuses on complex commercial
litigation. Mr. Strawn has successfully represented the company for over 10 years, including in a dispute over the ownership and
licensing of multiple patents. After prevailing in a jury trial that was upheld on appeal in 2009, the matter was settled on favorable
terms for the company. In 2010, Mr. Strawn became a founding partner of Strawn Pickens LLP in Houston, Texas. Prior to founding
Strawn Pickens, Mr. Strawn was the Co-Managing Partner of Cruse Scott Henderson &amp; Allen LLP, a law firm based in Houston,
Texas, since 1992. Mr. Strawn received his Juris Doctor from the University of Texas Law School and his bachelor&rsquo;s degree
from Dartmouth College.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Dr.
Joseph DiTrolio, M.D., Director</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
DiTroilio was appointed to our Board of Directors on September 4, 2014. Dr. DiTrolio has been the Chief Medical Officer of United
States at ImmuDyne, Inc. since May 29, 2013 pursuant to a 2012 consulting agreement. Dr. DiTrolio serves as an advisor of OneMedPlace
and as an advisor of Urovalve Inc. Dr. DiTrolio is recognized world-wide as an inventor, researcher and lecturer and is a Clinical
Professor of Urology, UMDNJ. He is the holder of several patents and is Clinical Professor of Surgery, Division of Urology at
New Jersey Medical School, and the recent Chairman of the Department of Urology for the St. Barnabas Medical Center Healthcare
System. He is a graduate of the University of Richmond, University of Paris, Sorbonne and New Jersey Medical School. He is a Diplomate
of the American Board of Urology and is well respected in the urology community for innovative techniques and product development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Dr.
Sven Rohmann, M.D., Director and Chief Medical Officer</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Rohmann was appointed to our board of directors and as Chief Medical Officer on September 15, 2015. Dr. Rohmann served 10 years
as an International Marketing Manager, Business Area Manager, and Global Head of the Strategic Marketing of the business area
oncology at Merck. During his tenure at Merck, he was involved in the successful licensing of Erbitux from ImClone and the establishment
of Merck Oncology. He served as the Head of laboratories performing cardiovascular preclinical research, then Evaluation Manager
and International Product Manager for cardiovascular products at Merck. In addition, Dr. Rohmann served as an Interim Chief Executive
Officer of BioVisioN AG, Hannover, Germany from 2003 to 2005.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Ryan
Aldridge, Director</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ryan
Aldridge, was appointed to our board of directors on February 1, 2017. Ryan Aldridge is the founder of Aranea Partners. Aranea
is a boutique capital markets advisory firm that specializes in investing in and advising companies in the healthcare sector.
Ryan is an advisor to high net worth investors and an investor and consultant to early stage biotechnology and healthcare companies.
Prior to Aranea, Ryan was the Director of Investor Relations at a long short hedge fund. Ryan graduated Gettysburg College in
2006 and is a CFA Charterholder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Justin
Schreiber, President Immudyne PR</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Justin
Schreiber was appointed as Immudyne PR&rsquo;s President on April 1, 2017. Mr. Schreiber is the President and founder of JLS Ventures,
a leading capital markets advisory firm that partners with entrepreneurs and emerging growth companies to build innovative and
disruptive brands with long-term investment value. Prior to founding JLS Ventures, Mr. Schreiber ran a consulting business that
provided investor relations, advisory services and capital raising solutions to small publicly traded companies. In addition to
his capital markets experience, Mr. Schreiber previously worked for a global healthcare consulting firm as well as in the foreign
currency trading business. He holds a BS in International Business from Elizabethtown College and a BA in International Management
from the ICN &Eacute;cole de management in Nancy, France.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Stefan
Galluppi, Chief Executive Officer, Immudyne PR</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stefan
Galluppi is the Chief Executive Officer of Immudyne PR and the Chief Operating Officer of Immudyne.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Previously,
Mr. Galluppi served as CTO at Redwood Scientific Technologies, where he oversaw the information technology infrastructure, ranging
from customer services software to Customer Relationship Management (CRM) systems, as well as software system development and
integration to streamline the B2C ordering process. Mr. Galluppi was also instrumental in helping create the framework for an
optimal back-end office infrastructure to support multiple national TV direct response advertising campaigns rated among the top
10 on the national TV IMS report rankings for performance. Mr. Galluppi&rsquo;s the former co-founder of a NT1 Hosting; a web
development, hosting and online marketing firm that design, developed and marketed hundreds of successful websites and campaigns.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Legal
Proceedings</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the past ten years, none of our current directors or executive officers has been:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    subject of any bankruptcy petition filed by or against any business of which such person was a general partner or executive
    officer either at the time of the bankruptcy or within two years prior to that time;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">convicted
    in a criminal proceeding or is subject to a pending criminal proceeding (excluding traffic violations and other minor offenses);</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject
    to any order, judgment or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction,
    permanently or temporarily enjoining, barring, suspending or otherwise limiting his involvement in any type of business, securities
    or banking activities;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">found
    by a court of competent jurisdiction (in a civil action), the SEC or the Commodity Futures Trading Commission to have violated
    a federal or state securities or commodities law, that has not been reversed, suspended, or vacated;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject
    of, or a party to, any order, judgment, decree or finding, not subsequently reversed, suspended or vacated, relating to an
    alleged violation of a federal or state securities or commodities law or regulation, law or regulation respecting financial
    institutions or insurance companies, law or regulation prohibiting mail or wire fraud or fraud in connection with any business
    entity; or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 24px; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject
    of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization,
    any registered entity or any equivalent exchange, association, entity or organization that has disciplinary authority over
    its members or persons associated with a member.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None
of our directors, officers or affiliates, or any beneficial owner of 5% or more of our common stock, or any associate of such
persons, is an adverse party in any material proceeding to, or has a material interest adverse to, us or any of our subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate
Governance</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently have no standing audit or nominating committees or committees performing similar functions, nor do we have written audit
or nominating committee charters. Our Board of Directors believes it unnecessary to have such committees at this time because
our Board of Directors can perform the functions of such committees adequately.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
established a Compensation Committee in January 2017. The Compensation Committee consists of Messrs. Strawn and Bruzzese. Mr.
Strawn is the Chairman of the Compensation Committee. The Compensation Committee is responsible for the design, review, recommendation
and approval of compensation arrangements for our directors, executive officers and key employees. The Compensation Committee
also reviews and determines compensation of our executive officers, including our Chief Executive Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have any defined policy or procedural requirements for shareholders to submit recommendations or nominations for directors.
The Board of Directors believes that, given the stage of our development, a specific nominating policy would be premature until
our business operations develop to a more advanced level. We currently do not have any specific or minimum criteria for the election
of nominees to the Board of Directors and we do not have any specific process or procedure for evaluating such nominees. The Board
of Directors will assess all candidates, whether submitted by management or shareholders, and make recommendations for election
or appointment. A shareholder who wishes to communicate with our Board of Directors may do so by directing a written request addressed
to our director at the address on the cover of this report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Code
of Ethics</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not yet adopted a code of ethics within the definition of Item 406 of Regulation S-K. Currently, we have a three named executive
officers,11  employees, as well as a few part-time employees and numerous additional consultants. As our business continues to
grow, and we become more experienced as a fully-reporting public company, our Board of Directors plans to implement a code of
ethics.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
16(a) Beneficial Ownership Reporting Compliance</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently not subject to Section 16(a) of the Exchange Act as we do not have a class of equity securities registered pursuant
to section 12 of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><A NAME="a_019"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
11. Executive Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a &ldquo;smaller reporting company,&rdquo; we have elected to follow the scaled disclosure requirements for smaller reporting
companies with respect to the disclosures required by Item 402 of Regulation S-K. Under such scaled disclosure, we are not required
to provide a Compensation Discussion and Analysis, Compensation Committee Report and certain other tabular and narrative disclosures
relating to executive compensation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Executive
Compensation </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information concerning the compensation of our principal executive officer for the years ended December
31, 2016 and 2015.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="25" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Summary Compensation Table</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Salary</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Option</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Awards</B></FONT></P></TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Non-Equity</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Incentive Plan</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Compensation</B></FONT></P></TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>All Other</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Compensation</B></FONT></P></TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Total</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; border-bottom: Black 1.5pt solid"><B>Name and Principal Position</B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Year</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">($)(1)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: left">Mark McLaughlin</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: center">2016</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">145,600</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="width: 1%; text-align: left">(3)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">145,600</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">President, Chief Executive Officer and Director(2)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center; vertical-align: top">2015</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right; vertical-align: top">145,600</TD><TD STYLE="text-align: right; vertical-align: top">&nbsp;</TD><TD STYLE="text-align: right; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: top">&nbsp;</TD><TD STYLE="text-align: right; vertical-align: top">-</TD><TD STYLE="text-align: right; vertical-align: top">&nbsp;</TD><TD STYLE="text-align: right; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: top">&nbsp;</TD><TD STYLE="text-align: right; vertical-align: top">-</TD><TD STYLE="text-align: left; vertical-align: top">(3)</TD><TD STYLE="text-align: right; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: top">&nbsp;</TD><TD STYLE="text-align: right; vertical-align: top">52,000</TD><TD STYLE="text-align: left; vertical-align: top">(4)</TD><TD STYLE="text-align: right; vertical-align: top">&nbsp;</TD>
    <TD STYLE="text-align: right; vertical-align: top">&nbsp;</TD><TD STYLE="text-align: right; vertical-align: top">197,600</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Justin Schreiber</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">2016</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">345,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">345,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">President, Immudyne PR(5)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Stefan Galluppi</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: center">2016</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"></TD><TD STYLE="text-align: right">30,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"></TD><TD STYLE="text-align: right">345,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">375,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Chief Executive Officer, Immudyne PR(6)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amounts
    shown reflect aggregate grant date fair value and, where applicable, incremental fair value as of modification date, of awards
    and do not reflect whether the recipient actually has realized a financial benefit from such grant, such as by exercising
    the options or selling the stock. A discussion of the assumptions used in calculating the award values may be found in Note
    2 to our financial statements contained herein.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    McLaughlin receives no compensation for serving as a member of our Board of Directors.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
    his employment agreement entered into on April 20, 2011, as amended, Mr. McLaughlin earns an annual incentive bonus award
    consisting of 5% of our pre-tax earnings payable each semi-annual fiscal year. We did not have any pre-tax earnings in 2016
    or 2015, and no incentive bonus was earned or awarded.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    December of 2014, the Board of Directors authorized a one-year extension of warrants to purchase 1.5 million shares of our
    common stock at $0.12 per share that were set to expire as consideration, in part, for certain monetary advances made by Mr.
    McLaughlin to the Company. The warrants with such one-year extension of the expiration date in 2014 had an incremental fair
    value of $7,000. The warrants were further extended in 2015 for an additional two-years as consideration for Mr. McLaughlin&rsquo;s
    personal guarantee of a loan made to the Company, extensions of various interest-free advances and for his provision of rent-free
    office spaces to the Company.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
    to the operating agreement of Immudyne PR, Mr. Schreiber was appointed as Immudyne PR&rsquo;s President on April 1, 2016.
    In connection the therewith, the Company entered into a services agreement with JLS Ventures, LLC, an entity owned and controlled
    by Mr. Schreiber. A total of 1,150,000 shares of the Company&rsquo;s common stock were issued to JLS Ventures, LLC in 2016,
    with a grant date fair value of $345,000. The Company retains the right to rescind the issuance of 1,000,000 shares of common
    stock issued to JLS Ventures LLC in the event Immudyne PR does not distribute at least $500,000 to the Company by December
    31, 2017. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
    to the operating agreement of Immudyne PR, Mr. Gallupi was appointed as Immudyne PR&rsquo;s Chief Executive officer on April
    1, 2016. In connection the therewith, the Company entered into a services agreement with American Nutra Tech, an entity owned
    and controlled by Mr. Gallupi. A total of 1,150,000 shares of the Company&rsquo;s common stock were issued to American Nutra
    Tech in 2016, with a grant date fair value of $345,000. The Company retains the right to rescind the issuance of 1,000,000
    shares of common stock issued to American Nutra Tech and is currently in negotiations with respect to such shares as well
    as Mr. Gallupi&rsquo;s overall compensation. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information concerning the outstanding equity awards held by our principal executive officer at December
31, 2016.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="19" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Outstanding Equity Awards at Fiscal Year-End for 2016</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Option Awards</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Name</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Securities</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Underlying</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Unexercised</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Options</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(#) Exercisable</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Securities</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Underlying</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Unexercised</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Options</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(#) Unexercisable</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Securities</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Underlying</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Unexercised</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Options</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(#) Unearned</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Option</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exercise</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Price ($)</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Option</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Expiration</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date</B></FONT></P></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%">Mark McLaughlin(1)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,000,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">0.10</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 11%; text-align: right">03/07/2018</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">339,473</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.10</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">12/31/2018</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,800,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.20</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">04/20/2021</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">500,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.40</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">04/20/2021</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">500,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.40</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">04/20/2021</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">500,000</TD><TD STYLE="text-align: left">(2)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.80</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">04/20/2021</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    options held by Mr. McLaughlin are fully vested from grant date and exercisable on a cashless basis.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    become earned and exercisable upon our achieving $10 million in revenues in any fiscal year prior to the expiration date.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Employment
Agreement</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 12, 2012, we entered into a five-year employment agreement with Mr. McLaughlin, our President and Chief Executive Officer,
under which he is to be compensated at $145,600 per annum. In addition to his base salary, Mr. McLaughlin will earn an annual
incentive bonus award consisting of 5% of our pre-tax earnings payable each semi-annual fiscal year. We also granted to Mr. McLaughlin
under his employment agreement, as amended, 10-year, fully-vested options to purchase an aggregate of 3.3 million shares of our
common stock, such options consisting of the right to purchase: (i) 1.8 million shares of our common stock at $0.20 per share;
(ii) 0.5 million shares of our common stock at $0.40 per share; (iii) 0.5 million shares of our common stock at $0.40 per share
upon our achieving $5 million in revenues in any fiscal year prior to the expiration date; and (iv) 0.5 million shares of our
common stock at $0.80 per share upon our achieving $10 million in revenues in any fiscal year prior to the expiration date. If
at any time prior to the expiration date of the options we merge into or are acquired by another company, any outstanding options
granted under Mr. McLaughlin&rsquo;s employment agreement will become immediately exercisable on the business day immediately
preceding the merger or acquisition at $0.40 per share or the preceding average 30-day market price of our common stock prior
to the announcement of such merger or acquisition, whichever price is lower.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to our entering into this employment agreement, we compensated Mr. McLaughlin for his services as our President at $10,000 per
month. From time to time he voluntarily deferred this compensation without interest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
employment agreement with Mr. McLaughlin contains provisions prohibiting competition by him following his employment with us.
Mr. McLaughlin&rsquo;s employment agreement specifies the conditions under which the agreement may be terminated and stipulates
that he shall not be entitled to severance payments upon termination. Mr. McLaughlin is entitled to retain any options granted
under his employment agreement and that remain outstanding at the time his employment agreement is terminated, however. We do
not have any other existing arrangements providing for payments or benefits in connection with the resignation, severance, retirement
or other termination of Mr. McLaughlin, or a change in control of the company or a change in his responsibilities following a
change in control. We currently do not have any defined pension plan for Mr. McLaughlin. We currently do not have any nonqualified
defined contribution or other plan that provides for the deferral of compensation for Mr. McLaughlin nor do we currently intend
to establish any such plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Services
Agreements </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 1, 2016, the Company entered into two services agreements (the &ldquo;Services Agreements&rdquo;) with each of JLS Ventures,
LLC (&ldquo;JLS&rdquo;), an entity wholly owned and operated by Justin Schreiber, President of Immudyne PR, and American Nutra
Tech (&ldquo;American Nutra Tech&rdquo;), an entity wholly owned and operated by Stefan Galluppi, Chief Executive Officer of Immudyne
PR. Under the terms of these Service Agreements each of JLS and American NutraTech are required to provide certain operational
management services and other business counsel to the Company and Inate. As consideration for these services, the Company issued
each of JLS and American NutraTech 1,000,000 restricted shares of its common stock, which issuance may be rescinded in the event
Inate did not distribute at least $500,000 to the Company by December 31, 2016. Inate did not make such distribution by December
31, 2016 and as such the Company held a rescission right with respect to the restricted shares issued to each of JLS and American
Nutra Tech. With respect to JLS, the Company agreed to permit JLS to retain the shares so long as the required distribution was
achieved by December 31, 2017. The Company is currently in negotiations with respect to the shares issued to American Nutra Tech
for which the Company has a rescission right. Additional shares and/or options may also be issued upon certain financial milestones
being achieved by Inate as specified in the Services Agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Compensation
of Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information concerning the compensation of our directors for the year ended December 31, 2016.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="21" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Director Compensation for 2016</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fees Earned or</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Paid in Cash</B></FONT></P></TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Option</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Awards</B></FONT></P></TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Non-Equity</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Incentive</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Plan</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Compensation</B></FONT></P></TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>All Other</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Compensation</B></FONT></P></TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Total</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Name</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">($)(1)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Anthony G. Bruzzese, M.D.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">(2)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">(2)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 40%; text-align: left">John R. Strawn, Jr.</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">(3)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">16,500</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">16,500</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Joseph DiTrolio, M.D.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">(4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">(4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">(4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Sven Rohmann, M.D.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amounts
    shown reflect aggregate grant date fair value and, where applicable, incremental fair value as of modification date, of awards
    and do not reflect whether the recipient actually has realized a financial benefit from such grant, such as by exercising
    the options or selling the stock. A discussion of the assumptions used in calculating the award values may be found in Note
    2 to our financial statements contained herein.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    of December 31, 2016, Dr. Bruzzese held fully-vested options to purchase an aggregate of 810,000 shares of our common stock,
    such options consisting of the right to purchase: (i) 560,000 shares of our common stock at $0.20 per share with an expiration
    date of April 20, 2021; and (ii) 250,000 shares of our common stock at $0.40 per share with an expiration date of April 20,
    2021, such options to become exercisable upon our achieving $5 million in revenues in any fiscal year prior to the expiration
    date. Each such option held by Dr. Bruzzese is exercisable on a cashless basis. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    of December 31, 2016, Mr. Strawn held fully-vested options to purchase an aggregate of 2,000,000 shares of our common stock,
    such options consisting of the right to purchase: (i) 1,000,000 shares of our common stock at $0.20 per share with an expiration
    date of July 1, 2021; (ii) 500,000 shares of our common stock at $0.40 per share with an expiration date of July 1, 2021;
    and (iii) 500,000 shares of our common stock at $0.40 per share with an expiration date of July 1, 2021, such options to become
    exercisable upon our achieving $5 million in revenues in any fiscal year prior to the expiration date. Each such option held
    by Mr. Strawn is exercisable on a cashless basis.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;(4)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
    his director&rsquo;s agreement effective as of September 4, 2014, Dr. DiTrolio was granted options consisting the right to
    purchase (i) 250,000 shares of our common stock at $0.20 per share with an expiration date of September 4, 2024; and (ii)
    125,000 shares of our common stock at an exercise price of $0.40 per share with an expiration date of September 4, 2024, such
    options to become exercisable upon our achieving $5 million in revenues in any fiscal year prior to the expiration date. Dr.
    DiTrolio was also granted options to purchase shares of our common stock in connection with his consulting agreement with
    the company. See &ldquo;Consulting Agreement with Directors&rdquo; under &ldquo;Certain Relationships and Related Transactions.&rdquo;
    </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors may determine remuneration to be paid to the directors with interested members refraining from voting. Our
independent directors each have entered into director&rsquo;s agreements with us, pursuant to which they will receive annual cash
compensation of an amount to be negotiated and agreed upon when we have the financial wherewithal to pay such compensation for
their service. We also made grants of 10-year, fully-vested options to purchase 810,000 and 2,000,000 shares of our common stock
as described in the footnotes to the above table to Dr. Bruzzese and Mr. Strawn, respectively, pursuant to their director&rsquo;s
agreements effective as of April 20, 2011. Dr. DiTrolio was granted 10-year, fully-vested options to purchase 325,000 shares of
our common stock as described in the footnote to the above table. If at any time prior to the expiration date of the options we
merge into or are acquired by another company, any outstanding options granted under the directors&rsquo; agreements will become
immediately exercisable on the business day immediately preceding the merger or acquisition at $0.40 per share or the preceding
average 30-day market price of our common stock prior to the announcement of such merger or acquisition, whichever price is lower.
We do not compensate our non-independent director, Mr. McLaughlin, for serving as our director. All directors are eligible to
receive reimbursement of expenses incurred with respect to attendance at board meetings, which is not included in the above table.
We do not maintain a medical, dental or retirement benefits plan specifically for our directors, but all directors are eligible
to participate in our employee group health and dental insurance plans.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><A NAME="a_020"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item
12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
following sets forth information as of May 15, 2017, regarding the number of shares of our common stock beneficially owned by
(i) each person that we know beneficially owns more than 5% of our outstanding common stock, (ii) each of our directors and named
executive officer and (iii) all of our directors and named executive officer as a group.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amounts and percentages of our common stock beneficially owned are reported on the basis of SEC rules governing the determination
of beneficial ownership of securities. Under the SEC rules, a person is deemed to be a &ldquo;beneficial owner&rdquo; of a security
if that person has or shares &ldquo;voting power,&rdquo; which includes the power to vote or to direct the voting of such security,
or &ldquo;investment power,&rdquo; which includes the power to dispose of or to direct the disposition of such security. A person
is also deemed to be a beneficial owner of any securities of which that person has the right to acquire beneficial ownership within
60 days through the exercise of any stock option, warrant or other right. Under these rules, more than one person may be deemed
a beneficial owner of the same securities and a person may be deemed to be a beneficial owner of securities as to which such person
has no economic interest. Unless otherwise indicated, each of the shareholders named in the table below, or his or her family
members, has sole voting and investment power with respect to such shares of our common stock. Except as otherwise indicated,
the address of each of the shareholders listed below is: c/o Immudyne, Inc., 50 Spring Meadow Rd., Mount Kisco, NY 10549.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid"><B>Name of beneficial owner</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Number of shares</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><B>Percent of class</B></TD><TD STYLE="padding-bottom: 1.5pt"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-style: italic">5% Shareholders</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Lane Deyoe <BR>11997 N. Lake Dr. <BR>Boynton Beach, FL 33436</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">3,945,629</TD><TD STYLE="width: 1%; text-align: left">(1)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">10.4</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-style: italic; text-align: left">Directors and named executive officers</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Mark McLaughlin</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,590,009</TD><TD STYLE="text-align: left">(2)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24.5</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Justin Schreiber</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,577,408</TD><TD STYLE="text-align: left">(3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11.7</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Stefan Galluppi</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,150,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.1</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Anthony G. Bruzzese, M.D.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,100,799</TD><TD STYLE="text-align: left">(4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.5</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">John R. Strawn, Jr.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,115,000</TD><TD STYLE="text-align: left">(5)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.7</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Joseph DiTrolio, M.D.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">325,000</TD><TD STYLE="text-align: left">(6)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Sven Rohmann, M.D.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Directors and named executive officer as a group(7 persons)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,858,216</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">46.1</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    195,000 shares and presently-exercisable warrants to purchase 474,831 shares held of record by the Deyoe Family Limited Partnership
    over which Mr. Deyoe has sole voting and dispositive power. Also includes presently-exercisable options to purchase 300,000
    shares. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of 588,236 shares held of record by McLaughlin International, Inc., presently-exercisable warrants to purchase 1,500,000 shares,
    presently-exercisable warrants to purchase 294,118 shares held of record by McLaughlin International, Inc. and presently-exercisable
    options to purchase 4,139,313 shares. Mr. McLaughlin has sole voting and dispositive power over all shares and warrants held
    of record by McLaughlin International, Inc.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of 2,768,272 shares held of record by JOJ Holdings, Inc., presently-exercisable warrants to purchase 809,136 shares and presently-exercisable
    options to purchase 1,000,000 </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of 115,000 shares held jointly with Dr. Bruzzese&rsquo;s spouse, presently-exercisable warrants to purchase 219,666 shares
    and presently-exercisable options to purchase 850,800 shares.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    400,000 shares and presently-exercisable warrants to purchase 200,000 shares held of record by Strawn Pickens LLP over which
    Mr. Strawn has shared voting and dispositive power, and presently-exercisable options to purchase 2,000,000 shares.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of presently-exercisable options to purchase 350,000 shares. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are not aware of any arrangements that could result in a change in control of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2016, we have no formal equity compensation plan in effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><A NAME="a_021"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
13. Certain Relationships and Related Transactions, and Director Independence</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the executive officer and director compensation arrangements discussed in &ldquo;Executive Compensation&rdquo; beginning
on page 32, the following describes transactions since January 1, 2015, to which we have been a participant, in which the amount
involved in the transaction exceeds the lesser of $120,000 or 1% of the average of our total assets at year end and in which any
of our directors, executive officer or holders of more than 5% of our capital stock, or any immediate family member of, or person
sharing the household with, any of these individuals, had or will have a direct or indirect material interest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Royalty
Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were subject to a royalty agreement, pursuant to which we are required to pay a monthly royalty of 8% on all sales of certain
skin care products up to $227,175. We entered into the royalty agreement to settle a suit between Mr. McLaughlin and us, over
disputed patent and licensing arrangements. Mr. McLaughlin, our President, has a 60% interest in the royalties paid under the
agreement, or $136,305, and Akin, Gump, Strauss, Hauer &amp; Feld L.L.P., Mr. McLaughlin&rsquo;s counsel in the matter, is entitled
to the remaining 40% interest. During the year ended December 31, 2015, the Company&rsquo;s sales reached the maximum amount under
which the Company is required to pay royalty under the agreement. Mr. McLaughlin converted royalties payable under the agreement
in the amount of $84,868 to 499,225 shares of the Company&rsquo;s common stock at a conversion rate of $0.17 per share. As consideration
for Mr. McLaughlin foregoing the cash payment due him for several years, we granted him a three year option to purchase 339,473
shares of Immudyne&rsquo;s common stock at $0.10 per share. Royalty expense under the agreement amounted to $0 and $20,157 for
the years ended December 31, 2016 and 2015, respectively</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Indebtedness
to our President, Directors and Shareholders</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, Mr. McLaughlin, our President, has made short-term advances to us for our operating needs. These advances bear no
interest, are unsecured and have no fixed terms of repayment. In 2014, the largest aggregate amount of principal outstanding was
$17,000 and no interest was paid thereon. In 2015, the largest principal amount outstanding was $30,000, and no interest was paid
thereon. As of December 31, 2016, no amounts are due to Mr. McLaughlin for any advances as they have repaid in full.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, Dr. Bruzzese, our Chairman, has made advances to us for our operating needs. These advances bore interest at 5%
per annum, were unsecured and had no fixed terms of repayment. Since 2014, the largest aggregate amount of principal outstanding
was $10,200. In 2014, no principal was paid and $595 of interest was paid. In 2015, $445.95 of interest was accrued and the total
principal amount and accrued interest was satisfied by the issuance of 60,000 shares of our common stock at $0.17 per share and
three year options to purchase 40,800 shares of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lane
Deyoe, a greater than 10% shareholder of company, loaned us $75,000 at 5% per annum for our operating needs on July 23, 2015.
As consideration for the extension of the loan, we granted Mr. Deyoe three year options to purchase 300,000 shares of our common
stock. In December 2015 the loan was satisfied through the issuance of 441,177 shares of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Justin
Schreiber, a greater than 5% shareholder of our company, and President of Immudyne PR, provided a $100,000 loan to the Company
in December of 2016 that bore no interest and which repaid in full in March 2017. In addition, in January of 2017, Mr. Schreiber
purchased $100,000 of 11% promissory notes of the Company and was issued 217,391 shares of its Common Stock in connection with
this purchase. $70,000 of the principal amount of this note has been repaid as of the date hereof. Finally, Mr. Schreiber also
received 434,782 shares of common stock in November of 2016 for a conversion of an equity contribution to Immudyne PR and was
issued 217,391 two-year warrants with an exercise price of $0.40 per share in connection with such conversion. A similar equity
contribution conversion took place in January of 2017, whereby Mr. Schreiber received 1,183 shares of common stock and 591,745
2-year warrants at an exercise price of $0.40 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Employment
Arrangements with an Immediate Family Member of our President</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brunilda
McLaughlin, the wife of Mr. McLaughlin, our President, is our full time accounting and accounts receivable employee. Under our
employment agreement with Mrs. McLaughlin, we compensate her for her full-time services with (a) cash compensation of $3,000 per
month; (b) 10-year, fully-vested options with cashless exercise rights to purchase 200,000 shares of our common stock at $0.20
per share; (c) 10-year, fully-vested options with cashless exercise rights to purchase 100,000 shares of our common stock at $0.40
per share, such options to become exercisable upon our achieving $5 million in revenues in any fiscal year prior to the expiration
date; and (d) an annual incentive bonus award amounting to 0.5% of our pre-tax earnings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Legal
Services Provided by Director</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Strawn
Pickens LLP, a law firm co-founded by one of our directors, Mr. Strawn, performs legal services on our behalf on an hourly-fee
basis in the ordinary course and has a contingency fee arrangement with us in a suit with former officers of the company and their
affiliated entities. In June 2012, we issued Strawn Pickens LLP 402,333 shares of our common stock and 3-year warrants to purchase
200,000 shares of our common stock at $0.40 per share in satisfaction of approximately $68,000 in legal services. In 2013, we
compensated Mr. Strawn $176,000 ($82,000 paid in 2013 and $94,000 paid in 2014) in conjunction with the Company&rsquo;s judgment
against and settlement with a former officer and affiliated parties. In 2016, there was no compensation provided to this director
for legal services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Office
Space Provided by our Officers</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
principal executive offices are in office space provided to us by our President, Mr. McLaughlin at $2,000 per month, which includes
rents, utilities and other office related expenditures. This arrangement commenced as of January 1, 2016. In addition, Immudyne
PR utilizes office space in Puerto Rico which is subleased by Mr. Schreiber. Immudyne PR incurs expense of approximately $4,000
a month for this office space.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Immudyne
PR Operating Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 1, 2016, the Company entered into a limited liability company operating agreement (with Taggart International Trust (&ldquo;Taggart&rdquo;)
and American Nutra Tech to amend and restate its existing agreements with these parties dated October 8, 2015 with respect to
the Company&rsquo;s joint venture doing business as Inate. The legal name of the joint venture limited liability company is ImmuDyne
PR LLC. Pursuant to the terms of the Operating Agreement, the Company increased its ownership and voting interest in the joint
venture to 78.16667%. Each of Taggart and American Nutra Tech hold an equity percentage of 11.3333% and 10.5%, respectively. Taggarat
International Trust is wholly owned by Justin Schreiber, President of Immudyne PR, and American Nutra Tech is wholly owned and
operated by Stefan Galluppi, Chief Executive Officer of Immudyne PR.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Services
Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 1, 2016, the Company entered into two services agreements with each of JLS, an entity wholly owned and operated by Justin
Schreiber, President of Immudyne PR, and American Nutra Tech, an entity wholly owned and operated by Stefan Galluppi, Chief Executive
Officer of Immudyne PR. Under the terms of these Service Agreements each of JLS and American NutraTech are required to provide
certain operational management services and other business counsel to the Company and Inate. As consideration for these services,
the Company issued each of JLS and American NutraTech 1,000,000 restricted shares of its common stock, which issuance may be rescinded
in the event Inate did not distribute at least $500,000 to the Company by December 31, 2016. Inate did not make such distribution
by December 31, 2016 and as such the Company held a rescission right with respect to the restricted shares issued to each of JLS
and American Nutra Tech. With respect to JLS the Company agreed to permit JLS to retain the shares so long as the required distribution
was achieved by December 31, 2017. The Company is currently in negotiations with respect to the shares issued to American Nutra
Tech for which the Company has a rescission right. Additional shares and/or options may also be issued upon certain financial
milestones being achieved by Inate as specified in the Services Agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consulting
Agreement with Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 12, 2012, we entered into a consultant agreement with one of our current directors, Joseph V. DiTroilio M.D. Under the
agreement Dr. DiTrolio is to serve as a Chief Medical Officer of North America of the Company for a term of three years. In connection
with the agreement Dr. DiTrolio was granted options consisting of the right to purchase (i) 100,000 shares of our common stock
at $0.20 per share with an expiration date of September 12, 2022; (ii) 250,000 shares of our common stock at $0.40 per share with
an expiration date of September 12, 2022, such options to become exercisable upon our achieving $5 million in revenues in any
fiscal year prior to the expiration date; and (iii) 250,000 shares of our common stock at $0.80 per share with an expiration date
of September 12, 2022, such options to become exercisable upon our achieving $10 million in revenues in any fiscal year prior
to the expiration date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Director
Independence</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors currently is comprised of five directors, Dr. Bruzzese, Dr. DiTrolio, Dr. Rohmann, Mr. Aldridge and Messrs.
McLaughlin and Strawn. While we are not subject to any director independence requirements because of our quotation on the OTC
Markets-OTQB, we have adopted the NASDAQ listed company standards for the purposes of determining director independence. Under
these standards, the Board of Directors has determined that Dr. Bruzzese qualifies as an independent director. In determining
the independence of our directors, the Board of Directors considered all transactions in which we and any director had any interest,
including those discussed under &ldquo;Certain Relationships and Related Transactions&rdquo; beginning on page [37] of this Annual
Report. The Board of Directors currently has no separately designated standing committees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><A NAME="a_022"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
14. Principal Accounting Fees and Services</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors has selected PKF O&rsquo;Connor Davies, LLP (&ldquo;PKF&rdquo;) as the independent registered public accounting
firm to audit our books and accounts for the fiscal years ending December 31, 2016 and 2015. PKF has served as our independent
accountant since 2010. The aggregate fees billed, or expected to be billed, for the last two fiscal years ended December 31, 2016
and 2015, for professional services rendered by PKF were as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2016</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2015</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font: 10pt Times New Roman, Times, Serif; text-align: left">Audit fees</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">128,712</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">49,289</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Audit-related fees</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Tax fees</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8,945</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,735</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">All other fees</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the above table, &ldquo;audit fees&rdquo; are fees billed for services provided related to the audit of our annual financial statements,
quarterly reviews of our interim financial statements, and services normally provided by the independent accountant in connection
with statutory and regulatory filings or engagements for those fiscal periods. &ldquo;Tax fees&rdquo; are fees billed, or to be
billed, by the independent accountant for professional services rendered for tax compliance, tax advice and tax planning.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Board of Directors pre-approves all services provided by our independent accountants. Our Board of Directors reviewed and approved
all of the above services and fees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 42; Value: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_023"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PART
IV</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><A NAME="a_024"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
15. Exhibits, Financial Statement Schedules</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following documents are filed as part of or are included in this Annual Report:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    statements listed in the Index to Financial Statements, filed as part of this Annual Report beginning on page F-1; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits
    listed in the Exhibit Index filed as part of this Annual Report.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: -36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_026"></A><B>IMMUDYNE, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For The Years Ended</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">December 31, 2016 and 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 90%; border-bottom: Black 1.5pt solid; padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font-size: 10pt"><B>Table of Contents</B></FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Table</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><FONT STYLE="font-size: 10pt"><A HREF="#report">Report of Independent Registered Public Accounting Firm</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">F-2</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><A HREF="#a_028"><FONT STYLE="font-size: 10pt">Balance Sheet as of December 31, 2016 and 2015</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">F-3</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><A HREF="#a_029"><FONT STYLE="font-size: 10pt">Statement of Operations for the years ended December 31, 2016 and 2015</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">F-4</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><A HREF="#a_030"><FONT STYLE="font-size: 10pt">Statement of
    Stockholders&rsquo; Equity (Deficit) for the years ended December 31, 2016 and 2015</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">F-5</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><A HREF="#a_031"><FONT STYLE="font-size: 10pt">Statement of Cash Flows for the years ended December 31, 2016 and 2015</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">F-6</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><A HREF="#a_032"><FONT STYLE="font-size: 10pt">Notes to Financial Statements</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">F-7</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 44; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center"><B><A NAME="report"></A>Report of Independent Registered
Public Accounting Firm</B></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt">&nbsp;</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"><B>To the Board of Directors and </B></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"><B>Stockholders of Immudyne, Inc.</B></P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt">We have audited the accompanying consolidated balance
sheets of Immudyne, Inc. as of December 31, 2016 and 2015, and the related consolidated statements of operations, stockholders&rsquo;
equity (deficit), and cash flows for the years then ended. These consolidated financial statements are the responsibility of the
Company&rsquo;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our
audits.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt">We conducted our audits in accordance with the standards
of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to
obtain reasonable assurance about whether the financial statements are free of material misstatement. We were not engaged to perform
an audit of the Company&rsquo;s internal control over financial reporting. Our audits included consideration of internal control
over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose
of expressing an opinion on the effectiveness of the Company&rsquo;s internal control over financial reporting. Accordingly, we
express no such opinion. An audit also includes examining on a test basis, evidence supporting the amounts and disclosures in the
financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating
the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt">In our opinion, the consolidated financial statements
referred to above present fairly, in all material respects, the financial position of Immudyne, Inc. at December 31, 2016 and 2015,
and the results of its operations and its cash flows for the years then ended in conformity with accounting principles generally
accepted in the United States of America.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt">The accompanying financial statements have been prepared
assuming that the Company will continue as a going concern. The Company has incurred a significant accumulated deficit through
December 31, 2016, and has incurred negative cash flows for the year ended December 31, 2016. These factors raise substantial doubt
about the Company's ability to continue as a going concern. Management's plans in regard to these matters are described in Note
1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt">/s/ PKF O&rsquo;Connor Davies, LLP</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0">Harrison, NY</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt">May 23, 2017</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_028"></A>Immudyne,
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
Balance Sheets</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31, 2016</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31, 2015</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">ASSETS</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>Current Assets</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-indent: 10pt">Cash</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">182,561</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">232,984</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Trade accounts receivable, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">444,743</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">154,436</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Other receivables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,250</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Inventory, net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">160,270</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">61,051</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 30pt">Total Current Assets</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">789,824</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">448,471</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Current Liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Accounts payable and accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">752,930</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">167,481</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Derivative liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">192,254</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Convertible notes payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Notes payable, net of discount</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">106,365</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">100,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 30pt">Total Current Liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,151,549</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">267,481</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Immudyne, Inc. Stockholders&rsquo; Equity (Deficit)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -10pt; padding-left: 20pt">Common stock, $0.01 par value; 50,000,000 shares authorized, 35,570,157 and 32,010,375 shares issued, 35,245,157 and 32,010,375 outstanding as of December 31, 2016 and 2015, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">355,701</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">320,103</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,070,064</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,366,313</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Accumulated (deficit)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(9,693,882</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(8,586,338</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(268,117</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100,078</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Treasury stock, 325,000 shares, at cost</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(87,053</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 30pt">Total Immudyne, Inc. Stockholders&rsquo; Equity (Deficit)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(355,170</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100,078</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Non-controlling interest</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(6,555</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">80,912</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 30pt">Total Stockholders&rsquo; Equity (Deficit)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(361,725</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">180,990</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 30pt">Total Liabilities and Stockholders&rsquo; Equity (Deficit)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">789,824</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">448,471</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-indent: 0"></P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_029"></A>Immudyne,
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
Statements of Operations</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Year Ended <BR> December 31,</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2016</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2015</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font-weight: bold; text-align: left">Net sales</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">5,238,604</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,218,862</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">Cost of sales</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,946,055</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">247,772</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Gross Profit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,292,549</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">971,090</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Operating expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Compensation and related expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,247,195</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">532,421</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Professional fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">477,401</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">114,890</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Marketing expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,710,357</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">230,661</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Research and development expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,925</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">General and administrative expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,032,278</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">331,410</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total operating expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,467,231</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,233,307</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Operating (Loss)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,174,682</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(262,217</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Gain on sale of Adiuvo Investment S.A. stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">127,261</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Interest (expense)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(48,611</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(37,476</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net Income (Loss) Before Taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,223,293</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(172,432</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Deferred income tax benefit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">13,200</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Net (Loss)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,223,293</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(159,232</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Net (loss) attributable to noncontrolling interests</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(115,749</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(97,240</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt">Net (loss) attributable to Immudyne, Inc.</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(1,107,544</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(61,992</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Basic and diluted (loss) per share attributable to Immudyne, Inc.</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(0.03</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(0.00</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Average number of common shares outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt">Basic</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">33,478,229</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">30,810,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">Diluted</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">33,478,229</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">30,810,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements&#9;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-indent: 0"></P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; margin-top: 0; text-align: center; margin-bottom: 0"><A NAME="a_030"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Immudyne,
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; margin-top: 0; text-align: center; margin-bottom: 0">Consolidated
Statement of Stockholders&rsquo; Equity (Deficit)</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; margin-top: 0; text-align: center; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2016 and 2015</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 9pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="22" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 9pt">Immudyne,
    Inc.</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 9pt">Additional</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 9pt">Common
    Stock</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 9pt">Paid-in</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 9pt">Accumulated</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 9pt">Treasury</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 9pt">Sub</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 9pt">Noncontrolling</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 9pt">Shares</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 9pt">Amount</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 9pt">Capital</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 9pt">(Deficit)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 9pt">Stock</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 9pt">Total</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 9pt">interest</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 9pt">Total</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 20%; font-size: 10pt; text-indent: -5pt; padding-left: 5pt"><FONT STYLE="font-size: 9pt">Balance at December&nbsp;31,
    2014</FONT></TD><TD STYLE="width: 1%; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="width: 7%; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">30,729,973</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="width: 7%; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">307,299</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="width: 7%; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">8,077,549</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="width: 7%; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">(8,524,346</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">)</FONT></TD><TD STYLE="width: 1%; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="width: 7%; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="width: 7%; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">(139,498</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">)</FONT></TD><TD STYLE="width: 1%; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="width: 7%; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">$</FONT></TD><TD STYLE="width: 7%; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">(139,498</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -5pt; padding-left: 10pt"><FONT STYLE="font-size: 9pt">Amortization
    of stock options</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">22,300</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">22,300</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">22,300</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -5pt; padding-left: 10pt"><FONT STYLE="font-size: 9pt">Purchase
    of company stock</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">(120,000</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">)</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">(1,200</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">)</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">(9,600</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">)</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">(10,800</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">)</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">(10,800</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -5pt; padding-left: 10pt"><FONT STYLE="font-size: 9pt">Issuance
    of company stock for notes and other payables</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">1,000,402</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">10,004</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">160,064</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">170,068</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">170,068</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -5pt; padding-left: 10pt"><FONT STYLE="font-size: 9pt">Issuance
    of common stock for services</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">500,000</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">5,000</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">60,000</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">65,000</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">65,000</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -5pt; padding-left: 10pt"><FONT STYLE="font-size: 9pt">Company
    stock cancelled</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">(100,000</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">)</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">(1,000</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">)</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">1,000</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -5pt; padding-left: 10pt"><FONT STYLE="font-size: 9pt">Extension
    of option and warrant expiration dates</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">55,000</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">55,000</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">55,000</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -5pt; padding-left: 10pt"><FONT STYLE="font-size: 9pt">Investment
    in subsidiary by noncontrolling interest</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">178,152</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">178,152</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -5pt; padding-left: 5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1.5pt; text-indent: -5pt; padding-left: 10pt"><FONT STYLE="font-size: 9pt">Net
    (loss)</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">(61,992</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">)</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">(61,992</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">)</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">(97,240</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">)</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">(159,232</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-indent: -5pt; padding-left: 5pt"><FONT STYLE="font-size: 9pt">Balance at December 31, 2015</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">32,010,375</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">320,103</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">8,366,313</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">(8,586,338</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">)</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">100,078</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">80,912</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">180,990</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -5pt; padding-left: 5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -5pt; padding-left: 10pt"><FONT STYLE="font-size: 9pt">Amortization
    of stock options</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">120,867</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">120,867</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">120,867</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -5pt; padding-left: 10pt"><FONT STYLE="font-size: 9pt">Issuance
    of common stock for services</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">2,300,000</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">23,000</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">360,333</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">383,333</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">383,333</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -5pt; padding-left: 10pt"><FONT STYLE="font-size: 9pt">Sale of
    common stock and warrants</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">275,000</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">2,750</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">60,500</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">63,250</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">63,250</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -5pt; padding-left: 10pt"><FONT STYLE="font-size: 9pt">Conversion
    of NCI equity for shares</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">434,782</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">4,348</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">95,652</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">100,000</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">100,000</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -5pt; padding-left: 10pt"><FONT STYLE="font-size: 9pt">Issuance
    of common stock for options exercise</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">300,000</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">3,000</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">27,000</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">30,000</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">30,000</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -5pt; padding-left: 10pt"><FONT STYLE="font-size: 9pt">Issuance
    of common stock in relation to debt offering</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">250,000</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">2,500</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">56,250</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">58,750</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">58,750</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -5pt; padding-left: 10pt"><FONT STYLE="font-size: 9pt">Issuance
    of warrants for services</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">20,585</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">20,585</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">20,585</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -5pt; padding-left: 10pt"><FONT STYLE="font-size: 9pt">Reduction
    in noncontrolling interest</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">91,612</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">91,612</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">(91,612</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">)</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -5pt; padding-left: 10pt"><FONT STYLE="font-size: 9pt">Purchase
    of treasury stock</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">(87,053</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">)</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">(87,053</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">)</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">(87,053</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -5pt; padding-left: 10pt"><FONT STYLE="font-size: 9pt">Issuance
    of stock options for services</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">63,206</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">63,206</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">63,206</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -5pt; padding-left: 10pt"><FONT STYLE="font-size: 9pt">Investment
    in subsidiary by noncontrolling interest</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">119,894</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">119,894</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -5pt; padding-left: 10pt"><FONT STYLE="font-size: 9pt">Reclassification
    of options, warrants and other contracts from equity to derivative liabilities</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">(192,254</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">)</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">(192,254</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">)</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">(192,254</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -5pt; padding-left: 5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1.5pt; text-indent: -5pt; padding-left: 10pt"><FONT STYLE="font-size: 9pt">Net
    (loss)</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">(1,107,544</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">)</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">(1,107,544</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">)</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">(115,749</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">)</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 9pt">(1,223,293</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 9pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 4pt; text-indent: -5pt; padding-left: 5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">Balance
    at December&nbsp;31, 2016</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">35,570,157</FONT></TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">355,701</FONT></TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">9,070,064</FONT></TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">(9,693,882</FONT></TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">(87,053</FONT></TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">(355,170</FONT></TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">(6,555</FONT></TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">(361,725</FONT></TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">)</FONT></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-indent: 0"></P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; margin-top: 0; text-align: center; margin-bottom: 0"><A NAME="a_031"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Immudyne,
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated
Statements of Cash Flows </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center">Year Ended</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid">December 31,</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2016</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2015</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left">CASH FLOWS FROM OPERATING ACTIVITIES</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Net (Loss)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(1,223,293</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(159,232</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Adjustments to reconcile net (loss) to net &nbsp;cash (used) by operating activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">Depreciation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">43,748</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Bad debt provision</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">71,136</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Amortization of debt discount</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">33,715</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Deferred tax benefit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(13,200</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Stock compensation expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">587,991</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">77,300</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Common stock issued for services</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">65,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Gain on sale of Adiuvo Investment S.A. stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(127,261</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Changes in Assets and Liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Trade accounts receivable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(361,443</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(139,466</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Other receivables</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,250</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">Inventory</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(99,219</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(20,043</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Accounts payable and accrued expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">585,449</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(21,970</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Net cash (used) by operating activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(407,914</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(295,124</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Proceeds from sale of Adiuvo Investment S.A. stock</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">127,261</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Investment in subsidiary by noncontrolling interest</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">219,894</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">178,152</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Increase in notes payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">200,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">305,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Proceeds from convertible note payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Repayment of notes payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(168,600</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(147,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Proceeds from options exercise</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">30,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Sale of common stock and warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">63,250</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Purchase of treasury stock</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(87,053</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(10,800</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Net cash provided by financing activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">357,491</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">325,352</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net (decrease) increase in cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(50,423</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">157,489</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Cash at beginning of the year</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">232,984</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">75,495</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Cash at end of the year</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">182,561</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">232,984</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-decoration: underline; text-align: left">Supplemental Disclosure of Cash Flow Information</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Cash paid during the period for interest</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">13,650</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">28,976</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Issuance of company stock for notes and other payables</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">170,068</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Issuance of common stock in relation to debt offering</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">58,750</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Reclassification of options, warrants and other contracts from equity to
    derivative liabilities</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">192,254</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Conversion of equity invested in subsidiary to common stock and warrants</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">100,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"><A NAME="a_032"></A><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Immudyne,
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to Consolidated Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
31, 2016</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Organization
    and Going Concern</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immudyne,
Inc. (the &ldquo;Company&rdquo;) is a Delaware corporation established to develop, manufacture and sell natural immune support
products containing the Company&rsquo;s proprietary yeast beta glucans, a group of beta glucans naturally occurring in the cell
walls of yeast that have been shown through testing and analysis to support the immune system. The Company&rsquo;s products include
once a day oral intake tablets and topical creams and gels for skin application. The Company concentrates its sales and marketing
efforts on healthcare professionals, distributors for its all-natural raw material ingredient products and direct-to-consumer
sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left">In 2015, the Company formed
a joint venture domiciled in Puerto Rico, Innate Skincare, LLC d/b/a Innate Scientific, LLC (&ldquo;Innate&rdquo;). Under the
terms of the joint venture agreement, the Company held a 33.3% equity interest, and a 51% controlling voting interest, in
Innate. On January 20, 2016, Innate amended its limited liability company operating agreement and changed its legal name to
Immudyne PR LLC (&ldquo;Immudyne PR&rdquo;). On April 1, 2016, Immudyne PR further amended its operating agreement and
restated the Company&rsquo;s ownership and voting interest in Immudyne PR increasing its ownership to 78.16667% resulting in
a charge to noncontrolling interest and additional paid-in-capital of $91,612. Immudyne PR was formed to launch a complete
skin care regime formulated using strategic ingredients provided by the Company. Immudyne PR is also currently pursuing other
opportunities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has funded operations in the past through the sales of its products, issuance of common stock and through loans and advances
from officers and directors. The Company&rsquo;s continued operations are dependent upon obtaining an increase in its sales volume
and the continued financial support from officers and directors or the issuance of additional shares of common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements have been prepared on the basis that the Company will continue as a going concern, which assumes
the realization of assets and the satisfaction of liabilities in the normal course of business. At December 31, 2016, the Company
has an accumulated deficit approximating $9.7 million and has incurred negative cash flows from operations. These conditions raise
substantial doubt about the Company's ability to continue as a going concern. The accompanying financial statements do not include
any adjustments that might result from the outcome of this uncertainty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the Company's cash balance at December 31, 2016, and projected cash needs for 2017, management estimates that it may need to
increase sales revenue and/or raise additional capital to cover operating and capital requirements for the 2017 year. Management
may raise the additional needed funds through increased sales volume, issuing additional shares of common stock or other equity
securities, or obtaining debt financing. Although management has been successful to date in raising necessary funding, there can
be no assurance that sales revenue will substantially increase or that any required future financing can be successfully completed
on a timely basis, or on terms acceptable to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Immudyne,
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to Consolidated Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
31, 2016</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Summary
    of Significant Accounting Policies</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Principles
of Consolidation</I></B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The Company evaluates the need to consolidate
affiliates based on standards set forth in ASC 810 Consolidation (&ldquo;ASC 810&rdquo;).</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The consolidated financial statements include
the accounts of the Company and its majority owned subsidiary, Immudyne PR and variable interest entities (VIE&rsquo;s) in which
the Company has been determined to be the primary beneficiary. The non- controlling interest in Immudyne PR represents the 21.833%
equity interest held by other members of the joint venture. All significant consolidated transactions and balances have been eliminated
in consolidation.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>Variable Interest Entities</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The Company follows ASC 810-10-15 guidance
with respect to accounting for variable interest entities (each, a &ldquo;VIE&rdquo;). These entities do not have sufficient equity
at risk to finance their activities without additional subordinated financial support from other parties or whose equity investors
lack any of the characteristics of a controlling financial interest. A variable interest is an investment or other interest that
will absorb portions of a VIE&rsquo;s expected losses or receive portions of its expected residual returns and are contractual,
ownership, or pecuniary in nature and that change with changes in the fair value of the entity&rsquo;s net assets. A reporting
entity is the primary beneficiary of a VIE and must consolidate it when that party has a variable interest, or combination of variable
interests, that provides it with a controlling financial interest. A party is deemed to have a controlling financial interest if
it meets both of the power and losses/benefits criteria. The power criterion is the ability to direct the activities of the VIE
that most significantly impact its economic performance. The losses/benefits criterion is the obligation to absorb losses from,
or right to receive benefits from, the VIE that could potentially be significant to the VIE. The VIE model requires an ongoing
reconsideration of whether a reporting entity is the primary beneficiary of a VIE due to changes in facts and circumstances.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">As of December 31, 2016 and 2015, the Company
consolidated nine and zero VIEs, respectively.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Immudyne PR as the primary beneficiary of Ace Account Management LLC, Innerwell Skincare
LLC, MCD Merchants LLC, One Equity Research LLC, Inate Gems LLC, Retriever Health Products LLC, Spurs 5, LLC, Salus LLC and Huntley
LLC which are qualified as VIEs. The assets and liabilities and revenues and expenses of these VIEs included in the financial
statements of Immudyne PR and further included in the consolidated financial statements. As of December 31, 2016, the VIEs had
assets of $10,306, liabilities of $5,748, revenues of $6,271, and operating expenses of $6,141. The assets and liabilities include
balances due from and due to the subsidiaries of Immudyne PR. These inter-company receivables and payables are eliminated upon
consolidation of the VIE with Immudyne PR and Immudyne. No assets were pledged or given as collateral against any borrowings.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Immudyne,
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Notes
to Consolidated Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">December
31, 2016</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>2.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Summary
    of Significant Accounting Policies</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The Company utilizes third party entities to
provide and increase credit card processing capacity and optimize corresponding rates and fees. A majority of these entities provide
this service as independent contractors in exchange for a one (1%) percent fee of the net revenues processed and collected by such
contractors from sales initiated by the Company. The VIEs consolidated in the Company&rsquo;s financial statements are primarily
contracted to credit card processing through one or more merchant banks contracted by each VIE. Upon receipt of funds by each VIE,
the collection of receipts less any returns, chargeback and other fees charged by such merchant bank is transferred to Immudyne
PR.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B><I>Use of Estimates</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><B><I></I></B>The
Company prepares its consolidated financial statements in conformity with accounting principles generally accepted in the United
States of America which requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Some of
the more significant estimates required to be made by management include the determination of reserves for accounts receivable,
returns and allowances, the accounting for derivatives, the valuation of inventory and stockholders&rsquo; equity based transactions.
Actual results could differ from those estimates.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B><I>Derivative Liabilities</I></B>&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">The Company evaluates
stock options, stock warrants or other contracts to determine if those contracts or embedded components of those contracts qualify
as derivatives to be separately accounted for under the relevant sections of Financial Accounting Standards Board (&ldquo;FASB&rdquo;)
Accounting Standards Codification (&ldquo;ASC&rdquo;) Topic 815-40, Derivative Instruments and Hedging: Contracts in Entity&rsquo;s
Own Equity. The result of this accounting treatment could be that the fair value of a financial instrument is classified as a derivative
instrument and is marked-to-market at each balance sheet date and recorded as a liability. In the event that the fair value is
recorded as a liability, the change in fair value is recorded in the consolidated statements of operations as other income or other
expense. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date
and then that fair value is reclassified to equity.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Financial instruments
that are initially classified as equity that become subject to reclassification under ASC Topic 815-40 are reclassified to a liability
account at the fair value of the instrument on the reclassification date.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">As of December 31, 2016, certain of the Company&rsquo;s
stock options, stock warrants and convertible debt instruments were accounted for as derivative liabilities due to insufficient
authorized shares of common stock to settle outstanding contracts. At December 31, 2016, the Company estimated the fair value
of these stock options, stock warrants and embedded conversion features using the Black-Scholes option pricing model (&ldquo;Black-Scholes&rdquo;)
in the amount of $192,254 was recorded upon issue&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><B><I>Sequencing Policy</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Under ASC 815-40-35, the
Company has adopted a sequencing policy whereby, in the event that reclassification of contracts from equity to assets or liabilities
is necessary pursuant to ASC 815 due to the Company&rsquo;s inability to demonstrate it has sufficient authorized shares, shares
will be allocated on the basis of the earliest issuance date of potentially dilutive instruments, with the earliest grants receiving
the first allocation of authorized but unissued shares, and all future instruments being classified as a derivative liability,
with the exception of instruments related to share-based compensation issued to employees or directors.&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><B><I>Inventory&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2016 and December 31, 2015, inventory consisted primarily of cosmetic and nutraceutical additives, and finished cosmetic
products. Inventory is maintained in the Company&rsquo;s leased Kentucky warehouse and third party warehouses in Pennsylvania
and Louisiana.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory
is valued at the lower of cost or market with cost determined on a first-in, first-out (&ldquo;FIFO&rdquo;) basis. Management
compares the cost of inventory with the net realizable value and an allowance is made for writing down inventory to market value,
if lower. At December 31, 2016 and December 31, 2015, the Company recorded an inventory reserve in the amount of $20,000. Inventory
consists of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31,<BR> 2016</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31,<BR> 2015</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 0.5in; background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 0pt">Raw materials</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">38,460</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">25,761</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Finished products</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">121,810</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">35,290</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">160,270</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">61,051</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Immudyne,
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to Consolidated Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
31, 2016</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Summary
    of Significant Accounting Policies (continued)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Revenue
Recognition</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: left">The Company&rsquo;s policy is to record revenue as earned
when a firm commitment, indicating sales quantity and price exists, delivery has taken place and collectability is reasonably assured.
The Company generally records sales of nutraceutical and cosmetic additives once the product is shipped to the customer, and for
sales of finished cosmetic products once the customer places the order and the product is simultaneously shipped, but in limited
cases if title does not pass until the product reaches the customer&rsquo;s delivery site, then recognition of revenue is deferred
until that time. Delivery is considered to have occurred when title and risk of loss have transferred to the customer. Provisions
for discounts, returns, allowances, customer rebates and other adjustments are netted with gross sales. The Company accounts for
such provisions during the same period in which the related revenues are earned. Customer discounts, returns and rebates approximated
$1,926,000 in the year ended December 31, 2016. Customer discounts, returns and rebates were not significant in the year ended
December 31, 2015.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: left">Delivery is considered to have occurred when title and
risk of loss have transferred to the customer. If title does not pass until the product reaches the customer&rsquo;s delivery site
or the customer accepts the product, then recognition of revenue is deferred until that time. There are no formal sales incentives
offered to any of the Company&rsquo;s customers. Volume discounts may be offered from time to time to customers purchasing large
quantities on a per transaction basis.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: left">Revenue for the year ended December 31, 2016 consisted
of nutraceutical and cosmetic additives ($997,964) and finished cosmetic products ($4,240,640). Revenue for the year ended December
31, 2015 consists of nutraceutical and cosmetic additives ($1,079,289) and finished cosmetic products ($139,573).</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Accounts
receivable</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Accounts receivable are carried at original
invoice amount less an estimate made for holdbacks and doubtful receivables based on a review of all outstanding amounts. Management
determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer&rsquo;s
financial condition, credit history and current economic conditions and sets up an allowance for doubtful accounts when collection
is uncertain. Customers&rsquo; accounts are written off when all attempts to collect have been exhausted. Recoveries of accounts
receivable previously written off are recorded as income when received. At December 31, 2016 and 2015 the accounts receivable reserve
was approximately $37,800 and $18,000, respectively. As of December 31, 2016, the reserve for sales returns and allowances was
approximately $50,500. No sales returns and allowances reserve existed at December 31, 2015.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Immudyne,
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to Consolidated Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
31, 2016</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Summary
    of Significant Accounting Policies (continued)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Segments</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
guidance for disclosures about segments of an enterprise requires that a public business enterprise report financial and descriptive
information about its operating segments. Generally, financial information is required to be reported on the basis used internally
for evaluating segment performance and resource allocation. The Company manages its operations in two reportable segments for
purposes of assessing performance and making operating decisions. Revenue is generated predominately in the United States, and
all significant assets are held in the United States, or United States territories.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies.
The Company allocates resources and evaluates the performance of segments based on income or loss from operations, excluding interest,
corporate expenses and other income (expenses).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the company&rsquo;s reportable segments is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt"><U>Total assets:</U></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt">December&nbsp;31,</FONT><BR>
<FONT STYLE="font-size: 10pt">2016</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt">December&nbsp;31,</FONT><BR>
<FONT STYLE="font-size: 10pt">2015</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 0.5in; background-color: white">&nbsp;</TD>
    <TD STYLE="background-color: #CCEEFF"><FONT STYLE="font-size: 10pt">Nutraceutical and Cosmetic Additives</FONT></TD>
    <TD STYLE="width: 1%; background-color: #CCEEFF">&nbsp;</TD>
    <TD STYLE="width: 1%; background-color: #CCEEFF"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 8%; background-color: #CCEEFF; text-align: right"><FONT STYLE="font-size: 10pt">556,234</FONT></TD>
    <TD STYLE="width: 1%; background-color: #CCEEFF">&nbsp;</TD>
    <TD STYLE="width: 1%; background-color: #CCEEFF">&nbsp;</TD>
    <TD STYLE="width: 1%; background-color: #CCEEFF"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 8%; background-color: #CCEEFF; text-align: right"><FONT STYLE="font-size: 10pt">412,324</FONT></TD>
    <TD STYLE="width: 1%; background-color: #CCEEFF">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Finished Cosmetic Products</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">422,288</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">101,828</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="background-color: #CCEEFF; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">Eliminations</FONT></TD>
    <TD STYLE="background-color: #CCEEFF; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; background-color: #CCEEFF">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; background-color: #CCEEFF; text-align: right"><FONT STYLE="font-size: 10pt">(188,698</FONT></TD>
    <TD STYLE="background-color: #CCEEFF; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">)</FONT></TD>
    <TD STYLE="background-color: #CCEEFF; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; background-color: #CCEEFF">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; background-color: #CCEEFF; text-align: right"><FONT STYLE="font-size: 10pt">(65,681</FONT></TD>
    <TD STYLE="background-color: #CCEEFF; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-size: 10pt"><B>Total</B></FONT></TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double"><FONT STYLE="font-size: 10pt"><B>$</B></FONT></TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"><FONT STYLE="font-size: 10pt"><B>789,824</B></FONT></TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: black 4.5pt double"><FONT STYLE="font-size: 10pt"><B>$</B></FONT></TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right"><FONT STYLE="font-size: 10pt"><B>448,471</B></FONT></TD>
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Year ended</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31, 2016</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31, 2015</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><U>Net sales by segment:</U></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 0.5in; background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Nutraceutical and Cosmetic Additives</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,024,264</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,092,289</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Finished Cosmetic Products</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4,240,640</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">139,573</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Eliminations</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(26,300</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(13,000</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">Total</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">5,238,604</TD><TD STYLE="padding-bottom: 4pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">1,218,862</TD><TD STYLE="padding-bottom: 4pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left">Net (loss) income by segment:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Nutraceutical and Cosmetic Additives</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">164,286</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">110,467</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Finished Cosmetic Products</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(388,121</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(158,402</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: left">Other unallocated amounts:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Corporate expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(950,847</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(214,282</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Other income (expense) &ndash; net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(48,611</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">89,785</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt">Consolidated income (loss) from operations</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(1,223,293</TD><TD STYLE="padding-bottom: 4pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">(172,432</TD><TD STYLE="padding-bottom: 4pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Immudyne,
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to Consolidated Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
31, 2016</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Summary
    of Significant Accounting Policies (continued)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Income
Taxes</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company files Corporate Federal and State tax returns, while Immudyne PR, which was formed as a limited liability corporation,
files a separate tax return with any tax liabilities or benefits passing through to its members.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company records current and deferred taxes in accordance with Accounting Standards Codification (ASC) 740, &ldquo;Accounting for
Income Taxes.&rdquo; This ASC requires recognition of deferred tax assets and liabilities for temporary differences between tax
basis of assets and liabilities and the amounts at which they are carried in the financial statements, based upon the enacted
rates in effect for the year in which the differences are expected to reverse. The Company establishes a valuation allowance when
necessary to reduce deferred tax assets to the amount expected to be realized. The Company periodically assesses the value of
its deferred tax asset, a majority of which has been generated by a history of net operating losses and determines the necessity
for a valuation allowance. ASC 740 also provides a recognition threshold and measurement attribute for the financial statement
recognition of a tax position taken or expected to be taken in a tax return. Using this guidance, a company may recognize the
tax benefit from an uncertain tax position in its financial statements only if it is more likely-than-not (i.e., a likelihood
of more than 50%) that the tax position will be sustained on examination by the taxing authorities, based on the technical merits
of the position.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s tax returns for all years since December 31, 2013, remain open to taxing authorities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Stock-Based
Compensation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company follows the provisions of ASC 718, &ldquo;Share-Based Payment&rdquo;. Under this guidance compensation cost generally
is recognized at fair value on the date of the grant and amortized over the respective vesting periods. The fair value of options
at the date of grant is estimated using the Black-Scholes option pricing model. The expected option life is derived from assumed
exercise rates based upon historical exercise patterns and represents the period of time that options granted are expected to
be outstanding. The expected volatility is based upon historical volatility of the Company&rsquo;s shares using weekly price observations
over an observation period that approximates the expected life of the options. The risk-free rate approximates the U.S. Treasury
yield curve rate in effect at the time of grant for periods similar to the expected option life. Due to limited history of forfeitures,
the estimated forfeiture rate included in the option valuation was zero.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of the assumptions require significant judgment and any changes could have a material impact in the determination of stock-based
compensation expense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<BR>
<B>Immudyne,
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to Consolidated Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
31, 2016</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Summary
    of Significant Accounting Policies (continued)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Earnings
(Loss) Per Share</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
earnings (loss) per common share is based on the weighted average number of shares outstanding during each period presented. Warrants
and options to purchase common stock are included as common stock equivalents only when dilutive. Potential common stock equivalents
are excluded from dilutive earnings per share when the effects would be antidilutive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: left"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Common stock equivalents comprising shares
underlying 16,302,447 options and warrants for the year ended December 31, 2016 have not been included in the loss per share calculation
as the effects are anti-dilutive. Common stock equivalents comprising shares underlying 12,775,273 options and warrants for the
year ended December 31, 2015 have not been included in the loss per share calculations as the effects are anti-dilutive.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Recent
Accounting Pronouncements</I></B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and
Cash Payments (&ldquo;ASU 2016-15&rdquo;). ASU 2016-15 addresses eight specific cash flow issues with the objective of reducing
diversity in practice regarding how certain cash receipts and cash payments are presented in the statement of cash flows. The
standard provides guidance on the classification of the following items: (1) debt prepayment or debt extinguishment costs, (2)
settlement of zero-coupon debt instruments, (3) contingent consideration payments made after a business combination, (4) proceeds
from the settlement of insurance claims, (5) proceeds from the settlement of corporate-owned life insurance policies, (6) distributions
received from equity method investments, (7) beneficial interests in securitization transactions, and (8) separately identifiable
cash flows. The Company is required to adopt ASU 2016-15 for fiscal years, and for interim periods within those fiscal years,
beginning after December 15, 2017 on a retrospective basis. Early adoption is permitted, including adoption in an interim period.
The Company is currently evaluating the impact of adoption of ASU 2016-15.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: left">In March 2016, the Financial
Accounting Standards Board (&ldquo;FASB&rdquo;) issued Accounting Standards Update (&ldquo;ASU&rdquo;) 2016-09,
&ldquo;Compensation &ndash; Stock Compensation: Improvements to Employee Share-Based Payment Accounting,&rdquo; which relates
to the accounting for employee share-based payments. This standard addresses several aspects of the accounting for
share-based payment award transactions, including: (a) income tax consequences; (b) classification flows of awards as either
equity or liabilities; and (c) classification on the statement of cash flows. This standard will be effective for fiscal
years beginning after December 15, 2016, including interim periods within those fiscal years. The Company is in the process
of evaluating the impact of the adoption of ASU 2016-09 on its consolidated financial statements. The adoption of ASU No.
2016-09 is not expected to have a material impact on the Company's consolidated financial statements or related
disclosures.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2016, a pronouncement was issued that creates new accounting and reporting guidelines for leasing arrangements. The new
guidance requires organizations that lease assets to recognize assets and liabilities on the balance sheet related to the rights
and obligations created by those leases, regardless of whether they are classified as finance or operating leases. Consistent
with current guidance, the recognition, measurement, and presentation of expenses and cash flows arising from a lease primarily
will depend on its classification as a finance or operating lease. The guidance also requires new disclosures to help financial
statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. The new standard is effective
for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period, with early
application permitted. The new standard is to be applied using a modified retrospective approach. The Company is in the process
of evaluating the impact of the new pronouncement on its consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Immudyne,
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to Consolidated Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
31, 2016</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Summary
    of Significant Accounting Policies (continued)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Recent
Accounting Pronouncements (continued)</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2014, the Financial Accounting Standards Board (&quot;FASB&quot;) issued accounting guidance, &quot;Revenue from Contracts
with Customers.&quot; The core principle of the new standard is for companies to recognize revenue to depict the transfer of goods
or services to customers in amounts that reflect the consideration (that is, payment) to which the company expects to be entitled
in exchange for those goods or services. The new standard also will result in enhanced disclosures about revenue, provide guidance
for transactions that were not previously addressed comprehensively (for example, service revenue and contract modifications)
and clarify guidance for multiple-element arrangements. The standard will be effective for fiscal years and interim periods within
those years beginning after December 15, 2017. Accordingly, the Company will adopt this standard in the first quarter of fiscal
year 2018. The Company is currently evaluating the impact this guidance will have on the consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 108pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: left">In July 2015, the Financial Accounting
Standards Board (&ldquo;FASB&rdquo;) issued Accounting Standards Update (&ldquo;ASU&rdquo;) 2015-11, &ldquo;Simplifying the Measurement
of Inventory.&rdquo; ASU 2015-11 applies to inventory that is measured using first-in, first-out (FIFO) or average cost. An entity
should measure inventory within the scope of ASU 2015-11 at the lower of cost and net realizable value. Net realizable value is
the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and
transportation. ASU 2015-11 is effective for fiscal years beginning after December 15, 2016. The adoption of ASU No. 2015-11 is
not expected to have a material impact on the Company's consolidated financial statements or related disclosures.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: left"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">In August 2014, the FASB issued ASU 2014-15,
&quot;Presentation of Financial Statements-Going Concern&quot;. This ASU is intended to define management's responsibility to evaluate
whether there is substantial doubt about an organization's ability to continue as a going concern and to provide related footnote
disclosures. It is effective for annual periods ending after December 15, 2016, with early adoption permitted. The Company does
not expect it to have a material effect on the Company's consolidated financial condition, results of operations, and cash flows.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">In May 2017, the FASB issued ASU 2017-09, Compensation
- Stock Compensation (Topic 718) : Scope of Modification Accounting. The new standard provides guidance about which changes to
the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. This pronouncement
is effective for annual reporting periods beginning after December 15, 2017 but early adoption is permitted. The Company is currently
evaluating the impact of adopting this guidance.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
other accounting standards that have been issued or proposed by the FASB that do not require adoption until a future date are
not expected to have a material impact on the consolidated financial statements upon adoption.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Fair
Value of Financial Instruments</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying value of the Company&rsquo;s financial instruments, including cash, trade accounts receivable, accounts payable and
accrued expenses and the face amount of notes payable approximate fair value for all periods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Noncontrolling
Interests</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for its less than 100% interest in Immudyne PR in accordance with ASC Topic 810, Consolidation, and accordingly
the Company presents noncontrolling interests as a component of equity on its consolidated balance sheet and reports the noncontrolling
interest&rsquo;s share of the Immudyne PR net loss attributable to noncontrolling interests in the consolidated statement of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B><I>Consolidation of Variable Interest Entities</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">In accordance with ASC 810-10-25-37 and as
amended by ASU 2009-17, the Company determines whether any legal entity in which the Company becomes involved is a VIE and subject
to consolidation. The Company conducts an assessment on an ongoing basis for each VIE including (1) the power to direct activities
of the VIE that most significantly impact the VIE&rsquo;s economic performance, and (2) the obligation to absorb losses or right
to receive benefits from the VIE that could potentially be significant to the VIE. As a result, the Company determined that nine
(9) entities were VIEs and subject to consolidation.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Immudyne,
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to Consolidated Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
31, 2016</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Summary
    of Significant Accounting Policies (continued)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Concentration
of Credit Risk</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company grants credit in the normal course of business to its customers. The Company periodically performs credit analysis and
monitors the financial condition of its customers to reduce credit risk.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company monitors its positions with, and the credit quality of, the financial institutions with which it invests. The Company,
at times, maintains balances in various operating accounts in excess of federally insured limits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">One
customer in the nutraceutical and cosmetic additives division accounted for 15% and 73% of consolidated sales for the years ended
December 31, 2016 and 2015, respectively. This customer accounted for 11% and 43% of accounts receivable at December 31, 2016
and December 31, 2015, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
second customer in the nutraceutical and cosmetic additives division accounted for 2% and 12% of consolidated sales for years
ended December 31, 2016 and 2015, respectively. This customer accounted for 8% and 24% of accounts receivable at December 31,
2016 and December 31, 2015, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">In the finished cosmetic products division,
two credit card processors accounted for 34.9% and 31.6% of accounts receivable at December 31, 2016. There were no significant
concentrations of accounts receivable in the finished cosmetic products division at December 31, 2015</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Furnishings
    and Equipment</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furnishings
and equipment consisted of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="font-family: Calibri,sans-serif; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid">December 31</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="font-family: Calibri,sans-serif; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2016</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2015</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-family: Calibri,sans-serif">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-family: Calibri,sans-serif">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 0.5in; background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 0pt">Furnishings and equipment, at cost </TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">679,291</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">679,291</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 0pt; padding-bottom: 1.5pt">Accumulated depreciation </TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">679,291</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">679,291</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="font-family: Calibri,sans-serif; text-indent: 0pt; padding-left: 0pt; padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 4pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 4pt double">-</TD><TD STYLE="text-align: left; padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 4pt double">$</TD><TD STYLE="text-align: right; border-bottom: Black 4pt double">-</TD><TD STYLE="text-align: left; padding-bottom: 4pt">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
expense amounted to $0 and $43,748 for years ended December 31, 2016 and 2015, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0pt; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investment
    in Adiuvo Investment S.A.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: left">In December 2013, the Company entered into a memorandum
of understanding (MOU) with Adiuvo Investment S.A. (AI), an investment company located in Poland, whereby AI paid the Company
$100,000 for the option, which expired in September 2014, to purchase up to 10% of the outstanding stock in the Company at $0.25
per share. In January 2014, the Company invested $100,000 in AI in exchange for a minority interest of less than 1% in AI, and
an option to acquire additional shares of AI up to an aggregate consideration of $1,500,000. Further, AI granted the Company the
right to participate in any subsequent public offerings of AI and the option to buy up to 10% of AI. During 2015 AI shares commenced
trading on the Warsaw exchange in Poland, and the Company sold its entire investment, receiving $127,261, net of transaction costs.
Due to the investment&rsquo;s limited liquidity and uncertain valuation prior to its sale, the Company accounted for its interest
in AI at no value. The proceeds of the Company&rsquo;s sale of AI stock, $127,261, are recorded as gain on sale of Adiuvo Investment
S.A. stock in the accompanying statement of operations for the year ended December 31, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif; margin-right: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Immudyne,
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Notes
to Consolidated Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">December
31, 2016</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>5.</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Notes
    Payable</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
payable are due to officers, directors, and shareholders and a commercial lender and are summarized as follows:&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Officers, Directors, and Shareholders</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Commercial Lenders</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 0.5in; background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Balance at December 31, 2014</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right">27,200</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right">27,200</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Borrowing</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">105,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">200,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">305,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Repayment</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(47,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(100,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(147,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Conversion to common stock</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(85,200</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(85,200</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">Balance at December 31, 2015</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">100,000</TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">100,000</TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Borrowing</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">300,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">300,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Repayment</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(68,600</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(100,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(168,600</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Debt discount</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(25,035</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(25,035</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">Balance at December 31, 2016</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">206,365</TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(100,000</TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">106,365</TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company periodically borrows from officers, directors, other related individuals, and from commercial lenders. During 2015 two
shareholders, with notes totaling $85,200, converted the notes to Company stock at $0.17 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left">In January 2015, the Company borrowed $100,000 from a commercial
lender. The loan required payment of principal and interest in 252 daily payments of $492 each commencing January 12, 2015. In
December 2015, the Company repaid the remaining outstanding principal balance. Interest for the year ended December 31, 2015 amounted
to $25,425.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left">In November 2015, the Company borrowed $100,000 from a
commercial lender. The loan incurred interest at 11% and with a maturity date of November 1, 2016. In October 2016, the Company
repaid the entire principal balance. Interest expense related to this loan for the years ended December 31, 2016 and 2015 amounted
to $9,479 and $1,543, respectively.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left">In the third quarter of 2016 the Company
commenced an offering pursuant to which it offered 11% subordinated promissory notes in fifty thousand ($50,000) dollar increments
combined with 62,500 shares of the Company&rsquo;s Common Stock for a maximum offering amount of $200,000 (the &ldquo;Offering&rdquo;).
In August and September 2016, the Company sold promissory notes totaling $150,000 to three unrelated individuals. Two of the promissory
notes totaling $100,000 are payable in February 2017 and one promissory note for $50,000 is payable in March 2017. In October
2016, the Company sold promissory notes totaling $50,000 to two unrelated individuals. These promissory notes are payable in October
2017. In connection with these promissory notes sold, pursuant to the Offering, the Company issued 250,000 shares of common stock
valued at $58,750 which was recorded as a debt discount and will be amortized over the term of these notes. Amortization of the
debt discounts for the year ended December 31, 2016 was $33,715. During 2016, the Company repaid $68,600 of the principle balance;
and as a result, the outstanding balances of these notes as of December 31, 2016, were $131,400. The balance of debt discount
related to the subordinated promissory notes is $25,035 at December 31, 2016. Interest expense related to these notes for the
year ended December 31, 2016 amounted to $5,416.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Immudyne,
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Notes
to Consolidated Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">December
31, 2016</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>5.</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Notes
    Payable (continued)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left">In December 2016, the Company borrowed $100,000 from an
officer and issued a convertible promissory note with a maturity date of February 28, 2017. The loan incurs no interest. This note
is convertible if not repaid by the maturity date at a conversion price of $0.23 per Unit. Each Unit shall consist of one share
of the Company&rsquo;s common stock and one three-year common-stock warrant to purchase one-half of one share of the Company&rsquo;s
common stock with an exercise price of $0.40 per share.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left">Interest expense related to loans from officers, directors
and other related individuals amounted to $5,416 and $10,508 for the years ended December 31, 2016 and 2015, respectively.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left">Total interest expense on notes payable, inclusive of
amortization of debt discount of $39,131 and $0, amounted to $48,611 and $37,476 for the years ended December 31, 2016 and 2015,
respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>6.</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Income
    Taxes</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left">The Company incurred a loss for the year ended December
31, 2016 and accordingly, no provision for federal income tax has been made in the accompanying financial statements. At December
31, 2016, the Company had available net operating loss carryforwards of approximately $3,953,000, expiring during various years
through 2036.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the deferred tax asset using an approximate 34% tax rate is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="background-color: white; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="background-color: white; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2016</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2015</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="background-color: white; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net operating
    loss</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,344,000</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">930,000</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Accounts receivable reserves</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">30,000</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Inventory reserves</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">7,000</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Stock compensation</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1.5pt solid">200,000</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1.5pt solid">-</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">Net deferred tax asset</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1.5pt solid">1,581,000</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1.5pt solid">-</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation allowance</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,581,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(930,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 4.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 4.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 4.5pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="border-bottom: black 4.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt">The net operating loss carryforwards could be subject to limitation
in any given year in the event of a change in ownership as defined by IRC Section 382.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
deferred tax benefit included in the 2015 statement of operations represents the change in the deferred tax liability at each
balance sheet date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
difference between the statutory and the effective tax rate is primarily due to a change in valuation allowance on deferred taxes,
as the Company has fully reserved the deferred tax asset resulting from available net operating loss carryforwards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Immudyne,
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Notes
to Consolidated Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">December
31, 2016</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>7.</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Stockholders&rsquo;
    Equity</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
May 2015, the Company purchased and retired 120,000 shares of outstanding Company common stock from an investor for $10,800.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
July 2015, the Company granted 300,000 options valued at $7,500 to a shareholder in conjunction with the issuance of a $75,000
note payable. The options are fully vested and expire in three years. In December 2015, the Company satisfied the $75,000 note
payable through the issuance of 441,177 shares of Company common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
December 2015, the Company satisfied $10,200 of notes payable to a director through the issuance of 60,000 shares of Company common
stock. The Company issued 40,800 options valued at $1,000 to the director in conjunction with this transaction. The options are
fully vested and expire in three years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
December 2015, the Company satisfied $84,868 of royalties payable to the Company&rsquo;s President through the issuance of 499,225
shares of Company common stock (see note 8). In conjunction with this transaction, the Company issued 339,473 options valued at
$13,000 to the President of the Company at an exercise price of $0.10 per share. The options are fully vested and expire in 3
years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
April 1, 2016, the Company entered into two agreements with two consultants to provide services over a nine- month period in exchange
for 2,300,000 shares of common stock. The Company calculated a fair value of $690,000 based on the market price of the shares
on the date of the agreements. During the third quarter of 2016, the Company and the consultants renegotiated the agreements by
extending the service requirement to December 31, 2017. For the year ended December 31, 2016, the Company has recognized expense
of $383,333 in connection with these agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
September 1, 2016, the Company issued 200,000 shares of common stock for $46,000. In connection with this issuance the Company
issued 100,000 warrants with an exercise price of $0.50 per share. These warrants are fully vested and expire in two years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
August 2016, the Company issued 125,000 shares of common stock pursuant to sale of two promissory notes in the Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
September 2016, the Company issued 62,500 shares of common stock pursuant to the sale of one promissory note in the Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
October 2016, the Company issued 62,500 shares of common stock pursuant to the sale of two promissory notes in the Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
November 2016, the Company issued 434,782 shares of common stock pursuant to a conversion of an equity contribution into Immudyne
PR by the noncontrolling interest. In connection with this issuance the Company issued 217,391 warrants with an exercise price
of $0.40 per share. These warrants are fully vested and expire in two years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
December 2016, the Company received proceeds of $30,000 from exercises of options at $0.10 per share. The Company issued 300,000
shares of common stock pursuant to these exercises.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 23, 2016, the Company issued 75,000 shares of common stock for $17,250. In connection with this issuance the Company
issued 37,500 warrants with an exercise price of $0.50 per share. These warrants are fully vested and expire in two years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2016, the Company purchased 325,000 shares of outstanding Company common stock through an exchange for a price per share of $0.23
to $0.29. As of the December 31, 2016, these shares being held by the Company valued at cost is $87,053 and are included in treasury
stock in the consolidated balance sheet.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Immudyne,
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
to Consolidated Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
31, 2016</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stockholders&rsquo;
    Equity (continued)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"><B><I>Additional Paid-In Capital</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><B><I>Noncontrolling Interest</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in">On April 1, 2016, the Company increased its ownership
in Immudyne PR from to 78.16667% decreasing the minority interest from 66.7% to 21.83% resulting in a charge to noncontrolling
interest and additional paid-in-capital of $91,612.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in">In 2016, the net change in loans, contributions
and distributions by other members of Immudyne PR resulted an increase in noncontrolling interests of $119,894.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in">For the years ended December 31, 2016 and 2015,
the net income (loss) of Immudyne PR attributed the Company amounted to $(115,749) and $(97,240), respectively.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><B><I>Service-Based Stock Options</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
October 2015 the Company issued 110,000 service-based options valued at $2,800 to two consultants at exercise prices of $0.20
per share. The options are fully vested and expire in 10 years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
November 2015 the Company cancelled 100,000 shares of company common stock and 200,000 fully vested service-based options issued
to two consultants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
November 2015 the Company issued 500,000 shares of common stock valued at $65,000 to a consultant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Also
in 2015, the Company extended the expiration date of 500,000 options held by a director one year from 2015 to 2016 and 1,500,000
warrants held by the Company&rsquo;s President two years from 2015 to 2017. The fair value of these modifications amounted to
$55,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
May 2016, the Company issued 175,000 service-based options valued at $40,829 to two consultants at exercise prices of $0.20 per
share. The options are fully vested and expire in 10 years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
July 2016, the Company issued 50,000 service-based options valued at $12,397 to a consultant with an exercise price of $0.20 per
share. The options are fully vested and expire in 10 years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left">In November 2016, the Company issued 50,000 service-based
options valued at $9,980 to a consultant with an exercise price of $0.50 per share. The options are fully vested and expire in
2 years.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left">Accordingly, stock based compensation for the years ended
December 31, 2016 and 2015 included $63,206 and $22,300, respectively, related to such service-based stock options.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">A
Summary of the outstanding service-based options are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Number of<BR>
 Options</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 0.5in; background-color: White">&nbsp;</TD>
    <TD>Balance at December 31, 2014</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">10,435,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD>Cancelled</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(200,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">Issued</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">790,273</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD>Balance at December 31, 2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,025,273</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD>Exercised</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">300,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD>Expired</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD>Cancelled</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(250,000</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">Issued</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid">275,000</TD><TD STYLE="text-align: left; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt">Balance at December 31, 2016</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 4pt">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 4pt double">10,700,273</TD><TD STYLE="text-align: left; padding-bottom: 4pt">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">All outstanding options are exercisable and
have a cashless exercise provision, and certain options provide for accelerated vesting provisions and modifications, as defined,
if the Company is sold or acquired. The intrinsic value of options outstanding and exercisable at December 31, 2016 and 2015 amounted
to $704,794 and $33,605, respectively. The intrinsic value of options exercised during the year ending December 31, 2016 was $54,000.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Immudyne,
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Notes
to Consolidated Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">December
31, 2016</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>7.</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Stockholders&rsquo;
    Equity (continued)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Service-Based
Stock Options (continued)</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
significant assumptions used to determine the fair values of options issued, using a Black-Scholes option-pricing model are as
follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt"><U>Significant assumptions:</U></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="background-color: #CCEEFF"><FONT STYLE="font-size: 10pt">Risk-free interest rate at grant date</FONT></TD>
    <TD STYLE="background-color: #CCEEFF">&nbsp;</TD>
    <TD NOWRAP STYLE="background-color: #CCEEFF">&nbsp;</TD>
    <TD NOWRAP STYLE="background-color: #CCEEFF; text-align: right"><FONT STYLE="font-size: 10pt">0.71% - 1.88</FONT></TD>
    <TD STYLE="background-color: #CCEEFF"><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Expected stock price volatility</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: right"><FONT STYLE="font-size: 10pt">217.4% - 248.4</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="background-color: #CCEEFF"><FONT STYLE="font-size: 10pt">Expected dividend payout</FONT></TD>
    <TD STYLE="background-color: #CCEEFF">&nbsp;</TD>
    <TD NOWRAP STYLE="background-color: #CCEEFF">&nbsp;</TD>
    <TD NOWRAP STYLE="background-color: #CCEEFF; text-align: right"><FONT STYLE="font-size: 10pt">&mdash;</FONT></TD>
    <TD STYLE="background-color: #CCEEFF">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Expected option life-years</FONT></TD>
    <TD>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2 to 3</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;years&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="background-color: white">&nbsp;</TD>
    <TD STYLE="background-color: #CCEEFF"><FONT STYLE="font-size: 10pt">Weighted average grant date fair value</FONT></TD>
    <TD STYLE="background-color: #CCEEFF">&nbsp;</TD>
    <TD NOWRAP STYLE="background-color: #CCEEFF"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD NOWRAP STYLE="background-color: #CCEEFF; text-align: right"><FONT STYLE="font-size: 10pt">0.22</FONT></TD>
    <TD STYLE="background-color: #CCEEFF">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Forfeiture rate</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 1%">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 10pt">0</FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">%</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white">&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
following is a summary of outstanding service-based options at December 31, 2016:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; border-bottom: Black 1.5pt solid">Exercise Price</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid">Number of<BR> Options</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Remaining Contractual Life</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 0.5in; background-color: White">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$0.10</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">1,380,273</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">1 year</FONT></TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">$0.20 - $0.25</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">8,120,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">5 years</FONT></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">$0.40 - $0.50</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">1,200,000</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">5 years</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-bottom: 4pt; padding-left: 10pt">Total</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">10,700,273</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Performance-Based
Stock Options</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company had granted performance-based options to purchase 4,400,000 shares of common stock at exercise prices of $0.40 to $0.80.
The options expire at various dates between 2021 and 2026 and are exercisable upon the Company achieving annual sales revenue
of $5,000,000 and $10,000,000. The fair value of these performance-based options aggregated $169,035 to be expensed over the implicit
service period commencing once management believes the performance criteria will be met.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left">In October 2016, the Company cancelled 287,500 of these service-based options valued at $17,999 to two
consultants. The fair value of these performance-based options as of year ended December 31, 2016 aggregated $151,036.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left">The performance criteria for options
exercisable upon the Company achieving annual sales revenue of $5,000,000, with a fair value amounting to $120,867, was met during
the year ended December 31, 2016. Accordingly, stock based compensation expense for the year ended December 31, 2016 includes
$120,867 related to such options. At December 31, 2016, the unearned compensation for all the performance based options is $30,169.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Immudyne,
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Notes
to Consolidated Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">December
31, 2016</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>7.</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Stockholders&rsquo;
    Equity (continued)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"><FONT STYLE="font: 8pt Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Warrants</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
following is a summary of outstanding and exercisable warrants:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Number of Shares</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Exercise Price</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Year&nbsp;of&nbsp;<BR> Expiration</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="background-color: White"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 0.5in; background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: left">Balance at December 31, 2014</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">3,772,720</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD><TD STYLE="width: 8%; text-align: center">0.29</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD><TD STYLE="width: 8%; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2015&nbsp;-&nbsp;2016</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">Expired</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,022,720</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">0.40</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">2015</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: left">Balance at December 31, 2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,750,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">0.16</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2016 - 2017</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: left">Issued</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">454,891</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center">0.42</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2018&nbsp;-&nbsp;2019</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">Expired</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(250,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">0.40</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">2016</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: left">Balance at December 31, 2016</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,954,981</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: center">0.19</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 4pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2017 - 2019</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
September 2016, the Company issued 100,000 warrants with an exercise price of $0.50 per share, in relation to a sale of common
stock. These warrants are fully vested and expire in two years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
September 2016, the Company issued 100,000 warrants with exercise prices between $0.20 and $0.50 per share, for consulting services.
These warrants are fully vested and expire in three years. The fair value of these warrants are $20,585 and is included in compensation
and related expenses in the accompanying statement of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
December 2016, the Company issued 37,500 warrants with an exercise price of $0.50 per share, in relation to a sale of common stock.
These warrants are fully vested and expire in two years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
December 2016, the Company issued 217,391 warrants with an exercise price of $0.40 per share, in relation to an issuance of common
stock. These warrants are fully vested and expire in two years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left">Warrants outstanding and exercisable amounted to 1,954,891
and 1,750,000 at December 31, 2016 and 2015, respectively. The weighted average exercise price of warrants outstanding at December
31, 2016 is $0.19. The warrants expire at various time between December 2017 and September 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
fair value of options and warrants granted (or extended) during the years ended December 31, 2016 and 2015, was estimated on the
date of grant (or extension) using the Black-Scholes option-pricing model with the following weighted-average assumptions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 8pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0 0 1.5pt; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">2016</TD><TD STYLE="padding: 0 0 1.5pt; font-size: 10pt; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding: 0 0 1.5pt; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1.5pt solid; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">2015</TD><TD STYLE="padding: 0 0 1.5pt; font-size: 10pt; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0; width: 0.5in">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">Expected
    volatility</TD><TD STYLE="width: 1%; font-size: 10pt; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">203</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">%</TD><TD STYLE="width: 1%; font-size: 10pt; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">50</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">Risk free
    interest rate</TD><TD STYLE="font-size: 10pt; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">.88</TD><TD STYLE="font-size: 10pt; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">%</TD><TD STYLE="font-size: 10pt; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">2</TD><TD STYLE="font-size: 10pt; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">Expected
    dividend yield</TD><TD STYLE="font-size: 10pt; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">-</TD><TD STYLE="font-size: 10pt; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">-</TD><TD STYLE="font-size: 10pt; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">Expected
    option term (in years)</TD><TD STYLE="font-size: 10pt; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">2
                                         - 3</FONT></TD><TD STYLE="font-size: 10pt; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">1
                                         - 5</FONT></TD><TD STYLE="font-size: 10pt; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">Weighted average grant date
    fair value</TD><TD STYLE="font-size: 10pt; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">$</TD><TD STYLE="font-size: 10pt; text-align: right; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">0.20</TD><TD STYLE="font-size: 10pt; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">$</TD><TD STYLE="font-size: 10pt; text-align: right; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">0.03</TD><TD STYLE="font-size: 10pt; text-align: left; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
</TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt">Under ASC 815-40-05, Accounting for Derivative Financial Instruments
Indexed to and Potentially Settled in a Company&rsquo;s Own Stock, in the event the Company does not have a sufficient number
of authorized and unissued shares of common stock to satisfy obligations for stock options, warrants and other instruments potentially
convertible into common stock, the fair value of these instruments should be reported as a liability. Pursuant to the outstanding
option, warrant and convertible debt agreements, there is currently no effective registration statement covering the shares of
common stock underlying these agreements, which are currently subject to a cashless exercise whereby the holders, at their option,
may surrender their options and warrants to the company in exchange for shares of common stock. The number of shares of common
stock into which an option or a warrant would be exchangeable in such a cashless exercise depends on both the exercise price of
the options or warrant and the market price of the common stock, each at or near the time of exercise. Because both of these factors
are variable, it is possible that we could have insufficient authorized shares to satisfy a cashless exercise. In this scenario,
if we were unable to obtain shareholder approval to increase the number of authorized shares, we could be obligated to settle
such a cashless exercise with cash rather than by issuing shares of common stock. Further, ASC 815-40-05 requires that we record
the potential settlement obligation at each reporting date using the current estimated fair value of these contracts s, with any
changes in fair value being recorded through our statement of operations. We will continue to report the potential settlement
obligation as a liability until such time as these contracts are exercised or expire or we are otherwise able to modify the warrant
agreement to remove the provisions which require this treatment.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Immudyne,
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Notes
to Consolidated Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">December
31, 2016</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>7.</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Stockholders&rsquo;
    Equity (continued)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B><I>Stock Based Compensation</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The total stock based compensation expense
related Service-Based Stock Options, Performance-Based Stock Options and Warrants issued for service amounted to $587,991 and
$142,300 for the years ended December 31, 2016 and 2015, respectively. Such amounts are included in compensation and related expenses
($587,991 in 2016 and $133,800 in 2015) and interest expense ($8,500 in 2015).</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT>&nbsp;</P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>8.</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Royalties</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company was subject to a royalty agreement based upon sales of certain skin care products. The agreement required the Company
to pay a royalty based upon 8% of such sales, up to $227,175. During the year ended December 31, 2015 the Company&rsquo;s sales
reached the maximum amount under which the Company was required to pay a royalty under this agreement. Royalty expense amounted
to $-0- and $20,157 for the years ended December 31, 2016 and 2015, respectively. During December 2015, the Company&rsquo;s President
who had a 60% interest in the royalties, converted royalties payable under the agreement in the amount of $84,868 to 499,225 shares
of Company stock at $0.17 cents per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Included
in accounts payable and accrued expenses at December 31, 2016 and 2015 was $56,579 in regards to this agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>9.</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Commitments
    and Contingencies</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Leases</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The Company leases a plant in Kentucky
under an operating lease which expired on May 31, 2016. Management is currently discussing renewal lease options for the
Kentucky plant and is operating on a month-to-month lease arrangement until a final agreement has been accepted. Monthly base
rental payments are approximately $9,000. Our principal executive offices are in office space provided to us by our
President, Mr. McLaughlin at the rate of $2,000 per month, which includes rents, utilities and other office related
expenditures. This arrangement commenced as of January 1, 2016. In addition, Immudyne PR utilizes office space in Puerto Rico
which is subleased from Mr. Schreiber (President of Immudyne PR)and incurs expense of approximately $4,000 a month for this
office space. Rent expense for the years ended December 31, 2016 and 2015, was $139,030 and $65,968, respectively.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Employment
and Consulting Agreements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company has entered into various agreements with officers, directors, employees and consultants that expire in one to five years.
The agreements provide for annual compensation of up to $145,000 and the issuance of stock options, at exercise prices of $0.40
and $0.80, to purchase 4,400,000 shares of common stock issuable upon the Company&rsquo;s revenue exceeding $5,000,000 and $10,000,000,
as defined. In addition, the agreements provide for bonus compensation to these individuals aggregating up to 15% (with no individual
having more than 5%) of the Company&rsquo;s pretax income.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Restricted
Stock and Options</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company has entered into two agreements on April 1, 2016 with two consultants of Immudyne PR for business development, marketing
and sales related services (the &ldquo;Consultant Agreements&rdquo;). The consultants are treated as employees for accounting
purposes. Upon signing, each consultant was issued 1,000,000 restricted shares of Immudyne, Inc. common stock. In addition, each
consultant shall receive an additional 150,000 restricted shares of Immudyne, Inc. common stock for each $500,000 distributed
by Immudyne PR to the Company. For each consultant, the amount of shares to be issued by the Company to the consultants shall be
capped at 1,500,000 restricted shares when Immudyne PR has transferred $5,000,000 to the Company, for a combined capped total
of 3,000,000 restricted shares. For the year ended December 31, 2016, 2,300,000 restricted shares of common stock have been issued
related to these agreements. The Company valued the shares at their grant date for a value of $0.30 per share for a total of $690,000
to be expensed over the estimated service period ending December 31, 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
addition, the Consulting Agreements provided that each consultant shall receive a bonus of an additional 750,000 restricted shares
of Immudyne, Inc. common stock, plus an option to buy 1,000,000 shares of Immudyne, Inc. common stock at $0.20/share (including
a cashless exercise feature) when Immudyne PR has transferred to the Company at each of the following three (3) thresholds: $1,250,000,
$2,000,000 and $3,000,000 for a total of 2,250,000 of restricted shares of Immudyne, Inc. common stock and options to purchase
up to 3,000,000 shares of Immudyne, Inc. common stock at $0.20/share. As of December 31, 2016, no bonus shares have been issued
and no options have been granted under this agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left">&nbsp;</P>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Immudyne,
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Notes
to Consolidated Financial Statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">December
31, 2016</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>9.</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Commitments
    and Contingencies (continued)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Legal
Matters</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
the normal course of business operations, the Company may become involved in various legal matters. At December 31, 2016, the Company&rsquo;s
management does not believe that there are any potential legal matters that could have an adverse effect on the Company&rsquo;s
financial position.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>10.</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Related
    Party Transactions</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.15pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.15pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">For the year ended December 31, 2016 one of the Company&rsquo;s
directors, acting as an advisor for the Company, provided legal and business advisory services and was compensated $16,145. During
2015 there was no compensation to this director. In addition, for the year ended December 31, 2016 the Company&rsquo;s President
received $24,000 for reimbursement of home office expenditures, including rent, utilities and other related expenses for two offices.
During 2015 the Company&rsquo;s president was not reimbursed for home office expenditures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">Immudyne, Inc. employs the wife of the
President of the Company Immudyne, Inc. and incurs $3,000 per month as an accountant, plus an annual incentive bonus award equal
to 0.5% of the Company&rsquo;s pre-tax earnings.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in">Immudyne PR utilizes BV Global Fulfillment, owned by the father of Mr. Schreiber, and
incurred $19,800 for the year ended December 31, 2016 for these services.</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">Taggart International Trust (&ldquo;Taggart&rdquo;),
a shareholder; provides credit card processing services through one or more merchant banks. Taggart did not receive any compensation
for these services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">JLS Ventures LLC, owned by a shareholder, provides
credit card processing services through one or more merchant banks. Taggart did not receive any compensation for these services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">JSDC, Inc., owned by a shareholder, provides
credit card processing services through one or more merchant banks. Taggart did not receive any compensation for these services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">Immudyne PR utilizes office space in Puerto Rico which
is subleased from Mr. Schreiber (President of Immudyne PR) incurs expense of approximately $4,000 a month for this office space.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 48px; text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>11.</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Subsequent
    Events</B>&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.15pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company has evaluated subsequent events through the date these financial statements were issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
January 2017, the Company issued 1,183,490 shares of common stock pursuant to a conversion of an equity contribution into Immudyne
PR by the noncontrolling interest. In connection with this issuance the Company issued 591,745 warrants with an exercise price
of $0.40 per share. These warrants are fully vested and expire in two years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left">In January 2017, the Company borrowed $200,000 and issued
a promissory note with a 5% original issue discount for a total principal amount of $210,000. The loan incurs 11% interest per
annum and matures in various tranches from February 2017 through April 2017. In addition, the Company issued 217,391 shares of
common stock related to this note. In February 2017, the Company repaid $70,000 of the principle balance of this note. In March,
pursuant to an offering described below, the Company converted the remaining $140,000 of the principle balance of the this note
in exchange for 559,179 shares of common stock and 304,348 warrants.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left">On March 27, 2017, the Company commenced an offering to
sell up to 4,000,000 shares of common stock at a price of $0.23 per share and warrants to purchase up to 2,000,000 shares of common
stock excisable any time prior to the secondary anniversary of the issuance. The warrants are paired with the stock on the basis
of one warrant for every two shares of stock purchased.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left">At the time of this filing, the Company received subscriptions
in the amount of 2,673,656 shares and issued 1,336,828 warrants and proceeds in the amount of $614,940. The Company also converted
two additional notes with the total principal balance of $50,000 in exchange for 196,000 shares of common stock and 98,000 warrants.</P>

<P STYLE="font: 10pt/107% Times New Roman, Times, Serif; margin: 0pt 0">.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: left">On April 24, 2017, the Company, issued 217,390 shares of
common stock pursuant to a stock subscription agreement and the Company issued 108,696 warrants with an exercise price of $0.40
per share for the stated consideration and satisfaction of obligation to pay $50,000 on the 180-day anniversary of the execution
of the Sole and Exclusive License, Royalty, and Advisory Agreement dated September 1, 2016 with Pilaris Laboratories, LLC</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">* * * * *</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;&nbsp;</P>



<P STYLE="margin: 0; padding: 0; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_027"></A>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pursuant
to the requirements of Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report
to be signed on its behalf by the undersigned, thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 60%; padding-bottom: 0; padding-right: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 4%; padding-bottom: 0; padding-right: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 36%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>IMMUDYNE,
    INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Registrant)</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><P STYLE="margin: 0pt 0">Date: May 23, 2017</P>


</TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/
    Mark McLaughlin</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Mark
                                         McLaughlin</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief
        Executive Officer</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Principal
        Executive Officer)</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Power
of Attorney</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0">KNOW ALL PERSONS BY THESE PRESENTS, that each person
whose signature appears below constitutes and appoints Mark McLaughlin his or her attorney-in-fact for him or her in any and all
capacities, to sign any amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents
in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that said attorney-in-fact,
or his substitute or substitutes, may do or cause to be done by virtue hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf
of the Registrant and in the capacities and on the dates indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 15%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp; Date</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Anthony Bruzzese &nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of the Board</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp; May 23, 2017</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anthony G. Bruzzese, M.D. &nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Mark McLaughlin &nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">President, Chief Executive Officer and Director</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Principal Executive, Financial and Accounting Officer)</P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp; May 23, 2017</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark McLaughlin &nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ John R. Strawn, Jr. &nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp; May 23, 2017</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John R. Strawn, Jr. &nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Joseph DiTrolio</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp; Director &nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;May 23, 2017</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joseph DiTrolio</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Sven Rohmann</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp; Director &nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;May 23, 2017</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sven Rohmann</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Ryan Aldridge</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp; Director &nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;May 23, 2017</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ryan Aldirdge</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"></P>

<!-- Field: Page; Sequence: 67; Options: NewSection; Value: 41 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>EXHIBIT
INDEX</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 10%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-right: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Exhibit
    No.</FONT></TD>
    <TD STYLE="width: 1%; padding-right: 0; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 89%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 0; padding-left: 0; text-indent: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Description</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.1</FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/948320/000114420412056821/v325879_ex3-1.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Certificate of Incorporation of Immudyne, Inc. (Incorporated herein by reference to Exhibit 3.1 to the Company&rsquo;s Registration on Form S-1 (File No. 333-184487) filed on October 18, 2012)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.2</FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/948320/000114420412056821/v325879_ex3-2.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Certificate of Amendment of Certificate of Incorporation of Immudyne, Inc. (Incorporated herein by reference to Exhibit 3.2 to the Company&rsquo;s Registration on Form S-1 (File No. 333-184487) filed on October 18, 2012)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.3</FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/948320/000114420412056821/v325879_ex3-3.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Bylaws of Immudyne, Inc. as currently in effect(Incorporated herein by reference to Exhibit 3.3 to the Company&rsquo;s Registration on Form S-1 (File No. 333-184487) filed on October 18, 2012)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.1</FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/948320/000114420412056821/v325879_ex3-1.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form of Subscription Agreement (Incorporated herein by reference to Exhibit 3.1 to the Company&rsquo;s Registration on Form S-1 (File No. 333-184487) filed on October 18, 2012)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5.1</FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/948320/000114420412056821/v325879_ex3-1.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Opinion of Newman &amp; Morrison LLP (Incorporated herein by reference to Exhibit 3.1 to the Company&rsquo;s Registration on Form S-1 (File No. 333-184487) filed on October 18, 2012)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.1</FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/948320/000114420412066573/v329691_ex10-1.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Written Description of Royalty Agreement between Immudyne, Inc. and Mark McLaughlin (Incorporated herein by reference to Exhibit 10.1 to Amendment No. 1 to the Company&rsquo;s Registration Statement on Form S-1 (File No. 333-184487) filed on December 5, 2012)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.2#</FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/948320/000114420412056821/v325879_ex10-2.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Employment Agreement, as amended, between Immudyne, Inc. and Mark McLaughlin, effective as of October 12, 2012 Incorporated herein by reference to Exhibit 10.2 to the Company&rsquo;s Registration on Form S-1 (File No. 333-184487) filed on October 18, 2012)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.3#</FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/948320/000114420412056821/v325879_ex10-3.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Director Agreement between Immudyne, Inc. and Anthony Bruzzese M.D., dated as of April 20, 2011 (Incorporated herein by reference to Exhibit 10.3 to the Company&rsquo;s Registration on Form S-1 (File No. 333-184487) filed on October 18, 2012)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.5#</FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/948320/000114420412056821/v325879_ex10-5.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Director and Legal Services Agreement between Immudyne, Inc. and John R. Strawn, dated as of April 20, 2011 (Incorporated herein by reference to Exhibit 10.5 to the Company&rsquo;s Registration on Form S-1 (File No. 333-184487) filed on October 18, 2012)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.6</FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/948320/000114420412066573/v329691_ex10-6.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Employment Agreement, as amended, between Immudyne, Inc. and Brunilda McLaughlin d/b/a McLaughlin International, dated as of April 20, 2011 (Incorporated herein by reference to Exhibit 10.6 to Amendment No. 1 to the Company&rsquo;s Registration Statement on Form S-1 (File No. 333-184487) filed on December 5, 2012)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.7</FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/948320/000114420412066573/v329691_ex10-7.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Lease
    Agreement, as amended, between Cabot Industrial Properties L.P. and Immudyne, Inc., dated May 15, 2011 (Incorporated herein
    by reference to Exhibit 10.7 to Amendment No. 1 to the Company&rsquo;s Registration Statement on Form S-1 (File No.
    333-184487) filed on December 5, 2012)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.8</FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/948320/000114420413003602/v332688_ex10-8.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Letter Agreement between Immudyne, Inc. and MMP, dated December 19, 2011(Incorporated herein by reference to Exhibit 10.8 to Amendment No. 3 to the Company&rsquo;s Registration Statement on Form S-1 (File No. 333-184487) filed on January 23, 2013)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.9</FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/948320/000121390016012306/f8k0416ex10ix_immudyneinc.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Operating Agreement of Immudyne PR LLC dated April 1, 2016 (Incorporated herein by reference to Exhibit 10.9 of the Company&rsquo;s Current Report on Form 8-K (File No. 333-184487) filed on April 7, 2016)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.10</FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/948320/000121390016012306/f8k0416ex10x_immudyneinc.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Services Agreement with JLS Ventures, LLC dated April 1, 2016 (Incorporated herein by reference to Exhibit 10.10 of the Company&rsquo;s Current Report on Form 8-K (File No. 333-184487) filed on April 7, 2016)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.11</FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="http://www.sec.gov/Archives/edgar/data/948320/000121390016012306/f8k0416ex10xi_immudyneinc.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Services Agreement with American Nutra Tech, LLC dated April 1, 2016 (Incorporated herein by reference to Exhibit 10.11 of the Company&rsquo;s Current Report on Form 8-K (File No. 333-184487) filed on April 7, 2016)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">24.1&dagger;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="#a_027"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Power of Attorney (Included on the Signature Page of this Annual Report on Form 10K)</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">31.1&dagger;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="f10k2016ex31i_immudyneinc.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Certification of Principal Executive Officer and Principal Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">32.2&dagger;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left"><A HREF="f10k2016ex32i_immudyneinc.htm"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, as signed by the Principal Executive Officer and Principal Financial Officer</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.INS&dagger;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL
    Instance Document</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.SCH&dagger;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL
    Schema Document</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.CAL&dagger;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL
    Calculation Linkbase Document</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.LAB&dagger;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL
    Definition Linkbase Document</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">101.PRE&dagger;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">XBRL
    Presentation Linkbase Document</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0px; padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 48px; padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">#</FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Indicates
    management contract or compensatory plan, contract or arrangement.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&dagger;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Filed
    herewith.</FONT></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; margin-top: 0; margin-bottom: 0; text-align: center">42</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: right"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: right">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>f10k2016ex31i_immudyneinc.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>CERTIFICATION
PURSUANT TO SECTION 302(a)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>OF
THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">I,
Mark McLaughlin, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 4%; padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.</FONT></TD>
    <TD STYLE="width: 96%; padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">I
    have reviewed this Annual Report on Form 10-K for the period ended December 31, 2016, of Immudyne Inc.;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 4%; padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.</FONT></TD>
    <TD STYLE="width: 96%; padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect
    to the period covered by this report;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 4%; padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.</FONT></TD>
    <TD STYLE="width: 96%; padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all
    material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
    presented in this report;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 4%; padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.</FONT></TD>
    <TD STYLE="width: 96%; padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
    registrant&rsquo;s other certifying officer(s) and I&nbsp;are responsible for establishing and maintaining disclosure controls
    and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as
    defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-indent: 0.5in; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 4%; padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 4%; padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a.</FONT></TD>
    <TD STYLE="width: 92%; padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under&nbsp;our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to
    us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 4%; padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 4%; padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">b.</FONT></TD>
    <TD STYLE="width: 92%; padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under&nbsp;our
    supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
    statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 4%; padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 4%; padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">c.</FONT></TD>
    <TD STYLE="width: 92%; padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report&nbsp;our conclusions
    about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based
    on such evaluation; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 4%; padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 4%; padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">d.</FONT></TD>
    <TD STYLE="width: 92%; padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report)&nbsp;that has materially
    affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting;
    and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-indent: 0.5in; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 4%; padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5.</FONT></TD>
    <TD STYLE="width: 96%; padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
    registrant&rsquo;s other certifying officer(s) and I have disclosed, based on&nbsp;our most recent evaluation of internal
    control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board
    of directors (or persons performing the equivalent functions):</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-indent: 0.5in; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 4%; padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 4%; padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a.</FONT></TD>
    <TD STYLE="width: 92%; padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
    are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
    information; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 4%; padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 4%; padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">b.</FONT></TD>
    <TD STYLE="width: 92%; padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 60%; padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date:
    May 23, 2017</FONT></TD>
    <TD STYLE="width: 4%; padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="width: 36%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/
    Mark McLaughlin</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Mark
                                         McLaughlin</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Principal
        Executive Officer and <BR>
Principal Financial Officer)</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>3
<FILENAME>f10k2016ex32i_immudyneinc.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>CERTIFICATION
PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>18
U.S.C. SECTION 1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>AS
ADOPTED PURSUANT TO SECTION 906</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>OF
THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
connection with the Annual Report on Form&nbsp;10-K of Immudyne Inc. (the &ldquo;Company&rdquo;) for the period ended December
31, 2016, as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Mark McLaughlin,
Chief Executive Officer of the Company, hereby certify, pursuant to 18&nbsp;U.S.C. &sect;1350, as adopted pursuant to Section
906 of the Sarbanes-Oxley Act of 2002, that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0; width: 4%; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(1)</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; text-align: left; width: 96%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The Report fully complies with the requirements of Section&nbsp;13(a)
or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. &sect;78m or &sect;78o(d)); and</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(2)</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The information contained in the Report fairly presents,
in all material respects, the financial condition and results of operations of the Company.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 60%; padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date:
    May 23, 2017</FONT></TD>
    <TD STYLE="width: 4%; padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="width: 36%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/
    Mark McLaughlin</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0; padding-bottom: 0; padding-left: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Mark
                                         McLaughlin</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Principal
        Executive Officer and <BR>
Principal Financial Officer</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">This
certification accompanies each Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent
required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange
Act of 1934, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">A
signed original of this written statement required by Section&nbsp;906 has been provided to the Company and will be retained by
the Company and furnished to the Securities and Exchange Commission or its staff upon request.</FONT></P>





</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>4
<FILENAME>immd-20161231.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated using Ez-XBRL version 8.0.0.0 [05/24/2017 05:53:45 AM] -->
<!-- Based on XBRL 2.1 -->

<xbrli:xbrl xmlns:immd="http://www.immudyne.com/20161231"
 xmlns:link="http://www.xbrl.org/2003/linkbase"
 xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
 xmlns:xlink="http://www.w3.org/1999/xlink"
 xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
 xmlns:xbrli="http://www.xbrl.org/2003/instance"
 xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
 xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
 xmlns:num="http://www.xbrl.org/dtr/type/numeric"
 xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
 xmlns:country="http://xbrl.sec.gov/country/2016-01-31"
 xmlns:currency="http://xbrl.sec.gov/currency/2016-01-31"
 xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31"
 xmlns:exch="http://xbrl.sec.gov/exch/2016-01-31"
 xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31"
 xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31"
 xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31"
 xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31"
 xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31"
 xmlns:us-types="http://fasb.org/us-types/2016-01-31"
 xmlns:xl="http://www.xbrl.org/2003/XLink"
 xmlns:utr="http://www.xbrl.org/2009/utr"
>
<link:schemaRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:type="simple" xlink:href="immd-20161231.xsd" />
<!-- Context Section  -->
<xbrli:context id="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-01-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-01-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_ClassOfFinancingReceivableTypeOfBorrowerAxis_CommercialLenderMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfFinancingReceivableTypeOfBorrowerAxis">immd:CommercialLenderMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_TitleOfIndividualAxis_BoardOfDirectorsChairmanMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_SummationMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">immd:SummationMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_NoncontrollingInterestMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jan_2015T00_00_00_TO_31_Jan_2015T00_00_00_ClassOfFinancingReceivableTypeOfBorrowerAxis_CommercialLenderMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfFinancingReceivableTypeOfBorrowerAxis">immd:CommercialLenderMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-01-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_May_2015T00_00_00_TO_31_May_2015T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_InvestorMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-05-01
</xbrli:startDate>
<xbrli:endDate>
2015-05-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Jul_2015T00_00_00_TO_31_Jul_2015T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_ShareholderMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">immd:ShareholderMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-07-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_02_Jul_2015T00_00_00_TO_31_Jul_2015T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_ShareholderMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">immd:ShareholderMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-02
</xbrli:startDate>
<xbrli:endDate>
2015-07-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_02_Jul_2015T00_00_00_TO_31_Jul_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">immd:ConsultantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-02
</xbrli:startDate>
<xbrli:endDate>
2015-07-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Oct_2015T00_00_00_TO_31_Oct_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">immd:ConsultantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-10-01
</xbrli:startDate>
<xbrli:endDate>
2015-10-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Nov_2015T00_00_00_TO_30_Nov_2015T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-11-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Nov_2015T00_00_00_TO_30_Nov_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">immd:ConsultantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-11-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_02_Nov_2015T00_00_00_TO_30_Nov_2015T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-11-02
</xbrli:startDate>
<xbrli:endDate>
2015-11-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_02_Nov_2015T00_00_00_TO_30_Nov_2015T00_00_00_ClassOfFinancingReceivableTypeOfBorrowerAxis_CommercialLenderMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfFinancingReceivableTypeOfBorrowerAxis">immd:CommercialLenderMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-11-02
</xbrli:startDate>
<xbrli:endDate>
2015-11-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_02_Nov_2015T00_00_00_TO_30_Nov_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">immd:ConsultantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-11-02
</xbrli:startDate>
<xbrli:endDate>
2015-11-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_ClassOfFinancingReceivableTypeOfBorrowerAxis_CommercialLenderMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfFinancingReceivableTypeOfBorrowerAxis">immd:CommercialLenderMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_TitleOfIndividualAxis_BoardOfDirectorsChairmanMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_SummationMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">immd:SummationMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_NoncontrollingInterestMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_ShareholderMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">immd:ShareholderMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_ConsolidationItemsAxis_NutraceuticalAndCosmeticMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">immd:NutraceuticalAndCosmeticMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_ConsolidationItemsAxis_CosmeticGoodsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">immd:CosmeticGoodsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_ConsolidationItemsAxis_IntersegmentEliminationMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_ConcentrationRiskByBenchmarkAxis_SalesMember_ConcentrationRiskNumberOfCustomersAxis_OneCustomerMember_ConsolidationItemsAxis_NutraceuticalAndCosmeticMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="immd:ConcentrationRiskNumberOfCustomersAxis">immd:OneCustomerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">immd:NutraceuticalAndCosmeticMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_ConcentrationRiskByBenchmarkAxis_SalesMember_ConcentrationRiskNumberOfCustomersAxis_SecondCustomerMember_ConsolidationItemsAxis_NutraceuticalAndCosmeticMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="immd:ConcentrationRiskNumberOfCustomersAxis">immd:SecondCustomerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">immd:NutraceuticalAndCosmeticMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_PerformanceBasedStockOptionsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">immd:PerformanceBasedStockOptionsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_OptionIndexedToIssuersEquityTypeAxis_EmployeeStockOptionMember_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_ShortTermDebtTypeAxis_NotesPayableOtherPayablesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskNumberOfCustomersAxis_OneCustomerMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="immd:ConcentrationRiskNumberOfCustomersAxis">immd:OneCustomerMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskNumberOfCustomersAxis_SecondCustomerMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="immd:ConcentrationRiskNumberOfCustomersAxis">immd:SecondCustomerMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_TitleOfIndividualAxis_OfficerMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:OfficerMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_TitleOfIndividualAxis_PresidentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:PresidentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_TitleOfIndividualAxis_DirectorMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_DirectorMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_PresidentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:PresidentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_ClassOfFinancingReceivableTypeOfBorrowerAxis_CommercialLenderMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfFinancingReceivableTypeOfBorrowerAxis">immd:CommercialLenderMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_TitleOfIndividualAxis_BoardOfDirectorsChairmanMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_SummationMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">immd:SummationMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_NoncontrollingInterestMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_ShareholderMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">immd:ShareholderMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_ConsolidationItemsAxis_NutraceuticalAndCosmeticMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">immd:NutraceuticalAndCosmeticMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_ConsolidationItemsAxis_CosmeticGoodsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">immd:CosmeticGoodsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_ConsolidationItemsAxis_IntersegmentEliminationMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_TitleOfIndividualAxis_PresidentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:PresidentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_TitleOfIndividualAxis_DirectorMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_PresidentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:PresidentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_PresidentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:PresidentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_TitleOfIndividualAxis_MajorityShareholderMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_PresidentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:PresidentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-12-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_01_Apr_2016T00_00_00_TO_01_Apr_2016T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_ImmudynePrLlcMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">immd:ImmudynePrLlcMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-04-01
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_01_Apr_2016T00_00_00_TO_01_Apr_2016T00_00_00_LegalEntityAxis_ImmudynePrLlcMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">immd:ImmudynePrLlcMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-04-01
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_01_Apr_2016T00_00_00_TO_01_Apr_2016T00_00_00_LegalEntityAxis_ImmudynePrLlcMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">immd:ImmudynePrLlcMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-04-01
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_01_Apr_2016T00_00_00_TO_01_Apr_2016T00_00_00_LegalEntityAxis_ImmudynePrLlcMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">immd:ImmudynePrLlcMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-04-01
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_25_Mar_2016T00_00_00_TO_01_Apr_2016T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-03-25
</xbrli:startDate>
<xbrli:endDate>
2016-04-01
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_25_Mar_2016T00_00_00_TO_01_Apr_2016T00_00_00_AwardTypeAxis_RestrictedStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-03-25
</xbrli:startDate>
<xbrli:endDate>
2016-04-01
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_25_Mar_2016T00_00_00_TO_01_Apr_2016T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">immd:ConsultantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-03-25
</xbrli:startDate>
<xbrli:endDate>
2016-04-01
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_25_Mar_2016T00_00_00_TO_01_Apr_2016T00_00_00_LegalEntityAxis_ImmudynePrLlcMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">immd:ImmudynePrLlcMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-03-25
</xbrli:startDate>
<xbrli:endDate>
2016-04-01
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_May_2016T00_00_00_TO_31_May_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">immd:ConsultantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-05-01
</xbrli:startDate>
<xbrli:endDate>
2016-05-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2016T00_00_00_TO_30_Jun_2016T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Aug_2016T00_00_00_TO_31_Aug_2016T00_00_00_SubsidiarySaleOfStockAxis_IPOMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-08-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Aug_2016T00_00_00_TO_31_Aug_2016T00_00_00_CashAndCashEquivalentsAxis_CommercialPaperMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-08-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_01_Sep_2016T00_00_00_TO_01_Sep_2016T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-09-01
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_01_Sep_2016T00_00_00_TO_01_Sep_2016T00_00_00_AwardTypeAxis_WarrantMember_SubsidiarySaleOfStockAxis_IPOMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-09-01
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_01_Sep_2016T00_00_00_TO_01_Sep_2016T00_00_00_AwardTypeAxis_WarrantMember_SubsidiarySaleOfStockAxis_ConsultingServicesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">immd:ConsultingServicesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-09-01
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_01_Sep_2016T00_00_00_TO_01_Sep_2016T00_00_00_AwardTypeAxis_WarrantMember_RangeAxis_MinimumMember_SubsidiarySaleOfStockAxis_ConsultingServicesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">immd:ConsultingServicesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-09-01
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_01_Sep_2016T00_00_00_TO_01_Sep_2016T00_00_00_AwardTypeAxis_WarrantMember_RangeAxis_MaximumMember_SubsidiarySaleOfStockAxis_ConsultingServicesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">immd:ConsultingServicesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-09-01
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_25_Aug_2016T00_00_00_TO_01_Sep_2016T00_00_00_AwardTypeAxis_WarrantMember_SubsidiarySaleOfStockAxis_IPOMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-08-25
</xbrli:startDate>
<xbrli:endDate>
2016-09-01
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_25_Aug_2016T00_00_00_TO_01_Sep_2016T00_00_00_AwardTypeAxis_WarrantMember_SubsidiarySaleOfStockAxis_ConsultingServicesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">immd:ConsultingServicesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-08-25
</xbrli:startDate>
<xbrli:endDate>
2016-09-01
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-07-01
</xbrli:startDate>
<xbrli:endDate>
2016-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_SubsidiarySaleOfStockAxis_IPOMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_CashAndCashEquivalentsAxis_CommercialPaperMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Oct_2016T00_00_00_TO_31_Oct_2016T00_00_00_SubsidiarySaleOfStockAxis_IPOMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-10-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Oct_2016T00_00_00_TO_31_Oct_2016T00_00_00_CashAndCashEquivalentsAxis_CommercialPaperMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-10-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_20_Oct_2016T00_00_00_TO_31_Oct_2016T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-10-20
</xbrli:startDate>
<xbrli:endDate>
2016-10-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_20_Oct_2016T00_00_00_TO_31_Oct_2016T00_00_00_AwardTypeAxis_PerformanceBasedStockOptionsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">immd:PerformanceBasedStockOptionsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-10-20
</xbrli:startDate>
<xbrli:endDate>
2016-10-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Nov_2016T00_00_00_TO_30_Nov_2016T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-11-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Nov_2016T00_00_00_TO_30_Nov_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">immd:ConsultantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-11-01
</xbrli:startDate>
<xbrli:endDate>
2016-11-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_23_Dec_2016T00_00_00_TO_23_Dec_2016T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-23
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_ClassOfFinancingReceivableTypeOfBorrowerAxis_CommercialLenderMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfFinancingReceivableTypeOfBorrowerAxis">immd:CommercialLenderMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_TitleOfIndividualAxis_BoardOfDirectorsChairmanMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_SummationMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">immd:SummationMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_NoncontrollingInterestMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidationItemsAxis_NutraceuticalAndCosmeticMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">immd:NutraceuticalAndCosmeticMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidationItemsAxis_CosmeticGoodsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">immd:CosmeticGoodsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidationItemsAxis_IntersegmentEliminationMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConcentrationRiskByBenchmarkAxis_SalesMember_ConcentrationRiskNumberOfCustomersAxis_OneCustomerMember_ConsolidationItemsAxis_NutraceuticalAndCosmeticMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="immd:ConcentrationRiskNumberOfCustomersAxis">immd:OneCustomerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">immd:NutraceuticalAndCosmeticMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConcentrationRiskByBenchmarkAxis_SalesMember_ConcentrationRiskNumberOfCustomersAxis_SecondCustomerMember_ConsolidationItemsAxis_NutraceuticalAndCosmeticMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="immd:ConcentrationRiskNumberOfCustomersAxis">immd:SecondCustomerMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">immd:NutraceuticalAndCosmeticMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_PerformanceBasedStockOptionsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">immd:PerformanceBasedStockOptionsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_OptionIndexedToIssuersEquityTypeAxis_EmployeeStockOptionMember_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_ShortTermDebtTypeAxis_NotesPayableOtherPayablesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskNumberOfCustomersAxis_OneCustomerMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="immd:ConcentrationRiskNumberOfCustomersAxis">immd:OneCustomerMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskNumberOfCustomersAxis_SecondCustomerMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="immd:ConcentrationRiskNumberOfCustomersAxis">immd:SecondCustomerMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_TitleOfIndividualAxis_OfficerMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:OfficerMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_TitleOfIndividualAxis_PresidentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:PresidentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_RestrictedStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_WarrantMember_SubsidiarySaleOfStockAxis_IPOMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_PerformanceBasedStockOptionsMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">immd:PerformanceBasedStockOptionsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_PerformanceBasedStockOptionsMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">immd:PerformanceBasedStockOptionsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeOneMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">immd:ExercisePriceRangeOneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeTwoMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">immd:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeThreeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">immd:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_RangeAxis_MaximumMember_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_RangeAxis_MinimumMember_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_RestrictedStockOneMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">immd:RestrictedStockOneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_RestrictedStockTwoMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">immd:RestrictedStockTwoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_RestrictedStockThreeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">immd:RestrictedStockThreeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_WarrantMember_SubsidiarySaleOfStockAxis_IssuanceOfCommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">immd:IssuanceOfCommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_LegalEntityAxis_ImmudynePrLlcMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">immd:ImmudynePrLlcMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis_OneCreditCardProcessorsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis">immd:OneCreditCardProcessorsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis_TwoCreditCardProcessorsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis">immd:TwoCreditCardProcessorsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ClassOfFinancingReceivableTypeOfBorrowerAxis_CommercialLenderMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfFinancingReceivableTypeOfBorrowerAxis">immd:CommercialLenderMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_TitleOfIndividualAxis_BoardOfDirectorsChairmanMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_SummationMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">immd:SummationMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_NoncontrollingInterestMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidationItemsAxis_NutraceuticalAndCosmeticMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">immd:NutraceuticalAndCosmeticMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidationItemsAxis_CosmeticGoodsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">immd:CosmeticGoodsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidationItemsAxis_IntersegmentEliminationMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_PerformanceBasedStockOptionsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">immd:PerformanceBasedStockOptionsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_TitleOfIndividualAxis_OfficerMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:OfficerMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_RestrictedStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">immd:ConsultantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_SubsidiarySaleOfStockAxis_IPOMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_WarrantMember_SubsidiarySaleOfStockAxis_IPOMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeOneMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">immd:ExercisePriceRangeOneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeTwoMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">immd:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeThreeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">immd:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_WarrantMember_SubsidiarySaleOfStockAxis_IssuanceOfCommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">immd:IssuanceOfCommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeTwoMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">immd:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeTwoMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">immd:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeThreeMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">immd:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeThreeMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">immd:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Jan_2017T00_00_00_TO_31_Jan_2017T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-01-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Jan_2017T00_00_00_TO_31_Jan_2017T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_CashAndCashEquivalentsAxis_CommercialPaperMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-01-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jan_2017T00_00_00_TO_31_Jan_2017T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-01-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jan_2017T00_00_00_TO_31_Jan_2017T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_CashAndCashEquivalentsAxis_CommercialPaperMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-01-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_28_Feb_2017T00_00_00_TO_28_Feb_2017T00_00_00_CashAndCashEquivalentsAxis_CommercialPaperTwoMember_SubsequentEventTypeAxis_SubsequentEventMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">immd:CommercialPaperTwoMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-02-28
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Feb_2017T00_00_00_TO_28_Feb_2017T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-02-01
</xbrli:startDate>
<xbrli:endDate>
2017-02-28
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Mar_2017T00_00_00_TO_27_Mar_2017T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-03-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-27
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_CashAndCashEquivalentsAxis_CommercialPaperOneMember_SubsequentEventTypeAxis_SubsequentEventMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">immd:CommercialPaperOneMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-03-01
</xbrli:startDate>
<xbrli:endDate>
2017-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_24_Apr_2017T00_00_00_TO_24_Apr_2017T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-04-24
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Apr_2017T00_00_00_TO_24_Apr_2017T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-04-01
</xbrli:startDate>
<xbrli:endDate>
2017-04-24
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_16_May_2017T00_00_00_TO_16_May_2017T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000948320</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-05-16
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<!-- Unit Section  -->
<!--
I~1\FVPHexeD5678YReqi>IhkevEkirxw<6c444c555cT{h>7G5EGE=H1=8FF1874I1E59;1J:85J=7H:<7J -->
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD_per_Share"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:unit id="pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<xbrli:unit id="Consultants"><xbrli:measure>immd:Consultants</xbrli:measure></xbrli:unit>
<xbrli:unit id="Thresholds"><xbrli:measure>immd:Thresholds</xbrli:measure></xbrli:unit>
<!-- Element Section  --><dei:EntityRegistrantName contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00">Immudyne, Inc.</dei:EntityRegistrantName>
<dei:EntityCentralIndexKey contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00">0000948320</dei:EntityCentralIndexKey>
<dei:AmendmentFlag contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00">false</dei:AmendmentFlag>
<dei:CurrentFiscalYearEndDate contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00">--12-31</dei:CurrentFiscalYearEndDate>
<dei:DocumentType contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00">10-K</dei:DocumentType>
<dei:DocumentPeriodEndDate contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00">2016-12-31</dei:DocumentPeriodEndDate>
<dei:DocumentFiscalYearFocus contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00">2016</dei:DocumentFiscalYearFocus>
<dei:DocumentFiscalPeriodFocus contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00">FY</dei:DocumentFiscalPeriodFocus>
<dei:EntityFilerCategory contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00">Smaller Reporting Company</dei:EntityFilerCategory>
<dei:EntityWellKnownSeasonedIssuer contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00">No</dei:EntityWellKnownSeasonedIssuer>
<dei:EntityVoluntaryFilers contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00">No</dei:EntityVoluntaryFilers>
<dei:EntityCurrentReportingStatus contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00">Yes</dei:EntityCurrentReportingStatus>
<dei:EntityPublicFloat contextRef="Context_As_Of_30_Jun_2016T00_00_00_TO_30_Jun_2016T00_00_00" unitRef="USD" decimals="0">5290842</dei:EntityPublicFloat>
<dei:EntityCommonStockSharesOutstanding contextRef="Context_As_Of_16_May_2017T00_00_00_TO_16_May_2017T00_00_00" unitRef="shares" decimals="INF">38406601</dei:EntityCommonStockSharesOutstanding>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">75495</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">73862</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">232984</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">182561</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:AccountsReceivableNetCurrent contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">154436</us-gaap:AccountsReceivableNetCurrent>
<us-gaap:AccountsReceivableNetCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">444743</us-gaap:AccountsReceivableNetCurrent>
<us-gaap:OtherReceivablesNetCurrent contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:OtherReceivablesNetCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">2250</us-gaap:OtherReceivablesNetCurrent>
<us-gaap:InventoryNet contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">61051</us-gaap:InventoryNet>
<us-gaap:InventoryNet contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">160270</us-gaap:InventoryNet>
<us-gaap:AssetsCurrent contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">448471</us-gaap:AssetsCurrent>
<us-gaap:AssetsCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">789824</us-gaap:AssetsCurrent>
<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">167481</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">752930</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
<us-gaap:DerivativeLiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:DerivativeLiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">192254</us-gaap:DerivativeLiabilitiesCurrent>
<us-gaap:ConvertibleNotesPayableCurrent contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:ConvertibleNotesPayableCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">100000</us-gaap:ConvertibleNotesPayableCurrent>
<us-gaap:NotesPayableCurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">27200</us-gaap:NotesPayableCurrent>
<us-gaap:NotesPayableCurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_ClassOfFinancingReceivableTypeOfBorrowerAxis_CommercialLenderMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:NotesPayableCurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_TitleOfIndividualAxis_BoardOfDirectorsChairmanMember" unitRef="USD" decimals="0">27200</us-gaap:NotesPayableCurrent>
<us-gaap:NotesPayableCurrent contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">100000</us-gaap:NotesPayableCurrent>
<us-gaap:NotesPayableCurrent contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_ClassOfFinancingReceivableTypeOfBorrowerAxis_CommercialLenderMember" unitRef="USD" decimals="0">100000</us-gaap:NotesPayableCurrent>
<us-gaap:NotesPayableCurrent contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_TitleOfIndividualAxis_BoardOfDirectorsChairmanMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:NotesPayableCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">106365</us-gaap:NotesPayableCurrent>
<us-gaap:NotesPayableCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ClassOfFinancingReceivableTypeOfBorrowerAxis_CommercialLenderMember" unitRef="USD" decimals="0">-100000</us-gaap:NotesPayableCurrent>
<us-gaap:NotesPayableCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_TitleOfIndividualAxis_BoardOfDirectorsChairmanMember" unitRef="USD" decimals="0">206365</us-gaap:NotesPayableCurrent>
<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">267481</us-gaap:LiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">1151549</us-gaap:LiabilitiesCurrent>
<us-gaap:CommonStockValue contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">320103</us-gaap:CommonStockValue>
<us-gaap:CommonStockValue contextRef="Context_As_Of_01_Sep_2016T00_00_00_TO_01_Sep_2016T00_00_00" unitRef="USD" decimals="0">46000</us-gaap:CommonStockValue>
<us-gaap:CommonStockValue contextRef="Context_As_Of_23_Dec_2016T00_00_00_TO_23_Dec_2016T00_00_00" unitRef="USD" decimals="0">17250</us-gaap:CommonStockValue>
<us-gaap:CommonStockValue contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">355701</us-gaap:CommonStockValue>
<us-gaap:AdditionalPaidInCapital contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">8366313</us-gaap:AdditionalPaidInCapital>
<us-gaap:AdditionalPaidInCapital contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">9070064</us-gaap:AdditionalPaidInCapital>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">-8586338</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">-9693882</us-gaap:RetainedEarningsAccumulatedDeficit>
<immd:Equity contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">100078</immd:Equity>
<immd:Equity contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">-268117</immd:Equity>
<us-gaap:TreasuryStockValue contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:TreasuryStockValue contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">87053</us-gaap:TreasuryStockValue>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">100078</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">-355170</us-gaap:StockholdersEquity>
<us-gaap:MinorityInterest contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">80912</us-gaap:MinorityInterest>
<us-gaap:MinorityInterest contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">-6555</us-gaap:MinorityInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">-139498</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">307299</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">8077549</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="0">-8524346</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_SummationMember" unitRef="USD" decimals="0">-139498</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">180990</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">320103</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">8366313</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="0">-8586338</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_SummationMember" unitRef="USD" decimals="0">100078</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USD" decimals="0">80912</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">-361725</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">355701</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">9070064</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="0">-9693882</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_SummationMember" unitRef="USD" decimals="0">-355170</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USD" decimals="0">-6555</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" decimals="0">-87053</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">448471</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">789824</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD_per_Share" decimals="2">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD_per_Share" decimals="2">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="shares" decimals="INF">50000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="shares" decimals="INF">50000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="shares" decimals="INF">32010375</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_TitleOfIndividualAxis_PresidentMember" unitRef="shares" decimals="INF">499225</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_TitleOfIndividualAxis_DirectorMember" unitRef="shares" decimals="INF">60000</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_31_Aug_2016T00_00_00_TO_31_Aug_2016T00_00_00_SubsidiarySaleOfStockAxis_IPOMember" unitRef="shares" decimals="INF">125000</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_01_Sep_2016T00_00_00_TO_01_Sep_2016T00_00_00" unitRef="shares" decimals="INF">200000</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_SubsidiarySaleOfStockAxis_IPOMember" unitRef="shares" decimals="INF">62500</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_31_Oct_2016T00_00_00_TO_31_Oct_2016T00_00_00_SubsidiarySaleOfStockAxis_IPOMember" unitRef="shares" decimals="INF">62500</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_30_Nov_2016T00_00_00_TO_30_Nov_2016T00_00_00" unitRef="shares" decimals="INF">434782</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_23_Dec_2016T00_00_00_TO_23_Dec_2016T00_00_00" unitRef="shares" decimals="INF">75000</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="shares" decimals="INF">35570157</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_SubsidiarySaleOfStockAxis_IPOMember" unitRef="shares" decimals="INF">62500</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="shares" decimals="INF">32010375</us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="shares" decimals="INF">35245157</us-gaap:CommonStockSharesOutstanding>
<us-gaap:TreasuryStockCommonShares contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="shares" xsi:nil="true"/>
<us-gaap:TreasuryStockCommonShares contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="shares" decimals="INF">325000</us-gaap:TreasuryStockCommonShares>
<us-gaap:Revenues contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">1218862</us-gaap:Revenues>
<us-gaap:Revenues contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_ConsolidationItemsAxis_NutraceuticalAndCosmeticMember" unitRef="USD" decimals="0">1092289</us-gaap:Revenues>
<us-gaap:Revenues contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_ConsolidationItemsAxis_CosmeticGoodsMember" unitRef="USD" decimals="0">139573</us-gaap:Revenues>
<us-gaap:Revenues contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_ConsolidationItemsAxis_IntersegmentEliminationMember" unitRef="USD" decimals="0">-13000</us-gaap:Revenues>
<us-gaap:Revenues contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">5238604</us-gaap:Revenues>
<us-gaap:Revenues contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidationItemsAxis_NutraceuticalAndCosmeticMember" unitRef="USD" decimals="0">1024264</us-gaap:Revenues>
<us-gaap:Revenues contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidationItemsAxis_CosmeticGoodsMember" unitRef="USD" decimals="0">4240640</us-gaap:Revenues>
<us-gaap:Revenues contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidationItemsAxis_IntersegmentEliminationMember" unitRef="USD" decimals="0">-26300</us-gaap:Revenues>
<us-gaap:CostOfRevenue contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">247772</us-gaap:CostOfRevenue>
<us-gaap:CostOfRevenue contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">1946055</us-gaap:CostOfRevenue>
<us-gaap:GrossProfit contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">971090</us-gaap:GrossProfit>
<us-gaap:GrossProfit contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">3292549</us-gaap:GrossProfit>
<immd:CompensationAndRelatedExpenses contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">532421</immd:CompensationAndRelatedExpenses>
<immd:CompensationAndRelatedExpenses contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">1247195</immd:CompensationAndRelatedExpenses>
<us-gaap:ProfessionalFees contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">114890</us-gaap:ProfessionalFees>
<us-gaap:ProfessionalFees contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">477401</us-gaap:ProfessionalFees>
<us-gaap:ProfessionalFees contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_LegalEntityAxis_ImmudynePrLlcMember" unitRef="USD" decimals="0">3000</us-gaap:ProfessionalFees>
<us-gaap:MarketingExpense contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">230661</us-gaap:MarketingExpense>
<us-gaap:MarketingExpense contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">1710357</us-gaap:MarketingExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">23925</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">331410</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">1032278</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:OperatingExpenses contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">1233307</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">4467231</us-gaap:OperatingExpenses>
<us-gaap:OperatingIncomeLoss contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">-262217</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">-1174682</us-gaap:OperatingIncomeLoss>
<us-gaap:GainOnSaleOfInvestments contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">127261</us-gaap:GainOnSaleOfInvestments>
<us-gaap:GainOnSaleOfInvestments contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:InterestExpense contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">37476</us-gaap:InterestExpense>
<us-gaap:InterestExpense contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_ClassOfFinancingReceivableTypeOfBorrowerAxis_CommercialLenderMember" unitRef="USD" decimals="0">25425</us-gaap:InterestExpense>
<us-gaap:InterestExpense contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_PerformanceBasedStockOptionsMember" unitRef="USD" decimals="0">8500</us-gaap:InterestExpense>
<us-gaap:InterestExpense contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_ShortTermDebtTypeAxis_NotesPayableOtherPayablesMember" unitRef="USD" decimals="0">37476</us-gaap:InterestExpense>
<us-gaap:InterestExpense contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_TitleOfIndividualAxis_OfficerMember" unitRef="USD" decimals="0">10508</us-gaap:InterestExpense>
<us-gaap:InterestExpense contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">48611</us-gaap:InterestExpense>
<us-gaap:InterestExpense contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_ShortTermDebtTypeAxis_NotesPayableOtherPayablesMember" unitRef="USD" decimals="0">49485</us-gaap:InterestExpense>
<us-gaap:InterestExpense contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_TitleOfIndividualAxis_OfficerMember" unitRef="USD" decimals="0">5416</us-gaap:InterestExpense>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">-172432</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">-1223293</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">-13200</us-gaap:DeferredIncomeTaxExpenseBenefit>
<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProfitLoss contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">-159232</us-gaap:ProfitLoss>
<us-gaap:ProfitLoss contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProfitLoss contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProfitLoss contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="0">-61992</us-gaap:ProfitLoss>
<us-gaap:ProfitLoss contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_SummationMember" unitRef="USD" decimals="0">-61992</us-gaap:ProfitLoss>
<us-gaap:ProfitLoss contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USD" decimals="0">-97240</us-gaap:ProfitLoss>
<us-gaap:ProfitLoss contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_ConsolidationItemsAxis_NutraceuticalAndCosmeticMember" unitRef="USD" decimals="0">110467</us-gaap:ProfitLoss>
<us-gaap:ProfitLoss contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_ConsolidationItemsAxis_CosmeticGoodsMember" unitRef="USD" decimals="0">-158402</us-gaap:ProfitLoss>
<us-gaap:ProfitLoss contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_ConsolidationItemsAxis_IntersegmentEliminationMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProfitLoss contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">-1223293</us-gaap:ProfitLoss>
<us-gaap:ProfitLoss contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="0">-1107544</us-gaap:ProfitLoss>
<us-gaap:ProfitLoss contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_SummationMember" unitRef="USD" decimals="0">-1107544</us-gaap:ProfitLoss>
<us-gaap:ProfitLoss contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USD" decimals="0">-115749</us-gaap:ProfitLoss>
<us-gaap:ProfitLoss contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProfitLoss contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidationItemsAxis_NutraceuticalAndCosmeticMember" unitRef="USD" decimals="0">164286</us-gaap:ProfitLoss>
<us-gaap:ProfitLoss contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidationItemsAxis_CosmeticGoodsMember" unitRef="USD" decimals="0">-388121</us-gaap:ProfitLoss>
<us-gaap:ProfitLoss contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidationItemsAxis_IntersegmentEliminationMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">-97240</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">-115749</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">-61992</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">-1107544</us-gaap:NetIncomeLoss>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD_per_Share" decimals="2">0.00</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD_per_Share" decimals="2">-0.03</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">30729973</us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">32010375</us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">35570157</us-gaap:SharesOutstanding>
<immd:AdjustmentsOfAdditionPaidInCapitalAmortizationOfStockOptions contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">22300</immd:AdjustmentsOfAdditionPaidInCapitalAmortizationOfStockOptions>
<immd:AdjustmentsOfAdditionPaidInCapitalAmortizationOfStockOptions contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">22300</immd:AdjustmentsOfAdditionPaidInCapitalAmortizationOfStockOptions>
<immd:AdjustmentsOfAdditionPaidInCapitalAmortizationOfStockOptions contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<immd:AdjustmentsOfAdditionPaidInCapitalAmortizationOfStockOptions contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_SummationMember" unitRef="USD" decimals="0">22300</immd:AdjustmentsOfAdditionPaidInCapitalAmortizationOfStockOptions>
<immd:AdjustmentsOfAdditionPaidInCapitalAmortizationOfStockOptions contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true"/>
<immd:AdjustmentsOfAdditionPaidInCapitalAmortizationOfStockOptions contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" xsi:nil="true"/>
<immd:AdjustmentsOfAdditionPaidInCapitalAmortizationOfStockOptions contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">120867</immd:AdjustmentsOfAdditionPaidInCapitalAmortizationOfStockOptions>
<immd:AdjustmentsOfAdditionPaidInCapitalAmortizationOfStockOptions contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<immd:AdjustmentsOfAdditionPaidInCapitalAmortizationOfStockOptions contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">120867</immd:AdjustmentsOfAdditionPaidInCapitalAmortizationOfStockOptions>
<immd:AdjustmentsOfAdditionPaidInCapitalAmortizationOfStockOptions contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<immd:AdjustmentsOfAdditionPaidInCapitalAmortizationOfStockOptions contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_SummationMember" unitRef="USD" decimals="0">120867</immd:AdjustmentsOfAdditionPaidInCapitalAmortizationOfStockOptions>
<immd:AdjustmentsOfAdditionPaidInCapitalAmortizationOfStockOptions contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true"/>
<immd:AdjustmentsOfAdditionPaidInCapitalAmortizationOfStockOptions contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="Context_Custom_01_May_2015T00_00_00_TO_31_May_2015T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_InvestorMember" unitRef="USD" decimals="0">10800</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
<us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">-10800</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
<us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">-1200</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
<us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-9600</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
<us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_SummationMember" unitRef="USD" decimals="0">-10800</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
<us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_TitleOfIndividualAxis_PresidentMember" unitRef="USD" decimals="0">13000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
<us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_TitleOfIndividualAxis_DirectorMember" unitRef="USD" decimals="0">1000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
<us-gaap:StockRepurchasedAndRetiredDuringPeriodShares contextRef="Context_Custom_01_May_2015T00_00_00_TO_31_May_2015T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_InvestorMember" unitRef="shares" decimals="INF">120000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
<us-gaap:StockRepurchasedAndRetiredDuringPeriodShares contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">-120000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
<us-gaap:StockRepurchasedAndRetiredDuringPeriodShares contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_TitleOfIndividualAxis_PresidentMember" unitRef="shares" decimals="INF">339473</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
<us-gaap:StockRepurchasedAndRetiredDuringPeriodShares contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_TitleOfIndividualAxis_DirectorMember" unitRef="shares" decimals="INF">40800</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">170068</us-gaap:StockIssuedDuringPeriodValueOther>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">10004</us-gaap:StockIssuedDuringPeriodValueOther>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">160064</us-gaap:StockIssuedDuringPeriodValueOther>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_SummationMember" unitRef="USD" decimals="0">170068</us-gaap:StockIssuedDuringPeriodValueOther>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueOther contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodSharesOther contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">1000402</us-gaap:StockIssuedDuringPeriodSharesOther>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">65000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">5000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">60000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_SummationMember" unitRef="USD" decimals="0">65000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_Custom_25_Mar_2016T00_00_00_TO_01_Apr_2016T00_00_00_AwardTypeAxis_RestrictedStockMember" unitRef="USD" decimals="0">500000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_Custom_25_Mar_2016T00_00_00_TO_01_Apr_2016T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantMember" unitRef="USD" decimals="0">690000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">383333</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">23000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">360333</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_SummationMember" unitRef="USD" decimals="0">383333</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_RestrictedStockMember" unitRef="USD" decimals="INF">2300000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">500000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
<us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="Context_Custom_25_Mar_2016T00_00_00_TO_01_Apr_2016T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantMember" unitRef="shares" decimals="INF">2300000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
<us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">2300000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">-1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_SummationMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited contextRef="Context_Custom_20_Oct_2016T00_00_00_TO_31_Oct_2016T00_00_00_AwardTypeAxis_PerformanceBasedStockOptionsMember" unitRef="USD" decimals="0">17999</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
<us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">-100000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
<us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited contextRef="Context_Custom_20_Oct_2016T00_00_00_TO_31_Oct_2016T00_00_00_AwardTypeAxis_PerformanceBasedStockOptionsMember" unitRef="shares" decimals="INF">287500</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
<immd:Adjustmentstoadditionalpaidincapitalsharebasedcompensationextensionstockoptionswarrantexpirationdates contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">55000</immd:Adjustmentstoadditionalpaidincapitalsharebasedcompensationextensionstockoptionswarrantexpirationdates>
<immd:Adjustmentstoadditionalpaidincapitalsharebasedcompensationextensionstockoptionswarrantexpirationdates contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">55000</immd:Adjustmentstoadditionalpaidincapitalsharebasedcompensationextensionstockoptionswarrantexpirationdates>
<immd:Adjustmentstoadditionalpaidincapitalsharebasedcompensationextensionstockoptionswarrantexpirationdates contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<immd:Adjustmentstoadditionalpaidincapitalsharebasedcompensationextensionstockoptionswarrantexpirationdates contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_SummationMember" unitRef="USD" decimals="0">55000</immd:Adjustmentstoadditionalpaidincapitalsharebasedcompensationextensionstockoptionswarrantexpirationdates>
<immd:Adjustmentstoadditionalpaidincapitalsharebasedcompensationextensionstockoptionswarrantexpirationdates contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true"/>
<immd:Adjustmentstoadditionalpaidincapitalsharebasedcompensationextensionstockoptionswarrantexpirationdates contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_Custom_02_Nov_2015T00_00_00_TO_30_Nov_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantMember" unitRef="USD" decimals="0">65000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">63250</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">2750</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">60500</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_SummationMember" unitRef="USD" decimals="0">63250</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_Custom_02_Nov_2015T00_00_00_TO_30_Nov_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantMember" unitRef="shares" decimals="INF">500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_Custom_01_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_PresidentMember" unitRef="shares" decimals="INF">499225</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">275000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">100000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
<us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">4348</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
<us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">95652</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
<us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_SummationMember" unitRef="USD" decimals="0">100000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
<us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">434782</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">30000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">27000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_SummationMember" unitRef="USD" decimals="0">30000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">300000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">300000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="Context_Custom_20_Oct_2016T00_00_00_TO_31_Oct_2016T00_00_00" unitRef="USD" decimals="0">58750</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">58750</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">2500</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">56250</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_SummationMember" unitRef="USD" decimals="0">58750</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="shares" decimals="INF">62500</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="Context_Custom_20_Oct_2016T00_00_00_TO_31_Oct_2016T00_00_00" unitRef="shares" decimals="INF">250000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">250000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
<us-gaap:AdjustmentOfWarrantsGrantedForServices contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentOfWarrantsGrantedForServices contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">20585</us-gaap:AdjustmentOfWarrantsGrantedForServices>
<us-gaap:AdjustmentOfWarrantsGrantedForServices contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentOfWarrantsGrantedForServices contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">20585</us-gaap:AdjustmentOfWarrantsGrantedForServices>
<us-gaap:AdjustmentOfWarrantsGrantedForServices contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentOfWarrantsGrantedForServices contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_SummationMember" unitRef="USD" decimals="0">20585</us-gaap:AdjustmentOfWarrantsGrantedForServices>
<us-gaap:AdjustmentOfWarrantsGrantedForServices contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentOfWarrantsGrantedForServices contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:MinorityInterestPeriodIncreaseDecrease contextRef="Context_Custom_25_Mar_2016T00_00_00_TO_01_Apr_2016T00_00_00_LegalEntityAxis_ImmudynePrLlcMember" unitRef="USD" decimals="0">91612</us-gaap:MinorityInterestPeriodIncreaseDecrease>
<us-gaap:MinorityInterestPeriodIncreaseDecrease contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:MinorityInterestPeriodIncreaseDecrease contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">91612</us-gaap:MinorityInterestPeriodIncreaseDecrease>
<us-gaap:MinorityInterestPeriodIncreaseDecrease contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:MinorityInterestPeriodIncreaseDecrease contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_SummationMember" unitRef="USD" decimals="0">91612</us-gaap:MinorityInterestPeriodIncreaseDecrease>
<us-gaap:MinorityInterestPeriodIncreaseDecrease contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USD" decimals="0">-91612</us-gaap:MinorityInterestPeriodIncreaseDecrease>
<us-gaap:MinorityInterestPeriodIncreaseDecrease contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">-87053</us-gaap:TreasuryStockValueAcquiredCostMethod>
<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_SummationMember" unitRef="USD" decimals="0">-87053</us-gaap:TreasuryStockValueAcquiredCostMethod>
<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" decimals="0">-87053</us-gaap:TreasuryStockValueAcquiredCostMethod>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">63206</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">63206</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_SummationMember" unitRef="USD" decimals="0">63206</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">178152</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
<us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_SummationMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USD" decimals="0">178152</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
<us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">119894</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
<us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_SummationMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USD" decimals="0">119894</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
<us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" xsi:nil="true"/>
<immd:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">-192254</immd:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities>
<immd:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<immd:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-192254</immd:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities>
<immd:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<immd:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_SummationMember" unitRef="USD" decimals="0">-192254</immd:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities>
<immd:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="USD" xsi:nil="true"/>
<immd:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:Depreciation contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">43748</us-gaap:Depreciation>
<us-gaap:Depreciation contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProvisionForDoubtfulAccounts contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProvisionForDoubtfulAccounts contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">71136</us-gaap:ProvisionForDoubtfulAccounts>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_ClassOfFinancingReceivableTypeOfBorrowerAxis_CommercialLenderMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">33715</us-gaap:AmortizationOfDebtDiscountPremium>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_TitleOfIndividualAxis_BoardOfDirectorsChairmanMember" unitRef="USD" decimals="0">-25035</us-gaap:AmortizationOfDebtDiscountPremium>
<us-gaap:ShareBasedCompensation contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">77300</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD" decimals="0">22300</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_PerformanceBasedStockOptionsMember" unitRef="USD" decimals="0">142300</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">587991</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD" decimals="INF">63206</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_PerformanceBasedStockOptionsMember" unitRef="USD" decimals="0">587991</us-gaap:ShareBasedCompensation>
<us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">65000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
<us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:GainLossOnSaleOfInvestments contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">127261</us-gaap:GainLossOnSaleOfInvestments>
<us-gaap:GainLossOnSaleOfInvestments contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">139466</us-gaap:IncreaseDecreaseInAccountsReceivable>
<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">361443</us-gaap:IncreaseDecreaseInAccountsReceivable>
<us-gaap:IncreaseDecreaseInOtherReceivables contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncreaseDecreaseInOtherReceivables contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">2250</us-gaap:IncreaseDecreaseInOtherReceivables>
<us-gaap:IncreaseDecreaseInInventories contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">20043</us-gaap:IncreaseDecreaseInInventories>
<us-gaap:IncreaseDecreaseInInventories contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">99219</us-gaap:IncreaseDecreaseInInventories>
<us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">-21970</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
<us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">585449</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">-295124</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">-407914</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:PaymentsForProceedsFromInvestments contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">-127261</us-gaap:PaymentsForProceedsFromInvestments>
<us-gaap:PaymentsForProceedsFromInvestments contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProceedsFromPaymentsToMinorityShareholders contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">178152</us-gaap:ProceedsFromPaymentsToMinorityShareholders>
<us-gaap:ProceedsFromPaymentsToMinorityShareholders contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">219894</us-gaap:ProceedsFromPaymentsToMinorityShareholders>
<us-gaap:IncreaseDecreaseInNotesPayableCurrent contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">305000</us-gaap:IncreaseDecreaseInNotesPayableCurrent>
<us-gaap:IncreaseDecreaseInNotesPayableCurrent contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">200000</us-gaap:IncreaseDecreaseInNotesPayableCurrent>
<us-gaap:ProceedsFromConvertibleDebt contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProceedsFromConvertibleDebt contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">100000</us-gaap:ProceedsFromConvertibleDebt>
<us-gaap:RepaymentsOfNotesPayable contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">147000</us-gaap:RepaymentsOfNotesPayable>
<us-gaap:RepaymentsOfNotesPayable contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_ClassOfFinancingReceivableTypeOfBorrowerAxis_CommercialLenderMember" unitRef="USD" decimals="0">100000</us-gaap:RepaymentsOfNotesPayable>
<us-gaap:RepaymentsOfNotesPayable contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_TitleOfIndividualAxis_BoardOfDirectorsChairmanMember" unitRef="USD" decimals="0">47000</us-gaap:RepaymentsOfNotesPayable>
<us-gaap:RepaymentsOfNotesPayable contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">168600</us-gaap:RepaymentsOfNotesPayable>
<us-gaap:RepaymentsOfNotesPayable contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_ClassOfFinancingReceivableTypeOfBorrowerAxis_CommercialLenderMember" unitRef="USD" decimals="0">100000</us-gaap:RepaymentsOfNotesPayable>
<us-gaap:RepaymentsOfNotesPayable contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_TitleOfIndividualAxis_BoardOfDirectorsChairmanMember" unitRef="USD" decimals="0">68600</us-gaap:RepaymentsOfNotesPayable>
<us-gaap:ProceedsFromStockOptionsExercised contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProceedsFromStockOptionsExercised contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_PresidentMember" unitRef="USD" decimals="0">55000</us-gaap:ProceedsFromStockOptionsExercised>
<us-gaap:ProceedsFromStockOptionsExercised contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">30000</us-gaap:ProceedsFromStockOptionsExercised>
<immd:IssuanceOfCommonStockAndWarrants contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<immd:IssuanceOfCommonStockAndWarrants contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">63250</immd:IssuanceOfCommonStockAndWarrants>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">-10800</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_ShareholderMember" unitRef="USD" decimals="INF">441177</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">-87053</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">325352</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">357491</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">157489</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">-50423</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:InterestPaid contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">28976</us-gaap:InterestPaid>
<us-gaap:InterestPaid contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">13650</us-gaap:InterestPaid>
<us-gaap:ConversionOfStockAmountIssued1 contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">170068</us-gaap:ConversionOfStockAmountIssued1>
<us-gaap:ConversionOfStockAmountIssued1 contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<immd:IssuanceOfCommonStockInRelationToDebtOffering contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<immd:IssuanceOfCommonStockInRelationToDebtOffering contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">58750</immd:IssuanceOfCommonStockInRelationToDebtOffering>
<immd:ConversionOfEquityInvestedInSubsidiaryToCommonStockAndWarrants contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<immd:ConversionOfEquityInvestedInSubsidiaryToCommonStockAndWarrants contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">100000</immd:ConversionOfEquityInvestedInSubsidiaryToCommonStockAndWarrants>
<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00">&lt;div&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0pt; margin-bottom: 0pt; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; width: 0.5in; text-align: justify; text-indent: 0pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;1.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; text-align: justify; text-indent: 0pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;Organization and Going Concern&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Immudyne, Inc. (the &amp;#8220;Company&amp;#8221;) is a Delaware corporation established to develop, manufacture and sell natural immune support products containing the Company&amp;#8217;s proprietary yeast beta glucans, a group of beta glucans naturally occurring in the cell walls of yeast that have been shown through testing and analysis to support the immune system. The Company&amp;#8217;s products include once a day oral intake tablets and topical creams and gels for skin application. The Company concentrates its sales and marketing efforts on healthcare professionals, distributors for its all-natural raw material ingredient products and direct-to-consumer sales.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In 2015, the Company formed a joint venture domiciled in Puerto Rico, Innate Skincare, LLC d/b/a Innate Scientific, LLC (&amp;#8220;Innate&amp;#8221;). Under the terms of the joint venture agreement, the Company held a 33.3% equity interest, and a 51% controlling voting interest, in Innate. On January 20, 2016, Innate amended its limited liability company operating agreement and changed its legal name to Immudyne PR LLC (&amp;#8220;Immudyne PR&amp;#8221;). On April 1, 2016, Immudyne PR further amended its operating agreement and restated the Company&amp;#8217;s ownership and voting interest in Immudyne PR increasing its ownership to 78.16667% resulting in a charge to noncontrolling interest and additional paid-in-capital of $91,612. Immudyne PR was formed to launch a complete skin care regime formulated using strategic ingredients provided by the Company. Immudyne PR is also currently pursuing other opportunities.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The Company has funded operations in the past through the sales of its products, issuance of common stock and through loans and advances from officers and directors. The Company&amp;#8217;s continued operations are dependent upon obtaining an increase in its sales volume and the continued financial support from officers and directors or the issuance of additional shares of common stock.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The accompanying financial statements have been
 prepared on the basis that the Company will continue as a going concern, which assumes the realization of assets and the satisfaction of liabilities in the normal course of business. At December 31, 2016, the Company has an accumulated deficit approximating $9.7 million and has incurred negative cash flows from operations. These conditions raise substantial doubt about the Company's ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Based on the Company's cash balance at December 31, 2016, and projected cash needs for 2017, management estimates that it may need to increase sales revenue and/or raise additional capital to cover operating and capital requirements for the 2017 year. Management may raise the additional needed funds through increased sales volume, issuing additional shares of common stock or other equity securities, or obtaining debt financing. Although management has been successful to date in raising necessary funding, there can be no assurance that sales revenue will substantially increase or that any required future financing can be successfully completed on a timely basis, or on terms acceptable to the Company.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00">&lt;div&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-size-adjust: none; font-stretch: normal;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; width: 0.5in; text-align: justify; text-indent: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;2.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; text-align: justify; text-indent: 0pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;Summary of Significant Accounting Policies&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;&lt;i&gt;Principles of Consolidation&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company evaluates the need to consolidate affiliates based on standards set forth in ASC 810 Consolidation (&amp;#8220;ASC 810&amp;#8221;).&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The consolidated financial statements include the accounts of the Company and its majority owned subsidiary, Immudyne PR and variable interest entities (VIE&amp;#8217;s) in which the Company has been determined to be the primary beneficiary. The non- controlling interest in Immudyne PR represents the 21.833% equity interest held by other members of the joint venture. All significant consolidated transactions and balances have been eliminated in consolidation.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Variable Interest Entities&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company follows ASC 810-10-15 guidance with respect to accounting for variable interest entities (each, a &amp;#8220;VIE&amp;#8221;). These entities do not have sufficient equity at risk to finance their activities without additional subordinated financial support from other parties or whose equity investors lack any of the characteristics of a controlling financial interest. A variable interest is an investment or other interest that will absorb portions of a VIE&amp;#8217;s expected losses or receive portions of its expected residual returns and are contractual, ownership, or pecuniary in nature and that change with changes in the fair value of the entity&amp;#8217;s net assets. A reporting entity is the primary beneficiary of a VIE and must consolidate it when that party has a variable interest, or combination of variable interests, that provides it with a controlling financial interest. A party is deemed to have a controlling financial interest if it meets both of the power and losses/benefits criteria. The power criterion is the ability to direct the activities of the VIE that most significantly impact its economic performance. The losses/benefits criterion is the obligation to absorb losses from, or right to receive benefits from, the VIE that could potentially be significant to the VIE. The VIE model requires an ongoing reconsideration of whether a reporting entity is the primary beneficiary of a VIE due to changes in facts and circumstances.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space:
 normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;As of December 31, 2016 and 2015, the Company consolidated nine and zero VIEs, respectively.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Immudyne PR as the primary beneficiary of Ace Account Management LLC, Innerwell Skincare LLC, MCD Merchants LLC, One Equity Research LLC, Inate Gems LLC, Retriever Health Products LLC, Spurs 5, LLC, Salus LLC and Huntley LLC which are qualified as VIEs. The assets and liabilities and revenues and expenses of these VIEs included in the financial statements of Immudyne PR and further included in the consolidated financial statements. As of December 31, 2016, the VIEs had assets of $10,306, liabilities of $5,748, revenues of $6,271, and operating expenses of $6,141. The assets and liabilities include balances due from and due to the subsidiaries of Immudyne PR. These inter-company receivables and payables are eliminated upon consolidation of the VIE with Immudyne PR and Immudyne. No assets were pledged or given as collateral against any borrowings.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company utilizes third party entities to provide and increase credit card processing capacity and optimize corresponding rates and fees. A majority of these entities provide this service as independent contractors in exchange for a one (1%) percent fee of the net revenues processed and collected by such contractors from sales initiated by the Company. The VIEs consolidated in the Company&amp;#8217;s financial statements are primarily contracted to credit card processing through one or more merchant banks contracted by each VIE. Upon receipt of funds by each VIE, the collection of receipts less any returns, chargeback and other fees charged by such merchant bank is transferred to Immudyne PR.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;The Company prepares its consolidated financial statements in conformity with accounting principles generally accepted in the United States of America which requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Some of the more significant estimates required to be made by management include the determination of reserves for accounts receivable, returns and allowances, the accounting for derivatives, the valuation of inventory and stockholders&amp;#8217; equity based transactions. Actual results could differ from those estimates.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Derivative Liabilities&lt;/i&gt;&lt;/b&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company evaluates stock options, stock warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for under the relevant sections of Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;) Topic 815-40, Derivative Instruments and Hedging: Contracts in Entity&amp;#8217;s Own Equity. The result of this accounting treatment could be that the fair value of a financial instrument is classified as a derivative instrument and is marked-to-market at each balance sheet date and recorded as a liability. In the
 event that the fair value is recorded as a liability, the change in fair value is recorded in the consolidated statements of operations as other income or other expense. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Financial instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815-40 are reclassified to a liability account at the fair value of the instrument on the reclassification date.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;As of December 31, 2016, certain of the Company&amp;#8217;s stock options, stock warrants and convertible debt instruments were accounted for as derivative liabilities due to insufficient authorized shares of common stock to settle outstanding contracts. At December 31, 2016, the Company estimated the fair value of these stock options, stock warrants and embedded conversion features using the Black-Scholes option pricing model (&amp;#8220;Black-Scholes&amp;#8221;) in the amount of $192,254 was recorded upon issue&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Sequencing Policy&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Under ASC 815-40-35, the Company has adopted a sequencing policy whereby, in the event that reclassification of contracts from equity to assets or liabilities is necessary pursuant to ASC 815 due to the Company&amp;#8217;s inability to demonstrate it has sufficient authorized shares, shares will be allocated on the basis of the earliest issuance date of potentially dilutive instruments, with the earliest grants receiving the first allocation of authorized but unissued shares, and all future instruments being classified as a derivative liability, with the exception of instruments related to share-based compensation issued to employees or directors.&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Inventory&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;At December 31, 2016 and December 31, 2015, inventory consisted primarily of cosmetic and nutraceutical additives, and finished cosmetic products. Inventory is maintained in the Company&amp;#8217;s leased Kentucky warehouse and third party warehouses in Pennsylvania and Louisiana.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Inventory is valued at the lower of cost or market with cost determined on a first-in, first-out (&amp;#8220;FIFO&amp;#8221;) basis. Management compares the cost of inventory with the net
 realizable value and an allowance is made for writing down inventory to market value, if lower. At December 31, 2016 and December 31, 2015, the Company recorded an inventory reserve in the amount of $20,000. Inventory consists of the following:&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;December&amp;#160;31,&lt;br /&gt;2016&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;December&amp;#160;31,&lt;br /&gt;2015&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="width: 0.5in; background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;Raw materials&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 125px; text-align: right;"&gt;38,460&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 125px; text-align: right;"&gt;25,761&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;Finished products&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;121,810&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;35,290&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;160,270&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;61,051&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0px; text-align: center; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company&amp;#8217;s policy is to record revenue as earned when a firm commitment, indicating sales quantity and price exists, delivery has taken place and collectability is reasonably assured. The Company generally records sales of nutraceutical and cosmetic additives once the product is shipped to the customer, and for sales of finished cosmetic products once the customer places the order and the product is simultaneously shipped, but in limited cases if title does not pass until the product reaches the customer&amp;#8217;s delivery site, then recognition of revenue is deferred until that time. Delivery is considered to have occurred when title and risk of loss have transferred to the customer.
 Provisions for discounts, returns, allowances, customer rebates and other adjustments are netted with gross sales. The Company accounts for such provisions during the same period in which the related revenues are earned. Customer discounts, returns and rebates approximated $1,926,000 in the year ended December 31, 2016. Customer discounts, returns and rebates were not significant in the year ended December 31, 2015.&lt;/p&gt;
&lt;p style="font: 10pt/14.26px 'times new roman', times, serif; margin: 0pt 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Delivery is considered to have occurred when title and risk of loss have transferred to the customer. If title does not pass until the product reaches the customer&amp;#8217;s delivery site or the customer accepts the product, then recognition of revenue is deferred until that time. There are no formal sales incentives offered to any of the Company&amp;#8217;s customers. Volume discounts may be offered from time to time to customers purchasing large quantities on a per transaction basis.&lt;/p&gt;
&lt;p style="font: 10pt/14.26px 'times new roman', times, serif; margin: 0pt 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Revenue for the year ended December 31, 2016 consisted of nutraceutical and cosmetic additives ($997,964) and finished cosmetic products ($4,240,640). Revenue for the year ended December 31, 2015 consists of nutraceutical and cosmetic additives ($1,079,289) and finished cosmetic products ($139,573).&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;i&gt;Accounts receivable&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Accounts receivable are carried at original invoice amount less an estimate made for holdbacks and doubtful receivables based on a review of all outstanding amounts. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer&amp;#8217;s financial condition, credit history and current economic conditions and sets up an allowance for doubtful accounts when collection is uncertain. Customers&amp;#8217; accounts are written off when all attempts to collect have been exhausted. Recoveries of accounts receivable previously written off are recorded as income when received. At December 31, 2016 and 2015 the accounts receivable reserve was approximately $37,800 and $18,000, respectively. As of December 31, 2016, the reserve for sales returns and allowances was approximately $50,500. No sales returns and allowances reserve existed at December 31, 2015.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;i&gt;Segments&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The guidance for disclosures about segments of an
 enterprise requires that a public business enterprise report financial and descriptive information about its operating segments. Generally, financial information is required to be reported on the basis used internally for evaluating segment performance and resource allocation. The Company manages its operations in two reportable segments for purposes of assessing performance and making operating decisions. Revenue is generated predominately in the United States, and all significant assets are held in the United States, or United States territories.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies. The Company allocates resources and evaluates the performance of segments based on income or loss from operations, excluding interest, corporate expenses and other income (expenses).&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;A summary of the company&amp;#8217;s reportable segments is as follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 10pt;"&gt;&lt;u&gt;Total assets:&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-size: 10pt;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;br /&gt;&lt;font style="font-size: 10pt;"&gt;2016&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-size: 10pt;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;br /&gt;&lt;font style="font-size: 10pt;"&gt;2015&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="width: 0.5in; background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;Nutraceutical and Cosmetic Additives&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 15px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 125px; text-align: right; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;556,234&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 15px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 125px; text-align: right; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;412,324&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 15px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 10pt;"&gt;Finished Cosmetic Products&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 10pt;"&gt;422,288&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 10pt;"&gt;101,828&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;Eliminations&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;(188,698&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;(65,681&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; background-color: #cceeff;"&gt;&lt;font style="font-size:
 10pt;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;789,824&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;448,471&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;" colspan="6"&gt;Year ended&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;" colspan="2"&gt;December&amp;#160;31, 2016&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;" colspan="2"&gt;December&amp;#160;31, 2015&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;u&gt;Net sales by segment:&lt;/u&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="width: 0.5in; background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;Nutraceutical and Cosmetic Additives&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 125px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;1,024,264&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 125px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;1,092,289&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;Finished Cosmetic Products&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;4,240,640&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch:
 normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;139,573&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"&gt;Eliminations&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;"&gt;(26,300&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"&gt;)&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;"&gt;(13,000&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-size-adjust: none; font-stretch: normal;"&gt;Total&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size-adjust: none; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size-adjust: none; font-stretch: normal;"&gt;5,238,604&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size-adjust: none; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size-adjust: none; font-stretch: normal;"&gt;1,218,862&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; text-decoration: underline; font-size-adjust: none; font-stretch: normal;"&gt;Net (loss) income by segment:&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;Nutraceutical and Cosmetic Additives&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;164,286&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;110,467&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;Finished Cosmetic Products&lt;/td&gt;
&lt;td style="font:
 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;(388,121&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;)&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;(158,402&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; text-decoration: underline; font-size-adjust: none; font-stretch: normal;"&gt;Other unallocated amounts:&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;Corporate expenses&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;(950,847&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;)&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;(214,282&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;Other income (expense) &amp;#8211; net&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;(48,611&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;)&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;89,785&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-size-adjust: none; font-stretch: normal;"&gt;Consolidated income (loss) from operations&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size-adjust: none; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size-adjust: none; font-stretch: normal;"&gt;(1,223,293&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-size-adjust: none; font-stretch: normal;"&gt;)&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size-adjust: none; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size-adjust: none; font-stretch: normal;"&gt;(172,432&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-size-adjust: none; font-stretch: normal;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new
 roman', times, serif; margin: 0pt 0pt 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The Company files Corporate Federal and State tax returns, while Immudyne PR, which was formed as a limited liability corporation, files a separate tax return with any tax liabilities or benefits passing through to its members.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The Company records current and deferred taxes in accordance with Accounting Standards Codification (ASC) 740, &amp;#8220;Accounting for Income Taxes.&amp;#8221; This ASC requires recognition of deferred tax assets and liabilities for temporary differences between tax basis of assets and liabilities and the amounts at which they are carried in the financial statements, based upon the enacted rates in effect for the year in which the differences are expected to reverse. The Company establishes a valuation allowance when necessary to reduce deferred tax assets to the amount expected to be realized. The Company periodically assesses the value of its deferred tax asset, a majority of which has been generated by a history of net operating losses and determines the necessity for a valuation allowance. ASC 740 also provides a recognition threshold and measurement attribute for the financial statement recognition of a tax position taken or expected to be taken in a tax return. Using this guidance, a company may recognize the tax benefit from an uncertain tax position in its financial statements only if it is more likely-than-not (i.e., a likelihood of more than 50%) that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The Company&amp;#8217;s tax returns for all years since December 31, 2013, remain open to taxing authorities.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The Company follows the provisions of ASC 718, &amp;#8220;Share-Based Payment&amp;#8221;. Under this guidance compensation cost generally is recognized at fair value on the date of the grant and amortized over the respective vesting periods. The fair value of options at the date of grant is estimated using the Black-Scholes option pricing model. The expected option life is derived from assumed exercise rates based upon historical exercise patterns and
 represents the period of time that options granted are expected to be outstanding. The expected volatility is based upon historical volatility of the Company&amp;#8217;s shares using weekly price observations over an observation period that approximates the expected life of the options. The risk-free rate approximates the U.S. Treasury yield curve rate in effect at the time of grant for periods similar to the expected option life. Due to limited history of forfeitures, the estimated forfeiture rate included in the option valuation was zero.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Many of the assumptions require significant judgment and any changes could have a material impact in the determination of stock-based compensation expense.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;i&gt;Earnings (Loss) Per Share&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Basic earnings (loss) per common share is based on the weighted average number of shares outstanding during each period presented. Warrants and options to purchase common stock are included as common stock equivalents only when dilutive. Potential common stock equivalents are excluded from dilutive earnings per share when the effects would be antidilutive.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Common stock equivalents comprising shares underlying 16,302,447 options and warrants for the year ended December 31, 2016 have not been included in the loss per share calculation as the effects are anti-dilutive. Common stock equivalents comprising shares underlying 12,775,273 options and warrants for the year ended December 31, 2015 have not been included in the loss per share calculations as the effects are anti-dilutive.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (&amp;#8220;ASU 2016-15&amp;#8221;). ASU 2016-15 addresses eight specific cash flow issues with the objective of reducing diversity in practice regarding how certain cash receipts and cash payments are presented in the statement of cash flows. The standard provides guidance on the classification of the following items: (1) debt
 prepayment or debt extinguishment costs, (2) settlement of zero-coupon debt instruments, (3) contingent consideration payments made after a business combination, (4) proceeds from the settlement of insurance claims, (5) proceeds from the settlement of corporate-owned life insurance policies, (6) distributions received from equity method investments, (7) beneficial interests in securitization transactions, and (8) separately identifiable cash flows. The Company is required to adopt ASU 2016-15 for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2017 on a retrospective basis. Early adoption is permitted, including adoption in an interim period. The Company is currently evaluating the impact of adoption of ASU 2016-15.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;In March 2016, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) 2016-09, &amp;#8220;Compensation &amp;#8211; Stock Compensation: Improvements to Employee Share-Based Payment Accounting,&amp;#8221; which relates to the accounting for employee share-based payments. This standard addresses several aspects of the accounting for share-based payment award transactions, including: (a) income tax consequences; (b) classification flows of awards as either equity or liabilities; and (c) classification on the statement of cash flows. This standard will be effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The Company is in the process of evaluating the impact of the adoption of ASU 2016-09 on its consolidated financial statements. The adoption of ASU No. 2016-09 is not expected to have a material impact on the Company's consolidated financial statements or related disclosures.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;In February 2016, a pronouncement was issued that creates new accounting and reporting guidelines for leasing arrangements. The new guidance requires organizations that lease assets to recognize assets and liabilities on the balance sheet related to the rights and obligations created by those leases, regardless of whether they are classified as finance or operating leases. Consistent with current guidance, the recognition, measurement, and presentation of expenses and cash flows arising from a lease primarily will depend on its classification as a finance or operating lease. The guidance also requires new disclosures to help financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. The new standard is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period, with early application permitted. The new standard is to be applied using a modified retrospective approach. The Company is in the process of evaluating the impact of the new pronouncement on its consolidated financial statements.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;In May 2014, the Financial Accounting Standards Board ("FASB") issued accounting guidance, "Revenue from Contracts with Customers." The core principle of the new standard is for companies to recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration (that is, payment) to which the company expects to be entitled in exchange for those goods or services. The new standard also will result in enhanced disclosures about revenue, provide guidance for transactions that were not previously addressed comprehensively (for example, service revenue and contract modifications) and clarify guidance for multiple-element arrangements. The standard will be effective for fiscal years and interim periods within those years beginning after December 15, 2017. Accordingly, the Company will adopt this standard in the first quarter of fiscal year 2018. The Company is currently evaluating the impact this guidance will have on the consolidated financial statements.&lt;/font&gt;&lt;/p&gt;
&lt;p
 style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 108pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;In July 2015, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) 2015-11, &amp;#8220;Simplifying the Measurement of Inventory.&amp;#8221; ASU 2015-11 applies to inventory that is measured using first-in, first-out (FIFO) or average cost. An entity should measure inventory within the scope of ASU 2015-11 at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. ASU 2015-11 is effective for fiscal years beginning after December 15, 2016. The adoption of ASU No. 2015-11 is not expected to have a material impact on the Company's consolidated financial statements or related disclosures.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;In August 2014, the FASB issued ASU 2014-15, "Presentation of Financial Statements-Going Concern". This ASU is intended to define management's responsibility to evaluate whether there is substantial doubt about an organization's ability to continue as a going concern and to provide related footnote disclosures. It is effective for annual periods ending after December 15, 2016, with early adoption permitted. The Company does not expect it to have a material effect on the Company's consolidated financial condition, results of operations, and cash flows.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;In May 2017, the FASB issued ASU 2017-09, Compensation - Stock Compensation (Topic 718) : Scope of Modification Accounting. The new standard provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. This pronouncement is effective for annual reporting periods beginning after December 15, 2017 but early adoption is permitted. The Company is currently evaluating the impact of adopting this guidance.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;All other accounting standards that have been issued or proposed by the FASB that do not require adoption until a future date are not expected to have a material impact on the consolidated financial statements upon adoption.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000;
 text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The carrying value of the Company&amp;#8217;s financial instruments, including cash, trade accounts receivable, accounts payable and accrued expenses and the face amount of notes payable approximate fair value for all periods.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;i&gt;Noncontrolling Interests&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The Company accounts for its less than 100% interest in Immudyne PR in accordance with ASC Topic 810, Consolidation, and accordingly the Company presents noncontrolling interests as a component of equity on its consolidated balance sheet and reports the noncontrolling interest&amp;#8217;s share of the Immudyne PR net loss attributable to noncontrolling interests in the consolidated statement of operations.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Consolidation of Variable Interest Entities&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;In accordance with ASC 810-10-25-37 and as amended by ASU 2009-17, the Company determines whether any legal entity in which the Company becomes involved is a VIE and subject to consolidation. The Company conducts an assessment on an ongoing basis for each VIE including (1) the power to direct activities of the VIE that most significantly impact the VIE&amp;#8217;s economic performance, and (2) the obligation to absorb losses or right to receive benefits from the VIE that could potentially be significant to the VIE. As a result, the Company determined that nine (9) entities were VIEs and subject to consolidation.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;i&gt;Concentration of Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The Company grants credit in the normal course of business to its customers. The Company periodically performs credit analysis and monitors the financial condition of its customers to reduce credit risk.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times
 new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The Company monitors its positions with, and the credit quality of, the financial institutions with which it invests. The Company, at times, maintains balances in various operating accounts in excess of federally insured limits.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;One customer in the nutraceutical and cosmetic additives division accounted for 15% and 73% of consolidated sales for the years ended December 31, 2016 and 2015, respectively. This customer accounted for 11% and 43% of accounts receivable at December 31, 2016 and December 31, 2015, respectively.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;A second customer in the nutraceutical and cosmetic additives division accounted for 2% and 12% of consolidated sales for years ended December 31, 2016 and 2015, respectively. This customer accounted for 8% and 24% of accounts receivable at December 31, 2016 and December 31, 2015, respectively.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;In the finished cosmetic products division, two credit card processors accounted for 34.9% and 31.6% of accounts receivable at December 31, 2016. There were no significant concentrations of accounts receivable in the finished cosmetic products division at December 31, 2015&lt;/p&gt;
&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
<us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00">&lt;div&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; width: 0.5in; text-indent: 0pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;3.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; text-indent: 0pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;Furnishings and Equipment&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Furnishings and equipment consisted of the following:&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"&gt;December 31&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2016&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2015&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: calibri, sans-serif;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: calibri, sans-serif;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 0.5in; background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;Furnishings and equipment, at cost&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 125px; text-align: right;"&gt;679,291&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 125px; text-align: right;"&gt;679,291&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;679,291&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;679,291&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; color: #000000; text-transform: none;
 text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Depreciation expense amounted to $0 and $43,748 for years ended December 31, 2016 and 2015, respectively.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
<us-gaap:InvestmentHoldingsTextBlock contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00">&lt;div&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; width: 0.5in; text-indent: 0pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;4.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; text-indent: 0pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;Investment in Adiuvo Investment S.A.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;In December 2013, the Company entered into a memorandum of understanding (MOU) with Adiuvo Investment S.A. (AI), an investment company located in Poland, whereby AI paid the Company $100,000 for the option, which expired in September 2014, to purchase up to 10% of the outstanding stock in the Company at $0.25 per share. In January 2014, the Company invested $100,000 in AI in exchange for a minority interest of less than 1% in AI, and an option to acquire additional shares of AI up to an aggregate consideration of $1,500,000. Further, AI granted the Company the right to participate in any subsequent public offerings of AI and the option to buy up to 10% of AI. During 2015 AI shares commenced trading on the Warsaw exchange in Poland, and the Company sold its entire investment, receiving $127,261, net of transaction costs. Due to the investment&amp;#8217;s limited liquidity and uncertain valuation prior to its sale, the Company accounted for its interest in AI at no value. The proceeds of the Company&amp;#8217;s sale of AI stock, $127,261, are recorded as gain on sale of Adiuvo Investment S.A. stock in the accompanying statement of operations for the year ended December 31, 2015.&lt;/p&gt;&lt;/div&gt;</us-gaap:InvestmentHoldingsTextBlock>
<us-gaap:DebtDisclosureTextBlock contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00">&lt;div&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 48px; text-align: justify; text-indent: 0px; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;5.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: justify; text-indent: 0px; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;Notes Payable&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Notes payable are due to officers, directors, and shareholders and a commercial lender and are summarized as follows:&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2"&gt;Officers, Directors, and Shareholders&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2"&gt;Commercial Lenders&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2"&gt;Total&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="width: 0.5in; background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Balance at December 31, 2014&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 125px; text-align: right; font-stretch: normal;"&gt;27,200&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 125px; text-align: right; font-stretch: normal;"&gt;-&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 125px; text-align: right; font-stretch: normal;"&gt;27,200&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Borrowing&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;105,000&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right;
 font-stretch: normal;"&gt;200,000&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;305,000&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Repayment&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;(47,000&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;)&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;(100,000&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;)&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;(147,000&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"&gt;Conversion to common stock&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;(85,200&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"&gt;)&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;-&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;(85,200&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"&gt;Balance at December 31, 2015&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;-&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;100,000&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;100,000&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td
 style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Borrowing&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;300,000&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;-&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;300,000&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Repayment&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;(68,600&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;)&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;(100,000&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;)&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;(168,600&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"&gt;Debt discount&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;(25,035&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"&gt;)&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;-&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;(25,035&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"&gt;Balance at December 31, 2016&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black;
 border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;206,365&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;(100,000&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"&gt;)&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;106,365&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;The Company periodically borrows from officers, directors, other related individuals, and from commercial lenders. During 2015 two shareholders, with notes totaling $85,200, converted the notes to Company stock at $0.17 per share.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;In January 2015, the Company borrowed $100,000 from a commercial lender. The loan required payment of principal and interest in 252 daily payments of $492 each commencing January 12, 2015. In December 2015, the Company repaid the remaining outstanding principal balance. Interest for the year ended December 31, 2015 amounted to $25,425.&lt;/p&gt;
&lt;p style="font: 10pt/14.26px 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;In November 2015, the Company borrowed $100,000 from a commercial lender. The loan incurred interest at 11% and with a maturity date of November 1, 2016. In October 2016, the Company repaid the entire principal balance. Interest expense related to this loan for the years ended December 31, 2016 and 2015 amounted to $9,479 and $1,543, respectively.&lt;/p&gt;
&lt;p style="font: 10pt/14.26px 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;In the third quarter of 2016 the Company commenced an offering pursuant to which it offered 11% subordinated promissory notes in fifty thousand ($50,000) dollar increments combined with 62,500 shares of the Company&amp;#8217;s Common Stock for a maximum offering amount of $200,000 (the &amp;#8220;Offering&amp;#8221;). In August and September 2016, the Company sold promissory notes totaling $150,000 to three unrelated individuals. Two of the promissory notes totaling $100,000 are payable in February 2017 and one promissory note for $50,000 is payable in March 2017. In October 2016, the Company sold promissory notes totaling $50,000 to two unrelated individuals. These promissory notes are payable in October 2017. In connection with these promissory notes sold, pursuant to the Offering, the Company issued 250,000 shares of common stock valued at $58,750 which was recorded as a debt discount and will be amortized over the term of these notes. Amortization of the debt discounts for the year ended December 31, 2016 was $33,715. During 2016, the Company repaid $68,600 of the principle balance; and as a result, the outstanding balances of these notes as of December 31, 2016, were $131,400. The balance of debt discount related to the subordinated promissory notes is $25,035 at December 31, 2016. Interest expense related to these notes for the year ended December 31, 2016 amounted to $5,416.&lt;/p&gt;
&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
<us-gaap:IncomeTaxDisclosureTextBlock contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00">&lt;div&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 48px; text-align: justify; text-indent: 0px; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;6.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: justify; text-indent: 0px; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;Income Taxes&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company incurred a loss for the year ended December 31, 2016 and accordingly, no provision for federal income tax has been made in the accompanying financial statements. At December 31, 2016, the Company had available net operating loss carryforwards of approximately $3,953,000, expiring during various years through 2036.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;A summary of the deferred tax asset using an approximate 34% tax rate is as follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="6"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;December 31&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;2016&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;2015&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;
 font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: #cceeff;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.5in; font-stretch: normal; background-color: white;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Net operating loss&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 125px; text-align: right; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;1,344,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 125px; text-align: right; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;930,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: white;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Accounts receivable reserves&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;30,000&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;-&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: #cceeff;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Inventory reserves&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;7,000&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;-&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: white;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;Stock compensation&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black;
 border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;200,000&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;-&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: #cceeff;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal; background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;Net deferred tax asset&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;1,581,000&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;-&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: white;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Valuation allowance&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;(1,581,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;(930,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: #cceeff;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-left: 10pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Total&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size:
 10pt;"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The net operating loss carryforwards could be subject to limitation in any given year in the event of a change in ownership as defined by IRC Section 382.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;The deferred tax benefit included in the 2015 statement of operations represents the change in the deferred tax liability at each balance sheet date.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;The difference between the statutory and the effective tax rate is primarily due to a change in valuation allowance on deferred taxes, as the Company has fully reserved the deferred tax asset resulting from available net operating loss carryforwards.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00">&lt;div&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 48px; text-align: justify; text-indent: 0px; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;7.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: justify; text-indent: 0px; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;Stockholders&amp;#8217; Equity&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;In May 2015, the Company purchased and retired 120,000 shares of outstanding Company common stock from an investor for $10,800.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;In July 2015, the Company granted 300,000 options valued at $7,500 to a shareholder in conjunction with the issuance of a $75,000 note payable. The options are fully vested and expire in three years. In December 2015, the Company satisfied the $75,000 note payable through the issuance of 441,177 shares of Company common stock.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;In December 2015, the Company satisfied $10,200 of notes payable to a director through the issuance of 60,000 shares of Company common stock. The Company issued 40,800 options valued at $1,000 to the director in conjunction with this transaction. The options are fully vested and expire in three years.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;In December 2015, the Company satisfied $84,868 of royalties payable to the Company&amp;#8217;s President through the issuance of 499,225 shares of Company common stock (see note 8). In conjunction with this transaction, the Company issued 339,473 options valued at $13,000 to the President of the Company at an exercise price of $0.10 per share. The options are fully vested and expire in 3 years.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;On April 1, 2016, the Company entered into two agreements with two consultants to provide services over a nine- month period in exchange for 2,300,000 shares of common stock. The Company calculated a fair value of $690,000 based on the market price of the shares on the date of the agreements. During the third quarter of 2016, the Company and the consultants renegotiated the agreements by extending the service requirement to December 31, 2017. For the year ended December 31, 2016, the Company has recognized expense of $383,333 in connection with these agreements.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font:
 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;On September 1, 2016, the Company issued 200,000 shares of common stock for $46,000. In connection with this issuance the Company issued 100,000 warrants with an exercise price of $0.50 per share. These warrants are fully vested and expire in two years.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;In August 2016, the Company issued 125,000 shares of common stock pursuant to sale of two promissory notes in the Offering.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;In September 2016, the Company issued 62,500 shares of common stock pursuant to the sale of one promissory note in the Offering.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;In October 2016, the Company issued 62,500 shares of common stock pursuant to the sale of two promissory notes in the Offering.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;In November 2016, the Company issued 434,782 shares of common stock pursuant to a conversion of an equity contribution into Immudyne PR by the noncontrolling interest. In connection with this issuance the Company issued 217,391 warrants with an exercise price of $0.40 per share. These warrants are fully vested and expire in two years.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;In December 2016, the Company received proceeds of $30,000 from exercises of options at $0.10 per share. The Company issued 300,000 shares of common stock pursuant to these exercises.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;On December 23, 2016, the Company issued 75,000 shares of common stock for $17,250. In connection with this issuance the Company issued 37,500 warrants with an exercise price of $0.50 per share. These warrants are fully vested and expire in two years.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px;
 letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;During 2016, the Company purchased 325,000 shares of outstanding Company common stock through an exchange for a price per share of $0.23 to $0.29. As of the December 31, 2016, these shares being held by the Company valued at cost is $87,053 and are included in treasury stock in the consolidated balance sheet.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;br /&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Additional Paid-In Capital&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Noncontrolling Interest&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;On April 1, 2016, the Company increased its ownership in Immudyne PR from to 78.16667% decreasing the minority interest from 66.7% to 21.83% resulting in a charge to noncontrolling interest and additional paid-in-capital of $91,612.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;In 2016, the net change in loans, contributions and distributions by other members of Immudyne PR resulted an increase in noncontrolling interests of $119,894.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;For the years ended December 31, 2016 and 2015, the net income (loss) of Immudyne PR attributed the Company amounted to $(115,749) and $(97,240), respectively.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Service-Based Stock Options&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;In October 2015 the Company issued 110,000 service-based options valued at $2,800 to two consultants at exercise prices of $0.20 per share. The options are fully vested and expire in 10 years.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;In November 2015 the Company cancelled 100,000 shares of company common stock and 200,000 fully vested service-based options issued to two
 consultants.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;In November 2015 the Company issued 500,000 shares of common stock valued at $65,000 to a consultant.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Also in 2015, the Company extended the expiration date of 500,000 options held by a director one year from 2015 to 2016 and 1,500,000 warrants held by the Company&amp;#8217;s President two years from 2015 to 2017. The fair value of these modifications amounted to $55,000.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;In May 2016, the Company issued 175,000 service-based options valued at $40,829 to two consultants at exercise prices of $0.20 per share. The options are fully vested and expire in 10 years.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;In July 2016, the Company issued 50,000 service-based options valued at $12,397 to a consultant with an exercise price of $0.20 per share. The options are fully vested and expire in 10 years.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;In November 2016, the Company issued 50,000 service-based options valued at $9,980 to a consultant with an exercise price of $0.50 per share. The options are fully vested and expire in 2 years.&lt;/p&gt;
&lt;p style="font: 10pt/14.26px 'times new roman', times, serif; margin: 0pt 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Accordingly, stock based compensation for the years ended December 31, 2016 and 2015 included $63,206 and $22,300, respectively, related to such service-based stock options.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;A Summary of the outstanding service-based options are as follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width:
 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Number of&lt;br /&gt;Options&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="width: 0.5in; background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;Balance at December 31, 2014&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 125px; text-align: right;"&gt;10,435,000&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;Cancelled&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(200,000&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;Issued&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;790,273&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;Balance at December 31, 2015&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;11,025,273&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;Exercised&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;300,000&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;Expired&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;50,000&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;Cancelled&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;(250,000&lt;/td&gt;
&lt;td style="text-align: left;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;Issued&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;275,000&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;Balance at December 31, 2016&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;10,700,273&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;All outstanding options are exercisable and have a cashless exercise provision, and certain options provide for accelerated vesting provisions and modifications, as defined, if the Company is sold or acquired. The intrinsic value of options outstanding and exercisable at December 31, 2016 and 2015 amounted to $704,794 and $33,605, respectively. The intrinsic value of options exercised during the year ending December 31, 2016 was $54,000.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;The significant assumptions used to determine the fair values of options issued, using a Black-Scholes option-pricing model are as follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px;
 white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;table align="center" style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 10pt;"&gt;&lt;u&gt;Significant assumptions:&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;Risk-free interest rate at grant date&lt;/font&gt;&lt;/td&gt;
&lt;td style="background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap" style="background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap" style="text-align: right; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;0.71% - 1.88&lt;/font&gt;&lt;/td&gt;
&lt;td style="background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 10pt;"&gt;Expected stock price volatility&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap" style="text-align: right;"&gt;&lt;font style="font-size: 10pt;"&gt;217.4% - 248.4&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;Expected dividend payout&lt;/font&gt;&lt;/td&gt;
&lt;td style="background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap" style="background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap" style="text-align: right; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;
&lt;td style="background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 10pt;"&gt;Expected option life-years&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap" style="text-align: right;"&gt;&lt;font style="font-size: 10pt;"&gt;2 to 3&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&amp;#160;years&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;Weighted average grant date fair value&lt;/font&gt;&lt;/td&gt;
&lt;td style="background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap" style="background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td nowrap="nowrap" style="text-align: right; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;0.22&lt;/font&gt;&lt;/td&gt;
&lt;td style="background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="width: 0.5in;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 10pt;"&gt;Forfeiture rate&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap" style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td nowrap="nowrap" style="width: 125px; text-align: right;"&gt;&lt;font style="font-size: 10pt;"&gt;0&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 37px;"&gt;&lt;font style="font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;The following is a summary of outstanding service-based options at December 31, 2016:&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;Exercise Price&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Number of&lt;br /&gt;Options&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Weighted Average Remaining Contractual Life&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"
 colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="width: 0.5in; background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;$0.10&lt;/td&gt;
&lt;td style="width: 15px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 141px; text-align: right; font-size: 10pt;"&gt;1,380,273&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: center; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 141px; text-align: center; font-size: 10pt;"&gt;&lt;font style="font-size: 10pt;"&gt;1 year&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;$0.20 - $0.25&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;8,120,000&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;"&gt;&lt;font style="font-size: 10pt;"&gt;5 years&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-size: 10pt;"&gt;$0.40 - $0.50&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;1,200,000&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;"&gt;&lt;font style="font-size: 10pt;"&gt;5 years&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; padding-left: 10pt; font-size: 10pt;"&gt;Total&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;10,700,273&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;&lt;i&gt;Performance-Based Stock Options&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;The Company had granted performance-based options to purchase 4,400,000 shares of common stock at exercise prices of $0.40 to $0.80. The options expire at various dates between 2021 and 2026 and are exercisable upon the Company achieving annual sales revenue of $5,000,000 and $10,000,000. The fair value of these performance-based options aggregated $169,035 to be expensed over the implicit service period commencing once management believes the performance criteria will be met.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;In October 2016, the Company cancelled 287,500 of these service-based options valued at $17,999 to two consultants. The fair value of these performance-based options as of year ended December 31, 2016 aggregated $151,036.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px;
 white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The performance criteria for options exercisable upon the Company achieving annual sales revenue of $5,000,000, with a fair value amounting to $120,867, was met during the year ended December 31, 2016. Accordingly, stock based compensation expense for the year ended December 31, 2016 includes $120,867 related to such options. At December 31, 2016, the unearned compensation for all the performance based options is $30,169.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;/font&gt;&amp;#160;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 8pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;The following is a summary of outstanding and exercisable warrants:&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 8pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Number of Shares&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Weighted Average Exercise Price&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Year&amp;#160;of&amp;#160;&lt;br /&gt;Expiration&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="background-color: white;"&gt;&lt;font style="font-size: 7pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 7pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 7pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;" colspan="2"&gt;&lt;font style="font-size: 7pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 7pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 7pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&lt;font style="font-size: 7pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 7pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 7pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&lt;font style="font-size: 7pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 7pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="width: 0.5in; background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;Balance at December 31, 2014&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 125px; text-align: right;"&gt;3,772,720&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 125px; text-align: center;"&gt;0.29&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 125px; text-align: center;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;2015&amp;#160;-&amp;#160;2016&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Expired&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(2,022,720&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;0.40&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;2015&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font
 style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;Balance at December 31, 2015&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1,750,000&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;0.16&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;2016 - 2017&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;Issued&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;454,891&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;0.42&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;2018&amp;#160;-&amp;#160;2019&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Expired&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(250,000&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;0.40&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;2016&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&lt;font style="font-size: 8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;Balance at December 31, 2016&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;1,954,981&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 4pt;"&gt;0.19&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 4pt;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;2017 - 2019&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;In September 2016, the Company issued 100,000 warrants with an exercise price of $0.50 per share, in relation to a sale of common stock. These warrants are fully vested and expire in two years.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 8pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font:
 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;In September 2016, the Company issued 100,000 warrants with exercise prices between $0.20 and $0.50 per share, for consulting services. These warrants are fully vested and expire in three years. The fair value of these warrants are $20,585 and is included in compensation and related expenses in the accompanying statement of operations.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 8pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;In December 2016, the Company issued 37,500 warrants with an exercise price of $0.50 per share, in relation to a sale of common stock. These warrants are fully vested and expire in two years.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 8pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;In December 2016, the Company issued 217,391 warrants with an exercise price of $0.40 per share, in relation to an issuance of common stock. These warrants are fully vested and expire in two years.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 8pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Warrants outstanding and exercisable amounted to 1,954,891 and 1,750,000 at December 31, 2016 and 2015, respectively. The weighted average exercise price of warrants outstanding at December 31, 2016 is $0.19. The warrants expire at various time between December 2017 and September 2019.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 8pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;The fair value of options and warrants granted (or extended) during the years ended December 31, 2016 and 2015, was estimated on the date of grant (or extension) using the Black-Scholes option-pricing model with the following weighted-average assumptions:&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 8pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding: 0px 0px 1.5pt; text-indent: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2016&lt;/td&gt;
&lt;td style="padding: 0px 0px 1.5pt; text-indent: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding: 0px 0px 1.5pt; text-indent: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2015&lt;/td&gt;
&lt;td style="padding: 0px 0px 1.5pt; text-indent: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px;"&gt;&lt;font style="font-size: 7pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;"&gt;&lt;font style="font-size: 7pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-indent: 0px; padding-top:
 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;"&gt;&lt;font style="font-size: 7pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;" colspan="2"&gt;&lt;font style="font-size: 7pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;"&gt;&lt;font style="font-size: 7pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;"&gt;&lt;font style="font-size: 7pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;" colspan="2"&gt;&lt;font style="font-size: 7pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;"&gt;&lt;font style="font-size: 7pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="width: 0.5in; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;"&gt;Expected volatility&lt;/td&gt;
&lt;td style="width: 15px; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 141px; text-align: right; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;"&gt;203&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;"&gt;%&lt;/td&gt;
&lt;td style="width: 15px; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 141px; text-align: right; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;"&gt;50&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;"&gt;Risk free interest rate&lt;/td&gt;
&lt;td style="text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;"&gt;.88&lt;/td&gt;
&lt;td style="text-align: left; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;"&gt;%&lt;/td&gt;
&lt;td style="text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;"&gt;2&lt;/td&gt;
&lt;td style="text-align: left; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;"&gt;Expected dividend yield&lt;/td&gt;
&lt;td style="text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;"&gt;Expected option term (in years)&lt;/td&gt;
&lt;td style="text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;"&gt;&lt;font style="font-size: 10pt;"&gt;2 - 3&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;"&gt;&lt;font style="font-size: 10pt;"&gt;1 - 5&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;"&gt;Weighted average grant date fair value&lt;/td&gt;
&lt;td style="text-indent: 0px; padding-top: 0px; padding-right: 0px;
 padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;"&gt;0.20&lt;/td&gt;
&lt;td style="text-align: left; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;"&gt;0.03&lt;/td&gt;
&lt;td style="text-align: left; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Under ASC 815-40-05, Accounting for Derivative Financial Instruments Indexed to and Potentially Settled in a Company&amp;#8217;s Own Stock, in the event the Company does not have a sufficient number of authorized and unissued shares of common stock to satisfy obligations for stock options, warrants and other instruments potentially convertible into common stock, the fair value of these instruments should be reported as a liability. Pursuant to the outstanding option, warrant and convertible debt agreements, there is currently no effective registration statement covering the shares of common stock underlying these agreements, which are currently subject to a cashless exercise whereby the holders, at their option, may surrender their options and warrants to the company in exchange for shares of common stock. The number of shares of common stock into which an option or a warrant would be exchangeable in such a cashless exercise depends on both the exercise price of the options or warrant and the market price of the common stock, each at or near the time of exercise. Because both of these factors are variable, it is possible that we could have insufficient authorized shares to satisfy a cashless exercise. In this scenario, if we were unable to obtain shareholder approval to increase the number of authorized shares, we could be obligated to settle such a cashless exercise with cash rather than by issuing shares of common stock. Further, ASC 815-40-05 requires that we record the potential settlement obligation at each reporting date using the current estimated fair value of these contracts s, with any changes in fair value being recorded through our statement of operations. We will continue to report the potential settlement obligation as a liability until such time as these contracts are exercised or expire or we are otherwise able to modify the warrant agreement to remove the provisions which require this treatment.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&lt;i&gt;Stock Based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The total stock based compensation expense related Service-Based Stock Options, Performance-Based Stock Options and Warrants issued for service amounted to $587,991 and $142,300 for the years ended December 31, 2016 and 2015, respectively. Such amounts are included in compensation and related expenses ($587,991 in 2016 and $133,800 in 2015) and interest expense ($8,500 in 2015).&lt;/p&gt;
&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
<immd:RoyaltiesDisclosureTextBlock contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00">&lt;div&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 48px; text-align: justify; text-indent: 0px; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;8.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: justify; text-indent: 0px; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;Royalties&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;The Company was subject to a royalty agreement based upon sales of certain skin care products. The agreement required the Company to pay a royalty based upon 8% of such sales, up to $227,175. During the year ended December 31, 2015 the Company&amp;#8217;s sales reached the maximum amount under which the Company was required to pay a royalty under this agreement. Royalty expense amounted to $-0- and $20,157 for the years ended December 31, 2016 and 2015, respectively. During December 2015, the Company&amp;#8217;s President who had a 60% interest in the royalties, converted royalties payable under the agreement in the amount of $84,868 to 499,225 shares of Company stock at $0.17 cents per share.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Included in accounts payable and accrued expenses at December 31, 2016 and 2015 was $56,579 in regards to this agreement.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</immd:RoyaltiesDisclosureTextBlock>
<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00">&lt;div&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 48px; text-align: justify; text-indent: 0px; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;9.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: justify; text-indent: 0px; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;Commitments and Contingencies&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company leases a plant in Kentucky under an operating lease which expired on May 31, 2016. Management is currently discussing renewal lease options for the Kentucky plant and is operating on a month-to-month lease arrangement until a final agreement has been accepted. Monthly base rental payments are approximately $9,000. Our principal executive offices are in office space provided to us by our President, Mr. McLaughlin at the rate of $2,000 per month, which includes rents, utilities and other office related expenditures. This arrangement commenced as of January 1, 2016. In addition, Immudyne PR utilizes office space in Puerto Rico which is subleased from Mr. Schreiber (President of Immudyne PR)and incurs expense of approximately $4,000 a month for this office space. Rent expense for the years ended December 31, 2016 and 2015, was $139,030 and $65,968, respectively.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;&lt;i&gt;Employment and Consulting Agreements&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;The Company has entered into various agreements with officers, directors, employees and consultants that expire in one to five years. The agreements provide for annual compensation of up to $145,000 and the issuance of stock options, at exercise prices of $0.40 and $0.80, to purchase 4,400,000 shares of common stock issuable upon the Company&amp;#8217;s revenue exceeding $5,000,000 and $10,000,000, as defined. In addition, the agreements provide for bonus compensation to these individuals aggregating up to 15% (with no individual having more than 5%) of the Company&amp;#8217;s pretax income.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal
 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;&lt;i&gt;Restricted Stock and Options&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;The Company has entered into two agreements on April 1, 2016 with two consultants of Immudyne PR for business development, marketing and sales related services (the &amp;#8220;Consultant Agreements&amp;#8221;). The consultants are treated as employees for accounting purposes. Upon signing, each consultant was issued 1,000,000 restricted shares of Immudyne, Inc. common stock. In addition, each consultant shall receive an additional 150,000 restricted shares of Immudyne, Inc. common stock for each $500,000 distributed by Immudyne PR to the Company. For each consultant, the amount of shares to be issued by the Company to the consultants shall be capped at 1,500,000 restricted shares when Immudyne PR has transferred $5,000,000 to the Company, for a combined capped total of 3,000,000 restricted shares. For the year ended December 31, 2016, 2,300,000 restricted shares of common stock have been issued related to these agreements. The Company valued the shares at their grant date for a value of $0.30 per share for a total of $690,000 to be expensed over the estimated service period ending December 31, 2017.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;In addition, the Consulting Agreements provided that each consultant shall receive a bonus of an additional 750,000 restricted shares of Immudyne, Inc. common stock, plus an option to buy 1,000,000 shares of Immudyne, Inc. common stock at $0.20/share (including a cashless exercise feature) when Immudyne PR has transferred to the Company at each of the following three (3) thresholds: $1,250,000, $2,000,000 and $3,000,000 for a total of 2,250,000 of restricted shares of Immudyne, Inc. common stock and options to purchase up to 3,000,000 shares of Immudyne, Inc. common stock at $0.20/share. As of December 31, 2016, no bonus shares have been issued and no options have been granted under this agreement.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;&lt;i&gt;Legal Matters&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;In the normal course of business operations, the Company may become involved in various legal matters. At December 31, 2016, the Company&amp;#8217;s management does not believe that there are any potential legal matters that could have an adverse effect on the Company&amp;#8217;s financial position.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
<us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00">&lt;div&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 48px; text-align: justify; text-indent: 0px; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;10.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: justify; text-indent: 0px; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;Related Party Transactions&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.15pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.15pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;For the year ended December 31, 2016 one of the Company&amp;#8217;s directors, acting as an advisor for the Company, provided legal and business advisory services and was compensated $16,145. During 2015 there was no compensation to this director. In addition, for the year ended December 31, 2016 the Company&amp;#8217;s President received $24,000 for reimbursement of home office expenditures, including rent, utilities and other related expenses for two offices. During 2015 the Company&amp;#8217;s president was not reimbursed for home office expenditures.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Immudyne, Inc. employs the wife of the President of the Company Immudyne, Inc. and incurs $3,000 per month as an accountant, plus an annual incentive bonus award equal to 0.5% of the Company&amp;#8217;s pre-tax earnings.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Immudyne PR utilizes BV Global Fulfillment, owned by the father of Mr. Schreiber, and incurred $19,800 for the year ended December 31, 2016 for these services.&lt;/p&gt;
&lt;p style="font: 13.33px/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Taggart International Trust (&amp;#8220;Taggart&amp;#8221;), a shareholder; provides credit card processing services through one or more merchant banks. Taggart did not receive any compensation for these services.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;JLS Ventures LLC, owned by a shareholder, provides credit card processing services through one or more merchant banks. Taggart did not receive any compensation for these services.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;JSDC, Inc., owned by a shareholder, provides credit card processing services through one or more merchant banks. Taggart did not receive any compensation for these services.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Immudyne PR utilizes office space in Puerto Rico which is subleased from Mr. Schreiber (President of Immudyne PR) incurs expense of approximately $4,000 a month for this office space.&lt;/p&gt;
&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
<us-gaap:SubsequentEventsTextBlock contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00">&lt;div&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 48px; text-align: justify; text-indent: 0px; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;11.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: justify; text-indent: 0px; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;Subsequent Events&lt;/b&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.15pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;The Company has evaluated subsequent events through the date these financial statements were issued.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;In January 2017, the Company issued 1,183,490 shares of common stock pursuant to a conversion of an equity contribution into Immudyne PR by the noncontrolling interest. In connection with this issuance the Company issued 591,745 warrants with an exercise price of $0.40 per share. These warrants are fully vested and expire in two years.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In January 2017, the Company borrowed $200,000 and issued a promissory note with a 5% original issue discount for a total principal amount of $210,000. The loan incurs 11% interest per annum and matures in various tranches from February 2017 through April 2017. In addition, the Company issued 217,391 shares of common stock related to this note. In February 2017, the Company repaid $70,000 of the principle balance of this note. In March, pursuant to an offering described below, the Company converted the remaining $140,000 of the principle balance of the this note in exchange for 559,179 shares of common stock and 304,348 warrants.&lt;/p&gt;&lt;p style="font: 10pt/14.26px 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;On March 27, 2017, the Company commenced an offering to sell up to 4,000,000 shares of common stock at a price of $0.23 per share and warrants to purchase up to 2,000,000 shares of common stock excisable any time prior to the secondary anniversary of the issuance. The warrants are paired with the stock on the basis of one warrant for every two shares of stock purchased.&lt;/p&gt;&lt;p style="font: 10pt/14.26px 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;At the time of
 this filing, the Company received subscriptions in the amount of 2,673,656 shares and issued 1,336,828 warrants and proceeds in the amount of $614,940. The Company also converted two additional notes with the total principal balance of $50,000 in exchange for 196,000 shares of common stock and 98,000 warrants.&lt;/p&gt;&lt;p style="font: 10pt/14.26px 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;On April 24, 2017, the Company, issued 217,390 shares of common stock pursuant to a stock subscription agreement and the Company issued 108,696 warrants with an exercise price of $0.40 per share for the stated consideration and satisfaction of obligation to pay $50,000 on the 180-day anniversary of the execution of the Sole and Exclusive License, Royalty, and Advisory Agreement dated September 1, 2016 with Pilaris Laboratories, LLC&lt;/p&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
<us-gaap:ConsolidationPolicyTextBlock contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00">&lt;div&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;&lt;i&gt;Principles of Consolidation&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company evaluates the need to consolidate affiliates based on standards set forth in ASC 810 Consolidation (&amp;#8220;ASC 810&amp;#8221;).&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The consolidated financial statements include the accounts of the Company and its majority owned subsidiary, Immudyne PR and variable interest entities (VIE&amp;#8217;s) in which the Company has been determined to be the primary beneficiary. The non- controlling interest in Immudyne PR represents the 21.833% equity interest held by other members of the joint venture. All significant consolidated transactions and balances have been eliminated in consolidation.&lt;/p&gt;
&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
<us-gaap:UseOfEstimates contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00">&lt;div&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;&lt;/i&gt;&lt;/b&gt;The Company prepares its consolidated financial statements in conformity with accounting principles generally accepted in the United States of America which requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Some of the more significant estimates required to be made by management include the determination of reserves for accounts receivable, returns and allowances, the accounting for derivatives, the valuation of inventory and stockholders&amp;#8217; equity based transactions. Actual results could differ from those estimates.&lt;/p&gt;
&lt;/div&gt;</us-gaap:UseOfEstimates>
<us-gaap:InventoryPolicyTextBlock contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;i&gt;Inventory&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;At December 31, 2016 and December 31, 2015, inventory consisted primarily of cosmetic and nutraceutical additives, and finished cosmetic products. Inventory is maintained in the Company&amp;#8217;s leased Kentucky warehouse and third party warehouses in Pennsylvania and Louisiana.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Inventory is valued at the lower of cost or market with cost determined on a first-in, first-out (&amp;#8220;FIFO&amp;#8221;) basis. Management compares the cost of inventory with the net realizable value and an allowance is made for writing down inventory to market value, if lower. At December 31, 2016 and December 31, 2015, the Company recorded an inventory reserve in the amount of $20,000. Inventory consists of the following:&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;December&amp;#160;31,&lt;br /&gt;2016&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;December&amp;#160;31,&lt;br /&gt;2015&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 0.5in; background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;Raw materials&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 125px; text-align: right;"&gt;38,460&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 125px; text-align: right;"&gt;25,761&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;Finished products&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;121,810&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;35,290&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;160,270&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;61,051&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
<us-gaap:RevenueRecognitionPolicyTextBlock contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;The Company&amp;#8217;s policy is to record revenue as earned when a firm commitment, indicating sales quantity and price exists, delivery has taken place and collectability is reasonably assured. The Company generally records sales of nutraceutical and cosmetic additives once the product is shipped to the customer, and for sales of finished cosmetic products once the customer places the order and the product is simultaneously shipped, but in limited cases if title does not pass until the product reaches the customer&amp;#8217;s delivery site, then recognition of revenue is deferred until that time. Delivery is considered to have occurred when title and risk of loss have transferred to the customer. Provisions for discounts, returns, allowances, customer rebates and other adjustments are netted with gross sales. The Company accounts for such provisions during the same period in which the related revenues are earned. Customer discounts, returns and rebates approximated $1,926,000 in the year ended December 31, 2016. Customer discounts, returns and rebates were not significant in the year ended December 31, 2015.&lt;/p&gt;&lt;p style="font: 10pt/14.26px 'times new roman', times, serif; margin: 0pt 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Delivery is considered to have occurred when title and risk of loss have transferred to the customer. If title does not pass until the product reaches the customer&amp;#8217;s delivery site or the customer accepts the product, then recognition of revenue is deferred until that time. There are no formal sales incentives offered to any of the Company&amp;#8217;s customers. Volume discounts may be offered from time to time to customers purchasing large quantities on a per transaction basis.&lt;/p&gt;&lt;p style="font: 10pt/14.26px 'times new roman', times, serif; margin: 0pt 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Revenue for the year ended December 31, 2016 consisted of nutraceutical and cosmetic additives ($997,964) and finished cosmetic products ($4,240,640). Revenue for the year ended December 31, 2015 consists of nutraceutical and cosmetic additives ($1,079,289) and finished cosmetic products ($139,573).&lt;/p&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
<us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;i&gt;Accounts receivable&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Accounts receivable are carried at original invoice amount less an estimate made for holdbacks and doubtful receivables based on a review of all outstanding amounts. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer&amp;#8217;s financial condition, credit history and current economic conditions and sets up an allowance for doubtful accounts when collection is uncertain. Customers&amp;#8217; accounts are written off when all attempts to collect have been exhausted. Recoveries of accounts receivable previously written off are recorded as income when received. At December 31, 2016 and 2015 the accounts receivable reserve was approximately $37,800 and $18,000, respectively. As of December 31, 2016, the reserve for sales returns and allowances was approximately $50,500. No sales returns and allowances reserve existed at December 31, 2015.&lt;/p&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
<us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00">&lt;div&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;i&gt;Segments&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The guidance for disclosures about segments of an enterprise requires that a public business enterprise report financial and descriptive information about its operating segments. Generally, financial information is required to be reported on the basis used internally for evaluating segment performance and resource allocation. The Company manages its operations in two reportable segments for purposes of assessing performance and making operating decisions. Revenue is generated predominately in the United States, and all significant assets are held in the United States, or United States territories.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies. The Company allocates resources and evaluates the performance of segments based on income or loss from operations, excluding interest, corporate expenses and other income (expenses).&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;A summary of the company&amp;#8217;s reportable segments is as follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 10pt;"&gt;&lt;u&gt;Total assets:&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-size: 10pt;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;br /&gt;&lt;font style="font-size: 10pt;"&gt;2016&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-size: 10pt;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;br /&gt;&lt;font style="font-size: 10pt;"&gt;2015&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="width: 0.5in; background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;Nutraceutical and Cosmetic Additives&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 15px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 125px; text-align: right; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;556,234&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 15px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; background-color: #cceeff;"&gt;&lt;font style="font-size:
 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 125px; text-align: right; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;412,324&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 15px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 10pt;"&gt;Finished Cosmetic Products&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 10pt;"&gt;422.288&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 10pt;"&gt;101,828&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;Eliminations&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;(188,698&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;(65,681&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;789,824&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;448,471&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="6"&gt;Year ended&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2"&gt;December&amp;#160;31, 2016&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2"&gt;December&amp;#160;31, 2015&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;u&gt;Net sales by segment:&lt;/u&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="width: 0.5in; background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;Nutraceutical and Cosmetic Additives&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 125px; text-align: right; font-stretch:
 normal;"&gt;1,024,264&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 125px; text-align: right; font-stretch: normal;"&gt;1,092,289&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;Finished Cosmetic Products&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;4,240,640&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;139,573&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;Eliminations&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;(26,300&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"&gt;)&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;(13,000&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"&gt;Total&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;5,238,604&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;1,218,862&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; text-decoration: underline; font-stretch: normal;"&gt;Net (loss) income by segment:&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;Nutraceutical and Cosmetic Additives&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;164,286&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times,
 serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;110,467&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;Finished Cosmetic Products&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;(388,121&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;)&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;(158,402&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; text-decoration: underline; font-stretch: normal;"&gt;Other unallocated amounts:&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;Corporate expenses&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;(950,847&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;)&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;(214,282&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;Other income (expense) - net&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;(48,611&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;)&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;89,785&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"&gt;Consolidated income (loss) from operations&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;(1,223,293&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"&gt;)&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;(172,432&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
<us-gaap:IncomeTaxPolicyTextBlock contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The Company files Corporate Federal and State tax returns, while Immudyne PR, which was formed as a limited liability corporation, files a separate tax return with any tax liabilities or benefits passing through to its members.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The Company records current and deferred taxes in accordance with Accounting Standards Codification (ASC) 740, &amp;#8220;Accounting for Income Taxes.&amp;#8221; This ASC requires recognition of deferred tax assets and liabilities for temporary differences between tax basis of assets and liabilities and the amounts at which they are carried in the financial statements, based upon the enacted rates in effect for the year in which the differences are expected to reverse. The Company establishes a valuation allowance when necessary to reduce deferred tax assets to the amount expected to be realized. The Company periodically assesses the value of its deferred tax asset, a majority of which has been generated by a history of net operating losses and determines the necessity for a valuation allowance. ASC 740 also provides a recognition threshold and measurement attribute for the financial statement recognition of a tax position taken or expected to be taken in a tax return. Using this guidance, a company may recognize the tax benefit from an uncertain tax position in its financial statements only if it is more likely-than-not (i.e., a likelihood of more than 50%) that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The Company&amp;#8217;s tax returns for all years since December 31, 2013, remain open to taxing authorities.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
<us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The Company follows the provisions of ASC 718, &amp;#8220;Share-Based Payment&amp;#8221;. Under this guidance compensation cost generally is recognized at fair value on the date of the grant and amortized over the respective vesting periods. The fair value of options at the date of grant is estimated using the Black-Scholes option pricing model. The expected option life is derived from assumed exercise rates based upon historical exercise patterns and represents the period of time that options granted are expected to be outstanding. The expected volatility is based upon historical volatility of the Company&amp;#8217;s shares using weekly price observations over an observation period that approximates the expected life of the options. The risk-free rate approximates the U.S. Treasury yield curve rate in effect at the time of grant for periods similar to the expected option life. Due to limited history of forfeitures, the estimated forfeiture rate included in the option valuation was zero.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Many of the assumptions require significant judgment and any changes could have a material impact in the determination of stock-based compensation expense.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
<us-gaap:EarningsPerSharePolicyTextBlock contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;i&gt;Earnings (Loss) Per Share&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Basic earnings (loss) per common share is based on the weighted average number of shares outstanding during each period presented. Warrants and options to purchase common stock are included as common stock equivalents only when dilutive. Potential common stock equivalents are excluded from dilutive earnings per share when the effects would be antidilutive.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Common stock equivalents comprising shares underlying 16,302,447 options and warrants for the year ended December 31, 2016 have not been included in the loss per share calculation as the effects are anti-dilutive. Common stock equivalents comprising shares underlying 12,775,273 options and warrants for the year ended December 31, 2015 have not been included in the loss per share calculations as the effects are anti-dilutive.&lt;/p&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (&amp;#8220;ASU 2016-15&amp;#8221;). ASU 2016-15 addresses eight specific cash flow issues with the objective of reducing diversity in practice regarding how certain cash receipts and cash payments are presented in the statement of cash flows. The standard provides guidance on the classification of the following items: (1) debt prepayment or debt extinguishment costs, (2) settlement of zero-coupon debt instruments, (3) contingent consideration payments made after a business combination, (4) proceeds from the settlement of insurance claims, (5) proceeds from the settlement of corporate-owned life insurance policies, (6) distributions received from equity method investments, (7) beneficial interests in securitization transactions, and (8) separately identifiable cash flows. The Company is required to adopt ASU 2016-15 for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2017 on a retrospective basis. Early adoption is permitted, including adoption in an interim period. The Company is currently evaluating the impact of adoption of ASU 2016-15.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;In March 2016, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) 2016-09, &amp;#8220;Compensation &amp;#8211; Stock Compensation: Improvements to Employee Share-Based Payment Accounting,&amp;#8221; which relates to the accounting for employee share-based payments. This standard addresses several aspects of the accounting for share-based payment award transactions, including: (a) income tax consequences; (b) classification flows of awards as either equity or liabilities; and (c) classification on the statement of cash flows. This standard will be effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The Company is in the process of evaluating the impact of the adoption of ASU 2016-09 on its consolidated financial statements. The adoption of ASU No. 2016-09 is not expected to have a material impact on the Company's consolidated financial statements or related disclosures.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;In February 2016, a pronouncement was issued that creates new accounting and reporting guidelines for leasing arrangements. The new guidance requires organizations that lease assets to recognize assets and liabilities on the balance sheet related to the rights and obligations created by those leases, regardless of whether they are classified as finance or operating leases. Consistent with current guidance, the recognition, measurement, and presentation of expenses and cash flows arising from a lease primarily will depend on its classification as a finance or operating lease. The guidance also requires new disclosures to help financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. The new standard is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period, with early application permitted. The new standard is to be applied using a modified retrospective approach. The Company is in the process of evaluating the impact of the new pronouncement on its consolidated financial statements.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal
 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;In May 2014, the Financial Accounting Standards Board ("FASB") issued accounting guidance, "Revenue from Contracts with Customers." The core principle of the new standard is for companies to recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration (that is, payment) to which the company expects to be entitled in exchange for those goods or services. The new standard also will result in enhanced disclosures about revenue, provide guidance for transactions that were not previously addressed comprehensively (for example, service revenue and contract modifications) and clarify guidance for multiple-element arrangements. The standard will be effective for fiscal years and interim periods within those years beginning after December 15, 2017. Accordingly, the Company will adopt this standard in the first quarter of fiscal year 2018. The Company is currently evaluating the impact this guidance will have on the consolidated financial statements.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 108pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;In July 2015, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) 2015-11, &amp;#8220;Simplifying the Measurement of Inventory.&amp;#8221; ASU 2015-11 applies to inventory that is measured using first-in, first-out (FIFO) or average cost. An entity should measure inventory within the scope of ASU 2015-11 at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. ASU 2015-11 is effective for fiscal years beginning after December 15, 2016. The adoption of ASU No. 2015-11 is not expected to have a material impact on the Company's consolidated financial statements or related disclosures.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;In August 2014, the FASB issued ASU 2014-15, "Presentation of Financial Statements-Going Concern". This ASU is intended to define management's responsibility to evaluate whether there is substantial doubt about an organization's ability to continue as a going concern and to provide related footnote disclosures. It is effective for annual periods ending after December 15, 2016, with early adoption permitted. The Company does not expect it to have a material effect on the Company's consolidated financial condition, results of operations, and cash flows.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;In May 2017, the FASB issued ASU 2017-09, Compensation - Stock Compensation (Topic 718) : Scope of Modification Accounting. The new standard provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. This pronouncement is effective for annual reporting periods beginning after December 15, 2017 but early adoption is permitted. The Company is currently evaluating the impact of adopting this guidance.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;All other accounting standards that have been issued or proposed by the FASB that do not require adoption until a future date are not expected to have a material impact on the consolidated financial statements upon adoption.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
<us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00">&lt;div&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The carrying value of the Company&amp;#8217;s financial instruments, including cash, trade accounts receivable, accounts payable and accrued expenses and the face amount of notes payable approximate fair value for all periods.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
<immd:MinorityInterestPolicyTextBlock contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;i&gt;Noncontrolling Interests&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The Company accounts for its less than 100% interest in Immudyne PR in accordance with ASC Topic 810, Consolidation, and accordingly the Company presents noncontrolling interests as a component of equity on its consolidated balance sheet and reports the noncontrolling interest&amp;#8217;s share of the Immudyne PR net loss attributable to noncontrolling interests in the consolidated statement of operations.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</immd:MinorityInterestPolicyTextBlock>
<us-gaap:ConsolidationVariableInterestEntityPolicy contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00">&lt;div&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Consolidation of Variable Interest Entities&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In accordance with ASC 810-10-25-37 and as amended by ASU 2009-17, the Company determines whether any legal entity in which the Company becomes involved is a VIE and subject to consolidation. The Company conducts an assessment on an ongoing basis for each VIE including (1) the power to direct activities of the VIE that most significantly impact the VIE&amp;#8217;s economic performance, and (2) the obligation to absorb losses or right to receive benefits from the VIE that could potentially be significant to the VIE. As a result, the Company determined that nine (9) entities were VIEs and subject to consolidation.&lt;/p&gt;
&lt;/div&gt;</us-gaap:ConsolidationVariableInterestEntityPolicy>
<us-gaap:ConcentrationRiskCreditRisk contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&lt;b&gt;&lt;i&gt;Concentration of Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The Company grants credit in the normal course of business to its customers. The Company periodically performs credit analysis and monitors the financial condition of its customers to reduce credit risk.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;The Company monitors its positions with, and the credit quality of, the financial institutions with which it invests. The Company, at times, maintains balances in various operating accounts in excess of federally insured limits.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;One customer in the nutraceutical and cosmetic additives division accounted for 15% and 73% of consolidated sales for the years ended December 31, 2016 and 2015, respectively. This customer accounted for 11% and 43% of accounts receivable at December 31, 2016 and December 31, 2015, respectively.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;A second customer in the nutraceutical and cosmetic additives division accounted for 2% and 12% of consolidated sales for years ended December 31, 2016 and 2015, respectively. This customer accounted for 8% and 24% of accounts receivable at December 31, 2016 and December 31, 2015, respectively.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;In the finished cosmetic products division, two credit card processors accounted for 34.9% and 31.6% of accounts receivable at December 31, 2016. There were no significant concentrations of accounts receivable in the finished cosmetic products division at December 31, 2015&lt;/p&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
<us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00">&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;December&amp;#160;31,&lt;br /&gt;2016&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;December&amp;#160;31,&lt;br /&gt;2015&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 0.5in; background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;Raw materials&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 125px; text-align: right;"&gt;38,460&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 125px; text-align: right;"&gt;25,761&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;Finished products&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;121,810&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;35,290&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;160,270&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;61,051&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
<us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00">&lt;div&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 10pt;"&gt;&lt;u&gt;Total assets:&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-size: 10pt;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;br /&gt;&lt;font style="font-size: 10pt;"&gt;2016&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-size: 10pt;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;br /&gt;&lt;font style="font-size: 10pt;"&gt;2015&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="width: 0.5in; background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;Nutraceutical and Cosmetic Additives&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 15px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 125px; text-align: right; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;556,234&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 15px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 125px; text-align: right; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;412,324&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 15px; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&lt;font style="font-size: 10pt;"&gt;Finished Cosmetic Products&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 10pt;"&gt;422,288&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&lt;font style="font-size: 10pt;"&gt;101,828&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;Eliminations&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;(188,698&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;(65,681&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;789,824&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;448,471&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;
&amp;#160;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="6"&gt;Year ended&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width:
 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2"&gt;December&amp;#160;31, 2016&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2"&gt;December&amp;#160;31, 2015&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;u&gt;Net sales by segment:&lt;/u&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-size: 10pt;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="width: 0.5in; background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;Nutraceutical and Cosmetic Additives&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 125px; text-align: right; font-stretch: normal;"&gt;1,024,264&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 125px; text-align: right; font-stretch: normal;"&gt;1,092,289&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;Finished Cosmetic Products&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;4,240,640&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;139,573&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;Eliminations&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;(26,300&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"&gt;)&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;(13,000&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"&gt;Total&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;5,238,604&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;1,218,862&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size:
 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; text-decoration: underline; font-stretch: normal;"&gt;Net (loss) income by segment:&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;Nutraceutical and Cosmetic Additives&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;164,286&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;110,467&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;Finished Cosmetic Products&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;(388,121&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;)&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;(158,402&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; text-decoration: underline; font-stretch: normal;"&gt;Other unallocated amounts:&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;Corporate expenses&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;(950,847&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;)&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;(214,282&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;Other income (expense) - net&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;(48,611&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;)&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;89,785&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch:
 normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"&gt;Consolidated income (loss) from operations&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;(1,223,293&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"&gt;)&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;(172,432&lt;/td&gt;
&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock>
<us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00">&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="background-color: white;"&gt;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"&gt;December 31&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2016&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2015&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: calibri, sans-serif;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: calibri, sans-serif;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 0.5in; background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;Furnishings and equipment, at cost&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 125px; text-align: right;"&gt;679,291&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 125px; text-align: right;"&gt;679,291&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;679,291&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;679,291&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
<us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00">&lt;div&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="6"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;December 31&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;2016&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;2015&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: #cceeff;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 0.5in; font-stretch: normal; background-color: white;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Net operating loss&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 125px; text-align: right; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;1,344,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"&gt;&lt;font
 style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 125px; text-align: right; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;930,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: white;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Accounts receivable reserves&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;30,000&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;-&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: #cceeff;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Inventory reserves&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;7,000&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;-&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: white;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;Stock compensation&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;200,000&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;-&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: #cceeff;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal; background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;Net deferred tax asset&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;1,581,000&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;-&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: white;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Valuation allowance&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;
 font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;(1,581,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;(930,000&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: #cceeff;"&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-left: 10pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;Total&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;-&lt;/font&gt;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif; font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 1250.4px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Year&amp;#160;of&amp;#160;&lt;br /&gt;Expiration&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 0.5in; background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;Balance at December 31, 2014&lt;/td&gt;&lt;td style="width: 12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 100px; text-align: right;"&gt;3,772,720&lt;/td&gt;&lt;td style="width: 12px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12px; text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 100px; text-align: center;"&gt;0.29&lt;/td&gt;&lt;td style="width: 12px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12px; text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 100px; text-align: center;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;2015&amp;#160;-&amp;#160;2016&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(2,022,720&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;0.40&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;2015&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;Balance at December 31, 2015&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1,750,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;0.16&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;2016 - 2017&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;Issued&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;454,891&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;0.42&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;2018&amp;#160;-&amp;#160;2019&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(250,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;0.40&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;2016&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:
 center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;Balance at December 31, 2016&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;1,954,981&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 4pt;"&gt;0.19&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 4pt;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;2017 - 2019&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;&lt;table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Number of&lt;br /&gt;Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 0.5in; background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;Balance at December 31, 2014&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 125px; text-align: right;"&gt;10,435,000&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;Cancelled&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(200,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;Issued&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;790,273&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;Balance at December 31, 2015&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;11,025,273&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;300,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;Expired&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;50,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;Cancelled&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;(250,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;Issued&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;275,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;Balance at December 31, 2016&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;10,700,273&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
<us-gaap:ScheduleOfAssumptionsUsedTableTextBlock contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember">&lt;div&gt;&lt;table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 1250.4px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2016&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2015&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 0.5in; background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Expected volatility&lt;/td&gt;&lt;td style="width: 12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 100px; text-align: right;"&gt;225&lt;/td&gt;&lt;td style="width: 12px; text-align: left;"&gt;%&lt;/td&gt;&lt;td style="width: 12px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 100px; text-align: right;"&gt;50&lt;/td&gt;&lt;td style="width: 12px; text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;2&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;Expected option term (in years)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;2 - 3&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;1 - 5&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;Weighted average grant date fair value&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.23&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.03&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAssumptionsUsedTableTextBlock>
<us-gaap:ScheduleOfAssumptionsUsedTableTextBlock contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;&lt;table align="center" style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 10pt;"&gt;&lt;u&gt;Significant assumptions:&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;Risk-free interest rate at grant date&lt;/font&gt;&lt;/td&gt;&lt;td style="background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: right; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;0.71% - 1.88&lt;/font&gt;&lt;/td&gt;&lt;td style="background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 10pt;"&gt;Expected stock price volatility&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: right;"&gt;&lt;font style="font-size: 10pt;"&gt;217.4% - 248.4&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;Expected dividend payout&lt;/font&gt;&lt;/td&gt;&lt;td style="background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: right; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&lt;td style="background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 10pt;"&gt;Expected option life-years&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: right;"&gt;&lt;font style="font-size: 10pt;"&gt;2 to 3&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&amp;#160;years&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;Weighted average grant date fair value&lt;/font&gt;&lt;/td&gt;&lt;td style="background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: right; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;0.22&lt;/font&gt;&lt;/td&gt;&lt;td style="background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="width: 0.5in;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 10pt;"&gt;Forfeiture rate&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="width: 125px; text-align: right;"&gt;&lt;font style="font-size: 10pt;"&gt;0&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 37px;"&gt;&lt;font style="font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAssumptionsUsedTableTextBlock>
<us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;/p&gt;&lt;table align="center" style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 10pt;"&gt;&lt;u&gt;Significant assumptions:&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;Risk-free interest rate at grant date&lt;/font&gt;&lt;/td&gt;&lt;td style="background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: right; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;0.71% - 1.88&lt;/font&gt;&lt;/td&gt;&lt;td style="background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 10pt;"&gt;Expected stock price volatility&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: right;"&gt;&lt;font style="font-size: 10pt;"&gt;217.4% - 248.4&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;Expected dividend payout&lt;/font&gt;&lt;/td&gt;&lt;td style="background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: right; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&lt;td style="background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 10pt;"&gt;Expected option life-years&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: right;"&gt;&lt;font style="font-size: 10pt;"&gt;2 to 3&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&amp;#160;years&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;Weighted average grant date fair value&lt;/font&gt;&lt;/td&gt;&lt;td style="background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td nowrap="nowrap" style="text-align: right; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;0.22&lt;/font&gt;&lt;/td&gt;&lt;td style="background-color: #cceeff;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="width: 0.5in;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&lt;font style="font-size: 10pt;"&gt;Forfeiture rate&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td nowrap="nowrap" style="width: 125px; text-align: right;"&gt;&lt;font style="font-size: 10pt;"&gt;0&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 37px;"&gt;&lt;font style="font-size: 10pt;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
<us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00">&lt;div&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2"&gt;Officers, Directors, and Shareholders&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2"&gt;Commercial Lenders&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2"&gt;Total&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="width: 0.5in; background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Balance at December 31, 2014&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 125px; text-align: right; font-stretch: normal;"&gt;27,200&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 125px; text-align: right; font-stretch: normal;"&gt;-&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 125px; text-align: right; font-stretch: normal;"&gt;27,200&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Borrowing&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;105,000&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;200,000&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;305,000&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Repayment&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;(47,000&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;)&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;(100,000&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;)&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal
 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;(147,000&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"&gt;Conversion to common stock&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;(85,200&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"&gt;)&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;-&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;(85,200&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"&gt;Balance at December 31, 2015&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;-&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;100,000&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;100,000&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Borrowing&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;300,000&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;-&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;300,000&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr
 style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Repayment&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;(68,600&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;)&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;(100,000&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;)&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;(168,600&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"&gt;Debt discount&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;(25,035&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"&gt;)&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;-&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;(25,035&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"&gt;)&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-size: 10pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="background-color: white;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"&gt;Balance at December 31, 2016&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;206,365&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;(100,000&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"&gt;)&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;$&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;106,365&lt;/td&gt;
&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="pure" decimals="4">0.3333</us-gaap:EquityMethodInvestmentOwnershipPercentage>
<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="Context_As_Of_01_Apr_2016T00_00_00_TO_01_Apr_2016T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_ImmudynePrLlcMember" unitRef="pure" decimals="7">0.7816667</us-gaap:EquityMethodInvestmentOwnershipPercentage>
<us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="pure" decimals="2">0.51</us-gaap:MinorityInterestOwnershipPercentageByParent>
<us-gaap:InventoryRawMaterials contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">25761</us-gaap:InventoryRawMaterials>
<us-gaap:InventoryRawMaterials contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">38460</us-gaap:InventoryRawMaterials>
<us-gaap:InventoryFinishedGoods contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">35290</us-gaap:InventoryFinishedGoods>
<us-gaap:InventoryFinishedGoods contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">121810</us-gaap:InventoryFinishedGoods>
<us-gaap:Assets contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">448471</us-gaap:Assets>
<us-gaap:Assets contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_ConsolidationItemsAxis_NutraceuticalAndCosmeticMember" unitRef="USD" decimals="0">412324</us-gaap:Assets>
<us-gaap:Assets contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_ConsolidationItemsAxis_CosmeticGoodsMember" unitRef="USD" decimals="0">101828</us-gaap:Assets>
<us-gaap:Assets contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_ConsolidationItemsAxis_IntersegmentEliminationMember" unitRef="USD" decimals="0">-65681</us-gaap:Assets>
<us-gaap:Assets contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">789824</us-gaap:Assets>
<us-gaap:Assets contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidationItemsAxis_NutraceuticalAndCosmeticMember" unitRef="USD" decimals="0">556234</us-gaap:Assets>
<us-gaap:Assets contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidationItemsAxis_CosmeticGoodsMember" unitRef="USD" decimals="3">422.288</us-gaap:Assets>
<us-gaap:Assets contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConsolidationItemsAxis_IntersegmentEliminationMember" unitRef="USD" decimals="0">-188698</us-gaap:Assets>
<immd:CorporateExpenses contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">214282</immd:CorporateExpenses>
<immd:CorporateExpenses contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">950847</immd:CorporateExpenses>
<us-gaap:OtherNonoperatingIncomeExpense contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">89785</us-gaap:OtherNonoperatingIncomeExpense>
<us-gaap:OtherNonoperatingIncomeExpense contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">-48611</us-gaap:OtherNonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">-172432</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">-1223293</us-gaap:NonoperatingIncomeExpense>
<immd:MinorityInterestRate contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="pure" decimals="5">0.21833</immd:MinorityInterestRate>
<us-gaap:InventoryLIFOReserve contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">20000</us-gaap:InventoryLIFOReserve>
<us-gaap:InventoryLIFOReserve contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">20000</us-gaap:InventoryLIFOReserve>
<us-gaap:SalesDiscountsReturnsAndAllowancesGoods contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">1926000</us-gaap:SalesDiscountsReturnsAndAllowancesGoods>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_OptionIndexedToIssuersEquityTypeAxis_EmployeeStockOptionMember_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">12775273</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_OptionIndexedToIssuersEquityTypeAxis_EmployeeStockOptionMember_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">16302447</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:ConcentrationRiskPercentage1 contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_ConcentrationRiskByBenchmarkAxis_SalesMember_ConcentrationRiskNumberOfCustomersAxis_OneCustomerMember_ConsolidationItemsAxis_NutraceuticalAndCosmeticMember" unitRef="pure" decimals="2">0.73</us-gaap:ConcentrationRiskPercentage1>
<us-gaap:ConcentrationRiskPercentage1 contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_ConcentrationRiskByBenchmarkAxis_SalesMember_ConcentrationRiskNumberOfCustomersAxis_SecondCustomerMember_ConsolidationItemsAxis_NutraceuticalAndCosmeticMember" unitRef="pure" decimals="2">0.12</us-gaap:ConcentrationRiskPercentage1>
<us-gaap:ConcentrationRiskPercentage1 contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskNumberOfCustomersAxis_OneCustomerMember" unitRef="pure" decimals="2">0.43</us-gaap:ConcentrationRiskPercentage1>
<us-gaap:ConcentrationRiskPercentage1 contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskNumberOfCustomersAxis_SecondCustomerMember" unitRef="pure" decimals="2">0.24</us-gaap:ConcentrationRiskPercentage1>
<us-gaap:ConcentrationRiskPercentage1 contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConcentrationRiskByBenchmarkAxis_SalesMember_ConcentrationRiskNumberOfCustomersAxis_OneCustomerMember_ConsolidationItemsAxis_NutraceuticalAndCosmeticMember" unitRef="pure" decimals="2">0.15</us-gaap:ConcentrationRiskPercentage1>
<us-gaap:ConcentrationRiskPercentage1 contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConcentrationRiskByBenchmarkAxis_SalesMember_ConcentrationRiskNumberOfCustomersAxis_SecondCustomerMember_ConsolidationItemsAxis_NutraceuticalAndCosmeticMember" unitRef="pure" decimals="2">0.02</us-gaap:ConcentrationRiskPercentage1>
<us-gaap:ConcentrationRiskPercentage1 contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskNumberOfCustomersAxis_OneCustomerMember" unitRef="pure" decimals="2">0.11</us-gaap:ConcentrationRiskPercentage1>
<us-gaap:ConcentrationRiskPercentage1 contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskNumberOfCustomersAxis_SecondCustomerMember" unitRef="pure" decimals="2">0.08</us-gaap:ConcentrationRiskPercentage1>
<us-gaap:ConcentrationRiskPercentage1 contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis_OneCreditCardProcessorsMember" unitRef="pure" decimals="3">0.349</us-gaap:ConcentrationRiskPercentage1>
<us-gaap:ConcentrationRiskPercentage1 contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis_TwoCreditCardProcessorsMember" unitRef="pure" decimals="3">0.316</us-gaap:ConcentrationRiskPercentage1>
<us-gaap:AccountsReceivableNet contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">18000</us-gaap:AccountsReceivableNet>
<us-gaap:AccountsReceivableNet contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">37800</us-gaap:AccountsReceivableNet>
<immd:NonControllingInterestDescription contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">100000</immd:NonControllingInterestDescription>
<us-gaap:SalesReturnsAndAllowancesGoods contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:SalesReturnsAndAllowancesGoods contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">50500</us-gaap:SalesReturnsAndAllowancesGoods>
<us-gaap:VariableInterestEntityConsolidatedCarryingAmountAssets contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">10306</us-gaap:VariableInterestEntityConsolidatedCarryingAmountAssets>
<us-gaap:VariableInterestEntityConsolidatedCarryingAmountLiabilities contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">5748</us-gaap:VariableInterestEntityConsolidatedCarryingAmountLiabilities>
<us-gaap:VariableInterestEntityActivityBetweenVIEAndEntityRevenues contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">6271</us-gaap:VariableInterestEntityActivityBetweenVIEAndEntityRevenues>
<us-gaap:VariableInterestEntityActivityBetweenVIEAndEntityOperatingIncomeOrLoss contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">6141</us-gaap:VariableInterestEntityActivityBetweenVIEAndEntityOperatingIncomeOrLoss>
<us-gaap:VariableInterestEntityConclusionToConsolidate contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00">Consolidated nine and zero.</us-gaap:VariableInterestEntityConclusionToConsolidate>
<us-gaap:VariableInterestEntityConclusionToConsolidate contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00">Consolidated nine and zero.</us-gaap:VariableInterestEntityConclusionToConsolidate>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">679291</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">679291</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">679291</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">679291</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<immd:OptionsPurchasedAmountPaid contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">100000</immd:OptionsPurchasedAmountPaid>
<us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="pure" decimals="2">0.10</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
<us-gaap:SharePrice contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD_per_Share" decimals="2">0.25</us-gaap:SharePrice>
<us-gaap:SharePrice contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD_per_Share" decimals="2">0.30</us-gaap:SharePrice>
<us-gaap:SharePrice contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_RestrictedStockMember" unitRef="USD_per_Share" decimals="2">0.20</us-gaap:SharePrice>
<us-gaap:SharePrice contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantMember" unitRef="USD_per_Share" decimals="2">0.20</us-gaap:SharePrice>
<us-gaap:MinorityInterestInJointVentures contextRef="Context_As_Of_31_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00" unitRef="USD" decimals="0">100000</us-gaap:MinorityInterestInJointVentures>
<us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="Context_Custom_01_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00" unitRef="USD" decimals="0">1500000</us-gaap:BusinessCombinationConsiderationTransferred1>
<us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableDescription contextRef="Context_Custom_01_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00">less than 1%.</us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableDescription>
<us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners contextRef="Context_As_Of_31_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00" unitRef="pure" decimals="2">0.10</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
<us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners contextRef="Context_As_Of_01_Apr_2016T00_00_00_TO_01_Apr_2016T00_00_00_LegalEntityAxis_ImmudynePrLlcMember" unitRef="pure" decimals="7">0.7816667</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
<us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners contextRef="Context_As_Of_01_Apr_2016T00_00_00_TO_01_Apr_2016T00_00_00_LegalEntityAxis_ImmudynePrLlcMember_RangeAxis_MaximumMember" unitRef="pure" decimals="3">0.667</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
<us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners contextRef="Context_As_Of_01_Apr_2016T00_00_00_TO_01_Apr_2016T00_00_00_LegalEntityAxis_ImmudynePrLlcMember_RangeAxis_MinimumMember" unitRef="pure" decimals="4">0.2183</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
<invest:InvestmentOptionsExpirationDate contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00">2014-09-30</invest:InvestmentOptionsExpirationDate>
<us-gaap:ProceedsFromNotesPayable contextRef="Context_Custom_01_Jan_2015T00_00_00_TO_31_Jan_2015T00_00_00_ClassOfFinancingReceivableTypeOfBorrowerAxis_CommercialLenderMember" unitRef="USD" decimals="0">100000</us-gaap:ProceedsFromNotesPayable>
<us-gaap:ProceedsFromNotesPayable contextRef="Context_Custom_02_Nov_2015T00_00_00_TO_30_Nov_2015T00_00_00_ClassOfFinancingReceivableTypeOfBorrowerAxis_CommercialLenderMember" unitRef="USD" decimals="0">100000</us-gaap:ProceedsFromNotesPayable>
<us-gaap:ProceedsFromNotesPayable contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">305000</us-gaap:ProceedsFromNotesPayable>
<us-gaap:ProceedsFromNotesPayable contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_ClassOfFinancingReceivableTypeOfBorrowerAxis_CommercialLenderMember" unitRef="USD" decimals="0">200000</us-gaap:ProceedsFromNotesPayable>
<us-gaap:ProceedsFromNotesPayable contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_TitleOfIndividualAxis_BoardOfDirectorsChairmanMember" unitRef="USD" decimals="0">105000</us-gaap:ProceedsFromNotesPayable>
<us-gaap:ProceedsFromNotesPayable contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">300000</us-gaap:ProceedsFromNotesPayable>
<us-gaap:ProceedsFromNotesPayable contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_ClassOfFinancingReceivableTypeOfBorrowerAxis_CommercialLenderMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProceedsFromNotesPayable contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_TitleOfIndividualAxis_BoardOfDirectorsChairmanMember" unitRef="USD" decimals="0">300000</us-gaap:ProceedsFromNotesPayable>
<us-gaap:ConversionOfStockAmountConverted1 contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">-85200</us-gaap:ConversionOfStockAmountConverted1>
<us-gaap:ConversionOfStockAmountConverted1 contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_ClassOfFinancingReceivableTypeOfBorrowerAxis_CommercialLenderMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:ConversionOfStockAmountConverted1 contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_TitleOfIndividualAxis_BoardOfDirectorsChairmanMember" unitRef="USD" decimals="0">-85200</us-gaap:ConversionOfStockAmountConverted1>
<us-gaap:ConvertibleNotesPayable contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_TitleOfIndividualAxis_MajorityShareholderMember" unitRef="USD" decimals="0">85200</us-gaap:ConvertibleNotesPayable>
<us-gaap:SharesIssuedPricePerShare contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_PresidentMember" unitRef="USD_per_Share" decimals="2">0.17</us-gaap:SharesIssuedPricePerShare>
<us-gaap:SharesIssuedPricePerShare contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_TitleOfIndividualAxis_MajorityShareholderMember" unitRef="USD_per_Share" decimals="2">0.17</us-gaap:SharesIssuedPricePerShare>
<us-gaap:DebtInstrumentPaymentTerms contextRef="Context_Custom_01_Jan_2015T00_00_00_TO_31_Jan_2015T00_00_00_ClassOfFinancingReceivableTypeOfBorrowerAxis_CommercialLenderMember">The loan required payment of principal and interest in 252 daily payments of $492 each commencing January 12, 2015.</us-gaap:DebtInstrumentPaymentTerms>
<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="Context_As_Of_30_Nov_2015T00_00_00_TO_30_Nov_2015T00_00_00" unitRef="pure" decimals="2">0.11</us-gaap:DebtInstrumentInterestRateStatedPercentage>
<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="Context_As_Of_31_Jan_2017T00_00_00_TO_31_Jan_2017T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_CashAndCashEquivalentsAxis_CommercialPaperMember" unitRef="pure" decimals="2">0.11</us-gaap:DebtInstrumentInterestRateStatedPercentage>
<us-gaap:DebtInstrumentMaturityDate contextRef="Context_Custom_02_Nov_2015T00_00_00_TO_30_Nov_2015T00_00_00">2016-11-01</us-gaap:DebtInstrumentMaturityDate>
<us-gaap:DebtInstrumentMaturityDate contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_TitleOfIndividualAxis_OfficerMember">2017-02-28</us-gaap:DebtInstrumentMaturityDate>
<us-gaap:InterestExpenseDebt contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">1543</us-gaap:InterestExpenseDebt>
<us-gaap:InterestExpenseDebt contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">9479</us-gaap:InterestExpenseDebt>
<us-gaap:DebtInstrumentInterestRateDuringPeriod contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="pure" decimals="2">0.11</us-gaap:DebtInstrumentInterestRateDuringPeriod>
<us-gaap:NotesPayable contextRef="Context_As_Of_31_Jul_2015T00_00_00_TO_31_Jul_2015T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_ShareholderMember" unitRef="USD" decimals="0">75000</us-gaap:NotesPayable>
<us-gaap:NotesPayable contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_ShareholderMember" unitRef="USD" decimals="0">75000</us-gaap:NotesPayable>
<us-gaap:NotesPayable contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_TitleOfIndividualAxis_DirectorMember" unitRef="USD" decimals="0">10200</us-gaap:NotesPayable>
<us-gaap:NotesPayable contextRef="Context_As_Of_31_Aug_2016T00_00_00_TO_31_Aug_2016T00_00_00_CashAndCashEquivalentsAxis_CommercialPaperMember" unitRef="USD" decimals="0">150000</us-gaap:NotesPayable>
<us-gaap:NotesPayable contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">50000</us-gaap:NotesPayable>
<us-gaap:NotesPayable contextRef="Context_As_Of_30_Sep_2016T00_00_00_TO_30_Sep_2016T00_00_00_CashAndCashEquivalentsAxis_CommercialPaperMember" unitRef="USD" decimals="0">150000</us-gaap:NotesPayable>
<us-gaap:NotesPayable contextRef="Context_As_Of_31_Oct_2016T00_00_00_TO_31_Oct_2016T00_00_00_CashAndCashEquivalentsAxis_CommercialPaperMember" unitRef="USD" decimals="0">50000</us-gaap:NotesPayable>
<us-gaap:NotesPayable contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">25035</us-gaap:NotesPayable>
<us-gaap:NotesPayable contextRef="Context_As_Of_31_Jan_2017T00_00_00_TO_31_Jan_2017T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_CashAndCashEquivalentsAxis_CommercialPaperMember" unitRef="USD" decimals="0">200000</us-gaap:NotesPayable>
<us-gaap:NotesPayable contextRef="Context_As_Of_28_Feb_2017T00_00_00_TO_28_Feb_2017T00_00_00_CashAndCashEquivalentsAxis_CommercialPaperTwoMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="USD" decimals="0">100000</us-gaap:NotesPayable>
<us-gaap:NotesPayable contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_CashAndCashEquivalentsAxis_CommercialPaperOneMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="USD" decimals="0">50000</us-gaap:NotesPayable>
<us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="Context_3ME_01_Jul_2016T00_00_00_TO_30_Sep_2016T00_00_00" unitRef="USD" decimals="0">200000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
<us-gaap:DebtInstrumentFaceAmount contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">68600</us-gaap:DebtInstrumentFaceAmount>
<us-gaap:NotesAndLoansPayableCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">131400</us-gaap:NotesAndLoansPayableCurrent>
<us-gaap:ConvertibleDebt contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_TitleOfIndividualAxis_OfficerMember" unitRef="USD" decimals="0">100000</us-gaap:ConvertibleDebt>
<us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD_per_Share" decimals="2">0.23</us-gaap:DebtInstrumentConvertibleConversionPrice1>
<invest:InvestmentOptionsExercisePrice contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_TitleOfIndividualAxis_PresidentMember" unitRef="USD_per_Share" decimals="2">0.10</invest:InvestmentOptionsExercisePrice>
<invest:InvestmentOptionsExercisePrice contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD_per_Share" decimals="2">0.40</invest:InvestmentOptionsExercisePrice>
<immd:TermOfWarrant contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00">P3Y</immd:TermOfWarrant>
<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">930000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">1344000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">930000</us-gaap:DeferredTaxAssetsValuationAllowance>
<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">1581000</us-gaap:DeferredTaxAssetsValuationAllowance>
<us-gaap:DeferredTaxAssetsInventory contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:DeferredTaxAssetsInventory contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">7000</us-gaap:DeferredTaxAssetsInventory>
<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">200000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
<us-gaap:DeferredTaxAssetsGross contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:DeferredTaxAssetsGross contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">1581000</us-gaap:DeferredTaxAssetsGross>
<us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:OperatingLossCarryforwards contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">3953000</us-gaap:OperatingLossCarryforwards>
<us-gaap:OperatingLossCarryforwardsExpirationDate contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00">2036-12-31</us-gaap:OperatingLossCarryforwardsExpirationDate>
<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="pure" decimals="2">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">3772720</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">10435000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">1750000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">11025273</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">1954981</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">10700273</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeOneMember" unitRef="shares" decimals="INF">1380273</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeTwoMember" unitRef="shares" decimals="0">8120000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeThreeMember" unitRef="shares" decimals="0">1150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">2022720</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_DirectorMember" unitRef="shares" decimals="INF">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="Context_Custom_02_Nov_2015T00_00_00_TO_30_Nov_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantMember" unitRef="shares" decimals="INF">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_Custom_02_Jul_2015T00_00_00_TO_31_Jul_2015T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_ShareholderMember" unitRef="shares" decimals="INF">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_Custom_02_Jul_2015T00_00_00_TO_31_Jul_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantMember" unitRef="shares" decimals="INF">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_Custom_01_Oct_2015T00_00_00_TO_31_Oct_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantMember" unitRef="shares" decimals="INF">110000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">790273</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_Custom_01_May_2016T00_00_00_TO_31_May_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantMember" unitRef="shares" decimals="INF">175000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_Custom_01_Nov_2016T00_00_00_TO_30_Nov_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantMember" unitRef="shares" decimals="INF">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">454891</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">275000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_PerformanceBasedStockOptionsMember" unitRef="shares" decimals="INF">4400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="pure" decimals="2">0.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="pure" decimals="2">0.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_RangeAxis_MaximumMember_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" decimals="4">0.0188</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_RangeAxis_MinimumMember_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" decimals="4">0.0071</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="pure" decimals="2">0.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="pure" decimals="2">2.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_RangeAxis_MaximumMember_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" decimals="3">2.484</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_RangeAxis_MinimumMember_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" decimals="3">2.174</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="pure" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="pure" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" xsi:nil="true"/>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember_RangeAxis_MaximumMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember_RangeAxis_MinimumMember">P1Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember_RangeAxis_MaximumMember">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember_RangeAxis_MinimumMember">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_RangeAxis_MaximumMember_AwardTypeAxis_EmployeeStockOptionMember">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_RangeAxis_MinimumMember_AwardTypeAxis_EmployeeStockOptionMember">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">0.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">0.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">0.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
<immd:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairvalueAssumptionsForfeitureRate contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" decimals="2">0.00</immd:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairvalueAssumptionsForfeitureRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">0.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">0.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">0.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeOneMember" unitRef="USD_per_Share" decimals="2">0.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeThreeMember" unitRef="USD_per_Share" decimals="2">0.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeTwoMember_RangeAxis_MinimumMember" unitRef="USD_per_Share" decimals="2">0.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeTwoMember_RangeAxis_MaximumMember" unitRef="USD_per_Share" decimals="2">0.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeThreeMember_RangeAxis_MinimumMember" unitRef="USD_per_Share" decimals="2">0.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeThreeMember_RangeAxis_MaximumMember" unitRef="USD_per_Share" decimals="2">0.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeOneMember">P1Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeTwoMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRangeThreeMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_Custom_02_Jul_2015T00_00_00_TO_31_Jul_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantMember" unitRef="USD_per_Share" decimals="2">0.20</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_Custom_01_Oct_2015T00_00_00_TO_31_Oct_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantMember" unitRef="USD_per_Share" decimals="2">0.20</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_Custom_01_May_2016T00_00_00_TO_31_May_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantMember" unitRef="USD_per_Share" decimals="2">0.20</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_Custom_01_Nov_2016T00_00_00_TO_30_Nov_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantMember" unitRef="USD_per_Share" decimals="2">0.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">0.42</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_PerformanceBasedStockOptionsMember_RangeAxis_MinimumMember" unitRef="USD_per_Share" decimals="2">0.40</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_PerformanceBasedStockOptionsMember_RangeAxis_MaximumMember" unitRef="USD_per_Share" decimals="2">0.80</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">0.40</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">0.40</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
<immd:ShareBasedCompensationArrangementByShareBasedPaymentBeinningYearOfExpiration contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember">2015 - 2016</immd:ShareBasedCompensationArrangementByShareBasedPaymentBeinningYearOfExpiration>
<immd:ShareBasedCompensationArrangementByShareBasedPaymentBeinningYearOfExpiration contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember">2016 - 2017</immd:ShareBasedCompensationArrangementByShareBasedPaymentBeinningYearOfExpiration>
<immd:ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationIssued contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember">2018 - 2019</immd:ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationIssued>
<immd:ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationExpired contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember">2015</immd:ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationExpired>
<immd:ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationExpired contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember">2016</immd:ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationExpired>
<immd:ShareBasedCompensationArrangementByShareBasedPaymentEndingYearOfExpiration contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_WarrantMember">2016 - 2017</immd:ShareBasedCompensationArrangementByShareBasedPaymentEndingYearOfExpiration>
<immd:ShareBasedCompensationArrangementByShareBasedPaymentEndingYearOfExpiration contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_WarrantMember">2017 - 2019</immd:ShareBasedCompensationArrangementByShareBasedPaymentEndingYearOfExpiration>
<us-gaap:AccruedRoyaltiesCurrentAndNoncurrent contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_TitleOfIndividualAxis_PresidentMember" unitRef="USD" decimals="0">84868</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
<us-gaap:AccruedRoyaltiesCurrentAndNoncurrent contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_PresidentMember" unitRef="USD" decimals="0">84868</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="Context_Custom_02_Jul_2015T00_00_00_TO_31_Jul_2015T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_ShareholderMember">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_TitleOfIndividualAxis_PresidentMember">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_DirectorMember">P1Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_PresidentMember">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_01_Sep_2016T00_00_00_TO_01_Sep_2016T00_00_00_AwardTypeAxis_WarrantMember_SubsidiarySaleOfStockAxis_IPOMember" unitRef="USD_per_Share" decimals="2">0.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_01_Sep_2016T00_00_00_TO_01_Sep_2016T00_00_00_AwardTypeAxis_WarrantMember_RangeAxis_MinimumMember_SubsidiarySaleOfStockAxis_ConsultingServicesMember" unitRef="USD_per_Share" decimals="2">0.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_01_Sep_2016T00_00_00_TO_01_Sep_2016T00_00_00_AwardTypeAxis_WarrantMember_RangeAxis_MaximumMember_SubsidiarySaleOfStockAxis_ConsultingServicesMember" unitRef="USD_per_Share" decimals="2">0.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">0.19</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_WarrantMember_SubsidiarySaleOfStockAxis_IPOMember" unitRef="USD_per_Share" decimals="2">0.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_WarrantMember_SubsidiarySaleOfStockAxis_IssuanceOfCommonStockMember" unitRef="USD_per_Share" decimals="2">0.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Jan_2017T00_00_00_TO_31_Jan_2017T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="USD_per_Share" decimals="2">0.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="USD_per_Share" decimals="2">0.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_24_Apr_2017T00_00_00_TO_24_Apr_2017T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="USD_per_Share" decimals="2">0.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross contextRef="Context_Custom_02_Jul_2015T00_00_00_TO_31_Jul_2015T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_ShareholderMember" unitRef="USD" decimals="0">7500</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross contextRef="Context_Custom_02_Jul_2015T00_00_00_TO_31_Jul_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantMember" unitRef="USD" decimals="0">12397</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross contextRef="Context_Custom_01_Oct_2015T00_00_00_TO_31_Oct_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantMember" unitRef="USD" decimals="0">2800</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross contextRef="Context_Custom_01_May_2016T00_00_00_TO_31_May_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantMember" unitRef="USD" decimals="0">40829</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross contextRef="Context_Custom_01_Nov_2016T00_00_00_TO_30_Nov_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantMember" unitRef="USD" decimals="0">9980</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">383333</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_PerformanceBasedStockOptionsMember" unitRef="USD" decimals="0">120867</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_PresidentMember" unitRef="shares" decimals="INF">1500000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_01_Sep_2016T00_00_00_TO_01_Sep_2016T00_00_00_AwardTypeAxis_WarrantMember_SubsidiarySaleOfStockAxis_IPOMember" unitRef="shares" decimals="INF">100000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_01_Sep_2016T00_00_00_TO_01_Sep_2016T00_00_00_AwardTypeAxis_WarrantMember_SubsidiarySaleOfStockAxis_ConsultingServicesMember" unitRef="shares" decimals="INF">100000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_WarrantMember_SubsidiarySaleOfStockAxis_IPOMember" unitRef="shares" decimals="INF">37500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_WarrantMember_SubsidiarySaleOfStockAxis_IssuanceOfCommonStockMember" unitRef="shares" decimals="INF">217391</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD_per_Share" decimals="2">0.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice>
<us-gaap:CommonStockOtherSharesOutstanding contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="shares" decimals="INF">325000</us-gaap:CommonStockOtherSharesOutstanding>
<immd:PurchaseOfCommonStockDescriptionOfTransaction contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00">Common stock through an exchange for a price per share of $0.23 to $0.29.</immd:PurchaseOfCommonStockDescriptionOfTransaction>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="Context_Custom_02_Jul_2015T00_00_00_TO_31_Jul_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="Context_Custom_01_Oct_2015T00_00_00_TO_31_Oct_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="Context_Custom_01_May_2016T00_00_00_TO_31_May_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="Context_Custom_01_Nov_2016T00_00_00_TO_30_Nov_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantMember">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="Context_As_Of_30_Nov_2015T00_00_00_TO_30_Nov_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantMember" unitRef="shares" decimals="INF">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
<immd:NumberOfConsultant contextRef="Context_Custom_01_Oct_2015T00_00_00_TO_31_Oct_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantMember" unitRef="Consultants" decimals="INF">2</immd:NumberOfConsultant>
<immd:NumberOfConsultant contextRef="Context_Custom_02_Nov_2015T00_00_00_TO_30_Nov_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantMember" unitRef="Consultants" decimals="INF">2</immd:NumberOfConsultant>
<immd:NumberOfConsultant contextRef="Context_Custom_01_May_2016T00_00_00_TO_31_May_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantMember" unitRef="Consultants" decimals="INF">2</immd:NumberOfConsultant>
<immd:NumberOfConsultant contextRef="Context_Custom_20_Oct_2016T00_00_00_TO_31_Oct_2016T00_00_00_AwardTypeAxis_PerformanceBasedStockOptionsMember" unitRef="Consultants" decimals="INF">2</immd:NumberOfConsultant>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD" decimals="0">704794</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD" decimals="0">33605</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">54000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
<us-gaap:DeferredCompensationEquity contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">133324</us-gaap:DeferredCompensationEquity>
<us-gaap:DeferredCompensationEquity contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_PerformanceBasedStockOptionsMember" unitRef="USD" decimals="0">30169</us-gaap:DeferredCompensationEquity>
<immd:FairValueOfPerformanceBasedStockOptions contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">151036</immd:FairValueOfPerformanceBasedStockOptions>
<immd:FairValueOfPerformanceBasedStockOptions contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_PerformanceBasedStockOptionsMember" unitRef="USD" decimals="0">169035</immd:FairValueOfPerformanceBasedStockOptions>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00">2017-12-31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_PerformanceBasedStockOptionsMember_RangeAxis_MinimumMember">2021-12-31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_PerformanceBasedStockOptionsMember_RangeAxis_MaximumMember">2026-12-31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
<immd:AnnualSalesRevenueTarget contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_PerformanceBasedStockOptionsMember" unitRef="USD" decimals="0">5000000</immd:AnnualSalesRevenueTarget>
<immd:AnnualSalesRevenueTarget contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_PerformanceBasedStockOptionsMember_RangeAxis_MinimumMember" unitRef="USD" decimals="0">5000000</immd:AnnualSalesRevenueTarget>
<immd:AnnualSalesRevenueTarget contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_PerformanceBasedStockOptionsMember_RangeAxis_MaximumMember" unitRef="USD" decimals="0">10000000</immd:AnnualSalesRevenueTarget>
<immd:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableFairValue contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_PerformanceBasedStockOptionsMember" unitRef="USD" decimals="0">120867</immd:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableFairValue>
<us-gaap:FairValueAdjustmentOfWarrants contextRef="Context_Custom_25_Aug_2016T00_00_00_TO_01_Sep_2016T00_00_00_AwardTypeAxis_WarrantMember_SubsidiarySaleOfStockAxis_ConsultingServicesMember" unitRef="USD" decimals="0">20585</us-gaap:FairValueAdjustmentOfWarrants>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Context_Custom_25_Aug_2016T00_00_00_TO_01_Sep_2016T00_00_00_AwardTypeAxis_WarrantMember_SubsidiarySaleOfStockAxis_IPOMember">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Context_Custom_25_Aug_2016T00_00_00_TO_01_Sep_2016T00_00_00_AwardTypeAxis_WarrantMember_SubsidiarySaleOfStockAxis_ConsultingServicesMember">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_WarrantMember_SubsidiarySaleOfStockAxis_IPOMember">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_WarrantMember_SubsidiarySaleOfStockAxis_IssuanceOfCommonStockMember">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_WarrantMember" unitRef="shares" decimals="INF">1954891</us-gaap:ClassOfWarrantOrRightOutstanding>
<immd:WarrantExercisable contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_WarrantMember" unitRef="shares" decimals="INF">1750000</immd:WarrantExercisable>
<immd:WarrantsExpireDateDescription contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_WarrantMember">The warrants expire at various time between December 2017 and September 2019.</immd:WarrantsExpireDateDescription>
<us-gaap:LaborAndRelatedExpense contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_PerformanceBasedStockOptionsMember" unitRef="USD" decimals="0">133800</us-gaap:LaborAndRelatedExpense>
<us-gaap:LaborAndRelatedExpense contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_PerformanceBasedStockOptionsMember" unitRef="USD" decimals="0">587991</us-gaap:LaborAndRelatedExpense>
<immd:PercentageOfRoyaltyBasedUponSales contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="pure" decimals="2">0.08</immd:PercentageOfRoyaltyBasedUponSales>
<immd:RoyaltyBasedUponSalesAmount contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">227175</immd:RoyaltyBasedUponSalesAmount>
<us-gaap:RoyaltyExpense contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">20157</us-gaap:RoyaltyExpense>
<us-gaap:RoyaltyExpense contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">0</us-gaap:RoyaltyExpense>
<immd:InterestInRoyalty contextRef="Context_Custom_01_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_PresidentMember" unitRef="pure" decimals="2">0.60</immd:InterestInRoyalty>
<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">56579</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">56579</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
<us-gaap:LeaseExpirationDate1 contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00">2016-05-31</us-gaap:LeaseExpirationDate1>
<us-gaap:OperatingLeasesRentExpenseMinimumRentals contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">9000</us-gaap:OperatingLeasesRentExpenseMinimumRentals>
<us-gaap:LeaseAndRentalExpense contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="0">65968</us-gaap:LeaseAndRentalExpense>
<us-gaap:LeaseAndRentalExpense contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">139030</us-gaap:LeaseAndRentalExpense>
<us-gaap:LeaseAndRentalExpense contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_TitleOfIndividualAxis_PresidentMember" unitRef="USD" decimals="0">2000</us-gaap:LeaseAndRentalExpense>
<us-gaap:SalariesWagesAndOfficersCompensation contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">145000</us-gaap:SalariesWagesAndOfficersCompensation>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD_per_Share" decimals="2">0.40</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD_per_Share" decimals="2">0.80</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
<immd:StockIssuedDuringPeriodPerformanceBasedOptionsToPurchaseCommonStock contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="shares" decimals="INF">4400000</immd:StockIssuedDuringPeriodPerformanceBasedOptionsToPurchaseCommonStock>
<us-gaap:SalesRevenueNet contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">5000000</us-gaap:SalesRevenueNet>
<immd:SalesRevenueIncreased contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">10000000</immd:SalesRevenueIncreased>
<immd:BonusPercentageOfCompensationForPretaxIncome contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="pure" decimals="2">0.15</immd:BonusPercentageOfCompensationForPretaxIncome>
<immd:PertaxIncomePercentage contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="pure" decimals="2">0.05</immd:PertaxIncomePercentage>
<us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="Context_Custom_25_Mar_2016T00_00_00_TO_01_Apr_2016T00_00_00_AwardTypeAxis_RestrictedStockMember" unitRef="shares" decimals="INF">150000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
<us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="Context_Custom_25_Mar_2016T00_00_00_TO_01_Apr_2016T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantMember" unitRef="shares" decimals="INF">1000000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
<us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="shares" decimals="INF">2250000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
<us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_LegalEntityAxis_ImmudynePrLlcMember" unitRef="shares" decimals="INF">1500000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
<immd:DebtLongTermAndShortTermCombinedAmountShares contextRef="Context_Custom_25_Mar_2016T00_00_00_TO_01_Apr_2016T00_00_00" unitRef="shares" decimals="INF">5000000</immd:DebtLongTermAndShortTermCombinedAmountShares>
<immd:DebtLongTermAndShortTermCombinedAmountShares contextRef="Context_Custom_25_Mar_2016T00_00_00_TO_01_Apr_2016T00_00_00_AwardTypeAxis_RestrictedStockMember" unitRef="shares" decimals="INF">3000000</immd:DebtLongTermAndShortTermCombinedAmountShares>
<us-gaap:RestrictedStockExpense contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_RestrictedStockMember" unitRef="USD" decimals="0">690000</us-gaap:RestrictedStockExpense>
<immd:BonusShares contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_RestrictedStockMember" unitRef="shares" decimals="INF">750000</immd:BonusShares>
<immd:OptionToBuyShares contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_RestrictedStockMember" unitRef="shares" decimals="INF">1000000</immd:OptionToBuyShares>
<us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="shares" decimals="INF">3000000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_RestrictedStockOneMember" unitRef="USD" decimals="0">1250000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_RestrictedStockTwoMember" unitRef="USD" decimals="0">2000000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_RestrictedStockThreeMember" unitRef="USD" decimals="0">3000000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_LegalEntityAxis_ImmudynePrLlcMember" unitRef="USD" decimals="0">5000000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
<immd:NumerOfThresholds contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="Thresholds" decimals="INF">3</immd:NumerOfThresholds>
<us-gaap:OperatingLeasesRentExpenseNet contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_LegalEntityAxis_ImmudynePrLlcMember" unitRef="USD" decimals="0">4000</us-gaap:OperatingLeasesRentExpenseNet>
<immd:CompensationForLegalServices contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">16145</immd:CompensationForLegalServices>
<immd:CompensationForLegalServices contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_LegalEntityAxis_ImmudynePrLlcMember" unitRef="USD" decimals="0">19800</immd:CompensationForLegalServices>
<immd:ReimbursementOfHomeOfficeExpenditures contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_TitleOfIndividualAxis_PresidentMember" unitRef="USD" decimals="0">24000</immd:ReimbursementOfHomeOfficeExpenditures>
<us-gaap:ConversionOfStockSharesIssued1 contextRef="Context_Custom_20_Oct_2016T00_00_00_TO_31_Oct_2016T00_00_00" unitRef="shares" decimals="INF">62500</us-gaap:ConversionOfStockSharesIssued1>
<us-gaap:ConversionOfStockSharesIssued1 contextRef="Context_Custom_01_Jan_2017T00_00_00_TO_31_Jan_2017T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="shares" decimals="INF">1183490</us-gaap:ConversionOfStockSharesIssued1>
<us-gaap:ConversionOfStockSharesIssued1 contextRef="Context_Custom_01_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="shares" decimals="INF">559179</us-gaap:ConversionOfStockSharesIssued1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="Context_Custom_01_Jan_2017T00_00_00_TO_31_Jan_2017T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="shares" decimals="INF">591745</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="Context_Custom_01_Mar_2017T00_00_00_TO_27_Mar_2017T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="shares" decimals="INF">1336828</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="Context_Custom_01_Apr_2017T00_00_00_TO_24_Apr_2017T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="shares" decimals="INF">108696</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="Context_Custom_01_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
<us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="Context_As_Of_31_Jan_2017T00_00_00_TO_31_Jan_2017T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_CashAndCashEquivalentsAxis_CommercialPaperMember" unitRef="pure" decimals="2">0.05</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
<us-gaap:DebtConversionOriginalDebtAmount1 contextRef="Context_Custom_01_Jan_2017T00_00_00_TO_31_Jan_2017T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_CashAndCashEquivalentsAxis_CommercialPaperMember" unitRef="USD" decimals="0">210000</us-gaap:DebtConversionOriginalDebtAmount1>
<us-gaap:RepaymentsOfDebt contextRef="Context_Custom_01_Feb_2017T00_00_00_TO_28_Feb_2017T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="USD" decimals="0">70000</us-gaap:RepaymentsOfDebt>
<immd:CommonStockSharesIssuedRelatedPromissoryNote contextRef="Context_Custom_01_Jan_2017T00_00_00_TO_31_Jan_2017T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="shares" decimals="INF">217391</immd:CommonStockSharesIssuedRelatedPromissoryNote>
<us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="Context_Custom_01_Mar_2017T00_00_00_TO_27_Mar_2017T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="USD" decimals="0">50000</us-gaap:DebtConversionConvertedInstrumentAmount1>
<us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="Context_Custom_01_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="USD" decimals="0">140000</us-gaap:DebtConversionConvertedInstrumentAmount1>
<us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="Context_Custom_01_Mar_2017T00_00_00_TO_27_Mar_2017T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="shares" decimals="INF">196000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
<us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="Context_Custom_01_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="shares" decimals="INF">559179</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
<us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1 contextRef="Context_Custom_01_Mar_2017T00_00_00_TO_27_Mar_2017T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="shares" decimals="INF">98000</us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1>
<us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1 contextRef="Context_Custom_01_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="shares" decimals="INF">304348</us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1>
<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="Context_Custom_01_Mar_2017T00_00_00_TO_27_Mar_2017T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="shares" decimals="INF">4000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
<immd:WarrantsToPurchaseOfCommonStock contextRef="Context_Custom_01_Mar_2017T00_00_00_TO_27_Mar_2017T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="shares" decimals="INF">2000000</immd:WarrantsToPurchaseOfCommonStock>
<us-gaap:SaleOfStockPricePerShare contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="USD_per_Share" decimals="2">0.23</us-gaap:SaleOfStockPricePerShare>
<us-gaap:CommonStockSharesSubscribedButUnissued contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="shares" decimals="INF">2673656</us-gaap:CommonStockSharesSubscribedButUnissued>
<us-gaap:CommonStockSharesSubscribedButUnissued contextRef="Context_As_Of_24_Apr_2017T00_00_00_TO_24_Apr_2017T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="shares" decimals="INF">217390</us-gaap:CommonStockSharesSubscribedButUnissued>
<us-gaap:CommonStockSharesSubscriptions contextRef="Context_As_Of_31_Mar_2017T00_00_00_TO_31_Mar_2017T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="USD" decimals="0">614940</us-gaap:CommonStockSharesSubscriptions>
<us-gaap:ContractualObligation contextRef="Context_As_Of_24_Apr_2017T00_00_00_TO_24_Apr_2017T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="USD" decimals="0">50000</us-gaap:ContractualObligation>
<us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">30000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
<immd:VariableInterestEntitiesPolicyTextBlock contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00">&lt;div&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Variable Interest Entities&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company follows ASC 810-10-15 guidance with respect to accounting for variable interest entities (each, a &amp;#8220;VIE&amp;#8221;). These entities do not have sufficient equity at risk to finance their activities without additional subordinated financial support from other parties or whose equity investors lack any of the characteristics of a controlling financial interest. A variable interest is an investment or other interest that will absorb portions of a VIE&amp;#8217;s expected losses or receive portions of its expected residual returns and are contractual, ownership, or pecuniary in nature and that change with changes in the fair value of the entity&amp;#8217;s net assets. A reporting entity is the primary beneficiary of a VIE and must consolidate it when that party has a variable interest, or combination of variable interests, that provides it with a controlling financial interest. A party is deemed to have a controlling financial interest if it meets both of the power and losses/benefits criteria. The power criterion is the ability to direct the activities of the VIE that most significantly impact its economic performance. The losses/benefits criterion is the obligation to absorb losses from, or right to receive benefits from, the VIE that could potentially be significant to the VIE. The VIE model requires an ongoing reconsideration of whether a reporting entity is the primary beneficiary of a VIE due to changes in facts and circumstances.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;As of December 31, 2016 and 2015, the Company consolidated nine and zero VIEs, respectively.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Immudyne PR as the primary beneficiary of Ace Account Management LLC, Innerwell Skincare LLC, MCD Merchants LLC, One Equity Research LLC, Inate Gems LLC, Retriever Health Products LLC, Spurs 5, LLC, Salus LLC and Huntley LLC which are qualified as VIEs. The assets and liabilities and revenues and expenses of these VIEs included in the financial statements of Immudyne PR and further included in the consolidated financial statements. As of December 31, 2016, the VIEs had assets of $10,306, liabilities of $5,748, revenues of $6,271, and operating expenses of $6,141. The assets and liabilities include balances due from and due to the subsidiaries of Immudyne PR. These inter-company receivables and payables are eliminated upon consolidation of the VIE with Immudyne PR and Immudyne. No assets were pledged or given as collateral against any borrowings.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company utilizes third party entities to provide and increase credit card processing capacity and optimize corresponding rates and fees. A majority of these entities provide this service as independent contractors in exchange for a one (1%) percent fee of the net revenues processed and collected by such contractors from sales initiated by the Company. The VIEs consolidated in the Company&amp;#8217;s financial statements are primarily contracted to credit card processing through one or more merchant banks contracted by each VIE. Upon receipt of funds by each VIE, the collection of receipts less any returns, chargeback and other fees charged by such merchant bank is transferred to Immudyne PR.&lt;/p&gt;
&lt;/div&gt;</immd:VariableInterestEntitiesPolicyTextBlock>
<immd:SequencingPolicyPolicyTextBlock contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00">&lt;div&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Sequencing Policy&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Under ASC 815-40-35, the Company has adopted a sequencing policy whereby, in the event that reclassification of contracts from equity to assets or liabilities is necessary pursuant to ASC 815 due to the Company&amp;#8217;s inability to demonstrate it has sufficient authorized shares, shares will be allocated on the basis of the earliest issuance date of potentially dilutive instruments, with the earliest grants receiving the first allocation of authorized but unissued shares, and all future instruments being classified as a derivative liability, with the exception of instruments related to share-based compensation issued to employees or directors.&amp;#160;&lt;/p&gt;
&lt;/div&gt;</immd:SequencingPolicyPolicyTextBlock>
<us-gaap:DerivativesPolicyTextBlock contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00">&lt;div&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;b&gt;&lt;i&gt;Derivative Liabilities&lt;/i&gt;&lt;/b&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company evaluates stock options, stock warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for under the relevant sections of Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) Accounting Standards Codification (&amp;#8220;ASC&amp;#8221;) Topic 815-40, Derivative Instruments and Hedging: Contracts in Entity&amp;#8217;s Own Equity. The result of this accounting treatment could be that the fair value of a financial instrument is classified as a derivative instrument and is marked-to-market at each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the consolidated statements of operations as other income or other expense. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Financial instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815-40 are reclassified to a liability account at the fair value of the instrument on the reclassification date.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;As of December 31, 2016, certain of the Company&amp;#8217;s stock options, stock warrants and convertible debt instruments were accounted for as derivative liabilities due to insufficient authorized shares of common stock to settle outstanding contracts. At December 31, 2016, the Company estimated the fair value of these stock options, stock warrants and embedded conversion features using the Black-Scholes option pricing model (&amp;#8220;Black-Scholes&amp;#8221;) in the amount of $192,254 was recorded upon issue&amp;#160;&lt;/p&gt;
&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
<immd:ReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" xsi:nil="true"/>
<immd:ReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="0">192254</immd:ReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities>
<immd:AnnualIncentiveBonusAwardPercentage contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_LegalEntityAxis_ImmudynePrLlcMember" unitRef="pure" decimals="3">0.005</immd:AnnualIncentiveBonusAwardPercentage>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="shares" decimals="INF">30810000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="shares" decimals="INF">33478229</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="shares" decimals="INF">30810000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="shares" decimals="INF">33478229</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>

<!-- Footnote Section -->
<link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>immd-20161231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<schema targetNamespace="http://www.immudyne.com/20161231" elementFormDefault="qualified"
xmlns:immd="http://www.immudyne.com/20161231"
 xmlns="http://www.w3.org/2001/XMLSchema"
 xmlns:link="http://www.xbrl.org/2003/linkbase"
 xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
 xmlns:xl="http://www.xbrl.org/2003/XLink"
 xmlns:xbrli="http://www.xbrl.org/2003/instance"
 xmlns:xlink="http://www.w3.org/1999/xlink"
 xmlns:negated="http://www.xbrl.org/2009/role/negated"
 xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31"
 xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes"
 xmlns:country="http://xbrl.sec.gov/country/2016-01-31"
 xmlns:currency="http://xbrl.sec.gov/currency/2016-01-31"
 xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31"
 xmlns:exch="http://xbrl.sec.gov/exch/2016-01-31"
 xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31"
 xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31"
 xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31"
 xmlns:us-types="http://fasb.org/us-types/2016-01-31"
 xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31"
 xmlns:ref="http://www.xbrl.org/2006/ref"
 xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact"
 xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
 xmlns:num="http://www.xbrl.org/dtr/type/numeric"
>
<annotation><appinfo>
<link:roleType roleURI="http://www.immudyne.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
<link:definition>001 - Document - Document and Entity Information</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/Consolidatedbalancesheets" id="Consolidatedbalancesheets">
<link:definition>002 - Statement - Consolidated Balance Sheets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
<link:definition>003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/ConsolidatedStatementsOfOperations" id="ConsolidatedStatementsOfOperations">
<link:definition>004 - Statement - Consolidated Statements of Operations</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/ConsolidatedStatementOfStockholdersEquityDeficit" id="ConsolidatedStatementOfStockholdersEquityDeficit">
<link:definition>005 - Statement - Consolidated Statement of Stockholders' Equity (Deficit)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
<link:definition>006 - Statement - Consolidated Statements of Cash Flows</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/OrganizationAndGoingConcern" id="OrganizationAndGoingConcern">
<link:definition>007 - Disclosure - Organization and Going Concern</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
<link:definition>008 - Disclosure - Summary of Significant Accounting Policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/FurnishingsAndEquipment" id="FurnishingsAndEquipment">
<link:definition>009 - Disclosure - Furnishings and Equipment</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/InvestmentInAdiuvoInvestmentS" id="InvestmentInAdiuvoInvestmentS">
<link:definition>010 - Disclosure - Investment in Adiuvo Investment S.A.</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/NotesPayable" id="NotesPayable">
<link:definition>011 - Disclosure - Notes Payable</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/IncomeTaxes" id="IncomeTaxes">
<link:definition>012 - Disclosure - Income Taxes</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/StockholdersEquity" id="StockholdersEquity">
<link:definition>013 - Disclosure - Stockholders' Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/Royalties" id="Royalties">
<link:definition>014 - Disclosure - Royalties</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
<link:definition>015 - Disclosure - Commitments and Contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
<link:definition>016 - Disclosure - Related Party Transactions</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/SubsequentEvents" id="SubsequentEvents">
<link:definition>017 - Disclosure - Subsequent Events</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
<link:definition>018 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
<link:definition>019 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/FurnishingsandEquipmentTables" id="FurnishingsandEquipmentTables">
<link:definition>020 - Disclosure - Furnishings and Equipment (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/NotesPayableTables" id="NotesPayableTables">
<link:definition>021 - Disclosure - Notes Payable (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
<link:definition>022 - Disclosure - Income Taxes (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
<link:definition>023 - Disclosure - Stockholders' Equity (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/OrganizationAndGoingConcernDetails" id="OrganizationAndGoingConcernDetails">
<link:definition>024 - Disclosure - Organization and Going Concern (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/SummaryOfSignificantAccountingPoliciesDetails" id="SummaryOfSignificantAccountingPoliciesDetails">
<link:definition>025 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/SummaryOfSignificantAccountingPoliciesDetails1" id="SummaryOfSignificantAccountingPoliciesDetails1">
<link:definition>026 - Disclosure - Summary of Significant Accounting Policies (Details 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/Summaryofsignificantaccountingpoliciesdetailstextual" id="Summaryofsignificantaccountingpoliciesdetailstextual">
<link:definition>027 - Disclosure - Summary of Significant Accounting Policies (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/FurnishingsandEquipmentDetails" id="FurnishingsandEquipmentDetails">
<link:definition>028 - Disclosure - Furnishings and Equipment (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/FurnishingsAndEquipmentDetailsTextual" id="FurnishingsAndEquipmentDetailsTextual">
<link:definition>029 - Disclosure - Furnishings and Equipment (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/InvestmentinAdiuvoInvestmentSADetails" id="InvestmentinAdiuvoInvestmentSADetails">
<link:definition>030 - Disclosure - Investment in Adiuvo Investment S.A. (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/NotesPayableDetails" id="NotesPayableDetails">
<link:definition>031 - Disclosure - Notes Payable (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/NotesPayableDetailsTextual" id="NotesPayableDetailsTextual">
<link:definition>032 - Disclosure - Notes Payable (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
<link:definition>033 - Disclosure - Income Taxes (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/IncomeTaxesDetailsTextual" id="IncomeTaxesDetailsTextual">
<link:definition>034 - Disclosure - Income Taxes (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/StockholdersEquityDetails" id="StockholdersEquityDetails">
<link:definition>035 - Disclosure - Stockholders' Equity (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/StockholdersEquityDetails1" id="StockholdersEquityDetails1">
<link:definition>036 - Disclosure - Stockholders' Equity (Details 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/StockholdersEquityDetails2" id="StockholdersEquityDetails2">
<link:definition>037 - Disclosure - Stockholders' Equity (Details 2)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/StockholdersEquityDetails4" id="StockholdersEquityDetails4">
<link:definition>038 - Disclosure - Stockholders' Equity (Details 3)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/StockholdersEquityDetails5" id="StockholdersEquityDetails5">
<link:definition>039 - Disclosure - Stockholders' Equity (Details 4)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/StockholdersEquityDetailsTextual" id="StockholdersEquityDetailsTextual">
<link:definition>040 - Disclosure - Stockholders' Equity (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/StockholdersEquityDetailsTextual1" id="StockholdersEquityDetailsTextual1">
<link:definition>041 - Disclosure - Stockholders' Equity (Details Textual 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/StockholdersEquityDetailsTextual2" id="StockholdersEquityDetailsTextual2">
<link:definition>042 - Disclosure - Stockholders' Equity (Details Textual 2)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/StockholdersEquityDetailsTextual3" id="StockholdersEquityDetailsTextual3">
<link:definition>043 - Disclosure - Stockholders' Equity (Details Textual 3)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/RoyaltiesDetails" id="RoyaltiesDetails">
<link:definition>044 - Disclosure - Royalties (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
<link:definition>045 - Disclosure - Commitments and Contingencies (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/RelatedPartyTransactionsDetails" id="RelatedPartyTransactionsDetails">
<link:definition>046 - Disclosure - Related Party Transactions (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immudyne.com/role/Subsequenteventsdetails" id="Subsequenteventsdetails">
<link:definition>047 - Disclosure - Subsequent Events (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="immd-20161231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="immd-20161231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="immd-20161231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="immd-20161231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
</appinfo></annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<import namespace="http://fasb.org/us-gaap/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/country/2016-01-31" schemaLocation="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/currency/2016-01-31" schemaLocation="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/exch/2016-01-31" schemaLocation="http://xbrl.sec.gov/exch/2016/exch-2016-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd"/>
<import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd"/>
<import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
<import namespace="http://fasb.org/us-types/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-types-2016-01-31.xsd"/>
<element name="DocumentAndEntityInformationAbstract" id="immd_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="Equity" id="immd_Equity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="CompensationAndRelatedExpenses" id="immd_CompensationAndRelatedExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="SummationMember" id="immd_SummationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="AdjustmentsOfAdditionPaidInCapitalAmortizationOfStockOptions" id="immd_AdjustmentsOfAdditionPaidInCapitalAmortizationOfStockOptions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="Adjustmentstoadditionalpaidincapitalsharebasedcompensationextensionstockoptionswarrantexpirationdates" id="immd_Adjustmentstoadditionalpaidincapitalsharebasedcompensationextensionstockoptionswarrantexpirationdates" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities" id="immd_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="IssuanceOfCommonStockAndWarrants" id="immd_IssuanceOfCommonStockAndWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="IssuanceOfCommonStockInRelationToDebtOffering" id="immd_IssuanceOfCommonStockInRelationToDebtOffering" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities" id="immd_ReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ConversionOfEquityInvestedInSubsidiaryToCommonStockAndWarrants" id="immd_ConversionOfEquityInvestedInSubsidiaryToCommonStockAndWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="RoyaltiesAbstract" id="immd_RoyaltiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="RoyaltiesDisclosureTextBlock" id="immd_RoyaltiesDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="VariableInterestEntitiesPolicyTextBlock" id="immd_VariableInterestEntitiesPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="SequencingPolicyPolicyTextBlock" id="immd_SequencingPolicyPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="MinorityInterestPolicyTextBlock" id="immd_MinorityInterestPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ImmudynePrLlcMember" id="immd_ImmudynePrLlcMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="OrganizationAndGoingConcernTextualAbstract" id="immd_OrganizationAndGoingConcernTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="NutraceuticalAndCosmeticMember" id="immd_NutraceuticalAndCosmeticMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="CosmeticGoodsMember" id="immd_CosmeticGoodsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="OtherUnallocatedAmountsAbstract" id="immd_OtherUnallocatedAmountsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="CorporateExpenses" id="immd_CorporateExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ConcentrationRiskNumberOfCustomersAxis" id="immd_ConcentrationRiskNumberOfCustomersAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" />
<element name="ConcentrationRiskNumberOfCustomersDomain" id="immd_ConcentrationRiskNumberOfCustomersDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="OneCustomerMember" id="immd_OneCustomerMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="SecondCustomerMember" id="immd_SecondCustomerMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="OneCreditCardProcessorsMember" id="immd_OneCreditCardProcessorsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="TwoCreditCardProcessorsMember" id="immd_TwoCreditCardProcessorsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="SummaryOfSignificantAccountingPoliciesTextualAbstract" id="immd_SummaryOfSignificantAccountingPoliciesTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="MinorityInterestRate" id="immd_MinorityInterestRate" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="NonControllingInterestDescription" id="immd_NonControllingInterestDescription" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="FurnishingsAndEquipmentTextualAbstract" id="immd_FurnishingsAndEquipmentTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="InvestmentInAdiuvoInvestmentTextualAbstract" id="immd_InvestmentInAdiuvoInvestmentTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="OptionsPurchasedAmountPaid" id="immd_OptionsPurchasedAmountPaid" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="NotesPayableAndAdvancesPayableTable" id="immd_NotesPayableAndAdvancesPayableTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" />
<element name="CommercialLenderMember" id="immd_CommercialLenderMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="NotesPayableAndAdvancesPayableLineItems" id="immd_NotesPayableAndAdvancesPayableLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="CommercialPaperOneMember" id="immd_CommercialPaperOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="CommercialPaperTwoMember" id="immd_CommercialPaperTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="NotesPayableTextualAbstract" id="immd_NotesPayableTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="TermOfWarrant" id="immd_TermOfWarrant" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="IncomeTaxesTextualAbstract" id="immd_IncomeTaxesTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairvalueAssumptionsForfeitureRate" id="immd_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairvalueAssumptionsForfeitureRate" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ExercisePriceRangeOneMember" id="immd_ExercisePriceRangeOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ExercisePriceRangeTwoMember" id="immd_ExercisePriceRangeTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ExercisePriceRangeThreeMember" id="immd_ExercisePriceRangeThreeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentBeinningYearOfExpiration" id="immd_ShareBasedCompensationArrangementByShareBasedPaymentBeinningYearOfExpiration" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationIssued" id="immd_ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationIssued" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationExpired" id="immd_ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationExpired" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentEndingYearOfExpiration" id="immd_ShareBasedCompensationArrangementByShareBasedPaymentEndingYearOfExpiration" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ShareholderMember" id="immd_ShareholderMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ConsultantMember" id="immd_ConsultantMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="StockholdersEquityTextualAbstract" id="immd_StockholdersEquityTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PurchaseOfCommonStockDescriptionOfTransaction" id="immd_PurchaseOfCommonStockDescriptionOfTransaction" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="NumberOfConsultant" id="immd_NumberOfConsultant" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PerformanceBasedStockOptionsMember" id="immd_PerformanceBasedStockOptionsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="FairValueOfPerformanceBasedStockOptions" id="immd_FairValueOfPerformanceBasedStockOptions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="AnnualSalesRevenueTarget" id="immd_AnnualSalesRevenueTarget" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableFairValue" id="immd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ConsultingServicesMember" id="immd_ConsultingServicesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="IssuanceOfCommonStockMember" id="immd_IssuanceOfCommonStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="WarrantExercisable" id="immd_WarrantExercisable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" />
<element name="WarrantsExpireDateDescription" id="immd_WarrantsExpireDateDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="RoyaltiesTextualAbstract" id="immd_RoyaltiesTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PercentageOfRoyaltyBasedUponSales" id="immd_PercentageOfRoyaltyBasedUponSales" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="RoyaltyBasedUponSalesAmount" id="immd_RoyaltyBasedUponSalesAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="InterestInRoyalty" id="immd_InterestInRoyalty" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="CommitmentsAndContingenciesTable" id="immd_CommitmentsAndContingenciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" />
<element name="RestrictedStockOneMember" id="immd_RestrictedStockOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="RestrictedStockTwoMember" id="immd_RestrictedStockTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="RestrictedStockThreeMember" id="immd_RestrictedStockThreeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="CommitmentsAndContingenciesLineItems" id="immd_CommitmentsAndContingenciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="CommitmentsAndContingenciesTextualAbstract" id="immd_CommitmentsAndContingenciesTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="StockIssuedDuringPeriodPerformanceBasedOptionsToPurchaseCommonStock" id="immd_StockIssuedDuringPeriodPerformanceBasedOptionsToPurchaseCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" />
<element name="SalesRevenueIncreased" id="immd_SalesRevenueIncreased" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="BonusPercentageOfCompensationForPretaxIncome" id="immd_BonusPercentageOfCompensationForPretaxIncome" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PertaxIncomePercentage" id="immd_PertaxIncomePercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="DebtLongTermAndShortTermCombinedAmountShares" id="immd_DebtLongTermAndShortTermCombinedAmountShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="BonusShares" id="immd_BonusShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="OptionToBuyShares" id="immd_OptionToBuyShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="NumerOfThresholds" id="immd_NumerOfThresholds" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" />
<element name="RelatedPartyTransactionsTextualAbstract" id="immd_RelatedPartyTransactionsTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="CompensationForLegalServices" id="immd_CompensationForLegalServices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ReimbursementOfHomeOfficeExpenditures" id="immd_ReimbursementOfHomeOfficeExpenditures" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="AnnualIncentiveBonusAwardPercentage" id="immd_AnnualIncentiveBonusAwardPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="SubsequentEventsTextualAbstract" id="immd_SubsequentEventsTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="CommonStockSharesIssuedRelatedPromissoryNote" id="immd_CommonStockSharesIssuedRelatedPromissoryNote" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="WarrantsToPurchaseOfCommonStock" id="immd_WarrantsToPurchaseOfCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>immd-20161231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#Consolidatedbalancesheets" roleURI="http://www.immudyne.com/role/Consolidatedbalancesheets"/>
<calculationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/Consolidatedbalancesheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_InventoryNet" order="40" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/Consolidatedbalancesheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_ConvertibleNotesPayableCurrent" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_NotesPayableCurrent" order="40" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/Consolidatedbalancesheets">
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_Equity" xlink:label="loc_immd_Equity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_immd_Equity" xlink:to="loc_us-gaap_CommonStockValue" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_immd_Equity" xlink:to="loc_us-gaap_AdditionalPaidInCapital" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_immd_Equity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" order="30" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/Consolidatedbalancesheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_Equity" xlink:label="loc_immd_Equity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_immd_Equity" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_TreasuryStockValue" order="20" use="optional" weight="-1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/Consolidatedbalancesheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaap_StockholdersEquity" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaap_MinorityInterest" order="20" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/Consolidatedbalancesheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_LiabilitiesCurrent" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="20" use="optional" weight="1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#ConsolidatedStatementsOfOperations" roleURI="http://www.immudyne.com/role/ConsolidatedStatementsOfOperations"/>
<calculationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/ConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit" xlink:to="loc_us-gaap_Revenues" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit" xlink:to="loc_us-gaap_CostOfRevenue" order="20" use="optional" weight="-1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/ConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_CompensationAndRelatedExpenses" xlink:label="loc_immd_CompensationAndRelatedExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_immd_CompensationAndRelatedExpenses" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ProfessionalFees" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MarketingExpense" xlink:label="loc_us-gaap_MarketingExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_MarketingExpense" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" order="50" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/ConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_GrossProfit" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OperatingExpenses" order="20" use="optional" weight="-1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/ConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_OperatingIncomeLoss" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainOnSaleOfInvestments" xlink:label="loc_us-gaap_GainOnSaleOfInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_GainOnSaleOfInvestments" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_InterestExpense" order="30" use="optional" weight="-1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/ConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" order="20" use="optional" weight="-1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/ConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_ProfitLoss" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="20" use="optional" weight="-1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.immudyne.com/role/ConsolidatedStatementsOfCashFlows"/>
<calculationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ProfitLoss" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_Depreciation" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" order="50" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" order="60" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="70" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments" order="80" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" order="90" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables" order="100" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories" order="110" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" order="120" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:label="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInNotesPayableCurrent" xlink:label="loc_us-gaap_IncreaseDecreaseInNotesPayableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInNotesPayableCurrent" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable" order="40" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised" order="50" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_IssuanceOfCommonStockAndWarrants" xlink:label="loc_immd_IssuanceOfCommonStockAndWarrants" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_immd_IssuanceOfCommonStockAndWarrants" order="60" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" order="70" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="loc_us-gaap_PaymentsForProceedsFromInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_PaymentsForProceedsFromInvestments" order="20" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" order="30" use="optional" weight="1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#SummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.immudyne.com/role/SummaryOfSignificantAccountingPoliciesDetails"/>
<calculationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/SummaryOfSignificantAccountingPoliciesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaap_InventoryRawMaterials" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="loc_us-gaap_InventoryRawMaterials" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="loc_us-gaap_InventoryFinishedGoods" order="20" use="optional" weight="1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#FurnishingsandEquipmentDetails" roleURI="http://www.immudyne.com/role/FurnishingsandEquipmentDetails"/>
<calculationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/FurnishingsandEquipmentDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="20" use="optional" weight="-1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#IncomeTaxesDetails" roleURI="http://www.immudyne.com/role/IncomeTaxesDetails"/>
<calculationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/IncomeTaxesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaap_DeferredTaxAssetsGross" order="50" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance" order="60" use="optional" weight="-1"/>
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>immd-20161231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" >
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#ConsolidatedStatementOfStockholdersEquityDeficit" roleURI="http://www.immudyne.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#StockholdersEquityTables" roleURI="http://www.immudyne.com/role/StockholdersEquityTables"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#OrganizationAndGoingConcernDetails" roleURI="http://www.immudyne.com/role/OrganizationAndGoingConcernDetails"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#SummaryOfSignificantAccountingPoliciesDetails1" roleURI="http://www.immudyne.com/role/SummaryOfSignificantAccountingPoliciesDetails1"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#Summaryofsignificantaccountingpoliciesdetailstextual" roleURI="http://www.immudyne.com/role/Summaryofsignificantaccountingpoliciesdetailstextual"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#NotesPayableDetails" roleURI="http://www.immudyne.com/role/NotesPayableDetails"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#NotesPayableDetailsTextual" roleURI="http://www.immudyne.com/role/NotesPayableDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#StockholdersEquityDetails" roleURI="http://www.immudyne.com/role/StockholdersEquityDetails"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#StockholdersEquityDetails1" roleURI="http://www.immudyne.com/role/StockholdersEquityDetails1"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#StockholdersEquityDetails2" roleURI="http://www.immudyne.com/role/StockholdersEquityDetails2"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#StockholdersEquityDetails4" roleURI="http://www.immudyne.com/role/StockholdersEquityDetails4"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#StockholdersEquityDetails5" roleURI="http://www.immudyne.com/role/StockholdersEquityDetails5"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#StockholdersEquityDetailsTextual" roleURI="http://www.immudyne.com/role/StockholdersEquityDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#StockholdersEquityDetailsTextual1" roleURI="http://www.immudyne.com/role/StockholdersEquityDetailsTextual1"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#StockholdersEquityDetailsTextual2" roleURI="http://www.immudyne.com/role/StockholdersEquityDetailsTextual2"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#StockholdersEquityDetailsTextual3" roleURI="http://www.immudyne.com/role/StockholdersEquityDetailsTextual3"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#RoyaltiesDetails" roleURI="http://www.immudyne.com/role/RoyaltiesDetails"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#CommitmentsAndContingenciesDetails" roleURI="http://www.immudyne.com/role/CommitmentsAndContingenciesDetails"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#RelatedPartyTransactionsDetails" roleURI="http://www.immudyne.com/role/RelatedPartyTransactionsDetails"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#Subsequenteventsdetails" roleURI="http://www.immudyne.com/role/Subsequenteventsdetails"/>
<definitionLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/ConsolidatedStatementOfStockholdersEquityDeficit">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_CommonStockMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_RetainedEarningsMember_6" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_TreasuryStockMember_7" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_SummationMember" xlink:label="loc_immd_SummationMember_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_immd_SummationMember_8" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_NoncontrollingInterestMember_9" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_10" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_SharesOutstanding_11" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_AdjustmentsOfAdditionPaidInCapitalAmortizationOfStockOptions" xlink:label="loc_immd_AdjustmentsOfAdditionPaidInCapitalAmortizationOfStockOptions_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_immd_AdjustmentsOfAdditionPaidInCapitalAmortizationOfStockOptions_12" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_13" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_14" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_15" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_16" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_17" order="80" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_18" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_18" order="90" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_19" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_19" order="100" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_20" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_20" order="110" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_Adjustmentstoadditionalpaidincapitalsharebasedcompensationextensionstockoptionswarrantexpirationdates" xlink:label="loc_immd_Adjustmentstoadditionalpaidincapitalsharebasedcompensationextensionstockoptionswarrantexpirationdates_21" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_immd_Adjustmentstoadditionalpaidincapitalsharebasedcompensationextensionstockoptionswarrantexpirationdates_21" order="120" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_22" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_22" order="130" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_23" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_23" order="140" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_24" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_24" order="150" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_25" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_25" order="160" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_26" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_26" order="170" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_27" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_27" order="180" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_28" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_28" order="190" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_29" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_29" order="200" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_30" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_30" order="210" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:label="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_31" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_31" order="220" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_32" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_32" order="230" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_33" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_33" order="240" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_34" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_34" order="250" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities" xlink:label="loc_immd_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities_35" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_immd_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities_35" order="260" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_36" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ProfitLoss_36" order="270" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/StockholdersEquityTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5" xlink:to="loc_us-gaap_EquityComponentDomain_6" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_6_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5" xlink:to="loc_us-gaap_EquityComponentDomain_6_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6" xlink:to="loc_us-gaap_WarrantMember_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_9" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_10" order="30" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/OrganizationAndGoingConcernDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ImmudynePrLlcMember" xlink:label="loc_immd_ImmudynePrLlcMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_immd_ImmudynePrLlcMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5" xlink:to="loc_us-gaap_EquityComponentDomain_6" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_6_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5" xlink:to="loc_us-gaap_EquityComponentDomain_6_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_OrganizationAndGoingConcernTextualAbstract" xlink:label="loc_immd_OrganizationAndGoingConcernTextualAbstract_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_immd_OrganizationAndGoingConcernTextualAbstract_8" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_OrganizationAndGoingConcernTextualAbstract_8" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_9" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_OrganizationAndGoingConcernTextualAbstract_8" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_10" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_OrganizationAndGoingConcernTextualAbstract_8" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_11" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:label="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_OrganizationAndGoingConcernTextualAbstract_8" xlink:to="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_12" order="30" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/SummaryOfSignificantAccountingPoliciesDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_0" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationItemsAxis" xlink:label="loc_us-gaap_ConsolidationItemsAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_1" xlink:to="loc_us-gaap_ConsolidationItemsAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationItemsDomain" xlink:label="loc_us-gaap_ConsolidationItemsDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConsolidationItemsAxis_2" xlink:to="loc_us-gaap_ConsolidationItemsDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationItemsDomain" xlink:label="loc_us-gaap_ConsolidationItemsDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConsolidationItemsAxis_2" xlink:to="loc_us-gaap_ConsolidationItemsDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_NutraceuticalAndCosmeticMember" xlink:label="loc_immd_NutraceuticalAndCosmeticMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationItemsDomain_3" xlink:to="loc_immd_NutraceuticalAndCosmeticMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_CosmeticGoodsMember" xlink:label="loc_immd_CosmeticGoodsMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationItemsDomain_3" xlink:to="loc_immd_CosmeticGoodsMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntersegmentEliminationMember" xlink:label="loc_us-gaap_IntersegmentEliminationMember_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationItemsDomain_3" xlink:to="loc_us-gaap_IntersegmentEliminationMember_6" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_0" xlink:to="loc_us-gaap_Assets_7" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_0" xlink:to="loc_us-gaap_Revenues_8" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_0" xlink:to="loc_us-gaap_ProfitLoss_9" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_OtherUnallocatedAmountsAbstract" xlink:label="loc_immd_OtherUnallocatedAmountsAbstract_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_0" xlink:to="loc_immd_OtherUnallocatedAmountsAbstract_10" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_CorporateExpenses" xlink:label="loc_immd_CorporateExpenses_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_OtherUnallocatedAmountsAbstract_10" xlink:to="loc_immd_CorporateExpenses_11" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_OtherUnallocatedAmountsAbstract_10" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_12" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_OtherUnallocatedAmountsAbstract_10" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_13" order="20" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/Summaryofsignificantaccountingpoliciesdetailstextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTable" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityLineItems_0" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTable_1" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_2" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_2" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5" xlink:to="loc_us-gaap_EquityComponentDomain_6" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_6_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5" xlink:to="loc_us-gaap_EquityComponentDomain_6_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6" xlink:to="loc_us-gaap_WarrantMember_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTable_1" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_us-gaap_SalesMember_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9" xlink:to="loc_us-gaap_SalesMember_10" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9" xlink:to="loc_us-gaap_AccountsReceivableMember_11" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ConcentrationRiskNumberOfCustomersAxis" xlink:label="loc_immd_ConcentrationRiskNumberOfCustomersAxis_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTable_1" xlink:to="loc_immd_ConcentrationRiskNumberOfCustomersAxis_12" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ConcentrationRiskNumberOfCustomersDomain" xlink:label="loc_immd_ConcentrationRiskNumberOfCustomersDomain_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_immd_ConcentrationRiskNumberOfCustomersAxis_12" xlink:to="loc_immd_ConcentrationRiskNumberOfCustomersDomain_13" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ConcentrationRiskNumberOfCustomersDomain" xlink:label="loc_immd_ConcentrationRiskNumberOfCustomersDomain_13_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_immd_ConcentrationRiskNumberOfCustomersAxis_12" xlink:to="loc_immd_ConcentrationRiskNumberOfCustomersDomain_13_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_OneCustomerMember" xlink:label="loc_immd_OneCustomerMember_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_ConcentrationRiskNumberOfCustomersDomain_13" xlink:to="loc_immd_OneCustomerMember_14" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_SecondCustomerMember" xlink:label="loc_immd_SecondCustomerMember_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_ConcentrationRiskNumberOfCustomersDomain_13" xlink:to="loc_immd_SecondCustomerMember_15" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationItemsAxis" xlink:label="loc_us-gaap_ConsolidationItemsAxis_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTable_1" xlink:to="loc_us-gaap_ConsolidationItemsAxis_16" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationItemsDomain" xlink:label="loc_us-gaap_ConsolidationItemsDomain_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConsolidationItemsAxis_16" xlink:to="loc_us-gaap_ConsolidationItemsDomain_17" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationItemsDomain" xlink:label="loc_us-gaap_ConsolidationItemsDomain_17_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConsolidationItemsAxis_16" xlink:to="loc_us-gaap_ConsolidationItemsDomain_17_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_NutraceuticalAndCosmeticMember" xlink:label="loc_immd_NutraceuticalAndCosmeticMember_18" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationItemsDomain_17" xlink:to="loc_immd_NutraceuticalAndCosmeticMember_18" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_CosmeticGoodsMember" xlink:label="loc_immd_CosmeticGoodsMember_19" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConsolidationItemsDomain_17" xlink:to="loc_immd_CosmeticGoodsMember_19" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis_20" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTable_1" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis_20" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndustryOfCounterpartyDomain" xlink:label="loc_us-gaap_IndustryOfCounterpartyDomain_21" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis_20" xlink:to="loc_us-gaap_IndustryOfCounterpartyDomain_21" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndustryOfCounterpartyDomain" xlink:label="loc_us-gaap_IndustryOfCounterpartyDomain_21_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis_20" xlink:to="loc_us-gaap_IndustryOfCounterpartyDomain_21_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_OneCreditCardProcessorsMember" xlink:label="loc_immd_OneCreditCardProcessorsMember_22" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndustryOfCounterpartyDomain_21" xlink:to="loc_immd_OneCreditCardProcessorsMember_22" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_TwoCreditCardProcessorsMember" xlink:label="loc_immd_TwoCreditCardProcessorsMember_23" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndustryOfCounterpartyDomain_21" xlink:to="loc_immd_TwoCreditCardProcessorsMember_23" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_SummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:label="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_24" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityLineItems_0" xlink:to="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_24" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_MinorityInterestRate" xlink:label="loc_immd_MinorityInterestRate_25" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_24" xlink:to="loc_immd_MinorityInterestRate_25" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryLIFOReserve" xlink:label="loc_us-gaap_InventoryLIFOReserve_26" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_24" xlink:to="loc_us-gaap_InventoryLIFOReserve_26" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesDiscountsReturnsAndAllowancesGoods" xlink:label="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoods_27" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_24" xlink:to="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoods_27" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_28" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_24" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_28" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_29" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_24" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_29" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_30" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_24" xlink:to="loc_us-gaap_Revenues_30" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="loc_us-gaap_AccountsReceivableNet_31" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_24" xlink:to="loc_us-gaap_AccountsReceivableNet_31" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_NonControllingInterestDescription" xlink:label="loc_immd_NonControllingInterestDescription_32" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_24" xlink:to="loc_immd_NonControllingInterestDescription_32" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesReturnsAndAllowancesGoods" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesGoods_33" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_24" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesGoods_33" order="80" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableInterestEntityConsolidatedCarryingAmountAssets" xlink:label="loc_us-gaap_VariableInterestEntityConsolidatedCarryingAmountAssets_34" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_24" xlink:to="loc_us-gaap_VariableInterestEntityConsolidatedCarryingAmountAssets_34" order="90" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableInterestEntityConsolidatedCarryingAmountLiabilities" xlink:label="loc_us-gaap_VariableInterestEntityConsolidatedCarryingAmountLiabilities_35" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_24" xlink:to="loc_us-gaap_VariableInterestEntityConsolidatedCarryingAmountLiabilities_35" order="100" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityRevenues" xlink:label="loc_us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityRevenues_36" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_24" xlink:to="loc_us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityRevenues_36" order="110" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityOperatingIncomeOrLoss" xlink:label="loc_us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityOperatingIncomeOrLoss_37" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_24" xlink:to="loc_us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityOperatingIncomeOrLoss_37" order="120" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableInterestEntityConclusionToConsolidate" xlink:label="loc_us-gaap_VariableInterestEntityConclusionToConsolidate_38" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_24" xlink:to="loc_us-gaap_VariableInterestEntityConclusionToConsolidate_38" order="130" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities" xlink:label="loc_immd_ReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities_39" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_24" xlink:to="loc_immd_ReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities_39" order="140" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/NotesPayableDetails">
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_NotesPayableAndAdvancesPayableLineItems" xlink:label="loc_immd_NotesPayableAndAdvancesPayableLineItems_0" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_NotesPayableAndAdvancesPayableTable" xlink:label="loc_immd_NotesPayableAndAdvancesPayableTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_immd_NotesPayableAndAdvancesPayableLineItems_0" xlink:to="loc_immd_NotesPayableAndAdvancesPayableTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfFinancingReceivableTypeOfBorrowerAxis" xlink:label="loc_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_immd_NotesPayableAndAdvancesPayableTable_1" xlink:to="loc_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfFinancingReceivableTypeOfBorrowerDomain" xlink:label="loc_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerAxis_2" xlink:to="loc_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfFinancingReceivableTypeOfBorrowerDomain" xlink:label="loc_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerAxis_2" xlink:to="loc_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_CommercialLenderMember" xlink:label="loc_immd_CommercialLenderMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerDomain_3" xlink:to="loc_immd_CommercialLenderMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_immd_NotesPayableAndAdvancesPayableTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_5" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_5" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BoardOfDirectorsChairmanMember" xlink:label="loc_us-gaap_BoardOfDirectorsChairmanMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6" xlink:to="loc_us-gaap_BoardOfDirectorsChairmanMember_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_NotesPayableAndAdvancesPayableLineItems_0" xlink:to="loc_us-gaap_NotesPayableCurrent_8" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_NotesPayableAndAdvancesPayableLineItems_0" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_9" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_NotesPayableAndAdvancesPayableLineItems_0" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_10" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_NotesPayableAndAdvancesPayableLineItems_0" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_11" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_NotesPayableAndAdvancesPayableLineItems_0" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_12" order="50" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/NotesPayableDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_2" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_2" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BoardOfDirectorsChairmanMember" xlink:label="loc_us-gaap_BoardOfDirectorsChairmanMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3" xlink:to="loc_us-gaap_BoardOfDirectorsChairmanMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OfficerMember" xlink:label="loc_us-gaap_OfficerMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3" xlink:to="loc_us-gaap_OfficerMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorityShareholderMember" xlink:label="loc_us-gaap_MajorityShareholderMember_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3" xlink:to="loc_us-gaap_MajorityShareholderMember_6" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_7" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_7" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_8" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_8_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_7" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_8_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_8" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_9" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfFinancingReceivableTypeOfBorrowerAxis" xlink:label="loc_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerAxis_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerAxis_10" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfFinancingReceivableTypeOfBorrowerDomain" xlink:label="loc_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerDomain_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerAxis_10" xlink:to="loc_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerDomain_11" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfFinancingReceivableTypeOfBorrowerDomain" xlink:label="loc_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerDomain_11_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerAxis_10" xlink:to="loc_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerDomain_11_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_CommercialLenderMember" xlink:label="loc_immd_CommercialLenderMember_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerDomain_11" xlink:to="loc_immd_CommercialLenderMember_12" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_13" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_13" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_14" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_14_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_13" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_14_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_14" xlink:to="loc_us-gaap_CommercialPaperMember_15" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_CommercialPaperOneMember" xlink:label="loc_immd_CommercialPaperOneMember_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_14" xlink:to="loc_immd_CommercialPaperOneMember_16" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_CommercialPaperTwoMember" xlink:label="loc_immd_CommercialPaperTwoMember_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_14" xlink:to="loc_immd_CommercialPaperTwoMember_17" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_18" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_18" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_19" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_18" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_19" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_19_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_18" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_19_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_20" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_19" xlink:to="loc_us-gaap_SubsequentEventMember_20" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_NotesPayableTextualAbstract" xlink:label="loc_immd_NotesPayableTextualAbstract_21" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_immd_NotesPayableTextualAbstract_21" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaap_ConvertibleNotesPayable_22" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_NotesPayableTextualAbstract_21" xlink:to="loc_us-gaap_ConvertibleNotesPayable_22" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_23" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_NotesPayableTextualAbstract_21" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_23" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_24" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_NotesPayableTextualAbstract_21" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_24" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentPaymentTerms" xlink:label="loc_us-gaap_DebtInstrumentPaymentTerms_25" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_NotesPayableTextualAbstract_21" xlink:to="loc_us-gaap_DebtInstrumentPaymentTerms_25" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_26" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_NotesPayableTextualAbstract_21" xlink:to="loc_us-gaap_InterestExpense_26" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_27" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_NotesPayableTextualAbstract_21" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_27" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_28" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_NotesPayableTextualAbstract_21" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_28" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_29" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_NotesPayableTextualAbstract_21" xlink:to="loc_us-gaap_InterestExpenseDebt_29" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_30" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_NotesPayableTextualAbstract_21" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_30" order="80" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_31" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_NotesPayableTextualAbstract_21" xlink:to="loc_us-gaap_NotesPayable_31" order="90" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_32" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_NotesPayableTextualAbstract_21" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_32" order="100" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_33" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_NotesPayableTextualAbstract_21" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_33" order="110" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_34" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_NotesPayableTextualAbstract_21" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_34" order="120" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_35" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_NotesPayableTextualAbstract_21" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_35" order="130" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_36" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_NotesPayableTextualAbstract_21" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_36" order="140" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesAndLoansPayableCurrent" xlink:label="loc_us-gaap_NotesAndLoansPayableCurrent_37" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_NotesPayableTextualAbstract_21" xlink:to="loc_us-gaap_NotesAndLoansPayableCurrent_37" order="150" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaap_ConvertibleDebt_38" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_NotesPayableTextualAbstract_21" xlink:to="loc_us-gaap_ConvertibleDebt_38" order="160" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_39" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_NotesPayableTextualAbstract_21" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_39" order="170" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentOptionsExercisePrice" xlink:label="loc_invest_InvestmentOptionsExercisePrice_40" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_NotesPayableTextualAbstract_21" xlink:to="loc_invest_InvestmentOptionsExercisePrice_40" order="180" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_TermOfWarrant" xlink:label="loc_immd_TermOfWarrant_41" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_NotesPayableTextualAbstract_21" xlink:to="loc_immd_TermOfWarrant_41" order="190" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/StockholdersEquityDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_7" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_8" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9" order="50" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/StockholdersEquityDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_RangeAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_2" xlink:to="loc_us-gaap_RangeMember_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_2" xlink:to="loc_us-gaap_RangeMember_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_3" xlink:to="loc_us-gaap_MaximumMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_3" xlink:to="loc_us-gaap_MinimumMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_6" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_9" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_10" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_11" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_12" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_13" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_14" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairvalueAssumptionsForfeitureRate" xlink:label="loc_immd_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairvalueAssumptionsForfeitureRate_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_9" xlink:to="loc_immd_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairvalueAssumptionsForfeitureRate_15" order="50" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/StockholdersEquityDetails2">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ExercisePriceRangeOneMember" xlink:label="loc_immd_ExercisePriceRangeOneMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_3" xlink:to="loc_immd_ExercisePriceRangeOneMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ExercisePriceRangeTwoMember" xlink:label="loc_immd_ExercisePriceRangeTwoMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_3" xlink:to="loc_immd_ExercisePriceRangeTwoMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ExercisePriceRangeThreeMember" xlink:label="loc_immd_ExercisePriceRangeThreeMember_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_3" xlink:to="loc_immd_ExercisePriceRangeThreeMember_6" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1" xlink:to="loc_us-gaap_RangeAxis_7" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_7" xlink:to="loc_us-gaap_RangeMember_8" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_8_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_7" xlink:to="loc_us-gaap_RangeMember_8_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_8" xlink:to="loc_us-gaap_MinimumMember_9" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_8" xlink:to="loc_us-gaap_MaximumMember_10" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_11" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_12" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_12_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_12_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_12" xlink:to="loc_us-gaap_EmployeeStockOptionMember_13" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract_14" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_15" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_16" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract_14" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_17" order="20" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/StockholdersEquityDetails4">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_WarrantMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_7" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_9" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_10" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ShareBasedCompensationArrangementByShareBasedPaymentBeinningYearOfExpiration" xlink:label="loc_immd_ShareBasedCompensationArrangementByShareBasedPaymentBeinningYearOfExpiration_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_immd_ShareBasedCompensationArrangementByShareBasedPaymentBeinningYearOfExpiration_11" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationIssued" xlink:label="loc_immd_ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationIssued_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_immd_ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationIssued_12" order="80" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationExpired" xlink:label="loc_immd_ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationExpired_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_immd_ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationExpired_13" order="90" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ShareBasedCompensationArrangementByShareBasedPaymentEndingYearOfExpiration" xlink:label="loc_immd_ShareBasedCompensationArrangementByShareBasedPaymentEndingYearOfExpiration_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_immd_ShareBasedCompensationArrangementByShareBasedPaymentEndingYearOfExpiration_14" order="100" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/StockholdersEquityDetails5">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_WarrantMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_RangeAxis_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_5" xlink:to="loc_us-gaap_RangeMember_6" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_5" xlink:to="loc_us-gaap_RangeMember_6_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MaximumMember_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MinimumMember_8" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_9" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_10" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_11" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_12" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_13" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_14" order="40" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/StockholdersEquityDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:label="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_0" xlink:to="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaap_InvestorMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_us-gaap_InvestorMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ShareholderMember" xlink:label="loc_immd_ShareholderMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_immd_ShareholderMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ConsultantMember" xlink:label="loc_immd_ConsultantMember_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_immd_ConsultantMember_6" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_7" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_7" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_8" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_8_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_7" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_8_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaap_DirectorMember_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_8" xlink:to="loc_us-gaap_DirectorMember_9" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PresidentMember" xlink:label="loc_us-gaap_PresidentMember_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_8" xlink:to="loc_us-gaap_PresidentMember_10" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_11" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_11" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_11" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12" xlink:to="loc_us-gaap_IPOMember_13" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" xlink:to="loc_dei_LegalEntityAxis_14" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_14" xlink:to="loc_dei_EntityDomain_15" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_15_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_14" xlink:to="loc_dei_EntityDomain_15_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ImmudynePrLlcMember" xlink:label="loc_immd_ImmudynePrLlcMember_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_15" xlink:to="loc_immd_ImmudynePrLlcMember_16" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" xlink:to="loc_us-gaap_RangeAxis_17" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_18" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_17" xlink:to="loc_us-gaap_RangeMember_18" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_18_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_17" xlink:to="loc_us-gaap_RangeMember_18_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_19" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_18" xlink:to="loc_us-gaap_MaximumMember_19" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_20" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_18" xlink:to="loc_us-gaap_MinimumMember_20" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_StockholdersEquityTextualAbstract" xlink:label="loc_immd_StockholdersEquityTextualAbstract_21" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_0" xlink:to="loc_immd_StockholdersEquityTextualAbstract_21" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_22" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_21" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_22" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_23" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_21" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_23" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_24" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_21" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_24" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_25" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_21" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_25" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_26" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_21" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_26" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_27" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_21" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_27" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_28" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_21" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_28" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_29" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_21" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_29" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xlink:label="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross_30" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_21" xlink:to="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross_30" order="80" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_31" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_21" xlink:to="loc_us-gaap_NotesPayable_31" order="90" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_32" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_21" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_32" order="100" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentOptionsExercisePrice" xlink:label="loc_invest_InvestmentOptionsExercisePrice_33" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_21" xlink:to="loc_invest_InvestmentOptionsExercisePrice_33" order="110" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_34" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_21" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_34" order="120" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_35" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_21" xlink:to="loc_us-gaap_CommonStockSharesIssued_35" order="130" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_36" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_21" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_36" order="140" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_37" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_21" xlink:to="loc_us-gaap_CommonStockValue_37" order="150" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_38" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_21" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_38" order="160" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_39" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_21" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_39" order="170" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_40" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_21" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_40" order="180" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockOtherSharesOutstanding" xlink:label="loc_us-gaap_CommonStockOtherSharesOutstanding_41" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_21" xlink:to="loc_us-gaap_CommonStockOtherSharesOutstanding_41" order="190" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_PurchaseOfCommonStockDescriptionOfTransaction" xlink:label="loc_immd_PurchaseOfCommonStockDescriptionOfTransaction_42" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_21" xlink:to="loc_immd_PurchaseOfCommonStockDescriptionOfTransaction_42" order="200" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_43" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_21" xlink:to="loc_us-gaap_TreasuryStockValue_43" order="210" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_44" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_21" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_44" order="220" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:label="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_45" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_21" xlink:to="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_45" order="230" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_46" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_21" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_46" order="240" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_47" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_21" xlink:to="loc_us-gaap_ProfitLoss_47" order="250" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/StockholdersEquityDetailsTextual1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:label="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_0" xlink:to="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_2" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_2" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PresidentMember" xlink:label="loc_us-gaap_PresidentMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3" xlink:to="loc_us-gaap_PresidentMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaap_DirectorMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3" xlink:to="loc_us-gaap_DirectorMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_6" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9" xlink:to="loc_us-gaap_RelatedPartyDomain_10" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_10_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9" xlink:to="loc_us-gaap_RelatedPartyDomain_10_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ConsultantMember" xlink:label="loc_immd_ConsultantMember_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_10" xlink:to="loc_immd_ConsultantMember_11" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_StockholdersEquityTextualAbstract" xlink:label="loc_immd_StockholdersEquityTextualAbstract_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_0" xlink:to="loc_immd_StockholdersEquityTextualAbstract_12" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_13" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xlink:label="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_12" xlink:to="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross_14" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_15" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_12" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_16" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_17" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_18" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_18" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_19" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_12" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_19" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_20" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_12" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_20" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_21" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_21" order="80" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_22" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_12" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_22" order="90" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_23" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_12" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_23" order="100" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_24" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_12" xlink:to="loc_us-gaap_ShareBasedCompensation_24" order="110" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_25" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_12" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_25" order="120" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_NumberOfConsultant" xlink:label="loc_immd_NumberOfConsultant_26" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_12" xlink:to="loc_immd_NumberOfConsultant_26" order="130" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_27" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_27" order="140" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_28" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_12" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_28" order="150" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_29" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_29" order="160" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/StockholdersEquityDetailsTextual2">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:label="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_0" xlink:to="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_PerformanceBasedStockOptionsMember" xlink:label="loc_immd_PerformanceBasedStockOptionsMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_immd_PerformanceBasedStockOptionsMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" xlink:to="loc_us-gaap_RangeAxis_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_5" xlink:to="loc_us-gaap_RangeMember_6" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_5" xlink:to="loc_us-gaap_RangeMember_6_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MinimumMember_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MaximumMember_8" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_StockholdersEquityTextualAbstract" xlink:label="loc_immd_StockholdersEquityTextualAbstract_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_0" xlink:to="loc_immd_StockholdersEquityTextualAbstract_9" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_10" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_9" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_11" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationEquity" xlink:label="loc_us-gaap_DeferredCompensationEquity_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_9" xlink:to="loc_us-gaap_DeferredCompensationEquity_12" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_FairValueOfPerformanceBasedStockOptions" xlink:label="loc_immd_FairValueOfPerformanceBasedStockOptions_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_9" xlink:to="loc_immd_FairValueOfPerformanceBasedStockOptions_13" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_14" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_15" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_AnnualSalesRevenueTarget" xlink:label="loc_immd_AnnualSalesRevenueTarget_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_9" xlink:to="loc_immd_AnnualSalesRevenueTarget_16" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableFairValue" xlink:label="loc_immd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableFairValue_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_9" xlink:to="loc_immd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableFairValue_17" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_18" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_18" order="80" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_19" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_19" order="90" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_NumberOfConsultant" xlink:label="loc_immd_NumberOfConsultant_20" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_9" xlink:to="loc_immd_NumberOfConsultant_20" order="100" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/StockholdersEquityDetailsTextual3">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:label="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_0" xlink:to="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_WarrantMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_PerformanceBasedStockOptionsMember" xlink:label="loc_immd_PerformanceBasedStockOptionsMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_immd_PerformanceBasedStockOptionsMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" xlink:to="loc_us-gaap_RangeAxis_6" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_6" xlink:to="loc_us-gaap_RangeMember_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_7_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_6" xlink:to="loc_us-gaap_RangeMember_7_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_7" xlink:to="loc_us-gaap_MinimumMember_8" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_7" xlink:to="loc_us-gaap_MaximumMember_9" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_10" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_10" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_11" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_11_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_10" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_11_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_11" xlink:to="loc_us-gaap_IPOMember_12" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ConsultingServicesMember" xlink:label="loc_immd_ConsultingServicesMember_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_11" xlink:to="loc_immd_ConsultingServicesMember_13" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_IssuanceOfCommonStockMember" xlink:label="loc_immd_IssuanceOfCommonStockMember_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_11" xlink:to="loc_immd_IssuanceOfCommonStockMember_14" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_StockholdersEquityTextualAbstract" xlink:label="loc_immd_StockholdersEquityTextualAbstract_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_0" xlink:to="loc_immd_StockholdersEquityTextualAbstract_15" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_15" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_16" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_15" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_17" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_18" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_15" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_18" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_19" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_19" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_20" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_15" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_20" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_WarrantExercisable" xlink:label="loc_immd_WarrantExercisable_21" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_15" xlink:to="loc_immd_WarrantExercisable_21" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_WarrantsExpireDateDescription" xlink:label="loc_immd_WarrantsExpireDateDescription_22" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_15" xlink:to="loc_immd_WarrantsExpireDateDescription_22" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_23" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_15" xlink:to="loc_us-gaap_ShareBasedCompensation_23" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="loc_us-gaap_LaborAndRelatedExpense_24" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_15" xlink:to="loc_us-gaap_LaborAndRelatedExpense_24" order="80" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_25" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_StockholdersEquityTextualAbstract_15" xlink:to="loc_us-gaap_InterestExpense_25" order="90" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/RoyaltiesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PresidentMember" xlink:label="loc_us-gaap_PresidentMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_us-gaap_PresidentMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_RoyaltiesTextualAbstract" xlink:label="loc_immd_RoyaltiesTextualAbstract_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_immd_RoyaltiesTextualAbstract_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_PercentageOfRoyaltyBasedUponSales" xlink:label="loc_immd_PercentageOfRoyaltyBasedUponSales_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_RoyaltiesTextualAbstract_5" xlink:to="loc_immd_PercentageOfRoyaltyBasedUponSales_6" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_RoyaltyBasedUponSalesAmount" xlink:label="loc_immd_RoyaltyBasedUponSalesAmount_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_RoyaltiesTextualAbstract_5" xlink:to="loc_immd_RoyaltyBasedUponSalesAmount_7" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_RoyaltiesTextualAbstract_5" xlink:to="loc_us-gaap_RoyaltyExpense_8" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_InterestInRoyalty" xlink:label="loc_immd_InterestInRoyalty_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_RoyaltiesTextualAbstract_5" xlink:to="loc_immd_InterestInRoyalty_9" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_RoyaltiesTextualAbstract_5" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_10" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_RoyaltiesTextualAbstract_5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_11" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_RoyaltiesTextualAbstract_5" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_12" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_RoyaltiesTextualAbstract_5" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_13" order="70" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/CommitmentsAndContingenciesDetails">
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_CommitmentsAndContingenciesLineItems" xlink:label="loc_immd_CommitmentsAndContingenciesLineItems_0" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_CommitmentsAndContingenciesTable" xlink:label="loc_immd_CommitmentsAndContingenciesTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_immd_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_immd_CommitmentsAndContingenciesTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_immd_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_RestrictedStockMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_RestrictedStockOneMember" xlink:label="loc_immd_RestrictedStockOneMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_immd_RestrictedStockOneMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_RestrictedStockTwoMember" xlink:label="loc_immd_RestrictedStockTwoMember_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_immd_RestrictedStockTwoMember_6" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_RestrictedStockThreeMember" xlink:label="loc_immd_RestrictedStockThreeMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_immd_RestrictedStockThreeMember_7" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_immd_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8" xlink:to="loc_us-gaap_RelatedPartyDomain_9" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_9_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8" xlink:to="loc_us-gaap_RelatedPartyDomain_9_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ConsultantMember" xlink:label="loc_immd_ConsultantMember_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_9" xlink:to="loc_immd_ConsultantMember_10" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_immd_CommitmentsAndContingenciesTable_1" xlink:to="loc_dei_LegalEntityAxis_11" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_11" xlink:to="loc_dei_EntityDomain_12" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_12_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_11" xlink:to="loc_dei_EntityDomain_12_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ImmudynePrLlcMember" xlink:label="loc_immd_ImmudynePrLlcMember_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_12" xlink:to="loc_immd_ImmudynePrLlcMember_13" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_immd_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_14" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_14" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_15" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_15_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_14" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_15_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PresidentMember" xlink:label="loc_us-gaap_PresidentMember_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_15" xlink:to="loc_us-gaap_PresidentMember_16" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_CommitmentsAndContingenciesTextualAbstract" xlink:label="loc_immd_CommitmentsAndContingenciesTextualAbstract_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_CommitmentsAndContingenciesLineItems_0" xlink:to="loc_immd_CommitmentsAndContingenciesTextualAbstract_17" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1_18" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_17" xlink:to="loc_us-gaap_LeaseExpirationDate1_18" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseMinimumRentals_19" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_17" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseMinimumRentals_19" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_20" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_17" xlink:to="loc_us-gaap_LeaseAndRentalExpense_20" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="loc_us-gaap_SalariesWagesAndOfficersCompensation_21" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_17" xlink:to="loc_us-gaap_SalariesWagesAndOfficersCompensation_21" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_22" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_17" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_22" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_23" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_17" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_23" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_StockIssuedDuringPeriodPerformanceBasedOptionsToPurchaseCommonStock" xlink:label="loc_immd_StockIssuedDuringPeriodPerformanceBasedOptionsToPurchaseCommonStock_24" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_17" xlink:to="loc_immd_StockIssuedDuringPeriodPerformanceBasedOptionsToPurchaseCommonStock_24" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_25" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_17" xlink:to="loc_us-gaap_SalesRevenueNet_25" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_SalesRevenueIncreased" xlink:label="loc_immd_SalesRevenueIncreased_26" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_17" xlink:to="loc_immd_SalesRevenueIncreased_26" order="80" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_BonusPercentageOfCompensationForPretaxIncome" xlink:label="loc_immd_BonusPercentageOfCompensationForPretaxIncome_27" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_17" xlink:to="loc_immd_BonusPercentageOfCompensationForPretaxIncome_27" order="90" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_PertaxIncomePercentage" xlink:label="loc_immd_PertaxIncomePercentage_28" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_17" xlink:to="loc_immd_PertaxIncomePercentage_28" order="100" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_29" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_17" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_29" order="110" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_30" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_17" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_30" order="120" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_31" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_17" xlink:to="loc_us-gaap_SharePrice_31" order="130" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_DebtLongTermAndShortTermCombinedAmountShares" xlink:label="loc_immd_DebtLongTermAndShortTermCombinedAmountShares_32" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_17" xlink:to="loc_immd_DebtLongTermAndShortTermCombinedAmountShares_32" order="140" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaap_RestrictedStockExpense_33" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_17" xlink:to="loc_us-gaap_RestrictedStockExpense_33" order="150" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_34" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_17" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_34" order="160" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_BonusShares" xlink:label="loc_immd_BonusShares_35" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_17" xlink:to="loc_immd_BonusShares_35" order="170" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_OptionToBuyShares" xlink:label="loc_immd_OptionToBuyShares_36" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_17" xlink:to="loc_immd_OptionToBuyShares_36" order="180" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_37" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_17" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_37" order="190" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_38" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_17" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_38" order="200" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_NumerOfThresholds" xlink:label="loc_immd_NumerOfThresholds_39" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_17" xlink:to="loc_immd_NumerOfThresholds_39" order="210" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_40" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_17" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_40" order="220" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/RelatedPartyTransactionsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_2" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_2" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PresidentMember" xlink:label="loc_us-gaap_PresidentMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3" xlink:to="loc_us-gaap_PresidentMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_dei_LegalEntityAxis_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_5" xlink:to="loc_dei_EntityDomain_6" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_6_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_5" xlink:to="loc_dei_EntityDomain_6_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ImmudynePrLlcMember" xlink:label="loc_immd_ImmudynePrLlcMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_6" xlink:to="loc_immd_ImmudynePrLlcMember_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_RelatedPartyTransactionsTextualAbstract" xlink:label="loc_immd_RelatedPartyTransactionsTextualAbstract_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_immd_RelatedPartyTransactionsTextualAbstract_8" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_CompensationForLegalServices" xlink:label="loc_immd_CompensationForLegalServices_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_RelatedPartyTransactionsTextualAbstract_8" xlink:to="loc_immd_CompensationForLegalServices_9" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ReimbursementOfHomeOfficeExpenditures" xlink:label="loc_immd_ReimbursementOfHomeOfficeExpenditures_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_RelatedPartyTransactionsTextualAbstract_8" xlink:to="loc_immd_ReimbursementOfHomeOfficeExpenditures_10" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_RelatedPartyTransactionsTextualAbstract_8" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_11" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_RelatedPartyTransactionsTextualAbstract_8" xlink:to="loc_us-gaap_ProfessionalFees_12" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_AnnualIncentiveBonusAwardPercentage" xlink:label="loc_immd_AnnualIncentiveBonusAwardPercentage_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_RelatedPartyTransactionsTextualAbstract_8" xlink:to="loc_immd_AnnualIncentiveBonusAwardPercentage_13" order="40" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/Subsequenteventsdetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3" xlink:to="loc_us-gaap_SubsequentEventMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_5" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_6" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_6_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_5" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_6_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_6" xlink:to="loc_us-gaap_CommercialPaperMember_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_SubsequentEventsTextualAbstract" xlink:label="loc_immd_SubsequentEventsTextualAbstract_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_immd_SubsequentEventsTextualAbstract_8" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_SubsequentEventsTextualAbstract_8" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_9" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_SubsequentEventsTextualAbstract_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_10" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_SubsequentEventsTextualAbstract_8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_11" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_SubsequentEventsTextualAbstract_8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_12" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_SubsequentEventsTextualAbstract_8" xlink:to="loc_us-gaap_NotesPayable_13" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_SubsequentEventsTextualAbstract_8" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_14" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_SubsequentEventsTextualAbstract_8" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_15" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_SubsequentEventsTextualAbstract_8" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_16" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_SubsequentEventsTextualAbstract_8" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_17" order="80" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_18" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_SubsequentEventsTextualAbstract_8" xlink:to="loc_us-gaap_RepaymentsOfDebt_18" order="90" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_CommonStockSharesIssuedRelatedPromissoryNote" xlink:label="loc_immd_CommonStockSharesIssuedRelatedPromissoryNote_19" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_SubsequentEventsTextualAbstract_8" xlink:to="loc_immd_CommonStockSharesIssuedRelatedPromissoryNote_19" order="100" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_20" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_SubsequentEventsTextualAbstract_8" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_20" order="110" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_21" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_SubsequentEventsTextualAbstract_8" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_21" order="120" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_22" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_SubsequentEventsTextualAbstract_8" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_22" order="130" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_23" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_SubsequentEventsTextualAbstract_8" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_23" order="140" use="optional"  />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_WarrantsToPurchaseOfCommonStock" xlink:label="loc_immd_WarrantsToPurchaseOfCommonStock_24" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_SubsequentEventsTextualAbstract_8" xlink:to="loc_immd_WarrantsToPurchaseOfCommonStock_24" order="150" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_25" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_SubsequentEventsTextualAbstract_8" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_25" order="160" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="loc_us-gaap_CommonStockSharesSubscribedButUnissued_26" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_SubsequentEventsTextualAbstract_8" xlink:to="loc_us-gaap_CommonStockSharesSubscribedButUnissued_26" order="170" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesSubscriptions" xlink:label="loc_us-gaap_CommonStockSharesSubscriptions_27" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_SubsequentEventsTextualAbstract_8" xlink:to="loc_us-gaap_CommonStockSharesSubscriptions_27" order="180" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaap_ContractualObligation_28" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_immd_SubsequentEventsTextualAbstract_8" xlink:to="loc_us-gaap_ContractualObligation_28" order="190" use="optional"  />
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>immd-20161231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_DocumentAndEntityInformationAbstract" xlink:label="loc_K196K48I138K_immd_DocumentAndEntityInformationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_immd_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document and Entity Information [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_immd_DocumentAndEntityInformationAbstract" xlink:to="lab_M318M60K350M_immd_DocumentAndEntityInformationAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_8H6FHF4I49GG985JF602_dei_EntityRegistrantName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_dei_EntityRegistrantName" xlink:to="lab_0J8HJH6K61II107LH824_dei_EntityRegistrantName"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_K196K48I138K_dei_EntityCentralIndexKey" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_dei_EntityCentralIndexKey" xlink:to="lab_M318M60K350M_dei_EntityCentralIndexKey"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_8H6FHF4I49GG985JF602_dei_AmendmentFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_dei_AmendmentFlag" xlink:to="lab_0J8HJH6K61II107LH824_dei_AmendmentFlag"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_K196K48I138K_dei_CurrentFiscalYearEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_dei_CurrentFiscalYearEndDate" xlink:to="lab_M318M60K350M_dei_CurrentFiscalYearEndDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_8H6FHF4I49GG985JF602_dei_DocumentType" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_dei_DocumentType" xlink:to="lab_0J8HJH6K61II107LH824_dei_DocumentType"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_K196K48I138K_dei_DocumentPeriodEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_dei_DocumentPeriodEndDate" xlink:to="lab_M318M60K350M_dei_DocumentPeriodEndDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_8H6FHF4I49GG985JF602_dei_DocumentFiscalYearFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_dei_DocumentFiscalYearFocus" xlink:to="lab_0J8HJH6K61II107LH824_dei_DocumentFiscalYearFocus"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_K196K48I138K_dei_DocumentFiscalPeriodFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_dei_DocumentFiscalPeriodFocus" xlink:to="lab_M318M60K350M_dei_DocumentFiscalPeriodFocus"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_8H6FHF4I49GG985JF602_dei_EntityFilerCategory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_dei_EntityFilerCategory" xlink:to="lab_0J8HJH6K61II107LH824_dei_EntityFilerCategory"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_K196K48I138K_dei_EntityWellKnownSeasonedIssuer" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_dei_EntityWellKnownSeasonedIssuer" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_M318M60K350M_dei_EntityWellKnownSeasonedIssuer"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_8H6FHF4I49GG985JF602_dei_EntityVoluntaryFilers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_dei_EntityVoluntaryFilers" xml:lang="en-US">Entity Voluntary Filers</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_dei_EntityVoluntaryFilers" xlink:to="lab_0J8HJH6K61II107LH824_dei_EntityVoluntaryFilers"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_K196K48I138K_dei_EntityCurrentReportingStatus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_dei_EntityCurrentReportingStatus" xml:lang="en-US">Entity Current Reporting Status</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_dei_EntityCurrentReportingStatus" xlink:to="lab_M318M60K350M_dei_EntityCurrentReportingStatus"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_8H6FHF4I49GG985JF602_dei_EntityPublicFloat" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_dei_EntityPublicFloat" xml:lang="en-US">Entity Public Float</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_dei_EntityPublicFloat" xlink:to="lab_0J8HJH6K61II107LH824_dei_EntityPublicFloat"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_K196K48I138K_dei_EntityCommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_M318M60K350M_dei_EntityCommonStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_StatementOfFinancialPositionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_StatementOfFinancialPositionAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_K196K48I138K_us-gaap_AssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_AssetsAbstract" xml:lang="en-US">ASSETS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_AssetsAbstract" xlink:to="lab_M318M60K350M_us-gaap_AssetsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_AssetsCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_AssetsCurrentAbstract" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_AssetsCurrentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_K196K48I138K_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_M318M60K350M_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash at beginning of the year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_M318M60K350M_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash at end of the year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_M318M60K350M_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_AccountsReceivableNetCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts Receivable, Net, Current, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Trade accounts receivable, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_AccountsReceivableNetCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_K196K48I138K_us-gaap_OtherReceivablesNetCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_OtherReceivablesNetCurrent" xml:lang="en-US">Other Receivables, Net, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_OtherReceivablesNetCurrent" xml:lang="en-US">Other receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_OtherReceivablesNetCurrent" xlink:to="lab_M318M60K350M_us-gaap_OtherReceivablesNetCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_InventoryNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_InventoryNet" xml:lang="en-US">Inventory, Net, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_InventoryNet" xml:lang="en-US">Inventory, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_InventoryNet" xml:lang="en-US">Inventory, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_InventoryNet" xml:lang="en-US">Inventory, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_InventoryNet" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_InventoryNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_K196K48I138K_us-gaap_AssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_M318M60K350M_us-gaap_AssetsCurrent" xml:lang="en-US">Total Current Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_AssetsCurrent" xlink:to="lab_M318M60K350M_us-gaap_AssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_K196K48I138K_us-gaap_LiabilitiesCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_M318M60K350M_us-gaap_LiabilitiesCurrentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US">Accounts payable and accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_K196K48I138K_us-gaap_DerivativeLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_DerivativeLiabilitiesCurrent" xml:lang="en-US">Derivative Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_DerivativeLiabilitiesCurrent" xml:lang="en-US">Derivative liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_DerivativeLiabilitiesCurrent" xlink:to="lab_M318M60K350M_us-gaap_DerivativeLiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_ConvertibleNotesPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ConvertibleNotesPayableCurrent" xml:lang="en-US">Convertible Notes Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ConvertibleNotesPayableCurrent" xml:lang="en-US">Convertible notes payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_ConvertibleNotesPayableCurrent" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_ConvertibleNotesPayableCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_K196K48I138K_us-gaap_NotesPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_NotesPayableCurrent" xml:lang="en-US">Notes Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_NotesPayableCurrent" xml:lang="en-US">Notes payable, net of discount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_M318M60K350M_us-gaap_NotesPayableCurrent" xml:lang="en-US">Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_M318M60K350M_us-gaap_NotesPayableCurrent" xml:lang="en-US">Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_NotesPayableCurrent" xlink:to="lab_M318M60K350M_us-gaap_NotesPayableCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_LiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total Current Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_LiabilitiesCurrent" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_LiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_K196K48I138K_us-gaap_StockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Immudyne, Inc. Stockholders' Equity (Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_StockholdersEquityAbstract" xlink:to="lab_M318M60K350M_us-gaap_StockholdersEquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_CommonStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, $0.01 par value; 50,000,000 shares authorized, 35,570,157 and 32,010,375 shares issued, 35,245,157 and 32,010,375 outstanding as of December 31, 2016 and 2015, respectively</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, $0.01 par value; 50,000,000 shares authorized, 30,609,973 shares issued and outstanding at June 30, 2015</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_CommonStockValue" xml:lang="en-US">Common stock issued, value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_CommonStockValue" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_CommonStockValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_K196K48I138K_us-gaap_AdditionalPaidInCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional Paid in Capital, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional paid-in capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_AdditionalPaidInCapital" xlink:to="lab_M318M60K350M_us-gaap_AdditionalPaidInCapital"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_RetainedEarningsAccumulatedDeficit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated (deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated (deficit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_RetainedEarningsAccumulatedDeficit"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_Equity" xlink:label="loc_K196K48I138K_immd_Equity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_immd_Equity" xml:lang="en-US">Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_immd_Equity" xml:lang="en-US">Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_M318M60K350M_immd_Equity" xml:lang="en-US">Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M318M60K350M_immd_Equity" xml:lang="en-US">It represents total of common stock, additional paid in capital and accumulated deficit.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_immd_Equity" xlink:to="lab_M318M60K350M_immd_Equity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_TreasuryStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_TreasuryStockValue" xml:lang="en-US">Treasury Stock, Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_TreasuryStockValue" xml:lang="en-US">Treasury stock, value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_TreasuryStockValue" xml:lang="en-US">Treasury stock, 325,000 shares, at cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_TreasuryStockValue" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_TreasuryStockValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_K196K48I138K_us-gaap_StockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_M318M60K350M_us-gaap_StockholdersEquity" xml:lang="en-US">Total Immudyne, Inc. Stockholders' Equity (Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_M318M60K350M_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_M318M60K350M_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_StockholdersEquity" xlink:to="lab_M318M60K350M_us-gaap_StockholdersEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_MinorityInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_MinorityInterest" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_MinorityInterest" xml:lang="en-US">Non-controlling interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_MinorityInterest" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_MinorityInterest"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_K196K48I138K_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_M318M60K350M_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Total Stockholders' Equity (Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_M318M60K350M_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_M318M60K350M_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_M318M60K350M_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_LiabilitiesAndStockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total Liabilities and Stockholders' Equity (Deficit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_LiabilitiesAndStockholdersEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_K196K48I138K_us-gaap_CommonStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_M318M60K350M_us-gaap_CommonStockParOrStatedValuePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_CommonStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_CommonStockSharesAuthorized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_K196K48I138K_us-gaap_CommonStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, shares issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_CommonStockSharesIssued" xlink:to="lab_M318M60K350M_us-gaap_CommonStockSharesIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_CommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_CommonStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="loc_K196K48I138K_us-gaap_TreasuryStockCommonShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_TreasuryStockCommonShares" xml:lang="en-US">Treasury Stock, Common, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_TreasuryStockCommonShares" xml:lang="en-US">Treasury stock, common, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_TreasuryStockCommonShares" xlink:to="lab_M318M60K350M_us-gaap_TreasuryStockCommonShares"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_IncomeStatementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_IncomeStatementAbstract" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_IncomeStatementAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="loc_K196K48I138K_us-gaap_Revenues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_Revenues" xml:lang="en-US">Revenues, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_Revenues" xml:lang="en-US">Total sales</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_Revenues" xml:lang="en-US">Net sales</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_M318M60K350M_us-gaap_Revenues" xml:lang="en-US">Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_Revenues" xlink:to="lab_M318M60K350M_us-gaap_Revenues"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_CostOfRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_CostOfRevenue" xml:lang="en-US">Cost of Revenue, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_CostOfRevenue" xml:lang="en-US">Cost of sales</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_CostOfRevenue" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_CostOfRevenue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_K196K48I138K_us-gaap_GrossProfit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_GrossProfit" xml:lang="en-US">Gross Profit, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_M318M60K350M_us-gaap_GrossProfit" xml:lang="en-US">Gross Profit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_GrossProfit" xlink:to="lab_M318M60K350M_us-gaap_GrossProfit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_OperatingExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_OperatingExpensesAbstract" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_OperatingExpensesAbstract"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_CompensationAndRelatedExpenses" xlink:label="loc_K196K48I138K_immd_CompensationAndRelatedExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_immd_CompensationAndRelatedExpenses" xml:lang="en-US">Compensation and Related Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_immd_CompensationAndRelatedExpenses" xml:lang="en-US">Compensation and related expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M318M60K350M_immd_CompensationAndRelatedExpenses" xml:lang="en-US">Represents the expense recognized during the period arising from equity-based compensation arrangements and related expenses (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_M318M60K350M_immd_CompensationAndRelatedExpenses" xml:lang="en-US">Compensation and related expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_immd_CompensationAndRelatedExpenses" xlink:to="lab_M318M60K350M_immd_CompensationAndRelatedExpenses"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_ProfessionalFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ProfessionalFees" xml:lang="en-US">Professional Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ProfessionalFees" xml:lang="en-US">Professional fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ProfessionalFees" xml:lang="en-US">Consulting expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ProfessionalFees" xml:lang="en-US">Accountant chareges per month</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ProfessionalFees" xml:lang="en-US">Professional fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_ProfessionalFees" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_ProfessionalFees"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MarketingExpense" xlink:label="loc_K196K48I138K_us-gaap_MarketingExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_MarketingExpense" xml:lang="en-US">Marketing Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_MarketingExpense" xml:lang="en-US">Marketing expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_MarketingExpense" xlink:to="lab_M318M60K350M_us-gaap_MarketingExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_ResearchAndDevelopmentExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_ResearchAndDevelopmentExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_K196K48I138K_us-gaap_GeneralAndAdministrativeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_M318M60K350M_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_M318M60K350M_us-gaap_GeneralAndAdministrativeExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_OperatingExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_OperatingExpenses" xml:lang="en-US">Total operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_OperatingExpenses" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_OperatingExpenses"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_K196K48I138K_us-gaap_OperatingIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss), Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_M318M60K350M_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_M318M60K350M_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating income (Loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_OperatingIncomeLoss" xlink:to="lab_M318M60K350M_us-gaap_OperatingIncomeLoss"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainOnSaleOfInvestments" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_GainOnSaleOfInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_GainOnSaleOfInvestments" xml:lang="en-US">Gain on Sale of Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_GainOnSaleOfInvestments" xml:lang="en-US">Gain on sale of Adiuvo Investment S.A. stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_GainOnSaleOfInvestments" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_GainOnSaleOfInvestments"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_K196K48I138K_us-gaap_InterestExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_InterestExpense" xml:lang="en-US">Interest Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_InterestExpense" xml:lang="en-US">Interest expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_M318M60K350M_us-gaap_InterestExpense" xml:lang="en-US">Interest expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_M318M60K350M_us-gaap_InterestExpense" xml:lang="en-US">Interest (expense)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_InterestExpense" xlink:to="lab_M318M60K350M_us-gaap_InterestExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Net Income (Loss) Before Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_K196K48I138K_us-gaap_DeferredIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_DeferredIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_DeferredIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred tax benefit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_DeferredIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred income tax benefit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_M318M60K350M_us-gaap_DeferredIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred income tax benefit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_M318M60K350M_us-gaap_DeferredIncomeTaxExpenseBenefit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_ProfitLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ProfitLoss" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ProfitLoss" xml:lang="en-US">Net (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ProfitLoss" xml:lang="en-US">Net (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ProfitLoss" xml:lang="en-US">Net (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ProfitLoss" xml:lang="en-US">Net (loss) income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_ProfitLoss" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_ProfitLoss"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_K196K48I138K_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xml:lang="en-US">Net income (loss) attributable to noncontrolling interests</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xml:lang="en-US">Net (loss) attributable to noncontrolling interests</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_M318M60K350M_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xml:lang="en-US">Net (loss) attributable to noncontrolling interests</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_M318M60K350M_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_NetIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_NetIncomeLoss" xml:lang="en-US">Net (loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_NetIncomeLoss" xml:lang="en-US">Net (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_NetIncomeLoss" xml:lang="en-US">Net (loss) attributable to Immudyne, Inc.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_NetIncomeLoss" xml:lang="en-US">Net (loss) income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_NetIncomeLoss" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_NetIncomeLoss"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_K196K48I138K_us-gaap_EarningsPerShareBasicAndDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Basic and diluted (loss) per share attributable to Immudyne, Inc.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_M318M60K350M_us-gaap_EarningsPerShareBasicAndDiluted"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_EarningsPerShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Earnings Per Share [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Average number of common shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_EarningsPerShareAbstract" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_EarningsPerShareAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_K196K48I138K_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Basic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_M318M60K350M_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_K196K48I138K_us-gaap_StatementOfStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_M318M60K350M_us-gaap_StatementOfStockholdersEquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_StatementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_StatementTable" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_StatementTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_K196K48I138K_us-gaap_StatementEquityComponentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_M318M60K350M_us-gaap_StatementEquityComponentsAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_EquityComponentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_EquityComponentDomain" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_EquityComponentDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_K196K48I138K_us-gaap_CommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_CommonStockMember" xlink:to="lab_M318M60K350M_us-gaap_CommonStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_AdditionalPaidInCapitalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_AdditionalPaidInCapitalMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_K196K48I138K_us-gaap_RetainedEarningsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_RetainedEarningsMember" xml:lang="en-US">Accumulated (Deficit) [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_RetainedEarningsMember" xml:lang="en-US">Accumulated (Deficit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_RetainedEarningsMember" xlink:to="lab_M318M60K350M_us-gaap_RetainedEarningsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_TreasuryStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_TreasuryStockMember" xml:lang="en-US">Treasury Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_TreasuryStockMember" xml:lang="en-US">Treasury Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_TreasuryStockMember" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_TreasuryStockMember"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_SummationMember" xlink:label="loc_K196K48I138K_immd_SummationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_immd_SummationMember" xml:lang="en-US">Summation [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_immd_SummationMember" xml:lang="en-US">Sub Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M318M60K350M_immd_SummationMember" xml:lang="en-US">Sub total Member.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_immd_SummationMember" xlink:to="lab_M318M60K350M_immd_SummationMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_NoncontrollingInterestMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_NoncontrollingInterestMember" xml:lang="en-US">Noncontrolling Interest [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_NoncontrollingInterestMember" xml:lang="en-US">Noncontrolling interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_NoncontrollingInterestMember" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_NoncontrollingInterestMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_K196K48I138K_us-gaap_StatementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_StatementLineItems" xlink:to="lab_M318M60K350M_us-gaap_StatementLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_SharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_SharesOutstanding" xml:lang="en-US">Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_SharesOutstanding" xml:lang="en-US">Balance, (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_SharesOutstanding" xml:lang="en-US">Balance (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_SharesOutstanding" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_SharesOutstanding"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_AdjustmentsOfAdditionPaidInCapitalAmortizationOfStockOptions" xlink:label="loc_K196K48I138K_immd_AdjustmentsOfAdditionPaidInCapitalAmortizationOfStockOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_immd_AdjustmentsOfAdditionPaidInCapitalAmortizationOfStockOptions" xml:lang="en-US">Adjustments Of Addition Paid In Capital Amortization Of Stock Options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_immd_AdjustmentsOfAdditionPaidInCapitalAmortizationOfStockOptions" xml:lang="en-US">Amortization of stock options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M318M60K350M_immd_AdjustmentsOfAdditionPaidInCapitalAmortizationOfStockOptions" xml:lang="en-US">Amount of decrease in additional paid in capital (APIC) resulting from amortization of stock options.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_immd_AdjustmentsOfAdditionPaidInCapitalAmortizationOfStockOptions" xlink:to="lab_M318M60K350M_immd_AdjustmentsOfAdditionPaidInCapitalAmortizationOfStockOptions"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xml:lang="en-US">Stock Repurchased and Retired During Period, Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xml:lang="en-US">Purchase of company stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xml:lang="en-US">Value of options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_K196K48I138K_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xml:lang="en-US">Purchase of company stock, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xml:lang="en-US">Value of options, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="lab_M318M60K350M_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_StockIssuedDuringPeriodValueOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_StockIssuedDuringPeriodValueOther" xml:lang="en-US">Stock Issued During Period, Value, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_StockIssuedDuringPeriodValueOther" xml:lang="en-US">Issuance of company stock for notes and other payables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_StockIssuedDuringPeriodValueOther"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_K196K48I138K_us-gaap_StockIssuedDuringPeriodSharesOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_StockIssuedDuringPeriodSharesOther" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_StockIssuedDuringPeriodSharesOther" xml:lang="en-US">Issuance of company stock for notes and other payables, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="lab_M318M60K350M_us-gaap_StockIssuedDuringPeriodSharesOther"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US">Common stock issued for services as per agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US">Issuance of common stock for services</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_K196K48I138K_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Common stock issued for services as per agreement, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Issuance of common stock for services, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_M318M60K350M_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xml:lang="en-US">Stock Issued During Period, Value, Share-based Compensation, Forfeited</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xml:lang="en-US">Company stock cancelled</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xml:lang="en-US">Company cancelled service-based options, value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_K196K48I138K_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xml:lang="en-US">Stock Issued During Period, Shares, Share-based Compensation, Forfeited</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xml:lang="en-US">Company stock cancelled, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_M318M60K350M_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xml:lang="en-US">Company cancelled service-based options, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:to="lab_M318M60K350M_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_Adjustmentstoadditionalpaidincapitalsharebasedcompensationextensionstockoptionswarrantexpirationdates" xlink:label="loc_8H6FHF4I49GG985JF602_immd_Adjustmentstoadditionalpaidincapitalsharebasedcompensationextensionstockoptionswarrantexpirationdates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_immd_Adjustmentstoadditionalpaidincapitalsharebasedcompensationextensionstockoptionswarrantexpirationdates" xml:lang="en-US">Adjustmentstoadditionalpaidincapitalsharebasedcompensationextensionstockoptionswarrantexpirationdates</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_immd_Adjustmentstoadditionalpaidincapitalsharebasedcompensationextensionstockoptionswarrantexpirationdates" xml:lang="en-US">Extension of option and warrant expiration dates</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_0J8HJH6K61II107LH824_immd_Adjustmentstoadditionalpaidincapitalsharebasedcompensationextensionstockoptionswarrantexpirationdates" xml:lang="en-US">Adjustments to additional paid in capital share based compensation extension stock options warrant expiration dates.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_immd_Adjustmentstoadditionalpaidincapitalsharebasedcompensationextensionstockoptionswarrantexpirationdates" xlink:to="lab_0J8HJH6K61II107LH824_immd_Adjustmentstoadditionalpaidincapitalsharebasedcompensationextensionstockoptionswarrantexpirationdates"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_K196K48I138K_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Sale of common stock and warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Issuance of company stock, value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_M318M60K350M_us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Purchase of Company stock, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Issuance of Company stock, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Sale of common stock and warrants, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Common stock shares issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Purchase of Company stock, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_K196K48I138K_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xml:lang="en-US">Conversion of NCI equity for shares, value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="lab_M318M60K350M_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xml:lang="en-US">Conversion of NCI equity for shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_K196K48I138K_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Issuance of common stock for options exercise</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_M318M60K350M_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Issuance of common stock for options exercise, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Number of Options, Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Number of Shares, Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Number of common stock exercises</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_K196K48I138K_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xml:lang="en-US">Issued of common stock, value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xml:lang="en-US">Issuance of common stock in relation to debt offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_M318M60K350M_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xml:lang="en-US">Issue of common stock, value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_M318M60K350M_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xml:lang="en-US">Issuance of common stock in relation to debt offering</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_M318M60K350M_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xml:lang="en-US">Issued of common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xml:lang="en-US">Issuance of common stock in relation to debt offering, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="loc_K196K48I138K_us-gaap_AdjustmentOfWarrantsGrantedForServices" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_AdjustmentOfWarrantsGrantedForServices" xml:lang="en-US">Adjustment of Warrants Granted for Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_AdjustmentOfWarrantsGrantedForServices" xml:lang="en-US">Issuance of warrants for services</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:to="lab_M318M60K350M_us-gaap_AdjustmentOfWarrantsGrantedForServices"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_MinorityInterestPeriodIncreaseDecrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_MinorityInterestPeriodIncreaseDecrease" xml:lang="en-US">Noncontrolling Interest, Period Increase (Decrease)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_MinorityInterestPeriodIncreaseDecrease" xml:lang="en-US">Charge to noncontrolling interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_MinorityInterestPeriodIncreaseDecrease" xml:lang="en-US">Reduction in noncontrolling interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_MinorityInterestPeriodIncreaseDecrease"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_K196K48I138K_us-gaap_TreasuryStockValueAcquiredCostMethod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_TreasuryStockValueAcquiredCostMethod" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_TreasuryStockValueAcquiredCostMethod" xml:lang="en-US">Purchase of treasury stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_M318M60K350M_us-gaap_TreasuryStockValueAcquiredCostMethod"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xml:lang="en-US">Issuance of stock options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xml:lang="en-US">Issuance of stock options for services</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:label="loc_K196K48I138K_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xml:lang="en-US">Noncontrolling Interest, Increase from Subsidiary Equity Issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xml:lang="en-US">Investment in subsidiary by noncontrolling interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:to="lab_M318M60K350M_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities" xlink:label="loc_8H6FHF4I49GG985JF602_immd_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_immd_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities" xml:lang="en-US">Adjustments To Additional Paid In Capital Share Based Compensation Reclassification Of Options Warrants And Other Contracts From Equity To Derivative Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_immd_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities" xml:lang="en-US">Reclassification of options, warrants and other contracts from equity to derivative liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_0J8HJH6K61II107LH824_immd_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities" xml:lang="en-US">Adjustment to additional paid-in capital share based compensation reclassification of options, warrants and other contracts from equity to derivative liabilities.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_immd_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities" xlink:to="lab_0J8HJH6K61II107LH824_immd_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_K196K48I138K_us-gaap_StatementOfCashFlowsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement Of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_M318M60K350M_us-gaap_StatementOfCashFlowsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided By (Used In) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_K196K48I138K_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments To Reconcile Net Income (Loss) To Cash Provided By (Used In) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net (loss) to net cash (used) provided by operating activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net (loss) to net cash (used) by operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_M318M60K350M_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_Depreciation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_Depreciation" xml:lang="en-US">Depreciation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_Depreciation" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_Depreciation"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_K196K48I138K_us-gaap_ProvisionForDoubtfulAccounts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_ProvisionForDoubtfulAccounts" xml:lang="en-US">Provision for Doubtful Accounts</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_ProvisionForDoubtfulAccounts" xml:lang="en-US">Bad debt provision</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_M318M60K350M_us-gaap_ProvisionForDoubtfulAccounts"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_AmortizationOfDebtDiscountPremium" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_AmortizationOfDebtDiscountPremium" xml:lang="en-US">Amortization of Debt Discount (Premium)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_AmortizationOfDebtDiscountPremium" xml:lang="en-US">Amortization of debt discount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_AmortizationOfDebtDiscountPremium" xml:lang="en-US">Debt discount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_AmortizationOfDebtDiscountPremium"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_K196K48I138K_us-gaap_ShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock based compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock compensation expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_M318M60K350M_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_ShareBasedCompensation" xlink:to="lab_M318M60K350M_us-gaap_ShareBasedCompensation"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xml:lang="en-US">Issuance of common stock for services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xml:lang="en-US">Issuance of warrants for services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xml:lang="en-US">Issuance of warrants for services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xml:lang="en-US">Common stock issued for services</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="loc_K196K48I138K_us-gaap_GainLossOnSaleOfInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_GainLossOnSaleOfInvestments" xml:lang="en-US">Gain (Loss) on Sale of Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_GainLossOnSaleOfInvestments" xml:lang="en-US">Gain on sale of Adiuvo Investment S.A. stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_M318M60K350M_us-gaap_GainLossOnSaleOfInvestments" xml:lang="en-US">Gain on sale of Adiuvo Investment S.A. stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_GainLossOnSaleOfInvestments" xlink:to="lab_M318M60K350M_us-gaap_GainLossOnSaleOfInvestments"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) In Operating Capital [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in Assets and Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_K196K48I138K_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Increase (Decrease) In Accounts Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_M318M60K350M_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Trade accounts receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_M318M60K350M_us-gaap_IncreaseDecreaseInAccountsReceivable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_IncreaseDecreaseInOtherReceivables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_IncreaseDecreaseInOtherReceivables" xml:lang="en-US">Increase (Decrease) in Other Receivables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_IncreaseDecreaseInOtherReceivables" xml:lang="en-US">Other receivables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_IncreaseDecreaseInOtherReceivables" xml:lang="en-US">Other receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_IncreaseDecreaseInOtherReceivables"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_K196K48I138K_us-gaap_IncreaseDecreaseInInventories" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_IncreaseDecreaseInInventories" xml:lang="en-US">Increase (Decrease) in Inventories, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_M318M60K350M_us-gaap_IncreaseDecreaseInInventories" xml:lang="en-US">Inventory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_M318M60K350M_us-gaap_IncreaseDecreaseInInventories"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Increase (Decrease) In Other Accounts Payable and Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Accounts payable and accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_K196K48I138K_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Negative cash flows from operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_M318M60K350M_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash (used) by operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_M318M60K350M_us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="loc_K196K48I138K_us-gaap_PaymentsForProceedsFromInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_PaymentsForProceedsFromInvestments" xml:lang="en-US">Payments for (Proceeds from) Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_PaymentsForProceedsFromInvestments" xml:lang="en-US">Proceeds from sale of Adiuvo Investment S.A. stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_M318M60K350M_us-gaap_PaymentsForProceedsFromInvestments" xml:lang="en-US">Proceeds from sale of Adiuvo Investment S.A. stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_PaymentsForProceedsFromInvestments" xlink:to="lab_M318M60K350M_us-gaap_PaymentsForProceedsFromInvestments"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided By (Used In) Financing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:label="loc_K196K48I138K_us-gaap_ProceedsFromPaymentsToMinorityShareholders" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_ProceedsFromPaymentsToMinorityShareholders" xml:lang="en-US">Proceeds from (Payments to) Noncontrolling Interests</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_ProceedsFromPaymentsToMinorityShareholders" xml:lang="en-US">Investment in subsidiary by noncontrolling interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:to="lab_M318M60K350M_us-gaap_ProceedsFromPaymentsToMinorityShareholders"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInNotesPayableCurrent" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_IncreaseDecreaseInNotesPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_IncreaseDecreaseInNotesPayableCurrent" xml:lang="en-US">Increase in notes payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_IncreaseDecreaseInNotesPayableCurrent" xml:lang="en-US">Increase in notes payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_IncreaseDecreaseInNotesPayableCurrent" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_IncreaseDecreaseInNotesPayableCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_K196K48I138K_us-gaap_ProceedsFromConvertibleDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_ProceedsFromConvertibleDebt" xml:lang="en-US">Proceeds from Convertible Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_ProceedsFromConvertibleDebt" xml:lang="en-US">Proceeds from convertible note payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_M318M60K350M_us-gaap_ProceedsFromConvertibleDebt"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_RepaymentsOfNotesPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_RepaymentsOfNotesPayable" xml:lang="en-US">Repayments of Notes Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_RepaymentsOfNotesPayable" xml:lang="en-US">Repayment of note payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_RepaymentsOfNotesPayable" xml:lang="en-US">Repayment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_RepaymentsOfNotesPayable" xml:lang="en-US">Repayment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_RepaymentsOfNotesPayable" xml:lang="en-US">Repayment of notes payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_RepaymentsOfNotesPayable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_K196K48I138K_us-gaap_ProceedsFromStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US">Proceeds from exercises of options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US">Proceeds from options exercise</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_M318M60K350M_us-gaap_ProceedsFromStockOptionsExercised"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_IssuanceOfCommonStockAndWarrants" xlink:label="loc_8H6FHF4I49GG985JF602_immd_IssuanceOfCommonStockAndWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_immd_IssuanceOfCommonStockAndWarrants" xml:lang="en-US">Issuance Of Common Stock And Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_immd_IssuanceOfCommonStockAndWarrants" xml:lang="en-US">Sale of common stock and warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_0J8HJH6K61II107LH824_immd_IssuanceOfCommonStockAndWarrants" xml:lang="en-US">Issuance of common stock and warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_immd_IssuanceOfCommonStockAndWarrants" xlink:to="lab_0J8HJH6K61II107LH824_immd_IssuanceOfCommonStockAndWarrants"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_K196K48I138K_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Purchase of treasury stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Issuance of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_M318M60K350M_us-gaap_ProceedsFromIssuanceOfCommonStock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash provided by financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_K196K48I138K_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease), Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_M318M60K350M_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Net (decrease) increase in cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="lab_M318M60K350M_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_SupplementalCashFlowInformationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental Disclosure of Cash Flow Information</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_SupplementalCashFlowInformationAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_K196K48I138K_us-gaap_InterestPaid" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_InterestPaid" xml:lang="en-US">Interest Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_InterestPaid" xml:lang="en-US">Cash paid during the period for interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_InterestPaid" xlink:to="lab_M318M60K350M_us-gaap_InterestPaid"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_ConversionOfStockAmountIssued1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ConversionOfStockAmountIssued1" xml:lang="en-US">Conversion of Stock, Amount Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ConversionOfStockAmountIssued1" xml:lang="en-US">Issuance of company stock for notes and other payables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_ConversionOfStockAmountIssued1" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_ConversionOfStockAmountIssued1"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_IssuanceOfCommonStockInRelationToDebtOffering" xlink:label="loc_K196K48I138K_immd_IssuanceOfCommonStockInRelationToDebtOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_immd_IssuanceOfCommonStockInRelationToDebtOffering" xml:lang="en-US">Issuance Of Common Stock In Relation To Debt Offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_immd_IssuanceOfCommonStockInRelationToDebtOffering" xml:lang="en-US">Issuance of common stock in relation to debt offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M318M60K350M_immd_IssuanceOfCommonStockInRelationToDebtOffering" xml:lang="en-US">Issuance of common stock in relation to debt offering.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_immd_IssuanceOfCommonStockInRelationToDebtOffering" xlink:to="lab_M318M60K350M_immd_IssuanceOfCommonStockInRelationToDebtOffering"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities" xlink:label="loc_8H6FHF4I49GG985JF602_immd_ReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_immd_ReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities" xml:lang="en-US">Reclassification Of Options Warrants And Other Contracts From Equity To Derivative Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_immd_ReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities" xml:lang="en-US">Reclassification of options, warrants and other contracts from equity to derivative liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_immd_ReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities" xml:lang="en-US">Recorded upon issue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_0J8HJH6K61II107LH824_immd_ReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities" xml:lang="en-US">Reclassification of options, warrants and other contracts to derivative liabilities.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_immd_ReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities" xlink:to="lab_0J8HJH6K61II107LH824_immd_ReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ConversionOfEquityInvestedInSubsidiaryToCommonStockAndWarrants" xlink:label="loc_K196K48I138K_immd_ConversionOfEquityInvestedInSubsidiaryToCommonStockAndWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_immd_ConversionOfEquityInvestedInSubsidiaryToCommonStockAndWarrants" xml:lang="en-US">Conversion Of Equity Invested In Subsidiary To Common Stock And Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_immd_ConversionOfEquityInvestedInSubsidiaryToCommonStockAndWarrants" xml:lang="en-US">Conversion of equity invested in subsidiary to common stock and warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M318M60K350M_immd_ConversionOfEquityInvestedInSubsidiaryToCommonStockAndWarrants" xml:lang="en-US">The conversion vale of equity invested in subsidiary to common stock and warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_immd_ConversionOfEquityInvestedInSubsidiaryToCommonStockAndWarrants" xlink:to="lab_M318M60K350M_immd_ConversionOfEquityInvestedInSubsidiaryToCommonStockAndWarrants"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization and Going Concern [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_K196K48I138K_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US">Organization, Consolidation and Presentation Of Financial Statements Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US">Organization and Going Concern</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US">Organization and Going Concern</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_M318M60K350M_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_AccountingPoliciesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Summary of Significant Accounting Policies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_AccountingPoliciesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_K196K48I138K_us-gaap_SignificantAccountingPoliciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Summary of Significant Accounting Policies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_M318M60K350M_us-gaap_SignificantAccountingPoliciesTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_PropertyPlantAndEquipmentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_PropertyPlantAndEquipmentAbstract" xml:lang="en-US">Furnishings and Equipment [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_PropertyPlantAndEquipmentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_K196K48I138K_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Furnishings and Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_M318M60K350M_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfInvestmentsAbstract" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_ScheduleOfInvestmentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ScheduleOfInvestmentsAbstract" xml:lang="en-US">Investment in Adiuvo Investment S.A. [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_ScheduleOfInvestmentsAbstract" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_ScheduleOfInvestmentsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentHoldingsTextBlock" xlink:label="loc_K196K48I138K_us-gaap_InvestmentHoldingsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_InvestmentHoldingsTextBlock" xml:lang="en-US">Investment Holdings [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_InvestmentHoldingsTextBlock" xml:lang="en-US">Investment in Adiuvo Investment S.A.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_InvestmentHoldingsTextBlock" xlink:to="lab_M318M60K350M_us-gaap_InvestmentHoldingsTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_DebtDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_DebtDisclosureAbstract" xml:lang="en-US">Notes Payable [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_DebtDisclosureAbstract" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_DebtDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_K196K48I138K_us-gaap_DebtDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">Debt Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">Notes Payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_M318M60K350M_us-gaap_DebtDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_IncomeTaxDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Taxes [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Taxes [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_IncomeTaxDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_K196K48I138K_us-gaap_IncomeTaxDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_M318M60K350M_us-gaap_IncomeTaxDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_StockholdersEquityNoteAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_StockholdersEquityNoteAbstract" xml:lang="en-US">Stockholders' Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_StockholdersEquityNoteAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_K196K48I138K_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders Equity Note Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_M318M60K350M_us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_RoyaltiesAbstract" xlink:label="loc_8H6FHF4I49GG985JF602_immd_RoyaltiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_immd_RoyaltiesAbstract" xml:lang="en-US">Royalties [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_immd_RoyaltiesAbstract" xlink:to="lab_0J8HJH6K61II107LH824_immd_RoyaltiesAbstract"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_RoyaltiesDisclosureTextBlock" xlink:label="loc_K196K48I138K_immd_RoyaltiesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_immd_RoyaltiesDisclosureTextBlock" xml:lang="en-US">Royalties Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_immd_RoyaltiesDisclosureTextBlock" xml:lang="en-US">Royalties</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M318M60K350M_immd_RoyaltiesDisclosureTextBlock" xml:lang="en-US">The entire disclosure for royalty agreement during the reporting period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_immd_RoyaltiesDisclosureTextBlock" xlink:to="lab_M318M60K350M_immd_RoyaltiesDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_K196K48I138K_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_M318M60K350M_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_RelatedPartyTransactionsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US">Related Party Transactions [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_RelatedPartyTransactionsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_K196K48I138K_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_M318M60K350M_us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_SubsequentEventsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_SubsequentEventsAbstract" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_SubsequentEventsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_K196K48I138K_us-gaap_SubsequentEventsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_M318M60K350M_us-gaap_SubsequentEventsTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_ConsolidationPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ConsolidationPolicyTextBlock" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ConsolidationPolicyTextBlock" xml:lang="en-US">Principles of Consolidation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_ConsolidationPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_VariableInterestEntitiesPolicyTextBlock" xlink:label="loc_K196K48I138K_immd_VariableInterestEntitiesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_immd_VariableInterestEntitiesPolicyTextBlock" xml:lang="en-US">Variable Interest Entities [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_immd_VariableInterestEntitiesPolicyTextBlock" xml:lang="en-US">Variable Interest Entities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M318M60K350M_immd_VariableInterestEntitiesPolicyTextBlock" xml:lang="en-US">It repressents variable interest entitues policy text block.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_immd_VariableInterestEntitiesPolicyTextBlock" xlink:to="lab_M318M60K350M_immd_VariableInterestEntitiesPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_UseOfEstimates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_UseOfEstimates" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_UseOfEstimates"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_K196K48I138K_us-gaap_DerivativesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_DerivativesPolicyTextBlock" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_DerivativesPolicyTextBlock" xml:lang="en-US">Derivative Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_M318M60K350M_us-gaap_DerivativesPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_SequencingPolicyPolicyTextBlock" xlink:label="loc_8H6FHF4I49GG985JF602_immd_SequencingPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_immd_SequencingPolicyPolicyTextBlock" xml:lang="en-US">Sequencing Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_immd_SequencingPolicyPolicyTextBlock" xml:lang="en-US">Sequencing Policy</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_0J8HJH6K61II107LH824_immd_SequencingPolicyPolicyTextBlock" xml:lang="en-US">It represents sequencing policy text block.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_immd_SequencingPolicyPolicyTextBlock" xlink:to="lab_0J8HJH6K61II107LH824_immd_SequencingPolicyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_K196K48I138K_us-gaap_InventoryPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_InventoryPolicyTextBlock" xml:lang="en-US">Inventory, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_InventoryPolicyTextBlock" xml:lang="en-US">Inventory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_M318M60K350M_us-gaap_InventoryPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_RevenueRecognitionPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US">Revenue Recognition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_RevenueRecognitionPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_K196K48I138K_us-gaap_TradeAndOtherAccountsReceivablePolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_TradeAndOtherAccountsReceivablePolicy" xml:lang="en-US">Trade and Other Accounts Receivable, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_TradeAndOtherAccountsReceivablePolicy" xml:lang="en-US">Accounts receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_M318M60K350M_us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_SegmentReportingPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_SegmentReportingPolicyPolicyTextBlock" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_SegmentReportingPolicyPolicyTextBlock" xml:lang="en-US">Segments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_K196K48I138K_us-gaap_IncomeTaxPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_M318M60K350M_us-gaap_IncomeTaxPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_CompensationRelatedCostsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_CompensationRelatedCostsPolicyTextBlock" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_CompensationRelatedCostsPolicyTextBlock" xml:lang="en-US">Stock-Based Compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_K196K48I138K_us-gaap_EarningsPerSharePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings (Loss) Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_M318M60K350M_us-gaap_EarningsPerSharePolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">Recent Accounting Pronouncements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_K196K48I138K_us-gaap_FairValueOfFinancialInstrumentsPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value Of Financial Instruments, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value of Financial Instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_M318M60K350M_us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_MinorityInterestPolicyTextBlock" xlink:label="loc_8H6FHF4I49GG985JF602_immd_MinorityInterestPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_immd_MinorityInterestPolicyTextBlock" xml:lang="en-US">Minority Interest [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_immd_MinorityInterestPolicyTextBlock" xml:lang="en-US">Noncontrolling Interests</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_0J8HJH6K61II107LH824_immd_MinorityInterestPolicyTextBlock" xml:lang="en-US">Disclosure of noncontrolling interests policy for credit risk.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_immd_MinorityInterestPolicyTextBlock" xlink:to="lab_0J8HJH6K61II107LH824_immd_MinorityInterestPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:label="loc_K196K48I138K_us-gaap_ConsolidationVariableInterestEntityPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_ConsolidationVariableInterestEntityPolicy" xml:lang="en-US">Consolidation, Variable Interest Entity, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_ConsolidationVariableInterestEntityPolicy" xml:lang="en-US">Consolidation of Variable Interest Entities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_ConsolidationVariableInterestEntityPolicy" xml:lang="en-US">Variable Interest Entities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:to="lab_M318M60K350M_us-gaap_ConsolidationVariableInterestEntityPolicy"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_ConcentrationRiskCreditRisk" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration of Credit Risk</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_ConcentrationRiskCreditRisk"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_K196K48I138K_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xml:lang="en-US">Schedule Of Inventory, Current [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xml:lang="en-US">Summary of inventory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_M318M60K350M_us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xml:lang="en-US">Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xml:lang="en-US">Summary of reportable segments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_K196K48I138K_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Summary of furnishings and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_M318M60K350M_us-gaap_PropertyPlantAndEquipmentTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Summary of notes payable and advances payable activity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_K196K48I138K_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule Of Deferred Tax Assets and Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of components of deferred tax liabilities and assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of deferred tax asset</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_M318M60K350M_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_K196K48I138K_us-gaap_AwardTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_AwardTypeAxis" xlink:to="lab_M318M60K350M_us-gaap_AwardTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Equity Award [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_K196K48I138K_us-gaap_EmployeeStockOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Employee Stock Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Stock Options [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_M318M60K350M_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Service-Based Stock Options [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_EmployeeStockOptionMember" xlink:to="lab_M318M60K350M_us-gaap_EmployeeStockOptionMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_WarrantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_WarrantMember" xml:lang="en-US">Warrant [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_WarrantMember" xml:lang="en-US">Warrant [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_WarrantMember" xml:lang="en-US">Warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_WarrantMember" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_WarrantMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_K196K48I138K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_M318M60K350M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Summary of outstanding service-based options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:label="loc_K196K48I138K_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xml:lang="en-US">Schedule of Assumptions Used [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xml:lang="en-US">Summary of significant assumptions used to determine fair values of options issued using Black-Scholes option-pricing model</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:to="lab_M318M60K350M_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xml:lang="en-US">Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xml:lang="en-US">Summary of outstanding service-based options exercise price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_K196K48I138K_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_M318M60K350M_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_K196K48I138K_us-gaap_RelatedPartyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_RelatedPartyDomain" xlink:to="lab_M318M60K350M_us-gaap_RelatedPartyDomain"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ImmudynePrLlcMember" xlink:label="loc_8H6FHF4I49GG985JF602_immd_ImmudynePrLlcMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_immd_ImmudynePrLlcMember" xml:lang="en-US">Immudyne Pr Llc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_immd_ImmudynePrLlcMember" xml:lang="en-US">Immudyne PR LLC [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_immd_ImmudynePrLlcMember" xml:lang="en-US">Immudyne PR [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_0J8HJH6K61II107LH824_immd_ImmudynePrLlcMember" xml:lang="en-US">Immudyne PR LLC.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_immd_ImmudynePrLlcMember" xlink:to="lab_0J8HJH6K61II107LH824_immd_ImmudynePrLlcMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_K196K48I138K_us-gaap_RelatedPartyTransactionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_RelatedPartyTransactionLineItems" xml:lang="en-US">Related Party Transaction [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_M318M60K350M_us-gaap_RelatedPartyTransactionLineItems"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_OrganizationAndGoingConcernTextualAbstract" xlink:label="loc_8H6FHF4I49GG985JF602_immd_OrganizationAndGoingConcernTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_immd_OrganizationAndGoingConcernTextualAbstract" xml:lang="en-US">Organization And Going Concern Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_immd_OrganizationAndGoingConcernTextualAbstract" xml:lang="en-US">Organization and Going Concern (Textual)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_0J8HJH6K61II107LH824_immd_OrganizationAndGoingConcernTextualAbstract" xml:lang="en-US">organization and going concern textual.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_immd_OrganizationAndGoingConcernTextualAbstract" xlink:to="lab_0J8HJH6K61II107LH824_immd_OrganizationAndGoingConcernTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_K196K48I138K_us-gaap_EquityMethodInvestmentOwnershipPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Equity Method Investment, Ownership Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Percentage of ownership of equity interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Percentage of ownership equity interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_M318M60K350M_us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_MinorityInterestOwnershipPercentageByParent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_MinorityInterestOwnershipPercentageByParent" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_MinorityInterestOwnershipPercentageByParent" xml:lang="en-US">Percentage of voting controlling interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_MinorityInterestOwnershipPercentageByParent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="loc_K196K48I138K_us-gaap_InventoryNetAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_InventoryNetAbstract" xml:lang="en-US">Inventory, Net [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_InventoryNetAbstract" xml:lang="en-US">Summary of inventory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_InventoryNetAbstract" xlink:to="lab_M318M60K350M_us-gaap_InventoryNetAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_InventoryRawMaterials" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_InventoryRawMaterials" xml:lang="en-US">Inventory, Raw Materials, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_InventoryRawMaterials" xml:lang="en-US">Raw materials</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_InventoryRawMaterials" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_InventoryRawMaterials"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_K196K48I138K_us-gaap_InventoryFinishedGoods" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_InventoryFinishedGoods" xml:lang="en-US">Inventory, Finished Goods, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_InventoryFinishedGoods" xml:lang="en-US">Finished products</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_InventoryFinishedGoods" xlink:to="lab_M318M60K350M_us-gaap_InventoryFinishedGoods"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationItemsAxis" xlink:label="loc_K196K48I138K_us-gaap_ConsolidationItemsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_ConsolidationItemsAxis" xml:lang="en-US">Consolidation Items [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_ConsolidationItemsAxis" xlink:to="lab_M318M60K350M_us-gaap_ConsolidationItemsAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationItemsDomain" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_ConsolidationItemsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ConsolidationItemsDomain" xml:lang="en-US">Consolidation Items [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_ConsolidationItemsDomain" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_ConsolidationItemsDomain"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_NutraceuticalAndCosmeticMember" xlink:label="loc_K196K48I138K_immd_NutraceuticalAndCosmeticMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_immd_NutraceuticalAndCosmeticMember" xml:lang="en-US">Nutraceutical And Cosmetic [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_immd_NutraceuticalAndCosmeticMember" xml:lang="en-US">Nutraceutical and cosmetic [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M318M60K350M_immd_NutraceuticalAndCosmeticMember" xml:lang="en-US">Nutraceutical and cosmetic member.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_immd_NutraceuticalAndCosmeticMember" xlink:to="lab_M318M60K350M_immd_NutraceuticalAndCosmeticMember"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_CosmeticGoodsMember" xlink:label="loc_8H6FHF4I49GG985JF602_immd_CosmeticGoodsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_immd_CosmeticGoodsMember" xml:lang="en-US">Cosmetic Goods [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_immd_CosmeticGoodsMember" xml:lang="en-US">Finished Cosmetic Products [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_0J8HJH6K61II107LH824_immd_CosmeticGoodsMember" xml:lang="en-US">Cosmetic goods member.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_immd_CosmeticGoodsMember" xlink:to="lab_0J8HJH6K61II107LH824_immd_CosmeticGoodsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntersegmentEliminationMember" xlink:label="loc_K196K48I138K_us-gaap_IntersegmentEliminationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_IntersegmentEliminationMember" xml:lang="en-US">Intersegment Eliminations [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_IntersegmentEliminationMember" xml:lang="en-US">Elimination [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_IntersegmentEliminationMember" xlink:to="lab_M318M60K350M_us-gaap_IntersegmentEliminationMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_EntityWideRevenueMajorCustomerLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_EntityWideRevenueMajorCustomerLineItems" xml:lang="en-US">Revenue, Major Customer [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_EntityWideRevenueMajorCustomerLineItems" xml:lang="en-US">Summary of reportable segments [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_K196K48I138K_us-gaap_Assets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_Assets" xml:lang="en-US">Assets, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_Assets" xml:lang="en-US">Total assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_M318M60K350M_us-gaap_Assets" xml:lang="en-US">Total Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_Assets" xlink:to="lab_M318M60K350M_us-gaap_Assets"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_OtherUnallocatedAmountsAbstract" xlink:label="loc_8H6FHF4I49GG985JF602_immd_OtherUnallocatedAmountsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_immd_OtherUnallocatedAmountsAbstract" xml:lang="en-US">Other Unallocated Amounts [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_immd_OtherUnallocatedAmountsAbstract" xml:lang="en-US">Other unallocated amounts:</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_0J8HJH6K61II107LH824_immd_OtherUnallocatedAmountsAbstract" xml:lang="en-US">Other unallocated amounts.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_immd_OtherUnallocatedAmountsAbstract" xlink:to="lab_0J8HJH6K61II107LH824_immd_OtherUnallocatedAmountsAbstract"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_CorporateExpenses" xlink:label="loc_K196K48I138K_immd_CorporateExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_immd_CorporateExpenses" xml:lang="en-US">Corporate Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_immd_CorporateExpenses" xml:lang="en-US">Corporate expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M318M60K350M_immd_CorporateExpenses" xml:lang="en-US">Represents the amount of unallocated corporate expenses.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_M318M60K350M_immd_CorporateExpenses" xml:lang="en-US">Corporate expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_immd_CorporateExpenses" xlink:to="lab_M318M60K350M_immd_CorporateExpenses"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_OtherNonoperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US">Other income (expense) - net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_OtherNonoperatingIncomeExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_K196K48I138K_us-gaap_NonoperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Consolidated income (loss) from operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_M318M60K350M_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Consolidated income (loss) from operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_M318M60K350M_us-gaap_NonoperatingIncomeExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTable" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_OptionIndexedToIssuersEquityTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_OptionIndexedToIssuersEquityTable" xml:lang="en-US">Option Indexed to Issuer's Equity [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_OptionIndexedToIssuersEquityTable" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_OptionIndexedToIssuersEquityTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_K196K48I138K_us-gaap_OptionIndexedToIssuersEquityTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_OptionIndexedToIssuersEquityTypeAxis" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="lab_M318M60K350M_us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_OptionIndexedToIssuersEquityTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_K196K48I138K_us-gaap_ConcentrationRiskByBenchmarkAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_ConcentrationRiskByBenchmarkAxis" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_M318M60K350M_us-gaap_ConcentrationRiskByBenchmarkAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_ConcentrationRiskBenchmarkDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ConcentrationRiskBenchmarkDomain" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_ConcentrationRiskBenchmarkDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_K196K48I138K_us-gaap_SalesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_SalesMember" xml:lang="en-US">Sales [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_SalesMember" xml:lang="en-US">Sales [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_SalesMember" xlink:to="lab_M318M60K350M_us-gaap_SalesMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_AccountsReceivableMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_AccountsReceivableMember" xml:lang="en-US">Accounts Receivable [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_AccountsReceivableMember" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_AccountsReceivableMember"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ConcentrationRiskNumberOfCustomersAxis" xlink:label="loc_K196K48I138K_immd_ConcentrationRiskNumberOfCustomersAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_immd_ConcentrationRiskNumberOfCustomersAxis" xml:lang="en-US">Concentration Risk Number Of Customers [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_immd_ConcentrationRiskNumberOfCustomersAxis" xlink:to="lab_M318M60K350M_immd_ConcentrationRiskNumberOfCustomersAxis"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ConcentrationRiskNumberOfCustomersDomain" xlink:label="loc_8H6FHF4I49GG985JF602_immd_ConcentrationRiskNumberOfCustomersDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_immd_ConcentrationRiskNumberOfCustomersDomain" xml:lang="en-US">Concentration Risk Number Of Customers [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_immd_ConcentrationRiskNumberOfCustomersDomain" xlink:to="lab_0J8HJH6K61II107LH824_immd_ConcentrationRiskNumberOfCustomersDomain"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_OneCustomerMember" xlink:label="loc_K196K48I138K_immd_OneCustomerMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_immd_OneCustomerMember" xml:lang="en-US">One Customer [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_immd_OneCustomerMember" xml:lang="en-US">One customer [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_immd_OneCustomerMember" xlink:to="lab_M318M60K350M_immd_OneCustomerMember"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_SecondCustomerMember" xlink:label="loc_8H6FHF4I49GG985JF602_immd_SecondCustomerMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_immd_SecondCustomerMember" xml:lang="en-US">Second Customer [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_immd_SecondCustomerMember" xml:lang="en-US">Second customer [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_immd_SecondCustomerMember" xlink:to="lab_0J8HJH6K61II107LH824_immd_SecondCustomerMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis" xlink:label="loc_K196K48I138K_us-gaap_AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis" xml:lang="en-US">Industry of Counterparty, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis" xlink:to="lab_M318M60K350M_us-gaap_AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndustryOfCounterpartyDomain" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_IndustryOfCounterpartyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_IndustryOfCounterpartyDomain" xml:lang="en-US">Industry of Counterparty [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_IndustryOfCounterpartyDomain" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_IndustryOfCounterpartyDomain"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_OneCreditCardProcessorsMember" xlink:label="loc_K196K48I138K_immd_OneCreditCardProcessorsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_immd_OneCreditCardProcessorsMember" xml:lang="en-US">One Credit Card Processors [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_immd_OneCreditCardProcessorsMember" xml:lang="en-US">One credit card processor [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M318M60K350M_immd_OneCreditCardProcessorsMember" xml:lang="en-US">One credit card processors member.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_immd_OneCreditCardProcessorsMember" xlink:to="lab_M318M60K350M_immd_OneCreditCardProcessorsMember"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_TwoCreditCardProcessorsMember" xlink:label="loc_8H6FHF4I49GG985JF602_immd_TwoCreditCardProcessorsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_immd_TwoCreditCardProcessorsMember" xml:lang="en-US">Two Credit Card Processors [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_immd_TwoCreditCardProcessorsMember" xml:lang="en-US">Two credit card processor [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_0J8HJH6K61II107LH824_immd_TwoCreditCardProcessorsMember" xml:lang="en-US">Two credit card processors member.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_immd_TwoCreditCardProcessorsMember" xlink:to="lab_0J8HJH6K61II107LH824_immd_TwoCreditCardProcessorsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:label="loc_K196K48I138K_us-gaap_OptionIndexedToIssuersEquityLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_OptionIndexedToIssuersEquityLineItems" xml:lang="en-US">Option Indexed to Issuer's Equity [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:to="lab_M318M60K350M_us-gaap_OptionIndexedToIssuersEquityLineItems"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_SummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:label="loc_8H6FHF4I49GG985JF602_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract" xml:lang="en-US">Summary Of Significant Accounting Policies Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract" xml:lang="en-US">Summary of Significant Accounting Policies (Textual)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_0J8HJH6K61II107LH824_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract" xml:lang="en-US">Summary of significant accounting policies textual.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:to="lab_0J8HJH6K61II107LH824_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_MinorityInterestRate" xlink:label="loc_K196K48I138K_immd_MinorityInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_immd_MinorityInterestRate" xml:lang="en-US">Minority Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_immd_MinorityInterestRate" xml:lang="en-US">Non controlling interest rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M318M60K350M_immd_MinorityInterestRate" xml:lang="en-US">Non controlling stated interest rate.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_immd_MinorityInterestRate" xlink:to="lab_M318M60K350M_immd_MinorityInterestRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryLIFOReserve" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_InventoryLIFOReserve" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_InventoryLIFOReserve" xml:lang="en-US">Inventory, LIFO Reserve</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_InventoryLIFOReserve" xml:lang="en-US">Inventory reserve</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_InventoryLIFOReserve" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_InventoryLIFOReserve"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesDiscountsReturnsAndAllowancesGoods" xlink:label="loc_K196K48I138K_us-gaap_SalesDiscountsReturnsAndAllowancesGoods" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_SalesDiscountsReturnsAndAllowancesGoods" xml:lang="en-US">Sales Discounts, Returns and Allowances, Goods</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_SalesDiscountsReturnsAndAllowancesGoods" xml:lang="en-US">Customer discounts, returns and rebates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_SalesDiscountsReturnsAndAllowancesGoods" xlink:to="lab_M318M60K350M_us-gaap_SalesDiscountsReturnsAndAllowancesGoods"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_K196K48I138K_us-gaap_ConcentrationRiskPercentage1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_ConcentrationRiskPercentage1" xml:lang="en-US">Concentration Risk, Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_ConcentrationRiskPercentage1" xml:lang="en-US">Concentration risk percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_M318M60K350M_us-gaap_ConcentrationRiskPercentage1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_AccountsReceivableNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_AccountsReceivableNet" xml:lang="en-US">Accounts Receivable, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_AccountsReceivableNet" xml:lang="en-US">Accounts receivable reserve</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_AccountsReceivableNet" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_AccountsReceivableNet"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_NonControllingInterestDescription" xlink:label="loc_K196K48I138K_immd_NonControllingInterestDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_immd_NonControllingInterestDescription" xml:lang="en-US">Non Controlling Interest Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_immd_NonControllingInterestDescription" xml:lang="en-US">Description of non controlling interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M318M60K350M_immd_NonControllingInterestDescription" xml:lang="en-US">The description of non controlling interest.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_immd_NonControllingInterestDescription" xlink:to="lab_M318M60K350M_immd_NonControllingInterestDescription"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesReturnsAndAllowancesGoods" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_SalesReturnsAndAllowancesGoods" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_SalesReturnsAndAllowancesGoods" xml:lang="en-US">Sales Returns and Allowances, Goods</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_SalesReturnsAndAllowancesGoods" xml:lang="en-US">Sales returns and allowances</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_SalesReturnsAndAllowancesGoods" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_SalesReturnsAndAllowancesGoods"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableInterestEntityConsolidatedCarryingAmountAssets" xlink:label="loc_K196K48I138K_us-gaap_VariableInterestEntityConsolidatedCarryingAmountAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_VariableInterestEntityConsolidatedCarryingAmountAssets" xml:lang="en-US">Variable Interest Entity, Consolidated, Carrying Amount, Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_VariableInterestEntityConsolidatedCarryingAmountAssets" xml:lang="en-US">Variable Interest Entity, assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_VariableInterestEntityConsolidatedCarryingAmountAssets" xlink:to="lab_M318M60K350M_us-gaap_VariableInterestEntityConsolidatedCarryingAmountAssets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableInterestEntityConsolidatedCarryingAmountLiabilities" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_VariableInterestEntityConsolidatedCarryingAmountLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_VariableInterestEntityConsolidatedCarryingAmountLiabilities" xml:lang="en-US">Variable Interest Entity, Consolidated, Carrying Amount, Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_VariableInterestEntityConsolidatedCarryingAmountLiabilities" xml:lang="en-US">Variable Interest Entity, liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_VariableInterestEntityConsolidatedCarryingAmountLiabilities" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_VariableInterestEntityConsolidatedCarryingAmountLiabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityRevenues" xlink:label="loc_K196K48I138K_us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityRevenues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityRevenues" xml:lang="en-US">Variable Interest Entity, Measure of Activity, Revenues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityRevenues" xml:lang="en-US">Variable Interest Entity, revenues</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityRevenues" xlink:to="lab_M318M60K350M_us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityRevenues"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityOperatingIncomeOrLoss" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityOperatingIncomeOrLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityOperatingIncomeOrLoss" xml:lang="en-US">Variable Interest Entity, Measure of Activity, Operating Income or Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityOperatingIncomeOrLoss" xml:lang="en-US">Variable Interest Entity, operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityOperatingIncomeOrLoss" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityOperatingIncomeOrLoss"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableInterestEntityConclusionToConsolidate" xlink:label="loc_K196K48I138K_us-gaap_VariableInterestEntityConclusionToConsolidate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_VariableInterestEntityConclusionToConsolidate" xml:lang="en-US">Variable Interest Entity, Conclusion to Consolidate, Change in Facts and Circumstances, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_VariableInterestEntityConclusionToConsolidate" xml:lang="en-US">consolidated VIE, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_VariableInterestEntityConclusionToConsolidate" xml:lang="en-US">Consolidated VIE, Description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_VariableInterestEntityConclusionToConsolidate" xlink:to="lab_M318M60K350M_us-gaap_VariableInterestEntityConclusionToConsolidate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_PropertyPlantAndEquipmentGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Furnishings and equipment, at cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_PropertyPlantAndEquipmentGross"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_K196K48I138K_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated depreciation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_M318M60K350M_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_PropertyPlantAndEquipmentNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Furnishings and equipment, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_PropertyPlantAndEquipmentNet"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_FurnishingsAndEquipmentTextualAbstract" xlink:label="loc_K196K48I138K_immd_FurnishingsAndEquipmentTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_immd_FurnishingsAndEquipmentTextualAbstract" xml:lang="en-US">Furnishings And Equipment Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_immd_FurnishingsAndEquipmentTextualAbstract" xml:lang="en-US">Furnishings and Equipment (Textual)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M318M60K350M_immd_FurnishingsAndEquipmentTextualAbstract" xml:lang="en-US">Furnishings and equipment.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_immd_FurnishingsAndEquipmentTextualAbstract" xlink:to="lab_M318M60K350M_immd_FurnishingsAndEquipmentTextualAbstract"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_InvestmentInAdiuvoInvestmentTextualAbstract" xlink:label="loc_8H6FHF4I49GG985JF602_immd_InvestmentInAdiuvoInvestmentTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_immd_InvestmentInAdiuvoInvestmentTextualAbstract" xml:lang="en-US">Investment In Adiuvo Investment Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_immd_InvestmentInAdiuvoInvestmentTextualAbstract" xml:lang="en-US">Investment In Adiuvo Investment S A (Textual)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_0J8HJH6K61II107LH824_immd_InvestmentInAdiuvoInvestmentTextualAbstract" xml:lang="en-US">Investment in Adiuvo Investment S.A.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_immd_InvestmentInAdiuvoInvestmentTextualAbstract" xlink:to="lab_0J8HJH6K61II107LH824_immd_InvestmentInAdiuvoInvestmentTextualAbstract"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_OptionsPurchasedAmountPaid" xlink:label="loc_K196K48I138K_immd_OptionsPurchasedAmountPaid" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_immd_OptionsPurchasedAmountPaid" xml:lang="en-US">Options Purchased Amount Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_immd_OptionsPurchasedAmountPaid" xml:lang="en-US">Amount paid for options purchased</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M318M60K350M_immd_OptionsPurchasedAmountPaid" xml:lang="en-US">Amount paid for options purchased.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_immd_OptionsPurchasedAmountPaid" xlink:to="lab_M318M60K350M_immd_OptionsPurchasedAmountPaid"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xml:lang="en-US">Percentage of interests acquired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_K196K48I138K_us-gaap_SharePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_SharePrice" xml:lang="en-US">Share Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_SharePrice" xml:lang="en-US">Share price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_SharePrice" xlink:to="lab_M318M60K350M_us-gaap_SharePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterestInJointVentures" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_MinorityInterestInJointVentures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_MinorityInterestInJointVentures" xml:lang="en-US">Noncontrolling Interest in Joint Ventures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_MinorityInterestInJointVentures" xml:lang="en-US">Minority interest in joint ventures</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_MinorityInterestInJointVentures" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_MinorityInterestInJointVentures"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_K196K48I138K_us-gaap_BusinessCombinationConsiderationTransferred1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_BusinessCombinationConsiderationTransferred1" xml:lang="en-US">Business Combination, Consideration Transferred</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_BusinessCombinationConsiderationTransferred1" xml:lang="en-US">Option to acquire additional shares amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_M318M60K350M_us-gaap_BusinessCombinationConsiderationTransferred1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableDescription" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableDescription" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableDescription" xml:lang="en-US">Percentage of equity interest in public offerings</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableDescription" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableDescription"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="loc_K196K48I138K_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xml:lang="en-US">Minority interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="lab_M318M60K350M_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentOptionsExpirationDate" xlink:label="loc_8H6FHF4I49GG985JF602_invest_InvestmentOptionsExpirationDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_invest_InvestmentOptionsExpirationDate" xml:lang="en-US">Investment Options, Expiration Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_invest_InvestmentOptionsExpirationDate" xml:lang="en-US">Options expired date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_invest_InvestmentOptionsExpirationDate" xlink:to="lab_0J8HJH6K61II107LH824_invest_InvestmentOptionsExpirationDate"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_NotesPayableAndAdvancesPayableTable" xlink:label="loc_K196K48I138K_immd_NotesPayableAndAdvancesPayableTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_immd_NotesPayableAndAdvancesPayableTable" xml:lang="en-US">Notes Payable And Advances Payable [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_immd_NotesPayableAndAdvancesPayableTable" xlink:to="lab_M318M60K350M_immd_NotesPayableAndAdvancesPayableTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfFinancingReceivableTypeOfBorrowerAxis" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerAxis" xml:lang="en-US">Class of Financing Receivable, Type of Borrower [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerAxis" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfFinancingReceivableTypeOfBorrowerDomain" xlink:label="loc_K196K48I138K_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerDomain" xml:lang="en-US">Class of Financing Receivable, Type of Borrower [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerDomain" xlink:to="lab_M318M60K350M_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerDomain"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_CommercialLenderMember" xlink:label="loc_8H6FHF4I49GG985JF602_immd_CommercialLenderMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_immd_CommercialLenderMember" xml:lang="en-US">Commercial Lender [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_immd_CommercialLenderMember" xml:lang="en-US">Commercial Lender [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_immd_CommercialLenderMember" xlink:to="lab_0J8HJH6K61II107LH824_immd_CommercialLenderMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_K196K48I138K_us-gaap_TitleOfIndividualAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_TitleOfIndividualAxis" xlink:to="lab_M318M60K350M_us-gaap_TitleOfIndividualAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Relationship to Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BoardOfDirectorsChairmanMember" xlink:label="loc_K196K48I138K_us-gaap_BoardOfDirectorsChairmanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_BoardOfDirectorsChairmanMember" xml:lang="en-US">Board of Directors Chairman [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_BoardOfDirectorsChairmanMember" xml:lang="en-US">Officers, Directors and Other [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_BoardOfDirectorsChairmanMember" xml:lang="en-US">Board of Directors Chairman [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_BoardOfDirectorsChairmanMember" xlink:to="lab_M318M60K350M_us-gaap_BoardOfDirectorsChairmanMember"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_NotesPayableAndAdvancesPayableLineItems" xlink:label="loc_8H6FHF4I49GG985JF602_immd_NotesPayableAndAdvancesPayableLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_immd_NotesPayableAndAdvancesPayableLineItems" xml:lang="en-US">Notes Payable And Advances Payable [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_immd_NotesPayableAndAdvancesPayableLineItems" xlink:to="lab_0J8HJH6K61II107LH824_immd_NotesPayableAndAdvancesPayableLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_K196K48I138K_us-gaap_ProceedsFromNotesPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_ProceedsFromNotesPayable" xml:lang="en-US">Proceeds from Notes Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_ProceedsFromNotesPayable" xml:lang="en-US">Borrowed</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_ProceedsFromNotesPayable" xml:lang="en-US">Borrowed from commercial lender</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_M318M60K350M_us-gaap_ProceedsFromNotesPayable" xml:lang="en-US">Borrowing</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_ProceedsFromNotesPayable" xlink:to="lab_M318M60K350M_us-gaap_ProceedsFromNotesPayable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_ConversionOfStockAmountConverted1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ConversionOfStockAmountConverted1" xml:lang="en-US">Conversion of Stock, Amount Converted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ConversionOfStockAmountConverted1" xml:lang="en-US">Conversion to common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_ConversionOfStockAmountConverted1" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_ConversionOfStockAmountConverted1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_K196K48I138K_us-gaap_DebtInstrumentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_DebtInstrumentTable" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_DebtInstrumentTable" xlink:to="lab_M318M60K350M_us-gaap_DebtInstrumentTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OfficerMember" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_OfficerMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_OfficerMember" xml:lang="en-US">Officer [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_OfficerMember" xml:lang="en-US">Officer [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_OfficerMember" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_OfficerMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorityShareholderMember" xlink:label="loc_K196K48I138K_us-gaap_MajorityShareholderMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_MajorityShareholderMember" xml:lang="en-US">Majority Shareholder [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_MajorityShareholderMember" xml:lang="en-US">Two Shareholders [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_MajorityShareholderMember" xlink:to="lab_M318M60K350M_us-gaap_MajorityShareholderMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_ShortTermDebtTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ShortTermDebtTypeAxis" xml:lang="en-US">Short-term Debt, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_ShortTermDebtTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_K196K48I138K_us-gaap_ShortTermDebtTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_ShortTermDebtTypeDomain" xml:lang="en-US">Short-term Debt, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_M318M60K350M_us-gaap_ShortTermDebtTypeDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_NotesPayableOtherPayablesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_NotesPayableOtherPayablesMember" xml:lang="en-US">Notes Payable, Other Payables [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_NotesPayableOtherPayablesMember" xml:lang="en-US">Notes Payable [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_NotesPayableOtherPayablesMember" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_NotesPayableOtherPayablesMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_K196K48I138K_us-gaap_CashAndCashEquivalentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_CashAndCashEquivalentsAxis" xml:lang="en-US">Cash and Cash Equivalents [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_M318M60K350M_us-gaap_CashAndCashEquivalentsAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xml:lang="en-US">Cash and Cash Equivalents [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_K196K48I138K_us-gaap_CommercialPaperMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_CommercialPaperMember" xml:lang="en-US">Commercial Paper [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_CommercialPaperMember" xml:lang="en-US">Promissory note [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_CommercialPaperMember" xlink:to="lab_M318M60K350M_us-gaap_CommercialPaperMember"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_CommercialPaperOneMember" xlink:label="loc_8H6FHF4I49GG985JF602_immd_CommercialPaperOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_immd_CommercialPaperOneMember" xml:lang="en-US">Commercial Paper One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_immd_CommercialPaperOneMember" xml:lang="en-US">Promissory note one [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_0J8HJH6K61II107LH824_immd_CommercialPaperOneMember" xml:lang="en-US">Commercial paper one .</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_immd_CommercialPaperOneMember" xlink:to="lab_0J8HJH6K61II107LH824_immd_CommercialPaperOneMember"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_CommercialPaperTwoMember" xlink:label="loc_K196K48I138K_immd_CommercialPaperTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_immd_CommercialPaperTwoMember" xml:lang="en-US">Commercial Paper Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_immd_CommercialPaperTwoMember" xml:lang="en-US">Promissory note two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M318M60K350M_immd_CommercialPaperTwoMember" xml:lang="en-US">Commercial paper two.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_immd_CommercialPaperTwoMember" xlink:to="lab_M318M60K350M_immd_CommercialPaperTwoMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_SubsequentEventTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_SubsequentEventTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_K196K48I138K_us-gaap_SubsequentEventTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_M318M60K350M_us-gaap_SubsequentEventTypeDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_SubsequentEventMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Events [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_SubsequentEventMember" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_SubsequentEventMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_K196K48I138K_us-gaap_DebtInstrumentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_DebtInstrumentLineItems" xml:lang="en-US">Debt Instrument [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_DebtInstrumentLineItems" xlink:to="lab_M318M60K350M_us-gaap_DebtInstrumentLineItems"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_NotesPayableTextualAbstract" xlink:label="loc_8H6FHF4I49GG985JF602_immd_NotesPayableTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_immd_NotesPayableTextualAbstract" xml:lang="en-US">Notes Payable Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_immd_NotesPayableTextualAbstract" xml:lang="en-US">Notes Payable (Textual)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_immd_NotesPayableTextualAbstract" xml:lang="en-US">Notes Payable (Textual)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_0J8HJH6K61II107LH824_immd_NotesPayableTextualAbstract" xml:lang="en-US">Notes payable textual.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_immd_NotesPayableTextualAbstract" xlink:to="lab_0J8HJH6K61II107LH824_immd_NotesPayableTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_K196K48I138K_us-gaap_ConvertibleNotesPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_ConvertibleNotesPayable" xml:lang="en-US">Convertible Notes Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_ConvertibleNotesPayable" xml:lang="en-US">Loans outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_ConvertibleNotesPayable" xml:lang="en-US">Convertible notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_ConvertibleNotesPayable" xlink:to="lab_M318M60K350M_us-gaap_ConvertibleNotesPayable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_SharesIssuedPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Shares Issued, Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Stock price per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Shares Issued, Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Stock price per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_SharesIssuedPricePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentPaymentTerms" xlink:label="loc_K196K48I138K_us-gaap_DebtInstrumentPaymentTerms" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_DebtInstrumentPaymentTerms" xml:lang="en-US">Debt Instrument, Payment Terms</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_DebtInstrumentPaymentTerms" xml:lang="en-US">Loan payable payment terms</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_DebtInstrumentPaymentTerms" xlink:to="lab_M318M60K350M_us-gaap_DebtInstrumentPaymentTerms"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_DebtInstrumentInterestRateStatedPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Interest rate on notes payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Interest rate on notes payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Interest rate on notes payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_K196K48I138K_us-gaap_DebtInstrumentMaturityDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_DebtInstrumentMaturityDate" xml:lang="en-US">Debt Instrument, Maturity Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_DebtInstrumentMaturityDate" xml:lang="en-US">Maturity date on notes payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_DebtInstrumentMaturityDate" xlink:to="lab_M318M60K350M_us-gaap_DebtInstrumentMaturityDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_InterestExpenseDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_InterestExpenseDebt" xml:lang="en-US">Interest Expense, Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_InterestExpenseDebt" xml:lang="en-US">Interest expense on notes payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_InterestExpenseDebt" xml:lang="en-US">Interest expense on notes payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_InterestExpenseDebt" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_InterestExpenseDebt"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_K196K48I138K_us-gaap_DebtInstrumentInterestRateDuringPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_DebtInstrumentInterestRateDuringPeriod" xml:lang="en-US">Debt Instrument, Interest Rate During Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_DebtInstrumentInterestRateDuringPeriod" xml:lang="en-US">Interest rate period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="lab_M318M60K350M_us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_NotesPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_NotesPayable" xml:lang="en-US">Notes Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_NotesPayable" xml:lang="en-US">Note repaid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_NotesPayable" xml:lang="en-US">Promissary note</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/zeroLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_NotesPayable" xml:lang="en-US">Note payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_NotesPayable" xml:lang="en-US">Promissary note</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_NotesPayable" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_NotesPayable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_K196K48I138K_us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xml:lang="en-US">Common stock for maximum offering</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_M318M60K350M_us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_DebtInstrumentFaceAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Debt Instrument, Face Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Outstanding principal balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Repaid of principal amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_DebtInstrumentFaceAmount"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesAndLoansPayableCurrent" xlink:label="loc_K196K48I138K_us-gaap_NotesAndLoansPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_NotesAndLoansPayableCurrent" xml:lang="en-US">Notes and Loans Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_NotesAndLoansPayableCurrent" xml:lang="en-US">Outsatanding balance of notes payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_NotesAndLoansPayableCurrent" xlink:to="lab_M318M60K350M_us-gaap_NotesAndLoansPayableCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_ConvertibleDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ConvertibleDebt" xml:lang="en-US">Convertible Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ConvertibleDebt" xml:lang="en-US">Convertible promissory note</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_ConvertibleDebt" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_ConvertibleDebt"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_K196K48I138K_us-gaap_DebtInstrumentConvertibleConversionPrice1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US">Conversion price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_M318M60K350M_us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentOptionsExercisePrice" xlink:label="loc_8H6FHF4I49GG985JF602_invest_InvestmentOptionsExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_invest_InvestmentOptionsExercisePrice" xml:lang="en-US">Investment Options, Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_invest_InvestmentOptionsExercisePrice" xml:lang="en-US">Exercise price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_invest_InvestmentOptionsExercisePrice" xlink:to="lab_0J8HJH6K61II107LH824_invest_InvestmentOptionsExercisePrice"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_TermOfWarrant" xlink:label="loc_K196K48I138K_immd_TermOfWarrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_immd_TermOfWarrant" xml:lang="en-US">Term Of Warrant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_immd_TermOfWarrant" xml:lang="en-US">Term of warrant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M318M60K350M_immd_TermOfWarrant" xml:lang="en-US">Term of warrant.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_immd_TermOfWarrant" xlink:to="lab_M318M60K350M_immd_TermOfWarrant"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xml:lang="en-US">Components of deferred tax liabilities and assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_K196K48I138K_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Net operating loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_M318M60K350M_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Allowance for Doubtful Accounts</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xml:lang="en-US">Accounts receivable reserves</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="loc_K196K48I138K_us-gaap_DeferredTaxAssetsInventory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_DeferredTaxAssetsInventory" xml:lang="en-US">Deferred Tax Assets, Inventory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_DeferredTaxAssetsInventory" xml:lang="en-US">Inventory Reserve Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_DeferredTaxAssetsInventory" xml:lang="en-US">Inventory reserves</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_DeferredTaxAssetsInventory" xlink:to="lab_M318M60K350M_us-gaap_DeferredTaxAssetsInventory"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US">Stock Compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_K196K48I138K_us-gaap_DeferredTaxAssetsGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Deferred Tax Assets, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Net deferred tax assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_M318M60K350M_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Net deferred tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_M318M60K350M_us-gaap_DeferredTaxAssetsGross"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_DeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Valuation allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Valuation allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_DeferredTaxAssetsValuationAllowance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_K196K48I138K_us-gaap_DeferredTaxAssetsLiabilitiesNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_DeferredTaxAssetsLiabilitiesNet" xml:lang="en-US">Deferred Tax Assets, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_M318M60K350M_us-gaap_DeferredTaxAssetsLiabilitiesNet" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_M318M60K350M_us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_IncomeTaxesTextualAbstract" xlink:label="loc_8H6FHF4I49GG985JF602_immd_IncomeTaxesTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_immd_IncomeTaxesTextualAbstract" xml:lang="en-US">Income Taxes Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_immd_IncomeTaxesTextualAbstract" xml:lang="en-US">Income Taxes (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_immd_IncomeTaxesTextualAbstract" xlink:to="lab_0J8HJH6K61II107LH824_immd_IncomeTaxesTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_K196K48I138K_us-gaap_OperatingLossCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Net operating loss carryforwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_OperatingLossCarryforwards" xlink:to="lab_M318M60K350M_us-gaap_OperatingLossCarryforwards"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_OperatingLossCarryforwardsExpirationDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_OperatingLossCarryforwardsExpirationDate" xml:lang="en-US">Operating Loss Carryforwards, Expiration Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_OperatingLossCarryforwardsExpirationDate" xml:lang="en-US">Operating loss carryforwards, expiration date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_OperatingLossCarryforwardsExpirationDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_K196K48I138K_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Percentage of tax rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_M318M60K350M_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Number of Options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Warrants outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Number of Options/Warrants, Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Number of Options/Warrants, Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_K196K48I138K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xml:lang="en-US">Number of Shares, Expired</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xml:lang="en-US">Number of shares, expired</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_M318M60K350M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xml:lang="en-US">Number of Shares, Expired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_M318M60K350M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Number of options, cancelled</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Number of Shares, Cancelled</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Number of Options, Cancelled</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_K196K48I138K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Number of options, Granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Number of Options, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_M318M60K350M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Number of Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/zeroLabel" xlink:label="lab_M318M60K350M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Options granted, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_M318M60K350M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Number of stock options issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_M318M60K350M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_RangeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_RangeAxis" xml:lang="en-US">Range [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_RangeAxis" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_RangeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_K196K48I138K_us-gaap_RangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_RangeMember" xml:lang="en-US">Range [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_RangeMember" xlink:to="lab_M318M60K350M_us-gaap_RangeMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_MaximumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_MaximumMember" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_MaximumMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_K196K48I138K_us-gaap_MinimumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_MinimumMember" xlink:to="lab_M318M60K350M_us-gaap_MinimumMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xml:lang="en-US">Summary of significant assumptions used to determine the fair values of options using black-scholes option-pricing model</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xml:lang="en-US">Summary of fair value of options and warrants granted using black-scholes option-pricing model with weighted-average assumptions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_K196K48I138K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk-free interest rate at grant date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk free interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_M318M60K350M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Expected stock price volatility</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Expected volatility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_K196K48I138K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Expected dividend payout</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Expected dividend yield</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_M318M60K350M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Expected option life-years</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/exampleGuidance" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Expected option term (in years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_K196K48I138K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xml:lang="en-US">Weighted average grant date fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="lab_M318M60K350M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairvalueAssumptionsForfeitureRate" xlink:label="loc_8H6FHF4I49GG985JF602_immd_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairvalueAssumptionsForfeitureRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_immd_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairvalueAssumptionsForfeitureRate" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fairvalue Assumptions Forfeiture Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_immd_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairvalueAssumptionsForfeitureRate" xml:lang="en-US">Forfeiture rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_0J8HJH6K61II107LH824_immd_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairvalueAssumptionsForfeitureRate" xml:lang="en-US">Share based compensation arrangement by share Based Payment Award fair value assumptions forfeiture rate.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_immd_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairvalueAssumptionsForfeitureRate" xlink:to="lab_0J8HJH6K61II107LH824_immd_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairvalueAssumptionsForfeitureRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_K196K48I138K_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xml:lang="en-US">Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="lab_M318M60K350M_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xml:lang="en-US">Exercise Price Range [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_K196K48I138K_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="lab_M318M60K350M_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ExercisePriceRangeOneMember" xlink:label="loc_8H6FHF4I49GG985JF602_immd_ExercisePriceRangeOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_immd_ExercisePriceRangeOneMember" xml:lang="en-US">Exercise Price Range One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_immd_ExercisePriceRangeOneMember" xml:lang="en-US">$0.10 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_0J8HJH6K61II107LH824_immd_ExercisePriceRangeOneMember" xml:lang="en-US">Exercise price range one.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_immd_ExercisePriceRangeOneMember" xlink:to="lab_0J8HJH6K61II107LH824_immd_ExercisePriceRangeOneMember"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ExercisePriceRangeTwoMember" xlink:label="loc_K196K48I138K_immd_ExercisePriceRangeTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_immd_ExercisePriceRangeTwoMember" xml:lang="en-US">Exercise Price Range Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_immd_ExercisePriceRangeTwoMember" xml:lang="en-US">$0.20 - $0.25 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M318M60K350M_immd_ExercisePriceRangeTwoMember" xml:lang="en-US">Exercise price range two member.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_immd_ExercisePriceRangeTwoMember" xlink:to="lab_M318M60K350M_immd_ExercisePriceRangeTwoMember"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ExercisePriceRangeThreeMember" xlink:label="loc_8H6FHF4I49GG985JF602_immd_ExercisePriceRangeThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_immd_ExercisePriceRangeThreeMember" xml:lang="en-US">Exercise Price Range Three [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_immd_ExercisePriceRangeThreeMember" xml:lang="en-US">0.40 - $0.50 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_0J8HJH6K61II107LH824_immd_ExercisePriceRangeThreeMember" xml:lang="en-US">Exercise price range three member.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_immd_ExercisePriceRangeThreeMember" xlink:to="lab_0J8HJH6K61II107LH824_immd_ExercisePriceRangeThreeMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_K196K48I138K_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="lab_M318M60K350M_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Beginning of Period [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract" xml:lang="en-US">Summary of outstanding service-based options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_K196K48I138K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price of warrants outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_M318M60K350M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Beginning Balance,</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_M318M60K350M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Ending Balance,</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:label="lab_M318M60K350M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_M318M60K350M_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Weighted Average Remaining Contractual Life</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_K196K48I138K_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price stock option issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Exercise price, Granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/zeroLabel" xlink:label="lab_M318M60K350M_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_M318M60K350M_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price, Expired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ShareBasedCompensationArrangementByShareBasedPaymentBeinningYearOfExpiration" xlink:label="loc_K196K48I138K_immd_ShareBasedCompensationArrangementByShareBasedPaymentBeinningYearOfExpiration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_immd_ShareBasedCompensationArrangementByShareBasedPaymentBeinningYearOfExpiration" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Beinning Year Of Expiration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_immd_ShareBasedCompensationArrangementByShareBasedPaymentBeinningYearOfExpiration" xml:lang="en-US">Year of Expiration, Begining Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M318M60K350M_immd_ShareBasedCompensationArrangementByShareBasedPaymentBeinningYearOfExpiration" xml:lang="en-US">Share based compensation arrangement by share based payment during period year of expiration.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_immd_ShareBasedCompensationArrangementByShareBasedPaymentBeinningYearOfExpiration" xlink:to="lab_M318M60K350M_immd_ShareBasedCompensationArrangementByShareBasedPaymentBeinningYearOfExpiration"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationIssued" xlink:label="loc_8H6FHF4I49GG985JF602_immd_ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_immd_ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationIssued" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Year Of Expiration, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_immd_ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationIssued" xml:lang="en-US">Year of Expiration, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_0J8HJH6K61II107LH824_immd_ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationIssued" xml:lang="en-US">Share based compensation arrangement by share based payment during period Issued.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_immd_ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationIssued" xlink:to="lab_0J8HJH6K61II107LH824_immd_ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationIssued"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationExpired" xlink:label="loc_K196K48I138K_immd_ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationExpired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_immd_ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationExpired" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Year Of Expiration, Expired</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_immd_ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationExpired" xml:lang="en-US">Year of Expiration, Expired</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M318M60K350M_immd_ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationExpired" xml:lang="en-US">Share based compensation arrangement by share based payment during period expired.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_immd_ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationExpired" xlink:to="lab_M318M60K350M_immd_ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationExpired"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ShareBasedCompensationArrangementByShareBasedPaymentEndingYearOfExpiration" xlink:label="loc_8H6FHF4I49GG985JF602_immd_ShareBasedCompensationArrangementByShareBasedPaymentEndingYearOfExpiration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_immd_ShareBasedCompensationArrangementByShareBasedPaymentEndingYearOfExpiration" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Ending Year Of Expiration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_immd_ShareBasedCompensationArrangementByShareBasedPaymentEndingYearOfExpiration" xml:lang="en-US">Year of Expiration, Ending Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_0J8HJH6K61II107LH824_immd_ShareBasedCompensationArrangementByShareBasedPaymentEndingYearOfExpiration" xml:lang="en-US">Share based compensation arrangement by share based payment during period year of expiration.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_immd_ShareBasedCompensationArrangementByShareBasedPaymentEndingYearOfExpiration" xlink:to="lab_0J8HJH6K61II107LH824_immd_ShareBasedCompensationArrangementByShareBasedPaymentEndingYearOfExpiration"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:label="loc_K196K48I138K_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xml:lang="en-US">Schedule of Deferred Compensation Arrangement with Individual, Share-based Payments [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:to="lab_M318M60K350M_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestorMember" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_InvestorMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_InvestorMember" xml:lang="en-US">Investor [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_InvestorMember" xml:lang="en-US">Investor [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_InvestorMember" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_InvestorMember"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ShareholderMember" xlink:label="loc_K196K48I138K_immd_ShareholderMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_immd_ShareholderMember" xml:lang="en-US">Shareholder [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_immd_ShareholderMember" xml:lang="en-US">Shareholder [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_immd_ShareholderMember" xlink:to="lab_M318M60K350M_immd_ShareholderMember"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ConsultantMember" xlink:label="loc_8H6FHF4I49GG985JF602_immd_ConsultantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_immd_ConsultantMember" xml:lang="en-US">Consultant [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_immd_ConsultantMember" xml:lang="en-US">Two consultants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_immd_ConsultantMember" xml:lang="en-US">Consultants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_0J8HJH6K61II107LH824_immd_ConsultantMember" xml:lang="en-US">Consultant.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_immd_ConsultantMember" xlink:to="lab_0J8HJH6K61II107LH824_immd_ConsultantMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_K196K48I138K_us-gaap_DirectorMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_DirectorMember" xml:lang="en-US">Director [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_DirectorMember" xml:lang="en-US">Director [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_DirectorMember" xlink:to="lab_M318M60K350M_us-gaap_DirectorMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PresidentMember" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_PresidentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_PresidentMember" xml:lang="en-US">President [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_PresidentMember" xml:lang="en-US">President [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_PresidentMember" xml:lang="en-US">Mr. McLaughlin [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_PresidentMember" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_PresidentMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_K196K48I138K_us-gaap_SubsidiarySaleOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_M318M60K350M_us-gaap_SubsidiarySaleOfStockAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_SaleOfStockNameOfTransactionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_SaleOfStockNameOfTransactionDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_K196K48I138K_us-gaap_IPOMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_IPOMember" xml:lang="en-US">IPO [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_IPOMember" xml:lang="en-US">IPO [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_IPOMember" xml:lang="en-US">Sale of common stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_IPOMember" xlink:to="lab_M318M60K350M_us-gaap_IPOMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_8H6FHF4I49GG985JF602_dei_LegalEntityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_dei_LegalEntityAxis" xlink:to="lab_0J8HJH6K61II107LH824_dei_LegalEntityAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_K196K48I138K_dei_EntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_dei_EntityDomain" xlink:to="lab_M318M60K350M_dei_EntityDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_StockholdersEquityTextualAbstract" xlink:label="loc_K196K48I138K_immd_StockholdersEquityTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_immd_StockholdersEquityTextualAbstract" xml:lang="en-US">Stockholders Equity Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_immd_StockholdersEquityTextualAbstract" xml:lang="en-US">Stockholder's Equity (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_immd_StockholdersEquityTextualAbstract" xlink:to="lab_M318M60K350M_immd_StockholdersEquityTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xml:lang="en-US">Accrued Royalties</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xml:lang="en-US">Royalties payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_K196K48I138K_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Stock expiration period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Options expiration period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_M318M60K350M_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Warrants exercise price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Weighted average exercise price of warrants outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xlink:label="loc_K196K48I138K_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xml:lang="en-US">Stock Granted, Value, Share-based Compensation, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xml:lang="en-US">Options granted, value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xml:lang="en-US">Number of options granted, value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xlink:to="lab_M318M60K350M_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_AllocatedShareBasedCompensationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Stock based compensation expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Recognized expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_AllocatedShareBasedCompensationExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_K196K48I138K_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Warrants issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_M318M60K350M_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Period Increase (Decrease), Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xml:lang="en-US">Options exercise price, per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockOtherSharesOutstanding" xlink:label="loc_K196K48I138K_us-gaap_CommonStockOtherSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_CommonStockOtherSharesOutstanding" xml:lang="en-US">Common Stock, Other Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_CommonStockOtherSharesOutstanding" xml:lang="en-US">Outstanding shares purchased</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_CommonStockOtherSharesOutstanding" xlink:to="lab_M318M60K350M_us-gaap_CommonStockOtherSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_PurchaseOfCommonStockDescriptionOfTransaction" xlink:label="loc_8H6FHF4I49GG985JF602_immd_PurchaseOfCommonStockDescriptionOfTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_immd_PurchaseOfCommonStockDescriptionOfTransaction" xml:lang="en-US">Purchase Of Common Stock Description Of Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_immd_PurchaseOfCommonStockDescriptionOfTransaction" xml:lang="en-US">Purchase of common stock description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_0J8HJH6K61II107LH824_immd_PurchaseOfCommonStockDescriptionOfTransaction" xml:lang="en-US">It represents about purchase price of common stock description.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_immd_PurchaseOfCommonStockDescriptionOfTransaction" xlink:to="lab_0J8HJH6K61II107LH824_immd_PurchaseOfCommonStockDescriptionOfTransaction"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_K196K48I138K_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Options fully vested and expiration period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_M318M60K350M_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xml:lang="en-US">Shares of common stock fully vested service-based options issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_NumberOfConsultant" xlink:label="loc_K196K48I138K_immd_NumberOfConsultant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_immd_NumberOfConsultant" xml:lang="en-US">Number Of Consultant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_immd_NumberOfConsultant" xml:lang="en-US">Number of consultant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M318M60K350M_immd_NumberOfConsultant" xml:lang="en-US">Number of consultant.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_immd_NumberOfConsultant" xlink:to="lab_M318M60K350M_immd_NumberOfConsultant"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Intrinsic value of options outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_K196K48I138K_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Intrinsic value of options exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_M318M60K350M_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xml:lang="en-US">Intrinsic value of options exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_PerformanceBasedStockOptionsMember" xlink:label="loc_K196K48I138K_immd_PerformanceBasedStockOptionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_immd_PerformanceBasedStockOptionsMember" xml:lang="en-US">Performance Based Stock Options [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_immd_PerformanceBasedStockOptionsMember" xml:lang="en-US">Performance Based Stock Options [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M318M60K350M_immd_PerformanceBasedStockOptionsMember" xml:lang="en-US">Performance based stock options.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_immd_PerformanceBasedStockOptionsMember" xlink:to="lab_M318M60K350M_immd_PerformanceBasedStockOptionsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationEquity" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_DeferredCompensationEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_DeferredCompensationEquity" xml:lang="en-US">Deferred Compensation Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_DeferredCompensationEquity" xml:lang="en-US">Unearned share based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_DeferredCompensationEquity" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_DeferredCompensationEquity"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_FairValueOfPerformanceBasedStockOptions" xlink:label="loc_K196K48I138K_immd_FairValueOfPerformanceBasedStockOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_immd_FairValueOfPerformanceBasedStockOptions" xml:lang="en-US">Fair Value Of Performance Based Stock Options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_immd_FairValueOfPerformanceBasedStockOptions" xml:lang="en-US">Fair value of performance-based stock options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M318M60K350M_immd_FairValueOfPerformanceBasedStockOptions" xml:lang="en-US">Fair value of performance-based stock options.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_immd_FairValueOfPerformanceBasedStockOptions" xlink:to="lab_M318M60K350M_immd_FairValueOfPerformanceBasedStockOptions"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xml:lang="en-US">Stock options, Expiration date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xml:lang="en-US">Stock options, expiration date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_AnnualSalesRevenueTarget" xlink:label="loc_K196K48I138K_immd_AnnualSalesRevenueTarget" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_immd_AnnualSalesRevenueTarget" xml:lang="en-US">Annual Sales Revenue Target</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_immd_AnnualSalesRevenueTarget" xml:lang="en-US">Annual sales revenue target</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M318M60K350M_immd_AnnualSalesRevenueTarget" xml:lang="en-US">Stock options exercisable upon the Company achieving annual sales revenue.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_immd_AnnualSalesRevenueTarget" xlink:to="lab_M318M60K350M_immd_AnnualSalesRevenueTarget"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableFairValue" xlink:label="loc_8H6FHF4I49GG985JF602_immd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_immd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableFairValue" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_immd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableFairValue" xml:lang="en-US">Fair value of options exercisable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_0J8HJH6K61II107LH824_immd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableFairValue" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Fair Value.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_immd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableFairValue" xlink:to="lab_0J8HJH6K61II107LH824_immd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableFairValue"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ConsultingServicesMember" xlink:label="loc_K196K48I138K_immd_ConsultingServicesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_immd_ConsultingServicesMember" xml:lang="en-US">Consulting Services [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_immd_ConsultingServicesMember" xml:lang="en-US">Consulting services [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_immd_ConsultingServicesMember" xlink:to="lab_M318M60K350M_immd_ConsultingServicesMember"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_IssuanceOfCommonStockMember" xlink:label="loc_8H6FHF4I49GG985JF602_immd_IssuanceOfCommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_immd_IssuanceOfCommonStockMember" xml:lang="en-US">Issuance Of Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_immd_IssuanceOfCommonStockMember" xml:lang="en-US">Issuance of Common Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_immd_IssuanceOfCommonStockMember" xlink:to="lab_0J8HJH6K61II107LH824_immd_IssuanceOfCommonStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_K196K48I138K_us-gaap_FairValueAdjustmentOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Fair Value Adjustment of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Fair value of warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_M318M60K350M_us-gaap_FairValueAdjustmentOfWarrants"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Warrants fully vested and expiration period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_K196K48I138K_us-gaap_ClassOfWarrantOrRightOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Warrants outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_M318M60K350M_us-gaap_ClassOfWarrantOrRightOutstanding"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_WarrantExercisable" xlink:label="loc_8H6FHF4I49GG985JF602_immd_WarrantExercisable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_immd_WarrantExercisable" xml:lang="en-US">Warrant Exercisable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_immd_WarrantExercisable" xml:lang="en-US">Warrant exercisable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_0J8HJH6K61II107LH824_immd_WarrantExercisable" xml:lang="en-US">Number of warrants exercisable.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_immd_WarrantExercisable" xlink:to="lab_0J8HJH6K61II107LH824_immd_WarrantExercisable"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_WarrantsExpireDateDescription" xlink:label="loc_K196K48I138K_immd_WarrantsExpireDateDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_immd_WarrantsExpireDateDescription" xml:lang="en-US">Warrants Expire Date Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_immd_WarrantsExpireDateDescription" xml:lang="en-US">Warrant expiration date, description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M318M60K350M_immd_WarrantsExpireDateDescription" xml:lang="en-US">Description of warrant expiration date.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_immd_WarrantsExpireDateDescription" xlink:to="lab_M318M60K350M_immd_WarrantsExpireDateDescription"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_LaborAndRelatedExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_LaborAndRelatedExpense" xml:lang="en-US">Labor and Related Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_LaborAndRelatedExpense" xml:lang="en-US">Compensation and related expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_LaborAndRelatedExpense" xml:lang="en-US">Compensation and related expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_LaborAndRelatedExpense" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_LaborAndRelatedExpense"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_RoyaltiesTextualAbstract" xlink:label="loc_K196K48I138K_immd_RoyaltiesTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_immd_RoyaltiesTextualAbstract" xml:lang="en-US">Royalties Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_immd_RoyaltiesTextualAbstract" xml:lang="en-US">Royalties (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_immd_RoyaltiesTextualAbstract" xlink:to="lab_M318M60K350M_immd_RoyaltiesTextualAbstract"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_PercentageOfRoyaltyBasedUponSales" xlink:label="loc_8H6FHF4I49GG985JF602_immd_PercentageOfRoyaltyBasedUponSales" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_immd_PercentageOfRoyaltyBasedUponSales" xml:lang="en-US">Percentage Of Royalty Based Upon Sales</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_immd_PercentageOfRoyaltyBasedUponSales" xml:lang="en-US">Percentage of royalty based upon sales</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_0J8HJH6K61II107LH824_immd_PercentageOfRoyaltyBasedUponSales" xml:lang="en-US">The percentage of royalty based upon sales.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_immd_PercentageOfRoyaltyBasedUponSales" xlink:to="lab_0J8HJH6K61II107LH824_immd_PercentageOfRoyaltyBasedUponSales"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_RoyaltyBasedUponSalesAmount" xlink:label="loc_K196K48I138K_immd_RoyaltyBasedUponSalesAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_immd_RoyaltyBasedUponSalesAmount" xml:lang="en-US">Royalty Based Upon Sales Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_immd_RoyaltyBasedUponSalesAmount" xml:lang="en-US">Royalty based upon sales amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M318M60K350M_immd_RoyaltyBasedUponSalesAmount" xml:lang="en-US">The amount of royalty based upon sales.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_immd_RoyaltyBasedUponSalesAmount" xlink:to="lab_M318M60K350M_immd_RoyaltyBasedUponSalesAmount"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_RoyaltyExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_RoyaltyExpense" xml:lang="en-US">Royalty Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_RoyaltyExpense" xml:lang="en-US">Royalty expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_RoyaltyExpense" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_RoyaltyExpense"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_InterestInRoyalty" xlink:label="loc_K196K48I138K_immd_InterestInRoyalty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_immd_InterestInRoyalty" xml:lang="en-US">Interest In Royalty</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_immd_InterestInRoyalty" xml:lang="en-US">Interest in royalty</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M318M60K350M_immd_InterestInRoyalty" xml:lang="en-US">The percentage of interest in royalty.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_immd_InterestInRoyalty" xlink:to="lab_M318M60K350M_immd_InterestInRoyalty"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xml:lang="en-US">Accounts Payable and Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xml:lang="en-US">Accounts payable and accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_CommitmentsAndContingenciesTable" xlink:label="loc_K196K48I138K_immd_CommitmentsAndContingenciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_immd_CommitmentsAndContingenciesTable" xml:lang="en-US">Commitments And Contingencies [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M318M60K350M_immd_CommitmentsAndContingenciesTable" xml:lang="en-US">This table lists commitments and contingencies.The line items identify information about the commitments and contingencies.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_immd_CommitmentsAndContingenciesTable" xlink:to="lab_M318M60K350M_immd_CommitmentsAndContingenciesTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_RestrictedStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_RestrictedStockMember" xml:lang="en-US">Restricted Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_RestrictedStockMember" xml:lang="en-US">Restricted Stock and Options [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_RestrictedStockMember" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_RestrictedStockMember"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_RestrictedStockOneMember" xlink:label="loc_K196K48I138K_immd_RestrictedStockOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_immd_RestrictedStockOneMember" xml:lang="en-US">Restricted Stock One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_immd_RestrictedStockOneMember" xml:lang="en-US">Restricted Stock One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M318M60K350M_immd_RestrictedStockOneMember" xml:lang="en-US">Restricted stock one.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_immd_RestrictedStockOneMember" xlink:to="lab_M318M60K350M_immd_RestrictedStockOneMember"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_RestrictedStockTwoMember" xlink:label="loc_8H6FHF4I49GG985JF602_immd_RestrictedStockTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_immd_RestrictedStockTwoMember" xml:lang="en-US">Restricted Stock Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_immd_RestrictedStockTwoMember" xml:lang="en-US">Restricted Stock Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_0J8HJH6K61II107LH824_immd_RestrictedStockTwoMember" xml:lang="en-US">Restricted stock two.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_immd_RestrictedStockTwoMember" xlink:to="lab_0J8HJH6K61II107LH824_immd_RestrictedStockTwoMember"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_RestrictedStockThreeMember" xlink:label="loc_K196K48I138K_immd_RestrictedStockThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_immd_RestrictedStockThreeMember" xml:lang="en-US">Restricted Stock Three [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_immd_RestrictedStockThreeMember" xml:lang="en-US">Restricted Stock Three [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M318M60K350M_immd_RestrictedStockThreeMember" xml:lang="en-US">Restricted stock three.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_immd_RestrictedStockThreeMember" xlink:to="lab_M318M60K350M_immd_RestrictedStockThreeMember"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_CommitmentsAndContingenciesLineItems" xlink:label="loc_8H6FHF4I49GG985JF602_immd_CommitmentsAndContingenciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_immd_CommitmentsAndContingenciesLineItems" xml:lang="en-US">Commitments And Contingencies [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_0J8HJH6K61II107LH824_immd_CommitmentsAndContingenciesLineItems" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_immd_CommitmentsAndContingenciesLineItems" xlink:to="lab_0J8HJH6K61II107LH824_immd_CommitmentsAndContingenciesLineItems"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_CommitmentsAndContingenciesTextualAbstract" xlink:label="loc_K196K48I138K_immd_CommitmentsAndContingenciesTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_immd_CommitmentsAndContingenciesTextualAbstract" xml:lang="en-US">Commitments And Contingencies Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_immd_CommitmentsAndContingenciesTextualAbstract" xml:lang="en-US">Commitments and Contingencies (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_immd_CommitmentsAndContingenciesTextualAbstract" xlink:to="lab_M318M60K350M_immd_CommitmentsAndContingenciesTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_LeaseExpirationDate1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_LeaseExpirationDate1" xml:lang="en-US">Lease Expiration Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_LeaseExpirationDate1" xml:lang="en-US">Operating lease expired date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_LeaseExpirationDate1" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_LeaseExpirationDate1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:label="loc_K196K48I138K_us-gaap_OperatingLeasesRentExpenseMinimumRentals" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_OperatingLeasesRentExpenseMinimumRentals" xml:lang="en-US">Operating Leases, Rent Expense, Minimum Rentals</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_OperatingLeasesRentExpenseMinimumRentals" xml:lang="en-US">Monthly base lease rental payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:to="lab_M318M60K350M_us-gaap_OperatingLeasesRentExpenseMinimumRentals"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_LeaseAndRentalExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_LeaseAndRentalExpense" xml:lang="en-US">Operating Leases, Rent Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_LeaseAndRentalExpense" xml:lang="en-US">Operating leases, rent expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_LeaseAndRentalExpense" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_LeaseAndRentalExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="loc_K196K48I138K_us-gaap_SalariesWagesAndOfficersCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_SalariesWagesAndOfficersCompensation" xml:lang="en-US">Salaries, Wages and Officers' Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_SalariesWagesAndOfficersCompensation" xml:lang="en-US">Annual compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_SalariesWagesAndOfficersCompensation" xlink:to="lab_M318M60K350M_us-gaap_SalariesWagesAndOfficersCompensation"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xml:lang="en-US">Stock options, Exercise Price Range, Lower Range Limit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xml:lang="en-US">Stock option exercise prices lower range limit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_K196K48I138K_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xml:lang="en-US">Stock options, Exercise Price Range, Upper Range Limit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xml:lang="en-US">Stock option exercise prices upper range limit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="lab_M318M60K350M_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_StockIssuedDuringPeriodPerformanceBasedOptionsToPurchaseCommonStock" xlink:label="loc_8H6FHF4I49GG985JF602_immd_StockIssuedDuringPeriodPerformanceBasedOptionsToPurchaseCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_immd_StockIssuedDuringPeriodPerformanceBasedOptionsToPurchaseCommonStock" xml:lang="en-US">Stock Issued During Period Performance Based Options To Purchase Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_immd_StockIssuedDuringPeriodPerformanceBasedOptionsToPurchaseCommonStock" xml:lang="en-US">Stock issued during period performance based options to purchase common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_0J8HJH6K61II107LH824_immd_StockIssuedDuringPeriodPerformanceBasedOptionsToPurchaseCommonStock" xml:lang="en-US">Represents the performance based options issued by the company to purchase common stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_immd_StockIssuedDuringPeriodPerformanceBasedOptionsToPurchaseCommonStock" xlink:to="lab_0J8HJH6K61II107LH824_immd_StockIssuedDuringPeriodPerformanceBasedOptionsToPurchaseCommonStock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_K196K48I138K_us-gaap_SalesRevenueNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_SalesRevenueNet" xml:lang="en-US">Revenue, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_SalesRevenueNet" xml:lang="en-US">Annual revenue base</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_SalesRevenueNet" xlink:to="lab_M318M60K350M_us-gaap_SalesRevenueNet"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_SalesRevenueIncreased" xlink:label="loc_8H6FHF4I49GG985JF602_immd_SalesRevenueIncreased" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_immd_SalesRevenueIncreased" xml:lang="en-US">Sales Revenue Increased</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_immd_SalesRevenueIncreased" xml:lang="en-US">Annual revenue exceeding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_0J8HJH6K61II107LH824_immd_SalesRevenueIncreased" xml:lang="en-US">Sales revenue increased.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_immd_SalesRevenueIncreased" xlink:to="lab_0J8HJH6K61II107LH824_immd_SalesRevenueIncreased"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_BonusPercentageOfCompensationForPretaxIncome" xlink:label="loc_K196K48I138K_immd_BonusPercentageOfCompensationForPretaxIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_immd_BonusPercentageOfCompensationForPretaxIncome" xml:lang="en-US">Bonus Percentage Of Compensation For Pretax Income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_immd_BonusPercentageOfCompensationForPretaxIncome" xml:lang="en-US">Percentage of bonus compensation for pretax income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M318M60K350M_immd_BonusPercentageOfCompensationForPretaxIncome" xml:lang="en-US">Percentage of bonus agreement compensation for pretax income during the reporting period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_immd_BonusPercentageOfCompensationForPretaxIncome" xlink:to="lab_M318M60K350M_immd_BonusPercentageOfCompensationForPretaxIncome"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_PertaxIncomePercentage" xlink:label="loc_8H6FHF4I49GG985JF602_immd_PertaxIncomePercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_immd_PertaxIncomePercentage" xml:lang="en-US">Pertax Income Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_immd_PertaxIncomePercentage" xml:lang="en-US">Pertax income percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_0J8HJH6K61II107LH824_immd_PertaxIncomePercentage" xml:lang="en-US">Pertax income percentage.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_immd_PertaxIncomePercentage" xlink:to="lab_0J8HJH6K61II107LH824_immd_PertaxIncomePercentage"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_K196K48I138K_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xml:lang="en-US">Restricted shares issued to consultants, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xml:lang="en-US">Restricted shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_M318M60K350M_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_DebtLongTermAndShortTermCombinedAmountShares" xlink:label="loc_8H6FHF4I49GG985JF602_immd_DebtLongTermAndShortTermCombinedAmountShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_immd_DebtLongTermAndShortTermCombinedAmountShares" xml:lang="en-US">Debt Long Term And Short Term Combined Amount Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_immd_DebtLongTermAndShortTermCombinedAmountShares" xml:lang="en-US">Combined capped</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_0J8HJH6K61II107LH824_immd_DebtLongTermAndShortTermCombinedAmountShares" xml:lang="en-US">Debt long term and short term combined amount shares.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_immd_DebtLongTermAndShortTermCombinedAmountShares" xlink:to="lab_0J8HJH6K61II107LH824_immd_DebtLongTermAndShortTermCombinedAmountShares"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_K196K48I138K_us-gaap_RestrictedStockExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_RestrictedStockExpense" xml:lang="en-US">Restricted Stock or Unit Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_RestrictedStockExpense" xml:lang="en-US">Restricted stock expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_RestrictedStockExpense" xlink:to="lab_M318M60K350M_us-gaap_RestrictedStockExpense"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_BonusShares" xlink:label="loc_8H6FHF4I49GG985JF602_immd_BonusShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_immd_BonusShares" xml:lang="en-US">Bonus Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_0J8HJH6K61II107LH824_immd_BonusShares" xml:lang="en-US">Additional bonus shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_0J8HJH6K61II107LH824_immd_BonusShares" xml:lang="en-US">It represents bonus of an additional shares.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_immd_BonusShares" xlink:to="lab_0J8HJH6K61II107LH824_immd_BonusShares"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_OptionToBuyShares" xlink:label="loc_K196K48I138K_immd_OptionToBuyShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_immd_OptionToBuyShares" xml:lang="en-US">Option To Buy Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_immd_OptionToBuyShares" xml:lang="en-US">Option to buy shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M318M60K350M_immd_OptionToBuyShares" xml:lang="en-US">Contracts conveying rights, but not obligations, to buy or sell a specific quantity of a security at a specified price during a specified period or at a specified date.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_immd_OptionToBuyShares" xlink:to="lab_M318M60K350M_immd_OptionToBuyShares"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xml:lang="en-US">Purchase common stock option</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_K196K48I138K_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xml:lang="en-US">Restricted shares value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="lab_M318M60K350M_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_NumerOfThresholds" xlink:label="loc_8H6FHF4I49GG985JF602_immd_NumerOfThresholds" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_immd_NumerOfThresholds" xml:lang="en-US">Numer Of Thresholds</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_immd_NumerOfThresholds" xml:lang="en-US">Numer of thresholds</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_0J8HJH6K61II107LH824_immd_NumerOfThresholds" xml:lang="en-US">Numer of thresholds.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_immd_NumerOfThresholds" xlink:to="lab_0J8HJH6K61II107LH824_immd_NumerOfThresholds"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_K196K48I138K_us-gaap_OperatingLeasesRentExpenseNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_OperatingLeasesRentExpenseNet" xml:lang="en-US">Operating Leases, Rent Expense, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_OperatingLeasesRentExpenseNet" xml:lang="en-US">Office space subleased from Mr. Schreiber</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_OperatingLeasesRentExpenseNet" xlink:to="lab_M318M60K350M_us-gaap_OperatingLeasesRentExpenseNet"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_RelatedPartyTransactionsTextualAbstract" xlink:label="loc_8H6FHF4I49GG985JF602_immd_RelatedPartyTransactionsTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_immd_RelatedPartyTransactionsTextualAbstract" xml:lang="en-US">Related Party Transactions Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_immd_RelatedPartyTransactionsTextualAbstract" xml:lang="en-US">Related Party Transactions (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_immd_RelatedPartyTransactionsTextualAbstract" xlink:to="lab_0J8HJH6K61II107LH824_immd_RelatedPartyTransactionsTextualAbstract"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_CompensationForLegalServices" xlink:label="loc_K196K48I138K_immd_CompensationForLegalServices" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_immd_CompensationForLegalServices" xml:lang="en-US">Compensation For Legal Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_immd_CompensationForLegalServices" xml:lang="en-US">Compensation for legal and business advisory services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M318M60K350M_immd_CompensationForLegalServices" xml:lang="en-US">Compensation for legal services.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_immd_CompensationForLegalServices" xlink:to="lab_M318M60K350M_immd_CompensationForLegalServices"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ReimbursementOfHomeOfficeExpenditures" xlink:label="loc_8H6FHF4I49GG985JF602_immd_ReimbursementOfHomeOfficeExpenditures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_immd_ReimbursementOfHomeOfficeExpenditures" xml:lang="en-US">Reimbursement Of Home Office Expenditures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_immd_ReimbursementOfHomeOfficeExpenditures" xml:lang="en-US">Reimbursement of home office expenditures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_0J8HJH6K61II107LH824_immd_ReimbursementOfHomeOfficeExpenditures" xml:lang="en-US">Reimbursement of home office expenditures.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_immd_ReimbursementOfHomeOfficeExpenditures" xlink:to="lab_0J8HJH6K61II107LH824_immd_ReimbursementOfHomeOfficeExpenditures"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_AnnualIncentiveBonusAwardPercentage" xlink:label="loc_K196K48I138K_immd_AnnualIncentiveBonusAwardPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_immd_AnnualIncentiveBonusAwardPercentage" xml:lang="en-US">Annual Incentive Bonus Award Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_immd_AnnualIncentiveBonusAwardPercentage" xml:lang="en-US">Annual incentive bonus award percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M318M60K350M_immd_AnnualIncentiveBonusAwardPercentage" xml:lang="en-US">Percentage of annual incentive bonus award.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_immd_AnnualIncentiveBonusAwardPercentage" xlink:to="lab_M318M60K350M_immd_AnnualIncentiveBonusAwardPercentage"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_SubsequentEventTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_SubsequentEventTable" xml:lang="en-US">Subsequent Event [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_SubsequentEventTable" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_SubsequentEventTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_K196K48I138K_us-gaap_SubsequentEventLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_SubsequentEventLineItems" xml:lang="en-US">Subsequent Event [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_SubsequentEventLineItems" xlink:to="lab_M318M60K350M_us-gaap_SubsequentEventLineItems"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_SubsequentEventsTextualAbstract" xlink:label="loc_8H6FHF4I49GG985JF602_immd_SubsequentEventsTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_immd_SubsequentEventsTextualAbstract" xml:lang="en-US">Subsequent Events Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_immd_SubsequentEventsTextualAbstract" xml:lang="en-US">Subsequent Events (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_immd_SubsequentEventsTextualAbstract" xlink:to="lab_0J8HJH6K61II107LH824_immd_SubsequentEventsTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_K196K48I138K_us-gaap_ConversionOfStockSharesIssued1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_ConversionOfStockSharesIssued1" xml:lang="en-US">Conversion of Stock, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_ConversionOfStockSharesIssued1" xml:lang="en-US">Common stock issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_ConversionOfStockSharesIssued1" xlink:to="lab_M318M60K350M_us-gaap_ConversionOfStockSharesIssued1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Issued of warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_K196K48I138K_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Warrants vested term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_M318M60K350M_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xml:lang="en-US">Original debt, discount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_K196K48I138K_us-gaap_DebtConversionOriginalDebtAmount1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_DebtConversionOriginalDebtAmount1" xml:lang="en-US">Debt Conversion, Original Debt, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_DebtConversionOriginalDebtAmount1" xml:lang="en-US">Original debt, principle amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="lab_M318M60K350M_us-gaap_DebtConversionOriginalDebtAmount1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_RepaymentsOfDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_RepaymentsOfDebt" xml:lang="en-US">Repayments of Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_RepaymentsOfDebt" xml:lang="en-US">Repaid principle balance of note</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_RepaymentsOfDebt" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_RepaymentsOfDebt"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_CommonStockSharesIssuedRelatedPromissoryNote" xlink:label="loc_K196K48I138K_immd_CommonStockSharesIssuedRelatedPromissoryNote" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_immd_CommonStockSharesIssuedRelatedPromissoryNote" xml:lang="en-US">Common Stock Shares Issued Related Promissory Note</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_immd_CommonStockSharesIssuedRelatedPromissoryNote" xml:lang="en-US">Common stock shares issued related promissory note</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_M318M60K350M_immd_CommonStockSharesIssuedRelatedPromissoryNote" xml:lang="en-US">Common stock shares issued related promissory note.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_immd_CommonStockSharesIssuedRelatedPromissoryNote" xlink:to="lab_M318M60K350M_immd_CommonStockSharesIssuedRelatedPromissoryNote"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_DebtConversionConvertedInstrumentAmount1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_DebtConversionConvertedInstrumentAmount1" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_DebtConversionConvertedInstrumentAmount1" xml:lang="en-US">Converted remaining principle balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_DebtConversionConvertedInstrumentAmount1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_K196K48I138K_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_M318M60K350M_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xml:lang="en-US">Converted shares of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_M318M60K350M_us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xml:lang="en-US">Debt Conversion, Converted Instrument, Warrants or Options Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xml:lang="en-US">Converted shares of warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_K196K48I138K_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xml:lang="en-US">Offering to sell shares of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_M318M60K350M_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_WarrantsToPurchaseOfCommonStock" xlink:label="loc_8H6FHF4I49GG985JF602_immd_WarrantsToPurchaseOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_immd_WarrantsToPurchaseOfCommonStock" xml:lang="en-US">Warrants To Purchase Of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_immd_WarrantsToPurchaseOfCommonStock" xml:lang="en-US">Warrants to purchase of common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_0J8HJH6K61II107LH824_immd_WarrantsToPurchaseOfCommonStock" xml:lang="en-US">Number of warrants topurchase of common stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_immd_WarrantsToPurchaseOfCommonStock" xlink:to="lab_0J8HJH6K61II107LH824_immd_WarrantsToPurchaseOfCommonStock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_K196K48I138K_us-gaap_SaleOfStockPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Sale of Stock, Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Sale of stock, price per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_M318M60K350M_us-gaap_SaleOfStockPricePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_CommonStockSharesSubscribedButUnissued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_CommonStockSharesSubscribedButUnissued" xml:lang="en-US">Common Stock, Shares Subscribed but Unissued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_CommonStockSharesSubscribedButUnissued" xml:lang="en-US">Subscriptions shares received</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_CommonStockSharesSubscribedButUnissued" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_CommonStockSharesSubscribedButUnissued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesSubscriptions" xlink:label="loc_K196K48I138K_us-gaap_CommonStockSharesSubscriptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_M318M60K350M_us-gaap_CommonStockSharesSubscriptions" xml:lang="en-US">Common Stock, Value, Subscriptions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_M318M60K350M_us-gaap_CommonStockSharesSubscriptions" xml:lang="en-US">Proceeds from subscription of shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_K196K48I138K_us-gaap_CommonStockSharesSubscriptions" xlink:to="lab_M318M60K350M_us-gaap_CommonStockSharesSubscriptions"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_8H6FHF4I49GG985JF602_us-gaap_ContractualObligation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ContractualObligation" xml:lang="en-US">Contractual Obligation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_0J8HJH6K61II107LH824_us-gaap_ContractualObligation" xml:lang="en-US">Satisfaction of obligation to pay amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_8H6FHF4I49GG985JF602_us-gaap_ContractualObligation" xlink:to="lab_0J8HJH6K61II107LH824_us-gaap_ContractualObligation"/>
</labelLink></linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>immd-20161231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#DocumentAndEntityInformation" roleURI="http://www.immudyne.com/role/DocumentAndEntityInformation"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#Consolidatedbalancesheets" roleURI="http://www.immudyne.com/role/Consolidatedbalancesheets"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.immudyne.com/role/ConsolidatedBalanceSheetsParenthetical"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#ConsolidatedStatementsOfOperations" roleURI="http://www.immudyne.com/role/ConsolidatedStatementsOfOperations"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#ConsolidatedStatementOfStockholdersEquityDeficit" roleURI="http://www.immudyne.com/role/ConsolidatedStatementOfStockholdersEquityDeficit"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.immudyne.com/role/ConsolidatedStatementsOfCashFlows"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#OrganizationAndGoingConcern" roleURI="http://www.immudyne.com/role/OrganizationAndGoingConcern"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://www.immudyne.com/role/SummaryOfSignificantAccountingPolicies"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#FurnishingsAndEquipment" roleURI="http://www.immudyne.com/role/FurnishingsAndEquipment"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#InvestmentInAdiuvoInvestmentS" roleURI="http://www.immudyne.com/role/InvestmentInAdiuvoInvestmentS"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#NotesPayable" roleURI="http://www.immudyne.com/role/NotesPayable"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#IncomeTaxes" roleURI="http://www.immudyne.com/role/IncomeTaxes"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#StockholdersEquity" roleURI="http://www.immudyne.com/role/StockholdersEquity"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#Royalties" roleURI="http://www.immudyne.com/role/Royalties"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#CommitmentsAndContingencies" roleURI="http://www.immudyne.com/role/CommitmentsAndContingencies"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#RelatedPartyTransactions" roleURI="http://www.immudyne.com/role/RelatedPartyTransactions"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#SubsequentEvents" roleURI="http://www.immudyne.com/role/SubsequentEvents"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.immudyne.com/role/SummaryOfSignificantAccountingPoliciesPolicies"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.immudyne.com/role/SummaryOfSignificantAccountingPoliciesTables"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#FurnishingsandEquipmentTables" roleURI="http://www.immudyne.com/role/FurnishingsandEquipmentTables"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#NotesPayableTables" roleURI="http://www.immudyne.com/role/NotesPayableTables"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#IncomeTaxesTables" roleURI="http://www.immudyne.com/role/IncomeTaxesTables"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#StockholdersEquityTables" roleURI="http://www.immudyne.com/role/StockholdersEquityTables"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#OrganizationAndGoingConcernDetails" roleURI="http://www.immudyne.com/role/OrganizationAndGoingConcernDetails"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#SummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.immudyne.com/role/SummaryOfSignificantAccountingPoliciesDetails"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#SummaryOfSignificantAccountingPoliciesDetails1" roleURI="http://www.immudyne.com/role/SummaryOfSignificantAccountingPoliciesDetails1"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#Summaryofsignificantaccountingpoliciesdetailstextual" roleURI="http://www.immudyne.com/role/Summaryofsignificantaccountingpoliciesdetailstextual"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#FurnishingsandEquipmentDetails" roleURI="http://www.immudyne.com/role/FurnishingsandEquipmentDetails"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#FurnishingsAndEquipmentDetailsTextual" roleURI="http://www.immudyne.com/role/FurnishingsAndEquipmentDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#InvestmentinAdiuvoInvestmentSADetails" roleURI="http://www.immudyne.com/role/InvestmentinAdiuvoInvestmentSADetails"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#NotesPayableDetails" roleURI="http://www.immudyne.com/role/NotesPayableDetails"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#NotesPayableDetailsTextual" roleURI="http://www.immudyne.com/role/NotesPayableDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#IncomeTaxesDetails" roleURI="http://www.immudyne.com/role/IncomeTaxesDetails"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#IncomeTaxesDetailsTextual" roleURI="http://www.immudyne.com/role/IncomeTaxesDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#StockholdersEquityDetails" roleURI="http://www.immudyne.com/role/StockholdersEquityDetails"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#StockholdersEquityDetails1" roleURI="http://www.immudyne.com/role/StockholdersEquityDetails1"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#StockholdersEquityDetails2" roleURI="http://www.immudyne.com/role/StockholdersEquityDetails2"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#StockholdersEquityDetails4" roleURI="http://www.immudyne.com/role/StockholdersEquityDetails4"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#StockholdersEquityDetails5" roleURI="http://www.immudyne.com/role/StockholdersEquityDetails5"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#StockholdersEquityDetailsTextual" roleURI="http://www.immudyne.com/role/StockholdersEquityDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#StockholdersEquityDetailsTextual1" roleURI="http://www.immudyne.com/role/StockholdersEquityDetailsTextual1"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#StockholdersEquityDetailsTextual2" roleURI="http://www.immudyne.com/role/StockholdersEquityDetailsTextual2"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#StockholdersEquityDetailsTextual3" roleURI="http://www.immudyne.com/role/StockholdersEquityDetailsTextual3"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#RoyaltiesDetails" roleURI="http://www.immudyne.com/role/RoyaltiesDetails"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#CommitmentsAndContingenciesDetails" roleURI="http://www.immudyne.com/role/CommitmentsAndContingenciesDetails"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#RelatedPartyTransactionsDetails" roleURI="http://www.immudyne.com/role/RelatedPartyTransactionsDetails"/>
<roleRef xlink:type="simple" xlink:href="immd-20161231.xsd#Subsequenteventsdetails" roleURI="http://www.immudyne.com/role/Subsequenteventsdetails"/>
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/DocumentAndEntityInformation">
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_DocumentAndEntityInformationAbstract" xlink:label="loc_immd_DocumentAndEntityInformationAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityRegistrantName_1" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityCentralIndexKey_2" order="10" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_AmendmentFlag_3" order="20" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_CurrentFiscalYearEndDate_4" order="30" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentType_5" order="40" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentPeriodEndDate_6" order="50" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentFiscalYearFocus_7" order="60" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_8" order="70" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityFilerCategory_9" order="80" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_10" order="90" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityVoluntaryFilers_11" order="100" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityCurrentReportingStatus_12" order="110" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityPublicFloat_13" order="120" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_14" order="130" use="optional" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/Consolidatedbalancesheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_AssetsAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_5" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2" xlink:to="loc_us-gaap_InventoryNet_6" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2" xlink:to="loc_us-gaap_AssetsCurrent_7" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9" xlink:to="loc_us-gaap_ConvertibleNotesPayableCurrent_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9" xlink:to="loc_us-gaap_NotesPayableCurrent_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9" xlink:to="loc_us-gaap_LiabilitiesCurrent_14" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8" xlink:to="loc_us-gaap_StockholdersEquityAbstract_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_15" xlink:to="loc_us-gaap_CommonStockValue_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_15" xlink:to="loc_us-gaap_AdditionalPaidInCapital_17" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_15" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_18" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_Equity" xlink:label="loc_immd_Equity_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_15" xlink:to="loc_immd_Equity_19" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_15" xlink:to="loc_us-gaap_TreasuryStockValue_20" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_15" xlink:to="loc_us-gaap_StockholdersEquity_21" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8" xlink:to="loc_us-gaap_MinorityInterest_22" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_23" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_24" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/ConsolidatedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesIssued_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="loc_us-gaap_TreasuryStockCommonShares_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_TreasuryStockCommonShares_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/ConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_Revenues_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="loc_us-gaap_CostOfRevenue_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_CostOfRevenue_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_GrossProfit_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingExpensesAbstract_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_CompensationAndRelatedExpenses" xlink:label="loc_immd_CompensationAndRelatedExpenses_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4" xlink:to="loc_immd_CompensationAndRelatedExpenses_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4" xlink:to="loc_us-gaap_ProfessionalFees_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MarketingExpense" xlink:label="loc_us-gaap_MarketingExpense_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4" xlink:to="loc_us-gaap_MarketingExpense_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_8" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_9" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4" xlink:to="loc_us-gaap_OperatingExpenses_10" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingIncomeLoss_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainOnSaleOfInvestments" xlink:label="loc_us-gaap_GainOnSaleOfInvestments_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_GainOnSaleOfInvestments_12" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_InterestExpense_13" order="60" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_14" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_15" order="80" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_ProfitLoss_16" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_17" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NetIncomeLoss_18" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_19" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareAbstract_20" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_21" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_22" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/ConsolidatedStatementOfStockholdersEquityDeficit">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_CommonStockMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_RetainedEarningsMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_TreasuryStockMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_SummationMember" xlink:label="loc_immd_SummationMember_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_immd_SummationMember_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_NoncontrollingInterestMember_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_SharesOutstanding_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_AdjustmentsOfAdditionPaidInCapitalAmortizationOfStockOptions" xlink:label="loc_immd_AdjustmentsOfAdditionPaidInCapitalAmortizationOfStockOptions_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_immd_AdjustmentsOfAdditionPaidInCapitalAmortizationOfStockOptions_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_15" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_16" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_17" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_18" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_19" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_20" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_21" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_Adjustmentstoadditionalpaidincapitalsharebasedcompensationextensionstockoptionswarrantexpirationdates" xlink:label="loc_immd_Adjustmentstoadditionalpaidincapitalsharebasedcompensationextensionstockoptionswarrantexpirationdates_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_immd_Adjustmentstoadditionalpaidincapitalsharebasedcompensationextensionstockoptionswarrantexpirationdates_22" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_23" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_24" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_25" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_26" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_27" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_28" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_29" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_29" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_30" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_30" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_31" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_31" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:label="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_32" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_32" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_33" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_33" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_34" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_34" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_35" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_35" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities" xlink:label="loc_immd_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities_36" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_immd_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities_36" order="250" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_37" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_ProfitLoss_37" order="260" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_38" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_38" order="270" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_39" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_SharesOutstanding_39" order="280" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_ProfitLoss_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_Depreciation_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_ShareBasedCompensation_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_11" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_11" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_11" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_11" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_14" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_11" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_15" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_16" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_17" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="loc_us-gaap_PaymentsForProceedsFromInvestments_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_17" xlink:to="loc_us-gaap_PaymentsForProceedsFromInvestments_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_19" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:label="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_19" xlink:to="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders_20" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInNotesPayableCurrent" xlink:label="loc_us-gaap_IncreaseDecreaseInNotesPayableCurrent_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_19" xlink:to="loc_us-gaap_IncreaseDecreaseInNotesPayableCurrent_21" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_19" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_22" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_19" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_23" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_19" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_24" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_IssuanceOfCommonStockAndWarrants" xlink:label="loc_immd_IssuanceOfCommonStockAndWarrants_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_19" xlink:to="loc_immd_IssuanceOfCommonStockAndWarrants_25" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_19" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_26" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_19" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_27" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_28" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_29" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_29" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_30" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_30" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_31" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_31" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_32" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_31" xlink:to="loc_us-gaap_InterestPaid_32" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="loc_us-gaap_ConversionOfStockAmountIssued1_33" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_31" xlink:to="loc_us-gaap_ConversionOfStockAmountIssued1_33" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_IssuanceOfCommonStockInRelationToDebtOffering" xlink:label="loc_immd_IssuanceOfCommonStockInRelationToDebtOffering_34" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_31" xlink:to="loc_immd_IssuanceOfCommonStockInRelationToDebtOffering_34" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities" xlink:label="loc_immd_ReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities_35" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_31" xlink:to="loc_immd_ReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities_35" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ConversionOfEquityInvestedInSubsidiaryToCommonStockAndWarrants" xlink:label="loc_immd_ConversionOfEquityInvestedInSubsidiaryToCommonStockAndWarrants_36" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_31" xlink:to="loc_immd_ConversionOfEquityInvestedInSubsidiaryToCommonStockAndWarrants_36" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/OrganizationAndGoingConcern">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/SummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/FurnishingsAndEquipment">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/InvestmentInAdiuvoInvestmentS">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfInvestmentsAbstract" xlink:label="loc_us-gaap_ScheduleOfInvestmentsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestmentHoldingsTextBlock" xlink:label="loc_us-gaap_InvestmentHoldingsTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsAbstract_0" xlink:to="loc_us-gaap_InvestmentHoldingsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/NotesPayable">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/IncomeTaxes">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/StockholdersEquity">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/Royalties">
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_RoyaltiesAbstract" xlink:label="loc_immd_RoyaltiesAbstract_0" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_RoyaltiesDisclosureTextBlock" xlink:label="loc_immd_RoyaltiesDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_RoyaltiesAbstract_0" xlink:to="loc_immd_RoyaltiesDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/CommitmentsAndContingencies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/RelatedPartyTransactions">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/SubsequentEvents">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_VariableInterestEntitiesPolicyTextBlock" xlink:label="loc_immd_VariableInterestEntitiesPolicyTextBlock_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_immd_VariableInterestEntitiesPolicyTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_UseOfEstimates_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_SequencingPolicyPolicyTextBlock" xlink:label="loc_immd_SequencingPolicyPolicyTextBlock_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_immd_SequencingPolicyPolicyTextBlock_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_10" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_11" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_12" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_13" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_14" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_MinorityInterestPolicyTextBlock" xlink:label="loc_immd_MinorityInterestPolicyTextBlock_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_immd_MinorityInterestPolicyTextBlock_15" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_16" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_17" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/SummaryOfSignificantAccountingPoliciesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/FurnishingsandEquipmentTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/NotesPayableTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/IncomeTaxesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/StockholdersEquityTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5" xlink:to="loc_us-gaap_EquityComponentDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6" xlink:to="loc_us-gaap_WarrantMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/OrganizationAndGoingConcernDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ImmudynePrLlcMember" xlink:label="loc_immd_ImmudynePrLlcMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_immd_ImmudynePrLlcMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5" xlink:to="loc_us-gaap_EquityComponentDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_OrganizationAndGoingConcernTextualAbstract" xlink:label="loc_immd_OrganizationAndGoingConcernTextualAbstract_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_8" xlink:to="loc_immd_OrganizationAndGoingConcernTextualAbstract_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_OrganizationAndGoingConcernTextualAbstract_9" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_OrganizationAndGoingConcernTextualAbstract_9" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_OrganizationAndGoingConcernTextualAbstract_9" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:label="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_OrganizationAndGoingConcernTextualAbstract_9" xlink:to="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/SummaryOfSignificantAccountingPoliciesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="loc_us-gaap_InventoryNetAbstract_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_InventoryNetAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaap_InventoryRawMaterials_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_1" xlink:to="loc_us-gaap_InventoryRawMaterials_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_1" xlink:to="loc_us-gaap_InventoryFinishedGoods_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_1" xlink:to="loc_us-gaap_InventoryNet_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/SummaryOfSignificantAccountingPoliciesDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationItemsAxis" xlink:label="loc_us-gaap_ConsolidationItemsAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_1" xlink:to="loc_us-gaap_ConsolidationItemsAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationItemsDomain" xlink:label="loc_us-gaap_ConsolidationItemsDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationItemsAxis_2" xlink:to="loc_us-gaap_ConsolidationItemsDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_NutraceuticalAndCosmeticMember" xlink:label="loc_immd_NutraceuticalAndCosmeticMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationItemsDomain_3" xlink:to="loc_immd_NutraceuticalAndCosmeticMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_CosmeticGoodsMember" xlink:label="loc_immd_CosmeticGoodsMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationItemsDomain_3" xlink:to="loc_immd_CosmeticGoodsMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IntersegmentEliminationMember" xlink:label="loc_us-gaap_IntersegmentEliminationMember_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationItemsDomain_3" xlink:to="loc_us-gaap_IntersegmentEliminationMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_1" xlink:to="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_7" xlink:to="loc_us-gaap_Assets_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_7" xlink:to="loc_us-gaap_Revenues_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_7" xlink:to="loc_us-gaap_ProfitLoss_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_OtherUnallocatedAmountsAbstract" xlink:label="loc_immd_OtherUnallocatedAmountsAbstract_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_7" xlink:to="loc_immd_OtherUnallocatedAmountsAbstract_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_CorporateExpenses" xlink:label="loc_immd_CorporateExpenses_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_OtherUnallocatedAmountsAbstract_11" xlink:to="loc_immd_CorporateExpenses_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_OtherUnallocatedAmountsAbstract_11" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_OtherUnallocatedAmountsAbstract_11" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_14" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/Summaryofsignificantaccountingpoliciesdetailstextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTable" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTable_1" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeAxis_2" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5" xlink:to="loc_us-gaap_EquityComponentDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6" xlink:to="loc_us-gaap_WarrantMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTable_1" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_us-gaap_SalesMember_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9" xlink:to="loc_us-gaap_SalesMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9" xlink:to="loc_us-gaap_AccountsReceivableMember_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ConcentrationRiskNumberOfCustomersAxis" xlink:label="loc_immd_ConcentrationRiskNumberOfCustomersAxis_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTable_1" xlink:to="loc_immd_ConcentrationRiskNumberOfCustomersAxis_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ConcentrationRiskNumberOfCustomersDomain" xlink:label="loc_immd_ConcentrationRiskNumberOfCustomersDomain_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_ConcentrationRiskNumberOfCustomersAxis_12" xlink:to="loc_immd_ConcentrationRiskNumberOfCustomersDomain_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_OneCustomerMember" xlink:label="loc_immd_OneCustomerMember_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_ConcentrationRiskNumberOfCustomersDomain_13" xlink:to="loc_immd_OneCustomerMember_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_SecondCustomerMember" xlink:label="loc_immd_SecondCustomerMember_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_ConcentrationRiskNumberOfCustomersDomain_13" xlink:to="loc_immd_SecondCustomerMember_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationItemsAxis" xlink:label="loc_us-gaap_ConsolidationItemsAxis_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTable_1" xlink:to="loc_us-gaap_ConsolidationItemsAxis_16" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConsolidationItemsDomain" xlink:label="loc_us-gaap_ConsolidationItemsDomain_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationItemsAxis_16" xlink:to="loc_us-gaap_ConsolidationItemsDomain_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_NutraceuticalAndCosmeticMember" xlink:label="loc_immd_NutraceuticalAndCosmeticMember_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationItemsDomain_17" xlink:to="loc_immd_NutraceuticalAndCosmeticMember_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_CosmeticGoodsMember" xlink:label="loc_immd_CosmeticGoodsMember_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConsolidationItemsDomain_17" xlink:to="loc_immd_CosmeticGoodsMember_19" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTable_1" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis_20" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndustryOfCounterpartyDomain" xlink:label="loc_us-gaap_IndustryOfCounterpartyDomain_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis_20" xlink:to="loc_us-gaap_IndustryOfCounterpartyDomain_21" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_OneCreditCardProcessorsMember" xlink:label="loc_immd_OneCreditCardProcessorsMember_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndustryOfCounterpartyDomain_21" xlink:to="loc_immd_OneCreditCardProcessorsMember_22" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_TwoCreditCardProcessorsMember" xlink:label="loc_immd_TwoCreditCardProcessorsMember_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndustryOfCounterpartyDomain_21" xlink:to="loc_immd_TwoCreditCardProcessorsMember_23" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityLineItems_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTable_1" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityLineItems_24" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_SummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:label="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityLineItems_24" xlink:to="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_25" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_MinorityInterestRate" xlink:label="loc_immd_MinorityInterestRate_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_25" xlink:to="loc_immd_MinorityInterestRate_26" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InventoryLIFOReserve" xlink:label="loc_us-gaap_InventoryLIFOReserve_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_25" xlink:to="loc_us-gaap_InventoryLIFOReserve_27" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesDiscountsReturnsAndAllowancesGoods" xlink:label="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoods_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_25" xlink:to="loc_us-gaap_SalesDiscountsReturnsAndAllowancesGoods_28" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_29" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_25" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_29" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_30" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_25" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_30" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_31" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_25" xlink:to="loc_us-gaap_Revenues_31" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="loc_us-gaap_AccountsReceivableNet_32" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_25" xlink:to="loc_us-gaap_AccountsReceivableNet_32" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_NonControllingInterestDescription" xlink:label="loc_immd_NonControllingInterestDescription_33" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_25" xlink:to="loc_immd_NonControllingInterestDescription_33" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesReturnsAndAllowancesGoods" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesGoods_34" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_25" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesGoods_34" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableInterestEntityConsolidatedCarryingAmountAssets" xlink:label="loc_us-gaap_VariableInterestEntityConsolidatedCarryingAmountAssets_35" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_25" xlink:to="loc_us-gaap_VariableInterestEntityConsolidatedCarryingAmountAssets_35" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableInterestEntityConsolidatedCarryingAmountLiabilities" xlink:label="loc_us-gaap_VariableInterestEntityConsolidatedCarryingAmountLiabilities_36" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_25" xlink:to="loc_us-gaap_VariableInterestEntityConsolidatedCarryingAmountLiabilities_36" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityRevenues" xlink:label="loc_us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityRevenues_37" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_25" xlink:to="loc_us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityRevenues_37" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityOperatingIncomeOrLoss" xlink:label="loc_us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityOperatingIncomeOrLoss_38" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_25" xlink:to="loc_us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityOperatingIncomeOrLoss_38" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableInterestEntityConclusionToConsolidate" xlink:label="loc_us-gaap_VariableInterestEntityConclusionToConsolidate_39" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_25" xlink:to="loc_us-gaap_VariableInterestEntityConclusionToConsolidate_39" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities" xlink:label="loc_immd_ReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities_40" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract_25" xlink:to="loc_immd_ReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities_40" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/FurnishingsandEquipmentDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/FurnishingsAndEquipmentDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_FurnishingsAndEquipmentTextualAbstract" xlink:label="loc_immd_FurnishingsAndEquipmentTextualAbstract_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_immd_FurnishingsAndEquipmentTextualAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_FurnishingsAndEquipmentTextualAbstract_1" xlink:to="loc_us-gaap_Depreciation_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/InvestmentinAdiuvoInvestmentSADetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfInvestmentsAbstract" xlink:label="loc_us-gaap_ScheduleOfInvestmentsAbstract_0" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_InvestmentInAdiuvoInvestmentTextualAbstract" xlink:label="loc_immd_InvestmentInAdiuvoInvestmentTextualAbstract_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsAbstract_0" xlink:to="loc_immd_InvestmentInAdiuvoInvestmentTextualAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_OptionsPurchasedAmountPaid" xlink:label="loc_immd_OptionsPurchasedAmountPaid_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_InvestmentInAdiuvoInvestmentTextualAbstract_1" xlink:to="loc_immd_OptionsPurchasedAmountPaid_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_InvestmentInAdiuvoInvestmentTextualAbstract_1" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_InvestmentInAdiuvoInvestmentTextualAbstract_1" xlink:to="loc_us-gaap_SharePrice_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterestInJointVentures" xlink:label="loc_us-gaap_MinorityInterestInJointVentures_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_InvestmentInAdiuvoInvestmentTextualAbstract_1" xlink:to="loc_us-gaap_MinorityInterestInJointVentures_5" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_InvestmentInAdiuvoInvestmentTextualAbstract_1" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_6" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableDescription" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableDescription_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_InvestmentInAdiuvoInvestmentTextualAbstract_1" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableDescription_7" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_InvestmentInAdiuvoInvestmentTextualAbstract_1" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_8" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GainOnSaleOfInvestments" xlink:label="loc_us-gaap_GainOnSaleOfInvestments_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_InvestmentInAdiuvoInvestmentTextualAbstract_1" xlink:to="loc_us-gaap_GainOnSaleOfInvestments_9" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentOptionsExpirationDate" xlink:label="loc_invest_InvestmentOptionsExpirationDate_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_InvestmentInAdiuvoInvestmentTextualAbstract_1" xlink:to="loc_invest_InvestmentOptionsExpirationDate_10" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/NotesPayableDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_NotesPayableAndAdvancesPayableTable" xlink:label="loc_immd_NotesPayableAndAdvancesPayableTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_immd_NotesPayableAndAdvancesPayableTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfFinancingReceivableTypeOfBorrowerAxis" xlink:label="loc_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_NotesPayableAndAdvancesPayableTable_1" xlink:to="loc_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfFinancingReceivableTypeOfBorrowerDomain" xlink:label="loc_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerAxis_2" xlink:to="loc_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_CommercialLenderMember" xlink:label="loc_immd_CommercialLenderMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerDomain_3" xlink:to="loc_immd_CommercialLenderMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_NotesPayableAndAdvancesPayableTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_5" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BoardOfDirectorsChairmanMember" xlink:label="loc_us-gaap_BoardOfDirectorsChairmanMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6" xlink:to="loc_us-gaap_BoardOfDirectorsChairmanMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_NotesPayableAndAdvancesPayableLineItems" xlink:label="loc_immd_NotesPayableAndAdvancesPayableLineItems_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_NotesPayableAndAdvancesPayableTable_1" xlink:to="loc_immd_NotesPayableAndAdvancesPayableLineItems_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_NotesPayableAndAdvancesPayableLineItems_8" xlink:to="loc_us-gaap_NotesPayableCurrent_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_NotesPayableAndAdvancesPayableLineItems_8" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_NotesPayableAndAdvancesPayableLineItems_8" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_NotesPayableAndAdvancesPayableLineItems_8" xlink:to="loc_us-gaap_ConversionOfStockAmountConverted1_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_NotesPayableAndAdvancesPayableLineItems_8" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_13" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_NotesPayableAndAdvancesPayableLineItems_8" xlink:to="loc_us-gaap_NotesPayableCurrent_14" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/NotesPayableDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_DebtInstrumentTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_2" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BoardOfDirectorsChairmanMember" xlink:label="loc_us-gaap_BoardOfDirectorsChairmanMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3" xlink:to="loc_us-gaap_BoardOfDirectorsChairmanMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OfficerMember" xlink:label="loc_us-gaap_OfficerMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3" xlink:to="loc_us-gaap_OfficerMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MajorityShareholderMember" xlink:label="loc_us-gaap_MajorityShareholderMember_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3" xlink:to="loc_us-gaap_MajorityShareholderMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_7" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_8" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfFinancingReceivableTypeOfBorrowerAxis" xlink:label="loc_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerAxis_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerAxis_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfFinancingReceivableTypeOfBorrowerDomain" xlink:label="loc_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerDomain_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerAxis_10" xlink:to="loc_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerDomain_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_CommercialLenderMember" xlink:label="loc_immd_CommercialLenderMember_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerDomain_11" xlink:to="loc_immd_CommercialLenderMember_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_13" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_14" xlink:to="loc_us-gaap_CommercialPaperMember_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_CommercialPaperOneMember" xlink:label="loc_immd_CommercialPaperOneMember_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_14" xlink:to="loc_immd_CommercialPaperOneMember_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_CommercialPaperTwoMember" xlink:label="loc_immd_CommercialPaperTwoMember_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_14" xlink:to="loc_immd_CommercialPaperTwoMember_17" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_18" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_18" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_19" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_19" xlink:to="loc_us-gaap_SubsequentEventMember_20" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_DebtInstrumentLineItems_21" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_NotesPayableTextualAbstract" xlink:label="loc_immd_NotesPayableTextualAbstract_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_21" xlink:to="loc_immd_NotesPayableTextualAbstract_22" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaap_ConvertibleNotesPayable_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_NotesPayableTextualAbstract_22" xlink:to="loc_us-gaap_ConvertibleNotesPayable_23" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_NotesPayableTextualAbstract_22" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_24" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_NotesPayableTextualAbstract_22" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_25" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentPaymentTerms" xlink:label="loc_us-gaap_DebtInstrumentPaymentTerms_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_NotesPayableTextualAbstract_22" xlink:to="loc_us-gaap_DebtInstrumentPaymentTerms_26" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_NotesPayableTextualAbstract_22" xlink:to="loc_us-gaap_InterestExpense_27" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_NotesPayableTextualAbstract_22" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_28" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_29" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_NotesPayableTextualAbstract_22" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_29" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_30" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_NotesPayableTextualAbstract_22" xlink:to="loc_us-gaap_InterestExpenseDebt_30" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_31" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_NotesPayableTextualAbstract_22" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_31" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_32" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_NotesPayableTextualAbstract_22" xlink:to="loc_us-gaap_NotesPayable_32" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_33" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_NotesPayableTextualAbstract_22" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_33" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_34" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_NotesPayableTextualAbstract_22" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_34" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_35" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_NotesPayableTextualAbstract_22" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_35" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_36" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_NotesPayableTextualAbstract_22" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_36" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_37" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_NotesPayableTextualAbstract_22" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_37" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesAndLoansPayableCurrent" xlink:label="loc_us-gaap_NotesAndLoansPayableCurrent_38" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_NotesPayableTextualAbstract_22" xlink:to="loc_us-gaap_NotesAndLoansPayableCurrent_38" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaap_ConvertibleDebt_39" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_NotesPayableTextualAbstract_22" xlink:to="loc_us-gaap_ConvertibleDebt_39" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_40" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_NotesPayableTextualAbstract_22" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_40" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentOptionsExercisePrice" xlink:label="loc_invest_InvestmentOptionsExercisePrice_41" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_NotesPayableTextualAbstract_22" xlink:to="loc_invest_InvestmentOptionsExercisePrice_41" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_TermOfWarrant" xlink:label="loc_immd_TermOfWarrant_42" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_NotesPayableTextualAbstract_22" xlink:to="loc_immd_TermOfWarrant_42" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/IncomeTaxesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_5" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_6" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7" order="50" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_8" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/IncomeTaxesDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_IncomeTaxesTextualAbstract" xlink:label="loc_immd_IncomeTaxesTextualAbstract_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_immd_IncomeTaxesTextualAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_IncomeTaxesTextualAbstract_1" xlink:to="loc_us-gaap_OperatingLossCarryforwards_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="loc_us-gaap_OperatingLossCarryforwardsExpirationDate_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_IncomeTaxesTextualAbstract_1" xlink:to="loc_us-gaap_OperatingLossCarryforwardsExpirationDate_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_IncomeTaxesTextualAbstract_1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/StockholdersEquityDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_9" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_10" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_11" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/StockholdersEquityDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_RangeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_2" xlink:to="loc_us-gaap_RangeMember_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_3" xlink:to="loc_us-gaap_MaximumMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_3" xlink:to="loc_us-gaap_MinimumMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_10" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_15" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairvalueAssumptionsForfeitureRate" xlink:label="loc_immd_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairvalueAssumptionsForfeitureRate_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_10" xlink:to="loc_immd_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairvalueAssumptionsForfeitureRate_16" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/StockholdersEquityDetails2">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ExercisePriceRangeOneMember" xlink:label="loc_immd_ExercisePriceRangeOneMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_3" xlink:to="loc_immd_ExercisePriceRangeOneMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ExercisePriceRangeTwoMember" xlink:label="loc_immd_ExercisePriceRangeTwoMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_3" xlink:to="loc_immd_ExercisePriceRangeTwoMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ExercisePriceRangeThreeMember" xlink:label="loc_immd_ExercisePriceRangeThreeMember_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_3" xlink:to="loc_immd_ExercisePriceRangeThreeMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1" xlink:to="loc_us-gaap_RangeAxis_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_7" xlink:to="loc_us-gaap_RangeMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_8" xlink:to="loc_us-gaap_MinimumMember_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_8" xlink:to="loc_us-gaap_MaximumMember_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_12" xlink:to="loc_us-gaap_EmployeeStockOptionMember_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_14" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract_15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract_15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_17" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract_15" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_18" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/StockholdersEquityDetails4">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_WarrantMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_10" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_11" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/zeroLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_12" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_13" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ShareBasedCompensationArrangementByShareBasedPaymentBeinningYearOfExpiration" xlink:label="loc_immd_ShareBasedCompensationArrangementByShareBasedPaymentBeinningYearOfExpiration_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_immd_ShareBasedCompensationArrangementByShareBasedPaymentBeinningYearOfExpiration_14" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationIssued" xlink:label="loc_immd_ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationIssued_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_immd_ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationIssued_15" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationExpired" xlink:label="loc_immd_ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationExpired_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_immd_ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationExpired_16" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ShareBasedCompensationArrangementByShareBasedPaymentEndingYearOfExpiration" xlink:label="loc_immd_ShareBasedCompensationArrangementByShareBasedPaymentEndingYearOfExpiration_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_immd_ShareBasedCompensationArrangementByShareBasedPaymentEndingYearOfExpiration_17" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/StockholdersEquityDetails5">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_WarrantMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_RangeAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_5" xlink:to="loc_us-gaap_RangeMember_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MaximumMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MinimumMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_10" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/exampleGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_15" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/StockholdersEquityDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:label="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaap_InvestorMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_us-gaap_InvestorMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ShareholderMember" xlink:label="loc_immd_ShareholderMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_immd_ShareholderMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ConsultantMember" xlink:label="loc_immd_ConsultantMember_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_immd_ConsultantMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_7" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaap_DirectorMember_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_8" xlink:to="loc_us-gaap_DirectorMember_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PresidentMember" xlink:label="loc_us-gaap_PresidentMember_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_8" xlink:to="loc_us-gaap_PresidentMember_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_11" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_12" xlink:to="loc_us-gaap_IPOMember_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" xlink:to="loc_dei_LegalEntityAxis_14" order="30" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_14" xlink:to="loc_dei_EntityDomain_15" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ImmudynePrLlcMember" xlink:label="loc_immd_ImmudynePrLlcMember_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_15" xlink:to="loc_immd_ImmudynePrLlcMember_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" xlink:to="loc_us-gaap_RangeAxis_17" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_17" xlink:to="loc_us-gaap_RangeMember_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_18" xlink:to="loc_us-gaap_MaximumMember_19" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_18" xlink:to="loc_us-gaap_MinimumMember_20" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_21" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_StockholdersEquityTextualAbstract" xlink:label="loc_immd_StockholdersEquityTextualAbstract_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_21" xlink:to="loc_immd_StockholdersEquityTextualAbstract_22" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_22" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_23" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_22" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_24" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_22" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_25" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_22" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_26" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_22" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_27" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_22" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_28" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_29" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_22" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_29" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_30" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_30" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/zeroLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xlink:label="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross_31" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_22" xlink:to="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross_31" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_32" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_22" xlink:to="loc_us-gaap_NotesPayable_32" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/zeroLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_33" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_22" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_33" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentOptionsExercisePrice" xlink:label="loc_invest_InvestmentOptionsExercisePrice_34" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_22" xlink:to="loc_invest_InvestmentOptionsExercisePrice_34" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_35" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_22" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_35" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_36" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_22" xlink:to="loc_us-gaap_CommonStockSharesIssued_36" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_37" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_22" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_37" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_38" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_22" xlink:to="loc_us-gaap_CommonStockValue_38" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_39" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_22" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_39" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_40" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_22" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_40" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_41" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_41" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockOtherSharesOutstanding" xlink:label="loc_us-gaap_CommonStockOtherSharesOutstanding_42" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_22" xlink:to="loc_us-gaap_CommonStockOtherSharesOutstanding_42" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_PurchaseOfCommonStockDescriptionOfTransaction" xlink:label="loc_immd_PurchaseOfCommonStockDescriptionOfTransaction_43" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_22" xlink:to="loc_immd_PurchaseOfCommonStockDescriptionOfTransaction_43" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_44" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_22" xlink:to="loc_us-gaap_TreasuryStockValue_44" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_45" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_22" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_45" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:label="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_46" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_22" xlink:to="loc_us-gaap_MinorityInterestPeriodIncreaseDecrease_46" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_47" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_22" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_47" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_48" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_22" xlink:to="loc_us-gaap_ProfitLoss_48" order="250" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/StockholdersEquityDetailsTextual1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:label="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_2" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PresidentMember" xlink:label="loc_us-gaap_PresidentMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3" xlink:to="loc_us-gaap_PresidentMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaap_DirectorMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3" xlink:to="loc_us-gaap_DirectorMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9" xlink:to="loc_us-gaap_RelatedPartyDomain_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ConsultantMember" xlink:label="loc_immd_ConsultantMember_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_10" xlink:to="loc_immd_ConsultantMember_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_StockholdersEquityTextualAbstract" xlink:label="loc_immd_StockholdersEquityTextualAbstract_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_12" xlink:to="loc_immd_StockholdersEquityTextualAbstract_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xlink:label="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_13" xlink:to="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_16" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_13" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_17" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_18" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_19" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_13" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_20" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_13" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_21" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_22" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_13" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_23" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_13" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_24" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_13" xlink:to="loc_us-gaap_ShareBasedCompensation_25" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_13" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_26" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_NumberOfConsultant" xlink:label="loc_immd_NumberOfConsultant_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_13" xlink:to="loc_immd_NumberOfConsultant_27" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_28" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_29" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_13" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_29" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_30" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_13" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_30" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/StockholdersEquityDetailsTextual2">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:label="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_PerformanceBasedStockOptionsMember" xlink:label="loc_immd_PerformanceBasedStockOptionsMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_immd_PerformanceBasedStockOptionsMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" xlink:to="loc_us-gaap_RangeAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_5" xlink:to="loc_us-gaap_RangeMember_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MinimumMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MaximumMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_StockholdersEquityTextualAbstract" xlink:label="loc_immd_StockholdersEquityTextualAbstract_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_9" xlink:to="loc_immd_StockholdersEquityTextualAbstract_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_10" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationEquity" xlink:label="loc_us-gaap_DeferredCompensationEquity_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_10" xlink:to="loc_us-gaap_DeferredCompensationEquity_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_FairValueOfPerformanceBasedStockOptions" xlink:label="loc_immd_FairValueOfPerformanceBasedStockOptions_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_10" xlink:to="loc_immd_FairValueOfPerformanceBasedStockOptions_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_15" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_16" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_AnnualSalesRevenueTarget" xlink:label="loc_immd_AnnualSalesRevenueTarget_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_10" xlink:to="loc_immd_AnnualSalesRevenueTarget_17" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableFairValue" xlink:label="loc_immd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableFairValue_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_10" xlink:to="loc_immd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableFairValue_18" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_10" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_19" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_10" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_20" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_NumberOfConsultant" xlink:label="loc_immd_NumberOfConsultant_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_10" xlink:to="loc_immd_NumberOfConsultant_21" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/StockholdersEquityDetailsTextual3">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:label="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_WarrantMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_PerformanceBasedStockOptionsMember" xlink:label="loc_immd_PerformanceBasedStockOptionsMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_immd_PerformanceBasedStockOptionsMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" xlink:to="loc_us-gaap_RangeAxis_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_6" xlink:to="loc_us-gaap_RangeMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_7" xlink:to="loc_us-gaap_MinimumMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_7" xlink:to="loc_us-gaap_MaximumMember_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_10" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_11" xlink:to="loc_us-gaap_IPOMember_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ConsultingServicesMember" xlink:label="loc_immd_ConsultingServicesMember_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_11" xlink:to="loc_immd_ConsultingServicesMember_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_IssuanceOfCommonStockMember" xlink:label="loc_immd_IssuanceOfCommonStockMember_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_11" xlink:to="loc_immd_IssuanceOfCommonStockMember_14" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_1" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_15" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_StockholdersEquityTextualAbstract" xlink:label="loc_immd_StockholdersEquityTextualAbstract_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_15" xlink:to="loc_immd_StockholdersEquityTextualAbstract_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_16" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_16" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_16" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_19" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_20" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_16" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_21" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_WarrantExercisable" xlink:label="loc_immd_WarrantExercisable_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_16" xlink:to="loc_immd_WarrantExercisable_22" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_WarrantsExpireDateDescription" xlink:label="loc_immd_WarrantsExpireDateDescription_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_16" xlink:to="loc_immd_WarrantsExpireDateDescription_23" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_16" xlink:to="loc_us-gaap_ShareBasedCompensation_24" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="loc_us-gaap_LaborAndRelatedExpense_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_16" xlink:to="loc_us-gaap_LaborAndRelatedExpense_25" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_StockholdersEquityTextualAbstract_16" xlink:to="loc_us-gaap_InterestExpense_26" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/RoyaltiesDetails">
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_RoyaltiesAbstract" xlink:label="loc_immd_RoyaltiesAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_RoyaltiesAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PresidentMember" xlink:label="loc_us-gaap_PresidentMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_us-gaap_PresidentMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_RoyaltiesTextualAbstract" xlink:label="loc_immd_RoyaltiesTextualAbstract_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5" xlink:to="loc_immd_RoyaltiesTextualAbstract_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_PercentageOfRoyaltyBasedUponSales" xlink:label="loc_immd_PercentageOfRoyaltyBasedUponSales_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_RoyaltiesTextualAbstract_6" xlink:to="loc_immd_PercentageOfRoyaltyBasedUponSales_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_RoyaltyBasedUponSalesAmount" xlink:label="loc_immd_RoyaltyBasedUponSalesAmount_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_RoyaltiesTextualAbstract_6" xlink:to="loc_immd_RoyaltyBasedUponSalesAmount_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_RoyaltiesTextualAbstract_6" xlink:to="loc_us-gaap_RoyaltyExpense_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_InterestInRoyalty" xlink:label="loc_immd_InterestInRoyalty_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_RoyaltiesTextualAbstract_6" xlink:to="loc_immd_InterestInRoyalty_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_RoyaltiesTextualAbstract_6" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_RoyaltiesTextualAbstract_6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_12" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_RoyaltiesTextualAbstract_6" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_13" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_RoyaltiesTextualAbstract_6" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_14" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/CommitmentsAndContingenciesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_CommitmentsAndContingenciesTable" xlink:label="loc_immd_CommitmentsAndContingenciesTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_immd_CommitmentsAndContingenciesTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_RestrictedStockMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_RestrictedStockOneMember" xlink:label="loc_immd_RestrictedStockOneMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_immd_RestrictedStockOneMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_RestrictedStockTwoMember" xlink:label="loc_immd_RestrictedStockTwoMember_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_immd_RestrictedStockTwoMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_RestrictedStockThreeMember" xlink:label="loc_immd_RestrictedStockThreeMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_immd_RestrictedStockThreeMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8" xlink:to="loc_us-gaap_RelatedPartyDomain_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ConsultantMember" xlink:label="loc_immd_ConsultantMember_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_9" xlink:to="loc_immd_ConsultantMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_CommitmentsAndContingenciesTable_1" xlink:to="loc_dei_LegalEntityAxis_11" order="20" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_11" xlink:to="loc_dei_EntityDomain_12" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ImmudynePrLlcMember" xlink:label="loc_immd_ImmudynePrLlcMember_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_12" xlink:to="loc_immd_ImmudynePrLlcMember_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_CommitmentsAndContingenciesTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_14" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PresidentMember" xlink:label="loc_us-gaap_PresidentMember_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_15" xlink:to="loc_us-gaap_PresidentMember_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_CommitmentsAndContingenciesLineItems" xlink:label="loc_immd_CommitmentsAndContingenciesLineItems_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_CommitmentsAndContingenciesTable_1" xlink:to="loc_immd_CommitmentsAndContingenciesLineItems_17" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_CommitmentsAndContingenciesTextualAbstract" xlink:label="loc_immd_CommitmentsAndContingenciesTextualAbstract_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_CommitmentsAndContingenciesLineItems_17" xlink:to="loc_immd_CommitmentsAndContingenciesTextualAbstract_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_18" xlink:to="loc_us-gaap_LeaseExpirationDate1_19" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesRentExpenseMinimumRentals" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseMinimumRentals_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_18" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseMinimumRentals_20" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_18" xlink:to="loc_us-gaap_LeaseAndRentalExpense_21" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="loc_us-gaap_SalariesWagesAndOfficersCompensation_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_18" xlink:to="loc_us-gaap_SalariesWagesAndOfficersCompensation_22" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_18" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_23" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_18" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_24" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_StockIssuedDuringPeriodPerformanceBasedOptionsToPurchaseCommonStock" xlink:label="loc_immd_StockIssuedDuringPeriodPerformanceBasedOptionsToPurchaseCommonStock_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_18" xlink:to="loc_immd_StockIssuedDuringPeriodPerformanceBasedOptionsToPurchaseCommonStock_25" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_18" xlink:to="loc_us-gaap_SalesRevenueNet_26" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_SalesRevenueIncreased" xlink:label="loc_immd_SalesRevenueIncreased_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_18" xlink:to="loc_immd_SalesRevenueIncreased_27" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_BonusPercentageOfCompensationForPretaxIncome" xlink:label="loc_immd_BonusPercentageOfCompensationForPretaxIncome_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_18" xlink:to="loc_immd_BonusPercentageOfCompensationForPretaxIncome_28" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_PertaxIncomePercentage" xlink:label="loc_immd_PertaxIncomePercentage_29" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_18" xlink:to="loc_immd_PertaxIncomePercentage_29" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_30" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_18" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_30" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_31" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_18" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_31" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_32" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_18" xlink:to="loc_us-gaap_SharePrice_32" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_DebtLongTermAndShortTermCombinedAmountShares" xlink:label="loc_immd_DebtLongTermAndShortTermCombinedAmountShares_33" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_18" xlink:to="loc_immd_DebtLongTermAndShortTermCombinedAmountShares_33" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaap_RestrictedStockExpense_34" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_18" xlink:to="loc_us-gaap_RestrictedStockExpense_34" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_35" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_18" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_35" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_BonusShares" xlink:label="loc_immd_BonusShares_36" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_18" xlink:to="loc_immd_BonusShares_36" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_OptionToBuyShares" xlink:label="loc_immd_OptionToBuyShares_37" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_18" xlink:to="loc_immd_OptionToBuyShares_37" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_38" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_18" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_38" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_39" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_18" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_39" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_NumerOfThresholds" xlink:label="loc_immd_NumerOfThresholds_40" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_18" xlink:to="loc_immd_NumerOfThresholds_40" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_41" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_CommitmentsAndContingenciesTextualAbstract_18" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_41" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/RelatedPartyTransactionsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_2" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PresidentMember" xlink:label="loc_us-gaap_PresidentMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3" xlink:to="loc_us-gaap_PresidentMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_dei_LegalEntityAxis_5" order="10" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_5" xlink:to="loc_dei_EntityDomain_6" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ImmudynePrLlcMember" xlink:label="loc_immd_ImmudynePrLlcMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_6" xlink:to="loc_immd_ImmudynePrLlcMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_RelatedPartyTransactionsTextualAbstract" xlink:label="loc_immd_RelatedPartyTransactionsTextualAbstract_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_8" xlink:to="loc_immd_RelatedPartyTransactionsTextualAbstract_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_CompensationForLegalServices" xlink:label="loc_immd_CompensationForLegalServices_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_RelatedPartyTransactionsTextualAbstract_9" xlink:to="loc_immd_CompensationForLegalServices_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_ReimbursementOfHomeOfficeExpenditures" xlink:label="loc_immd_ReimbursementOfHomeOfficeExpenditures_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_RelatedPartyTransactionsTextualAbstract_9" xlink:to="loc_immd_ReimbursementOfHomeOfficeExpenditures_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_RelatedPartyTransactionsTextualAbstract_9" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_RelatedPartyTransactionsTextualAbstract_9" xlink:to="loc_us-gaap_ProfessionalFees_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_AnnualIncentiveBonusAwardPercentage" xlink:label="loc_immd_AnnualIncentiveBonusAwardPercentage_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_RelatedPartyTransactionsTextualAbstract_9" xlink:to="loc_immd_AnnualIncentiveBonusAwardPercentage_14" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immudyne.com/role/Subsequenteventsdetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3" xlink:to="loc_us-gaap_SubsequentEventMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_5" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_6" xlink:to="loc_us-gaap_CommercialPaperMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventLineItems_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_SubsequentEventsTextualAbstract" xlink:label="loc_immd_SubsequentEventsTextualAbstract_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8" xlink:to="loc_immd_SubsequentEventsTextualAbstract_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_SubsequentEventsTextualAbstract_9" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_SubsequentEventsTextualAbstract_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_SubsequentEventsTextualAbstract_9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_SubsequentEventsTextualAbstract_9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_SubsequentEventsTextualAbstract_9" xlink:to="loc_us-gaap_NotesPayable_14" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_SubsequentEventsTextualAbstract_9" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_15" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_SubsequentEventsTextualAbstract_9" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_16" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_SubsequentEventsTextualAbstract_9" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_17" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_SubsequentEventsTextualAbstract_9" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_18" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_SubsequentEventsTextualAbstract_9" xlink:to="loc_us-gaap_RepaymentsOfDebt_19" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_CommonStockSharesIssuedRelatedPromissoryNote" xlink:label="loc_immd_CommonStockSharesIssuedRelatedPromissoryNote_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_SubsequentEventsTextualAbstract_9" xlink:to="loc_immd_CommonStockSharesIssuedRelatedPromissoryNote_20" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_SubsequentEventsTextualAbstract_9" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_21" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_SubsequentEventsTextualAbstract_9" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_22" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_SubsequentEventsTextualAbstract_9" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1_23" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_SubsequentEventsTextualAbstract_9" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_24" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="immd-20161231.xsd#immd_WarrantsToPurchaseOfCommonStock" xlink:label="loc_immd_WarrantsToPurchaseOfCommonStock_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_SubsequentEventsTextualAbstract_9" xlink:to="loc_immd_WarrantsToPurchaseOfCommonStock_25" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_SubsequentEventsTextualAbstract_9" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_26" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="loc_us-gaap_CommonStockSharesSubscribedButUnissued_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_SubsequentEventsTextualAbstract_9" xlink:to="loc_us-gaap_CommonStockSharesSubscribedButUnissued_27" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesSubscriptions" xlink:label="loc_us-gaap_CommonStockSharesSubscriptions_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_SubsequentEventsTextualAbstract_9" xlink:to="loc_us-gaap_CommonStockSharesSubscriptions_28" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaap_ContractualObligation_29" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_immd_SubsequentEventsTextualAbstract_9" xlink:to="loc_us-gaap_ContractualObligation_29" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6770160352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>May 16, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Immudyne, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000948320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Smaller Reporting Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,290,842<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,406,601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6770492752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="nump">$ 182,561<span></span>
</td>
<td class="nump">$ 232,984<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Trade accounts receivable, net</a></td>
<td class="nump">444,743<span></span>
</td>
<td class="nump">154,436<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">2,250<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">160,270<span></span>
</td>
<td class="nump">61,051<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">789,824<span></span>
</td>
<td class="nump">448,471<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">752,930<span></span>
</td>
<td class="nump">167,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liabilities</a></td>
<td class="nump">192,254<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible notes payable</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable, net of discount</a></td>
<td class="nump">106,365<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">1,151,549<span></span>
</td>
<td class="nump">267,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Immudyne, Inc. Stockholders' Equity (Deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value; 50,000,000 shares authorized, 35,570,157 and 32,010,375 shares issued, 35,245,157 and 32,010,375 outstanding as of December 31, 2016 and 2015, respectively</a></td>
<td class="nump">355,701<span></span>
</td>
<td class="nump">320,103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">9,070,064<span></span>
</td>
<td class="nump">8,366,313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated (deficit)</a></td>
<td class="num">(9,693,882)<span></span>
</td>
<td class="num">(8,586,338)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_Equity', window );">Equity</a></td>
<td class="num">(268,117)<span></span>
</td>
<td class="nump">100,078<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, 325,000 shares, at cost</a></td>
<td class="num">(87,053)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Immudyne, Inc. Stockholders' Equity (Deficit)</a></td>
<td class="num">(355,170)<span></span>
</td>
<td class="nump">100,078<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interest</a></td>
<td class="num">(6,555)<span></span>
</td>
<td class="nump">80,912<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total Stockholders' Equity (Deficit)</a></td>
<td class="num">(361,725)<span></span>
</td>
<td class="nump">180,990<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Equity (Deficit)</a></td>
<td class="nump">$ 789,824<span></span>
</td>
<td class="nump">$ 448,471<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents total of common stock, additional paid in capital and accumulated deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13433-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13495-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4590271-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4568740-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6755645040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">35,570,157<span></span>
</td>
<td class="nump">32,010,375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">35,245,157<span></span>
</td>
<td class="nump">32,010,375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, common, shares</a></td>
<td class="nump">325,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6770882128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net sales</a></td>
<td class="nump">$ 5,238,604<span></span>
</td>
<td class="nump">$ 1,218,862<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of sales</a></td>
<td class="nump">1,946,055<span></span>
</td>
<td class="nump">247,772<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross Profit</a></td>
<td class="nump">3,292,549<span></span>
</td>
<td class="nump">971,090<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_CompensationAndRelatedExpenses', window );">Compensation and related expenses</a></td>
<td class="nump">1,247,195<span></span>
</td>
<td class="nump">532,421<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional fees</a></td>
<td class="nump">477,401<span></span>
</td>
<td class="nump">114,890<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketingExpense', window );">Marketing expenses</a></td>
<td class="nump">1,710,357<span></span>
</td>
<td class="nump">230,661<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">23,925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">1,032,278<span></span>
</td>
<td class="nump">331,410<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">4,467,231<span></span>
</td>
<td class="nump">1,233,307<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating (Loss)</a></td>
<td class="num">(1,174,682)<span></span>
</td>
<td class="num">(262,217)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainOnSaleOfInvestments', window );">Gain on sale of Adiuvo Investment S.A. stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">127,261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest (expense)</a></td>
<td class="num">(48,611)<span></span>
</td>
<td class="num">(37,476)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net Income (Loss) Before Taxes</a></td>
<td class="num">(1,223,293)<span></span>
</td>
<td class="num">(172,432)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax benefit</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">13,200<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (Loss)</a></td>
<td class="num">(1,223,293)<span></span>
</td>
<td class="num">(159,232)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net (loss) attributable to noncontrolling interests</a></td>
<td class="num">(115,749)<span></span>
</td>
<td class="num">(97,240)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) attributable to Immudyne, Inc.</a></td>
<td class="num">$ (1,107,544)<span></span>
</td>
<td class="num">$ (61,992)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted (loss) per share attributable to Immudyne, Inc.</a></td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Average number of common shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic</a></td>
<td class="nump">33,478,229<span></span>
</td>
<td class="nump">30,810,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted</a></td>
<td class="nump">33,478,229<span></span>
</td>
<td class="nump">30,810,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_CompensationAndRelatedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements and related expenses (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_CompensationAndRelatedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=63044130<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the carrying value and the sale price of an investment.  A gain would be recognized when the sale price of the investment is greater than the carrying value of the investment.  This element refers to the Gain included in earnings and not to the cash proceeds of the sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services. Costs of public relations and corporate promotions are typically considered to be marketing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591551-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488393&amp;loc=d3e606610-122999<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 225<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=6488370&amp;loc=d3e13550-115849<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591551-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Weighted-Average Number of Common Shares Outstanding<br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6771795408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statement of Stockholders' Equity (Deficit) - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated (Deficit)</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Sub Total</div></th>
<th class="th"><div>Noncontrolling interest</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2014</a></td>
<td class="num">$ (139,498)<span></span>
</td>
<td class="nump">$ 307,299<span></span>
</td>
<td class="nump">$ 8,077,549<span></span>
</td>
<td class="num">$ (8,524,346)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (139,498)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, (in shares) at Dec. 31, 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,729,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_AdjustmentsOfAdditionPaidInCapitalAmortizationOfStockOptions', window );">Amortization of stock options</a></td>
<td class="nump">22,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,300<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">22,300<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Purchase of company stock</a></td>
<td class="num">(10,800)<span></span>
</td>
<td class="num">$ (1,200)<span></span>
</td>
<td class="num">(9,600)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(10,800)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Purchase of company stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(120,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of company stock for notes and other payables</a></td>
<td class="nump">170,068<span></span>
</td>
<td class="nump">$ 10,004<span></span>
</td>
<td class="nump">160,064<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">170,068<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of company stock for notes and other payables, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for services</a></td>
<td class="nump">65,000<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">65,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited', window );">Company stock cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,000)<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited', window );">Company stock cancelled, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_Adjustmentstoadditionalpaidincapitalsharebasedcompensationextensionstockoptionswarrantexpirationdates', window );">Extension of option and warrant expiration dates</a></td>
<td class="nump">55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">55,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentOfWarrantsGrantedForServices', window );">Issuance of warrants for services</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Investment in subsidiary by noncontrolling interest</a></td>
<td class="nump">178,152<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">178,152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (Loss)</a></td>
<td class="num">(159,232)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(61,992)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(61,992)<span></span>
</td>
<td class="num">(97,240)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2015</a></td>
<td class="nump">180,990<span></span>
</td>
<td class="nump">$ 320,103<span></span>
</td>
<td class="nump">8,366,313<span></span>
</td>
<td class="num">(8,586,338)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">100,078<span></span>
</td>
<td class="nump">80,912<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,010,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_AdjustmentsOfAdditionPaidInCapitalAmortizationOfStockOptions', window );">Amortization of stock options</a></td>
<td class="nump">120,867<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">120,867<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">120,867<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for services</a></td>
<td class="nump">383,333<span></span>
</td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="nump">360,333<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">383,333<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock and warrants</a></td>
<td class="nump">63,250<span></span>
</td>
<td class="nump">$ 2,750<span></span>
</td>
<td class="nump">60,500<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">63,250<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock and warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Conversion of NCI equity for shares, value</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">$ 4,348<span></span>
</td>
<td class="nump">95,652<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Conversion of NCI equity for shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">434,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock for options exercise</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">27,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock for options exercise, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issued of common stock, value</a></td>
<td class="nump">58,750<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="nump">56,250<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">58,750<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock in relation to debt offering, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentOfWarrantsGrantedForServices', window );">Issuance of warrants for services</a></td>
<td class="nump">20,585<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">20,585<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">20,585<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestPeriodIncreaseDecrease', window );">Reduction in noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">91,612<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">91,612<span></span>
</td>
<td class="num">(91,612)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchase of treasury stock</a></td>
<td class="num">(87,053)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(87,053)<span></span>
</td>
<td class="num">(87,053)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Issuance of stock options for services</a></td>
<td class="nump">63,206<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">63,206<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">63,206<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Investment in subsidiary by noncontrolling interest</a></td>
<td class="nump">119,894<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">119,894<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities', window );">Reclassification of options, warrants and other contracts from equity to derivative liabilities</a></td>
<td class="num">(192,254)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(192,254)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(192,254)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (Loss)</a></td>
<td class="num">(1,223,293)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,107,544)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,107,544)<span></span>
</td>
<td class="num">(115,749)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2016</a></td>
<td class="num">$ (361,725)<span></span>
</td>
<td class="nump">$ 355,701<span></span>
</td>
<td class="nump">$ 9,070,064<span></span>
</td>
<td class="num">$ (9,693,882)<span></span>
</td>
<td class="num">$ (87,053)<span></span>
</td>
<td class="num">$ (355,170)<span></span>
</td>
<td class="num">$ (6,555)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,570,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_AdjustmentsOfAdditionPaidInCapitalAmortizationOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from amortization of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_AdjustmentsOfAdditionPaidInCapitalAmortizationOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid-in capital share based compensation reclassification of options, warrants and other contracts from equity to derivative liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_Adjustmentstoadditionalpaidincapitalsharebasedcompensationextensionstockoptionswarrantexpirationdates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital share based compensation extension stock options warrant expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_Adjustmentstoadditionalpaidincapitalsharebasedcompensationextensionstockoptionswarrantexpirationdates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentOfWarrantsGrantedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment for noncash service expenses paid for by granting of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentOfWarrantsGrantedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of recognized equity-based compensation related to stock options during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in balance of noncontrolling interest in the subsidiary during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4568740-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569655-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591551-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of forfeitures of stock or other type of equity issued of any equity-based compensation plan other than an employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph c(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4590271-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4568740-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=immd_SummationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=immd_SummationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6757954928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (Loss)</a></td>
<td class="num">$ (1,223,293)<span></span>
</td>
<td class="num">$ (159,232)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net (loss) to net cash (used) by operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">43,748<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Bad debt provision</a></td>
<td class="nump">71,136<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">33,715<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax benefit</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(13,200)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock compensation expense</a></td>
<td class="nump">587,991<span></span>
</td>
<td class="nump">77,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Common stock issued for services</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">65,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfInvestments', window );">Gain on sale of Adiuvo Investment S.A. stock</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(127,261)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in Assets and Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Trade accounts receivable</a></td>
<td class="num">(361,443)<span></span>
</td>
<td class="num">(139,466)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other receivables</a></td>
<td class="num">(2,250)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(99,219)<span></span>
</td>
<td class="num">(20,043)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">585,449<span></span>
</td>
<td class="num">(21,970)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash (used) by operating activities</a></td>
<td class="num">(407,914)<span></span>
</td>
<td class="num">(295,124)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromInvestments', window );">Proceeds from sale of Adiuvo Investment S.A. stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">127,261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsToMinorityShareholders', window );">Investment in subsidiary by noncontrolling interest</a></td>
<td class="nump">219,894<span></span>
</td>
<td class="nump">178,152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInNotesPayableCurrent', window );">Increase in notes payable</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">305,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible note payable</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayment of notes payable</a></td>
<td class="num">(168,600)<span></span>
</td>
<td class="num">(147,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from options exercise</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_IssuanceOfCommonStockAndWarrants', window );">Sale of common stock and warrants</a></td>
<td class="nump">63,250<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Purchase of treasury stock</a></td>
<td class="num">(87,053)<span></span>
</td>
<td class="num">(10,800)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">357,491<span></span>
</td>
<td class="nump">325,352<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net (decrease) increase in cash</a></td>
<td class="num">(50,423)<span></span>
</td>
<td class="nump">157,489<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash at beginning of the year</a></td>
<td class="nump">232,984<span></span>
</td>
<td class="nump">75,495<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash at end of the year</a></td>
<td class="nump">182,561<span></span>
</td>
<td class="nump">232,984<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Disclosure of Cash Flow Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid during the period for interest</a></td>
<td class="nump">13,650<span></span>
</td>
<td class="nump">28,976<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountIssued1', window );">Issuance of company stock for notes and other payables</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">170,068<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_IssuanceOfCommonStockInRelationToDebtOffering', window );">Issuance of common stock in relation to debt offering</a></td>
<td class="nump">58,750<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_ReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities', window );">Reclassification of options, warrants and other contracts from equity to derivative liabilities</a></td>
<td class="nump">192,254<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_ConversionOfEquityInvestedInSubsidiaryToCommonStockAndWarrants', window );">Conversion of equity invested in subsidiary to common stock and warrants</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_ConversionOfEquityInvestedInSubsidiaryToCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The conversion vale of equity invested in subsidiary to common stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_ConversionOfEquityInvestedInSubsidiaryToCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_IssuanceOfCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_IssuanceOfCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_IssuanceOfCommonStockInRelationToDebtOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock in relation to debt offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_IssuanceOfCommonStockInRelationToDebtOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_ReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification of options, warrants and other contracts to derivative liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_ReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28541-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Expense (or Benefit)<br> -URI http://asc.fasb.org/extlink&amp;oid=63044130<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in current portion (due within one year or one business cycle) of obligations evidenced by formal promissory notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash paid (received) associated with the acquisition or disposal of all investments, including securities and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3098-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3095-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from (to) a noncontrolling interest. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591551-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, accounts receivable and notes receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.5)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760806816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Going Concern<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and Going Concern [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Going Concern</a></td>
<td class="text"><div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0pt; margin-bottom: 0pt; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" border="0" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; width: 0.5in; text-align: justify; text-indent: 0pt; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b>1.</b></font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; text-align: justify; text-indent: 0pt; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b>Organization and Going Concern</b></font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Immudyne, Inc. (the &#8220;Company&#8221;) is a Delaware corporation established to develop, manufacture and sell natural immune support products containing the Company&#8217;s proprietary yeast beta glucans, a group of beta glucans naturally occurring in the cell walls of yeast that have been shown through testing and analysis to support the immune system. The Company&#8217;s products include once a day oral intake tablets and topical creams and gels for skin application. The Company concentrates its sales and marketing efforts on healthcare professionals, distributors for its all-natural raw material ingredient products and direct-to-consumer sales.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In 2015, the Company formed a joint venture domiciled in Puerto Rico, Innate Skincare, LLC d/b/a Innate Scientific, LLC (&#8220;Innate&#8221;). Under the terms of the joint venture agreement, the Company held a 33.3% equity interest, and a 51% controlling voting interest, in Innate. On January 20, 2016, Innate amended its limited liability company operating agreement and changed its legal name to Immudyne PR LLC (&#8220;Immudyne PR&#8221;). On April 1, 2016, Immudyne PR further amended its operating agreement and restated the Company&#8217;s ownership and voting interest in Immudyne PR increasing its ownership to 78.16667% resulting in a charge to noncontrolling interest and additional paid-in-capital of $91,612. Immudyne PR was formed to launch a complete skin care regime formulated using strategic ingredients provided by the Company. Immudyne PR is also currently pursuing other opportunities.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The Company has funded operations in the past through the sales of its products, issuance of common stock and through loans and advances from officers and directors. The Company&#8217;s continued operations are dependent upon obtaining an increase in its sales volume and the continued financial support from officers and directors or the issuance of additional shares of common stock.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The accompanying financial statements have been
 prepared on the basis that the Company will continue as a going concern, which assumes the realization of assets and the satisfaction of liabilities in the normal course of business. At December 31, 2016, the Company has an accumulated deficit approximating $9.7 million and has incurred negative cash flows from operations. These conditions raise substantial doubt about the Company's ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Based on the Company's cash balance at December 31, 2016, and projected cash needs for 2017, management estimates that it may need to increase sales revenue and/or raise additional capital to cover operating and capital requirements for the 2017 year. Management may raise the additional needed funds through increased sales volume, issuing additional shares of common stock or other equity securities, or obtaining debt financing. Although management has been successful to date in raising necessary funding, there can be no assurance that sales revenue will substantially increase or that any required future financing can be successfully completed on a timely basis, or on terms acceptable to the Company.</font></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=35735333&amp;loc=d3e288-107754<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 272<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=d3e5614-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6927126848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div>
<table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-size-adjust: none; font-stretch: normal;">
<td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; width: 0.5in; text-align: justify; text-indent: 0pt; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b>2.</b></font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; text-align: justify; text-indent: 0pt; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b>Summary of Significant Accounting Policies</b></font></td>
</tr>
</table>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b><i>&#160;</i></b></font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><b><i>Principles of Consolidation</i></b></font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company evaluates the need to consolidate affiliates based on standards set forth in ASC 810 Consolidation (&#8220;ASC 810&#8221;).</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">The consolidated financial statements include the accounts of the Company and its majority owned subsidiary, Immudyne PR and variable interest entities (VIE&#8217;s) in which the Company has been determined to be the primary beneficiary. The non- controlling interest in Immudyne PR represents the 21.833% equity interest held by other members of the joint venture. All significant consolidated transactions and balances have been eliminated in consolidation.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>Variable Interest Entities</i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company follows ASC 810-10-15 guidance with respect to accounting for variable interest entities (each, a &#8220;VIE&#8221;). These entities do not have sufficient equity at risk to finance their activities without additional subordinated financial support from other parties or whose equity investors lack any of the characteristics of a controlling financial interest. A variable interest is an investment or other interest that will absorb portions of a VIE&#8217;s expected losses or receive portions of its expected residual returns and are contractual, ownership, or pecuniary in nature and that change with changes in the fair value of the entity&#8217;s net assets. A reporting entity is the primary beneficiary of a VIE and must consolidate it when that party has a variable interest, or combination of variable interests, that provides it with a controlling financial interest. A party is deemed to have a controlling financial interest if it meets both of the power and losses/benefits criteria. The power criterion is the ability to direct the activities of the VIE that most significantly impact its economic performance. The losses/benefits criterion is the obligation to absorb losses from, or right to receive benefits from, the VIE that could potentially be significant to the VIE. The VIE model requires an ongoing reconsideration of whether a reporting entity is the primary beneficiary of a VIE due to changes in facts and circumstances.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space:
 normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">As of December 31, 2016 and 2015, the Company consolidated nine and zero VIEs, respectively.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">Immudyne PR as the primary beneficiary of Ace Account Management LLC, Innerwell Skincare LLC, MCD Merchants LLC, One Equity Research LLC, Inate Gems LLC, Retriever Health Products LLC, Spurs 5, LLC, Salus LLC and Huntley LLC which are qualified as VIEs. The assets and liabilities and revenues and expenses of these VIEs included in the financial statements of Immudyne PR and further included in the consolidated financial statements. As of December 31, 2016, the VIEs had assets of $10,306, liabilities of $5,748, revenues of $6,271, and operating expenses of $6,141. The assets and liabilities include balances due from and due to the subsidiaries of Immudyne PR. These inter-company receivables and payables are eliminated upon consolidation of the VIE with Immudyne PR and Immudyne. No assets were pledged or given as collateral against any borrowings.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company utilizes third party entities to provide and increase credit card processing capacity and optimize corresponding rates and fees. A majority of these entities provide this service as independent contractors in exchange for a one (1%) percent fee of the net revenues processed and collected by such contractors from sales initiated by the Company. The VIEs consolidated in the Company&#8217;s financial statements are primarily contracted to credit card processing through one or more merchant banks contracted by each VIE. Upon receipt of funds by each VIE, the collection of receipts less any returns, chargeback and other fees charged by such merchant bank is transferred to Immudyne PR.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>Use of Estimates</i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>&#160;</i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i></i></b>The Company prepares its consolidated financial statements in conformity with accounting principles generally accepted in the United States of America which requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Some of the more significant estimates required to be made by management include the determination of reserves for accounts receivable, returns and allowances, the accounting for derivatives, the valuation of inventory and stockholders&#8217; equity based transactions. Actual results could differ from those estimates.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>Derivative Liabilities</i></b>&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company evaluates stock options, stock warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for under the relevant sections of Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 815-40, Derivative Instruments and Hedging: Contracts in Entity&#8217;s Own Equity. The result of this accounting treatment could be that the fair value of a financial instrument is classified as a derivative instrument and is marked-to-market at each balance sheet date and recorded as a liability. In the
 event that the fair value is recorded as a liability, the change in fair value is recorded in the consolidated statements of operations as other income or other expense. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">Financial instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815-40 are reclassified to a liability account at the fair value of the instrument on the reclassification date.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">As of December 31, 2016, certain of the Company&#8217;s stock options, stock warrants and convertible debt instruments were accounted for as derivative liabilities due to insufficient authorized shares of common stock to settle outstanding contracts. At December 31, 2016, the Company estimated the fair value of these stock options, stock warrants and embedded conversion features using the Black-Scholes option pricing model (&#8220;Black-Scholes&#8221;) in the amount of $192,254 was recorded upon issue&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>Sequencing Policy</i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">Under ASC 815-40-35, the Company has adopted a sequencing policy whereby, in the event that reclassification of contracts from equity to assets or liabilities is necessary pursuant to ASC 815 due to the Company&#8217;s inability to demonstrate it has sufficient authorized shares, shares will be allocated on the basis of the earliest issuance date of potentially dilutive instruments, with the earliest grants receiving the first allocation of authorized but unissued shares, and all future instruments being classified as a derivative liability, with the exception of instruments related to share-based compensation issued to employees or directors.&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>Inventory&#160;</i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">At December 31, 2016 and December 31, 2015, inventory consisted primarily of cosmetic and nutraceutical additives, and finished cosmetic products. Inventory is maintained in the Company&#8217;s leased Kentucky warehouse and third party warehouses in Pennsylvania and Louisiana.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Inventory is valued at the lower of cost or market with cost determined on a first-in, first-out (&#8220;FIFO&#8221;) basis. Management compares the cost of inventory with the net
 realizable value and an allowance is made for writing down inventory to market value, if lower. At December 31, 2016 and December 31, 2015, the Company recorded an inventory reserve in the amount of $20,000. Inventory consists of the following:</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p>
<table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="background-color: white;">&#160;</td>
<td>&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">December&#160;31,<br />2016</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">December&#160;31,<br />2015</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="background-color: white;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: right;" colspan="2">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: right;" colspan="2">&#160;</td>
<td>&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="width: 0.5in; background-color: white;">&#160;</td>
<td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">Raw materials</td>
<td style="width: 15px;">&#160;</td>
<td style="width: 15px; text-align: left;">$</td>
<td style="width: 125px; text-align: right;">38,460</td>
<td style="width: 15px; text-align: left;">&#160;</td>
<td style="width: 15px;">&#160;</td>
<td style="width: 15px; text-align: left;">$</td>
<td style="width: 125px; text-align: right;">25,761</td>
<td style="width: 15px; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">Finished products</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">121,810</td>
<td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">35,290</td>
<td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;">&#160;</td>
<td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">&#160;</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">160,270</td>
<td style="text-align: left; padding-bottom: 4pt;">&#160;</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">61,051</td>
<td style="text-align: left; padding-bottom: 4pt;">&#160;</td>
</tr>
</table>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0px; text-align: center; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b>&#160;</b></font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b><i>Revenue Recognition</i></b></font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company&#8217;s policy is to record revenue as earned when a firm commitment, indicating sales quantity and price exists, delivery has taken place and collectability is reasonably assured. The Company generally records sales of nutraceutical and cosmetic additives once the product is shipped to the customer, and for sales of finished cosmetic products once the customer places the order and the product is simultaneously shipped, but in limited cases if title does not pass until the product reaches the customer&#8217;s delivery site, then recognition of revenue is deferred until that time. Delivery is considered to have occurred when title and risk of loss have transferred to the customer.
 Provisions for discounts, returns, allowances, customer rebates and other adjustments are netted with gross sales. The Company accounts for such provisions during the same period in which the related revenues are earned. Customer discounts, returns and rebates approximated $1,926,000 in the year ended December 31, 2016. Customer discounts, returns and rebates were not significant in the year ended December 31, 2015.</p>
<p style="font: 10pt/14.26px 'times new roman', times, serif; margin: 0pt 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">Delivery is considered to have occurred when title and risk of loss have transferred to the customer. If title does not pass until the product reaches the customer&#8217;s delivery site or the customer accepts the product, then recognition of revenue is deferred until that time. There are no formal sales incentives offered to any of the Company&#8217;s customers. Volume discounts may be offered from time to time to customers purchasing large quantities on a per transaction basis.</p>
<p style="font: 10pt/14.26px 'times new roman', times, serif; margin: 0pt 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">Revenue for the year ended December 31, 2016 consisted of nutraceutical and cosmetic additives ($997,964) and finished cosmetic products ($4,240,640). Revenue for the year ended December 31, 2015 consists of nutraceutical and cosmetic additives ($1,079,289) and finished cosmetic products ($139,573).</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b><i>Accounts receivable</i></b></font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">Accounts receivable are carried at original invoice amount less an estimate made for holdbacks and doubtful receivables based on a review of all outstanding amounts. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer&#8217;s financial condition, credit history and current economic conditions and sets up an allowance for doubtful accounts when collection is uncertain. Customers&#8217; accounts are written off when all attempts to collect have been exhausted. Recoveries of accounts receivable previously written off are recorded as income when received. At December 31, 2016 and 2015 the accounts receivable reserve was approximately $37,800 and $18,000, respectively. As of December 31, 2016, the reserve for sales returns and allowances was approximately $50,500. No sales returns and allowances reserve existed at December 31, 2015.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b><i>&#160;</i></b></font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b><i>Segments</i></b></font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The guidance for disclosures about segments of an
 enterprise requires that a public business enterprise report financial and descriptive information about its operating segments. Generally, financial information is required to be reported on the basis used internally for evaluating segment performance and resource allocation. The Company manages its operations in two reportable segments for purposes of assessing performance and making operating decisions. Revenue is generated predominately in the United States, and all significant assets are held in the United States, or United States territories.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies. The Company allocates resources and evaluates the performance of segments based on income or loss from operations, excluding interest, corporate expenses and other income (expenses).</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">A summary of the company&#8217;s reportable segments is as follows:</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p>
<table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="background-color: white;">&#160;</td>
<td><font style="font-size: 10pt;"><u>Total assets:</u></font></td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font-size: 10pt;">December&#160;31,</font><br /><font style="font-size: 10pt;">2016</font></td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font-size: 10pt;">December&#160;31,</font><br /><font style="font-size: 10pt;">2015</font></td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="width: 0.5in; background-color: white;">&#160;</td>
<td style="background-color: #cceeff;"><font style="font-size: 10pt;">Nutraceutical and Cosmetic Additives</font></td>
<td style="width: 15px; background-color: #cceeff;">&#160;</td>
<td style="width: 15px; background-color: #cceeff;"><font style="font-size: 10pt;">$</font></td>
<td style="width: 125px; text-align: right; background-color: #cceeff;"><font style="font-size: 10pt;">556,234</font></td>
<td style="width: 15px; background-color: #cceeff;">&#160;</td>
<td style="width: 15px; background-color: #cceeff;">&#160;</td>
<td style="width: 15px; background-color: #cceeff;"><font style="font-size: 10pt;">$</font></td>
<td style="width: 125px; text-align: right; background-color: #cceeff;"><font style="font-size: 10pt;">412,324</font></td>
<td style="width: 15px; background-color: #cceeff;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td>&#160;</td>
<td><font style="font-size: 10pt;">Finished Cosmetic Products</font></td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: right;"><font style="font-size: 10pt;">422,288</font></td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: right;"><font style="font-size: 10pt;">101,828</font></td>
<td>&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="background-color: white;">&#160;</td>
<td style="padding-bottom: 1.5pt; background-color: #cceeff;"><font style="font-size: 10pt;">Eliminations</font></td>
<td style="padding-bottom: 1.5pt; background-color: #cceeff;">&#160;</td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; background-color: #cceeff;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; background-color: #cceeff;"><font style="font-size: 10pt;">(188,698</font></td>
<td style="padding-bottom: 1.5pt; background-color: #cceeff;"><font style="font-size: 10pt;">)</font></td>
<td style="padding-bottom: 1.5pt; background-color: #cceeff;">&#160;</td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; background-color: #cceeff;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; background-color: #cceeff;"><font style="font-size: 10pt;">(65,681</font></td>
<td style="padding-bottom: 1.5pt; background-color: #cceeff;"><font style="font-size:
 10pt;">)</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td>&#160;</td>
<td style="padding-bottom: 4pt;"><font style="font-size: 10pt;"><b>Total</b></font></td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double;"><font style="font-size: 10pt;"><b>$</b></font></td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double;"><font style="font-size: 10pt;"><b>789,824</b></font></td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double;"><font style="font-size: 10pt;"><b>$</b></font></td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double;"><font style="font-size: 10pt;"><b>448,471</b></font></td>
<td style="padding-bottom: 4pt;">&#160;</td>
</tr>
</table>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p>
<table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="background-color: white;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;" colspan="6">Year ended</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="background-color: white;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;" colspan="2">December&#160;31, 2016</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;" colspan="2">December&#160;31, 2015</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="background-color: white;">&#160;</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><u>Net sales by segment:</u></td>
<td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt;" colspan="2">&#160;</td>
<td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt;" colspan="2">&#160;</td>
<td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="width: 0.5in; background-color: white;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;">Nutraceutical and Cosmetic Additives</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-size-adjust: none; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-size-adjust: none; font-stretch: normal;">$</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 125px; text-align: right; font-size-adjust: none; font-stretch: normal;">1,024,264</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-size-adjust: none; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-size-adjust: none; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-size-adjust: none; font-stretch: normal;">$</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 125px; text-align: right; font-size-adjust: none; font-stretch: normal;">1,092,289</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-size-adjust: none; font-stretch: normal;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;">Finished Cosmetic Products</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-size-adjust: none; font-stretch: normal;">4,240,640</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch:
 normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-size-adjust: none; font-stretch: normal;">139,573</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;">Eliminations</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;">(26,300</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;">)</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;">(13,000</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-size-adjust: none; font-stretch: normal;">Total</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-size-adjust: none; font-stretch: normal;">&#160;</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size-adjust: none; font-stretch: normal;">$</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size-adjust: none; font-stretch: normal;">5,238,604</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-size-adjust: none; font-stretch: normal;">&#160;</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-size-adjust: none; font-stretch: normal;">&#160;</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size-adjust: none; font-stretch: normal;">$</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size-adjust: none; font-stretch: normal;">1,218,862</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-size-adjust: none; font-stretch: normal;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; text-decoration: underline; font-size-adjust: none; font-stretch: normal;">Net (loss) income by segment:</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;">Nutraceutical and Cosmetic Additives</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;">$</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-size-adjust: none; font-stretch: normal;">164,286</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;">$</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-size-adjust: none; font-stretch: normal;">110,467</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;">Finished Cosmetic Products</td>
<td style="font:
 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-size-adjust: none; font-stretch: normal;">(388,121</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;">)</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-size-adjust: none; font-stretch: normal;">(158,402</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; text-decoration: underline; font-size-adjust: none; font-stretch: normal;">Other unallocated amounts:</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;">Corporate expenses</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-size-adjust: none; font-stretch: normal;">(950,847</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;">)</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-size-adjust: none; font-stretch: normal;">(214,282</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;">Other income (expense) &#8211; net</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-size-adjust: none; font-stretch: normal;">(48,611</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;">)</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-size-adjust: none; font-stretch: normal;">89,785</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;">&#160;</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-size-adjust: none; font-stretch: normal;">Consolidated income (loss) from operations</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-size-adjust: none; font-stretch: normal;">&#160;</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size-adjust: none; font-stretch: normal;">$</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size-adjust: none; font-stretch: normal;">(1,223,293</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-size-adjust: none; font-stretch: normal;">)</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-size-adjust: none; font-stretch: normal;">&#160;</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size-adjust: none; font-stretch: normal;">$</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size-adjust: none; font-stretch: normal;">(172,432</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-size-adjust: none; font-stretch: normal;">)</td>
</tr>
</table>
<p style="font: 10pt/normal 'times new
 roman', times, serif; margin: 0pt 0pt 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b><i>Income Taxes</i></b></font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The Company files Corporate Federal and State tax returns, while Immudyne PR, which was formed as a limited liability corporation, files a separate tax return with any tax liabilities or benefits passing through to its members.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The Company records current and deferred taxes in accordance with Accounting Standards Codification (ASC) 740, &#8220;Accounting for Income Taxes.&#8221; This ASC requires recognition of deferred tax assets and liabilities for temporary differences between tax basis of assets and liabilities and the amounts at which they are carried in the financial statements, based upon the enacted rates in effect for the year in which the differences are expected to reverse. The Company establishes a valuation allowance when necessary to reduce deferred tax assets to the amount expected to be realized. The Company periodically assesses the value of its deferred tax asset, a majority of which has been generated by a history of net operating losses and determines the necessity for a valuation allowance. ASC 740 also provides a recognition threshold and measurement attribute for the financial statement recognition of a tax position taken or expected to be taken in a tax return. Using this guidance, a company may recognize the tax benefit from an uncertain tax position in its financial statements only if it is more likely-than-not (i.e., a likelihood of more than 50%) that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The Company&#8217;s tax returns for all years since December 31, 2013, remain open to taxing authorities.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b><i>Stock-Based Compensation</i></b></font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The Company follows the provisions of ASC 718, &#8220;Share-Based Payment&#8221;. Under this guidance compensation cost generally is recognized at fair value on the date of the grant and amortized over the respective vesting periods. The fair value of options at the date of grant is estimated using the Black-Scholes option pricing model. The expected option life is derived from assumed exercise rates based upon historical exercise patterns and
 represents the period of time that options granted are expected to be outstanding. The expected volatility is based upon historical volatility of the Company&#8217;s shares using weekly price observations over an observation period that approximates the expected life of the options. The risk-free rate approximates the U.S. Treasury yield curve rate in effect at the time of grant for periods similar to the expected option life. Due to limited history of forfeitures, the estimated forfeiture rate included in the option valuation was zero.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Many of the assumptions require significant judgment and any changes could have a material impact in the determination of stock-based compensation expense.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b><i>Earnings (Loss) Per Share</i></b></font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Basic earnings (loss) per common share is based on the weighted average number of shares outstanding during each period presented. Warrants and options to purchase common stock are included as common stock equivalents only when dilutive. Potential common stock equivalents are excluded from dilutive earnings per share when the effects would be antidilutive.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">Common stock equivalents comprising shares underlying 16,302,447 options and warrants for the year ended December 31, 2016 have not been included in the loss per share calculation as the effects are anti-dilutive. Common stock equivalents comprising shares underlying 12,775,273 options and warrants for the year ended December 31, 2015 have not been included in the loss per share calculations as the effects are anti-dilutive.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b><i>Recent Accounting Pronouncements</i></b>&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (&#8220;ASU 2016-15&#8221;). ASU 2016-15 addresses eight specific cash flow issues with the objective of reducing diversity in practice regarding how certain cash receipts and cash payments are presented in the statement of cash flows. The standard provides guidance on the classification of the following items: (1) debt
 prepayment or debt extinguishment costs, (2) settlement of zero-coupon debt instruments, (3) contingent consideration payments made after a business combination, (4) proceeds from the settlement of insurance claims, (5) proceeds from the settlement of corporate-owned life insurance policies, (6) distributions received from equity method investments, (7) beneficial interests in securitization transactions, and (8) separately identifiable cash flows. The Company is required to adopt ASU 2016-15 for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2017 on a retrospective basis. Early adoption is permitted, including adoption in an interim period. The Company is currently evaluating the impact of adoption of ASU 2016-15.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">In March 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-09, &#8220;Compensation &#8211; Stock Compensation: Improvements to Employee Share-Based Payment Accounting,&#8221; which relates to the accounting for employee share-based payments. This standard addresses several aspects of the accounting for share-based payment award transactions, including: (a) income tax consequences; (b) classification flows of awards as either equity or liabilities; and (c) classification on the statement of cash flows. This standard will be effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The Company is in the process of evaluating the impact of the adoption of ASU 2016-09 on its consolidated financial statements. The adoption of ASU No. 2016-09 is not expected to have a material impact on the Company's consolidated financial statements or related disclosures.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">In February 2016, a pronouncement was issued that creates new accounting and reporting guidelines for leasing arrangements. The new guidance requires organizations that lease assets to recognize assets and liabilities on the balance sheet related to the rights and obligations created by those leases, regardless of whether they are classified as finance or operating leases. Consistent with current guidance, the recognition, measurement, and presentation of expenses and cash flows arising from a lease primarily will depend on its classification as a finance or operating lease. The guidance also requires new disclosures to help financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. The new standard is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period, with early application permitted. The new standard is to be applied using a modified retrospective approach. The Company is in the process of evaluating the impact of the new pronouncement on its consolidated financial statements.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">In May 2014, the Financial Accounting Standards Board ("FASB") issued accounting guidance, "Revenue from Contracts with Customers." The core principle of the new standard is for companies to recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration (that is, payment) to which the company expects to be entitled in exchange for those goods or services. The new standard also will result in enhanced disclosures about revenue, provide guidance for transactions that were not previously addressed comprehensively (for example, service revenue and contract modifications) and clarify guidance for multiple-element arrangements. The standard will be effective for fiscal years and interim periods within those years beginning after December 15, 2017. Accordingly, the Company will adopt this standard in the first quarter of fiscal year 2018. The Company is currently evaluating the impact this guidance will have on the consolidated financial statements.</font></p>
<p
 style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 108pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">In July 2015, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2015-11, &#8220;Simplifying the Measurement of Inventory.&#8221; ASU 2015-11 applies to inventory that is measured using first-in, first-out (FIFO) or average cost. An entity should measure inventory within the scope of ASU 2015-11 at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. ASU 2015-11 is effective for fiscal years beginning after December 15, 2016. The adoption of ASU No. 2015-11 is not expected to have a material impact on the Company's consolidated financial statements or related disclosures.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">In August 2014, the FASB issued ASU 2014-15, "Presentation of Financial Statements-Going Concern". This ASU is intended to define management's responsibility to evaluate whether there is substantial doubt about an organization's ability to continue as a going concern and to provide related footnote disclosures. It is effective for annual periods ending after December 15, 2016, with early adoption permitted. The Company does not expect it to have a material effect on the Company's consolidated financial condition, results of operations, and cash flows.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">In May 2017, the FASB issued ASU 2017-09, Compensation - Stock Compensation (Topic 718) : Scope of Modification Accounting. The new standard provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. This pronouncement is effective for annual reporting periods beginning after December 15, 2017 but early adoption is permitted. The Company is currently evaluating the impact of adopting this guidance.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">All other accounting standards that have been issued or proposed by the FASB that do not require adoption until a future date are not expected to have a material impact on the consolidated financial statements upon adoption.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b><i>Fair Value of Financial Instruments</i></b></font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000;
 text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The carrying value of the Company&#8217;s financial instruments, including cash, trade accounts receivable, accounts payable and accrued expenses and the face amount of notes payable approximate fair value for all periods.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b><i>Noncontrolling Interests</i></b></font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The Company accounts for its less than 100% interest in Immudyne PR in accordance with ASC Topic 810, Consolidation, and accordingly the Company presents noncontrolling interests as a component of equity on its consolidated balance sheet and reports the noncontrolling interest&#8217;s share of the Immudyne PR net loss attributable to noncontrolling interests in the consolidated statement of operations.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>Consolidation of Variable Interest Entities</i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">In accordance with ASC 810-10-25-37 and as amended by ASU 2009-17, the Company determines whether any legal entity in which the Company becomes involved is a VIE and subject to consolidation. The Company conducts an assessment on an ongoing basis for each VIE including (1) the power to direct activities of the VIE that most significantly impact the VIE&#8217;s economic performance, and (2) the obligation to absorb losses or right to receive benefits from the VIE that could potentially be significant to the VIE. As a result, the Company determined that nine (9) entities were VIEs and subject to consolidation.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b><i>Concentration of Credit Risk</i></b></font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The Company grants credit in the normal course of business to its customers. The Company periodically performs credit analysis and monitors the financial condition of its customers to reduce credit risk.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt/normal 'times
 new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The Company monitors its positions with, and the credit quality of, the financial institutions with which it invests. The Company, at times, maintains balances in various operating accounts in excess of federally insured limits.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">One customer in the nutraceutical and cosmetic additives division accounted for 15% and 73% of consolidated sales for the years ended December 31, 2016 and 2015, respectively. This customer accounted for 11% and 43% of accounts receivable at December 31, 2016 and December 31, 2015, respectively.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">A second customer in the nutraceutical and cosmetic additives division accounted for 2% and 12% of consolidated sales for years ended December 31, 2016 and 2015, respectively. This customer accounted for 8% and 24% of accounts receivable at December 31, 2016 and December 31, 2015, respectively.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">In the finished cosmetic products division, two credit card processors accounted for 34.9% and 31.6% of accounts receivable at December 31, 2016. There were no significant concentrations of accounts receivable in the finished cosmetic products division at December 31, 2015</p>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18861-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18743-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18854-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760814288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Furnishings and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Furnishings and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Furnishings and Equipment</a></td>
<td class="text"><div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; width: 0.5in; text-indent: 0pt; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b>3.</b></font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; text-indent: 0pt; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b>Furnishings and Equipment</b></font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Furnishings and equipment consisted of the following:</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-family: calibri, sans-serif;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6">December 31</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-family: calibri, sans-serif;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2016</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2015</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td style="font-family: calibri, sans-serif;">&#160;</td><td style="font-family: calibri, sans-serif;">&#160;</td><td style="font-family: calibri, sans-serif;" colspan="2">&#160;</td><td style="font-family: calibri, sans-serif;">&#160;</td><td style="font-family: calibri, sans-serif;">&#160;</td><td style="font-family: calibri, sans-serif;" colspan="2">&#160;</td><td style="font-family: calibri, sans-serif;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 0.5in; background-color: white;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">Furnishings and equipment, at cost</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 125px; text-align: right;">679,291</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 125px; text-align: right;">679,291</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">Accumulated depreciation</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">679,291</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">679,291</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt; font-family: calibri, sans-serif;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">-</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">-</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; color: #000000; text-transform: none;
 text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Depreciation expense amounted to $0 and $43,748 for years ended December 31, 2016 and 2015, respectively.</font></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13-14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=d3e2921-110230<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6927126848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Adiuvo Investment S.A.<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsAbstract', window );"><strong>Investment in Adiuvo Investment S.A. [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentHoldingsTextBlock', window );">Investment in Adiuvo Investment S.A.</a></td>
<td class="text"><div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; width: 0.5in; text-indent: 0pt; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b>4.</b></font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0pt; text-indent: 0pt; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b>Investment in Adiuvo Investment S.A.</b></font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b>&#160;</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">In December 2013, the Company entered into a memorandum of understanding (MOU) with Adiuvo Investment S.A. (AI), an investment company located in Poland, whereby AI paid the Company $100,000 for the option, which expired in September 2014, to purchase up to 10% of the outstanding stock in the Company at $0.25 per share. In January 2014, the Company invested $100,000 in AI in exchange for a minority interest of less than 1% in AI, and an option to acquire additional shares of AI up to an aggregate consideration of $1,500,000. Further, AI granted the Company the right to participate in any subsequent public offerings of AI and the option to buy up to 10% of AI. During 2015 AI shares commenced trading on the Warsaw exchange in Poland, and the Company sold its entire investment, receiving $127,261, net of transaction costs. Due to the investment&#8217;s limited liquidity and uncertain valuation prior to its sale, the Company accounted for its interest in AI at no value. The proceeds of the Company&#8217;s sale of AI stock, $127,261, are recorded as gain on sale of Adiuvo Investment S.A. stock in the accompanying statement of operations for the year ended December 31, 2015.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentHoldingsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investment holdings. This includes the long positions of investments for the entity. It contains investments in affiliated and unaffiliated issuers. The investments include securities and non securities (i.e. commodities and futures contracts).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-12C)<br> -URI http://asc.fasb.org/extlink&amp;oid=50485924&amp;loc=d3e611225-123010<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14)<br> -URI http://asc.fasb.org/extlink&amp;oid=50485924&amp;loc=d3e611322-123010<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13)<br> -URI http://asc.fasb.org/extlink&amp;oid=50485924&amp;loc=d3e611282-123010<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12)<br> -URI http://asc.fasb.org/extlink&amp;oid=50485924&amp;loc=d3e611133-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentHoldingsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760814288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Notes Payable</a></td>
<td class="text"><div>
<table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;">
<td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 48px; text-align: justify; text-indent: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>5.</b></font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: justify; text-indent: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>Notes Payable</b></font></td>
</tr>
</table>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b><i>&#160;</i></b></font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Notes payable are due to officers, directors, and shareholders and a commercial lender and are summarized as follows:&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p>
<table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="background-color: white;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">Officers, Directors, and Shareholders</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">Commercial Lenders</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">Total</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="width: 0.5in; background-color: white;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Balance at December 31, 2014</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">$</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 125px; text-align: right; font-stretch: normal;">27,200</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">$</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 125px; text-align: right; font-stretch: normal;">-</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">$</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 125px; text-align: right; font-stretch: normal;">27,200</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Borrowing</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">105,000</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right;
 font-stretch: normal;">200,000</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">305,000</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Repayment</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">(47,000</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">)</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">(100,000</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">)</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">(147,000</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">Conversion to common stock</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">(85,200</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">)</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">-</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">(85,200</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">Balance at December 31, 2015</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">-</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">100,000</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">100,000</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td
 style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Borrowing</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">$</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">300,000</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">$</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">-</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">$</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">300,000</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Repayment</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">(68,600</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">)</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">(100,000</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">)</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">(168,600</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">Debt discount</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">(25,035</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">)</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">-</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">(25,035</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">Balance at December 31, 2016</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black;
 border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">206,365</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">(100,000</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">)</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">106,365</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">&#160;</td>
</tr>
</table>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The Company periodically borrows from officers, directors, other related individuals, and from commercial lenders. During 2015 two shareholders, with notes totaling $85,200, converted the notes to Company stock at $0.17 per share.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">In January 2015, the Company borrowed $100,000 from a commercial lender. The loan required payment of principal and interest in 252 daily payments of $492 each commencing January 12, 2015. In December 2015, the Company repaid the remaining outstanding principal balance. Interest for the year ended December 31, 2015 amounted to $25,425.</p>
<p style="font: 10pt/14.26px 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">In November 2015, the Company borrowed $100,000 from a commercial lender. The loan incurred interest at 11% and with a maturity date of November 1, 2016. In October 2016, the Company repaid the entire principal balance. Interest expense related to this loan for the years ended December 31, 2016 and 2015 amounted to $9,479 and $1,543, respectively.</p>
<p style="font: 10pt/14.26px 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">In the third quarter of 2016 the Company commenced an offering pursuant to which it offered 11% subordinated promissory notes in fifty thousand ($50,000) dollar increments combined with 62,500 shares of the Company&#8217;s Common Stock for a maximum offering amount of $200,000 (the &#8220;Offering&#8221;). In August and September 2016, the Company sold promissory notes totaling $150,000 to three unrelated individuals. Two of the promissory notes totaling $100,000 are payable in February 2017 and one promissory note for $50,000 is payable in March 2017. In October 2016, the Company sold promissory notes totaling $50,000 to two unrelated individuals. These promissory notes are payable in October 2017. In connection with these promissory notes sold, pursuant to the Offering, the Company issued 250,000 shares of common stock valued at $58,750 which was recorded as a debt discount and will be amortized over the term of these notes. Amortization of the debt discounts for the year ended December 31, 2016 was $33,715. During 2016, the Company repaid $68,600 of the principle balance; and as a result, the outstanding balances of these notes as of December 31, 2016, were $131,400. The balance of debt discount related to the subordinated promissory notes is $25,035 at December 31, 2016. Interest expense related to these notes for the year ended December 31, 2016 amounted to $5,416.</p>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6927126848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div>
<table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;">
<td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 48px; text-align: justify; text-indent: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>6.</b></font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: justify; text-indent: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>Income Taxes</b></font></td>
</tr>
</table>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company incurred a loss for the year ended December 31, 2016 and accordingly, no provision for federal income tax has been made in the accompanying financial statements. At December 31, 2016, the Company had available net operating loss carryforwards of approximately $3,953,000, expiring during various years through 2036.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">A summary of the deferred tax asset using an approximate 34% tax rate is as follows:</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p>
<table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;">
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="6"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">December 31</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;">
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">2016</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">2015</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;
 font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;">
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;" colspan="2"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;" colspan="2"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: #cceeff;">
<td style="font: 10pt/normal 'times new roman', times, serif; width: 0.5in; font-stretch: normal; background-color: white;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Net operating loss</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 125px; text-align: right; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">1,344,000</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 125px; text-align: right; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">930,000</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: white;">
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Accounts receivable reserves</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">30,000</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">-</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
</tr>
<tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: #cceeff;">
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Inventory reserves</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">7,000</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">-</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
</tr>
<tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: white;">
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">Stock compensation</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black;
 border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">200,000</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">-</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
</tr>
<tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: #cceeff;">
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal; background-color: white;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">Net deferred tax asset</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">1,581,000</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">-</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
</tr>
<tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: white;">
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Valuation allowance</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">(1,581,000</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">(930,000</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</font></td>
</tr>
<tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: #cceeff;">
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-left: 10pt; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Total</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size:
 10pt;">-</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
</tr>
</table>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The net operating loss carryforwards could be subject to limitation in any given year in the event of a change in ownership as defined by IRC Section 382.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The deferred tax benefit included in the 2015 statement of operations represents the change in the deferred tax liability at each balance sheet date.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The difference between the statutory and the effective tax rate is primarily due to a change in valuation allowance on deferred taxes, as the Company has fully reserved the deferred tax asset resulting from available net operating loss carryforwards.</font></p>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32718-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760797680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><div>
<table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;">
<td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 48px; text-align: justify; text-indent: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>7.</b></font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: justify; text-indent: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>Stockholders&#8217; Equity</b></font></td>
</tr>
</table>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">In May 2015, the Company purchased and retired 120,000 shares of outstanding Company common stock from an investor for $10,800.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">In July 2015, the Company granted 300,000 options valued at $7,500 to a shareholder in conjunction with the issuance of a $75,000 note payable. The options are fully vested and expire in three years. In December 2015, the Company satisfied the $75,000 note payable through the issuance of 441,177 shares of Company common stock.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">In December 2015, the Company satisfied $10,200 of notes payable to a director through the issuance of 60,000 shares of Company common stock. The Company issued 40,800 options valued at $1,000 to the director in conjunction with this transaction. The options are fully vested and expire in three years.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">In December 2015, the Company satisfied $84,868 of royalties payable to the Company&#8217;s President through the issuance of 499,225 shares of Company common stock (see note 8). In conjunction with this transaction, the Company issued 339,473 options valued at $13,000 to the President of the Company at an exercise price of $0.10 per share. The options are fully vested and expire in 3 years.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">On April 1, 2016, the Company entered into two agreements with two consultants to provide services over a nine- month period in exchange for 2,300,000 shares of common stock. The Company calculated a fair value of $690,000 based on the market price of the shares on the date of the agreements. During the third quarter of 2016, the Company and the consultants renegotiated the agreements by extending the service requirement to December 31, 2017. For the year ended December 31, 2016, the Company has recognized expense of $383,333 in connection with these agreements.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p>
<p style="font:
 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">On September 1, 2016, the Company issued 200,000 shares of common stock for $46,000. In connection with this issuance the Company issued 100,000 warrants with an exercise price of $0.50 per share. These warrants are fully vested and expire in two years.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">In August 2016, the Company issued 125,000 shares of common stock pursuant to sale of two promissory notes in the Offering.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">In September 2016, the Company issued 62,500 shares of common stock pursuant to the sale of one promissory note in the Offering.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">In October 2016, the Company issued 62,500 shares of common stock pursuant to the sale of two promissory notes in the Offering.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">In November 2016, the Company issued 434,782 shares of common stock pursuant to a conversion of an equity contribution into Immudyne PR by the noncontrolling interest. In connection with this issuance the Company issued 217,391 warrants with an exercise price of $0.40 per share. These warrants are fully vested and expire in two years.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">In December 2016, the Company received proceeds of $30,000 from exercises of options at $0.10 per share. The Company issued 300,000 shares of common stock pursuant to these exercises.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">On December 23, 2016, the Company issued 75,000 shares of common stock for $17,250. In connection with this issuance the Company issued 37,500 warrants with an exercise price of $0.50 per share. These warrants are fully vested and expire in two years.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px;
 letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">During 2016, the Company purchased 325,000 shares of outstanding Company common stock through an exchange for a price per share of $0.23 to $0.29. As of the December 31, 2016, these shares being held by the Company valued at cost is $87,053 and are included in treasury stock in the consolidated balance sheet.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><br /></font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>Additional Paid-In Capital</i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>&#160;</i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>&#160;</i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>Noncontrolling Interest</i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">On April 1, 2016, the Company increased its ownership in Immudyne PR from to 78.16667% decreasing the minority interest from 66.7% to 21.83% resulting in a charge to noncontrolling interest and additional paid-in-capital of $91,612.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">In 2016, the net change in loans, contributions and distributions by other members of Immudyne PR resulted an increase in noncontrolling interests of $119,894.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">For the years ended December 31, 2016 and 2015, the net income (loss) of Immudyne PR attributed the Company amounted to $(115,749) and $(97,240), respectively.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>Service-Based Stock Options</i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">In October 2015 the Company issued 110,000 service-based options valued at $2,800 to two consultants at exercise prices of $0.20 per share. The options are fully vested and expire in 10 years.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">In November 2015 the Company cancelled 100,000 shares of company common stock and 200,000 fully vested service-based options issued to two
 consultants.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">In November 2015 the Company issued 500,000 shares of common stock valued at $65,000 to a consultant.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Also in 2015, the Company extended the expiration date of 500,000 options held by a director one year from 2015 to 2016 and 1,500,000 warrants held by the Company&#8217;s President two years from 2015 to 2017. The fair value of these modifications amounted to $55,000.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">In May 2016, the Company issued 175,000 service-based options valued at $40,829 to two consultants at exercise prices of $0.20 per share. The options are fully vested and expire in 10 years.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">In July 2016, the Company issued 50,000 service-based options valued at $12,397 to a consultant with an exercise price of $0.20 per share. The options are fully vested and expire in 10 years.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">In November 2016, the Company issued 50,000 service-based options valued at $9,980 to a consultant with an exercise price of $0.50 per share. The options are fully vested and expire in 2 years.</p>
<p style="font: 10pt/14.26px 'times new roman', times, serif; margin: 0pt 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Accordingly, stock based compensation for the years ended December 31, 2016 and 2015 included $63,206 and $22,300, respectively, related to such service-based stock options.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">A Summary of the outstanding service-based options are as follows:</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width:
 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p>
<table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="background-color: white;">&#160;</td>
<td>&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Number of<br />Options</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="width: 0.5in; background-color: white;">&#160;</td>
<td>Balance at December 31, 2014</td>
<td style="width: 15px;">&#160;</td>
<td style="width: 15px; text-align: left;">&#160;</td>
<td style="width: 125px; text-align: right;">10,435,000</td>
<td style="width: 15px; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td>Cancelled</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(200,000</td>
<td style="text-align: left;">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;">&#160;</td>
<td style="padding-bottom: 1.5pt;">Issued</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">790,273</td>
<td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;">&#160;</td>
<td>Balance at December 31, 2015</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">11,025,273</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td>Exercised</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">300,000</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;">&#160;</td>
<td>Expired</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">50,000</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td>Cancelled</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">(250,000</td>
<td style="text-align: left;">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;">&#160;</td>
<td style="padding-bottom: 1.5pt;">Issued</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">275,000</td>
<td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;">&#160;</td>
<td style="padding-bottom: 4pt;">Balance at December 31, 2016</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 4pt;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">10,700,273</td>
<td style="text-align: left; padding-bottom: 4pt;">&#160;</td>
</tr>
</table>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">All outstanding options are exercisable and have a cashless exercise provision, and certain options provide for accelerated vesting provisions and modifications, as defined, if the Company is sold or acquired. The intrinsic value of options outstanding and exercisable at December 31, 2016 and 2015 amounted to $704,794 and $33,605, respectively. The intrinsic value of options exercised during the year ending December 31, 2016 was $54,000.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The significant assumptions used to determine the fair values of options issued, using a Black-Scholes option-pricing model are as follows:</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px;
 white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"></p>
<table align="center" style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="background-color: white;">&#160;</td>
<td><font style="font-size: 10pt;"><u>Significant assumptions:</u></font></td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td nowrap="nowrap" colspan="2">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="background-color: white;">&#160;</td>
<td style="background-color: #cceeff;"><font style="font-size: 10pt;">Risk-free interest rate at grant date</font></td>
<td style="background-color: #cceeff;">&#160;</td>
<td nowrap="nowrap" style="background-color: #cceeff;">&#160;</td>
<td nowrap="nowrap" style="text-align: right; background-color: #cceeff;"><font style="font-size: 10pt;">0.71% - 1.88</font></td>
<td style="background-color: #cceeff;"><font style="font-size: 10pt;">%</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td>&#160;</td>
<td><font style="font-size: 10pt;">Expected stock price volatility</font></td>
<td>&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap" style="text-align: right;"><font style="font-size: 10pt;">217.4% - 248.4</font></td>
<td><font style="font-size: 10pt;">%</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="background-color: white;">&#160;</td>
<td style="background-color: #cceeff;"><font style="font-size: 10pt;">Expected dividend payout</font></td>
<td style="background-color: #cceeff;">&#160;</td>
<td nowrap="nowrap" style="background-color: #cceeff;">&#160;</td>
<td nowrap="nowrap" style="text-align: right; background-color: #cceeff;"><font style="font-size: 10pt;">&#8212;</font></td>
<td style="background-color: #cceeff;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td>&#160;</td>
<td><font style="font-size: 10pt;">Expected option life-years</font></td>
<td>&#160;</td>
<td nowrap="nowrap">&#160;</td>
<td nowrap="nowrap" style="text-align: right;"><font style="font-size: 10pt;">2 to 3</font></td>
<td><font style="font-size: 10pt;">&#160;&#160;years&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="background-color: white;">&#160;</td>
<td style="background-color: #cceeff;"><font style="font-size: 10pt;">Weighted average grant date fair value</font></td>
<td style="background-color: #cceeff;">&#160;</td>
<td nowrap="nowrap" style="background-color: #cceeff;"><font style="font-size: 10pt;">$</font></td>
<td nowrap="nowrap" style="text-align: right; background-color: #cceeff;"><font style="font-size: 10pt;">0.22</font></td>
<td style="background-color: #cceeff;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="width: 0.5in;">&#160;</td>
<td><font style="font-size: 10pt;">Forfeiture rate</font></td>
<td style="width: 15px;">&#160;</td>
<td nowrap="nowrap" style="width: 15px;">&#160;</td>
<td nowrap="nowrap" style="width: 125px; text-align: right;"><font style="font-size: 10pt;">0</font></td>
<td style="width: 37px;"><font style="font-size: 10pt;">%</font></td>
</tr>
</table>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; background-color: white; -webkit-text-stroke-width: 0px;">&#160;<font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The following is a summary of outstanding service-based options at December 31, 2016:</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p>
<table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="background-color: white;">&#160;</td>
<td style="font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">Exercise Price</td>
<td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Number of<br />Options</td>
<td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Weighted Average Remaining Contractual Life</td>
<td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="background-color: white;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;"
 colspan="2">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt;" colspan="2">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="width: 0.5in; background-color: white;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">$0.10</td>
<td style="width: 15px; font-size: 10pt;">&#160;</td>
<td style="width: 15px; text-align: left; font-size: 10pt;">&#160;</td>
<td style="width: 141px; text-align: right; font-size: 10pt;">1,380,273</td>
<td style="width: 15px; text-align: left; font-size: 10pt;">&#160;</td>
<td style="width: 15px; font-size: 10pt;">&#160;</td>
<td style="width: 15px; text-align: center; font-size: 10pt;">&#160;</td>
<td style="width: 141px; text-align: center; font-size: 10pt;"><font style="font-size: 10pt;">1 year</font></td>
<td style="width: 15px; text-align: left; font-size: 10pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="font-size: 10pt;">$0.20 - $0.25</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">8,120,000</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt;"><font style="font-size: 10pt;">5 years</font></td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;">&#160;</td>
<td style="padding-bottom: 1.5pt; font-size: 10pt;">$0.40 - $0.50</td>
<td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">1,200,000</td>
<td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt;"><font style="font-size: 10pt;">5 years</font></td>
<td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="padding-bottom: 4pt; padding-left: 10pt; font-size: 10pt;">Total</td>
<td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td>
<td style="text-align: right; font-size: 10pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">10,700,273</td>
<td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 4pt; font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt;">&#160;</td>
<td style="text-align: left; padding-bottom: 4pt; font-size: 10pt;">&#160;</td>
</tr>
</table>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b><i>Performance-Based Stock Options</i></b></font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The Company had granted performance-based options to purchase 4,400,000 shares of common stock at exercise prices of $0.40 to $0.80. The options expire at various dates between 2021 and 2026 and are exercisable upon the Company achieving annual sales revenue of $5,000,000 and $10,000,000. The fair value of these performance-based options aggregated $169,035 to be expensed over the implicit service period commencing once management believes the performance criteria will be met.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">In October 2016, the Company cancelled 287,500 of these service-based options valued at $17,999 to two consultants. The fair value of these performance-based options as of year ended December 31, 2016 aggregated $151,036.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px;
 white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The performance criteria for options exercisable upon the Company achieving annual sales revenue of $5,000,000, with a fair value amounting to $120,867, was met during the year ended December 31, 2016. Accordingly, stock based compensation expense for the year ended December 31, 2016 includes $120,867 related to such options. At December 31, 2016, the unearned compensation for all the performance based options is $30,169.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"></font>&#160;&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b><i>Warrants</i></b></font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 8pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The following is a summary of outstanding and exercisable warrants:</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 8pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p>
<table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="background-color: white;">&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Number of Shares</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Weighted Average Exercise Price</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Year&#160;of&#160;<br />Expiration</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="background-color: white;"><font style="font-size: 7pt;">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 7pt;">&#160;</font></td>
<td><font style="font-size: 7pt;">&#160;</font></td>
<td style="text-align: right;" colspan="2"><font style="font-size: 7pt;">&#160;</font></td>
<td><font style="font-size: 7pt;">&#160;</font></td>
<td><font style="font-size: 7pt;">&#160;</font></td>
<td style="text-align: center;" colspan="2"><font style="font-size: 7pt;">&#160;</font></td>
<td><font style="font-size: 7pt;">&#160;</font></td>
<td><font style="font-size: 7pt;">&#160;</font></td>
<td style="text-align: center;" colspan="2"><font style="font-size: 7pt;">&#160;</font></td>
<td><font style="font-size: 7pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="width: 0.5in; background-color: white;">&#160;</td>
<td style="text-align: left;">Balance at December 31, 2014</td>
<td style="width: 15px;">&#160;</td>
<td style="width: 15px; text-align: left;">&#160;</td>
<td style="width: 125px; text-align: right;">3,772,720</td>
<td style="width: 15px; text-align: left;">&#160;</td>
<td style="width: 15px;">&#160;</td>
<td style="width: 15px; text-align: center;">&#160;</td>
<td style="width: 125px; text-align: center;">0.29</td>
<td style="width: 15px; text-align: left;">&#160;</td>
<td style="width: 15px;">&#160;</td>
<td style="width: 15px; text-align: center;">&#160;</td>
<td style="width: 125px; text-align: center;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">2015&#160;-&#160;2016</font></td>
<td style="width: 15px; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="text-align: left; padding-bottom: 1.5pt;">Expired</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(2,022,720</td>
<td style="text-align: left; padding-bottom: 1.5pt;">)</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: center; padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: center; padding-bottom: 1.5pt;">0.40</td>
<td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: center; padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: center; padding-bottom: 1.5pt;">2015</td>
<td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt;">&#160;</font></td>
<td><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: right;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: left;"><font
 style="font-size: 8pt;">&#160;</font></td>
<td><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: center;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: center;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt;">&#160;</font></td>
<td><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: center;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: center;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="text-align: left;">Balance at December 31, 2015</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1,750,000</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;">0.16</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">2016 - 2017</font></td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;">&#160;</td>
<td style="text-align: left;">Issued</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">454,891</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;">0.42</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: center;">&#160;</td>
<td style="text-align: center;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">2018&#160;-&#160;2019</font></td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="text-align: left; padding-bottom: 1.5pt;">Expired</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(250,000</td>
<td style="text-align: left; padding-bottom: 1.5pt;">)</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: center; padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: center; padding-bottom: 1.5pt;">0.40</td>
<td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: center; padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: center; padding-bottom: 1.5pt;">2016</td>
<td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt;">&#160;</font></td>
<td><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: right;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt;">&#160;</font></td>
<td><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: center;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: center;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt;">&#160;</font></td>
<td><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: center;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: center;"><font style="font-size: 8pt;">&#160;</font></td>
<td style="text-align: left;"><font style="font-size: 8pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="text-align: left; padding-bottom: 4pt;">Balance at December 31, 2016</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,954,981</td>
<td style="text-align: left; padding-bottom: 4pt;">&#160;</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="text-align: center; padding-bottom: 4pt;">&#160;</td>
<td style="text-align: center; padding-bottom: 4pt;">0.19</td>
<td style="text-align: left; padding-bottom: 4pt;">&#160;</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="text-align: center; padding-bottom: 4pt;">&#160;</td>
<td style="text-align: center; padding-bottom: 4pt;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">2017 - 2019</font></td>
<td style="text-align: left; padding-bottom: 4pt;">&#160;</td>
</tr>
</table>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">In September 2016, the Company issued 100,000 warrants with an exercise price of $0.50 per share, in relation to a sale of common stock. These warrants are fully vested and expire in two years.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 8pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font:
 10pt/normal 'times new roman', times, serif; font-stretch: normal;">In September 2016, the Company issued 100,000 warrants with exercise prices between $0.20 and $0.50 per share, for consulting services. These warrants are fully vested and expire in three years. The fair value of these warrants are $20,585 and is included in compensation and related expenses in the accompanying statement of operations.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 8pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">In December 2016, the Company issued 37,500 warrants with an exercise price of $0.50 per share, in relation to a sale of common stock. These warrants are fully vested and expire in two years.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 8pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">In December 2016, the Company issued 217,391 warrants with an exercise price of $0.40 per share, in relation to an issuance of common stock. These warrants are fully vested and expire in two years.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 8pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Warrants outstanding and exercisable amounted to 1,954,891 and 1,750,000 at December 31, 2016 and 2015, respectively. The weighted average exercise price of warrants outstanding at December 31, 2016 is $0.19. The warrants expire at various time between December 2017 and September 2019.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 8pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The fair value of options and warrants granted (or extended) during the years ended December 31, 2016 and 2015, was estimated on the date of grant (or extension) using the Black-Scholes option-pricing model with the following weighted-average assumptions:</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 8pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p>
<table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px;">&#160;</td>
<td style="text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td>
<td style="padding: 0px 0px 1.5pt; text-indent: 0px; font-size: 10pt;">&#160;</td>
<td style="text-align: center; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2016</td>
<td style="padding: 0px 0px 1.5pt; text-indent: 0px; font-size: 10pt;">&#160;</td>
<td style="padding: 0px 0px 1.5pt; text-indent: 0px; font-size: 10pt;">&#160;</td>
<td style="text-align: center; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2015</td>
<td style="padding: 0px 0px 1.5pt; text-indent: 0px; font-size: 10pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px;"><font style="font-size: 7pt;">&#160;</font></td>
<td style="text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;"><font style="font-size: 7pt;">&#160;</font></td>
<td style="text-indent: 0px; padding-top:
 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;"><font style="font-size: 7pt;">&#160;</font></td>
<td style="text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;" colspan="2"><font style="font-size: 7pt;">&#160;</font></td>
<td style="text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;"><font style="font-size: 7pt;">&#160;</font></td>
<td style="text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;"><font style="font-size: 7pt;">&#160;</font></td>
<td style="text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;" colspan="2"><font style="font-size: 7pt;">&#160;</font></td>
<td style="text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;"><font style="font-size: 7pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="width: 0.5in; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; background-color: white;">&#160;</td>
<td style="text-align: left; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;">Expected volatility</td>
<td style="width: 15px; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td>
<td style="width: 15px; text-align: left; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td>
<td style="width: 141px; text-align: right; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;">203</td>
<td style="width: 15px; text-align: left; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;">%</td>
<td style="width: 15px; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td>
<td style="width: 15px; text-align: left; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td>
<td style="width: 141px; text-align: right; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;">50</td>
<td style="width: 15px; text-align: left; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;">%</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; background-color: white;">&#160;</td>
<td style="text-align: left; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;">Risk free interest rate</td>
<td style="text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td>
<td style="text-align: left; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td>
<td style="text-align: right; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;">.88</td>
<td style="text-align: left; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;">%</td>
<td style="text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td>
<td style="text-align: left; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td>
<td style="text-align: right; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;">2</td>
<td style="text-align: left; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;">%</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; background-color: white;">&#160;</td>
<td style="text-align: left; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;">Expected dividend yield</td>
<td style="text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td>
<td style="text-align: left; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td>
<td style="text-align: right; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;">-</td>
<td style="text-align: left; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td>
<td style="text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td>
<td style="text-align: left; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td>
<td style="text-align: right; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;">-</td>
<td style="text-align: left; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; background-color: white;">&#160;</td>
<td style="text-align: left; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;">Expected option term (in years)</td>
<td style="text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td>
<td style="text-align: left; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td>
<td style="text-align: right; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;"><font style="font-size: 10pt;">2 - 3</font></td>
<td style="text-align: left; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td>
<td style="text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td>
<td style="text-align: left; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td>
<td style="text-align: right; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;"><font style="font-size: 10pt;">1 - 5</font></td>
<td style="text-align: left; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; background-color: white;">&#160;</td>
<td style="text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;">Weighted average grant date fair value</td>
<td style="text-indent: 0px; padding-top: 0px; padding-right: 0px;
 padding-left: 0px; font-size: 10pt;">&#160;</td>
<td style="text-align: left; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;">$</td>
<td style="text-align: right; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;">0.20</td>
<td style="text-align: left; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td>
<td style="text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td>
<td style="text-align: left; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;">$</td>
<td style="text-align: right; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;">0.03</td>
<td style="text-align: left; text-indent: 0px; padding-top: 0px; padding-right: 0px; padding-left: 0px; font-size: 10pt;">&#160;</td>
</tr>
</table>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Under ASC 815-40-05, Accounting for Derivative Financial Instruments Indexed to and Potentially Settled in a Company&#8217;s Own Stock, in the event the Company does not have a sufficient number of authorized and unissued shares of common stock to satisfy obligations for stock options, warrants and other instruments potentially convertible into common stock, the fair value of these instruments should be reported as a liability. Pursuant to the outstanding option, warrant and convertible debt agreements, there is currently no effective registration statement covering the shares of common stock underlying these agreements, which are currently subject to a cashless exercise whereby the holders, at their option, may surrender their options and warrants to the company in exchange for shares of common stock. The number of shares of common stock into which an option or a warrant would be exchangeable in such a cashless exercise depends on both the exercise price of the options or warrant and the market price of the common stock, each at or near the time of exercise. Because both of these factors are variable, it is possible that we could have insufficient authorized shares to satisfy a cashless exercise. In this scenario, if we were unable to obtain shareholder approval to increase the number of authorized shares, we could be obligated to settle such a cashless exercise with cash rather than by issuing shares of common stock. Further, ASC 815-40-05 requires that we record the potential settlement obligation at each reporting date using the current estimated fair value of these contracts s, with any changes in fair value being recorded through our statement of operations. We will continue to report the potential settlement obligation as a liability until such time as these contracts are exercised or expire or we are otherwise able to modify the warrant agreement to remove the provisions which require this treatment.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><b><i>Stock Based Compensation</i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The total stock based compensation expense related Service-Based Stock Options, Performance-Based Stock Options and Warrants issued for service amounted to $587,991 and $142,300 for the years ended December 31, 2016 and 2015, respectively. Such amounts are included in compensation and related expenses ($587,991 in 2016 and $133,800 in 2015) and interest expense ($8,500 in 2015).</p>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74567-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Preferred Stock<br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6927146784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_RoyaltiesAbstract', window );"><strong>Royalties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_RoyaltiesDisclosureTextBlock', window );">Royalties</a></td>
<td class="text"><div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 48px; text-align: justify; text-indent: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>8.</b></font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: justify; text-indent: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>Royalties</b></font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The Company was subject to a royalty agreement based upon sales of certain skin care products. The agreement required the Company to pay a royalty based upon 8% of such sales, up to $227,175. During the year ended December 31, 2015 the Company&#8217;s sales reached the maximum amount under which the Company was required to pay a royalty under this agreement. Royalty expense amounted to $-0- and $20,157 for the years ended December 31, 2016 and 2015, respectively. During December 2015, the Company&#8217;s President who had a 60% interest in the royalties, converted royalties payable under the agreement in the amount of $84,868 to 499,225 shares of Company stock at $0.17 cents per share.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Included in accounts payable and accrued expenses at December 31, 2016 and 2015 was $56,579 in regards to this agreement.</font></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_RoyaltiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_RoyaltiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_RoyaltiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for royalty agreement during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_RoyaltiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6927155520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div>
<table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0">
<tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;">
<td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 48px; text-align: justify; text-indent: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>9.</b></font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: justify; text-indent: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>Commitments and Contingencies</b></font></td>
</tr>
</table>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b><i>Leases</i></b></font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company leases a plant in Kentucky under an operating lease which expired on May 31, 2016. Management is currently discussing renewal lease options for the Kentucky plant and is operating on a month-to-month lease arrangement until a final agreement has been accepted. Monthly base rental payments are approximately $9,000. Our principal executive offices are in office space provided to us by our President, Mr. McLaughlin at the rate of $2,000 per month, which includes rents, utilities and other office related expenditures. This arrangement commenced as of January 1, 2016. In addition, Immudyne PR utilizes office space in Puerto Rico which is subleased from Mr. Schreiber (President of Immudyne PR)and incurs expense of approximately $4,000 a month for this office space. Rent expense for the years ended December 31, 2016 and 2015, was $139,030 and $65,968, respectively.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b><i>Employment and Consulting Agreements</i></b></font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The Company has entered into various agreements with officers, directors, employees and consultants that expire in one to five years. The agreements provide for annual compensation of up to $145,000 and the issuance of stock options, at exercise prices of $0.40 and $0.80, to purchase 4,400,000 shares of common stock issuable upon the Company&#8217;s revenue exceeding $5,000,000 and $10,000,000, as defined. In addition, the agreements provide for bonus compensation to these individuals aggregating up to 15% (with no individual having more than 5%) of the Company&#8217;s pretax income.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p>
<p style="font: 10pt/normal
 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b><i>Restricted Stock and Options</i></b></font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The Company has entered into two agreements on April 1, 2016 with two consultants of Immudyne PR for business development, marketing and sales related services (the &#8220;Consultant Agreements&#8221;). The consultants are treated as employees for accounting purposes. Upon signing, each consultant was issued 1,000,000 restricted shares of Immudyne, Inc. common stock. In addition, each consultant shall receive an additional 150,000 restricted shares of Immudyne, Inc. common stock for each $500,000 distributed by Immudyne PR to the Company. For each consultant, the amount of shares to be issued by the Company to the consultants shall be capped at 1,500,000 restricted shares when Immudyne PR has transferred $5,000,000 to the Company, for a combined capped total of 3,000,000 restricted shares. For the year ended December 31, 2016, 2,300,000 restricted shares of common stock have been issued related to these agreements. The Company valued the shares at their grant date for a value of $0.30 per share for a total of $690,000 to be expensed over the estimated service period ending December 31, 2017.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">In addition, the Consulting Agreements provided that each consultant shall receive a bonus of an additional 750,000 restricted shares of Immudyne, Inc. common stock, plus an option to buy 1,000,000 shares of Immudyne, Inc. common stock at $0.20/share (including a cashless exercise feature) when Immudyne PR has transferred to the Company at each of the following three (3) thresholds: $1,250,000, $2,000,000 and $3,000,000 for a total of 2,250,000 of restricted shares of Immudyne, Inc. common stock and options to purchase up to 3,000,000 shares of Immudyne, Inc. common stock at $0.20/share. As of December 31, 2016, no bonus shares have been issued and no options have been granted under this agreement.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;<font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b><i>Legal Matters</i></b></font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">In the normal course of business operations, the Company may become involved in various legal matters. At December 31, 2016, the Company&#8217;s management does not believe that there are any potential legal matters that could have an adverse effect on the Company&#8217;s financial position.</font></p>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=73718637&amp;loc=d3e25287-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6927176176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><div>
<table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;">
<td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 48px; text-align: justify; text-indent: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>10.</b></font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: justify; text-indent: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>Related Party Transactions</b></font></td>
</tr>
</table>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.15pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>&#160;</b></font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.15pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">For the year ended December 31, 2016 one of the Company&#8217;s directors, acting as an advisor for the Company, provided legal and business advisory services and was compensated $16,145. During 2015 there was no compensation to this director. In addition, for the year ended December 31, 2016 the Company&#8217;s President received $24,000 for reimbursement of home office expenditures, including rent, utilities and other related expenses for two offices. During 2015 the Company&#8217;s president was not reimbursed for home office expenditures.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Immudyne, Inc. employs the wife of the President of the Company Immudyne, Inc. and incurs $3,000 per month as an accountant, plus an annual incentive bonus award equal to 0.5% of the Company&#8217;s pre-tax earnings.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Immudyne PR utilizes BV Global Fulfillment, owned by the father of Mr. Schreiber, and incurred $19,800 for the year ended December 31, 2016 for these services.</p>
<p style="font: 13.33px/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Taggart International Trust (&#8220;Taggart&#8221;), a shareholder; provides credit card processing services through one or more merchant banks. Taggart did not receive any compensation for these services.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">JLS Ventures LLC, owned by a shareholder, provides credit card processing services through one or more merchant banks. Taggart did not receive any compensation for these services.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">JSDC, Inc., owned by a shareholder, provides credit card processing services through one or more merchant banks. Taggart did not receive any compensation for these services.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Immudyne PR utilizes office space in Puerto Rico which is subleased from Mr. Schreiber (President of Immudyne PR) incurs expense of approximately $4,000 a month for this office space.</p>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6701252240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: top; font-stretch: normal;"><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; width: 48px; text-align: justify; text-indent: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>11.</b></font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding: 0px; text-align: justify; text-indent: 0px; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>Subsequent Events</b>&#160;</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.15pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The Company has evaluated subsequent events through the date these financial statements were issued.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">In January 2017, the Company issued 1,183,490 shares of common stock pursuant to a conversion of an equity contribution into Immudyne PR by the noncontrolling interest. In connection with this issuance the Company issued 591,745 warrants with an exercise price of $0.40 per share. These warrants are fully vested and expire in two years.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In January 2017, the Company borrowed $200,000 and issued a promissory note with a 5% original issue discount for a total principal amount of $210,000. The loan incurs 11% interest per annum and matures in various tranches from February 2017 through April 2017. In addition, the Company issued 217,391 shares of common stock related to this note. In February 2017, the Company repaid $70,000 of the principle balance of this note. In March, pursuant to an offering described below, the Company converted the remaining $140,000 of the principle balance of the this note in exchange for 559,179 shares of common stock and 304,348 warrants.</p><p style="font: 10pt/14.26px 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On March 27, 2017, the Company commenced an offering to sell up to 4,000,000 shares of common stock at a price of $0.23 per share and warrants to purchase up to 2,000,000 shares of common stock excisable any time prior to the secondary anniversary of the issuance. The warrants are paired with the stock on the basis of one warrant for every two shares of stock purchased.</p><p style="font: 10pt/14.26px 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">At the time of
 this filing, the Company received subscriptions in the amount of 2,673,656 shares and issued 1,336,828 warrants and proceeds in the amount of $614,940. The Company also converted two additional notes with the total principal balance of $50,000 in exchange for 196,000 shares of common stock and 98,000 warrants.</p><p style="font: 10pt/14.26px 'times new roman', times, serif; margin: 0pt 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On April 24, 2017, the Company, issued 217,390 shares of common stock pursuant to a stock subscription agreement and the Company issued 108,696 warrants with an exercise price of $0.40 per share for the stated consideration and satisfaction of obligation to pay $50,000 on the 180-day anniversary of the execution of the Sole and Exclusive License, Royalty, and Advisory Agreement dated September 1, 2016 with Pilaris Laboratories, LLC</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6755834960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b><i>Principles of Consolidation</i></b></font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company evaluates the need to consolidate affiliates based on standards set forth in ASC 810 Consolidation (&#8220;ASC 810&#8221;).</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The consolidated financial statements include the accounts of the Company and its majority owned subsidiary, Immudyne PR and variable interest entities (VIE&#8217;s) in which the Company has been determined to be the primary beneficiary. The non- controlling interest in Immudyne PR represents the 21.833% equity interest held by other members of the joint venture. All significant consolidated transactions and balances have been eliminated in consolidation.</p>
</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_VariableInterestEntitiesPolicyTextBlock', window );">Variable Interest Entities</a></td>
<td class="text"><div>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Variable Interest Entities</i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company follows ASC 810-10-15 guidance with respect to accounting for variable interest entities (each, a &#8220;VIE&#8221;). These entities do not have sufficient equity at risk to finance their activities without additional subordinated financial support from other parties or whose equity investors lack any of the characteristics of a controlling financial interest. A variable interest is an investment or other interest that will absorb portions of a VIE&#8217;s expected losses or receive portions of its expected residual returns and are contractual, ownership, or pecuniary in nature and that change with changes in the fair value of the entity&#8217;s net assets. A reporting entity is the primary beneficiary of a VIE and must consolidate it when that party has a variable interest, or combination of variable interests, that provides it with a controlling financial interest. A party is deemed to have a controlling financial interest if it meets both of the power and losses/benefits criteria. The power criterion is the ability to direct the activities of the VIE that most significantly impact its economic performance. The losses/benefits criterion is the obligation to absorb losses from, or right to receive benefits from, the VIE that could potentially be significant to the VIE. The VIE model requires an ongoing reconsideration of whether a reporting entity is the primary beneficiary of a VIE due to changes in facts and circumstances.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">As of December 31, 2016 and 2015, the Company consolidated nine and zero VIEs, respectively.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Immudyne PR as the primary beneficiary of Ace Account Management LLC, Innerwell Skincare LLC, MCD Merchants LLC, One Equity Research LLC, Inate Gems LLC, Retriever Health Products LLC, Spurs 5, LLC, Salus LLC and Huntley LLC which are qualified as VIEs. The assets and liabilities and revenues and expenses of these VIEs included in the financial statements of Immudyne PR and further included in the consolidated financial statements. As of December 31, 2016, the VIEs had assets of $10,306, liabilities of $5,748, revenues of $6,271, and operating expenses of $6,141. The assets and liabilities include balances due from and due to the subsidiaries of Immudyne PR. These inter-company receivables and payables are eliminated upon consolidation of the VIE with Immudyne PR and Immudyne. No assets were pledged or given as collateral against any borrowings.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company utilizes third party entities to provide and increase credit card processing capacity and optimize corresponding rates and fees. A majority of these entities provide this service as independent contractors in exchange for a one (1%) percent fee of the net revenues processed and collected by such contractors from sales initiated by the Company. The VIEs consolidated in the Company&#8217;s financial statements are primarily contracted to credit card processing through one or more merchant banks contracted by each VIE. Upon receipt of funds by each VIE, the collection of receipts less any returns, chargeback and other fees charged by such merchant bank is transferred to Immudyne PR.</p>
</div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Use of Estimates</i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>&#160;</i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i></i></b>The Company prepares its consolidated financial statements in conformity with accounting principles generally accepted in the United States of America which requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Some of the more significant estimates required to be made by management include the determination of reserves for accounts receivable, returns and allowances, the accounting for derivatives, the valuation of inventory and stockholders&#8217; equity based transactions. Actual results could differ from those estimates.</p>
</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Liabilities</a></td>
<td class="text"><div>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Derivative Liabilities</i></b>&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company evaluates stock options, stock warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for under the relevant sections of Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 815-40, Derivative Instruments and Hedging: Contracts in Entity&#8217;s Own Equity. The result of this accounting treatment could be that the fair value of a financial instrument is classified as a derivative instrument and is marked-to-market at each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the consolidated statements of operations as other income or other expense. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Financial instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815-40 are reclassified to a liability account at the fair value of the instrument on the reclassification date.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">As of December 31, 2016, certain of the Company&#8217;s stock options, stock warrants and convertible debt instruments were accounted for as derivative liabilities due to insufficient authorized shares of common stock to settle outstanding contracts. At December 31, 2016, the Company estimated the fair value of these stock options, stock warrants and embedded conversion features using the Black-Scholes option pricing model (&#8220;Black-Scholes&#8221;) in the amount of $192,254 was recorded upon issue&#160;</p>
</div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_SequencingPolicyPolicyTextBlock', window );">Sequencing Policy</a></td>
<td class="text"><div>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Sequencing Policy</i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Under ASC 815-40-35, the Company has adopted a sequencing policy whereby, in the event that reclassification of contracts from equity to assets or liabilities is necessary pursuant to ASC 815 due to the Company&#8217;s inability to demonstrate it has sufficient authorized shares, shares will be allocated on the basis of the earliest issuance date of potentially dilutive instruments, with the earliest grants receiving the first allocation of authorized but unissued shares, and all future instruments being classified as a derivative liability, with the exception of instruments related to share-based compensation issued to employees or directors.&#160;</p>
</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b><i>Inventory</i></b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">At December 31, 2016 and December 31, 2015, inventory consisted primarily of cosmetic and nutraceutical additives, and finished cosmetic products. Inventory is maintained in the Company&#8217;s leased Kentucky warehouse and third party warehouses in Pennsylvania and Louisiana.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Inventory is valued at the lower of cost or market with cost determined on a first-in, first-out (&#8220;FIFO&#8221;) basis. Management compares the cost of inventory with the net realizable value and an allowance is made for writing down inventory to market value, if lower. At December 31, 2016 and December 31, 2015, the Company recorded an inventory reserve in the amount of $20,000. Inventory consists of the following:</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td>&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">December&#160;31,<br />2016</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">December&#160;31,<br />2015</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 0.5in; background-color: white;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">Raw materials</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 125px; text-align: right;">38,460</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 125px; text-align: right;">25,761</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">Finished products</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">121,810</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">35,290</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">160,270</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">61,051</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b><i>Revenue Recognition</i></b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">The Company&#8217;s policy is to record revenue as earned when a firm commitment, indicating sales quantity and price exists, delivery has taken place and collectability is reasonably assured. The Company generally records sales of nutraceutical and cosmetic additives once the product is shipped to the customer, and for sales of finished cosmetic products once the customer places the order and the product is simultaneously shipped, but in limited cases if title does not pass until the product reaches the customer&#8217;s delivery site, then recognition of revenue is deferred until that time. Delivery is considered to have occurred when title and risk of loss have transferred to the customer. Provisions for discounts, returns, allowances, customer rebates and other adjustments are netted with gross sales. The Company accounts for such provisions during the same period in which the related revenues are earned. Customer discounts, returns and rebates approximated $1,926,000 in the year ended December 31, 2016. Customer discounts, returns and rebates were not significant in the year ended December 31, 2015.</p><p style="font: 10pt/14.26px 'times new roman', times, serif; margin: 0pt 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Delivery is considered to have occurred when title and risk of loss have transferred to the customer. If title does not pass until the product reaches the customer&#8217;s delivery site or the customer accepts the product, then recognition of revenue is deferred until that time. There are no formal sales incentives offered to any of the Company&#8217;s customers. Volume discounts may be offered from time to time to customers purchasing large quantities on a per transaction basis.</p><p style="font: 10pt/14.26px 'times new roman', times, serif; margin: 0pt 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Revenue for the year ended December 31, 2016 consisted of nutraceutical and cosmetic additives ($997,964) and finished cosmetic products ($4,240,640). Revenue for the year ended December 31, 2015 consists of nutraceutical and cosmetic additives ($1,079,289) and finished cosmetic products ($139,573).</p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts receivable</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b><i>Accounts receivable</i></b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Accounts receivable are carried at original invoice amount less an estimate made for holdbacks and doubtful receivables based on a review of all outstanding amounts. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer&#8217;s financial condition, credit history and current economic conditions and sets up an allowance for doubtful accounts when collection is uncertain. Customers&#8217; accounts are written off when all attempts to collect have been exhausted. Recoveries of accounts receivable previously written off are recorded as income when received. At December 31, 2016 and 2015 the accounts receivable reserve was approximately $37,800 and $18,000, respectively. As of December 31, 2016, the reserve for sales returns and allowances was approximately $50,500. No sales returns and allowances reserve existed at December 31, 2015.</p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><div>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b><i>Segments</i></b></font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The guidance for disclosures about segments of an enterprise requires that a public business enterprise report financial and descriptive information about its operating segments. Generally, financial information is required to be reported on the basis used internally for evaluating segment performance and resource allocation. The Company manages its operations in two reportable segments for purposes of assessing performance and making operating decisions. Revenue is generated predominately in the United States, and all significant assets are held in the United States, or United States territories.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies. The Company allocates resources and evaluates the performance of segments based on income or loss from operations, excluding interest, corporate expenses and other income (expenses).</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">A summary of the company&#8217;s reportable segments is as follows:</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p>
<table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="background-color: white;">&#160;</td>
<td><font style="font-size: 10pt;"><u>Total assets:</u></font></td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font-size: 10pt;">December&#160;31,</font><br /><font style="font-size: 10pt;">2016</font></td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font-size: 10pt;">December&#160;31,</font><br /><font style="font-size: 10pt;">2015</font></td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="width: 0.5in; background-color: white;">&#160;</td>
<td style="background-color: #cceeff;"><font style="font-size: 10pt;">Nutraceutical and Cosmetic Additives</font></td>
<td style="width: 15px; background-color: #cceeff;">&#160;</td>
<td style="width: 15px; background-color: #cceeff;"><font style="font-size: 10pt;">$</font></td>
<td style="width: 125px; text-align: right; background-color: #cceeff;"><font style="font-size: 10pt;">556,234</font></td>
<td style="width: 15px; background-color: #cceeff;">&#160;</td>
<td style="width: 15px; background-color: #cceeff;">&#160;</td>
<td style="width: 15px; background-color: #cceeff;"><font style="font-size:
 10pt;">$</font></td>
<td style="width: 125px; text-align: right; background-color: #cceeff;"><font style="font-size: 10pt;">412,324</font></td>
<td style="width: 15px; background-color: #cceeff;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td>&#160;</td>
<td><font style="font-size: 10pt;">Finished Cosmetic Products</font></td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: right;"><font style="font-size: 10pt;">422.288</font></td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: right;"><font style="font-size: 10pt;">101,828</font></td>
<td>&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="background-color: white;">&#160;</td>
<td style="padding-bottom: 1.5pt; background-color: #cceeff;"><font style="font-size: 10pt;">Eliminations</font></td>
<td style="padding-bottom: 1.5pt; background-color: #cceeff;">&#160;</td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; background-color: #cceeff;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; background-color: #cceeff;"><font style="font-size: 10pt;">(188,698</font></td>
<td style="padding-bottom: 1.5pt; background-color: #cceeff;"><font style="font-size: 10pt;">)</font></td>
<td style="padding-bottom: 1.5pt; background-color: #cceeff;">&#160;</td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; background-color: #cceeff;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; background-color: #cceeff;"><font style="font-size: 10pt;">(65,681</font></td>
<td style="padding-bottom: 1.5pt; background-color: #cceeff;"><font style="font-size: 10pt;">)</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td>&#160;</td>
<td style="padding-bottom: 4pt;"><font style="font-size: 10pt;"><b>Total</b></font></td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double;"><font style="font-size: 10pt;"><b>$</b></font></td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double;"><font style="font-size: 10pt;"><b>789,824</b></font></td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double;"><font style="font-size: 10pt;"><b>$</b></font></td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double;"><font style="font-size: 10pt;"><b>448,471</b></font></td>
<td style="padding-bottom: 4pt;">&#160;</td>
</tr>
</table>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p>
<table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="background-color: white;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="6">Year ended</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="background-color: white;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">December&#160;31, 2016</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">December&#160;31, 2015</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="background-color: white;">&#160;</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><u>Net sales by segment:</u></td>
<td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt;" colspan="2">&#160;</td>
<td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt;" colspan="2">&#160;</td>
<td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="width: 0.5in; background-color: white;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">Nutraceutical and Cosmetic Additives</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">$</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 125px; text-align: right; font-stretch:
 normal;">1,024,264</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">$</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 125px; text-align: right; font-stretch: normal;">1,092,289</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">Finished Cosmetic Products</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">4,240,640</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">139,573</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">Eliminations</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">(26,300</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">)</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">(13,000</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">Total</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">&#160;</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">5,238,604</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">&#160;</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">&#160;</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">1,218,862</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; text-decoration: underline; font-stretch: normal;">Net (loss) income by segment:</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">Nutraceutical and Cosmetic Additives</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">$</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">164,286</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times,
 serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">$</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">110,467</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">Finished Cosmetic Products</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">(388,121</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">)</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">(158,402</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; text-decoration: underline; font-stretch: normal;">Other unallocated amounts:</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">Corporate expenses</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">(950,847</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">)</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">(214,282</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">Other income (expense) - net</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">(48,611</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">)</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">89,785</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;">&#160;</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">Consolidated income (loss) from operations</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">&#160;</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">(1,223,293</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">)</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">&#160;</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">(172,432</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">)</td>
</tr>
</table>
</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b><i>Income Taxes</i></b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The Company files Corporate Federal and State tax returns, while Immudyne PR, which was formed as a limited liability corporation, files a separate tax return with any tax liabilities or benefits passing through to its members.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The Company records current and deferred taxes in accordance with Accounting Standards Codification (ASC) 740, &#8220;Accounting for Income Taxes.&#8221; This ASC requires recognition of deferred tax assets and liabilities for temporary differences between tax basis of assets and liabilities and the amounts at which they are carried in the financial statements, based upon the enacted rates in effect for the year in which the differences are expected to reverse. The Company establishes a valuation allowance when necessary to reduce deferred tax assets to the amount expected to be realized. The Company periodically assesses the value of its deferred tax asset, a majority of which has been generated by a history of net operating losses and determines the necessity for a valuation allowance. ASC 740 also provides a recognition threshold and measurement attribute for the financial statement recognition of a tax position taken or expected to be taken in a tax return. Using this guidance, a company may recognize the tax benefit from an uncertain tax position in its financial statements only if it is more likely-than-not (i.e., a likelihood of more than 50%) that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The Company&#8217;s tax returns for all years since December 31, 2013, remain open to taxing authorities.</font></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b><i>Stock-Based Compensation</i></b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The Company follows the provisions of ASC 718, &#8220;Share-Based Payment&#8221;. Under this guidance compensation cost generally is recognized at fair value on the date of the grant and amortized over the respective vesting periods. The fair value of options at the date of grant is estimated using the Black-Scholes option pricing model. The expected option life is derived from assumed exercise rates based upon historical exercise patterns and represents the period of time that options granted are expected to be outstanding. The expected volatility is based upon historical volatility of the Company&#8217;s shares using weekly price observations over an observation period that approximates the expected life of the options. The risk-free rate approximates the U.S. Treasury yield curve rate in effect at the time of grant for periods similar to the expected option life. Due to limited history of forfeitures, the estimated forfeiture rate included in the option valuation was zero.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Many of the assumptions require significant judgment and any changes could have a material impact in the determination of stock-based compensation expense.</font></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings (Loss) Per Share</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b><i>Earnings (Loss) Per Share</i></b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Basic earnings (loss) per common share is based on the weighted average number of shares outstanding during each period presented. Warrants and options to purchase common stock are included as common stock equivalents only when dilutive. Potential common stock equivalents are excluded from dilutive earnings per share when the effects would be antidilutive.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Common stock equivalents comprising shares underlying 16,302,447 options and warrants for the year ended December 31, 2016 have not been included in the loss per share calculation as the effects are anti-dilutive. Common stock equivalents comprising shares underlying 12,775,273 options and warrants for the year ended December 31, 2015 have not been included in the loss per share calculations as the effects are anti-dilutive.</p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b><i>Recent Accounting Pronouncements</i></b>&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (&#8220;ASU 2016-15&#8221;). ASU 2016-15 addresses eight specific cash flow issues with the objective of reducing diversity in practice regarding how certain cash receipts and cash payments are presented in the statement of cash flows. The standard provides guidance on the classification of the following items: (1) debt prepayment or debt extinguishment costs, (2) settlement of zero-coupon debt instruments, (3) contingent consideration payments made after a business combination, (4) proceeds from the settlement of insurance claims, (5) proceeds from the settlement of corporate-owned life insurance policies, (6) distributions received from equity method investments, (7) beneficial interests in securitization transactions, and (8) separately identifiable cash flows. The Company is required to adopt ASU 2016-15 for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2017 on a retrospective basis. Early adoption is permitted, including adoption in an interim period. The Company is currently evaluating the impact of adoption of ASU 2016-15.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">In March 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-09, &#8220;Compensation &#8211; Stock Compensation: Improvements to Employee Share-Based Payment Accounting,&#8221; which relates to the accounting for employee share-based payments. This standard addresses several aspects of the accounting for share-based payment award transactions, including: (a) income tax consequences; (b) classification flows of awards as either equity or liabilities; and (c) classification on the statement of cash flows. This standard will be effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The Company is in the process of evaluating the impact of the adoption of ASU 2016-09 on its consolidated financial statements. The adoption of ASU No. 2016-09 is not expected to have a material impact on the Company's consolidated financial statements or related disclosures.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">In February 2016, a pronouncement was issued that creates new accounting and reporting guidelines for leasing arrangements. The new guidance requires organizations that lease assets to recognize assets and liabilities on the balance sheet related to the rights and obligations created by those leases, regardless of whether they are classified as finance or operating leases. Consistent with current guidance, the recognition, measurement, and presentation of expenses and cash flows arising from a lease primarily will depend on its classification as a finance or operating lease. The guidance also requires new disclosures to help financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. The new standard is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period, with early application permitted. The new standard is to be applied using a modified retrospective approach. The Company is in the process of evaluating the impact of the new pronouncement on its consolidated financial statements.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal
 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">In May 2014, the Financial Accounting Standards Board ("FASB") issued accounting guidance, "Revenue from Contracts with Customers." The core principle of the new standard is for companies to recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration (that is, payment) to which the company expects to be entitled in exchange for those goods or services. The new standard also will result in enhanced disclosures about revenue, provide guidance for transactions that were not previously addressed comprehensively (for example, service revenue and contract modifications) and clarify guidance for multiple-element arrangements. The standard will be effective for fiscal years and interim periods within those years beginning after December 15, 2017. Accordingly, the Company will adopt this standard in the first quarter of fiscal year 2018. The Company is currently evaluating the impact this guidance will have on the consolidated financial statements.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 108pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">In July 2015, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2015-11, &#8220;Simplifying the Measurement of Inventory.&#8221; ASU 2015-11 applies to inventory that is measured using first-in, first-out (FIFO) or average cost. An entity should measure inventory within the scope of ASU 2015-11 at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. ASU 2015-11 is effective for fiscal years beginning after December 15, 2016. The adoption of ASU No. 2015-11 is not expected to have a material impact on the Company's consolidated financial statements or related disclosures.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">In August 2014, the FASB issued ASU 2014-15, "Presentation of Financial Statements-Going Concern". This ASU is intended to define management's responsibility to evaluate whether there is substantial doubt about an organization's ability to continue as a going concern and to provide related footnote disclosures. It is effective for annual periods ending after December 15, 2016, with early adoption permitted. The Company does not expect it to have a material effect on the Company's consolidated financial condition, results of operations, and cash flows.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">In May 2017, the FASB issued ASU 2017-09, Compensation - Stock Compensation (Topic 718) : Scope of Modification Accounting. The new standard provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. This pronouncement is effective for annual reporting periods beginning after December 15, 2017 but early adoption is permitted. The Company is currently evaluating the impact of adopting this guidance.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">All other accounting standards that have been issued or proposed by the FASB that do not require adoption until a future date are not expected to have a material impact on the consolidated financial statements upon adoption.</font></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b><i>Fair Value of Financial Instruments</i></b></font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The carrying value of the Company&#8217;s financial instruments, including cash, trade accounts receivable, accounts payable and accrued expenses and the face amount of notes payable approximate fair value for all periods.</font></p>
</div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_MinorityInterestPolicyTextBlock', window );">Noncontrolling Interests</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b><i>Noncontrolling Interests</i></b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The Company accounts for its less than 100% interest in Immudyne PR in accordance with ASC Topic 810, Consolidation, and accordingly the Company presents noncontrolling interests as a component of equity on its consolidated balance sheet and reports the noncontrolling interest&#8217;s share of the Immudyne PR net loss attributable to noncontrolling interests in the consolidated statement of operations.</font></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationVariableInterestEntityPolicy', window );">Consolidation of Variable Interest Entities</a></td>
<td class="text"><div>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><b><i>Consolidation of Variable Interest Entities</i></b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In accordance with ASC 810-10-25-37 and as amended by ASU 2009-17, the Company determines whether any legal entity in which the Company becomes involved is a VIE and subject to consolidation. The Company conducts an assessment on an ongoing basis for each VIE including (1) the power to direct activities of the VIE that most significantly impact the VIE&#8217;s economic performance, and (2) the obligation to absorb losses or right to receive benefits from the VIE that could potentially be significant to the VIE. As a result, the Company determined that nine (9) entities were VIEs and subject to consolidation.</p>
</div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;"><b><i>Concentration of Credit Risk</i></b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The Company grants credit in the normal course of business to its customers. The Company periodically performs credit analysis and monitors the financial condition of its customers to reduce credit risk.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">The Company monitors its positions with, and the credit quality of, the financial institutions with which it invests. The Company, at times, maintains balances in various operating accounts in excess of federally insured limits.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">One customer in the nutraceutical and cosmetic additives division accounted for 15% and 73% of consolidated sales for the years ended December 31, 2016 and 2015, respectively. This customer accounted for 11% and 43% of accounts receivable at December 31, 2016 and December 31, 2015, respectively.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">A second customer in the nutraceutical and cosmetic additives division accounted for 2% and 12% of consolidated sales for years ended December 31, 2016 and 2015, respectively. This customer accounted for 8% and 24% of accounts receivable at December 31, 2016 and December 31, 2015, respectively.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0px 0pt 0.5in; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">In the finished cosmetic products division, two credit card processors accounted for 34.9% and 31.6% of accounts receivable at December 31, 2016. There were no significant concentrations of accounts receivable in the finished cosmetic products division at December 31, 2015</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_MinorityInterestPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of noncontrolling interests policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_MinorityInterestPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_SequencingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents sequencing policy text block.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_SequencingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_VariableInterestEntitiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It repressents variable interest entitues policy text block.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_VariableInterestEntitiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6875567&amp;loc=d3e14489-108613<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68064133&amp;loc=d3e61082-112788<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28088331&amp;loc=SL29635902-196195<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13531-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68064133&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=d3e5614-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355100-122828<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationVariableInterestEntityPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=64801991&amp;loc=SL6759159-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=64801991&amp;loc=d3e5728-111685<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2AA<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=64801991&amp;loc=SL6759068-111685<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationVariableInterestEntityPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=d3e41620-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5579240-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=SL5579245-113959<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=d3e41675-113959<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64837297&amp;loc=d3e41638-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13279-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4492-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4556-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for trade and other accounts receivables. This disclosure may include the basis at which such receivables are carried in the entity's statements of financial position (for example, net realizable value), how the entity determines the level of its allowance for doubtful accounts, when impairments, charge-offs or recoveries are recognized, and the entity's income recognition policies for such receivables, including its treatment of related fees and costs, its treatment of premiums, discounts or unearned income, when accrual of interest is discontinued, how the entity records payments received on nonaccrual receivables and its policy for resuming accrual of interest on such receivables.  If the enterprise holds a large number of similar loans, disclosure may include the accounting policy for the anticipation of prepayments and significant assumptions underlying prepayment estimates for amortization of premiums, discounts, and nonrefundable fees and costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66008989&amp;loc=SL6953423-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65890831&amp;loc=d3e10133-111534<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=66008989&amp;loc=d3e5212-111524<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=66008989&amp;loc=d3e5093-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6927185184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Summary of inventory</a></td>
<td class="text"><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td>&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">December&#160;31,<br />2016</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">December&#160;31,<br />2015</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 0.5in; background-color: white;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">Raw materials</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 125px; text-align: right;">38,460</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 125px; text-align: right;">25,761</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">Finished products</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">121,810</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">35,290</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">160,270</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">61,051</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock', window );">Summary of reportable segments</a></td>
<td class="text"><div>
<table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="background-color: white;">&#160;</td>
<td><font style="font-size: 10pt;"><u>Total assets:</u></font></td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font-size: 10pt;">December&#160;31,</font><br /><font style="font-size: 10pt;">2016</font></td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font-size: 10pt;">December&#160;31,</font><br /><font style="font-size: 10pt;">2015</font></td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="width: 0.5in; background-color: white;">&#160;</td>
<td style="background-color: #cceeff;"><font style="font-size: 10pt;">Nutraceutical and Cosmetic Additives</font></td>
<td style="width: 15px; background-color: #cceeff;">&#160;</td>
<td style="width: 15px; background-color: #cceeff;"><font style="font-size: 10pt;">$</font></td>
<td style="width: 125px; text-align: right; background-color: #cceeff;"><font style="font-size: 10pt;">556,234</font></td>
<td style="width: 15px; background-color: #cceeff;">&#160;</td>
<td style="width: 15px; background-color: #cceeff;">&#160;</td>
<td style="width: 15px; background-color: #cceeff;"><font style="font-size: 10pt;">$</font></td>
<td style="width: 125px; text-align: right; background-color: #cceeff;"><font style="font-size: 10pt;">412,324</font></td>
<td style="width: 15px; background-color: #cceeff;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td>&#160;</td>
<td><font style="font-size: 10pt;">Finished Cosmetic Products</font></td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: right;"><font style="font-size: 10pt;">422,288</font></td>
<td>&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: right;"><font style="font-size: 10pt;">101,828</font></td>
<td>&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="background-color: white;">&#160;</td>
<td style="padding-bottom: 1.5pt; background-color: #cceeff;"><font style="font-size: 10pt;">Eliminations</font></td>
<td style="padding-bottom: 1.5pt; background-color: #cceeff;">&#160;</td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; background-color: #cceeff;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; background-color: #cceeff;"><font style="font-size: 10pt;">(188,698</font></td>
<td style="padding-bottom: 1.5pt; background-color: #cceeff;"><font style="font-size: 10pt;">)</font></td>
<td style="padding-bottom: 1.5pt; background-color: #cceeff;">&#160;</td>
<td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; background-color: #cceeff;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; background-color: #cceeff;"><font style="font-size: 10pt;">(65,681</font></td>
<td style="padding-bottom: 1.5pt; background-color: #cceeff;"><font style="font-size: 10pt;">)</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td>&#160;</td>
<td style="padding-bottom: 4pt;"><font style="font-size: 10pt;"><b>Total</b></font></td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double;"><font style="font-size: 10pt;"><b>$</b></font></td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double;"><font style="font-size: 10pt;"><b>789,824</b></font></td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double;"><font style="font-size: 10pt;"><b>$</b></font></td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double;"><font style="font-size: 10pt;"><b>448,471</b></font></td>
<td style="padding-bottom: 4pt;">&#160;</td>
</tr>
</table>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0pt 0pt 0pt 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p>
&#160;
<table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="background-color: white;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="6">Year ended</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="background-color: white;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width:
 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">December&#160;31, 2016</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">December&#160;31, 2015</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="background-color: white;">&#160;</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><u>Net sales by segment:</u></td>
<td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt;" colspan="2">&#160;</td>
<td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td>
<td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td>
<td style="text-align: center; font-size: 10pt;" colspan="2">&#160;</td>
<td style="padding-bottom: 1.5pt; font-size: 10pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="width: 0.5in; background-color: white;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">Nutraceutical and Cosmetic Additives</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">$</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 125px; text-align: right; font-stretch: normal;">1,024,264</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">$</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 125px; text-align: right; font-stretch: normal;">1,092,289</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">Finished Cosmetic Products</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">4,240,640</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">139,573</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">Eliminations</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">(26,300</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">)</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">(13,000</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">Total</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">&#160;</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">5,238,604</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">&#160;</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">&#160;</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">1,218,862</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;">&#160;</td>
<td style="font-size:
 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; text-decoration: underline; font-stretch: normal;">Net (loss) income by segment:</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">Nutraceutical and Cosmetic Additives</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">$</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">164,286</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">$</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">110,467</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">Finished Cosmetic Products</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">(388,121</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">)</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">(158,402</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; text-decoration: underline; font-stretch: normal;">Other unallocated amounts:</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">Corporate expenses</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">(950,847</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">)</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">(214,282</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">Other income (expense) - net</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">(48,611</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">)</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">89,785</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch:
 normal;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;">&#160;</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">Consolidated income (loss) from operations</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">&#160;</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">(1,223,293</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">)</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">&#160;</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">(172,432</td>
<td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">)</td>
</tr>
</table>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760784912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Furnishings and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Furnishings and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of furnishings and equipment</a></td>
<td class="text"><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="background-color: white;"></td><td style="text-align: center; padding-bottom: 1.5pt; font-family: calibri, sans-serif;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6">December 31</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-family: calibri, sans-serif;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2016</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2015</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td style="font-family: calibri, sans-serif;">&#160;</td><td style="font-family: calibri, sans-serif;">&#160;</td><td style="font-family: calibri, sans-serif;" colspan="2">&#160;</td><td style="font-family: calibri, sans-serif;">&#160;</td><td style="font-family: calibri, sans-serif;">&#160;</td><td style="font-family: calibri, sans-serif;" colspan="2">&#160;</td><td style="font-family: calibri, sans-serif;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 0.5in; background-color: white;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">Furnishings and equipment, at cost</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 125px; text-align: right;">679,291</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 125px; text-align: right;">679,291</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">Accumulated depreciation</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">679,291</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">679,291</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt; font-family: calibri, sans-serif;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">-</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">-</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6646392624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Summary of notes payable and advances payable activity</a></td>
<td class="text"><div>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p>
<table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="background-color: white;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">Officers, Directors, and Shareholders</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">Commercial Lenders</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2">Total</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="width: 0.5in; background-color: white;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Balance at December 31, 2014</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">$</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 125px; text-align: right; font-stretch: normal;">27,200</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">$</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 125px; text-align: right; font-stretch: normal;">-</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">$</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 125px; text-align: right; font-stretch: normal;">27,200</td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Borrowing</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">105,000</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">200,000</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">305,000</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Repayment</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">(47,000</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">)</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">(100,000</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">)</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal
 'times new roman', times, serif; text-align: right; font-stretch: normal;">(147,000</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">Conversion to common stock</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">(85,200</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">)</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">-</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">(85,200</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">Balance at December 31, 2015</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">-</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">100,000</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">100,000</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Borrowing</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">$</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">300,000</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">$</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">-</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">$</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">300,000</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
</tr>
<tr
 style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Repayment</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">(68,600</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">)</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">(100,000</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">)</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">(168,600</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">Debt discount</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">(25,035</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">)</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">-</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">(25,035</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="background-color: white;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
<td style="text-align: right; font-size: 10pt;">&#160;</td>
<td style="text-align: left; font-size: 10pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="background-color: white;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">Balance at December 31, 2016</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">206,365</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">(100,000</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">)</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">$</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;">106,365</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;">&#160;</td>
</tr>
</table>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760784912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of components of deferred tax liabilities and assets</a></td>
<td class="text"><div>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p>
<table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;">
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="6"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">December 31</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;">
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">2016</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">2015</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal;">
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;" colspan="2"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;" colspan="2"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: #cceeff;">
<td style="font: 10pt/normal 'times new roman', times, serif; width: 0.5in; font-stretch: normal; background-color: white;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Net operating loss</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 125px; text-align: right; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">1,344,000</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"><font
 style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 125px; text-align: right; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">930,000</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: white;">
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Accounts receivable reserves</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">30,000</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">-</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
</tr>
<tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: #cceeff;">
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Inventory reserves</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">7,000</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;">-</td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</td>
</tr>
<tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: white;">
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">Stock compensation</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">200,000</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">-</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
</tr>
<tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: #cceeff;">
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal; background-color: white;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">Net deferred tax asset</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">1,581,000</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">&#160;</td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;">-</td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;">&#160;</td>
</tr>
<tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: white;">
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Valuation allowance</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;
 font-size: 10pt;">&#160;</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">(1,581,000</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">(930,000</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">)</font></td>
</tr>
<tr style="font: 10pt/normal 'times new roman', times, serif; vertical-align: bottom; font-stretch: normal; background-color: #cceeff;">
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal; background-color: white;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; padding-left: 10pt; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">Total</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">$</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4.5pt; border-bottom-style: double; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">-</font></td>
<td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif; font-size: 10pt;">&#160;</font></td>
</tr>
</table>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6770234624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of outstanding service-based options</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 1250.4px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td>&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Number of Shares</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Year&#160;of&#160;<br />Expiration</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 0.5in; background-color: white;">&#160;</td><td>Balance at December 31, 2014</td><td style="width: 12px;">&#160;</td><td style="width: 12px; text-align: left;">&#160;</td><td style="width: 100px; text-align: right;">3,772,720</td><td style="width: 12px; text-align: left;">&#160;</td><td style="width: 12px;">&#160;</td><td style="width: 12px; text-align: center;">&#160;</td><td style="width: 100px; text-align: center;">0.29</td><td style="width: 12px; text-align: left;">&#160;</td><td style="width: 12px;">&#160;</td><td style="width: 12px; text-align: center;">&#160;</td><td style="width: 100px; text-align: center;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">2015&#160;-&#160;2016</font></td><td style="width: 12px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="padding-bottom: 1.5pt;">Expired</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(2,022,720</td><td style="text-align: left; padding-bottom: 1.5pt;">)</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt;">0.40</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt;">2015</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: center;">&#160;</td><td style="text-align: center;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: center;">&#160;</td><td style="text-align: center;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td>Balance at December 31, 2015</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1,750,000</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: center;">&#160;</td><td style="text-align: center;">0.16</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: center;">&#160;</td><td style="text-align: center;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">2016 - 2017</font></td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;">&#160;</td><td>Issued</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">454,891</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: center;">&#160;</td><td style="text-align: center;">0.42</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: center;">&#160;</td><td style="text-align: center;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">2018&#160;-&#160;2019</font></td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="padding-bottom: 1.5pt;">Expired</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(250,000</td><td style="text-align: left; padding-bottom: 1.5pt;">)</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt;">0.40</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt;">2016</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align:
 center;">&#160;</td><td style="text-align: center;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: center;">&#160;</td><td style="text-align: center;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="padding-bottom: 4pt;">Balance at December 31, 2016</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,954,981</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: center; padding-bottom: 4pt;">&#160;</td><td style="text-align: center; padding-bottom: 4pt;">0.19</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: center; padding-bottom: 4pt;">&#160;</td><td style="text-align: center; padding-bottom: 4pt;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">2017 - 2019</font></td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock', window );">Summary of significant assumptions used to determine fair values of options issued using Black-Scholes option-pricing model</a></td>
<td class="text"><div><table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 1250.4px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td>&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2016</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2015</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 0.5in; background-color: white;">&#160;</td><td style="text-align: left;">Expected volatility</td><td style="width: 12px;">&#160;</td><td style="width: 12px; text-align: left;">&#160;</td><td style="width: 100px; text-align: right;">225</td><td style="width: 12px; text-align: left;">%</td><td style="width: 12px;">&#160;</td><td style="width: 12px; text-align: left;">&#160;</td><td style="width: 100px; text-align: right;">50</td><td style="width: 12px; text-align: left;">%</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="text-align: left;">Risk free interest rate</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1</td><td style="text-align: left;">%</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">2</td><td style="text-align: left;">%</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;">&#160;</td><td style="text-align: left;">Expected dividend yield</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td style="text-align: left;">Expected option term (in years)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">2 - 3</font></td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">1 - 5</font></td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;">&#160;</td><td>Weighted average grant date fair value</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">0.23</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">0.03</td><td style="text-align: left;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Service-Based Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of outstanding service-based options</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p><table align="center" style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td>&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Number of<br />Options</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 0.5in; background-color: white;">&#160;</td><td>Balance at December 31, 2014</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 125px; text-align: right;">10,435,000</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td>Cancelled</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">(200,000</td><td style="text-align: left;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;">&#160;</td><td style="padding-bottom: 1.5pt;">Issued</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">790,273</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;">&#160;</td><td>Balance at December 31, 2015</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">11,025,273</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td>Exercised</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">300,000</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;">&#160;</td><td>Expired</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">50,000</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td>Cancelled</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">(250,000</td><td style="text-align: left;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;">&#160;</td><td style="padding-bottom: 1.5pt;">Issued</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">275,000</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="background-color: white;">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="background-color: white;">&#160;</td><td style="padding-bottom: 4pt;">Balance at December 31, 2016</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">10,700,273</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock', window );">Summary of significant assumptions used to determine fair values of options issued using Black-Scholes option-pricing model</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p><table align="center" style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td><font style="font-size: 10pt;"><u>Significant assumptions:</u></font></td><td style="padding-bottom: 1.5pt;">&#160;</td><td nowrap="nowrap" colspan="2">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td style="background-color: #cceeff;"><font style="font-size: 10pt;">Risk-free interest rate at grant date</font></td><td style="background-color: #cceeff;">&#160;</td><td nowrap="nowrap" style="background-color: #cceeff;">&#160;</td><td nowrap="nowrap" style="text-align: right; background-color: #cceeff;"><font style="font-size: 10pt;">0.71% - 1.88</font></td><td style="background-color: #cceeff;"><font style="font-size: 10pt;">%</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td>&#160;</td><td><font style="font-size: 10pt;">Expected stock price volatility</font></td><td>&#160;</td><td nowrap="nowrap">&#160;</td><td nowrap="nowrap" style="text-align: right;"><font style="font-size: 10pt;">217.4% - 248.4</font></td><td><font style="font-size: 10pt;">%</font></td></tr><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td style="background-color: #cceeff;"><font style="font-size: 10pt;">Expected dividend payout</font></td><td style="background-color: #cceeff;">&#160;</td><td nowrap="nowrap" style="background-color: #cceeff;">&#160;</td><td nowrap="nowrap" style="text-align: right; background-color: #cceeff;"><font style="font-size: 10pt;">&#8212;</font></td><td style="background-color: #cceeff;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>&#160;</td><td><font style="font-size: 10pt;">Expected option life-years</font></td><td>&#160;</td><td nowrap="nowrap">&#160;</td><td nowrap="nowrap" style="text-align: right;"><font style="font-size: 10pt;">2 to 3</font></td><td><font style="font-size: 10pt;">&#160;&#160;years&#160;</font></td></tr><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td style="background-color: #cceeff;"><font style="font-size: 10pt;">Weighted average grant date fair value</font></td><td style="background-color: #cceeff;">&#160;</td><td nowrap="nowrap" style="background-color: #cceeff;"><font style="font-size: 10pt;">$</font></td><td nowrap="nowrap" style="text-align: right; background-color: #cceeff;"><font style="font-size: 10pt;">0.22</font></td><td style="background-color: #cceeff;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="width: 0.5in;">&#160;</td><td><font style="font-size: 10pt;">Forfeiture rate</font></td><td style="width: 15px;">&#160;</td><td nowrap="nowrap" style="width: 15px;">&#160;</td><td nowrap="nowrap" style="width: 125px; text-align: right;"><font style="font-size: 10pt;">0</font></td><td style="width: 37px;"><font style="font-size: 10pt;">%</font></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Summary of outstanding service-based options exercise price</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 36pt; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-stretch: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"></p><table align="center" style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; orphans: 2; widows: 2; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td><font style="font-size: 10pt;"><u>Significant assumptions:</u></font></td><td style="padding-bottom: 1.5pt;">&#160;</td><td nowrap="nowrap" colspan="2">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td style="background-color: #cceeff;"><font style="font-size: 10pt;">Risk-free interest rate at grant date</font></td><td style="background-color: #cceeff;">&#160;</td><td nowrap="nowrap" style="background-color: #cceeff;">&#160;</td><td nowrap="nowrap" style="text-align: right; background-color: #cceeff;"><font style="font-size: 10pt;">0.71% - 1.88</font></td><td style="background-color: #cceeff;"><font style="font-size: 10pt;">%</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td>&#160;</td><td><font style="font-size: 10pt;">Expected stock price volatility</font></td><td>&#160;</td><td nowrap="nowrap">&#160;</td><td nowrap="nowrap" style="text-align: right;"><font style="font-size: 10pt;">217.4% - 248.4</font></td><td><font style="font-size: 10pt;">%</font></td></tr><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td style="background-color: #cceeff;"><font style="font-size: 10pt;">Expected dividend payout</font></td><td style="background-color: #cceeff;">&#160;</td><td nowrap="nowrap" style="background-color: #cceeff;">&#160;</td><td nowrap="nowrap" style="text-align: right; background-color: #cceeff;"><font style="font-size: 10pt;">&#8212;</font></td><td style="background-color: #cceeff;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>&#160;</td><td><font style="font-size: 10pt;">Expected option life-years</font></td><td>&#160;</td><td nowrap="nowrap">&#160;</td><td nowrap="nowrap" style="text-align: right;"><font style="font-size: 10pt;">2 to 3</font></td><td><font style="font-size: 10pt;">&#160;&#160;years&#160;</font></td></tr><tr style="vertical-align: bottom;"><td style="background-color: white;">&#160;</td><td style="background-color: #cceeff;"><font style="font-size: 10pt;">Weighted average grant date fair value</font></td><td style="background-color: #cceeff;">&#160;</td><td nowrap="nowrap" style="background-color: #cceeff;"><font style="font-size: 10pt;">$</font></td><td nowrap="nowrap" style="text-align: right; background-color: #cceeff;"><font style="font-size: 10pt;">0.22</font></td><td style="background-color: #cceeff;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="width: 0.5in;">&#160;</td><td><font style="font-size: 10pt;">Forfeiture rate</font></td><td style="width: 15px;">&#160;</td><td nowrap="nowrap" style="width: 15px;">&#160;</td><td nowrap="nowrap" style="width: 125px; text-align: right;"><font style="font-size: 10pt;">0</font></td><td style="width: 37px;"><font style="font-size: 10pt;">%</font></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the assumptions used to determine for pension plans and/or other employee benefit plans the benefit obligation and net benefit cost, including assumed discount rates, rate increase in compensation increase, and expected long-term rates of return on plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=65897934&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAssumptionsUsedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6770882256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Going Concern (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Apr. 01, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_OrganizationAndGoingConcernTextualAbstract', window );"><strong>Organization and Going Concern (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of ownership equity interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.33%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Percentage of voting controlling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (9,693,882)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8,586,338)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_OrganizationAndGoingConcernTextualAbstract', window );"><strong>Organization and Going Concern (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestPeriodIncreaseDecrease', window );">Reduction in noncontrolling interest</a></td>
<td class="nump">$ 91,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=immd_ImmudynePrLlcMember', window );">Immudyne PR LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_OrganizationAndGoingConcernTextualAbstract', window );"><strong>Organization and Going Concern (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of ownership equity interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78.16667%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_OrganizationAndGoingConcernTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>organization and going concern textual.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_OrganizationAndGoingConcernTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66011266&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in balance of noncontrolling interest in the subsidiary during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4568740-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=immd_ImmudynePrLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=immd_ImmudynePrLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760997728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Summary of inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 38,460<span></span>
</td>
<td class="nump">$ 25,761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished products</a></td>
<td class="nump">121,810<span></span>
</td>
<td class="nump">35,290<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">$ 160,270<span></span>
</td>
<td class="nump">$ 61,051<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6758129808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Summary of reportable segments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">$ 789,824<span></span>
</td>
<td class="nump">$ 448,471<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total sales</a></td>
<td class="nump">5,238,604<span></span>
</td>
<td class="nump">1,218,862<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income</a></td>
<td class="num">(1,223,293)<span></span>
</td>
<td class="num">(159,232)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_OtherUnallocatedAmountsAbstract', window );"><strong>Other unallocated amounts:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_CorporateExpenses', window );">Corporate expenses</a></td>
<td class="num">(950,847)<span></span>
</td>
<td class="num">(214,282)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense) - net</a></td>
<td class="num">(48,611)<span></span>
</td>
<td class="nump">89,785<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Consolidated income (loss) from operations</a></td>
<td class="num">(1,223,293)<span></span>
</td>
<td class="num">(172,432)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationItemsAxis=immd_NutraceuticalAndCosmeticMember', window );">Nutraceutical and cosmetic [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Summary of reportable segments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">556,234<span></span>
</td>
<td class="nump">412,324<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total sales</a></td>
<td class="nump">1,024,264<span></span>
</td>
<td class="nump">1,092,289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income</a></td>
<td class="nump">164,286<span></span>
</td>
<td class="nump">110,467<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationItemsAxis=immd_CosmeticGoodsMember', window );">Finished Cosmetic Products [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Summary of reportable segments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">422.288<span></span>
</td>
<td class="nump">101,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total sales</a></td>
<td class="nump">4,240,640<span></span>
</td>
<td class="nump">139,573<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income</a></td>
<td class="num">(388,121)<span></span>
</td>
<td class="num">(158,402)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Elimination [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Summary of reportable segments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="num">(188,698)<span></span>
</td>
<td class="num">(65,681)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total sales</a></td>
<td class="num">(26,300)<span></span>
</td>
<td class="num">(13,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_CorporateExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of unallocated corporate expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_CorporateExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_OtherUnallocatedAmountsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other unallocated amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_OtherUnallocatedAmountsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideRevenueMajorCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideRevenueMajorCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591551-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationItemsAxis=immd_NutraceuticalAndCosmeticMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationItemsAxis=immd_NutraceuticalAndCosmeticMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationItemsAxis=immd_CosmeticGoodsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationItemsAxis=immd_CosmeticGoodsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6771096112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract', window );"><strong>Summary of Significant Accounting Policies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_MinorityInterestRate', window );">Non controlling interest rate</a></td>
<td class="nump">21.833%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLIFOReserve', window );">Inventory reserve</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesDiscountsReturnsAndAllowancesGoods', window );">Customer discounts, returns and rebates</a></td>
<td class="nump">1,926,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">5,238,604<span></span>
</td>
<td class="nump">1,218,862<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable reserve</a></td>
<td class="nump">37,800<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_NonControllingInterestDescription', window );">Description of non controlling interest</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesReturnsAndAllowancesGoods', window );">Sales returns and allowances</a></td>
<td class="nump">50,500<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityConsolidatedCarryingAmountAssets', window );">Variable Interest Entity, assets</a></td>
<td class="nump">10,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityConsolidatedCarryingAmountLiabilities', window );">Variable Interest Entity, liabilities</a></td>
<td class="nump">5,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityRevenues', window );">Variable Interest Entity, revenues</a></td>
<td class="nump">6,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityOperatingIncomeOrLoss', window );">Variable Interest Entity, operating expenses</a></td>
<td class="nump">$ 6,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityConclusionToConsolidate', window );">Consolidated VIE, Description</a></td>
<td class="text">Consolidated nine and zero.<span></span>
</td>
<td class="text">Consolidated nine and zero.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_ReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities', window );">Recorded upon issue</a></td>
<td class="nump">$ 192,254<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationItemsAxis=immd_NutraceuticalAndCosmeticMember', window );">Nutraceutical and cosmetic [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract', window );"><strong>Summary of Significant Accounting Policies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">1,024,264<span></span>
</td>
<td class="nump">1,092,289<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationItemsAxis=immd_CosmeticGoodsMember', window );">Finished Cosmetic Products [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract', window );"><strong>Summary of Significant Accounting Policies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 4,240,640<span></span>
</td>
<td class="nump">$ 139,573<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesMember', window );">Sales [Member] | One customer [Member] | Nutraceutical and cosmetic [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract', window );"><strong>Summary of Significant Accounting Policies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">73.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesMember', window );">Sales [Member] | Second customer [Member] | Nutraceutical and cosmetic [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract', window );"><strong>Summary of Significant Accounting Policies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | One credit card processor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract', window );"><strong>Summary of Significant Accounting Policies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">34.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | Two credit card processor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract', window );"><strong>Summary of Significant Accounting Policies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">31.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | One customer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract', window );"><strong>Summary of Significant Accounting Policies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">43.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | Second customer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract', window );"><strong>Summary of Significant Accounting Policies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Option [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract', window );"><strong>Summary of Significant Accounting Policies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">16,302,447<span></span>
</td>
<td class="nump">12,775,273<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_MinorityInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non controlling stated interest rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_MinorityInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_NonControllingInterestDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of non controlling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_NonControllingInterestDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_ReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification of options, warrants and other contracts to derivative liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_ReclassificationOfOptionsWarrantsAndOtherContractsFromEquityToDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_SummaryOfSignificantAccountingPoliciesTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies textual.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_SummaryOfSignificantAccountingPoliciesTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, the amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business, reduced to their estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Antidilution<br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Diluted Earnings Per Share<br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Contingent Stock Agreement<br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6351-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13531-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6404-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13537-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLIFOReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which inventory stated at last-in first-out (LIFO) is less than (in excess of) inventory stated at other inventory cost methods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLIFOReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesDiscountsReturnsAndAllowancesGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate of: (i) sales discounts given by the entity, including, but not limited to, early payments of accounts due, (ii) the total deduction from sales during the period arising from goods returned by customers (other than under warranty provisions), and (iii) price reductions (allowance, price protection agreements) given by the entity. Discounts, returns and allowances are a deduction from gross revenue in arriving at net revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 50<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68069731&amp;loc=d3e63676-111659<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 15<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68051624&amp;loc=d3e47468-111626<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesDiscountsReturnsAndAllowancesGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesReturnsAndAllowancesGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total deduction from sales during the period arising from goods returned by customers (other than under warranty provisions) and price reductions (allowance, price protection agreements) given by the entity. Returns and allowances are a deduction from gross revenue in arriving at net revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesReturnsAndAllowancesGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityOperatingIncomeOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income (loss) from operations derived by the reporting entity during the period from the Variable Interest Entity (VIE).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph d<br> -URI http://asc.fasb.org/extlink&amp;oid=64801991&amp;loc=d3e5747-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityOperatingIncomeOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income between the reporting entity and the Variable Interest Entity (VIE).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph d<br> -URI http://asc.fasb.org/extlink&amp;oid=64801991&amp;loc=d3e5747-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityActivityBetweenVIEAndEntityRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityConclusionToConsolidate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the primary factors that caused the change in conclusion to consolidate a Variable Interest Entity (VIE) in the most recent financial statements (for example, the VIE was previously consolidated and is not currently consolidated) and the effect of the change on the reporting entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=64801991&amp;loc=SL6759159-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityConclusionToConsolidate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityConsolidatedCarryingAmountAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the consolidated Variable Interest Entity's assets included in the reporting entity's statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=64801991&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityConsolidatedCarryingAmountAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityConsolidatedCarryingAmountLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the consolidated Variable Interest Entity's liabilities included in the reporting entity's statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=64801991&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityConsolidatedCarryingAmountLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationItemsAxis=immd_NutraceuticalAndCosmeticMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationItemsAxis=immd_NutraceuticalAndCosmeticMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationItemsAxis=immd_CosmeticGoodsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationItemsAxis=immd_CosmeticGoodsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_ConcentrationRiskNumberOfCustomersAxis=immd_OneCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_ConcentrationRiskNumberOfCustomersAxis=immd_OneCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_ConcentrationRiskNumberOfCustomersAxis=immd_SecondCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_ConcentrationRiskNumberOfCustomersAxis=immd_SecondCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis=immd_OneCreditCardProcessorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis=immd_OneCreditCardProcessorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis=immd_TwoCreditCardProcessorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByIndustryOfCounterpartyTypeAxis=immd_TwoCreditCardProcessorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6927329168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Furnishings and Equipment (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Furnishings and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Furnishings and equipment, at cost</a></td>
<td class="nump">$ 679,291<span></span>
</td>
<td class="nump">$ 679,291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">679,291<span></span>
</td>
<td class="nump">679,291<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Furnishings and equipment, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760931104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Furnishings and Equipment (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_FurnishingsAndEquipmentTextualAbstract', window );"><strong>Furnishings and Equipment (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 43,748<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_FurnishingsAndEquipmentTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Furnishings and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_FurnishingsAndEquipmentTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6758421360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investment in Adiuvo Investment S.A. (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_InvestmentInAdiuvoInvestmentTextualAbstract', window );"><strong>Investment In Adiuvo Investment S A (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_OptionsPurchasedAmountPaid', window );">Amount paid for options purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Percentage of interests acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestInJointVentures', window );">Minority interest in joint ventures</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Option to acquire additional shares amount</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableDescription', window );">Percentage of equity interest in public offerings</a></td>
<td class="text">less than 1%.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Minority interest rate</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainOnSaleOfInvestments', window );">Gain on sale of Adiuvo Investment S.A. stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 127,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentOptionsExpirationDate', window );">Options expired date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep. 30,  2014<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_InvestmentInAdiuvoInvestmentTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in Adiuvo Investment S.A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_InvestmentInAdiuvoInvestmentTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_OptionsPurchasedAmountPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount paid for options purchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_OptionsPurchasedAmountPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_InvestmentOptionsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date of the option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 12<br> -Section 13<br> -Footnote 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">invest_InvestmentOptionsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>invest_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of equity interests issued or issuable to acquire the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65885119&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6578-128477<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the carrying value and the sale price of an investment.  A gain would be recognized when the sale price of the investment is greater than the carrying value of the investment.  This element refers to the Gain included in earnings and not to the cash proceeds of the sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestInJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of the equity interests owned by noncontrolling shareholders, partners, or other equity holders in joint ventures included in the entity's consolidated financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4568740-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestInJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6770808800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2015</div></th>
<th class="th"><div>Jan. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_NotesPayableAndAdvancesPayableLineItems', window );"><strong>Notes Payable And Advances Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,200<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 27,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Borrowing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">305,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayment of notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(168,600)<span></span>
</td>
<td class="num">(147,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(85,200)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,715<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,365<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_BoardOfDirectorsChairmanMember', window );">Board of Directors Chairman [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_NotesPayableAndAdvancesPayableLineItems', window );"><strong>Notes Payable And Advances Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,200<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">27,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Borrowing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">105,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayment of notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(68,600)<span></span>
</td>
<td class="num">(47,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(85,200)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,035)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206,365<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerAxis=immd_CommercialLenderMember', window );">Commercial Lender [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_NotesPayableAndAdvancesPayableLineItems', window );"><strong>Notes Payable And Advances Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Borrowing</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayment of notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (100,000)<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_NotesPayableAndAdvancesPayableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_NotesPayableAndAdvancesPayableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28541-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerAxis=immd_CommercialLenderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfFinancingReceivableTypeOfBorrowerAxis=immd_CommercialLenderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6773805952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2016</div></th>
<th class="th"><div>Nov. 30, 2015</div></th>
<th class="th"><div>Jan. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Feb. 28, 2017</div></th>
<th class="th"><div>Jan. 31, 2017</div></th>
<th class="th"><div>Aug. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_NotesPayableTextualAbstract', window );"><strong>Notes Payable (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Borrowed from commercial lender</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 305,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,611<span></span>
</td>
<td class="nump">37,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date on notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov.  01,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense on notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,479<span></span>
</td>
<td class="nump">1,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest rate period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Promissary note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">25,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issued of common stock</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Common stock for maximum offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issued of common stock, value</a></td>
<td class="nump">$ 58,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,715<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Repaid of principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesAndLoansPayableCurrent', window );">Outsatanding balance of notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 131,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentOptionsExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_TermOfWarrant', window );">Term of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Promissory note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_NotesPayableTextualAbstract', window );"><strong>Notes Payable (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Promissary note</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Promissory note [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_NotesPayableTextualAbstract', window );"><strong>Notes Payable (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Promissary note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=immd_CommercialPaperOneMember', window );">Promissory note one [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_NotesPayableTextualAbstract', window );"><strong>Notes Payable (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Promissary note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=immd_CommercialPaperTwoMember', window );">Promissory note two [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_NotesPayableTextualAbstract', window );"><strong>Notes Payable (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Promissary note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerAxis=immd_CommercialLenderMember', window );">Commercial Lender [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_NotesPayableTextualAbstract', window );"><strong>Notes Payable (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Borrowed from commercial lender</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPaymentTerms', window );">Loan payable payment terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The loan required payment of principal and interest in 252 daily payments of $492 each commencing January 12, 2015.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Notes Payable, Other Payables [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_NotesPayableTextualAbstract', window );"><strong>Notes Payable (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,485<span></span>
</td>
<td class="nump">37,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_BoardOfDirectorsChairmanMember', window );">Board of Directors Chairman [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_NotesPayableTextualAbstract', window );"><strong>Notes Payable (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Borrowed from commercial lender</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">105,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,035)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_OfficerMember', window );">Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_NotesPayableTextualAbstract', window );"><strong>Notes Payable (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,416<span></span>
</td>
<td class="nump">10,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date on notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 28,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_MajorityShareholderMember', window );">Two Shareholders [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_NotesPayableTextualAbstract', window );"><strong>Notes Payable (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_NotesPayableTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Notes payable textual.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_NotesPayableTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_TermOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_TermOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_InvestmentOptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price of the option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 12<br> -Section 13<br> -Footnote 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">invest_InvestmentOptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>invest_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28541-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488278&amp;loc=d3e603758-122996<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6928298&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6479336&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of all long-term notes and loans payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=immd_CommercialPaperOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=immd_CommercialPaperOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=immd_CommercialPaperTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=immd_CommercialPaperTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfFinancingReceivableTypeOfBorrowerAxis=immd_CommercialLenderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfFinancingReceivableTypeOfBorrowerAxis=immd_CommercialLenderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_OfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_OfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_MajorityShareholderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_MajorityShareholderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6759088000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract', window );"><strong>Components of deferred tax liabilities and assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">$ 1,344,000<span></span>
</td>
<td class="nump">$ 930,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts', window );">Accounts receivable reserves</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventory reserves</a></td>
<td class="nump">7,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock Compensation</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Net deferred tax assets</a></td>
<td class="nump">1,581,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(1,581,000)<span></span>
</td>
<td class="num">(930,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Asset<br> -URI http://asc.fasb.org/extlink&amp;oid=6510090<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the allowance for doubtful accounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6925744704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details Textual)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_IncomeTaxesTextualAbstract', window );"><strong>Income Taxes (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 3,953,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsExpirationDate', window );">Operating loss carryforwards, expiration date</a></td>
<td class="text">Dec. 31,  2036<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Percentage of tax rate</a></td>
<td class="nump">34.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_IncomeTaxesTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_IncomeTaxesTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date of each operating loss carryforward included in operating loss carryforward, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6758877024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - Service-Based Stock Options [Member] - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options/Warrants, Beginning balance</a></td>
<td class="nump">11,025,273<span></span>
</td>
<td class="nump">10,435,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of Shares, Expired</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Cancelled</a></td>
<td class="num">(250,000)<span></span>
</td>
<td class="num">(200,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Issued</a></td>
<td class="nump">275,000<span></span>
</td>
<td class="nump">790,273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options/Warrants, Ending balance</a></td>
<td class="nump">10,700,273<span></span>
</td>
<td class="nump">11,025,273<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6759116064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details 1) - Stock Options [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2016 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Summary of significant assumptions used to determine the fair values of options using black-scholes option-pricing model</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend payout</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Weighted average grant date fair value</a></td>
<td class="nump">$ 0.22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairvalueAssumptionsForfeitureRate', window );">Forfeiture rate</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Summary of significant assumptions used to determine the fair values of options using black-scholes option-pricing model</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate at grant date</a></td>
<td class="nump">1.88%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">248.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected option life-years</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Summary of significant assumptions used to determine the fair values of options using black-scholes option-pricing model</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate at grant date</a></td>
<td class="nump">0.71%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">217.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected option life-years</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairvalueAssumptionsForfeitureRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share Based Payment Award fair value assumptions forfeiture rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairvalueAssumptionsForfeitureRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6770809664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details 2) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract', window );"><strong>Summary of outstanding service-based options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options</a></td>
<td class="nump">10,700,273<span></span>
</td>
<td class="nump">11,025,273<span></span>
</td>
<td class="nump">10,435,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=immd_ExercisePriceRangeOneMember', window );">$0.10 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract', window );"><strong>Summary of outstanding service-based options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options</a></td>
<td class="nump">1,380,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=immd_ExercisePriceRangeTwoMember', window );">$0.20 - $0.25 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract', window );"><strong>Summary of outstanding service-based options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options</a></td>
<td class="nump">8,120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=immd_ExercisePriceRangeTwoMember', window );">$0.20 - $0.25 [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract', window );"><strong>Summary of outstanding service-based options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 0.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=immd_ExercisePriceRangeTwoMember', window );">$0.20 - $0.25 [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract', window );"><strong>Summary of outstanding service-based options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=immd_ExercisePriceRangeThreeMember', window );">0.40 - $0.50 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract', window );"><strong>Summary of outstanding service-based options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 0.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options</a></td>
<td class="nump">1,150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=immd_ExercisePriceRangeThreeMember', window );">0.40 - $0.50 [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract', window );"><strong>Summary of outstanding service-based options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 0.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=immd_ExercisePriceRangeThreeMember', window );">0.40 - $0.50 [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract', window );"><strong>Summary of outstanding service-based options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeBeginningOfPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=immd_ExercisePriceRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=immd_ExercisePriceRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=immd_ExercisePriceRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=immd_ExercisePriceRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=immd_ExercisePriceRangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=immd_ExercisePriceRangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6772462880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details 3) - Warrant [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options/Warrants, Beginning balance</a></td>
<td class="nump">1,750,000<span></span>
</td>
<td class="nump">3,772,720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Shares, Issued</a></td>
<td class="nump">454,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of Shares, Expired</a></td>
<td class="num">(250,000)<span></span>
</td>
<td class="num">(2,022,720)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options/Warrants, Ending balance</a></td>
<td class="nump">1,954,981<span></span>
</td>
<td class="nump">1,750,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Beginning Balance,</a></td>
<td class="nump">$ 0.16<span></span>
</td>
<td class="nump">$ 0.29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Issued</a></td>
<td class="nump">0.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Expired</a></td>
<td class="nump">0.40<span></span>
</td>
<td class="nump">0.40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Ending Balance,</a></td>
<td class="nump">$ 0.19<span></span>
</td>
<td class="nump">$ 0.16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_ShareBasedCompensationArrangementByShareBasedPaymentBeinningYearOfExpiration', window );">Year of Expiration, Begining Balance</a></td>
<td class="text">2016 - 2017<span></span>
</td>
<td class="text">2015 - 2016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationIssued', window );">Year of Expiration, Issued</a></td>
<td class="text">2018 - 2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationExpired', window );">Year of Expiration, Expired</a></td>
<td class="text">2016<span></span>
</td>
<td class="text">2015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_ShareBasedCompensationArrangementByShareBasedPaymentEndingYearOfExpiration', window );">Year of Expiration, Ending Balance</a></td>
<td class="text">2017 - 2019<span></span>
</td>
<td class="text">2016 - 2017<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_ShareBasedCompensationArrangementByShareBasedPaymentBeinningYearOfExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment during period year of expiration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_ShareBasedCompensationArrangementByShareBasedPaymentBeinningYearOfExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_ShareBasedCompensationArrangementByShareBasedPaymentEndingYearOfExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment during period year of expiration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_ShareBasedCompensationArrangementByShareBasedPaymentEndingYearOfExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment during period expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment during period Issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_ShareBasedCompensationArrangementByShareBasedPaymentYearOfExpirationIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6759026784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details 4) - Warrant [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Summary of fair value of options and warrants granted using black-scholes option-pricing model with weighted-average assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">203.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">88.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Weighted average grant date fair value</a></td>
<td class="nump">$ 0.20<span></span>
</td>
<td class="nump">$ 0.03<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Summary of fair value of options and warrants granted using black-scholes option-pricing model with weighted-average assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected option term (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Summary of fair value of options and warrants granted using black-scholes option-pricing model with weighted-average assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected option term (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6774854944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2016</div></th>
<th class="th"><div>Jul. 31, 2015</div></th>
<th class="th"><div>May 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 23, 2016</div></th>
<th class="th"><div>Nov. 30, 2016</div></th>
<th class="th"><div>Oct. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 01, 2016</div></th>
<th class="th"><div>Aug. 31, 2016</div></th>
<th class="th"><div>Jan. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_StockholdersEquityTextualAbstract', window );"><strong>Stockholder's Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Value of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (10,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock issued for services as per agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 383,333<span></span>
</td>
<td class="nump">65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (87,053)<span></span>
</td>
<td class="num">$ (10,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentOptionsExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Recognized expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 383,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,570,157<span></span>
</td>
<td class="nump">32,010,375<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="nump">434,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 355,701<span></span>
</td>
<td class="nump">$ 320,103<span></span>
</td>
<td class="nump">$ 17,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercises of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice', window );">Options exercise price, per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Outstanding shares purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">325,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_PurchaseOfCommonStockDescriptionOfTransaction', window );">Purchase of common stock description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Common stock through an exchange for a price per share of $0.23 to $0.29.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87,053<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Minority interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Investment in subsidiary by noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,894<span></span>
</td>
<td class="nump">178,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,223,293)<span></span>
</td>
<td class="num">(159,232)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=immd_ImmudynePrLlcMember', window );">Immudyne PR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_StockholdersEquityTextualAbstract', window );"><strong>Stockholder's Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Minority interest rate</a></td>
<td class="nump">78.16667%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestPeriodIncreaseDecrease', window );">Charge to noncontrolling interest</a></td>
<td class="nump">$ 91,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=immd_ImmudynePrLlcMember', window );">Immudyne PR [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_StockholdersEquityTextualAbstract', window );"><strong>Stockholder's Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Minority interest rate</a></td>
<td class="nump">66.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=immd_ImmudynePrLlcMember', window );">Immudyne PR [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_StockholdersEquityTextualAbstract', window );"><strong>Stockholder's Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Minority interest rate</a></td>
<td class="nump">21.83%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_StockholdersEquityTextualAbstract', window );"><strong>Stockholder's Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,500<span></span>
</td>
<td class="nump">62,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember', window );">Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_StockholdersEquityTextualAbstract', window );"><strong>Stockholder's Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Value of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Value of options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_PresidentMember', window );">President [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_StockholdersEquityTextualAbstract', window );"><strong>Stockholder's Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Value of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Value of options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">339,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Royalties payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentOptionsExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">499,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_StockholdersEquityTextualAbstract', window );"><strong>Stockholder's Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Value of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Value of options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=immd_ShareholderMember', window );">Shareholder [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_StockholdersEquityTextualAbstract', window );"><strong>Stockholder's Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross', window );">Options granted, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 441,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=immd_ConsultantMember', window );">Two consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_StockholdersEquityTextualAbstract', window );"><strong>Stockholder's Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Common stock issued for services as per agreement, shares</a></td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock issued for services as per agreement</a></td>
<td class="nump">$ 690,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_PurchaseOfCommonStockDescriptionOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents about purchase price of common stock description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_PurchaseOfCommonStockDescriptionOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_StockholdersEquityTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_StockholdersEquityTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_InvestmentOptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price of the option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 12<br> -Section 13<br> -Footnote 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">invest_InvestmentOptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>invest_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockOtherSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockOtherSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in balance of noncontrolling interest in the subsidiary during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4568740-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569655-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=68079674&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=65897068&amp;loc=SL4591551-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=64809438&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in the weighted average exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, before forfeitures, of stock or other type of equity granted of any equity-based compensation plan other than an employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=immd_ImmudynePrLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=immd_ImmudynePrLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_PresidentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_PresidentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=immd_ShareholderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=immd_ShareholderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=immd_ConsultantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=immd_ConsultantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6771293136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details Textual 1)<br></strong></div></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2016 </div>
<div>USD ($) </div>
<div>Consultants </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2015 </div>
<div>USD ($) </div>
<div>Consultants </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2015 </div>
<div>USD ($) </div>
<div>Consultants </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_StockholdersEquityTextualAbstract', window );"><strong>Stockholder's Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of company stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercises of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">587,991<span></span>
</td>
<td class="nump">$ 77,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_StockholdersEquityTextualAbstract', window );"><strong>Stockholder's Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of stock options issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275,000<span></span>
</td>
<td class="nump">790,273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of options, cancelled | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of shares, expired | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,206<span></span>
</td>
<td class="nump">$ 22,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Intrinsic value of options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">704,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Intrinsic value of options exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member] | Consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_StockholdersEquityTextualAbstract', window );"><strong>Stockholder's Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of stock options issued | shares</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross', window );">Number of options granted, value</a></td>
<td class="nump">$ 9,980<span></span>
</td>
<td class="nump">$ 40,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="nump">$ 12,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price stock option issued | $ / shares</a></td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="nump">$ 0.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.20<span></span>
</td>
<td class="nump">$ 0.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Options fully vested and expiration period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Shares of common stock fully vested service-based options issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of options, cancelled | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of company stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_NumberOfConsultant', window );">Number of consultant | Consultants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_PresidentMember', window );">President [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_StockholdersEquityTextualAbstract', window );"><strong>Stockholder's Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_PresidentMember', window );">President [Member] | Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_StockholdersEquityTextualAbstract', window );"><strong>Stockholder's Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercises of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember', window );">Director [Member] | Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_StockholdersEquityTextualAbstract', window );"><strong>Stockholder's Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of shares, expired | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_NumberOfConsultant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of consultant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_NumberOfConsultant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_StockholdersEquityTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_StockholdersEquityTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, before forfeitures, of stock or other type of equity granted of any equity-based compensation plan other than an employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=immd_ConsultantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=immd_ConsultantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_PresidentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_PresidentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6758416672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details Textual 2)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2016 </div>
<div>USD ($) </div>
<div>Consultants </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_StockholdersEquityTextualAbstract', window );"><strong>Stockholder's Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Recognized expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 383,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationEquity', window );">Unearned share based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133,324<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_FairValueOfPerformanceBasedStockOptions', window );">Fair value of performance-based stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 151,036<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Stock options, expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=immd_PerformanceBasedStockOptionsMember', window );">Performance Based Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_StockholdersEquityTextualAbstract', window );"><strong>Stockholder's Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of stock options issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Recognized expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,867<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationEquity', window );">Unearned share based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_FairValueOfPerformanceBasedStockOptions', window );">Fair value of performance-based stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,035<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_AnnualSalesRevenueTarget', window );">Annual sales revenue target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableFairValue', window );">Fair value of options exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,867<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited', window );">Company cancelled service-based options, shares | shares</a></td>
<td class="nump">287,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited', window );">Company cancelled service-based options, value</a></td>
<td class="nump">$ 17,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_NumberOfConsultant', window );">Number of consultant | Consultants</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=immd_PerformanceBasedStockOptionsMember', window );">Performance Based Stock Options [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_StockholdersEquityTextualAbstract', window );"><strong>Stockholder's Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Stock options, expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price stock option issued | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_AnnualSalesRevenueTarget', window );">Annual sales revenue target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=immd_PerformanceBasedStockOptionsMember', window );">Performance Based Stock Options [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_StockholdersEquityTextualAbstract', window );"><strong>Stockholder's Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Stock options, expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price stock option issued | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_AnnualSalesRevenueTarget', window );">Annual sales revenue target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_AnnualSalesRevenueTarget">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock options exercisable upon the Company achieving annual sales revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_AnnualSalesRevenueTarget</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_FairValueOfPerformanceBasedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of performance-based stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_FairValueOfPerformanceBasedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_NumberOfConsultant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of consultant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_NumberOfConsultant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Fair Value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_StockholdersEquityTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_StockholdersEquityTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued under share-based plans to employees or officers which is the unearned portion, accounted for under the fair value method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66904339&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the equity-based award expires, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of forfeitures of stock or other type of equity issued of any equity-based compensation plan other than an employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph c(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=immd_PerformanceBasedStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=immd_PerformanceBasedStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6758662528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details Textual 3) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 01, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_StockholdersEquityTextualAbstract', window );"><strong>Stockholder's Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 587,991<span></span>
</td>
<td class="nump">$ 77,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,611<span></span>
</td>
<td class="nump">$ 37,476<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_StockholdersEquityTextualAbstract', window );"><strong>Stockholder's Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,954,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_WarrantExercisable', window );">Warrant exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,750,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_WarrantsExpireDateDescription', window );">Warrant expiration date, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The warrants expire at various time between December 2017 and September 2019.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrants [Member] | Sale of common stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_StockholdersEquityTextualAbstract', window );"><strong>Stockholder's Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Warrants fully vested and expiration period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrants [Member] | Consulting services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_StockholdersEquityTextualAbstract', window );"><strong>Stockholder's Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="nump">$ 20,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Warrants fully vested and expiration period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrants [Member] | Issuance of Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_StockholdersEquityTextualAbstract', window );"><strong>Stockholder's Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Warrants fully vested and expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrants [Member] | Minimum [Member] | Consulting services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_StockholdersEquityTextualAbstract', window );"><strong>Stockholder's Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="nump">$ 0.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrants [Member] | Maximum [Member] | Consulting services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_StockholdersEquityTextualAbstract', window );"><strong>Stockholder's Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=immd_PerformanceBasedStockOptionsMember', window );">Performance Based Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_StockholdersEquityTextualAbstract', window );"><strong>Stockholder's Equity (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 587,991<span></span>
</td>
<td class="nump">$ 142,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Compensation and related expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 587,991<span></span>
</td>
<td class="nump">133,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_StockholdersEquityTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_StockholdersEquityTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_WarrantExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_WarrantExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_WarrantsExpireDateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of warrant expiration date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_WarrantsExpireDateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of expenditures for salaries, wages, profit sharing and incentive compensation, and other employee benefits, including equity-based compensation, and pension and other postretirement benefit expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=immd_ConsultingServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=immd_ConsultingServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=immd_IssuanceOfCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=immd_IssuanceOfCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=immd_PerformanceBasedStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=immd_PerformanceBasedStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6772791984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalties (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_RoyaltiesTextualAbstract', window );"><strong>Royalties (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_PercentageOfRoyaltyBasedUponSales', window );">Percentage of royalty based upon sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_RoyaltyBasedUponSalesAmount', window );">Royalty based upon sales amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 227,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 20,157<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">$ 56,579<span></span>
</td>
<td class="nump">$ 56,579<span></span>
</td>
<td class="nump">56,579<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_PresidentMember', window );">President [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_RoyaltiesTextualAbstract', window );"><strong>Royalties (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_InterestInRoyalty', window );">Interest in royalty</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Royalties payable</a></td>
<td class="nump">$ 84,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,868<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares issued</a></td>
<td class="nump">499,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Stock price per share</a></td>
<td class="nump">$ 0.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.17<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_InterestInRoyalty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of interest in royalty.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_InterestInRoyalty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_PercentageOfRoyaltyBasedUponSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of royalty based upon sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_PercentageOfRoyaltyBasedUponSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_RoyaltiesTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_RoyaltiesTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_RoyaltyBasedUponSalesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of royalty based upon sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_RoyaltyBasedUponSalesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(1),(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_PresidentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_PresidentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6758916528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 01, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>Thresholds </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_CommitmentsAndContingenciesTextualAbstract', window );"><strong>Commitments and Contingencies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Operating lease expired date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 31,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseMinimumRentals', window );">Monthly base lease rental payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Operating leases, rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139,030<span></span>
</td>
<td class="nump">$ 65,968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalariesWagesAndOfficersCompensation', window );">Annual compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 145,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Stock option exercise prices lower range limit | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Stock option exercise prices upper range limit | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_StockIssuedDuringPeriodPerformanceBasedOptionsToPurchaseCommonStock', window );">Stock issued during period performance based options to purchase common stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Annual revenue base</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_SalesRevenueIncreased', window );">Annual revenue exceeding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_BonusPercentageOfCompensationForPretaxIncome', window );">Percentage of bonus compensation for pretax income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_PertaxIncomePercentage', window );">Pertax income percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock issued for services as per agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 383,333<span></span>
</td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_DebtLongTermAndShortTermCombinedAmountShares', window );">Combined capped | shares</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Stock options, Expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Purchase common stock option | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_NumerOfThresholds', window );">Numer of thresholds | Thresholds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_PresidentMember', window );">Mr. McLaughlin [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_CommitmentsAndContingenciesTextualAbstract', window );"><strong>Commitments and Contingencies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Operating leases, rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=immd_ImmudynePrLlcMember', window );">Immudyne PR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_CommitmentsAndContingenciesTextualAbstract', window );"><strong>Commitments and Contingencies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted shares value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Office space subleased from Mr. Schreiber</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=immd_ConsultantMember', window );">Two consultants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_CommitmentsAndContingenciesTextualAbstract', window );"><strong>Commitments and Contingencies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted shares issued | shares</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock issued for services as per agreement</a></td>
<td class="nump">$ 690,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock and Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_CommitmentsAndContingenciesTextualAbstract', window );"><strong>Commitments and Contingencies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted shares issued | shares</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock issued for services as per agreement</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_DebtLongTermAndShortTermCombinedAmountShares', window );">Combined capped | shares</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockExpense', window );">Restricted stock expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 690,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_BonusShares', window );">Additional bonus shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_OptionToBuyShares', window );">Option to buy shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=immd_RestrictedStockOneMember', window );">Restricted Stock One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_CommitmentsAndContingenciesTextualAbstract', window );"><strong>Commitments and Contingencies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted shares value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=immd_RestrictedStockTwoMember', window );">Restricted Stock Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_CommitmentsAndContingenciesTextualAbstract', window );"><strong>Commitments and Contingencies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted shares value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=immd_RestrictedStockThreeMember', window );">Restricted Stock Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_CommitmentsAndContingenciesTextualAbstract', window );"><strong>Commitments and Contingencies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted shares value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_BonusPercentageOfCompensationForPretaxIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of bonus agreement compensation for pretax income during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_BonusPercentageOfCompensationForPretaxIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_BonusShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents bonus of an additional shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_BonusShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_CommitmentsAndContingenciesTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_CommitmentsAndContingenciesTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_DebtLongTermAndShortTermCombinedAmountShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt long term and short term combined amount shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_DebtLongTermAndShortTermCombinedAmountShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_NumerOfThresholds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Numer of thresholds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_NumerOfThresholds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_OptionToBuyShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contracts conveying rights, but not obligations, to buy or sell a specific quantity of a security at a specified price during a specified period or at a specified date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_OptionToBuyShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_PertaxIncomePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Pertax income percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_PertaxIncomePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_SalesRevenueIncreased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales revenue increased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_SalesRevenueIncreased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_StockIssuedDuringPeriodPerformanceBasedOptionsToPurchaseCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the performance based options issued by the company to purchase common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_StockIssuedDuringPeriodPerformanceBasedOptionsToPurchaseCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseMinimumRentals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the payments that the lessee is obligated to make or can be required to make in connection with a property under the terms of an agreement classified as an operating lease, excluding contingent rentals and a guarantee by the lessee of the lessor's debt and the lessee's obligation to pay (apart from the rental payments) executory costs such as insurance, maintenance, and taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41499-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=7661868&amp;loc=d3e34039-112682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseMinimumRentals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncash expense that represents the cost of restricted stock or unit distributed to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesWagesAndOfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenditures for salaries for officers and non-officers. Does not include allocated share-based compensation, pension and post-retirement benefit expense or other labor-related non-salary expense. For commercial and industrial companies, excludes any direct and overhead labor that is included in cost of goods sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesWagesAndOfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the equity-based award expires, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_PresidentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_PresidentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=immd_ImmudynePrLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=immd_ImmudynePrLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=immd_ConsultantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=immd_ConsultantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=immd_RestrictedStockOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=immd_RestrictedStockOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=immd_RestrictedStockTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=immd_RestrictedStockTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=immd_RestrictedStockThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=immd_RestrictedStockThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6759671488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_RelatedPartyTransactionsTextualAbstract', window );"><strong>Related Party Transactions (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_CompensationForLegalServices', window );">Compensation for legal and business advisory services</a></td>
<td class="nump">$ 16,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Accountant chareges per month</a></td>
<td class="nump">477,401<span></span>
</td>
<td class="nump">$ 114,890<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=immd_ImmudynePrLlcMember', window );">Immudyne PR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_RelatedPartyTransactionsTextualAbstract', window );"><strong>Related Party Transactions (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_CompensationForLegalServices', window );">Compensation for legal and business advisory services</a></td>
<td class="nump">19,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Office space subleased from Mr. Schreiber</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Accountant chareges per month</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_AnnualIncentiveBonusAwardPercentage', window );">Annual incentive bonus award percentage</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_PresidentMember', window );">President [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_RelatedPartyTransactionsTextualAbstract', window );"><strong>Related Party Transactions (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_ReimbursementOfHomeOfficeExpenditures', window );">Reimbursement of home office expenditures</a></td>
<td class="nump">$ 24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_AnnualIncentiveBonusAwardPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of annual incentive bonus award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_AnnualIncentiveBonusAwardPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_CompensationForLegalServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Compensation for legal services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_CompensationForLegalServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_ReimbursementOfHomeOfficeExpenditures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reimbursement of home office expenditures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_ReimbursementOfHomeOfficeExpenditures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_RelatedPartyTransactionsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_RelatedPartyTransactionsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488393&amp;loc=d3e606610-122999<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 225<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=6488370&amp;loc=d3e13550-115849<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=immd_ImmudynePrLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=immd_ImmudynePrLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_PresidentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_PresidentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.7.0.1</span><table class="report" border="0" cellspacing="2" id="idp6759717280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2016</div></th>
<th class="th"><div>Apr. 24, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 27, 2017</div></th>
<th class="th"><div>Feb. 28, 2017</div></th>
<th class="th"><div>Jan. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Aug. 31, 2016</div></th>
<th class="th"><div>Nov. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_SubsequentEventsTextualAbstract', window );"><strong>Subsequent Events (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Common stock issued</a></td>
<td class="nump">62,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Promissary note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,035<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Outstanding principal balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Promissory note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_SubsequentEventsTextualAbstract', window );"><strong>Subsequent Events (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Promissary note</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Events [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_SubsequentEventsTextualAbstract', window );"><strong>Subsequent Events (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">559,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,183,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Issued of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,336,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">591,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.40<span></span>
</td>
<td class="nump">$ 0.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Warrants vested term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repaid principle balance of note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_CommonStockSharesIssuedRelatedPromissoryNote', window );">Common stock shares issued related promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Converted remaining principle balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,000<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Converted shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">559,179<span></span>
</td>
<td class="nump">196,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1', window );">Converted shares of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">304,348<span></span>
</td>
<td class="nump">98,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Offering to sell shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_WarrantsToPurchaseOfCommonStock', window );">Warrants to purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscribedButUnissued', window );">Subscriptions shares received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217,390<span></span>
</td>
<td class="nump">2,673,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscriptions', window );">Proceeds from subscription of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 614,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Satisfaction of obligation to pay amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Events [Member] | Promissory note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_immd_SubsequentEventsTextualAbstract', window );"><strong>Subsequent Events (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Promissary note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Original debt, discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Original debt, principle amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_CommonStockSharesIssuedRelatedPromissoryNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock shares issued related promissory note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_CommonStockSharesIssuedRelatedPromissoryNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_SubsequentEventsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_SubsequentEventsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_immd_WarrantsToPurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants topurchase of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">immd_WarrantsToPurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>immd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesSubscribedButUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesSubscribedButUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesSubscriptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Monetary value of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesSubscriptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options that are exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>57
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( #>FMTH?(\\#P    !,"   +    7W)E;',O+G)E;'.MDD^+
MPD ,Q;]*F?L:5\'#8CUYZ6U9_ )Q)OU#.Y,A$[%^>X>];+=44/ 87O+>CT?V
M/S2@=AQ2V\54C'X(J32M:OP"2+8ECVG%D4)6:A:/FD=I(*+ML2'8K-<[D*F'
M.>RGGD7E2B.5^S3%":4A+<TXP)6E/S/WJVR;A5ND9T*YKCM+1[873T$7LF<;
M!I99-G\LCNVW<+ZT+/0:S>,*P).B0\5?UX^8 TBTH_0(:+L A#&^NQT:E8(C
M-R."?S]PN -02P,$%     @ -Z:W2F;S"V""    L0   !    !D;V-0<F]P
M<R]A<' N>&UL38Y-"\(P$$3_2NG=;BGB06) L$?!D_>0;FP@R8;-"OGYIH(?
MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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MN?[PNPB[8.S6_F/CLZ!LX===R"]02P,$%     @ -Z:W2IE<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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M8LFY AT.;W3"2M_.TX!!J4PWU7TQW%'#0/%NO'[1]!^0_P502P,$%     @
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MBCS(XXX @F!*11+$(Q+%$27-0DH8(\)JS9C/;/PNC9 AU>R% R:#!!-P?I@
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M5=5EPZH^-7PO9?%X_K IG^KVK6O>'TZ/CYT^U-6^?S1N=GX^[_Y_4$L#!!0
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M.-1N^)_+MG6M;RMB62[>^D"C9GW1\%1S52Q<].L0C(98L^K.MP-LM$(B/(+
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M^ I3/7M*IN(?X0+2AP<E/D>!TL:5%+UUJ"86+T6)]W%O==R'\8;O)]@Z@$\
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M#S8;$BH?CK=XMN.8C88WW?2#V/R-\U=02P,$%     @ -Z:W2FL:QT>U 0
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M4/MPW./9CF,V&MYTTP]B\S<N_@)02P,$%     @ -Z:W2H2 "SZS 0  T@,
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M?S;3F$V&PW[^06SYQL5O4$L#!!0    ( #>FMTI-V@OUM0$  -(#   9
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M971S+W-H965T,3@N>&UL=59AC]HP#/TK57_ -0X4"BI(<-.T29N$;MKM<X
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MYP1"305.\9OCB;>=]0Y2Y@-KX0?8G\-9.XNL+#67T!NN>J2A*?!#>CQE'A\
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M$BH?CK=XMN.8C88WW?2#V/R-\W=02P,$%     @ -Z:W2IM0RRRX 0  T@,
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M@LJ%XZT_FW',1L-A-_T@-G_C_ ]02P,$%     @ -Z:W2M;EC3#_ 0  , 8
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MAHX(HM5'"Q^S6/DW](G!&D&$P35F<XL)/#R* $TTL/S@RB/$!4)4(+0"X95
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MM* X;VA\!2\&T<4;FG"(W1<4T3%JAI!-6,()1C&$N<P81!<P(,"\>5VAP@Q
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MXKYLIL]FP=E13=;.=;Q?_ =02P,$%     @ -Z:W2FXYO7#<!   JQH  !D
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M/._TJ72F5("T\UYDJ%+>4\. P%FH;BK[S)S69B!HVU]$:+@-B_]02P,$%
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M:B4%LS'1$GXV$U5X%;MT4G^0L^@TM)^@'C.+>*F&N9V][V7L3? #\W/3">_
MI!IB9M2<&)-$Z00/2F*M+I]I0\E)ZF6JUMR.8+N1K!]OEV"ZXHK_4$L#!!0
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M>3?LGH>!DD?W99",GR>K?U!+ P04    "  WIK=*+292&GT#  " $   &0
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M9NJ^'<[$PX,4)W/>C\9_.JS^ U!+ P04    "  WIK=*OT'KMY4"  #/"
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MS+18,Q"TZW\?HN$?9O$?4$L#!!0    ( #>FMTKSM03[2 0  + 6   9
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M=CTR?ZO$SLQD3F"#8]AP_[P1D4B)B<P)&' ,!NX>QXHF1<&9H@@6<)\%WIO
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M3P1#(5K+">:()CBQ[*&]D!D28O-%Q;,>UQK<3T8(Y/D+P_7,;A+(YR8U#3%
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MHXD Q(1+K@FR+#.QHQPK@5KM"B67H\^$@D(]&XY<'>AHU(_[TZFSXJ%5/GX
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MT%?G(Z;:X3">] )Q(*T#2<TV.]46U3"$?S=XZ,<C9NO8?*6$C\E"3+6.* >
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ML*7)G* LDBV*+<8.B(A2Y"RRG;%;BWG? 8%2R5^;.03:6<%T O6R%J #8X8
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M$<NN;HC^C74/=6)DP@29?WG',1-<;X*<<"LT'!6$#\5*X;O(FMW8H>(*6\8
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M.A73KNLEP"4(Y 0:X1IHRU,:T J$$A;JFZYK14;LZ@U5J@>>X!@S4B VRNU
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M1I (BG)(OD"+VQ6B]AR[@?)\DA:3,L>,*(^4R\IDA=;MO4LW:*Q9Z4:7-KM
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M'DYJ[V8AUM3OQ][+$@8GI-'16]:1!QKOG98;JQ=TTXR#]VX#AJ[ZVBSHG6D
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M\03U,-URC;F'R4N;'/0;D,:%%/O[8 '#3CB@#6$)OB&,KA6U607AE&T]/+-
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M36X.!6F9OK-+=,$$3_9G*SQ:CK-6(T6")_L+Y+3E5Z[@]*9,?P)02P,$%
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MU@=D8)PY7;P R"$".>QM)N^X70/($0(YB@OY9%9<R3_MA3:Z?VJI5L2S%\+
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MWLH!  #B'   &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSQ=G-3L)
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MR3=02P$"% ,4    "  WIK=*'R// \     3 @  "P              @ $
M    7W)E;',O+G)E;'-02P$"% ,4    "  WIK=*9O,+8((   "Q    $
M            @ 'I    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( #>F
MMTK/F@K([P   "L"   1              "  9D!  !D;V-0<F]P<R]C;W)E
M+GAM;%!+ 0(4 Q0    ( #>FMTJ97)PC$ 8  )PG   3              "
M ;<"  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ -Z:W2DQ/A7:=
M @  GPD  !@              ( !^ @  'AL+W=O<FMS:&5E=',O<VAE970Q
M+GAM;%!+ 0(4 Q0    ( #>FMTH=DJQQ<@,  'L.   8              "
M <L+  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    "  WIK=*
MK)$B/0X"   /!@  &               @ %S#P  >&PO=V]R:W-H965T<R]S
M:&5E=#,N>&UL4$L! A0#%     @ -Z:W2OWCA J[ P  MP\  !@
M     ( !MQ$  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    (
M #>FMTJPXP;$E@8  *LG   8              "  :@5  !X;"]W;W)K<VAE
M971S+W-H965T-2YX;6Q02P$"% ,4    "  WIK=*Y<D#"Y0$   *%@  &
M            @ %T'   >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#
M%     @ -Z:W2G"["RZS 0  T@,  !@              ( !/B$  'AL+W=O
M<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( #>FMTJ" 63@M0$  -(#
M   8              "  2<C  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q0
M2P$"% ,4    "  WIK=*,.<GD[4!  #2 P  &               @ $2)0
M>&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ -Z:W2DNIG1*S
M 0  T@,  !D              ( !_28  'AL+W=O<FMS:&5E=',O<VAE970Q
M,"YX;6Q02P$"% ,4    "  WIK=*/H@W][0!  #2 P  &0
M@ 'G*   >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( #>F
MMTJ%*!L;M $  -(#   9              "  =(J  !X;"]W;W)K<VAE971S
M+W-H965T,3(N>&UL4$L! A0#%     @ -Z:W2FL:QT>U 0  T@,  !D
M         ( !O2P  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4
M    "  WIK=*A( +/K,!  #2 P  &0              @ &I+@  >&PO=V]R
M:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( #>FMTI-V@OUM0$  -(#
M   9              "  9,P  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL
M4$L! A0#%     @ -Z:W2F"Z*8:U 0  T@,  !D              ( !?S(
M 'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    "  WIK=*(N1:
MH;0!  #2 P  &0              @ %K-   >&PO=V]R:W-H965T<R]S:&5E
M=#$W+GAM;%!+ 0(4 Q0    ( #>FMTIN9LM5G (  $0*   9
M  "  58V  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @
M-Z:W2ES]\VC& 0  -P0  !D              ( !*3D  'AL+W=O<FMS:&5E
M=',O<VAE970Q.2YX;6Q02P$"% ,4    "  WIK=*7DKX^[<!  #2 P  &0
M            @ $F.P  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4
M Q0    ( #>FMTJOR/POMP$  -(#   9              "  10]  !X;"]W
M;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ -Z:W2IM0RRRX 0
MT@,  !D              ( ! C\  'AL+W=O<FMS:&5E=',O<VAE970R,BYX
M;6Q02P$"% ,4    "  WIK=*UN6-,/\!   P!@  &0              @ 'Q
M0   >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( #>FMTHD
MA,X/1P(  $L'   9              "  2=#  !X;"]W;W)K<VAE971S+W-H
M965T,C0N>&UL4$L! A0#%     @ -Z:W2GN!_Q;I 0  [P0  !D
M     ( !I44  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #>FMTK%N+ER?0(  ),(   9              "
M ;A3  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ -Z:W
M2O/3LR%N P  Z@\  !D              ( !;%8  'AL+W=O<FMS:&5E=',O
M<VAE970S,2YX;6Q02P$"% ,4    "  WIK=*;CF]<-P$  "K&@  &0
M        @ $16@  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0
M   ( #>FMTJ#\C$0+0(  !D'   9              "  21?  !X;"]W;W)K
M<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ -Z:W2E]UU6?< 0  H@0
M !D              ( !B&$  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q0
M2P$"% ,4    "  WIK=*886_#4D"  #N!@  &0              @ &;8P
M>&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( #>FMTJJL )X
M40(  !0(   9              "  1MF  !X;"]W;W)K<VAE971S+W-H965T
M,S8N>&UL4$L! A0#%     @ -Z:W2CUP*M44 P  H0T  !D
M ( !HV@  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    "  W
MIK=*2]+3RL$"   4"@  &0              @ 'N:P  >&PO=V]R:W-H965T
M<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( #>FMTHD1+2J8@(  !\(   9
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M970T,RYX;6Q02P$"% ,4    "  WIK=*OT'KMY4"  #/"   &0
M    @ &N@@  >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    (
M #>FMTKSM03[2 0  + 6   9              "  7J%  !X;"]W;W)K<VAE
M971S+W-H965T-#4N>&UL4$L! A0#%     @ -Z:W2K$&F+-B @  X <  !D
M             ( !^8D  'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"
M% ,4    "  WIK=*Q%\N"?8#  !>$P  &0              @ &2C   >&PO
M=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( #>FMTKZ OP:]VT
M ,>L 0 4              "  ;^0  !X;"]S:&%R9613=')I;F=S+GAM;%!+
M 0(4 Q0    ( #>FMTJA@D#L/@(  & *   -              "  >C^  !X
M;"]S='EL97,N>&UL4$L! A0#%     @ -Z:W2@15_K)Z P  W1X   \
M         ( !40$! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( #>FMTH?
M(?K>R@$  .(<   :              "  ?@$ 0!X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<U!+ 0(4 Q0    ( #>FMTK]T  :O@$  .T<   3
M      "  ?H& 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     X #@ .@\
' .D( 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.7.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>192</ContextCount>
  <ElementCount>292</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>49</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="immd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="immd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/Consolidatedbalancesheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="immd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="immd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/ConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="immd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statement of Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/ConsolidatedStatementOfStockholdersEquityDeficit</Role>
      <ShortName>Consolidated Statement of Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="immd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="immd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>007 - Disclosure - Organization and Going Concern</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/OrganizationAndGoingConcern</Role>
      <ShortName>Organization and Going Concern</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="immd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>008 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="immd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>009 - Disclosure - Furnishings and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/FurnishingsAndEquipment</Role>
      <ShortName>Furnishings and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="immd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>010 - Disclosure - Investment in Adiuvo Investment S.A.</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/InvestmentInAdiuvoInvestmentS</Role>
      <ShortName>Investment in Adiuvo Investment S.A.</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="immd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>011 - Disclosure - Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.immudyne.com/role/NotesPayable</Role>
      <ShortName>Notes Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="immd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>012 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="immd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>013 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="immd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>014 - Disclosure - Royalties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/Royalties</Role>
      <ShortName>Royalties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="immd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>015 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="immd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>016 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="immd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>017 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="immd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>018 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.immudyne.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="immd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>019 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.immudyne.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="immd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>020 - Disclosure - Furnishings and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/FurnishingsandEquipmentTables</Role>
      <ShortName>Furnishings and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.immudyne.com/role/FurnishingsAndEquipment</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="immd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>021 - Disclosure - Notes Payable (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.immudyne.com/role/NotesPayableTables</Role>
      <ShortName>Notes Payable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.immudyne.com/role/NotesPayable</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="immd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>022 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.immudyne.com/role/IncomeTaxes</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="immd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>023 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.immudyne.com/role/StockholdersEquity</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="immd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>024 - Disclosure - Organization and Going Concern (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/OrganizationAndGoingConcernDetails</Role>
      <ShortName>Organization and Going Concern (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immudyne.com/role/OrganizationAndGoingConcern</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="immd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>025 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/SummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immudyne.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="immd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>026 - Disclosure - Summary of Significant Accounting Policies (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/SummaryOfSignificantAccountingPoliciesDetails1</Role>
      <ShortName>Summary of Significant Accounting Policies (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immudyne.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="immd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>027 - Disclosure - Summary of Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/Summaryofsignificantaccountingpoliciesdetailstextual</Role>
      <ShortName>Summary of Significant Accounting Policies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immudyne.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="immd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>028 - Disclosure - Furnishings and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/FurnishingsandEquipmentDetails</Role>
      <ShortName>Furnishings and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immudyne.com/role/FurnishingsandEquipmentTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="immd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>029 - Disclosure - Furnishings and Equipment (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/FurnishingsAndEquipmentDetailsTextual</Role>
      <ShortName>Furnishings and Equipment (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immudyne.com/role/FurnishingsandEquipmentTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="immd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>030 - Disclosure - Investment in Adiuvo Investment S.A. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/InvestmentinAdiuvoInvestmentSADetails</Role>
      <ShortName>Investment in Adiuvo Investment S.A. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immudyne.com/role/InvestmentInAdiuvoInvestmentS</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="immd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>031 - Disclosure - Notes Payable (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.immudyne.com/role/NotesPayableDetails</Role>
      <ShortName>Notes Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immudyne.com/role/NotesPayableTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="immd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>032 - Disclosure - Notes Payable (Details Textual)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.immudyne.com/role/NotesPayableDetailsTextual</Role>
      <ShortName>Notes Payable (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immudyne.com/role/NotesPayableTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="immd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>033 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immudyne.com/role/IncomeTaxesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="immd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>034 - Disclosure - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/IncomeTaxesDetailsTextual</Role>
      <ShortName>Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immudyne.com/role/IncomeTaxesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="immd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>035 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immudyne.com/role/StockholdersEquityTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="immd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>036 - Disclosure - Stockholders' Equity (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/StockholdersEquityDetails1</Role>
      <ShortName>Stockholders' Equity (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immudyne.com/role/StockholdersEquityTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="immd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>037 - Disclosure - Stockholders' Equity (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/StockholdersEquityDetails2</Role>
      <ShortName>Stockholders' Equity (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immudyne.com/role/StockholdersEquityTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="immd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>038 - Disclosure - Stockholders' Equity (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/StockholdersEquityDetails4</Role>
      <ShortName>Stockholders' Equity (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immudyne.com/role/StockholdersEquityTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="immd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>039 - Disclosure - Stockholders' Equity (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/StockholdersEquityDetails5</Role>
      <ShortName>Stockholders' Equity (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immudyne.com/role/StockholdersEquityTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="immd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>040 - Disclosure - Stockholders' Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/StockholdersEquityDetailsTextual</Role>
      <ShortName>Stockholders' Equity (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immudyne.com/role/StockholdersEquityTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="immd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>041 - Disclosure - Stockholders' Equity (Details Textual 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/StockholdersEquityDetailsTextual1</Role>
      <ShortName>Stockholders' Equity (Details Textual 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immudyne.com/role/StockholdersEquityTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="immd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>042 - Disclosure - Stockholders' Equity (Details Textual 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/StockholdersEquityDetailsTextual2</Role>
      <ShortName>Stockholders' Equity (Details Textual 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immudyne.com/role/StockholdersEquityTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="immd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>043 - Disclosure - Stockholders' Equity (Details Textual 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/StockholdersEquityDetailsTextual3</Role>
      <ShortName>Stockholders' Equity (Details Textual 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immudyne.com/role/StockholdersEquityTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="immd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>044 - Disclosure - Royalties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/RoyaltiesDetails</Role>
      <ShortName>Royalties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immudyne.com/role/Royalties</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="immd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>045 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immudyne.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="immd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>046 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immudyne.com/role/RelatedPartyTransactions</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="immd-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>047 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immudyne.com/role/Subsequenteventsdetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immudyne.com/role/SubsequentEvents</ParentRole>
      <Position>47</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>immd-20161231.xml</File>
    <File>immd-20161231.xsd</File>
    <File>immd-20161231_cal.xml</File>
    <File>immd-20161231_def.xml</File>
    <File>immd-20161231_lab.xml</File>
    <File>immd-20161231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>63
<FILENAME>0001213900-17-005790-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-17-005790-xbrl.zip
M4$L#!!0    ( #>FMTI6FJFL3.8  -)M#  1    :6UM9"TR,#$V,3(S,2YX
M;6SLO6F3VTB2*/A=9O,?\#2J:<F,F2)X4]55SU(IJ3I[)&6:4M7SVG;79" 0
M3*($ BP<F6*MV?[V=?<(7"1X R! QGLS4TH0AX>[AU_AQ]__]X^II3PRUS,=
M^Y?GZF7SN<)LW3%,^^&7Y[]__7 Q>*[\[U__X]G?_]?%A?(;LYFK^<Q0 @]N
M4-[_=?%_WG[Y&#ZO#"Z;^/^5_ZO9?=WJO&XUU;[2[+[IMM]TNLK5I_]'N;@(
M7_56\^ U\ R]H'6I\M_@UQ\CUS+?X/]5 #;;>V-.I\8OSR>^/WOS^O73T],E
M7 B,N<TN=6>*'^FIK;;Z_#^>B?LMT_Z>NA_?=>FX#W!OL_T:?Q[!UY\K2O0(
MWF&8T4/)!WJO^8^IVY<^\=2F^]7A</B:?DW=[IE9-\/+U=?_Y]/'>WW"IMJ%
M:7N^9NL 5PHL<\U2XD?B9TS/Z;34_KJG^!W)AVS'MH-I]C.&[[[VYS/V&FZZ
M@+N8:^JI9S<_N/P0X=3/1'B7(]Q/WJX[@>V[\_3]'M,O'YS'U^)'XH2+IGH!
MO)!\-'!=X.A5SXI?5SQL,#/[.?@!'^DL/\)^Z)/L9_"7%=\Q[4?F^=F/\=_P
MP?;R@[9FZE[V<_03/J8N/^:9>O9#\,.J1_R9N^(9^&7%0X%W\:!IL^BYL>:-
MB,[BAQ7H@%^1<;S,Y^B7%0_^L-;P_?_YN+ O ]]=>?OP-?Q*-Z/$PAW]QJ-]
M^H6-%=KA;S17=QV+K9<#KV>N,V.N;P+,L>3A+\"5_/+<,Z<S*[HV<=GXE^<H
M\BY"R7;YPS.>*Z]#R7GMV#[[X2OW3/=1Z JARL6F+GXT06**&[]]^/?[;TWU
MVS\U^QLRT==F\QO_GZ^WW]KJMW=,3U]_'K^.V;[IS^._30.OC$WF*H2-].)#
MAKB^^>_GOS;A_PT[@W:K^??7BP_C"U]G?P%P93I&_#<(.-=_!SH'+H5;H*G&
MSR=_CX VD@^H+6"2Y ?#7\,K\2=?IY"X'JM7WK?;<2;^:H%7KCK\%4B*?\T)
M28+Y.HM(6KI>720)69\_DJX#SW>FB2U:,RPM;-'.KEMT";%%;=$EO"Y=KQ1>
M%[BOZ"VZ-9*^75N:Y]V./Y@V&)_@!WQA.C,?M9'%OH)&NQV_=5S7>6+NU0_3
M^W;M3,'ZTTW-^@AT9>XG-ATQMQQ$"_YC#U-F1V@PX),_9I:IFSZ'13%,^)T[
M0,(N>;/+$I__BNKZ3?9"__XZ\YL)*B7 JSMC?#5]"Y!S8QOFHVD$FD4<\-;1
M7.-V_,YTP6)Q7.]ZHIGN5+/KP0F9:WK^:_CS^L6=%?7O?1#:N)CW?P:P M@/
M,\>&/[U(#CCVO>_HW^M!^+7+B1E@:5V2YA'-KPS#1!]%L^XTT[BQK[69Z6O6
M2=%_[1HE+T2\\(7YFFDSX[WFVJ!0O9-B@NS%2>I'U+\/IE,-M\E)D)WLO84E
M26)'Q/[LV/@=U[$LV PW\!67>?Y)4#Z\;=T2)2=$G/#599H7N//3,_LR5B;I
M'M']?S37!<!.BN*I-9T5K:^>P,?%N ?1]OUT9CESQHCS;V?U4>JI9<1T7;F>
M^M)X*:+<71%1[LJ@7E6">@M1].ZN4?1N45'TF)D^:?-,9EJ^_H59F"9R!R#/
MOX+4]#0ZJ_3>SI._$"O=T/&V4Q,6VGYAL8!)K[ <WNGNRCO=8D]@_AE8V7)H
MZ?H.K',_T5PV<:S:"*!=N(?[F(LK+%PG 2OT"]5)+<D+%>:%94G2OVBV=I(D
M_4*UT"[LLZ7=N@N; 3A>8/FU\6URM'F+X^Q%I)X58PL5"1XUFV7P=<;UZB8I
M )*&%^UFD0[-K>YG[O[EZW+WR]V_<O>KS1T-9'B@T-W_V7G,W/U+UZN\^U6U
MD-V_.Y+DYI>;OV0FC0W4>F[E91&I[F@@+2 V?\M_^^TO@YD5"V;6F9FD+I&Z
MI/*,G2[R67*/Q*%>773/SF<?!17Y[(I5J7BJIGAJRTDRE[Z$7/K381>9?"^9
MY$ FD=GZDGGV9AZ9WB_990=VD?4 DCMD 4&)!03GPCJRXD RBBQ1D,RQB3ED
M38-DBB6FD/FFQ\\WK2OOX.F38YD&N0 W(*V%*1OXKJ:SP#=US;JRC6O'FS+X
MHQY,D[THP2#KER:Y90]N"5'XF^,8-0FAK&61C/5(OMB#+\@_%'AY;YE3TZY1
M\&05A\3U46L6)]EE [OHL%J7$/;%]+Z_G;]EMCZ9:NYW;J9H%A,;;_GFSP%>
MOQWSI!B@ 3UR:[/P0OS@2:JVM:B+^3.!PT/R6L(<E2UH(*3G$B7R2*N1*KU&
M>_&> 6B&W(Z5V(Y9Q) [LL([,AWCN6/NV,%T$IW1\(%$;*0FIO9"L(?X8_.J
M)(^LXQ&.JAO;8#^8\=6Y\;P =CT/LVZ1\WM",>9M,%%2ZJ\,=^=^%C)Q7/\K
M<Z?OV,B/^/JSXS/O3IMC\N:M/V&N^'=-Y&'FHI)'K&M7)QGF(&OV2J>Y*UZ<
M_GN@FUEU;MO>0EV%FNIZCY+ABV?X+/=!\OQ1733)]BO*#&['8U.O"Y-NJ"I(
MK44RP^[,<.<RCVAU$NRPL!K)$#FE4'W[HMD/W*WXI/TPI\&T'NR2LZ^Y]7<C
M=,7?2.%-,F8!C&G:DC'W8<PDWB1C[JY"PY+&>G#>!@V:7HQDAQS23$^";8[1
M)$*R:D58M69.0@5Y]9P=D\6A!#7K7[+88:R<R0VR'4GEVY%4EC%D=Y&R)W56
MB?JR68BDN>S]4>ZDSOKP@FSE<<[4EYTYSHC8LM&&Y 39-^.<Z5ZK%.6JY 57
MEM:RJ\7ITU@VJ3CR@+SJL,*I5@)6J1RN;L27+23.@LRR(\194/\D#MN/?_!=
M,_K6*^_GZ#DXE:6N3*DY^92:RO+>#FYBS1AM%R=1<L*B%*I5P&^%3#G? %^V
MIOBD_>&XL*#:Q7LVR.^5ZZHOS>-)UE*45U:4+^7) C-4*$\6F.=JYB*3]%+,
MDWE]!^:YF4X#8VZS._>C59-@X<X!XXPU%BY,>A?-3HI_\E4@.['#1_:@6>\)
M^KK1W&#FFP7P)5&W)6K=RG/S(O;VDN0(];BGPE!U**NM!$,574=;#D,)&[;5
M!5&R)4=5JEQGP;P#/+4O6MWMS;LEQ.8\G7P7Q"YX]U^8Y[NF[HM&D-7>DAN\
M_,RUE&#NUYL?3G@*?1TFPM>;>:1W<+J,  3_I,V7&:&==7W;DZL3EC;'.,^J
MB83K[A0-HP<*K!IO?OMG8&?P=<;U2IFAB\9Z[Z+=+,K[@TU^%3QD;O[EZ_?!
MR#,-4W/GV&O_=DRLSO7!W6T]-N_*)222C,*UE.&(#8H]0-J>MM>:-\&\2?@/
M)M$_ G:2=;^\+/Y.F]7E!&GU>M*%OTL+JSO509W?LUFF7;=TO=)B;UALT&MK
M)*T[)S\%D7C@67IM16_-^4M8>*;]<,_<1U.O2W/^"K!;TD)>PI]DO?5Q?,F2
MQXC\2[8_ MLGC_DDVQ_C!%6R_4JVC\.XF4Z>M&1/UY)=#KP-=HTH#PL^6BB:
M)Z7,K8\\K"R[MC_Q5KB!E1DEKG:X9!FK_5VC[\-48#GWZ'NF/59YO"YK[P*C
M[SL@Z104]+$59V5I*Z/O)4;?"Z6Z^NU6]S//7):ORQV=-VW59K'G:=O35N[H
M\G9T050/O9GF]F2OE"6S9"$"GEH)R;?90EQ ;-YNX@Z(E3/;RW//JL(FD1WU
MV7G,M*.6KE=J^RT**;40LR-.XML:2S*)3R;QK=G]NXU^66+L?'=_JQW6/:?Y
M.NMZI7=_ZZ+5SG_WIX<Y+:G1:J-H.8*U,^N5,2)K,U;E.)TCC],Y'4Z2\W=*
MF+]S.NPB!_9()CF02>2$'\D\>S./' DDV64'=I$SA"1WR*%#)0X=.A?6D5.*
M)*-LQ2BUZG):E;%&I\,<<@Z29(KEZ*V<EE/XM)R3YQ8Y7D?RA9S'4_0\GI-B
M%QU6ZQ+"OIC>][?SM\S6)U/-Y2F@F$\I-M[RS9\#O'X[YMD?0 -ZY-9FX87X
MP9-4;6M1%_-G H>')'"$R1A;T$!(SR5*Y)$_(E5ZC?;B/0/0#+D=*[$=LX@A
M=V2%=Z3,]I4\LHE'.*IN;(/]8,97Y\;S MCU/%2V17+K"<4)M\%$23FN,F29
M>SQ[XKC^5^9.W[&1'_'U9\=GWITVQP2\6W_"7/'OFLC#S$4EC\G6KDXRS$'6
M[)6N.P%LR3B%\T WL^K<MKV%N@HUU?4>)<,7S_!9[H/D^:.Z:)+M5Z2*WX['
MIEX7)MV0&9Y:BV2&W9FA9E,?-[!#^0,>:\P0.[BW=1L!5Y"ON?5WCS$1[NP9
MLPZCY*K(F$5/ECL=QI3CT"7QY;0\R0RR36Y>9P&5:Y-[&@RY^>"PKH93[L>D
MTG2J/'_6R>.L%G]*GW/[,U3-Y=1!7PQP2R%INNI=!?[$<<V_F/$[-BE)D._.
MTK YT_L?V,3$8W=@1;&8<9<OW]JL'FQ< #K$9EB#%,FAQ^?0KT^.Y-"52)$<
M6@$.G;A,2M%U:)%<NHY+5TUO.I'"SS)&*<GBTH(8,C5%[X09,N^1=I(A2XMT
MU\:%R?+$5ZU%\L/>_% ;AV$+?I!V?@[\4!_S?!N.D%9UH0=BGA=@6/1V7+M&
MI!4X(B.&78-"R;'K./8C>]"L][1<SHO3:6#,;7"I/UH5KZLUF/EF ?R0&Y87
M(;F@F,J \ >J1/KH:+9W91L9S<^]M_,;VPA K<QQCP;8$&-& QY":8G%'"XS
M3/\:1,J=Z^C,\QRW)G5:QZTB6'SWP<1(U->L)(G<457?46#(RQU5K1VUEB1G
MM:.B48&98VLJ/Y-E>6Q-H?,4MT:2'+%RY!$KE64,.3&EA(DIE:6^'( B:2[G
MF10^SZ2FO"#'DYPS]>6TD3,BMAP>(CE!S@(Y9[K7JF*W*GWR*DOK$\F/JT+N
M6F5I?'VB[9"KU!.X;L27<S3.@LQR+,994%_V\3X[DLNVA*=+6]DBZ51I*3L>
MG1)MOS!+@^7?4:8.\+>GZ:2.WLZ3OPA[V_8"RZ_-/MY^:9$!GE[@63'""72K
M.G87J<K25G8I.XDN997E+]DTYS2;YIPYP]6FI/5D>N"<.\/5IV;VA%K:5);I
M9"WM>=325I8!2U:S=>U%6S7UNWV$Y BM;"6S+S-[G1K;GA2S%]T7]]R9/3;<
MI&S/R\Z5TKUV#"_E^]$8_L0DO&B_T%]D^.7KZ..P/P/,*WJ$_Q.YD0O7:\*4
MV8N)Z9RYJL+IW<=> G6D][=KS9M@4BG\!]/*'\$-3E;"\D+Q.VU6ESR<W!ED
MZR^OQF2Z"'<)I?7E3CYZ-]$-1HJC8XFCA>8F_5V;FRSQ2%[-30KG$2G"3E.$
M59:CN4YN#;Y]8*-EALZ\OCV+QF&ADQ*4ZSAKH2M-&@UY1?FK(:47U7+KHC4H
M4BUOSZ$GQ6W5(?BR$&OM*L32/)*_6OZDN1D\TL^X+GFD)!YI[\HC[8M6ORA%
MUU[!(IG7)8N4HC?:Q08;MJ?W]H9-E)]V6CRRJV&S39J>9-#]E):42#536@5Z
M9YUO5[,LNR;KNF214F1"YZ+5*5(F2()73B9T=I4):1[)5R:H/5 /\V46R;I>
MW0;+@*3NA=K;=R/]KXL+Y7?;])5[1D5PBG)Q$5[_CV<W_Y_Z?W_XU]T_V _V
MKMOK#_[]A?UI_GHS^<X>WW\WW1]/?^_IG4Y'[W:[^M?_=_)K_[?N^]_>__(/
M]9?!AP_JH-^Y4=]WAS^K_WPSZ/[SE_X_WOR]_T_Q 0Y)@)]&TOQ^_^[YK^+B
ME%I4L5]-S^FTU/X;^"V$//PI_!N?SWB;1Z?22R\4;$<_[OA&@.';#(U5?#AZ
M,15WLU\3-W\.P+K3?,?=<S%+S^/%=\QVJ /$\FNW75+J%:_3T*]?^2Q(+#C]
M6?QI1SS&I93+Y%FHM=R51)@TX$T<RUCQYOCW32]&YG]O46^MU+[X.\Y5>4^[
M\PM[,#T?LX\_:U.FB!WUA8WW'XSP_-=P.$M#N;'UR[^_7O4YA#'^[9KA+ #K
MQC;8C_]F\YQ@2<JJE=\* ;D"5!F(K@^6]I 3 &/-\AC_=NKUX3>O ]?%2Z:G
M:]:_F>:^Y]HAI\]?\)0-#L"J;X6PO'/T8"J4;4[?5YL7_\T_GGSYX@?O2+3G
MN_(X7R7]_=2W%@&)4?,!KG@Y@I(&8N$[V6!P2/,$Y,._L\!(?">])3^8%G.O
M 4T/CIO7AKR?:A:\5?G"9H[KF_:#@GE8FCU/[L_4A],P_0^SK/^VG2?['J2>
M8S,#BQG@??E ]]E)@K'B6VF _N58@0TF( <Z+TJE 5GXQH+@Y+LZ0B@V5,R-
M8_Z-^GC3M]+PW 4C,+T_6([F9P(AXG'-;_\,LL#(N/Y<095&+T$#2S&8;@(;
M>;\\!PB[K6%ST&DEH4Q L("JN-R%9_S=!CZ:F0;RX6I8=S*Q8UB%^98 ]^;S
MA^>_M@>=9J_75%-X70,8+F%#7 Z'S;ASN/=?FA5D"]#%G-+."N)WML-ZO]L9
M=O_^>B>X<ET(N+MLA@!W%]EGZ?KZA;0'O=8Q%Q)AOKN"(ELNI-5N#0>=2JQD
M"\&R;B7JH-7MJ0>L9'E>U&?F"]%5!BG4;J?3[L4+6 =/KG ?B'CP@?N=]NYP
MW_H3YB9&916.[1^>^<8VK5^>^V[ GK_.$98#,=AJ=9LQ_E;#DH3XQL;X%1@Z
M\',9W-E3F]W$[DI^_B"P#MWUO6:KW]P,UY7G,=\K<3=W.H-./X&P% "'078@
MROJ#X:#5V08RL9'OM#DR(@A3N );Q_AH:B/3,GV3E8E1M=?O#-1E.;,%>$6N
MZE!J@"7:;AZ\JG?@C3UJOOG(2B/.&G%Z,#2'2H4AB-0$BZ^#)V7,." ^P$5!
MG863'041CH;''. Y%),8"DNPYWJ(DK#O"_"!+D:KWTK">S0@<QFXN#VG%+B0
MO08$'I]$AVJ;!<8_&I1%,%)%5YH'IQ6P1PX6H;UVKULX?DN: ;MNI1<EL5)1
M4TW7"JW=J'@<$[FU8"*OMW:.9)NI7;7;&6X+9"+&65I0K VW-MM)HR<-PY[P
M-=4PRIA&8=;U];YE;\$FRP6\5CN;PEG7UU.XGXIGY 1>;@S8[G;[374[^%8,
M"BV#"0?M7J^M)N-JV;#D!>Z!6!TV^\UFK[,3N(L3.,'3#:8!=:%^Q\:8B%4&
MHB\&W4&OW1[$H&^&JX!5'(C_BV%OV!X,6KNN@C>AH"%J99G5?4!UXK/[0'$H
MLEJ]@:KVE\ (49<:%%BDVEECK>X)PX&8&?2;W83,608B"2)=Q:0BYGKEL]!J
M*'* \5 & R6C)N/2ZX'\9-J."]?"F:2EZ)?F4$U(BT40#@;O4 SVNMWN=N M
MX_;&UJT 3\'O,.' L:]\WS5'@4^NCI,]![:,X-2%VAYVAFMY=Q_0*XN,#1-'
MEUNQKK7;FOW6<"AQQW&W=H3]AHW?[Z<<L/-&Y(H9]QLLQE:GW>E)%&8/BI<B
M<&O4K1V[OKVQ6*<E9\T7K^1*#[53P<(:KC4!:\3H6T3O<]7U"Q&X\\;= ;I^
M,8ATWHC<3]<O1(?.&X6[Z/K-GOHY86X75;_.4S]O+-;&>C@X@M3#<Y03(?LV
MO:CS-!\6CGC.&W?[FP]+ASKGC<A]S(>E8YGS1N%.H8+-0?1S0MW>]L-"*/V\
ML;B%_;!@_Z=/Q/+'7B+_Y<HVCG.FMEBML FFW.'/N:9A%_@3IL6=YMZZQ#\&
M'7;>,9<**PLA0:*E1F(QK>>_-B]7I*>L J^(U>Q*D,)7LSAL(W^:K*B\[3:;
M2TGP*Z'*$_B=2% X\%3%7A[6>02PWUT#.(>H/*!7))7>P7>HE=&2-EFQM,X0
MRU.JO[ P37;;=?4V,%I.R[H*'C)WQ_+U;::X;UR5VNH6OZP]4T-7@-S:M.5S
MH40S&^3,Z[E0HH>4*)Z_;G4_D[^6K]=G54WP'AXS:;5T?0OYU>[TDQYM(2#O
MF8V\ N1^"7LX7\7-0UC=?H6 K@R_;]=_I71[9%7WE4/!SX>=6IWN>G9: 7[*
M818/T?W%H7[;K-B=H<D%DPOVP$J(TCGBC\P.5D"9[J]T:-9!2QVD>M.$GRX,
MG&_PH.=8ID%QO1N?346\*O!=36>!;^I@4-K&M>--&?RQU<$A6,B#8046$0+]
MF^,8V\1[U?:PVV]7 '"*-(FVM>\MD]I?;IVAE6+P Y=P8&2GVVH/>LU.B> 4
MPL^M3JM7A47LRL^=5J?9ZY3)#04P=*O7WL30@!?_=BQ^*5Y*MSK]?C]E0B<^
M?PA<!S?.Z/2:W>X6@/WF.IYWYSKC%>5-N:)KV >-D*!@XN/[PW1H&6%KV$JE
M42\ %0Z\B*8%@\CXPJC\ZOT/O%B&-=!M@^!119W3>F#R@_E0'H3-H6*;P"V!
M#O&/J&>>1P?='U@IMI;:&239<A&" Z$[M"];O]])AMY+A^[;1_:@6;Q5)1?A
MHL7SG?O1VD9MINV0=?!_TMSO#%N+"L8H08*WF[UDN\%%" Z$[M ]! *SG?3V
MUH'WA7E,<W7LEO@.!+WES$C'EH?)83(:OA::/,'>'<5K_-+?F,U<,@NO##!-
MJ%\Y]ILJ#8OMMMI1DRIR/4#YPGYPAY1VJY5,%-T!^-L9C@R(&;L4%[O=;C<3
MFVL)AD,!/+@C9Z_?:JN[ GACZ\Z4?00KIG@<@DW>:JE9.(RA.!S(0W,P5;7?
MZ25#W1N@_$TS[5N;!T>Q$Z7GHT@JA27[K:0V6@%(/K#F*CC#C)CR!&6_TT]4
M[BU\OVC0"N_!!#Y)4IN6O;RK)\TUHAE2=\P=.]A@26=O-8_Q1)S;&=KRVP0?
M!JF3@K*7<C]Q7/\K<Z?OV"@>BY7L^T2=>L6_MUG/D5DO^Y3_=CPV]2T;Q76;
M@X+ /U3C#7JJ>C30"F"5SK S*&H;[]T^;7M6Z7;4;1D]U*,?7&>*\)IV &)1
M*%J0$V\9B!#&[_NJ_6#>^Q]@#3JN 1+4G5-\<(=\TGR-&+7?ZK1;R846MIKJ
M(.U@HZJ%0P?:I6/M'1LSUV5&]!K!CF_!V2@EBGFAME.-3S< E"_LN1IM/,I9
MDJ>@=H>MY":+/UX@2(>6(Y6'O#R+?RH#]3Z5-CUU.*P8F^Q4[5)!^/<O.1F"
M9FR6O9@"#F[59J?7K\@Z=CV[!<DYZ#1+9ZD\SF_S$D2YVRHYH/ H98C R/UN
MIU.MA>S6-ZB**]A?0*IJMY\\/:[":@ZKK<\;U@*D>:_3&O3*QGE>TKP]&*@M
MM2+0YR7-/S,_=O_VKA+-U^%8L%UV!K'H]1U^JI$6/?DML 3B+%C)J<\? M?A
M2%U03RLA"]5V6._X5O-,'0^Q32OP5R3K'X;#=;69"4;? %B^:\BMOO0"%M'>
M:Q'[9>,7VO5T5<XYM3Y-YA6O3=DOJDJB@(6U%JLJ"EA8H<UGMB[?R5P8I;A=
M&7\$XO3U=AS&:U+1FJLIMA;XBU2L*+L1IV@EI.>T*'GV8$BKL]S"VN6<':JV
M\T0SS+]:K&X7]_3L2']@X]I:K'$_?[B,I1V<8MT<]/HU8M?B^\=5EI"%::OS
M8X)*JZM2HZGG1_L:Z*LCQV_IJ2]L%KCZ!)/UJ-K&-UUFO M<;&_&7-,Q5D\B
MN@;<.%-<SR=MGJE_EZ^+<IX[S?7G7UW-]C2=)WS,D[^(B"/FJ&9TH\E*5!LD
MXQH[+"Q/?.2<!5'+->7:U?5";9T>"O;7WQ?#WNFA8V\57='U[';$>8I[/,\)
M)]59U7%5;4ZIWZL[UV4UMFC6D3=W[&R7/<.@I&6O:61S+-MJ94^\YAYH66Z+
M<S!>2K1'5J#BHKZXR*F=9;L][/07.R37& &[MKWL[*.U5RR?-S];DB54/5)"
M%2%V^U^<U[(.I/+AS]6A0-F^.-R@5LL](/C7RQCL4*NUY^,I''L5.P7M:K\]
M\_0%CKV6'#R Y26()($JB,M5IA_*S.;B/).U*]F6=/SR!\>]9^ZCJ9?1RJ'7
M7;;=MH7NN,O*51&>*A;VUX^]#*/^)%!2J-H\RHIV4:$GN]]+T*Q'65<A6G:'
MY8C 2ZO[[9/F+A_2P4JO9HO7TSTPO@ =7%/W1?>++:5Q1;ATG^7O$'?"XH+
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MS/!&/[HP<GS?F8IK3XYKQ(_2^QQW-H&/OE%:!)+SQ/^)"[KPS+_8A4:E$2%
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M\969ZQB!+DQ#S<3R8 6!6H!$[?_LX;TSUV0^&&W*'-QC7QG!'\J#%>A MP:
M^> ZP4QQQJD?PD];<\71]< EM\"TZ3.HJI4G^,W#I_A+_8GF*Q/MD<%;F*UX
M$^<);X97/TR ;AZF]]"Z-%NSYA[@!Q8?K@=?&BYQ#J;F]%+YNGHY?.FFK5N!
MP104R; (0P- "56 D>],(8D+M^$G0>VC%:!@>&#*+STP !YVAN)]AT5ILYDE
MZCY37T;\Z@SK/6$%"HY>]S1,%<4WP.[\SFA5; PO@M^ N!.F6?Y$1YH#H&/F
M>51_"F@V3.!W<Q3@$1-]&-\&*+P(2>QJ3_!.V(LF+>+!98:):1'1@O&C!IU2
M@74(K&][P92Y'*++$D40UQ!2 DE=(RDM\7]4_-_8"@9D&DGEA\)U"KI54_X
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M_N6_;MXG#SY?X1;C(?_%H#N%)@R&7CQ.%<(M/.*@SER3S-D1LRD2#__F86W
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M_&@]'LTC,5-S>C#P_Z)YV>IBW3AO87>IX%1$S0YP4EX\GRD:JD%+!5 BB%&
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MI"B!#$)1_LQGP>$* 3^!Y3>6ID"+.[V%!>%#<&4)/G";098 /\.%#LY21MM
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M2EHOQQPIW2L*B0DGXKS8(KOV1HK(BFW *K*.7% 5162K*"1&Y6B2'\YR0>?
MX-W:\<,SJ?VE]I<+.O:"MFZ/5H(<DP24"Y(<604"'D>][M@A8P]PP@#L9=>T
MI1XN:$&?EXZJBUM8=#:P>QY3#<AVO-6]*'Y1K>YBDM7&]JP%+%1MM#N=J)'#
MB5'QM'GTM%=W-CMPV&Z>^?ZKC+6UNE5AOC9'V<,2KG11;^(RG9F/E)[@,GCL
M420<U[;!>ND?W'%,2.XMDDX?P]4F:;[=A_=9:V6D9<Z^Z3[>:-D<>&,_,MO'
M C4I/HO?:WTI/:O_02D]*V!K5J57_,YP\))_K!9AMD>5TL>%IR"\G&''_!4-
M@ ]:6*N GJ-589&JP'&&K%KY(24Y\D9E]%_.WL,N*#J*4[$S#?$8:;F,JJI\
M)67.T66.VN@.5*D?):_6@%>E?JS*640]SR5+7="_-"O@7;PT+$W&QE8GLK(R
M2%6RP*PGDHXND O V\NT05+_W?+J1-8A=WU%D'22N[[P?)8*[?G*6(L5.(NM
MYQ8,70=L ":^72Z#?<6&NR>R62JI6#IK!.3F@5$%8*G S,9<QFM5#5\7<G><
M[X+JS[YRNV^!KV?GN]_+:.5;[^YJY8X/J36NL GLQE:INA-8!DXR\(+1'TRG
MP0J6.35]'N0T;07[KSZ8C\SF'6-%6U?V*$9Q:8H^T>P'ZO?J/-G,]2;F#'LW
M&FQ,XS]&<^7FR[5R+V8\M <MV5=U_]:"BW*IJ#2YE(22W9>K0Z>OBQU51\R&
MG8;#[W0K,&@H"^U0&EH5M5G&K2H$@6-C\<<,LY:Q#@3OC;?P4L-6R]1&IH43
MNS2?C] +YWEX$X9I"? !.=>RZEPC=W<]Z$2[VZ2)7+C%1LQ_PH;J-!X'MG)
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MK_NL' &I"?#=?:8CY->L]MB60G+WQ'QR@$11Q!@$.'A(YOSZFYE5>)$ "9
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MO7CWWMLI2!=N+$FF,6.75.]Q#H(%#<EN60(EK<Z18VJ+U_;L1,X_&!(!2]@
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MJ:(Y<R1<-H:TQT>'/5(Q^1ME,)8[79HP-Z%I>,RBGX(]03 :BZ5I3 TO2/#
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M*$2?5M*ST5J28'^V@Q*D#8QD91T&_84TKG2'8/*^FEE 5E/7<E8GJK8^LF>
MJS7'.$\.<7FK<F,6"IU$35C<-%U[/E8BQIW_4=E<())XP@FE3P1A$9$I#0^B
M;8E.<W*S:\^: ^?LWSYOP-^YZO^R(Y'W$C-Y081@XDI%)R5RIIQ#%^':9N&<
M [)2"R[?_27]W;0G@)=/OCDS3),G=]G/5I3],]-$,6BRU%*.C@LE[BACZD6<
MZRX4/W)9>$OO8O?N5;>[_'E:35)B9&L -Y^5X/^F/3Z"!0MB&V"Q-!'B_N:
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M-P.E)X][G61K-,UT[;A>@AT,HPXVJ&JXD6!8UQQCVLD;T9YE72]1QH.M A-
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M&(G#CDAP#/<'KF':KJ@>X.>)K[)&ABOI#F= N)2]2<F%HE.5&Z8DRHE\Q)
M#IN$*:"\_(''?D26ID.!6B]H:@*FERNX::W[09 ,2:S@3^=\* 4'*):YZ6K8
M:X62-I,5(4'KJ2CW$Y;F1^Q*>A] N[DMCJM@$U&/?ISJ)8_50=!+8==<K_R+
M4)M:9*QXBNGN%?J5MF,X,Y%<5]+)6=YG]0B<FVH$K21Z(80"BB>\N_%7'B",
MO]&<7!)K-LHJY!Q^<X4S,%W>M(KO&67;ELF7 90@#?^R37\1M0C$O!6L7 M?
MQG.NL:,-HE+\-WP^:/6$<M($1F6!NF#0?8S-L  7L0QOD7G3RI16IM2!O,#
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M'('K=]X)+3.WS)Q@YJ$J][I-3 7<JO.O==S;G :>:[AW?!KX#5T1W[2?E0\
MQS]?P$BSH)V9DD'D76W+7@>XPJ<3;L #^_J9ZS.[.>DEH#TK,K>[I>-QZ;BK
M/V,]]#GN#-6F$B<^<71F8'^?R&?[B>DXAIKRR&CXL>1I/R6 VW=P<BCLTV32
MS6+AZRN+27?W]-%T+CW3$$!G@:$45](DK#M%Y=XTM(EA&MXJ'# *6KTLEM4
MS*7F)%<!M'ES"6'#SX+G:2ZK(TV8Q68X@7JI\4G2WAP,H,<Y3L3&CQ?4/RIS
M2'/+=:U(:(FS0R0X&$W576GJ.PY.BN<S[6?,H<GS> _CF&.<9>SH-(.8#NQU
M--L8Y(:E:_B*][9.LX]I@/W%]</[M]*PUY$ES@LC5>W\'GL.Y\7'K_NK\&>
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M2N"T!!LE]F&P*]J-M@06_4ETX5L.0244"P#$GOEF',/]<3ES&,?OYAO^O'J
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M=+%-1[,Z:+2=&_)XQUOO=MW>[4(2\]A99#4A)+M"ZN5T%:BM:O^%5.9OU\W
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M6[3+#*L%5V??-65SQSNN@RL>6P3NH;M3(V7FM7G2J[4[RD/]UIVNH2J&?7\
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M$J) 3+P9"(4W9DL(8Y:B;6\V0WW,\9UR5&"&M<KO7:0"O*F4T%V<,QQ2&.X
M]]WQ$L:(#T0'O8;6;(&3]A;P?B@)_'MW+;(!C$WFDQ6DLF_#$K#0F2UQ6F>)
M0I)'YEXAZ]4&\60^C8G_^Y*$ 0_9K_](N(/F,37R45QCD3HNLWW>M[*/,(\J
M^6]>*MO[(9/^NFSD<K@$;'D3DJ>&55.0F8WRH?VB$:(\*:M;%IC0!<#H?[(;
M'@7]1'@:RV'R(<U"I#H",^K_$&$18GY(6$(A_X\J0L9)4HB72>D6WM,DB@!=
M<P>#%ICG\S[@T:<O$S:.R1V?G3Z"V;1O26NVPH]5*V32I LJY'F%0"^7V"V+
MW"04([;D #"1!G!_O!)>(36!K=&,^<<JY@I[FB#D KH%\5@F[$+O,1X%*'DD
MQ9-I"G0]B1'NX;LJW 6+A["7BE$?3H]&1]U"_@N)(8_TUV 6PA3HTA,SKL,J
MKI+'RYBZ!> 8\Y_P 3SG3EE]8(;O6)^6@L63/-U"3X^BLYU-?V[&\D3;Q0S1
M<[<PO2=K$,:;(*'XKQG!TRJ"&X9NP79)H@C);4#LY#SV%"$/Q$6T54=@AO9]
M%5I%A-SN2T*Z!?<]#$66=0=HO'Z@ #/@*\<@UE8ST!^T.9SR>U* ITKH%LK3
M9,;@'PE7Y?I1S+H\;Z@\-:.JY6D%GY<R=@W,-NG62U*T^E1MN$.JYOV0_^K8
MR5$[X!]$P+J5J3(.LZ&T_&X;0Z62.V8F)0$&2OZLVJ6>Q&B(8RWSLR;:'<5=
MS?)4L W/S0C7YX =157)_510]<=F3&L3PXY"JF>")9]M:S4#W"I;["C0->?X
M5S &*&2-Y_TYG1E\+=&L/_87K[RDN([9H5T84C+)=BQFZVBYZC:ARZNE&F$?
MOL!40XNMM'3W!;;RAMVT%IFS B&P 6B5X1.DZ,3P.4[R&S(OXC1;SI!2;V^Y
MA[2+CMG/D@:4'&$#C=DF6G9=DRMTT]%97G)F8#RH:Z4=J=D0[=^.=GTM%*\L
MD?XR=%1:$NU(C08Y>='[TZXN$C5S+EG U&#&NRFG?@76Y')JVLTP:VFV&>;.
M^I;-847%D6C/S?!J27;Y%*.;DUA'KS2'[<UFC+5<VHAQ1V>PZ6JNFBU;F\U8
MZYFQY8)N%^>U%<QA ]B6W/9$SVWKT.Y>%FO#\[@![V,+WGI&6HOW\2O>*1*G
M#7B?6O#6W^76XGWRBG>*Q/L&O-];\-9?R=;B??J*MR$\::0R8G^JY8_UV+]&
M*R9LFS;2#9G9!EI.V<H&K_MJ!=ZF[75#9K:"EG*VL\+K;EN&]Z2=%4XL5FCY
M^K=JA:[MP9L+P*6T27MJQMA^G;BK*5+-O>$2P"WHS)!O=\VXJV:P72DN3_(&
M(K,!MKA^W%7TBZO#4-X<#LKW%\R-9K2;KR7_94 6_X@:2O=P[LEB1&>B),IY
MCZ%H);[72I\M9>D74>RIG]=T^HVK=/0<A3F)D%Q3&DF:J(I"UG$N(JL&4U\L
MB0LA*TB%NQ_D@^\-]J /!WQ;?<HV<DJ;$,RVU8:SP- Y1?B\WE:1RE+8KSJ#
MO"(0_U74">(-7!-"8P\;JZS9ZH2E!=INB2_%U+"(__5SOKYXU!\>]T^&1\\L
M2 >V1?\;C;;L/^?;KG]S#;:6/><,HLOW+3JK+7MFZ5/V9V0<P#!F^9-^(:JM
MUC7EPNK&8F#+?O<+$=N.P521K<T@5+[\/SM 82SNUFH<*N/F?SN,1"O]UF84
M&R;Y:X?>]4IP;;HON-*?_4+ M@.H5I5KTWW.(W[LTG6UQERKOG,F^6N[WIO*
M*+9Q1B&E)2[AD3X*)SC\L,L(6KI"I?=XUY[KJ^ZU'8TJY;H0LMW@:NLWMID5
M.8_XT2^8M\5%KP78!H8JUPZ&,5<QW&X0!']YR3CJ:T:^?,^4LHP>,BLN*\=2
M7P%Q-&,QE=-29'$B,ORM'7D:7LJ"K6?\&<*+<0PCD?KT/)!1G?=BFHC@4U+Q
M< ^1X$'R!4E:OJSG812&XLY.3LMX)L@[343K3Y0DJ[P3Q,7WO,%G3]-/K3H@
M-<@?J&.,"%_8@*Y-HYR#D!F'F<:#<=Z4%30\[_D4!J*XV!X&?TFB%<0L_Q8C
M.W;@ZYT_S#^1D4HU$>ZL;&&3BK8!G.U)67E56M#_#*,9I(IV6DNJ3EJ7]"P@
M$4#XNTVP4?#?)+T>R2;S41#(C/0.H&",+\$*Q2 <17SI9]_!9(7E)BMY6J3H
MN)N8;V??/<YF1<68@$Q%$*ZXD@C[J9)L"2@464[@*U,:/L?\IU!5:$U2K9\
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M0%@D6'7=AFF?UE,#CZ1+RU_^#U!+ P04    "  WIK=*<',X@10S  #0R@,
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MX*RU ;!9KKM':5('R8&=Z=B-<RI M^$E !1B9SF8+[^6U_[TC^+R+VE_EQO
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M8A.F 8\+!<X]1Z^0;&_\)J0UVG=B$ZM/ [CZ3]E^),# ?2HVL?H 0)75+ 2
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MX4%X"C>P;0HCL*V,QS_+L<"2X!_D?R&U5AMF1&*!;$_MPH]YTSO8;>@'(0;
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M?-8&.Y4(%*3=\_+2DQ5P]D9(21L,U4TPKB1#\(YIE6'>^JC:;NJQACXJC-6
ML+TJ:681H M7[XQ[%?(_49H5>3G)$W,/__@0DU\UWBSL<>,.$5GBWU^0V#TL
M%RRB!Y2L>6FQX!!IJ5:$'@V'PT%(F1D'GDC$G"E?=1L\'\J28*KTAO7E62=_
M(.61'(C[4YPL49#E)*V$9/)9O5\S5C0$N,*Q6 $H<R4O[>8M>BW^TC<WZ;:_
MI?(9>BX@4N @9:+DO7<?(-*] 2P5YS E4QHZ2"D@!ZY$N[S8A]@"*%^S5%[$
M^A; 8@6@G)(CRV@/^96X@8L7E0% 4V'J3RX$NEX)6]IRP/2GPM2]P2CO$; K
MD:@N\\W:(R"R7\)-OP>ZT A;[CI@ZTFDR7!%U[3L7. LWW.W)>RJ'UVA\&!
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M7HL_\4U",@/8S%>L+D@%3%K<4QH](VE)=A%Z@JDN?B=RCM#ZV$Q2W$-@7!B
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MT>+!"RJ"- K_H#B&7J*KU:I$@Q8]67"BQZ'&G4'W^6.*_LXQ2>2Q3);Z=IQ
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M:3J6",!!RH<K)%S64*XVD,UR0N:$W(4(*0VND/R=W:VR86B0.FM,FW6 S"D
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MW/Q8O>X</X.NR4@:D[$*#3L6B6_ ;4G%]M,7M"O;+6TC/F0TR/?9P=\=IN(
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M12F;T\8TGC+KO@=C*'O39PZ&CV4HA?.L^*N;+KE%@R/\21=_55H#1WZ)J:8
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M&F7MM):-*MN.T^B HH]1DF:B4+<,CQT34#3("S2@:!CI\<*K*)K@< 1;:TJ
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M(5C$N -FS6L)24P:ZA6IZ4G# $-$^0BPS1_%O4$-D/V#RGFH,CNCN&R> ^H
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MR_O3Q+H4)Z7+.-I&2>">2'" "9QWS8RM[V1KVI,6 910F 14JPV^W'56JV_
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MRR^[2)I&%^JW/>J;/DMN8/?LMF@-]ZTE";,3:B)RL7@AC&GA5;=[E#?D<:Q
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MSX)E3+@?XD]D]4YZV4\%[PD8DAJ6,>HZ+K > 2:+9<7AS-<IT.6 PR]PA&K
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M;"]'8VO>D+JX_^<?!VCF^WEG6"GRR'NSR'M?BKRR74?DD;K;3D!6TS$6YS[
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M[#5C]=_L9_8?_EB"_>'_!U!+ P04    "  WIK=*\3 2<"9)  "W?@4 %0
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MZ/SZ 05I4OV2Z\!K,E3^[-0BV:YP2.:!R:TU2K!$$:[3O;LNO#NL19(08BH
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M/ GL0')P"+&W%F6D(I#+>[4/WKE;*O3DXDY^B3,R3:%GH8%1P=/%#KF-*!,
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M4U^B(K7TB6B+%W:$3Y+:F]\* &$M"CJZH^OP'@4Y<IKS[8GL;V1Z[*Q'^H/
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MICL!*G-Z%]/<DNGV+J#,KLU'(<.AM"]$HD/NI#[%THS;@H[0*0Z5:,W>W.7
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M6V\F\GQ(>&#'F$#M8+;+$*D>[,WVS@FPALTP-^5@876L:NQ\?(NTV+EK[YP
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M@.LP&G3F1PD_>->:3C@GX;9]@':YR<MBA\\W49*<D_UENXKB-S?VQ6Y)RJ-
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M(S(<X[^0_X4P+:[98*CY)CG;-K;*W(6@KS=AOP]/U<6P/U7L-J :IHK$W6.
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M>_KN[ON>)_0H&\=[GM#^2\=-<Z %_2@5HI#BEGG>BOJ-W8?61"X:&7Z[Q>(
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MK>ER5TYO_=!U:3N]BV\"3ZPB8C0%RR[#I!)#.\2;\R3<6O6B1,&3LQS+E-5
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MX":[XR6P$Y%@E(D%#B;\^!9I\7C7'MP ",;C!@E@8ZL4>4P:ZZWD6@_H+'6
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M)5SJR R(#&],V"J PTF/$"]PFG5#ZG67!C?G!^]M1OU8R/_4ELQU6(OC$"G
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G+3(P,38Q,C,Q7W!R92YX;6Q02P4&      8 !@"* 0  7>H!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
